ctg-studies (1)

NCT Number	Study Title	Study URL	Acronym	Study Status
NCT02026505	Evaluation of Cardiotoxic Effects of Bortezomib	https://beta.clinicaltrials.gov/study/NCT02026505		COMPLETED
NCT01790152	Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment	https://beta.clinicaltrials.gov/study/NCT01790152		RECRUITING
NCT00678405	Trial of a Breathlessness Intervention Service for Intractable Breathlessness	https://beta.clinicaltrials.gov/study/NCT00678405		UNKNOWN
NCT03721952	Facilitating Communication Study	https://beta.clinicaltrials.gov/study/NCT03721952	FCS2	RECRUITING
NCT04635852	Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Cancer Patients	https://beta.clinicaltrials.gov/study/NCT04635852	EFFENDYS	COMPLETED
NCT03650205	Ivabradine to Prevent Anthracycline-induced Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT03650205	IPAC	UNKNOWN
NCT04827563	Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib	https://beta.clinicaltrials.gov/study/NCT04827563		RECRUITING
NCT00687349	Improving Clinician Communication Skills (ICCS)	https://beta.clinicaltrials.gov/study/NCT00687349	ICCS	COMPLETED
NCT00067249	Women's Use of Alternative Medicine: A Multiethnic Study	https://beta.clinicaltrials.gov/study/NCT00067249		COMPLETED
NCT02216149	Effects of S-1 and Capecitabine on Coronary Artery Blood Flow	https://beta.clinicaltrials.gov/study/NCT02216149	FluoHeart	TERMINATED
NCT05797649	Comparing N-terminal-proB-type Natriuretic Peptide With Other Criteria in Pleural Fluid Analysis	https://beta.clinicaltrials.gov/study/NCT05797649		NOT_YET_RECRUITING
NCT04704349	Latest Imaging SPECT System Evaluation Phase 1	https://beta.clinicaltrials.gov/study/NCT04704349	LISSE1	COMPLETED
NCT03051191	Pathogenic Mechanisms of Cancer and Cardiovascular Diseases	https://beta.clinicaltrials.gov/study/NCT03051191		COMPLETED
NCT00668291	Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the CARNEY Complex (CNC)	https://beta.clinicaltrials.gov/study/NCT00668291	EVACARNEY	COMPLETED
NCT05138991	Reproducibility and Accuracy of a Portable System for Early Detection of Cardiac Dysfunction in Childhood Cancer Survivors	https://beta.clinicaltrials.gov/study/NCT05138991		RECRUITING
NCT01171508	Circadian Disturbances After Breast Cancer Surgery	https://beta.clinicaltrials.gov/study/NCT01171508	CIRCA	COMPLETED
NCT00779571	The Female Health Dietary Intervention Study	https://beta.clinicaltrials.gov/study/NCT00779571	FEMIN	COMPLETED
NCT02674204	STOP Heart Disease in Breast Cancer Survivors Trial	https://beta.clinicaltrials.gov/study/NCT02674204	STOP	TERMINATED
NCT03645317	Avoiding Cardiac Toxicity in Lung Cancer Patients Treated With Curative-intent Radiotherapy	https://beta.clinicaltrials.gov/study/NCT03645317	ACCOLADE	UNKNOWN
NCT01730417	Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG	https://beta.clinicaltrials.gov/study/NCT01730417	mIBG	COMPLETED
NCT04318405	Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).	https://beta.clinicaltrials.gov/study/NCT04318405	Real-CHOICE	ACTIVE_NOT_RECRUITING
NCT03946852	Abdominal Regional Perfusion in Donation After Cardiac Death for Multi-Organ Transplantation	https://beta.clinicaltrials.gov/study/NCT03946852		NOT_YET_RECRUITING
NCT00001452	Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex	https://beta.clinicaltrials.gov/study/NCT00001452		COMPLETED
NCT02054052	Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer	https://beta.clinicaltrials.gov/study/NCT02054052		COMPLETED
NCT01586104	Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases	https://beta.clinicaltrials.gov/study/NCT01586104		COMPLETED
NCT03186404	Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracycline Pilot Study	https://beta.clinicaltrials.gov/study/NCT03186404	SPARE-HF	ACTIVE_NOT_RECRUITING
NCT03838627	Feasibility and Agreement of Remote Evaluation of Resting Heart Rate and Heart Rate Variability in Survivors of Hodgkin Lymphoma Treated With Chest Radiation (PILOT STUDY-SURVIVOR)	https://beta.clinicaltrials.gov/study/NCT03838627		ACTIVE_NOT_RECRUITING
NCT03604627	Study of Coronary Calcium Score as a Marker of Post-radiation Vascular Dysplasia in Adults Treated During Childhood for Cancer With Mediastinal Irradiation	https://beta.clinicaltrials.gov/study/NCT03604627	COROCAN	ACTIVE_NOT_RECRUITING
NCT05036252	Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT05036252		RECRUITING
NCT01944826	The TAKO-TSUBO And Cancer Registry	https://beta.clinicaltrials.gov/study/NCT01944826	TTAC	UNKNOWN
NCT04361552	Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)	https://beta.clinicaltrials.gov/study/NCT04361552		WITHDRAWN
NCT05411705	Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury	https://beta.clinicaltrials.gov/study/NCT05411705	Circular	RECRUITING
NCT02610426	Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer	https://beta.clinicaltrials.gov/study/NCT02610426		RECRUITING
NCT05753254	Effect on Markers of Cardiovascular, Reproductive and Cancer Risk From Firefighting Training	https://beta.clinicaltrials.gov/study/NCT05753254	BIOBRAND3	NOT_YET_RECRUITING
NCT04473703	Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in NSCLC Patients	https://beta.clinicaltrials.gov/study/NCT04473703		NOT_YET_RECRUITING
NCT03553654	Low-dose CT-based Method for Detection of Subclinical Anthracycline-induced Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT03553654		COMPLETED
NCT01143454	Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System	https://beta.clinicaltrials.gov/study/NCT01143454		RECRUITING
NCT01328054	A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval	https://beta.clinicaltrials.gov/study/NCT01328054		COMPLETED
NCT02423356	Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin	https://beta.clinicaltrials.gov/study/NCT02423356		COMPLETED
NCT02509156	Stem Cell Injection in Cancer Survivors	https://beta.clinicaltrials.gov/study/NCT02509156	SENECA	COMPLETED
NCT05261256	Cardiac Impairments Following Pediatric Cardiotoxic Anti-cancer Treatment	https://beta.clinicaltrials.gov/study/NCT05261256		ENROLLING_BY_INVITATION
NCT02368054	Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization	https://beta.clinicaltrials.gov/study/NCT02368054	HSBAPCB	COMPLETED
NCT02615054	Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors	https://beta.clinicaltrials.gov/study/NCT02615054		ACTIVE_NOT_RECRUITING
NCT05731375	Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage	https://beta.clinicaltrials.gov/study/NCT05731375	MUSCLE	NOT_YET_RECRUITING

NCT00247975	Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy	https://beta.clinicaltrials.gov/study/NCT00247975		TERMINATED
NCT02177175	Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification	https://beta.clinicaltrials.gov/study/NCT02177175		COMPLETED
NCT03444259	Prospective Project to Identify Biomarkers of Morbidity and Mortality in Cardiovascular Interventional Patients	https://beta.clinicaltrials.gov/study/NCT03444259	CAREBANK	ACTIVE_NOT_RECRUITING
NCT02652975	Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium	https://beta.clinicaltrials.gov/study/NCT02652975	ABCDE	COMPLETED
NCT03685175	Using Hyperpolarized [1-13C]Pyruvate to Detect Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT03685175	HPCardiotox	ENROLLING_BY_INVITATION
NCT01114659	The Study of Polycystic Ovary Syndrome(PCOS) With Gene and Questionnaire	https://beta.clinicaltrials.gov/study/NCT01114659		COMPLETED
NCT01468675	Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care	https://beta.clinicaltrials.gov/study/NCT01468675		COMPLETED
NCT04400903	Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer	https://beta.clinicaltrials.gov/study/NCT04400903		TERMINATED
NCT02080390	Strain Imaging in Breast Cancer Patients Receiving Trastuzumab	https://beta.clinicaltrials.gov/study/NCT02080390		COMPLETED
NCT00708903	Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)	https://beta.clinicaltrials.gov/study/NCT00708903		COMPLETED
NCT00903890	Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma	https://beta.clinicaltrials.gov/study/NCT00903890		COMPLETED
NCT02809456	Mitigation of Radiation Pneumonitis, Fibrosis and Heart Toxicity With Nicorandil in Lung Cancer Patients	https://beta.clinicaltrials.gov/study/NCT02809456		UNKNOWN
NCT02881203	Breast Radiotherapy Audio Visual Enhancement for Sparing the Heart	https://beta.clinicaltrials.gov/study/NCT02881203	BRAVEHeart	ACTIVE_NOT_RECRUITING
NCT01395303	Polymorphisms in the Vitamin D System and Health	https://beta.clinicaltrials.gov/study/NCT01395303		COMPLETED
NCT02641145	Molecular Imaging of Primary Amyloid Cardiomyopathy	https://beta.clinicaltrials.gov/study/NCT02641145	MICA	RECRUITING
NCT05226416	Analysis of Health Status of Comorbid Adult Patients With COVID-19 Hospitalised in Fourth Wave of SARS-CoV-2 Infection	https://beta.clinicaltrials.gov/study/NCT05226416	ACTIV4	COMPLETED
NCT04574050	SELF-BREATHE RCT for Chronic Breathlessness	https://beta.clinicaltrials.gov/study/NCT04574050		RECRUITING
NCT00858039	Cardiotoxicity of Adjuvant Trastuzumab	https://beta.clinicaltrials.gov/study/NCT00858039	CATS	COMPLETED
NCT05656079	To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlle	https://beta.clinicaltrials.gov/study/NCT05656079	easy laugh	RECRUITING
NCT02101879	Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and Taxanes	https://beta.clinicaltrials.gov/study/NCT02101879		UNKNOWN
NCT02178579	Prospective Observation of Cardiac Safety With Proteasome Inhibition	https://beta.clinicaltrials.gov/study/NCT02178579	PROTECT	COMPLETED
NCT01669239	Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer	https://beta.clinicaltrials.gov/study/NCT01669239	Opti-HER	COMPLETED
NCT05099679	Pilot Study for Black Men With Prostate Cancer: Optimization Of Mental and Heart Health, the BOOM-Heart Study	https://beta.clinicaltrials.gov/study/NCT05099679		RECRUITING
NCT00309439	ALA and Prostate Cancer	https://beta.clinicaltrials.gov/study/NCT00309439		UNKNOWN
NCT05378139	Continuous Wireless Monitoring of Vital Signs and Automated Alerts in Hospitalized Patients	https://beta.clinicaltrials.gov/study/NCT05378139		ACTIVE_NOT_RECRUITING
NCT05775939	PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung Cancer, EUCLID Trial	https://beta.clinicaltrials.gov/study/NCT05775939		RECRUITING
NCT02006979	Acute Exercise Cardioprotection From Doxorubicin	https://beta.clinicaltrials.gov/study/NCT02006979		COMPLETED
NCT02065908	Circulating MicroRNA as Biomarker of Cardiotoxicity in Breast Cancer	https://beta.clinicaltrials.gov/study/NCT02065908		COMPLETED
NCT05756608	Fibrosis in Chronic and Delayed Myocardial Infarction	https://beta.clinicaltrials.gov/study/NCT05756608	FCDMI	RECRUITING
NCT02429479	Preparing Family Caregivers to Make Medical Decisions for Their Loved Ones	https://beta.clinicaltrials.gov/study/NCT02429479		COMPLETED
NCT00385879	The Effects of Case Management in a Medicaid Managed Care Plan	https://beta.clinicaltrials.gov/study/NCT00385879		UNKNOWN
NCT02604979	The Influences of Long Periods of Pneumoperitoneum and Head up Position on the Variation of Heart-rate Corrected QT Interval During Robotic-assisted Laparoscopic Gastrectomy - Observational Study	https://beta.clinicaltrials.gov/study/NCT02604979		COMPLETED
NCT02333279	Cancer Development In Organ Transplant Recipients	https://beta.clinicaltrials.gov/study/NCT02333279		COMPLETED
NCT04024917	Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis	https://beta.clinicaltrials.gov/study/NCT04024917	COCOON	RECRUITING
NCT03356171	Cardiac Coherence Combined With Personal Physical Activity in Patients With Cancer	https://beta.clinicaltrials.gov/study/NCT03356171	APACCHE	UNKNOWN
NCT03850171	Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study	https://beta.clinicaltrials.gov/study/NCT03850171		TERMINATED
NCT01714271	Promotora-based Latino Family CVD Risk Reduction	https://beta.clinicaltrials.gov/study/NCT01714271		UNKNOWN
NCT01733706	Early Smoking Reduction or Cessation by Means of no Nicotine Electronic Cigarette Added to Standard Counselling.	https://beta.clinicaltrials.gov/study/NCT01733706		COMPLETED
NCT00002827	Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease	https://beta.clinicaltrials.gov/study/NCT00002827		COMPLETED
NCT03235427	The CAROLE (CArdiac Related Oncologic Late Effects) Study	https://beta.clinicaltrials.gov/study/NCT03235427	CAROLE	COMPLETED
NCT03620071	GoalKeeper: Intelligent Information Sharing for Children With Medical Complexity	https://beta.clinicaltrials.gov/study/NCT03620071	GoalKeeper	UNKNOWN
NCT00459771	Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT00459771		COMPLETED
NCT05921279	Understanding CARdiac Events in Breast Cancer	https://beta.clinicaltrials.gov/study/NCT05921279	UCARE	RECRUITING
NCT02798679	Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT02798679		COMPLETED
NCT00229879	Rare Tumor Case Review	https://beta.clinicaltrials.gov/study/NCT00229879		TERMINATED
NCT00037245	Androgens and Subclinical Atherosclerosis in Young Women - Ancillary to CARDIA	https://beta.clinicaltrials.gov/study/NCT00037245		COMPLETED
NCT04407845	Atrial Fibrillation in Patients Receiving Ibrutinib	https://beta.clinicaltrials.gov/study/NCT04407845	FABRIC	UNKNOWN
NCT03530215	Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA)	https://beta.clinicaltrials.gov/study/NCT03530215	EROCA	COMPLETED
NCT02942615	The Safety Management of Cardiac Toxicity in Breast Cancer Patients Under Multidiscipline Therapy.	https://beta.clinicaltrials.gov/study/NCT02942615		ACTIVE_NOT_RECRUITING
NCT04036045	Approaches to Identify Early Biomarkers and Pathogenesis of Anthracycline Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT04036045		NOT_YET_RECRUITING
NCT03258515	A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers	https://beta.clinicaltrials.gov/study/NCT03258515		COMPLETED
NCT03394859	Electronic Medical Records and Genomics (eMERGE) Phase III	https://beta.clinicaltrials.gov/study/NCT03394859	eMERGE	COMPLETED
NCT04758650	Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and Cardiac sarcoïdosis.	https://beta.clinicaltrials.gov/study/NCT04758650	MITRAS	RECRUITING
NCT04567875	Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma	https://beta.clinicaltrials.gov/study/NCT04567875	Apa-CARDIO1	UNKNOWN
NCT02547168	Determining the True Incidence of Atrial Fibrillation Before and After Lung Resection	https://beta.clinicaltrials.gov/study/NCT02547168	Lung-AF	TERMINATED
NCT04865159	Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies	https://beta.clinicaltrials.gov/study/NCT04865159		ACTIVE_NOT_RECRUITING
NCT00005459	Risk of Coronary Heart Disease in Women With Polycystic Ovary Syndrome	https://beta.clinicaltrials.gov/study/NCT00005459		COMPLETED
NCT05522959	Cardio-Oncology Rehabilitation Exercise	https://beta.clinicaltrials.gov/study/NCT05522959	CORE	RECRUITING
NCT00733759	Contrast Echocardiography in Patients With Pulmonary Arteriovenous Malformations (PAVMs)	https://beta.clinicaltrials.gov/study/NCT00733759		WITHDRAWN
NCT03211520	Magnetic Resonance Imaging:A Window to Anthracycline Toxicity	https://beta.clinicaltrials.gov/study/NCT03211520		ACTIVE_NOT_RECRUITING
NCT05358093	Cardiac Toxicity of Hypo Fractionated Radiotherapy in Left Breast Cancer	https://beta.clinicaltrials.gov/study/NCT05358093		NOT_YET_RECRUITING
NCT05786482	Evidence Based Mental Wellness Programming Online for Adults Across Chronic Physical Conditions	https://beta.clinicaltrials.gov/study/NCT05786482	EMPOwer	RECRUITING
NCT00499382	Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging	https://beta.clinicaltrials.gov/study/NCT00499382		TERMINATED
NCT03983382	A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients	https://beta.clinicaltrials.gov/study/NCT03983382		ACTIVE_NOT_RECRUITING
NCT03674450	Lung Heart Rate Variability	https://beta.clinicaltrials.gov/study/NCT03674450	HRV	WITHDRAWN
NCT04717050	Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity	https://beta.clinicaltrials.gov/study/NCT04717050		RECRUITING
NCT02668250	Influence of a Multi-parametric Optimization Strategy for General Anesthesia on Postoperative Morbidity and Mortality	https://beta.clinicaltrials.gov/study/NCT02668250	OPTI-AGED	COMPLETED

NCT05699915	Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors	https://beta.clinicaltrials.gov/study/NCT05699915	CAVACI	RECRUITING
NCT02487615	Genetical, Anthropometrical and Biochemical Factors Influencing High Risk Subclinical Atherosclerosis	https://beta.clinicaltrials.gov/study/NCT02487615		COMPLETED
NCT04046315	Early Detection of Cardiac Damage With CMR in Women With Breast Cancer	https://beta.clinicaltrials.gov/study/NCT04046315	EARLY-CATCH	UNKNOWN
NCT01270750	Bosentan for Severe Mitral Valve Dysfunction	https://beta.clinicaltrials.gov/study/NCT01270750	BOSMIVAR	UNKNOWN
NCT03748550	Exercise to Prevent AnthraCycline-based Cardio-Toxicity Study 2.0 (EXACT2)	https://beta.clinicaltrials.gov/study/NCT03748550	EXACT 2	RECRUITING
NCT01793168	Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford	https://beta.clinicaltrials.gov/study/NCT01793168	CoRDS	RECRUITING
NCT04472468	Primary Percutaneous Pericardiotomy for Malignant Pericardial Effusion (PMAP)	https://beta.clinicaltrials.gov/study/NCT04472468	PMAP	RECRUITING
NCT03050268	Familial Investigations of Childhood Cancer Predisposition	https://beta.clinicaltrials.gov/study/NCT03050268	SJFAMILY	RECRUITING
NCT00854568	Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL	https://beta.clinicaltrials.gov/study/NCT00854568		COMPLETED
NCT03391115	Personalized Experiences to Inform Improved Communication for Minorities With Life Limiting Illness	https://beta.clinicaltrials.gov/study/NCT03391115		COMPLETED
NCT05703126	Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML	https://beta.clinicaltrials.gov/study/NCT05703126		RECRUITING
NCT00159926	Cleansing of Suction Blood in Cardiac Surgery for Reduced Inflammatory Response	https://beta.clinicaltrials.gov/study/NCT00159926		TERMINATED
NCT01431326	Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care	https://beta.clinicaltrials.gov/study/NCT01431326	PTN_POPS	COMPLETED
NCT01867879	Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors	https://beta.clinicaltrials.gov/study/NCT01867879		COMPLETED
NCT05598879	Global Cardio Oncology Registry	https://beta.clinicaltrials.gov/study/NCT05598879	G-COR	RECRUITING
NCT05652179	Effect of Stellate Ganglion Block on Cardiac and Renal Function After Cardiopulmonary Bypass Cardiac Surgery	https://beta.clinicaltrials.gov/study/NCT05652179		RECRUITING
NCT00000479	Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer	https://beta.clinicaltrials.gov/study/NCT00000479	WHS	COMPLETED
NCT02181049	Cardiac and Vascular Late Sequelae in Long-term Survivors of Childhood Cancer (CVSS)	https://beta.clinicaltrials.gov/study/NCT02181049	CVSS	ACTIVE_NOT_RECRUITING
NCT03767517	A Culturally-Based Palliative Care Tele-consult Program for Rural Southern Elders	https://beta.clinicaltrials.gov/study/NCT03767517		RECRUITING
NCT05607017	Losartan in Prevention of Radiation-Induced Heart Failure	https://beta.clinicaltrials.gov/study/NCT05607017		NOT_YET_RECRUITING
NCT02596126	Secondary Prevention of Cardiovascular Disease in the Elderly Trial	https://beta.clinicaltrials.gov/study/NCT02596126	SECURE	COMPLETED
NCT02020226	A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors	https://beta.clinicaltrials.gov/study/NCT02020226		UNKNOWN
NCT02440906	Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project	https://beta.clinicaltrials.gov/study/NCT02440906	WIN	COMPLETED
NCT02232126	Social Work Intervention Focused on Transitions	https://beta.clinicaltrials.gov/study/NCT02232126	SWIFT	COMPLETED
NCT03969693	Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation	https://beta.clinicaltrials.gov/study/NCT03969693		NOT_YET_RECRUITING
NCT01230905	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart	https://beta.clinicaltrials.gov/study/NCT01230905	AST	COMPLETED
NCT04039516	Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy	https://beta.clinicaltrials.gov/study/NCT04039516	CHARRT	NOT_YET_RECRUITING
NCT00190593	Raloxifene Use for The Heart	https://beta.clinicaltrials.gov/study/NCT00190593		COMPLETED
NCT04072393	Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers	https://beta.clinicaltrials.gov/study/NCT04072393		RECRUITING
NCT01511263	Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis	https://beta.clinicaltrials.gov/study/NCT01511263	EpiCardiAL	TERMINATED
NCT04996693	On Dose Efficiency of Modern CT-scanners in Chest Scans	https://beta.clinicaltrials.gov/study/NCT04996693		RECRUITING
NCT01150916	B-type Natriuretic Peptide in the Diagnosis of Heart Failure Related Ascites	https://beta.clinicaltrials.gov/study/NCT01150916		COMPLETED
NCT01904903	Cardiac Safety Study in Patients With HER2 + Breast Cancer	https://beta.clinicaltrials.gov/study/NCT01904903	SAFE-HEaRt	COMPLETED
NCT02996903	Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AnglOgraphy IN Daily Practice in 2017	https://beta.clinicaltrials.gov/study/NCT02996903	PROTECTION-	COMPLETED
NCT03575650	Early Detection of Imaging-derived Subclinical Cardiac Injuries	https://beta.clinicaltrials.gov/study/NCT03575650	EMIRA	RECRUITING
NCT00501345	Aspirin in Patients With Myocardial Infarction and Thrombocytopenia	https://beta.clinicaltrials.gov/study/NCT00501345		TERMINATED
NCT05215509	Exercise-induced Cardiac Adaptions in Rheumatoid Arthritis Patients During Interleukin-6 vs. Tumor Necrosis Factor Antibody Therapy	https://beta.clinicaltrials.gov/study/NCT05215509	RABEX	RECRUITING
NCT01448083	Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four Hours	https://beta.clinicaltrials.gov/study/NCT01448083		UNKNOWN
NCT05563883	Atrial Fibrillation and Cancer: a Nationwide French Cohort Study	https://beta.clinicaltrials.gov/study/NCT05563883		ACTIVE_NOT_RECRUITING
NCT04961307	Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab	https://beta.clinicaltrials.gov/study/NCT04961307		UNKNOWN
NCT02062983	Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients	https://beta.clinicaltrials.gov/study/NCT02062983		SUSPENDED
NCT04632407	Can Flaxseed Prevent Broken Hearts in Women With Breast Cancer Study?	https://beta.clinicaltrials.gov/study/NCT04632407	CANFLAX	UNKNOWN
NCT05611307	Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors	https://beta.clinicaltrials.gov/study/NCT05611307		RECRUITING
NCT01038583	Aspirin in Reducing Events in the Elderly	https://beta.clinicaltrials.gov/study/NCT01038583	ASPREE	ACTIVE_NOT_RECRUITING
NCT04190433	Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial	https://beta.clinicaltrials.gov/study/NCT04190433		WITHDRAWN

NCT03987633	EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality	https://beta.clinicaltrials.gov/study/NCT03987633		RECRUITING
NCT02344433	Using Virtual Counselors to Overcome Genetic Literacy Barriers	https://beta.clinicaltrials.gov/study/NCT02344433	VICKY	COMPLETED
NCT05344547	Women With Polycystic Ovary Syndrome Are at High Risk for Cardiac Insults	https://beta.clinicaltrials.gov/study/NCT05344547		COMPLETED
NCT01281787	PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer	https://beta.clinicaltrials.gov/study/NCT01281787	PRESAGE	COMPLETED
NCT01016886	Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research	https://beta.clinicaltrials.gov/study/NCT01016886	MANTICORE	UNKNOWN
NCT02632786	The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis	https://beta.clinicaltrials.gov/study/NCT02632786	PRONTO	COMPLETED
NCT00106886	HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study)	https://beta.clinicaltrials.gov/study/NCT00106886		UNKNOWN
NCT01022086	Assessment of Cardiotoxicity by Cardiac Magnetic Resonance (CMR) in Breast Cancer Patients Receiving Trastuzumab	https://beta.clinicaltrials.gov/study/NCT01022086		UNKNOWN
NCT04663685	MoveStrong at Home	https://beta.clinicaltrials.gov/study/NCT04663685		UNKNOWN
NCT01817686	Study of Default Options in Advance Directives	https://beta.clinicaltrials.gov/study/NCT01817686		COMPLETED
NCT02645786	Thyrotropin Over-suppression and Heart	https://beta.clinicaltrials.gov/study/NCT02645786		COMPLETED
NCT03909386	Non-interventional Study on Patients With Atrial Fibrillation and Cancer	https://beta.clinicaltrials.gov/study/NCT03909386	BLITZ-AFCanc	COMPLETED
NCT04338386	Detection and Pathogenesis of Novel Protein F	https://beta.clinicaltrials.gov/study/NCT04338386		NOT_YET_RECRUITING
NCT05023785	The HIMALAYAS Trial and Lifestyle Changes in Pediatric, Adolescent and Young Adult Cancer Survivors Study: A Multicentre Randomized Controlled Trial	https://beta.clinicaltrials.gov/study/NCT05023785	HIMALAYAS	NOT_YET_RECRUITING
NCT03480087	Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma	https://beta.clinicaltrials.gov/study/NCT03480087	Cardiocare	COMPLETED
NCT02784587	Feasibility of Perioperative Stellate Ganglion Blocks in Cardiac Surgery	https://beta.clinicaltrials.gov/study/NCT02784587		COMPLETED
NCT03535987	Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy	https://beta.clinicaltrials.gov/study/NCT03535987		COMPLETED
NCT04655885	Cardiac Output Optimization on Postoperative Complications in Major Hepatic Surgery	https://beta.clinicaltrials.gov/study/NCT04655885	OPTILIVER	RECRUITING
NCT05932485	Effect of Stellate Ganglion Block on New Atrial Fibrillation After Coronary Artery Bypass Grafting	https://beta.clinicaltrials.gov/study/NCT05932485		RECRUITING
NCT02175147	Patient-centred Integrated Palliative Care Pathways in Advanced Cancer and Chronic Disease	https://beta.clinicaltrials.gov/study/NCT02175147	InSup-C	UNKNOWN
NCT04552587	The HEART Study (Healthy Eating and Recovery Together)	https://beta.clinicaltrials.gov/study/NCT04552587		COMPLETED
NCT00651222	Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy	https://beta.clinicaltrials.gov/study/NCT00651222		COMPLETED
NCT02501707	Echocardiography for RILI Prediction	https://beta.clinicaltrials.gov/study/NCT02501707		TERMINATED
NCT01230983	Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma	https://beta.clinicaltrials.gov/study/NCT01230983	T-Cell #4	COMPLETED
NCT02451007	Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors	https://beta.clinicaltrials.gov/study/NCT02451007		COMPLETED
NCT02717507	Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors	https://beta.clinicaltrials.gov/study/NCT02717507		ACTIVE_NOT_RECRUITING
NCT00784095	Outlook Quality of Life Intervention	https://beta.clinicaltrials.gov/study/NCT00784095		COMPLETED
NCT05406635	Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer	https://beta.clinicaltrials.gov/study/NCT05406635	HER2BIC	RECRUITING
NCT04138095	Virtual Reality as an Adjunct to Management of Pain and Anxiety in Palliative Care	https://beta.clinicaltrials.gov/study/NCT04138095		UNKNOWN
NCT00122135	A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making	https://beta.clinicaltrials.gov/study/NCT00122135	Aim3	COMPLETED
NCT01047735	The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes	https://beta.clinicaltrials.gov/study/NCT01047735	TRIABETES	ACTIVE_NOT_RECRUITING
NCT00300495	Study of Amiodarone Given Before Lung Surgery to Prevent Atrial Fibrillation After Lung Resection	https://beta.clinicaltrials.gov/study/NCT00300495		TERMINATED
NCT02722525	Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer	https://beta.clinicaltrials.gov/study/NCT02722525		ACTIVE_NOT_RECRUITING
NCT03232125	Effect of Ramosetron on Heart Rate-corrected QT Interval During Robot-assisted Laparoscopic Prostatectomy With Steep Trendelenburg Position	https://beta.clinicaltrials.gov/study/NCT03232125		COMPLETED
NCT05184725	CARINAE for Stress Relief in Perioperative Care	https://beta.clinicaltrials.gov/study/NCT05184725	CARINAE	COMPLETED
NCT00921492	Acupuncture and Gonadotropin-releasing Hormone Pulse Generator and Stress Axis in Polycystic Ovary Syndrome	https://beta.clinicaltrials.gov/study/NCT00921492	PCOSLFEA	COMPLETED
NCT04461392	Exercise Response After Revalidation in Cancer Patients	https://beta.clinicaltrials.gov/study/NCT04461392		UNKNOWN
NCT04749212	Perioperative Troponin I and NT Pro-BNP in Lung Resection	https://beta.clinicaltrials.gov/study/NCT04749212		RECRUITING
NCT02430012	Quality Measurement and Improvement Study of Surgical Coronary Revascularization: Secondary Prevention	https://beta.clinicaltrials.gov/study/NCT02430012	MISSION-1	COMPLETED
NCT03574012	SmART Heart: Study of mHealth Apps to Reduce Cancer-Treatment Effects on the Heart	https://beta.clinicaltrials.gov/study/NCT03574012		COMPLETED
NCT03557255	Levosimendan for Cardiac Patients Undergoing Major Abdominal Cancer Surgeries	https://beta.clinicaltrials.gov/study/NCT03557255		COMPLETED
NCT00321048	Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With ABC	https://beta.clinicaltrials.gov/study/NCT00321048		COMPLETED
NCT03089151	Denver Garden Environment and Microbiome Study Disease	https://beta.clinicaltrials.gov/study/NCT03089151	DGEM	COMPLETED
NCT05732051	Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients	https://beta.clinicaltrials.gov/study/NCT05732051	NARNIA	RECRUITING
NCT00591851	Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility	https://beta.clinicaltrials.gov/study/NCT00591851		COMPLETED
NCT05600751	Radiosurgery of Ganglion StELlatum In Patients With REFractory Angina Pectoris	https://beta.clinicaltrials.gov/study/NCT05600751	RELIEF-AP	RECRUITING
NCT05198648	Trigeminal Nerve Cardiac Reflex During Resection of Cerebellopontine Angle Tumors and Postoperative Myocardial Injury	https://beta.clinicaltrials.gov/study/NCT05198648		RECRUITING
NCT01738451	A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors	https://beta.clinicaltrials.gov/study/NCT01738451		COMPLETED
NCT00885612	10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)	https://beta.clinicaltrials.gov/study/NCT00885612		COMPLETED
NCT04636255	Physical Capacity in Hodgkin Lymphoma Survivors	https://beta.clinicaltrials.gov/study/NCT04636255		RECRUITING
NCT02309255	The NOR-COR Study for Coronary Prevention	https://beta.clinicaltrials.gov/study/NCT02309255		COMPLETED
NCT01848912	Temperature, Heart and Respiratory Rate Investigation Along With Variability Evaluation and Serum Biomarkers (THRRIVES)	https://beta.clinicaltrials.gov/study/NCT01848912	THRRIVES	COMPLETED
NCT02505412	Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients	https://beta.clinicaltrials.gov/study/NCT02505412		UNKNOWN
NCT04508855	Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)	https://beta.clinicaltrials.gov/study/NCT04508855	MAFIC	RECRUITING
NCT02605512	BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study	https://beta.clinicaltrials.gov/study/NCT02605512	BACCARAT	UNKNOWN
NCT00162955	Prevention of CHOP-induced Chronic Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT00162955		COMPLETED
NCT05309655	Cardiac Outcomes With Near-Complete Estrogen Deprivation	https://beta.clinicaltrials.gov/study/NCT05309655	CROWN	RECRUITING
NCT02622412	Evaluation of a Multi-professional Breathlessness Service for Patients With Breathlessness Due to Any Advanced Disease	https://beta.clinicaltrials.gov/study/NCT02622412	BreathEase	COMPLETED
NCT02665312	Cardiotoxicity and Risk Factors in Patients With Colorectal Cancer Receiving Fluoropyrimidine	https://beta.clinicaltrials.gov/study/NCT02665312		UNKNOWN
NCT04541212	Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or Leukemia	https://beta.clinicaltrials.gov/study/NCT04541212	CarChem	RECRUITING
NCT05504148	Protection of Cardiovascular Function With Crocin in BrEast Cancer Patients Undergoing Radiotherapy and Chemotherapy	https://beta.clinicaltrials.gov/study/NCT05504148	ProtECtion	RECRUITING
NCT00777751	Radiation Therapy and Cardiac Enzymes	https://beta.clinicaltrials.gov/study/NCT00777751		COMPLETED
NCT05258448	COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)	https://beta.clinicaltrials.gov/study/NCT05258448	COLA	RECRUITING
NCT03375892	The Use of Deep Inspiration Breath Hold and Prone Irradiation to Decrease Cardiac Radiation Exposure	https://beta.clinicaltrials.gov/study/NCT03375892		COMPLETED
NCT03746392	Project to Improve Communication About Serious Illness - Pilot Study	https://beta.clinicaltrials.gov/study/NCT03746392	PICSI-P	COMPLETED

NCT01018719	Evaluation of Radiation Induced Toxicity to the Heart by Multi-detector Computed Tomography (MDCT)	https://beta.clinicaltrials.gov/study/NCT01018719		UNKNOWN
NCT03978819	ANI Parasympathetic Monitoring in Neurosurgery	https://beta.clinicaltrials.gov/study/NCT03978819	ANI	COMPLETED
NCT01143519	Study of the Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage	https://beta.clinicaltrials.gov/study/NCT01143519		COMPLETED
NCT04413487	Early Detection of Heart Problems in Cancer Patients Receiving Chemotherapy	https://beta.clinicaltrials.gov/study/NCT04413487		WITHDRAWN
NCT00215085	Cardiac Tumors in Children	https://beta.clinicaltrials.gov/study/NCT00215085		TERMINATED
NCT02471885	Effect of Remote Ischaemic Conditioning in Oncology Patients	https://beta.clinicaltrials.gov/study/NCT02471885	ERIC-ONC	UNKNOWN
NCT01572883	Effect of Concomitant Radiotherapy and Trastuzumab on Cardiotoxicity of Patients Treated for Early Breast Cancer	https://beta.clinicaltrials.gov/study/NCT01572883		COMPLETED
NCT01018927	Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects	https://beta.clinicaltrials.gov/study/NCT01018927		TERMINATED
NCT04409379	Association Between Telomere Length and Cardiac Dysfunction	https://beta.clinicaltrials.gov/study/NCT04409379		COMPLETED
NCT05159479	Defining Robust Predictors of Chemotherapy Related Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT05159479		RECRUITING
NCT01436604	Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin ®) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance Imaging	https://beta.clinicaltrials.gov/study/NCT01436604	MRTOX	TERMINATED
NCT01271127	Screening for Coronary Artery Disease After Mediastinal Irradiation	https://beta.clinicaltrials.gov/study/NCT01271127	SCAR	COMPLETED
NCT03785704	Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer	https://beta.clinicaltrials.gov/study/NCT03785704		RECRUITING
NCT01280227	Supporting Patient Provider Communication in Paediatric Care	https://beta.clinicaltrials.gov/study/NCT01280227	SiSom	COMPLETED
NCT02199366	Study of Cardiac MRI in Patients With Left-Sided Breast Cancer Receiving Radiation Therapy	https://beta.clinicaltrials.gov/study/NCT02199366		ACTIVE_NOT_RECRUITING
NCT00436566	Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery	https://beta.clinicaltrials.gov/study/NCT00436566		COMPLETED
NCT01758419	The Role of Myocardial SPECT in Evaluation of Irradiation-induced Changes.	https://beta.clinicaltrials.gov/study/NCT01758419		UNKNOWN
NCT05784766	Screening for Atrial Fibrillation in Patients With Cancer: A Pilot Randomized Controlled Clinical Trial	https://beta.clinicaltrials.gov/study/NCT05784766	SARIC	NOT_YET_RECRUITING
NCT01480219	Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patie	https://beta.clinicaltrials.gov/study/NCT01480219		COMPLETED
NCT02988219	Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method	https://beta.clinicaltrials.gov/study/NCT02988219		COMPLETED
NCT03164148	Heart Rate Variability (HRV) in Pituitary Adenoma	https://beta.clinicaltrials.gov/study/NCT03164148		UNKNOWN
NCT04726319	Family History App in Personalized Medicine	https://beta.clinicaltrials.gov/study/NCT04726319	FHAMe	ACTIVE_NOT_RECRUITING
NCT02688166	Cardiac MRI Biomarker Testing (GCC 1618)	https://beta.clinicaltrials.gov/study/NCT02688166		TERMINATED
NCT01082419	Acoustic Radiation Force Impulse Imaging (ARFI) : a New Technique to Assess Liver Elasticity	https://beta.clinicaltrials.gov/study/NCT01082419	NARFI	COMPLETED
NCT00782366	Predictive Genetic Risk Assessment Trial	https://beta.clinicaltrials.gov/study/NCT00782366	PGT	COMPLETED
NCT01724450	Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT01724450	Ceccy	COMPLETED
NCT04856267	Exploration of Arrhythmia Burden in Cardiac Amyloidosis Using Implantable Loop Recorders	https://beta.clinicaltrials.gov/study/NCT04856267	EXACLIBUR	RECRUITING
NCT01510743	Ultrasound Guided Central Vein Catheterization and Complications	https://beta.clinicaltrials.gov/study/NCT01510743		COMPLETED
NCT05635266	A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives	https://beta.clinicaltrials.gov/study/NCT05635266		RECRUITING
NCT03603366	Study to Evaluate How Patients Regard the Benefits and Risks of Low-dose Aspirin for the Prevention of Heart and Blood Vessels Disease and for the Prevention of Cancer of the Colon and Rectum	https://beta.clinicaltrials.gov/study/NCT03603366		COMPLETED
NCT01849614	Assessment of Ability of Breath Hold for Left-sided Breast Cancer Radiation Therapy to Reduce Side Effects to Heart	https://beta.clinicaltrials.gov/study/NCT01849614		COMPLETED
NCT03137537	Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.	https://beta.clinicaltrials.gov/study/NCT03137537		TERMINATED
NCT05934214	EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database	https://beta.clinicaltrials.gov/study/NCT05934214	EXIT	ACTIVE_NOT_RECRUITING
NCT05761314	Solid Tumors in RASopathies	https://beta.clinicaltrials.gov/study/NCT05761314	4218	RECRUITING
NCT02149914	The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients	https://beta.clinicaltrials.gov/study/NCT02149914		UNKNOWN
NCT04939883	Effects of Carvedilol on Cardiotoxicity in Cancer Patients Submitted to Anthracycline Therapy	https://beta.clinicaltrials.gov/study/NCT04939883	CardioTox	RECRUITING
NCT03760237	Cardiovascular Function in Acute Leukemia	https://beta.clinicaltrials.gov/study/NCT03760237		ENROLLING_BY_INVITATION
NCT00924937	CORonary Diet Intervention With Olive Oil and Cardiovascular PREVention	https://beta.clinicaltrials.gov/study/NCT00924937	CORDIOPREV	COMPLETED
NCT00779285	Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)	https://beta.clinicaltrials.gov/study/NCT00779285		TERMINATED
NCT00655447	Examining the Long-Term Risks of Oophorectomy	https://beta.clinicaltrials.gov/study/NCT00655447		COMPLETED
NCT02084147	PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases	https://beta.clinicaltrials.gov/study/NCT02084147		COMPLETED
NCT05594485	Retrospective Study of Carebot AI CXR Performance in Preclinical Practice	https://beta.clinicaltrials.gov/study/NCT05594485		COMPLETED
NCT04037319	Atrial Fibrillation After Surgery for Colorectal Cancer	https://beta.clinicaltrials.gov/study/NCT04037319	AFAR	RECRUITING
NCT03984019	Cardiac Changes After Stereotactic Radiotherapy for Early Stage NSCLC Cancer or Lung Metastasis	https://beta.clinicaltrials.gov/study/NCT03984019	HALO	TERMINATED
NCT04790266	Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients	https://beta.clinicaltrials.gov/study/NCT04790266	CARDIOTOX	RECRUITING
NCT05320406	RElugolix VErsus LeUprolide Cardiac Trial	https://beta.clinicaltrials.gov/study/NCT05320406	REVELUTION	RECRUITING
NCT00333008	A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.	https://beta.clinicaltrials.gov/study/NCT00333008		UNKNOWN
NCT03266809	CARdiac Function Evaluation in Breast Cancer Patients	https://beta.clinicaltrials.gov/study/NCT03266809	CARE-B	COMPLETED
NCT01152606	A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin	https://beta.clinicaltrials.gov/study/NCT01152606		COMPLETED
NCT02236806	Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab	https://beta.clinicaltrials.gov/study/NCT02236806	SAFE	ACTIVE_NOT_RECRUITING
NCT02550808	Metabolic Changes in Patients With Chronic Cardiopulmonary Disease	https://beta.clinicaltrials.gov/study/NCT02550808		UNKNOWN
NCT05690009	Real Clinical Practice Register of AlbUminuRia Detection in Patients With Previously undiAgnosed Chronic Kidney Disease	https://beta.clinicaltrials.gov/study/NCT05690009	AURA	RECRUITING
NCT01370109	Cardiovascular Effects of Sunitinib Therapy (CREST)	https://beta.clinicaltrials.gov/study/NCT01370109		COMPLETED
NCT05676606	Cardiotoxicity Monitoring With Single-lead Electrocardiogram	https://beta.clinicaltrials.gov/study/NCT05676606		RECRUITING
NCT04092309	Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation	https://beta.clinicaltrials.gov/study/NCT04092309		UNKNOWN

NCT00575406	Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma	https://beta.clinicaltrials.gov/study/NCT00575406	NHL-14	COMPLETED
NCT03269708	Improving Cardiac Secondary Prevention	https://beta.clinicaltrials.gov/study/NCT03269708		UNKNOWN
NCT00673608	Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload	https://beta.clinicaltrials.gov/study/NCT00673608		COMPLETED
NCT05595109	Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients	https://beta.clinicaltrials.gov/study/NCT05595109		ENROLLING_BY_INVITATION
NCT05575791	Evaluation of Preoperative Acceptance of Proactive Palliative Care Intervention	https://beta.clinicaltrials.gov/study/NCT05575791	iCare	RECRUITING
NCT04294108	Why in Hospital After VATS Lobectomy	https://beta.clinicaltrials.gov/study/NCT04294108		COMPLETED
NCT00590291	Molecular Determinants of Coronaruy Artery Disease	https://beta.clinicaltrials.gov/study/NCT00590291	GeneQuest	TERMINATED
NCT05507879	Characterization of TRPC6 to Predict and Prevent Chemotherapy Related Cardiac Toxicity and Heart Failure in Patients With Breast Cancer	https://beta.clinicaltrials.gov/study/NCT05507879		RECRUITING
NCT04810091	Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor	https://beta.clinicaltrials.gov/study/NCT04810091		RECRUITING
NCT02249520	Calibration of MR and PET-MR Imaging Protocols at RIC	https://beta.clinicaltrials.gov/study/NCT02249520		RECRUITING
NCT03243604	cARdiotoxicity Profile of aBIraTeRone in prostAte Cancer : a pharmacoviGilancE Study	https://beta.clinicaltrials.gov/study/NCT03243604	ARBITRAGE	COMPLETED
NCT05726604	4D CT Scan Versus 3D CT Scan Concerning Cardiac Dosimetry Assesment for Left Sided Breast Cancers Radiotherapy	https://beta.clinicaltrials.gov/study/NCT05726604	RD3D4	RECRUITING
NCT03221127	Kuopio Ischaemic Heart Disease Risk Factor Study (Nutrition Component)	https://beta.clinicaltrials.gov/study/NCT03221127		ACTIVE_NOT_RECRUITING
NCT03286127	Palliative Outcome Evaluation Muenster I	https://beta.clinicaltrials.gov/study/NCT03286127	POEM I	UNKNOWN
NCT05584163	Pilot Study to Evaluate the Prevention and Safety of Doxorubicin-induced Cardiomyopathy Using Extracorporeal Shock Waves	https://beta.clinicaltrials.gov/study/NCT05584163		RECRUITING
NCT03934905	Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction	https://beta.clinicaltrials.gov/study/NCT03934905		RECRUITING
NCT01135849	B-Receptor Signaling in Cardiomyopathy	https://beta.clinicaltrials.gov/study/NCT01135849		COMPLETED
NCT04199663	Socioeconomic Status, Secondary Prevention Activities and Recurrence After a Myocardial Infarction	https://beta.clinicaltrials.gov/study/NCT04199663		COMPLETED
NCT04150120	eHealth as an Aid for Facilitating and Supporting Self-management in Families With Long-term Childhood Illness	https://beta.clinicaltrials.gov/study/NCT04150120	eChildHealth	ENROLLING_BY_INVITATION
NCT00001620	Screening for Hematology Branch Protocols	https://beta.clinicaltrials.gov/study/NCT00001620		ENROLLING_BY_INVITATION
NCT03830320	Positron Emission Tomography (PET) Imaging of Thrombosis	https://beta.clinicaltrials.gov/study/NCT03830320		RECRUITING
NCT02440620	Cardiac Toxicity in Medical Treatment of Breast Cancer	https://beta.clinicaltrials.gov/study/NCT02440620	CaTOB	COMPLETED
NCT04466020	SELF - BREATHE for Chronic Breathlessness	https://beta.clinicaltrials.gov/study/NCT04466020		COMPLETED
NCT05377320	PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study	https://beta.clinicaltrials.gov/study/NCT05377320		NOT_YET_RECRUITING
NCT00005605	Tamoxifen to Prevent Bone Loss and Heart Disease in Premenopausal Women Receiving Chemotherapy for Stage I or Stage II Breast Cancer	https://beta.clinicaltrials.gov/study/NCT00005605		COMPLETED
NCT03935282	Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors	https://beta.clinicaltrials.gov/study/NCT03935282	AH-HA	ACTIVE_NOT_RECRUITING
NCT02780882	SOM230 Ectopic ACTH-producing Tumors	https://beta.clinicaltrials.gov/study/NCT02780882		WITHDRAWN
NCT00968682	CADY Study ICORG 08-01	https://beta.clinicaltrials.gov/study/NCT00968682		COMPLETED
NCT01758445	Proton Radiation for Stage II/III Breast Cancer	https://beta.clinicaltrials.gov/study/NCT01758445		ACTIVE_NOT_RECRUITING
NCT00460616	Cardiac Valve Complications in Prolactinomas Treated With Cabergoline	https://beta.clinicaltrials.gov/study/NCT00460616	ValveCab	COMPLETED
NCT04463316	GROWing Up With Rare GENEtic Syndromes	https://beta.clinicaltrials.gov/study/NCT04463316	GROW UR GEI	RECRUITING
NCT00790400	Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)	https://beta.clinicaltrials.gov/study/NCT00790400	EXIST-2	COMPLETED
NCT05775822	Coronary Artery Calcium and Cardiovascular Risk Factors Analysis After RT or Breast Cancer	https://beta.clinicaltrials.gov/study/NCT05775822	RadioTherapy	RECRUITING
NCT04026737	Cardiovascular Effects of CART Cell Therapy	https://beta.clinicaltrials.gov/study/NCT04026737	CVE-CART	COMPLETED
NCT01906437	Cardiac Fibrosis by CMR in Patients With Cancer	https://beta.clinicaltrials.gov/study/NCT01906437		WITHDRAWN
NCT00003937	Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma	https://beta.clinicaltrials.gov/study/NCT00003937		COMPLETED
NCT03678337	Prevention and Pharmacological Management of Cardiac Adverse Drug Reactions Induced by Drugs Used in Oncology.	https://beta.clinicaltrials.gov/study/NCT03678337	PICARO	UNKNOWN
NCT05786014	The Effects of Two Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic Chemotherapies	https://beta.clinicaltrials.gov/study/NCT05786014		NOT_YET_RECRUITING
NCT01462383	The Role of the EKG in Anticancer Drug Development	https://beta.clinicaltrials.gov/study/NCT01462383		COMPLETED
NCT04429633	Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer	https://beta.clinicaltrials.gov/study/NCT04429633		RECRUITING
NCT00633633	Lifestyle Intervention for Heart Failure	https://beta.clinicaltrials.gov/study/NCT00633633		ACTIVE_NOT_RECRUITING
NCT01262222	Patients Undergoing Major Cancer Surgery: Incidence and Predictive Value for Postoperative Cardiac Events	https://beta.clinicaltrials.gov/study/NCT01262222		COMPLETED
NCT00002900	SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial	https://beta.clinicaltrials.gov/study/NCT00002900		COMPLETED
NCT03206333	Automated Quantification of Coronary Artery Calcifications on Radiotherapy Planning CTs for Cardiovascular Risk Prediction in Breast Cancer Patients: the BRAGATSTON Study	https://beta.clinicaltrials.gov/study/NCT03206333		UNKNOWN
NCT01026233	Cardiac Safety Study of Brentuximab Vedotin (SGN-35)	https://beta.clinicaltrials.gov/study/NCT01026233		COMPLETED
NCT02677714	99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer	https://beta.clinicaltrials.gov/study/NCT02677714		TERMINATED
NCT01665300	Usefulness of Myocardial Deformation Imaging for Trastuzumab-induced Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT01665300		COMPLETED
NCT01892800	Right Side of Heart Function After Lung Surgery	https://beta.clinicaltrials.gov/study/NCT01892800		UNKNOWN
NCT01112800	Markers of Anthracycline-Related Cardiac Muscle Injury	https://beta.clinicaltrials.gov/study/NCT01112800		WITHDRAWN
NCT05064514	Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease	https://beta.clinicaltrials.gov/study/NCT05064514	TRICAR	ACTIVE_NOT_RECRUITING
NCT03836300	Parent-Infant Inter(X)Action Intervention (PIXI)	https://beta.clinicaltrials.gov/study/NCT03836300		ENROLLING_BY_INVITATION
NCT02536014	Effect of Dexmedetomidine on Heart-rate Corrected QT(QTc) Interval Prolongation During Robotic-assisted Laparoscopic Radical Prostatectomy -Randomized Blind Clinical Trial-	https://beta.clinicaltrials.gov/study/NCT02536014		COMPLETED
NCT03342300	Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma	https://beta.clinicaltrials.gov/study/NCT03342300	PDVPSTS	WITHDRAWN
NCT02789800	Patient-Centred Innovations for Persons With Multimorbidity - Quebec	https://beta.clinicaltrials.gov/study/NCT02789800	PACEinMM-QC	COMPLETED
NCT01968200	Prevention of Anthracycline-induced Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT01968200	ICOS-ONE	ACTIVE_NOT_RECRUITING

NCT05201014	Cancer Survivor Cardiomyopathy Detection	https://beta.clinicaltrials.gov/study/NCT05201014	CASCADE	RECRUITING
NCT01016756	Genetic Analysis of PHACE Syndrome (Hemangioma With Other Congenital Anomalies)	https://beta.clinicaltrials.gov/study/NCT01016756	PHACE	COMPLETED
NCT05184790	LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology	https://beta.clinicaltrials.gov/study/NCT05184790	LEARN	NOT_YET_RECRUITING
NCT01384097	An Algorithm for Intra-operative Goal-directed Haemodynamic Management in Non-cardiac Surgery	https://beta.clinicaltrials.gov/study/NCT01384097	ERAS_feasi	COMPLETED
NCT02742597	Patient-Centred Innovations for Persons With Multimorbidity - Ontario	https://beta.clinicaltrials.gov/study/NCT02742597	PACEinMM-ON	COMPLETED
NCT05040867	Exercise Prescription Guided by Heart Rate Variability in Breast Cancer Patients	https://beta.clinicaltrials.gov/study/NCT05040867		NOT_YET_RECRUITING
NCT04892667	Early Detection of Patients at Risk of Developing Anthracycline Cardiotoxicity With TEP/CT -FDG	https://beta.clinicaltrials.gov/study/NCT04892667	DETECT	RECRUITING
NCT01253590	Cardiac Monitoring of Post-Operative Cancer Patients Experiencing Atrial Fibrillation	https://beta.clinicaltrials.gov/study/NCT01253590		TERMINATED
NCT05110690	Behavioral Activation and Medication Optimization for Perioperative Mental Health	https://beta.clinicaltrials.gov/study/NCT05110690		COMPLETED
NCT02971397	Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	https://beta.clinicaltrials.gov/study/NCT02971397		UNKNOWN
NCT04630743	Cognitive and Behavioral Intervention for the Management of Episodic Breathlessness in Patients With Advanced Disease	https://beta.clinicaltrials.gov/study/NCT04630743	CoBeMEB	COMPLETED
NCT02275143	Computed Tomography (CT) Coronary Angiogram Evaluation in Cancer Patients Having CT Thorax, Abdomen and Pelvis	https://beta.clinicaltrials.gov/study/NCT02275143		COMPLETED
NCT02696707	An Integrated Consent Model Study to Compare Two Standard of Care Schedules for Monitoring Cardiac Function in Patients Receiving Trastuzumab for Early Stage Breast Cancer	https://beta.clinicaltrials.gov/study/NCT02696707	OTT 15-05	COMPLETED
NCT05094843	The Cardiac Stress and Electrocardiographic Changes Caused by Lung Cancer Surgery	https://beta.clinicaltrials.gov/study/NCT05094843		RECRUITING
NCT01554943	Late Cardiac Evaluation of the Three Arm Belgian Trial Involving Node-positive Early Breast Cancer Patients	https://beta.clinicaltrials.gov/study/NCT01554943		COMPLETED
NCT01044290	Outlook Quality of Life Intervention Study	https://beta.clinicaltrials.gov/study/NCT01044290		COMPLETED
NCT00955890	Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer	https://beta.clinicaltrials.gov/study/NCT00955890	cardioprotec	TERMINATED
NCT00710697	Cardiac Safety Assessment Study of Picoplatin in Solid Tumors	https://beta.clinicaltrials.gov/study/NCT00710697		UNKNOWN
NCT03450590	Heart Rate Variability and Cardiorespiratory Complications During Ophthalmic Arterial Chemotherapy for Retinoblastoma	https://beta.clinicaltrials.gov/study/NCT03450590		COMPLETED
NCT05078190	Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer	https://beta.clinicaltrials.gov/study/NCT05078190	CCT2	RECRUITING
NCT03181997	Outcomes of Transcatheter Aortic Valve Implantation in Oncology Patients With Severe Aortic Stenosis	https://beta.clinicaltrials.gov/study/NCT03181997	TOP-AS	COMPLETED
NCT02018497	Essential Hypotension and Allostasis Registry	https://beta.clinicaltrials.gov/study/NCT02018497	ESSENTIAL	ACTIVE_NOT_RECRUITING
NCT02943590	STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)	https://beta.clinicaltrials.gov/study/NCT02943590		ACTIVE_NOT_RECRUITING
NCT03038997	Early Detection of Cardiac Toxicity in Childhood Cancer Survivors	https://beta.clinicaltrials.gov/study/NCT03038997		TERMINATED
NCT02010190	Vascular Assessment in Adult Survivors of Childhood Cancer	https://beta.clinicaltrials.gov/study/NCT02010190		COMPLETED
NCT04242667	Penn Biobank Return of Research Results Program	https://beta.clinicaltrials.gov/study/NCT04242667		ENROLLING_BY_INVITATION
NCT00563407	Novel Surrogate Markers as Predictors of Radiation Toxicity in Breast Cancer Patients Undergoing Helical Tomotherapy Compared to Standard Radiation Therapy	https://beta.clinicaltrials.gov/study/NCT00563407		TERMINATED
NCT00806507	Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients	https://beta.clinicaltrials.gov/study/NCT00806507		COMPLETED
NCT03790943	Cardiac Dysfunction in Childhood Cancer Survivors	https://beta.clinicaltrials.gov/study/NCT03790943	Cardio-Onco	RECRUITING
NCT02922543	A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use	https://beta.clinicaltrials.gov/study/NCT02922543		COMPLETED
NCT02772367	Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients	https://beta.clinicaltrials.gov/study/NCT02772367		RECRUITING
NCT05063643	Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude	https://beta.clinicaltrials.gov/study/NCT05063643		NOT_YET_RECRUITING
NCT05867667	Cardiac Rehabilitation to Improve Breast Cancer Outcomes	https://beta.clinicaltrials.gov/study/NCT05867667	CRIBCO	NOT_YET_RECRUITING
NCT05010109	Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation	https://beta.clinicaltrials.gov/study/NCT05010109		RECRUITING
NCT05315908	COVID-19 Testing in Underserved and Vulnerable Populations	https://beta.clinicaltrials.gov/study/NCT05315908		TERMINATED
NCT05617391	An Evaluation of Concordance of Smartwatch ECG and One Clinical ECG and Comparison of The Two ECGS in Terms of Predictive Risks	https://beta.clinicaltrials.gov/study/NCT05617391		RECRUITING
NCT05001009	Goals of Care Conversations Study	https://beta.clinicaltrials.gov/study/NCT05001009	LSTDI	ENROLLING_BY_INVITATION
NCT04222608	The BRAvAdO Registry	https://beta.clinicaltrials.gov/study/NCT04222608	BRAvAdO	UNKNOWN
NCT04896242	Multimodal Assesment of Acute Cardiac Toxicity Induced by Thoracic Radiotherapy in Cancer Patients	https://beta.clinicaltrials.gov/study/NCT04896242		ACTIVE_NOT_RECRUITING
NCT05252065	Cardiac Substructure Radiation Dose and Early Clinical Monitoring of Stage N2-3 Non-Small Cell Lung Cancer	https://beta.clinicaltrials.gov/study/NCT05252065		NOT_YET_RECRUITING
NCT03492242	Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction	https://beta.clinicaltrials.gov/study/NCT03492242	CHIMeRA	COMPLETED
NCT01014065	A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect)	https://beta.clinicaltrials.gov/study/NCT01014065	SUPER	COMPLETED
NCT05019365	Investigating the Long-term Cardiac Sequelae of Trastuzumab Therapy	https://beta.clinicaltrials.gov/study/NCT05019365		RECRUITING
NCT04065165	Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome	https://beta.clinicaltrials.gov/study/NCT04065165	TELEFIRST	WITHDRAWN
NCT04547465	2D Speckle-tracking Echocardiography in Chemotherapy-induced Cardiomyopathy With Cardiovascular Risk Factors	https://beta.clinicaltrials.gov/study/NCT04547465		RECRUITING
NCT04118530	Long Term Arrhythmia Risk and Cardiovascular Events in Hematopoietic Stem Cell Transplant	https://beta.clinicaltrials.gov/study/NCT04118530	ARCHER	RECRUITING
NCT02220231	Echocardiographic Evaluation of the Change on Pulmonary Blood Flow and Cardiac Function Induced by Capnothorax During One Lung Ventilation	https://beta.clinicaltrials.gov/study/NCT02220231		COMPLETED
NCT03673631	Oxygenation Methods and Non-invasive Ventilation in Patients With Acute Respiratory Failure and a do Not Intubate Order	https://beta.clinicaltrials.gov/study/NCT03673631	OXYPAL	UNKNOWN
NCT04014231	Novel Single Wave Assessment in Measuring Cardiac Dysfunction and Metabolic Syndrome in Patients With Cancer	https://beta.clinicaltrials.gov/study/NCT04014231		ACTIVE_NOT_RECRUITING

NCT03862131	PROactive Evaluation of Function to Avoid CardioToxicity	https://beta.clinicaltrials.gov/study/NCT03862131	PROACT	TERMINATED
NCT03964142	Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT03964142	ONCORE	COMPLETED
NCT03437642	Psyhosomatic Medicine in Oncologic and Cardiac Disease Study	https://beta.clinicaltrials.gov/study/NCT03437642	PSYCHONIC	UNKNOWN
NCT02796365	Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via Chemotherapy	https://beta.clinicaltrials.gov/study/NCT02796365	HF-PROACTIV	COMPLETED
NCT03394365	Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab an	https://beta.clinicaltrials.gov/study/NCT03394365	ALLELE	RECRUITING
NCT00547365	Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction	https://beta.clinicaltrials.gov/study/NCT00547365		COMPLETED
NCT04680442	Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction	https://beta.clinicaltrials.gov/study/NCT04680442	SCHOLAR-2	RECRUITING
NCT04852965	Late Anthracycline Induced Cardiotoxicity- Childhood Cancer Survivors	https://beta.clinicaltrials.gov/study/NCT04852965		RECRUITING
NCT04262830	Cancer Therapy Effects on the Heart	https://beta.clinicaltrials.gov/study/NCT04262830	CTEH	RECRUITING
NCT03748030	Hybrid PET/MR Imaging of Acute Cardiac Inflammation After Left-Sided Breast Cancer Radiotherapy	https://beta.clinicaltrials.gov/study/NCT03748030	RICT-BREAST	UNKNOWN
NCT01809730	Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients	https://beta.clinicaltrials.gov/study/NCT01809730		WITHDRAWN
NCT05443321	Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes	https://beta.clinicaltrials.gov/study/NCT05443321		RECRUITING
NCT05724121	Observational Study of Cardiac Arrhythmias in Subjects Treated With BTK Inhibitors	https://beta.clinicaltrials.gov/study/NCT05724121		RECRUITING
NCT02975921	Betadine Pleurodesis Via Tunneled Pleural Catheters	https://beta.clinicaltrials.gov/study/NCT02975921		WITHDRAWN
NCT05705531	A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma	https://beta.clinicaltrials.gov/study/NCT05705531		NOT_YET_RECRUITING
NCT03981731	Management of Perioperative Anxiety by the Cardiac Coherence Technique Coupled With a Hypnosis Session	https://beta.clinicaltrials.gov/study/NCT03981731	COHEC	COMPLETED
NCT03510689	Genetics and Heart Health After Cancer Therapy	https://beta.clinicaltrials.gov/study/NCT03510689	Gene-HEART	COMPLETED
NCT02078388	Correlation Between Genetic Variants and Long-term Cardiac Effects Induced by Doxorubicin in Breast Cancer Patients	https://beta.clinicaltrials.gov/study/NCT02078388		UNKNOWN
NCT02250989	The Influence of Glycaemia and Insulinemia on Vasomotor Endothelial Function After Myocardial Infarction	https://beta.clinicaltrials.gov/study/NCT02250989	INGLIVEF	UNKNOWN
NCT05011721	Digital Phenotyping in Young Breast Cancer Patients Treated With Neoadjuvant Chemotherapy	https://beta.clinicaltrials.gov/study/NCT05011721	NeoFit	RECRUITING
NCT02907021	Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2	https://beta.clinicaltrials.gov/study/NCT02907021	SCHOLAR	COMPLETED
NCT04143230	Identification of In-hospital Patients in Need of Palliative Care Using a New Simplified Screening Tool	https://beta.clinicaltrials.gov/study/NCT04143230	SST2017	COMPLETED
NCT05130489	CAR T Cell Therapy Related Cardiovascular Outcomes	https://beta.clinicaltrials.gov/study/NCT05130489	CARTCO	COMPLETED
NCT02426788	CBT Plus SMC Compared to SMC for Persistent Physical Symptoms in Secondary Care (PRINCE)	https://beta.clinicaltrials.gov/study/NCT02426788	PRINCE	COMPLETED
NCT02096588	Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin	https://beta.clinicaltrials.gov/study/NCT02096588		ACTIVE_NOT_RECRUITING
NCT01904331	Breast Cancer Long-term Outcome of Cardiac Dysfunction	https://beta.clinicaltrials.gov/study/NCT01904331	BLOC	COMPLETED
NCT03694431	Comparative Trial of Home-Based Palliative Care	https://beta.clinicaltrials.gov/study/NCT03694431	HomePal	TERMINATED
NCT05869721	Effects of Yoga on Women With Breast Cancer	https://beta.clinicaltrials.gov/study/NCT05869721		RECRUITING
NCT00526331	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy	https://beta.clinicaltrials.gov/study/NCT00526331		COMPLETED
NCT02009631	A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors	https://beta.clinicaltrials.gov/study/NCT02009631		COMPLETED
NCT05465031	Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)	https://beta.clinicaltrials.gov/study/NCT05465031		NOT_YET_RECRUITING
NCT05945121	Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation	https://beta.clinicaltrials.gov/study/NCT05945121		NOT_YET_RECRUITING
NCT03431896	Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis	https://beta.clinicaltrials.gov/study/NCT03431896	MED-hATTR	RECRUITING
NCT02771795	A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC	https://beta.clinicaltrials.gov/study/NCT02771795		TERMINATED
NCT01574196	Assessment of Cardiac Autonomic Function in Adulthood After Chemotherapy or Radiotherapy in Childhood	https://beta.clinicaltrials.gov/study/NCT01574196	SALTO-SNA	COMPLETED
NCT02502396	Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center	https://beta.clinicaltrials.gov/study/NCT02502396		COMPLETED
NCT02541435	Acute and Long-term Cardiovascular Toxicity After Modern Radiotherapy for Breast Cancer	https://beta.clinicaltrials.gov/study/NCT02541435		RECRUITING
NCT04198896	The Sakakibara Health Integrative Profile of Atherosclerotic-Carcinogenesis Hypothesis (SHIP-AC)	https://beta.clinicaltrials.gov/study/NCT04198896	SHIP-AC	COMPLETED
NCT05927246	Radiotherapy-Associated Atrial Fibrillation	https://beta.clinicaltrials.gov/study/NCT05927246	RADAF	COMPLETED
NCT00939146	Outlook: An Intervention to Improve Quality of Life in Serious Illness	https://beta.clinicaltrials.gov/study/NCT00939146		COMPLETED
NCT03259438	The Vitality Project for Fatigued Female Cancer Survivors	https://beta.clinicaltrials.gov/study/NCT03259438		UNKNOWN
NCT03461588	Prospective Assessment of Radiation-induced Heart Injury in Left-sided Breast Cancer	https://beta.clinicaltrials.gov/study/NCT03461588		COMPLETED

NCT05923242	Translating ECHOS2 Into an mHealth Platform	https://beta.clinicaltrials.gov/study/NCT05923242	ECHOS2	RECRUITING
NCT05180942	Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS	https://beta.clinicaltrials.gov/study/NCT05180942	SOCRATES	RECRUITING
NCT04568161	Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses	https://beta.clinicaltrials.gov/study/NCT04568161		RECRUITING
NCT02471053	Exercise to Prevent AnthrCycline-based Cardio-Toxicity Study	https://beta.clinicaltrials.gov/study/NCT02471053	EXACT	COMPLETED
NCT05089461	A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor	https://beta.clinicaltrials.gov/study/NCT05089461		SUSPENDED
NCT03418961	S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer	https://beta.clinicaltrials.gov/study/NCT03418961		RECRUITING
NCT03505736	Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer	https://beta.clinicaltrials.gov/study/NCT03505736		COMPLETED
NCT03949634	Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)	https://beta.clinicaltrials.gov/study/NCT03949634		UNKNOWN
NCT03937934	Study Title: Food Rx	https://beta.clinicaltrials.gov/study/NCT03937934		COMPLETED
NCT05335928	Abatacept in Immune Checkpoint Inhibitor Myocarditis	https://beta.clinicaltrials.gov/study/NCT05335928	ATRIUM	RECRUITING
NCT03486340	Prevention of Chest Pain in Chemo-treated Cancer Patients	https://beta.clinicaltrials.gov/study/NCT03486340	CATCH	RECRUITING
NCT00500734	Cardiomyopathy Tissue Bank in a Cancer Population	https://beta.clinicaltrials.gov/study/NCT00500734		UNKNOWN
NCT04729634	Survey Of Mobilisation and Breathing Exercises After Thoracic and Abdominal Surgery	https://beta.clinicaltrials.gov/study/NCT04729634	SOMBATA	COMPLETED
NCT04755140	Endoprosthesis Metal Toxicity Study	https://beta.clinicaltrials.gov/study/NCT04755140		RECRUITING
NCT03474835	Ischemic Heart Disease in Male With Prostate Adenocarcinoma	https://beta.clinicaltrials.gov/study/NCT03474835		UNKNOWN
NCT00016276	Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer	https://beta.clinicaltrials.gov/study/NCT00016276		TERMINATED
NCT01093235	Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer	https://beta.clinicaltrials.gov/study/NCT01093235		UNKNOWN
NCT05643235	Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors	https://beta.clinicaltrials.gov/study/NCT05643235		RECRUITING
NCT01991340	H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast Cancer	https://beta.clinicaltrials.gov/study/NCT01991340		COMPLETED
NCT03498040	Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors	https://beta.clinicaltrials.gov/study/NCT03498040	CRUSOE-NETs	NOT_YET_RECRUITING
NCT00716898	Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients	https://beta.clinicaltrials.gov/study/NCT00716898		COMPLETED
NCT03039140	Cardiac Rehabilitation Program in Improving Cardiorespiratory Fitness in Stage 0-III Breast Cancer Survivors	https://beta.clinicaltrials.gov/study/NCT03039140		COMPLETED
NCT01896440	Heart Safety Study of Ondansetron in Children Receiving Chemotherapy	https://beta.clinicaltrials.gov/study/NCT01896440		WITHDRAWN
NCT04939857	Effect of Trimetazidine on Radiotherapy-induced Heart Damage.	https://beta.clinicaltrials.gov/study/NCT04939857		UNKNOWN
NCT03459898	Assessment of Left-sided Cardiac Sparing Through the Use of 3-dimensional Surface Matching-based Deep Inspiration Breath Hold and Active Breathing Control	https://beta.clinicaltrials.gov/study/NCT03459898		COMPLETED
NCT03934957	Hamburg City Health Study - a German Cohort Study	https://beta.clinicaltrials.gov/study/NCT03934957	HCHS	RECRUITING
NCT01772498	HRV Biofeedback for Brain Tumour Survivors	https://beta.clinicaltrials.gov/study/NCT01772498		SUSPENDED
NCT05132998	Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors	https://beta.clinicaltrials.gov/study/NCT05132998		COMPLETED
NCT05403736	Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial	https://beta.clinicaltrials.gov/study/NCT05403736	CARMA	ACTIVE_NOT_RECRUITING
NCT04047901	Effect of Physical Training in Patients With Heart Failure Caused by Chemotherapy for Cancer Treatment	https://beta.clinicaltrials.gov/study/NCT04047901		UNKNOWN
NCT00960401	A Study of Atherosclerosis in Patients After Radiation Treatment for Breast Cancer	https://beta.clinicaltrials.gov/study/NCT00960401	ABCART	UNKNOWN
NCT02984124	Communication During Hospitalization About Resuscitation Trial	https://beta.clinicaltrials.gov/study/NCT02984124	CHART	ACTIVE_NOT_RECRUITING
NCT03692624	Use of Heart Rate Variability (HRV) Biofeedback for Cancer Survivors	https://beta.clinicaltrials.gov/study/NCT03692624		COMPLETED
NCT04351880	Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge	https://beta.clinicaltrials.gov/study/NCT04351880		COMPLETED
NCT00827801	M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) Symptom Management Program	https://beta.clinicaltrials.gov/study/NCT00827801		COMPLETED
NCT03183180	Prevalence of Secondary Cardiac Damage in Rheumatic Fever Patients and Penicillin Secondary Prophylaxis	https://beta.clinicaltrials.gov/study/NCT03183180		UNKNOWN
NCT02920580	The NEUROlogically-impaired Extubation Timing Trial	https://beta.clinicaltrials.gov/study/NCT02920580	NEURO-ETT	UNKNOWN
NCT04073524	The Wild Man Programme - a Nature-based Rehabilitation Enhancing Quality of Life for Men on Long-term Sick Leave	https://beta.clinicaltrials.gov/study/NCT04073524		UNKNOWN
NCT03234101	Meta-Analyses of Low-risk Lifestyle Behaviours and Patient Important Outcomes	https://beta.clinicaltrials.gov/study/NCT03234101		UNKNOWN
NCT04407780	Cardio-Oncology Registry	https://beta.clinicaltrials.gov/study/NCT04407780	CONFUCIUS	RECRUITING
NCT00002624	Video-Assisted Surgery Followed by Radiation Therapy in Treating Patients With Stage I Non-small Cell Lung Cancer and Poor Heart and Lung Function	https://beta.clinicaltrials.gov/study/NCT00002624		COMPLETED
NCT03923036	Anticancer Vigilance Of Cardiac Events (AVOCETTE) in Metastatic Colorectal Cancer	https://beta.clinicaltrials.gov/study/NCT03923036	AVOCETTE	UNKNOWN
NCT04562636	Evaluating a Messaging Campaign in the United States	https://beta.clinicaltrials.gov/study/NCT04562636		COMPLETED
NCT05718128	Clinical Study of Endocardial Myocardial Biopsy	https://beta.clinicaltrials.gov/study/NCT05718128		RECRUITING
NCT04674501	Radiotherapy for Thoracic and Breast Cancer and the Related Cardiotoxicity Following Treatment (RACCOON)	https://beta.clinicaltrials.gov/study/NCT04674501		UNKNOWN
NCT05068180	Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients	https://beta.clinicaltrials.gov/study/NCT05068180		RECRUITING
NCT01446224	Cardiovascular and Torsades de Pointes Monitoring for Pazopanib	https://beta.clinicaltrials.gov/study/NCT01446224		COMPLETED
NCT05718401	The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based Metabolomics	https://beta.clinicaltrials.gov/study/NCT05718401		ENROLLING_BY_INVITATION
NCT02274480	Diffusion Weighted Imaging as a Biomarker for Detection of Chemotherapy Induced Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT02274480		COMPLETED
NCT05209880	Advance Care Planning in the Emergency Department	https://beta.clinicaltrials.gov/study/NCT05209880		RECRUITING
NCT01741480	Early Warning System	https://beta.clinicaltrials.gov/study/NCT01741480		COMPLETED
NCT04826601	The Physical and Psychologic Effects of Aromatherapy in Cancer Patients During Chemotherapy	https://beta.clinicaltrials.gov/study/NCT04826601		UNKNOWN
NCT01627080	Cardiac Biomarker Study in Esophageal Cancer Patients Treated With Chemotherapy and Radiation	https://beta.clinicaltrials.gov/study/NCT01627080		WITHDRAWN

NCT02794324	The HeartSpare Study (Stage I)	https://beta.clinicaltrials.gov/study/NCT02794324		COMPLETED
NCT03333824	Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer	https://beta.clinicaltrials.gov/study/NCT03333824		COMPLETED
NCT01110824	Prevention of Left Ventricular Dysfunction During Chemotherapy	https://beta.clinicaltrials.gov/study/NCT01110824	OVERCOME	COMPLETED
NCT03930680	Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane	https://beta.clinicaltrials.gov/study/NCT03930680	PHOENIX1	RECRUITING
NCT02955524	Topical Anesthesia and Intra-arterial Chemotherapy for Retinoblastoma	https://beta.clinicaltrials.gov/study/NCT02955524	TOPIAC	WITHDRAWN
NCT00530101	The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT00530101		COMPLETED
NCT05150080	Early Identification and Evaluation of Cyclophosphamide Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT05150080	EIECC	RECRUITING
NCT03389724	Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia	https://beta.clinicaltrials.gov/study/NCT03389724		COMPLETED
NCT01434134	Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy	https://beta.clinicaltrials.gov/study/NCT01434134	PRADA	COMPLETED
NCT03177928	Cardiac Changes in Myeloproliferative Neoplasms	https://beta.clinicaltrials.gov/study/NCT03177928		UNKNOWN
NCT01857141	Comparative Study on the Effects of Epidural Dexmedetomidine on Heart Rate Variability During General Anesthesia in Patients Undergoing Gastrectomy	https://beta.clinicaltrials.gov/study/NCT01857141		COMPLETED
NCT02921828	A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg	https://beta.clinicaltrials.gov/study/NCT02921828		COMPLETED
NCT01805778	Preventing Cardiac Sequelae in Pediatric Cancer Survivors	https://beta.clinicaltrials.gov/study/NCT01805778	PCS2	COMPLETED
NCT03727958	Simultaneous Coronary Artery Evaluation and Lung Cancer CT Screening	https://beta.clinicaltrials.gov/study/NCT03727958	SIMULTANEOU	UNKNOWN
NCT04291378	The DBCG Proton Trial: Photon Versus Proton Radiation Therapy for Early Breast Cancer	https://beta.clinicaltrials.gov/study/NCT04291378		RECRUITING
NCT04461223	Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR	https://beta.clinicaltrials.gov/study/NCT04461223		UNKNOWN
NCT00164658	Evaluating Tools for Health Promotion and Disease Prevention	https://beta.clinicaltrials.gov/study/NCT00164658		COMPLETED
NCT00005578	Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease	https://beta.clinicaltrials.gov/study/NCT00005578		COMPLETED
NCT05454878	Atrial Fibrillation Monitoring on Patients With Lymphoma After Chemotherapy	https://beta.clinicaltrials.gov/study/NCT05454878		NOT_YET_RECRUITING
NCT04939558	Cardiorespiratory Diagnostic Study	https://beta.clinicaltrials.gov/study/NCT04939558	CARES	COMPLETED
NCT04894123	Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients	https://beta.clinicaltrials.gov/study/NCT04894123		RECRUITING
NCT05338723	Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients	https://beta.clinicaltrials.gov/study/NCT05338723		RECRUITING
NCT00575523	Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy	https://beta.clinicaltrials.gov/study/NCT00575523	atropinePEI	COMPLETED
NCT05718284	High Flow Nasal Cannula After Esophagectomy	https://beta.clinicaltrials.gov/study/NCT05718284	OSSIGENA1V	RECRUITING
NCT02348684	Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation	https://beta.clinicaltrials.gov/study/NCT02348684		COMPLETED
NCT04281784	Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)	https://beta.clinicaltrials.gov/study/NCT04281784	PICSI-H	COMPLETED
NCT03737084	Effects of Compassion Training to Patients Undergoing HSCT on Biological and Psychosocial Parameters	https://beta.clinicaltrials.gov/study/NCT03737084		COMPLETED
NCT02132884	Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer	https://beta.clinicaltrials.gov/study/NCT02132884		TERMINATED
NCT01259284	Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer	https://beta.clinicaltrials.gov/study/NCT01259284		TERMINATED
NCT01671696	Defining Late Onset Occult Asymptomatic Cardiotoxicity in Childhood Cancer Survivors Exposed to Anthracycline Therapy	https://beta.clinicaltrials.gov/study/NCT01671696		ACTIVE_NOT_RECRUITING
NCT03882580	Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care	https://beta.clinicaltrials.gov/study/NCT03882580	NEOCARDIO	RECRUITING
NCT03448757	Determination of Autonomic Responses to the Exposure of Low Energy Electromagnetic Fields With Frequency Modulation in Patients With Advanced Hepatocellular Carcinoma and Healthy Individuals.	https://beta.clinicaltrials.gov/study/NCT03448757		UNKNOWN
NCT00577798	Cardiac Magnetic Resonance Imaging in Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin	https://beta.clinicaltrials.gov/study/NCT00577798		COMPLETED
NCT00002657	SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant	https://beta.clinicaltrials.gov/study/NCT00002657		COMPLETED
NCT01301040	Early Cardiac Toxicity of Adjuvant CT in Elderly BC.	https://beta.clinicaltrials.gov/study/NCT01301040		TERMINATED
NCT04361240	Cardiotoxicity in Breast Cancer Patients Treated With Proton or Photon Radiotherapy: A RadComp Ancillary Study	https://beta.clinicaltrials.gov/study/NCT04361240		ENROLLING_BY_INVITATION
NCT02086695	Early Detection of Broken Hearts in Cancer Patients	https://beta.clinicaltrials.gov/study/NCT02086695	ASPER	COMPLETED
NCT03971344	Impact of Serious Pediatric Illness on Parent and Sibling Health	https://beta.clinicaltrials.gov/study/NCT03971344		COMPLETED
NCT04820569	Long-term Heart-specific Mortality in the Presence of Competing Risks Among Patients With Non-metastatic Gastric Adenocarcinoma Undergoing Resection and Chemotherapy	https://beta.clinicaltrials.gov/study/NCT04820569	GaCCoR-01	COMPLETED
NCT05777369	R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma	https://beta.clinicaltrials.gov/study/NCT05777369		NOT_YET_RECRUITING
NCT04291235	The NEUROlogically-impaired Extubation Timing Trial (NEURO-ETT)	https://beta.clinicaltrials.gov/study/NCT04291235		UNKNOWN
NCT02004834	Levobupivacaine and Lidocaine for Paravertebral Block Causes Greater Hemodynamic Oscillations Than Levobupivacaine	https://beta.clinicaltrials.gov/study/NCT02004834		ACTIVE_NOT_RECRUITING
NCT00590434	Yield and Safety of Colonoscopy in Patients Older Than 80 Years	https://beta.clinicaltrials.gov/study/NCT00590434		COMPLETED
NCT02130934	Cardiac 3D MRI in Pediatric Cancer Patients	https://beta.clinicaltrials.gov/study/NCT02130934		WITHDRAWN
NCT05819528	Primary Cardiac Lymphoma: Italian Multicenter Experience	https://beta.clinicaltrials.gov/study/NCT05819528		NOT_YET_RECRUITING
NCT02654340	Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)	https://beta.clinicaltrials.gov/study/NCT02654340	TuScCom	TERMINATED
NCT05900544	Maximizing Benefit of Lung Cancer Screening Incidental Findings of Cardiovascular, Respiratory and Breast Measures	https://beta.clinicaltrials.gov/study/NCT05900544		NOT_YET_RECRUITING
NCT04094974	Heartrate Variability and Intraoperative Brain Conditions in Supratentorial Tumors	https://beta.clinicaltrials.gov/study/NCT04094974		COMPLETED
NCT04395495	RASopathy Biorepository	https://beta.clinicaltrials.gov/study/NCT04395495		RECRUITING
NCT04331535	The Genomic Medicine at VA Study	https://beta.clinicaltrials.gov/study/NCT04331535	GenoVA	RECRUITING
NCT04260269	Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study	https://beta.clinicaltrials.gov/study/NCT04260269	CardioSwitch	ENROLLING_BY_INVITATION
NCT04325269	Continuous Ambulatory ECG Monitoring for Detection of Postoperative Atrial Fibrillation Following Thoracic Surgery	https://beta.clinicaltrials.gov/study/NCT04325269		UNKNOWN
NCT00000611	Women's Health Initiative (WHI)	https://beta.clinicaltrials.gov/study/NCT00000611		COMPLETED
NCT05223413	REmote iSchemic condItioning in Lymphoma Patients REceiving ANthraCyclinEs	https://beta.clinicaltrials.gov/study/NCT05223413	RESILIENCE	RECRUITING
NCT00532064	Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy	https://beta.clinicaltrials.gov/study/NCT00532064		TERMINATED
NCT04928261	Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy	https://beta.clinicaltrials.gov/study/NCT04928261		ACTIVE_NOT_RECRUITING
NCT04652973	Evaluation of Atherosclerotic Plaques in Abdominal CT Studies	https://beta.clinicaltrials.gov/study/NCT04652973		ACTIVE_NOT_RECRUITING

NCT05833360	Prospective Study of oncRNA Stratification of Cancer by Size and Stage	https://beta.clinicaltrials.gov/study/NCT05833360		NOT_YET_RECRUITING
NCT02136277	Vascular Changes During Colorectal Surgery	https://beta.clinicaltrials.gov/study/NCT02136277	MaMiFlo	UNKNOWN
NCT04746729	Health Effects of CArdiac FluoRoscopy and MOderN Radiotherapy in PediatriCs - Radiotherapy	https://beta.clinicaltrials.gov/study/NCT04746729	HARMONIC-R	RECRUITING
NCT03781661	Providing Patient Information and CT Examination Results	https://beta.clinicaltrials.gov/study/NCT03781661	INFOCT	COMPLETED
NCT01658553	A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	https://beta.clinicaltrials.gov/study/NCT01658553		COMPLETED
NCT02874664	A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer	https://beta.clinicaltrials.gov/study/NCT02874664		COMPLETED
NCT04461561	Using NPT to Evaluate Providing PPC as ELNEC-PPC WBT for Nurses	https://beta.clinicaltrials.gov/study/NCT04461561	ELNEC-PPC	UNKNOWN
NCT04867564	Radiation-induced Cardiac Toxicity After Non-small Cell Lung Cancer Radiotherapy	https://beta.clinicaltrials.gov/study/NCT04867564		RECRUITING
NCT02815553	Cardiac Tumors Interventional （Radio Frequency/Laser Ablation）Therapy	https://beta.clinicaltrials.gov/study/NCT02815553	CTIH	RECRUITING
NCT02962661	Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines	https://beta.clinicaltrials.gov/study/NCT02962661		RECRUITING
NCT02472353	Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer	https://beta.clinicaltrials.gov/study/NCT02472353		TERMINATED
NCT04885088	Smart Home Care of Cloud Base ECG on the Cardiotoxicity Prevention on the Cancer Patients.	https://beta.clinicaltrials.gov/study/NCT04885088	AI	UNKNOWN
NCT05806138	A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction	https://beta.clinicaltrials.gov/study/NCT05806138		NOT_YET_RECRUITING
NCT05184088	Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis	https://beta.clinicaltrials.gov/study/NCT05184088	CArdiag	RECRUITING
NCT00799188	CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial	https://beta.clinicaltrials.gov/study/NCT00799188	CERTICOEUR	UNKNOWN
NCT04669730	Baduanjin Exercise on Meridian Energy, Lung Function and Heart Rate Variability in Patients Undergoing Lung Operative.	https://beta.clinicaltrials.gov/study/NCT04669730		UNKNOWN
NCT02079272	REBECCA Study (RadiothErapy for BrEast Cancer and CArdiotoxicity)	https://beta.clinicaltrials.gov/study/NCT02079272	REBECCA	WITHDRAWN
NCT04044872	Hyperpolarized Carbon 13-Based Metabolic Imaging to Detect Radiation-Induced Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT04044872		ACTIVE_NOT_RECRUITING
NCT05271162	Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines	https://beta.clinicaltrials.gov/study/NCT05271162	EMPACT	NOT_YET_RECRUITING
NCT03750110	Yorkshire Enhanced Stop Smoking Study	https://beta.clinicaltrials.gov/study/NCT03750110	YESS	COMPLETED
NCT04718610	Heart Rate Variability, Vagus Nerve and Cancer	https://beta.clinicaltrials.gov/study/NCT04718610		UNKNOWN
NCT01425710	Non-invasive Evaluation of Fluid Status and Cardiac Output During Operative Treatment of Pheochromcytoma	https://beta.clinicaltrials.gov/study/NCT01425710		COMPLETED
NCT05414162	Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy	https://beta.clinicaltrials.gov/study/NCT05414162		RECRUITING
NCT03711110	Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)	https://beta.clinicaltrials.gov/study/NCT03711110	CARTIER	RECRUITING
NCT04030546	Ivabradine to Prevent Anthracycline-induced Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT04030546		UNKNOWN
NCT01219010	A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma	https://beta.clinicaltrials.gov/study/NCT01219010		COMPLETED
NCT01110031	Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects	https://beta.clinicaltrials.gov/study/NCT01110031		COMPLETED
NCT04275830	The Effects of Heart Rate Variability Biofeedback Training on Hematopoietic Cell Transplantation Patients	https://beta.clinicaltrials.gov/study/NCT04275830		COMPLETED
NCT04995848	Telepalliation - Digital Platform for Patients in Palliation and Their Relatives	https://beta.clinicaltrials.gov/study/NCT04995848		RECRUITING
NCT03866148	Obstructive Sleep Apnoea and Cardiac Arrhythmias	https://beta.clinicaltrials.gov/study/NCT03866148	OSCA	ACTIVE_NOT_RECRUITING
NCT01531751	High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease	https://beta.clinicaltrials.gov/study/NCT01531751	DIACAL	WITHDRAWN
NCT01280825	The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing	https://beta.clinicaltrials.gov/study/NCT01280825		RECRUITING
NCT01956773	Family Health History in Diverse Care Settings (FHH)	https://beta.clinicaltrials.gov/study/NCT01956773	FHH	COMPLETED
NCT03505164	The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor	https://beta.clinicaltrials.gov/study/NCT03505164		COMPLETED
NCT00019864	Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma	https://beta.clinicaltrials.gov/study/NCT00019864		TERMINATED
NCT02123173	Hemodynamic Changes During One Lung Ventilation in Non-intubated Vedio-assisted Thoracoscopic Operations	https://beta.clinicaltrials.gov/study/NCT02123173		COMPLETED
NCT01698164	Multi-centre Clinical Trial on Hormone Replacement Treatment in China	https://beta.clinicaltrials.gov/study/NCT01698164		UNKNOWN
NCT05132673	Cardiac Autonomic Dysfunction in Childhood Cancer Survivors	https://beta.clinicaltrials.gov/study/NCT05132673		SUSPENDED
NCT01071473	Resistance and Aerobic Exercise for Subclinical Anthracycline Cardiomyopathy	https://beta.clinicaltrials.gov/study/NCT01071473		COMPLETED
NCT05559164	Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted	https://beta.clinicaltrials.gov/study/NCT05559164		RECRUITING
NCT02841046	The Effect of Goal-directed Therapy Guided by Stroke Volume Variation and Cardiac Index in Non-severe Surgical Patients	https://beta.clinicaltrials.gov/study/NCT02841046		COMPLETED
NCT02951273	Cerebral Blood Flow During Propofol Anaesthesia	https://beta.clinicaltrials.gov/study/NCT02951273		COMPLETED
NCT00561977	Cancer Dietary Objectives Study	https://beta.clinicaltrials.gov/study/NCT00561977	CanDo	COMPLETED
NCT03589729	Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers	https://beta.clinicaltrials.gov/study/NCT03589729		RECRUITING
NCT01560260	Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors	https://beta.clinicaltrials.gov/study/NCT01560260		COMPLETED
NCT00861029	VEG111485: A QTc Study of Pazopanib	https://beta.clinicaltrials.gov/study/NCT00861029		COMPLETED
NCT05750953	Nurse-assisted Intervention "eHealth@ Hospital -2-home"	https://beta.clinicaltrials.gov/study/NCT05750953	Ehealth@H2H	NOT_YET_RECRUITING
NCT05444062	Quebec Lung Cancer Screening PLUS Trial	https://beta.clinicaltrials.gov/study/NCT05444062	QLC+	NOT_YET_RECRUITING
NCT00094562	A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss	https://beta.clinicaltrials.gov/study/NCT00094562		COMPLETED
NCT01719562	MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum	https://beta.clinicaltrials.gov/study/NCT01719562		COMPLETED
NCT04486573	Cardiac Effects From Radiation Therapy by MRI	https://beta.clinicaltrials.gov/study/NCT04486573		RECRUITING
NCT05596760	Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers	https://beta.clinicaltrials.gov/study/NCT05596760	PICSI-M	NOT_YET_RECRUITING
NCT02496260	Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy	https://beta.clinicaltrials.gov/study/NCT02496260		COMPLETED
NCT00420160	Does Moderate Intensity Exercise Help Prevent Smoking Relapse Among Women?	https://beta.clinicaltrials.gov/study/NCT00420160		COMPLETED
NCT04392960	Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis	https://beta.clinicaltrials.gov/study/NCT04392960		RECRUITING
NCT01874561	Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization	https://beta.clinicaltrials.gov/study/NCT01874561		COMPLETED
NCT04066153	Patient Reported Unmet Needs for Function and Supportive Occupational- and Physiotherapy Rehabilitation Interventions	https://beta.clinicaltrials.gov/study/NCT04066153		COMPLETED
NCT01782053	Communicating Smoking Risks Through Graphic Warning Labels	https://beta.clinicaltrials.gov/study/NCT01782053		COMPLETED
NCT05595577	Improving Exercise Capacity With a Tailored Physical Activity Intervention	https://beta.clinicaltrials.gov/study/NCT05595577	PALS	RECRUITING
NCT04670094	Comorbidities and Risk Score in COVID-19 Patients	https://beta.clinicaltrials.gov/study/NCT04670094	Comorbidities	COMPLETED
NCT04283994	Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)	https://beta.clinicaltrials.gov/study/NCT04283994	PICSI-H	RECRUITING
NCT04182594	Cardiovascular Events in GnRH Agonist vs. Antagonist	https://beta.clinicaltrials.gov/study/NCT04182594		UNKNOWN
NCT03879629	TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol	https://beta.clinicaltrials.gov/study/NCT03879629	TACTIC	RECRUITING

NCT00728429	Aerobic Exercise in Patients Receiving Chemotherapy for Cancer	https://beta.clinicaltrials.gov/study/NCT00728429		TERMINATED
NCT00441077	Interventions to Educate An Underserved Population About Inherited Disease Risks	https://beta.clinicaltrials.gov/study/NCT00441077		COMPLETED
NCT02939729	Physiotherapy Prehabilitation in Patients Undergoing Cardiac or Thoracic Surgery	https://beta.clinicaltrials.gov/study/NCT02939729		COMPLETED
NCT01672294	Caregiver Outlook: An Intervention to Improve Caregiving in Serious Illness	https://beta.clinicaltrials.gov/study/NCT01672294		COMPLETED
NCT04036032	Role of Aerobic Exercise to Modulate Cardiotoxicity in Long Term Cancer Survivors Exposed to Anthracycline Therapy	https://beta.clinicaltrials.gov/study/NCT04036032		ACTIVE_NOT_RECRUITING
NCT05478018	Type 1 Interferon Induced Changes to Exercise Adaptations in Systemic Lupus Erythematosus Patients	https://beta.clinicaltrials.gov/study/NCT05478018	LUPEX	RECRUITING
NCT03089502	Efficacy of Cardio-Oncology Rehabilitation Exercise for Women With Breast Cancer and Treatment Related Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT03089502	CORE	TERMINATED
NCT03516994	Reducing Disparities in the Quality of Advance Care Planning for Older Adults	https://beta.clinicaltrials.gov/study/NCT03516994	EQUALACP	ENROLLING_BY_INVITATION
NCT02404818	Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Treated With Radiation Therapy	https://beta.clinicaltrials.gov/study/NCT02404818		COMPLETED
NCT01948232	Pilot Study of Perindopril in Childhood Cancer Survivors	https://beta.clinicaltrials.gov/study/NCT01948232		WITHDRAWN
NCT04183218	Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes in Non-metastatic, Non-recurrent Lung and Esophageal Cancer Patients	https://beta.clinicaltrials.gov/study/NCT04183218		ACTIVE_NOT_RECRUITING
NCT02921802	A Study of Special Use Results Surveillance of Revlimid 5mg Capsules	https://beta.clinicaltrials.gov/study/NCT02921802		COMPLETED
NCT04510532	Early Detection of CMP in Patients With Breast Cancer Using Cardiac Magnetic Resonance	https://beta.clinicaltrials.gov/study/NCT04510532		RECRUITING
NCT00688532	Study of Coronary Heart Disease (CHD) & Heart Failure (HF) Risk in Prostate Cancer Patients, Taking Casodex or Not	https://beta.clinicaltrials.gov/study/NCT00688532		COMPLETED
NCT05930418	Cardiovascular Magnetic Resonance Prognosticators in Pediatric Oncology Patients With Sepsis	https://beta.clinicaltrials.gov/study/NCT05930418		RECRUITING
NCT00705094	Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients	https://beta.clinicaltrials.gov/study/NCT00705094		COMPLETED
NCT03559894	Severe and Transient Hypoxemia During Selective Intra-arterial Chemotherapy for Retinoblastoma in Children: Evaluation of the Right-sided Heart Function.	https://beta.clinicaltrials.gov/study/NCT03559894		UNKNOWN
NCT00735618	Relaxation and Heart Rate Variability	https://beta.clinicaltrials.gov/study/NCT00735618		COMPLETED
NCT00627029	Evaluation of Programs of Coordinated Care and Disease Management	https://beta.clinicaltrials.gov/study/NCT00627029	Coca	UNKNOWN
NCT00620529	The Effects of Fish Oils on Blood Pressure, Heart Rate Variability and Liver Fat in the Polycystic Ovary Syndrome	https://beta.clinicaltrials.gov/study/NCT00620529	fops	COMPLETED
NCT04822077	Study on Proton Radiotherapy of Thymic Malignancies	https://beta.clinicaltrials.gov/study/NCT04822077	PROTHYM	RECRUITING
NCT02626377	Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté	https://beta.clinicaltrials.gov/study/NCT02626377	ICE	TERMINATED
NCT01719094	RITHM - Resonance Imaging Trial for Heart Biomarkers in Adolescent/Young (AYA) Cancer Survivors	https://beta.clinicaltrials.gov/study/NCT01719094		COMPLETED
NCT01050829	Gadobutrol Magnevist-controlled Body Study	https://beta.clinicaltrials.gov/study/NCT01050829		COMPLETED
NCT02077218	Computed Tomography and Biomarker Analysis in Diagnosing Coronary Artery Disease in Asymptomatic Patients Who Have Undergone Stem Cell Transplant	https://beta.clinicaltrials.gov/study/NCT02077218		COMPLETED
NCT00005418	Epidemiology of Cardiotoxicity in Children With Cancer	https://beta.clinicaltrials.gov/study/NCT00005418		COMPLETED
NCT05539794	Exercise and Lifestyle in Adolescent Cancer (HEALTHYADOL)	https://beta.clinicaltrials.gov/study/NCT05539794	HEALTHYADOI	RECRUITING
NCT05728632	Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines	https://beta.clinicaltrials.gov/study/NCT05728632	CONTROL	ACTIVE_NOT_RECRUITING
NCT05796518	Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors	https://beta.clinicaltrials.gov/study/NCT05796518		RECRUITING
NCT03660618	LSFG-SKIN, Laser Speckle Flowgraphy	https://beta.clinicaltrials.gov/study/NCT03660618		TERMINATED
NCT02044718	Medical Record Study on Adverse Events Requiring a Higher Level of Care in Flemish Hospitals	https://beta.clinicaltrials.gov/study/NCT02044718		COMPLETED
NCT05587023	Effect of Ultrasound-guided Left Stellate Ganglion Block on Rapid Recovery of Patients Undergoing Cardiac Valve Replacement and Its Mechanism	https://beta.clinicaltrials.gov/study/NCT05587023		ACTIVE_NOT_RECRUITING
NCT04916223	Study to Determine Therapeutic Massage Dosing to Improve Quality of Life in Hospitalized Patients Receiving Palliative Care	https://beta.clinicaltrials.gov/study/NCT04916223		COMPLETED
NCT02897778	Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors	https://beta.clinicaltrials.gov/study/NCT02897778		COMPLETED
NCT01105923	Study of an Intervention to Improve Problem List Accuracy and Use	https://beta.clinicaltrials.gov/study/NCT01105923	MAPLE	UNKNOWN
NCT03904732	Study to Develop a Prediction Model to Understand the Effect of Low-dose Aspirin on Cancer That Develops in the Colon and/or the Rectum, Diseases That Affects the Heart or Blood Vessels and Safety Outcomes in Europe	https://beta.clinicaltrials.gov/study/NCT03904732	PEACOCS	COMPLETED
NCT01009918	Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab	https://beta.clinicaltrials.gov/study/NCT01009918		COMPLETED
NCT01225978	Refining Information Technology Support for Genetics in Medicine	https://beta.clinicaltrials.gov/study/NCT01225978	RISGIM	UNKNOWN
NCT01370278	Clearance Of Mucus In Stents (COMIS)	https://beta.clinicaltrials.gov/study/NCT01370278		ACTIVE_NOT_RECRUITING
NCT05200078	Deep Inspiration Breath-hold Radiotherapy for Left-sided Breast Cancer	https://beta.clinicaltrials.gov/study/NCT05200078		RECRUITING
NCT03474458	A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy	https://beta.clinicaltrials.gov/study/NCT03474458		ACTIVE_NOT_RECRUITING
NCT03885258	Melatonin Replacement Therapy in Pinealectomized Patients	https://beta.clinicaltrials.gov/study/NCT03885258		COMPLETED
NCT01742702	HaemoDYNAMICs in Primary and Secondary Hypertension	https://beta.clinicaltrials.gov/study/NCT01742702	DYNAMIC	RECRUITING
NCT02052102	Study to See Whether Breath-Hold Techniques During RT Are Effective in Helping to Improve Sparing of the Heart	https://beta.clinicaltrials.gov/study/NCT02052102		UNKNOWN
NCT02858778	Timing of Acute Palliative Care Consultation in Critically Ill Patients	https://beta.clinicaltrials.gov/study/NCT02858778		UNKNOWN
NCT01032278	Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)	https://beta.clinicaltrials.gov/study/NCT01032278		UNKNOWN
NCT04298372	Frontline Lenalidomide for AL Amyloidosis Involving Myocardium	https://beta.clinicaltrials.gov/study/NCT04298372		UNKNOWN
NCT05298072	Identification of Novel Inflammation-related Biomarkers for Early Detection of Anthracycline-induced Cardiotoxicity in Breast Cancer Patients	https://beta.clinicaltrials.gov/study/NCT05298072		NOT_YET_RECRUITING
NCT03760588	Prevention of Cardiac Dysfunction During Breast Cancer Therapy	https://beta.clinicaltrials.gov/study/NCT03760588	PRADAII	ACTIVE_NOT_RECRUITING
NCT03886155	Cardiac Amyloidosis Screening at Trigger Finger Release	https://beta.clinicaltrials.gov/study/NCT03886155	CAST	COMPLETED
NCT03940625	Anthracycline Induced Cardiotoxicity - Early Detection by Combination of Diastolic Strain and T2-mapping	https://beta.clinicaltrials.gov/study/NCT03940625	ANKE	COMPLETED
NCT05473325	Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)	https://beta.clinicaltrials.gov/study/NCT05473325	BRANCH-P	NOT_YET_RECRUITING
NCT04962425	Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients	https://beta.clinicaltrials.gov/study/NCT04962425		UNKNOWN
NCT00342992	Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study	https://beta.clinicaltrials.gov/study/NCT00342992		COMPLETED
NCT04246125	Patient Skin Dose in Interventional Radiology	https://beta.clinicaltrials.gov/study/NCT04246125	DPPRI	COMPLETED
NCT00165425	Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation	https://beta.clinicaltrials.gov/study/NCT00165425		ACTIVE_NOT_RECRUITING
NCT01362855	Advance Care Planning Evaluation in Hospitalized Elderly Patients	https://beta.clinicaltrials.gov/study/NCT01362855	ACCEPT	COMPLETED
NCT04023110	Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab	https://beta.clinicaltrials.gov/study/NCT04023110	CCTGuide Pilo	ACTIVE_NOT_RECRUITING
NCT05836246	The Development of Quantitative Ultrasound Imaging Software Platform	https://beta.clinicaltrials.gov/study/NCT05836246		ENROLLING_BY_INVITATION
NCT03928210	Digoxin Induced Dissolution of CTC Clusters	https://beta.clinicaltrials.gov/study/NCT03928210		ACTIVE_NOT_RECRUITING
NCT00671346	NORVIT and WENBIT - Long-term Follow-up	https://beta.clinicaltrials.gov/study/NCT00671346	NORVITWENBI	UNKNOWN
NCT03042910	A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors	https://beta.clinicaltrials.gov/study/NCT03042910		COMPLETED
NCT01239446	Hybrid SPECT/CTCA for the Assessment of the Presence and Hemodynamic Significance of CAD in Asymptomatic Patients.	https://beta.clinicaltrials.gov/study/NCT01239446		UNKNOWN
NCT01210846	A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors	https://beta.clinicaltrials.gov/study/NCT01210846		COMPLETED
NCT02628665	Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer	https://beta.clinicaltrials.gov/study/NCT02628665		UNKNOWN
NCT05125965	Contribution of Cardiac MRI in the Early Diagnosis of Myocarditis Induced by Immunotherapy	https://beta.clinicaltrials.gov/study/NCT05125965	MEDIIMYO	NOT_YET_RECRUITING
NCT03211442	Implications of MEDIcal Low Dose RADiation Exposure - BReast Cancer Acute Coronary Events	https://beta.clinicaltrials.gov/study/NCT03211442	MEDIRAD-BRA	UNKNOWN

NCT04737265	Pilot Study of an NTproBNP Guided Strategy of Cardioprotection	https://beta.clinicaltrials.gov/study/NCT04737265	NTproBNP-Gui	RECRUITING
NCT03377465	Biomarkers, Hemodynamic and Echocardiographic Predictors of Ischemic Strokes and Their Influence on the Course and Prognosis	https://beta.clinicaltrials.gov/study/NCT03377465		COMPLETED
NCT05939089	Cardiovascular Assessment of Pediatric Cancer Survivors	https://beta.clinicaltrials.gov/study/NCT05939089	CASPER	COMPLETED
NCT01933789	Improving Communication About Serious Illness	https://beta.clinicaltrials.gov/study/NCT01933789	ICSI	COMPLETED
NCT05596188	Anxiety Before Non-cardiac Surgery in Adults	https://beta.clinicaltrials.gov/study/NCT05596188		RECRUITING
NCT03098589	Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)	https://beta.clinicaltrials.gov/study/NCT03098589		RECRUITING
NCT02379988	Prone Breath Hold Technique to Decrease Cardiac and Pulmonary Doses in Women Receiving Left Breast Radiotherapy	https://beta.clinicaltrials.gov/study/NCT02379988		COMPLETED
NCT02993172	The Copenhagen City Heart Study	https://beta.clinicaltrials.gov/study/NCT02993172	CCHS	COMPLETED
NCT05197972	Assessment of Cardiac Coherence Associated With Medical Hypnosis on Preoperative Anxiety in Oncological Surgery	https://beta.clinicaltrials.gov/study/NCT05197972	COHEC2	RECRUITING
NCT01641562	Diagnosis and Prediction of Taxanes Induced Cardiac Dysfunction	https://beta.clinicaltrials.gov/study/NCT01641562	CARDIOTAX	COMPLETED
NCT05892146	Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction	https://beta.clinicaltrials.gov/study/NCT05892146		RECRUITING
NCT05781672	Prediction of Delayed Toxic Cardiomyopathy in Children	https://beta.clinicaltrials.gov/study/NCT05781672	SpeckleAnthra	RECRUITING
NCT04598646	The HIMALAYAS Pilot Study	https://beta.clinicaltrials.gov/study/NCT04598646	HIMALAYAS-P	NOT_YET_RECRUITING
NCT03297346	Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer	https://beta.clinicaltrials.gov/study/NCT03297346	EARLY-HEART	UNKNOWN
NCT00875238	Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab	https://beta.clinicaltrials.gov/study/NCT00875238	PACE in BC	COMPLETED
NCT05407272	Explore the Sharing Model Intervene to Improve the Knowledge, Attitudes, Service Intentions and Service Start-up Effects of the Eight Major Non-cancer Disease End-stage Caregivers on Well-being and Palliative Care	https://beta.clinicaltrials.gov/study/NCT05407272		COMPLETED
NCT05114772	Pre Procedural Biomarkers Might Predict Recurrent Atrial Fibrillation After Catheter Ablation	https://beta.clinicaltrials.gov/study/NCT05114772		COMPLETED
NCT03416972	Detecting Radiation-Induced Cardiac Toxicity After Non-Small Cell Lung Cancer Radiotherapy	https://beta.clinicaltrials.gov/study/NCT03416972	RICT-LUNG	UNKNOWN
NCT05832138	ONLOOP Trial: Evaluating a New Surveillance and Support System for Survivors of Childhood Cancer in Ontario	https://beta.clinicaltrials.gov/study/NCT05832138		NOT_YET_RECRUITING
NCT05174338	Cardiac Amyloidosis Registry Study	https://beta.clinicaltrials.gov/study/NCT05174338	CARS	ENROLLING_BY_INVITATION
NCT05096338	Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer	https://beta.clinicaltrials.gov/study/NCT05096338	PCT	RECRUITING
NCT00749372	MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions	https://beta.clinicaltrials.gov/study/NCT00749372	T2*MRI	COMPLETED
NCT02306538	Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI	https://beta.clinicaltrials.gov/study/NCT02306538	EMBRACE-MR	ACTIVE_NOT_RECRUITING
NCT05355662	Prognosis Analysis of Elderly Donor Liver in Liver Transplantation	https://beta.clinicaltrials.gov/study/NCT05355662		COMPLETED
NCT03301389	Cardiac Magnetic Resonance for Early Detection of Chemotherapy or Radiation Therapy Induced Cardiotoxicity in Breast Cancer (CareBest)	https://beta.clinicaltrials.gov/study/NCT03301389		RECRUITING
NCT05851053	Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study	https://beta.clinicaltrials.gov/study/NCT05851053	BLOC-II	RECRUITING
NCT04805853	Myocardial Pathological Changes in Patients of Type 2 Diabetes With or Without PCOS Using Cardiac Magnetic Resonance	https://beta.clinicaltrials.gov/study/NCT04805853		UNKNOWN
NCT02494453	Pilot Study of Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy	https://beta.clinicaltrials.gov/study/NCT02494453		COMPLETED
NCT05423860	Phase I Human Analytics (HALO) Study	https://beta.clinicaltrials.gov/study/NCT05423860	HALO	RECRUITING
NCT05454553	Efficacy of Deep Inspiration Breath Hold and Intensity-modulated Radiotherapy in Preventing PErfusion Defect for Left Sided Breast Cancer (EDIPE)	https://beta.clinicaltrials.gov/study/NCT05454553	EDIPE	RECRUITING
NCT03308773	Disease Prevention in Clinical Practice Base on Patient Specific Physiology	https://beta.clinicaltrials.gov/study/NCT03308773	STOPDISEASE	ENROLLING_BY_INVITATION
NCT03128060	Expanding Access to Home-Based Palliative Care	https://beta.clinicaltrials.gov/study/NCT03128060		TERMINATED
NCT02357953	Transpulmonary Thermodilution Using an Implented Central Venous Access Port	https://beta.clinicaltrials.gov/study/NCT02357953	ThermoD-PAC	COMPLETED
NCT00563953	Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years	https://beta.clinicaltrials.gov/study/NCT00563953	CAPRICE	COMPLETED

NCT03847753	Exploring the Comorbidity Between Mental Disorders and General Medical Conditions	https://beta.clinicaltrials.gov/study/NCT03847753	COMO-GMC	COMPLETED
NCT02571894	The Cardio-Oncology Breast Cancer Study	https://beta.clinicaltrials.gov/study/NCT02571894	COBC	UNKNOWN
NCT02543294	REcovery of Left Ventricular Dysfunction in CAncer Patients (RECAP Trial)	https://beta.clinicaltrials.gov/study/NCT02543294		COMPLETED
NCT02859194	The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients	https://beta.clinicaltrials.gov/study/NCT02859194		COMPLETED
NCT03577002	Team-based Versus Primary Care Clinician-led Advance Care Planning in Practice-based Research Networks	https://beta.clinicaltrials.gov/study/NCT03577002		UNKNOWN
NCT03155802	Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines	https://beta.clinicaltrials.gov/study/NCT03155802		UNKNOWN
NCT05521178	Cardiotoxicities in Patients Receiving BTKi	https://beta.clinicaltrials.gov/study/NCT05521178		NOT_YET_RECRUITING
NCT02666378	Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer	https://beta.clinicaltrials.gov/study/NCT02666378		RECRUITING
NCT00005494	Prospective Study of Health in Runners and Walkers	https://beta.clinicaltrials.gov/study/NCT00005494		COMPLETED
NCT03941184	Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity	https://beta.clinicaltrials.gov/study/NCT03941184		COMPLETED
NCT05645653	Nurse-led Medication Self-management Intervention in the Improvement of Medication Adherence	https://beta.clinicaltrials.gov/study/NCT05645653		NOT_YET_RECRUITING
NCT01369953	Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants	https://beta.clinicaltrials.gov/study/NCT01369953		COMPLETED
NCT05880160	Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction	https://beta.clinicaltrials.gov/study/NCT05880160	HER-SAFE	NOT_YET_RECRUITING
NCT05366153	Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer	https://beta.clinicaltrials.gov/study/NCT05366153	REDEEM-CAD	NOT_YET_RECRUITING
NCT01173341	Cardiotoxicity of Cancer Therapy (CCT)	https://beta.clinicaltrials.gov/study/NCT01173341		ENROLLING_BY_INVITATION
NCT00284336	Caelyx Adjuvant in Elderly Breast Cancer	https://beta.clinicaltrials.gov/study/NCT00284336		COMPLETED
NCT04037436	Functional Exercise and Nutrition Education Program for Older Adults	https://beta.clinicaltrials.gov/study/NCT04037436	MoveStrong	COMPLETED
NCT03000036	Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients	https://beta.clinicaltrials.gov/study/NCT03000036		COMPLETED
NCT04116281	Short and Long Term Effects of a Physical Therapy Program After Breast Cancer Surgery	https://beta.clinicaltrials.gov/study/NCT04116281		SUSPENDED
NCT01944813	Advance Care Planning: A Way to Improve End-of-life Care Life Care	https://beta.clinicaltrials.gov/study/NCT01944813		UNKNOWN
NCT05638269	A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China	https://beta.clinicaltrials.gov/study/NCT05638269		RECRUITING
NCT00003070	Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer	https://beta.clinicaltrials.gov/study/NCT00003070		COMPLETED
NCT05913999	Serial PET MPI in Patients Undergoing Cancer Treatment	https://beta.clinicaltrials.gov/study/NCT05913999		ENROLLING_BY_INVITATION
NCT01080170	The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer	https://beta.clinicaltrials.gov/study/NCT01080170	Silhouette	COMPLETED
NCT02769299	Cardiotoxicity of Radiation Therapy (CTRT)	https://beta.clinicaltrials.gov/study/NCT02769299		COMPLETED
NCT03534570	Gated Radiotherapy in Left Sided Breast Cancer Patients	https://beta.clinicaltrials.gov/study/NCT03534570	GATTUM	UNKNOWN
NCT01415999	Cardiovascular Function in Adult Survivors of Childhood Malignancies	https://beta.clinicaltrials.gov/study/NCT01415999		COMPLETED
NCT01375699	Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers	https://beta.clinicaltrials.gov/study/NCT01375699		COMPLETED
NCT04877899	Mazankowski Alberta Heart Institute (MAHI) EchoGo Discovery 1 Protocol	https://beta.clinicaltrials.gov/study/NCT04877899		ENROLLING_BY_INVITATION
NCT03818776	Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC	https://beta.clinicaltrials.gov/study/NCT03818776		COMPLETED
NCT04696081	Atrial Fibrillation in Active Cancer Patients	https://beta.clinicaltrials.gov/study/NCT04696081	AFIB-CANCER	RECRUITING
NCT00126581	Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer	https://beta.clinicaltrials.gov/study/NCT00126581		COMPLETED
NCT04328181	Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT)	https://beta.clinicaltrials.gov/study/NCT04328181	SPEQUA	RECRUITING
NCT01498276	Family Genetics Health Education and Healthy Behaviors	https://beta.clinicaltrials.gov/study/NCT01498276		COMPLETED
NCT00677781	Impact of Microparticles on Postoperative Complications in Surgical Patients	https://beta.clinicaltrials.gov/study/NCT00677781		COMPLETED
NCT04706481	Archival of Human Biological Samples in CU-Med Biobank	https://beta.clinicaltrials.gov/study/NCT04706481		RECRUITING
NCT05615376	Beat to Beat A Study in Paediatric, Adolescent and Young Adult Patients Who Are Undergoing or Have Undergone Cancer Therapy to Evaluate the Agreement Between QTc Measured Using 12 Lead Electrocardiogram (ECG)	https://beta.clinicaltrials.gov/study/NCT05615376		RECRUITING
NCT01708798	Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer	https://beta.clinicaltrials.gov/study/NCT01708798		TERMINATED
NCT05746598	Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Cisplatin Among Egyptian Non-small Cell Lung Cancer Patients	https://beta.clinicaltrials.gov/study/NCT05746598		RECRUITING
NCT05209776	Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy	https://beta.clinicaltrials.gov/study/NCT05209776	LI-ARVC	RECRUITING
NCT00039481	Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors	https://beta.clinicaltrials.gov/study/NCT00039481		COMPLETED
NCT04891081	Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease	https://beta.clinicaltrials.gov/study/NCT04891081		UNKNOWN
NCT05636774	Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial	https://beta.clinicaltrials.gov/study/NCT05636774	EMPATICC	NOT_YET_RECRUITING
NCT05687474	Baby Detect : Genomic Newborn Screening	https://beta.clinicaltrials.gov/study/NCT05687474		RECRUITING
NCT05025774	Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise	https://beta.clinicaltrials.gov/study/NCT05025774	FLASHLITE	NOT_YET_RECRUITING
NCT00636844	Detection of Chemotherapy Induced Cardiotoxicity	https://beta.clinicaltrials.gov/study/NCT00636844		COMPLETED
NCT03313544	Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1	https://beta.clinicaltrials.gov/study/NCT03313544		RECRUITING
NCT00004074	Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu	https://beta.clinicaltrials.gov/study/NCT00004074		COMPLETED

NCT03265574	PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?	https://beta.clinicaltrials.gov/study/NCT03265574	PROACT	RECRUITING
NCT00679874	Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR)	https://beta.clinicaltrials.gov/study/NCT00679874	Cardiotox	TERMINATED
NCT00724581	Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer	https://beta.clinicaltrials.gov/study/NCT00724581	PASCART	UNKNOWN
NCT03166813	Remote Ischaemic Preconditioning in Childhood Cancer	https://beta.clinicaltrials.gov/study/NCT03166813		COMPLETED
NCT00132613	Trial of Drainage With or Without Bleomycin Instillation for Malignant Pericardial Effusion	https://beta.clinicaltrials.gov/study/NCT00132613		COMPLETED
NCT01913769	Monitoring Radiobiological Effects in Thoracic Malignancy by Using Myocardial Perfusion Scan	https://beta.clinicaltrials.gov/study/NCT01913769		UNKNOWN
NCT02220569	PhysioFlow to Detect Cardiotoxicity in Chemo	https://beta.clinicaltrials.gov/study/NCT02220569	PULSE-ECCho	UNKNOWN
NCT05804669	A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome	https://beta.clinicaltrials.gov/study/NCT05804669		RECRUITING
NCT05082311	Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma	https://beta.clinicaltrials.gov/study/NCT05082311	PheoCard	COMPLETED
NCT00325611	Multidisciplinary Inpatient Palliative Care Intervention	https://beta.clinicaltrials.gov/study/NCT00325611		COMPLETED
NCT05879211	Goal Concordant Care Learning Laboratory	https://beta.clinicaltrials.gov/study/NCT05879211		NOT_YET_RECRUITING
NCT04467411	Randomised Controlled Study of Physical Exercise Intervention in Breast Cancer Patients at Risk of Anthracycline-induced Cardiomyopathy: The EMBRACE Study	https://beta.clinicaltrials.gov/study/NCT04467411	EMBRACE	RECRUITING
NCT00869011	Exercise for Patients With Renal Cell Cancer Receiving Sunitinib	https://beta.clinicaltrials.gov/study/NCT00869011		UNKNOWN
NCT03523611	Right Ventricular Inflammation After Lung Resection	https://beta.clinicaltrials.gov/study/NCT03523611		UNKNOWN
NCT04305613	Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy	https://beta.clinicaltrials.gov/study/NCT04305613	CLARITY	ENROLLING_BY_INVITATION
NCT05194111	Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan	https://beta.clinicaltrials.gov/study/NCT05194111	TREAT-HF	RECRUITING
NCT05361811	Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial	https://beta.clinicaltrials.gov/study/NCT05361811		RECRUITING
NCT05077111	A Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia	https://beta.clinicaltrials.gov/study/NCT05077111	VATS	ACTIVE_NOT_RECRUITING
NCT05879913	Coronary CT Angiography Scan in Prostate Cancer	https://beta.clinicaltrials.gov/study/NCT05879913		NOT_YET_RECRUITING

Brief Summary	Study Results
The purpose of this study is to learn more about how a drug commonly used to treat multiple myeloma can affect the heart. In this study, the investigators will learn whether a drug called how a drug (called bortezomib, or Velcade) receive for multiple myeloma affects the heart. Bortezomib is part of the standard treatment and its effects on multiple The investigators want to learn whether damage occurs to the heart after taking bortezomib for multiple myeloma, whether it is reversible, and we can predict damage to the heart before it occurs.	NO
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving d	NO
The aim of this study is to evaluate the impact of a Breathlessness Intervention Service (BIS) on the quality of life of patients and families affected by intractable breathlessness. The questions to be addressed by this research 1. Is BIS more effective than standard care for patients with intractable breathlessness from advanced malignant or non-malignant disease? 2. Does it reduce patient and carer distress due to breathlessness, and increase patients' sense of mastery of the symptom? 3. What are the experiences and views of those who use BIS, their informal carers and the clinicians who refer to it? 4. Does BIS offer value for money for the NHS?	NO
This study is a randomized clinical trial of an intervention to improve outcomes for patients and their family by using ICU nurse facilitators to support, model, and teach communication strategies that enable patients and their	NO
*Episodic breathlessness (or dyspnea) is one form of chronic refractory breathlessness characterized by a severe worsening of breathlessness intensity or unpleasantness beyond usual fluctuations in the patient's perception	NO
There is evidence for the effectiveness of opioids for the relief of chronic refractory breathlessness. There is no evaluated and proven standard treatment for the relief of episodic breathlessness at the moment but immediate- This pilot study aims to evaluate relative efficacy, feasibility and time to onset of two different opioids (fentanyl and morphine) in order to improve the management of episodic breathlessness.	NO
Anthracyclines are associated with cardiotoxic effects. Previous studies suggest that enalapril, and or carvedilol, protect against cardiovascular effects of these drugs. Ivabradine selectively reduces heart rate through inhibition of the cardiac pace maker IF channel, thus prolonging the duration of spontaneous depolarization in the sinus node. Additionally, ivabradine might preserve myocard Ivabradine has been shown to improve outcome in patients with heart failure and angina. The aim of this study is to evaluate whether ivabradine might prevent anthracycline-induced cardiotoxicity.	NO
This study will explore why some multiple myeloma patients who receive carfilzomib (an anti-cancer medication) experience shortness of breath while others do not. The purpose of this research is to gather information on the	NO
This research study is a randomized trial to evaluate a training program that is designed to improve the communication skills of clinicians. The training program focuses on care for patients with serious illnesses and their fami	NO
The purpose of this study is to examine socio-cultural factors of women's use of complementary and alternative medicine (CAM). The effects of socioeconomic status, social networks and acculturation on CAM use will be as	NO
Fluoropyrimidine chemotherapy agents , such as 5-fluorouracil and capecitabine, are occasionally associated with cardiac toxicity. Clinical fluoropyrimidine cardiotoxicity is infrequent, but subclinical toxicity may be much mo	NO
To assess the discriminative properties of pleural fluid (PF) N-terminal-proB-type-natriuretic-peptide (NTproBNP) levels in identifying heart failure (HF)-associated pleural effusions (PE).	NO
Monocentric study for the evaluation of a whole body CZT scintigraphy system.	NO
Subjects with cardiovascular diseases (CVD) have higher incidence of cancers compared to general population. The investigators hypothesized that shared molecular mechanism play a pivotal role in the pathogenesis of CVD	NO
Cohort CNC-PPNAD will be investigated with clinical, genetic, biological and imaging work-up every year during 3 years. Cohort L-MC will be investigated clinically at inclusion and a PERKAR1A genotype will be performed.	NO
The clinical trial compares the reproducibility and accuracy of cardiac tonometry-based portable systems that may detect early cardiac dysfunction (SphygmoCor® Xcel and Oscar 2™ ambulatory blood pressure monitor) at l	NO
The purpose of this study is to investigate circadian disturbances after breast cancer surgery by means of monitoring sleep and heart-rate variability, by measuring a metabolite of melatonin in urine and by questionnaires and	NO
This study has two phases: 1. In phase 1 of the study (8 weeks),the effect of two different low calorie diets on manifestations of PCOS, including risk factors for the metabolic syndrome and cardiovascular risk profile will be compared. 2. In phase 2 the long term effect (next 44 weeks) on sustained weight-loss and the above mentioned parameters will be compared and evaluated.	NO
The purpose of this study is to to examine the effects of atorvastatin, a type of statin, on changes to the heart among women undergoing breast cancer treatment. Atorvastatin may reduce or eliminate the harmful effects of cl	YES
Radiotherapy plays a major role in the treatment of lung cancer and recent advances in radiotherapy have led to better cure rates. However, the radiotherapy dose needed to destroy the cancer cells can unfortunately also da	NO
The goal of this proposal is to produce and test high specific activity Ultratrace iobenguane I 123 in normal human volunteers.	NO
Real-CHOICE - designed as a prospective, longitudinal, observational, non-interventional study - will investigate the attitude of patients and physicians towards IV (intravenous) iron therapy in general and IIM (iron isomaltosic	NO
The main purpose of this study is to increase the pool of organs available for donation by performing ARP to recondition donation after cardiac death (DCD) organs prior to transplantation. We will compare the outcomes of o	NO
Lentiginosis refers to groups of diseases marked by the presence of pigmented spots on the skin. These conditions are most commonly associated with multiple tumors and changes in hormone producing glands. The cause	NO
Primary pigmented nodular adrenocortical disease (PPNAD) is a pituitary-independent, primary adrenal form of hypercortisolism characterized by; 1. Resistance to suppression by the drug dexamethasone 2. The body is unable to secrete cortisol in a normal rhythm 3. Distinct microscopic changes of both adrenal glands PPNAD can be associated with tumors (myxomas) of the skin, heart, breast, tumors (swannomas) of the nerve sheaths, pigmented spots (nevi and lentigines) of the skin, growth hormone (GH) producing tumors of the pituitar This study proposes to use standard methods of clinical testing for endocrine and nonendocrine diseases and genetic testing in order to; 1. Define the genetic basis for PPNAD and/or the Carney Complex. 2. Determine the molecular changes associated with the development of the tumors. 3. Identify carriers of the disease. 4. Determine the prognosis for carriers and affected individuals. 5. Provide sufficient data for genetic counseling of families with PPNAD and/or Carney Complex.\<TAB\>	
Malignant pleural or pericardial effusion is common in lung cancer, and intrapleural drugs injection is important in the treatment. Non- cytotoxic drugs include those with a sclerosing effect that produces pleurodesis, which is	NO
This pilot clinical trial studies intensity-modulated radiation therapy (IMRT) in treating younger patients with lung metastases. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill mc	NO
Anthracycline (AC) chemotherapy has substantially reduced the mortality rate from several common cancers globally. Unfortunately, AC treatment is associated with up to 19% risk of heart failure (HF). Current standard of car We will conduct a pilot double blinded, placebo controlled, randomized controlled trial to assess whether pre-treatment with statins before AC can prevent heart dysfunction. Eligible patients with cardiovascular risk factors s	NO
Primary Objective The objective is to determine the feasibility and agreement of remote evaluation of resting heart rate and HRV using the commercially available WHOOP® wrist monitor, compared to in-office measurements Elucidating the mechanisms that contribute to adverse cardiovascular outcomes and reduced quality of life among the growing population of childhood cancer survivors is paramount. Cancer, certain cancer drugs, radiation t The objective is to determine the feasibility and agreement of remote evaluation of resting heart rate and HRV using the commercially available WHOOP® wrist monitor, compared to in-office measurements using AtCor Medi	NO
To measure coronary calcium score in adults treated during childhood or adolescence for irradiation cancer in the heart and / or anthracycline area and compare them to determine whether irradiation of the heart area is asso	NO
The purpose of this study is to find out how much oxygen is used during a cardiopulmonary exercise test (CPET) in women who have mild cardiotoxicity after standard treatment for HER2-positive breast cancer, and to see w	NO
Prospective, multicenter, observational registry collecting data from subjects with Tako-Tsubo (stress-induced) cardiomyopathy (TTC). Uniform, complete, and accurate data will be collected on the subject's medical history, c The objectives are to evaluate the prevalence and incidence of cancer in patients with TTC, to document the underlying causes of death during hospital stay and during follow-up, to determine the long-term prognosis, and to	NO
This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious c	NO
To assess the efficacy and safety of an optimised dosing regimen of rhTPO's prophylactic treatment of cancer treatment-induced thrombocytopenia(CTIT) and to explore the cardioprotective effect of rhTPO in cancer patients	NO
This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with congestive heart failure receiving therapy for breast cancer. Studying samp	NO
Epidemiological studies based on Danish registries have observed that Danish male firefighters have more cardiovascular disease, infertility diagnose and a trend to increased risk of cancer than other Danish employed males The training facilities of real-fire extinguishing exercises in Denmark operate using wood or natural gas fire, which will have differential gradients of smoke, soot and possibly heat. The investigators will use different training co	NO
This is a prospective, open label, single arm study. A total of 300 patients with primary non-small cell lung cancer treated with PD-1/PD-L1 immune checkpoint inhibitors(ICIs) are expected to included . All patients will follow	NO
Prospective single arm study to evaluate a low-dose CT-based protocol for early detection of myocardial dysfunction in 50 cancer patients undergoing anthracycline-based chemotherapy.	NO
Background: - Researchers are interested in studying individuals who have known or suspected metabolic or genetic diseases that put them at a high risk for heart diseases or diseases of their blood vessels. To improve the results of the Objectives: - To study individuals who have or are at risk for cardiovascular diseases, as well as their unaffected relatives and healthy volunteers. Eligibility: - Individuals between 1 and 100 years of age. Participants may be healthy volunteers, individuals with cardiovascular diseases, or unaffected relatives of individuals with cardiovascular diseases. Design: * Participants will have some or all of the following tests, as directed by the study researchers: * Photography of the face and full body * Body measurements * Radiography, including chest or limb x-rays * Metabolic stress testing to study heart and muscle function * Echocardiography to study heart function * Magnetic resonance imaging (MRI) studies, including cardiovascular MRI, angiography, and contrast MRI, to study heart function and performance * Computed tomography (CT) angiogram to obtain images of the heart and lungs * Positron emission tomography (PET) imaging to study possible fat infiltration of the heart * Six-minute walk test to study heart, lung, and muscle function and performance * Vascular ultrasound to study blood vessel walls * Blood, tissue, and other specimens will be collected for research and testing, and will be taken either as part of the clinical study or during surgical procedures. * Follow-up studies may be performed under separate research protocols.	NO
This study will estimate the effect of lapatinib on cardiac repolarization (QTc interval duration) in subjects with advanced solid tumors. The study treatment period will occur over five days and an End of Study visit will be conc	YES
The purpose of this study is to investigate the heart functioning of patients being treated with with doxorubicin chemotherapy who have sarcoma, lymphoma or breast cancer in order to better predict risk of developing sympt	NO
The primary purpose of this study is to examine the safety and feasibility of delivering allogeneic human mesenchymal stem cells (allo-MSCs) by transendocardial injection to cancer survivors with left ventricular (LV) dysfunct The secondary purpose of this study is to obtain preliminary evidence for therapeutic efficacy of allo-MSCs delivered by transendocardial injection to cancer survivors with LV dysfunction secondary to AIC.	YES
This study aims at investigating the feasibility of recruitment and application of a method regarding early detection of subclinical changes in cardiac health after completion of acute cancer treatment during childhood and adc	NO
Cervical conization is done for pre-cancer disease. The procedure is performed with local anesthesia and general anesthesia. Local anesthesia is given by paracervical block, and several different local anesthetics is being us	NO
This is for participants with a history of HER2-positive breast cancer and were treated with chemotherapy that increases the risk of abnormal heart function. Strain (a marker of heart function) is a new method of monitoring he	NO
The goal of this observational study is to demonstrate the ability of using non-invasive Phosphorus (31P) Magnetic Resonance Spectroscopy (MRS) to monitor changes of in-vivo markers of mitochondrial function in skeletal a • Can 31P-MRS be used to monitor changes of in vivo markers of mitochondrial function in skeletal and cardiac muscles in large B- or T-cell lymphoma patients during treatment with (R-)CHOP? To be able to answer this main question, participants will undergo 31P-MRS imaging of the calf muscles and of the heart 3 times during the study period.	NO

Breast cancer is very common and afflicts 1 in 9 North American women. The treatment of breast cancer often requires the use of chemotherapy including "anthracyclines". Anthracyclines can damage the heart resulting in h L-carnitine is a substance that is produced naturally in the body and is required for normal heart function. Animal studies have suggested that L-carnitine protects the heart from the effects of anthracyclines, however this has This study will assess the potential role of L-carnitine in the prevention of anthracycline induced heart damage. The investigators will enroll 144 patients into this study. Patients will be randomly assigned to L-carnitine therapy	NO
The purpose of this study is to find out the effects, good and/or bad, of a beta blocker (carvedilol) on heart function during treatment with anti-HER2 medication(s) including trastuzumab (Herceptin).	YES
The objective of CAREBANK study is to establish definitive relationships with human cardiac samples and clinical phenotypes in patients undergoing cardiac procedures. Specifically, the investigators aim at comparing atrial	NO
Several cytotoxic regimens are related to endothelial cell damage and vascular toxicity. Endothelial dysfunction is implicated in the pathogenesis of all known cardiovascular diseases (CVD) and closely related to the metaboli In the epidemiological part of the project, the investigators will determine the prevalence and incidence of cardiovascular and metabolic morbidity/mortality in early BC patients compared to the Danish background population In the clinical part, the investigators will study the changes of endothelial function and metabolic parameters in BC patients receiving chemotherapy. With increasing number of BC survivors, long-term consequences of curative cancer treatment should be studied. The investigators hypothesize that cytotoxic therapy worsens metabolic parameters possibly through endoth	NO
The anthracycline doxorubicin, first introduced in the 1960's, continues to be an effectively utilized antineoplastic drug. Even at relatively low cumulative doses there is risk of cardiotoxicity. However, the incidence of subclinic	NO
Polycystic ovary syndrome (PCOS) is an extremely common disorder in women of reproductive age. Diagnosis of PCOS is principally based on clinical and physical findings. Diagnostic criteria and PCOS definitions used by	NO
We evaluated whether collection of risk factors to generate an electronic health record (EHR)-linked personalized health risk appraisal (HRA) for coronary heart disease (CHD), diabetes, breast and colorectal cancer (CRC) was	YES
This study examines heart rate monitoring variability for the early detection of pancreatic cancer. Pancreatic cancer is a very difficult disease to detect early. This study is being done to observe the heart rate variability in patie	NO
The purpose of this research study is to evaluate the effects of the chemotherapeutic drug, Trastuzumab (Herceptin) on the heart. Trastuzumab (Herceptin) is used to treat specific types of breast cancer and is known to caus	NO
The purpose of this study is to determine whether HKI-272 affects the rhythms of the heart (cardiac repolarization).	NO
This study is to inquire by mailed survey regarding the cardiac and general health of patients previously treated for Hodgkin's and non-Hodgkin's lymphoma with radiation therapy/anthracycline chemotherapy.	NO
This project will test the effect of nicorandil to mitigate the lung damage that can occur as a side effect of radiation therapy for lung cancer. Thousands of veterans develop lung cancer every year, and are treated by radiation	NO
This study investigates the Breathe Well device to test whether it is superior to the existing treatment standard of the Varian Realtime Position Management (RPM) system in assisting patients with deep inspiration breath hold	NO
Polymorphisms in the vitamin D system appear to affect the serum 25(OH)D levels. If so one would expect these polymorphisms to be associated with vitamin D related conditions and diseases, which will be tested in the pre	NO
Cardiac amyloidosis is a major cause of early treatment-related death and poor overall survival in individuals with systemic light chain amyloidosis. This project will develop a novel approach to visualize cardiac amyloid depo	NO
Depersonalized multi-centered registry initiated to analyze dynamics of non-infectious diseases after SARS-CoV-2 infection in population of Eurasian adult patients.	NO
A feasibility RCT comprising two groups: 1. Intervention (SELF-BREATHE in addition to standard NHS care) 2. Control group (standard / currently available NHS care)	NO
Trastuzumab (Herceptin®) increases the chances of cure in patients with Her-2 overexpressing early breast cancer. Unfortunately, both the chemotherapy drugs used in this setting (anthracyclines) and trastuzumab are known The principal aim of this study is to evaluate the utility of NT pro-BNP as a predictive biomarker for the development of trastuzumab related cardiotoxicity (TRC). The investigators will also examine if single nucleotide polymor	NO
To evaluate the safety and efficacy of pegylated liposomal doxorubicin/cyclophosphamide/trastuzumab/pertuzumab followed by docetaxel/ trastuzumab/pertuzumab compared with epirubicin/cyclophosphamide followed by	NO
Approximately 15-25% of all breast cancers are human epidermal growth factor receptor 2 (HER2) positive and it has been well known that HER2 overexpression is associated with more aggressive phenotype and poor progi Trastuzumab administration as an adjuvant and in metastatic HER2 positive breast cancer is associated with both symptomatic and asymptomatic cardiotoxicity. The incidence of trastuzumab-mediated cardiotoxicity were 2 Pertuzumab, a recombinant humanized monoclonal antibody binding to the HER2 dimerization domain, prevents dimerization of HER2 with other HER receptors (HER3,HER1, and HER4) especially with HER3. Blocking HER2 Pertuzumab is indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metasta Treatment of breast cancer with pertuzumab plus trastuzumab plus docetaxel as first line treatment until disease progression might be complicated by cardiotoxicity in up to 14.5% of the Patients. Cardinale et al showed that troponin I (TNI) positive identifies trastuzumab-treated patients who are at risk for cardiotoxicity and are unlikely to recover from cardiac dysfunction despite HF therapy. There is very little data about the reversibility and identification of patients at risk for cardiotoxicity of the pertuzumab plus trastuzumab plus docetaxel regimen and of those who will not recover from cardiac dysfunction,this i based on this background , this study aim is to evaluate the cardiotoxicity of pertuzumab plus trastuzumab plus docetaxel regimen and the application of troponin I (TNI) and Brain natriuretic peptide (BNP) in this setting.	NO
The purpose of this study is to better define and understand potential cardiac toxicities of proteasome inhibitors and to understand optimal management strategies to treat and prevent cardiovascular events.	NO
This is a prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer	NO
Pilot study to determine the feasibility of providing psychosocial and cardiac rehabilitation services to address socioeconomic health disparities and improve wellbeing for black men with prostate cancer.	NO
The problem is the lack of data from randomized controlled trials to throw light on the ALA-prostate cancer issue. There is therefore a need to acquire evidence from a randomized controlled study to illustrate the effect of ALA	NO
The primary aim of this study is to test and assess the implementation and effectiveness of continuous wireless vital signs monitoring with real-time alerts on: The frequency of patients monitored with adequate data quality as adequate clinical user satisfaction in the initial versus the last part of the trial (primary outcome).	NO
This clinical trial examines positron emission tomography (PET)/computed tomography (CT) in evaluating cardiac radiation damage in patients with lung cancer. As part of the treatment for lung cancer, patients will undergo ra	NO
In rodents, a single bout of exercise prior to injection of a chemotherapy agent used to treat breast cancer prevents or attenuates a number of markers of cardiac injury. This study will investigate whether this finding translate	YES
In the proposed project the investigators will asses whether changes in expression of selected circulating microRNAs in serum could comprise a sensitive and specific biomarker of cardiotoxicity in cancer patients treated wit	NO
In this study the investigators aim to examine the role that fibrosis plays in heart conditions such as aortic stenosis , chemotherapy-induced cardiotoxicity and carcinoid syndrome . Fibrosis is a common final result following a	NO
The overarching goal of the project is to improve the process and experience of surrogate decision-making by family caregivers. Since feeling unprepared to make surrogate decisions is a major contributor to caregiver stress	NO
The purpose of this study is to evaluate whether or not case management by a social worker and nurse can decrease the number of emergency room visits, increase the number of primary care doctor visits, and increase qua	NO
Sympathetic activity could be increased during robot-assisted laparoscopic gastrectomy, which is performed in a head up position under CO2 pneumoperitoneum. Stimulation of the sympathetic nervous system prolongs the QT interval and can increases the susceptibility to life threatening cardiac arrhythmias. Thus the investigators decided to evaluate the heart-rate corrected QT interval (QTc interval) during robotic-assisted laparoscopic gastrectomy.	NO
The investigators will determine the cancer risk in organ transplant recipients compared to the general population with the help of statistical analysis. Secondly the investigators will try to characterize the different cancer type	NO
The investigator proposes to use the cardiac coherence technique to diminish anxiety before the surgery of a peritoneal carcinosis of colon or stomach or ovary and pseudomyxoma or peritoneal mesothelioma.	NO
APACCHE (Adapted Physical Activity and Cardiac Coherence in HEmatologic patients) study investigates effects of heart rate variability biofeedback training, combined with classical adapted physical activity, on health-relate	NO
Breast cancer is the most common cancer among women worldwide. Similarly, Hodgkin and non- Hodgkin lymphomas make up two of the most prevalent cancers in men and women. Even though remarkable improvements The concept of 'Exercise is Medicine' has become well established in exercise-oncology research. Exercise therapy is now considered a safe and well-tolerated adjunct therapy inducing beneficial effects on body compositio Therefore, the aim of the study is to compare left ventricular (LV) function measured by LV global longitudinal strain (GLS) in breast cancer and lymphoma patients undergoing Anth-bC randomised to completing an exercise-b Additional measurements include aortic distensibility as part of the echocardiographic examination and exercise capacity through cardiopulmonary exercise testing. QoL and fatigue will be assessed in a questionnaire, compl Women and men aged 18 years and older with histologically confirmed breast cancer or lymphoma (ECOG grade 0-2) who are Anth-bC naïve and with reasonable life expectancy will be included in the study. The exercise programme is part of onco-rehabilitation programmes at the Inselspital Bern, the Spital AG Thun and the Bürgerspital Solothurn. Programmes last for 12 weeks and offer two supervised sessions per week (@ 60 A total of 120 patients will be recruited. Measurements will be performed at baseline, after 3 months (week 13) and after 6 months (week 26).	NO
This family environment-focused health behavior change intervention is being carried out by extensively trained community health workers (promotores) familiar with the community in East Los Angeles. The hypothesis being	NO
The aim of this study is the evaluation of early smoking reduction or cessation by means of no nicotine electronic cigarette added to standard counselling.	NO
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy with PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy, with or without dexrazoxane, followed by radiation therapy in treating young patients with newly diagnosed stage I, stage II,	NO
CAROLE seeks to evaluate the relationship between chest Radiation Therapy and coronary artery disease. The purpose of CAROLE is to check the heart health of women who received breast cancer treatments in the past and protect them from future heart disease.	NO
This proposal addresses the major challenge of improving health outcomes for children with cancer and other complex conditions, for whom the effectiveness of outpatient care depends on care coordination across a diverse	NO
Evaluating the effect of the angiotensin II-receptor (AT1) blocker candesartan vs placebo in prevention of trastuzumab-associated cardiotoxicity in patients with primary breast cancer treated with trastuzumab.	NO
In Ireland, over 3,000 patients are diagnosed with breast cancer annually, and 1 in 9 Irish women will be diagnosed with breast cancer in their lifetime. There is evidence that female breast cancer survivors are more likely to di	NO
This research is focused on evaluating pathways for identifying, managing, and overcoming side effects of cancer therapies that can negatively impact quality-of-life and overall outcomes for women during and after cancer t	
The purpose of this study is to determine whether pre-existing cardiac fibrosis is a predictor of cancer treatment-related cardiotoxicity.	NO
The purpose of this study is to do a literature review and combine all of the cases of the intrapericardial teratoma tumor and see if some conclusions can be made about this rare tumor in children.	NO
To examine whether serum androgens, measured earlier in life, and variation in genes related to androgen synthesis, metabolism, and signaling are associated with early-onset subclinical coronary atherosclerosis in young ad	NO
Ibrutinib (a tyrosine kinase inhibitor targeting Bruton) is a standard of treatment in haematology. According to retrospective data, atrial fibrillation and systemic hypertension are common ibrutinib-related advserse events. The	NO
Antineoplastic and immunomodulating agents may lead to various cardio-vascular adverse reactions. This study investigates reports of cardio-vascular toxicities for treatment including Anatomical Therapeutic Chemical (ATC	NO
This trial is to explore the optimal strategies for guaranteeing the cardiac safety of breast cancer patients following adjuvant radiotherapy in the modern era of multidisciplinary treatment.	NO
Early microRNAs (miRs) and Cardiac Magnetic Resonance (CMR)-derived strain analysis and detection of genes contributing to Anthracycline-Induced Cardiotoxicity (AIC) sensitivity and resistance will identify pediatric cance	NO
This is a randomized, placebo-controlled, double-blind, 3-way crossover phase I study being conducted on healthy volunteers to investigate the effect of single dose of AZD6094 (600 mg) on cardiac repolarization under well	NO
The Electronic Medical Records and Genomics (eMERGE) Network is in its third phase and during this time is enrolling and sequencing 25,000 individuals on a custom sequencing panel of clinically relevant, actionable genes	NO
Phase II study to evaluate the clinical potential of 68GaNOTA-anti-MMR-VHH2 for in vivo imaging of Macrophage Mannose Receptor (MMR)-expressing Macrophages by means of Positron Emission Tomography (PET) in pati	NO
This is a prospective observational study on a cohort of patients with castration-resistant prostate cancer M0, treated with Apalutamide, at the Oncology Unit of the "Andrea Tortora" Hospital of Pagani. Data will be collected In case of a favorable opinion from the patient, the CRF will be filled in. Patients with CRPC M0 treated with Apalutamide, belonging to the Oncology Unit of the Pagani Hospital "Andrea Tortora" and of the other Oncology Un	NO
Lung resections for pulmonary malignancies offer the best chance of survival for patients, but these procedures carry a significant burden of post-operative morbidity and mortality. Patients are particularly at high risk for post	NO
A Phase I, open-label clinical pharmacology study designed to evaluate the effect of tipifarnib on cardiac repolarization (corrected QT interval \(QTc\) duration) following a single dose of 900 mg and after repeated twice daily a	NO
To investigate whether women with Polycystic Ovary syndrome (PCOS) have evidence of an increased prevalence rate of subclinical atherosclerosis as measured by the presence of plaque, increased intima-medial carotid ar	NO
Women with breast cancer who are referred to the cardiac rehabilitation program at the Toronto Rehabilitation Institute will be invited to enrol in this observational study. Participants will take part in an established 16-week m	NO
Pulmonary arteriovenous malformations (PAVMs) are thin-walled abnormal vessels which provide direct capillary-free communications between the pulmonary and systemic circulations. Patients with PAVMs have usually hav	NO
The study is being conducted to see which cardiac tests that monitor how the heart functions during and after treatment with anthracyclines are most effective. This study will assess a new way to check the heart function of	NO
Worldwide, Breast cancer is the most common cancer in women,where 1.7 million new cases diagnosed in 2012 . In 2020 number doubled as 2.3 million women diagnosed with breast cancer. According to ACS 1 in 8 wome Similarly again, In Egypt breast cancer is the most common malignancy in women about 22,700 new cases recorded in 2020. Accounting for 38.8% of cancers in this population and forecasted to be approximately 46,000 in Post-operative radiotherapy is fundamental part of treatment after either conservative surgery or mastectomy . Conventionally fractionated radiation therapy (CFRT) ,Delivering 45-50 GY in 1.8-2 GY daily fractions for 5 days p Cardiac toxicity is potentially long or short term complication of various anticancer therapies systemic therapy as anthracyclines or biological agent implicated in causing irreversible cardiac dysfunction. Radiotherapy also have cardio toxic effect through different mechanisms	NO
Chronic physical conditions are defined as conditions that require ongoing management and treatment over extended periods of time. Chronic physical conditions are not only leading causes of death and disability in North A After the program, the research team will conduct interviews with participants to allow them to share their other feedback about the program. The researchers will also send surveys to the participants eight weeks after the pr	NO
Primary Objective: * Evaluate the agreement between radionuclide ventriculography (RNV) and gated F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in calculating left ventricular ejection fraction (	NO
The purpose of this study is to test whether patients with breast cancer who are being treated with non-anthracycline trastuzumab therapy can safely be monitored for heart related side effects less often than usual.	NO
The purpose of this study is to examine the effects of heart-rate variability biofeedback training on lung cancer patients receiving definitive radiation therapy. The target population consists of non-small cell lung cancer (NSCL	NO
This study is about testing whether exercise will improve fitness and lessen risk factors related to heart disease, diabetes, and obesity in Latina breast cancer survivors.	NO
With the increasing aging population demographics and life expectancies, the number of very elderly patients undergoing surgery is rising. Elderly patients constitute an increasingly large proportion of the high-risk surgical gr Cardiac complications and postoperative pulmonary complications are equally prevalent and contribute similarly to morbidity, mortality, and length of hospital stay. Specific optimization strategy of general anesthesia has bee Our hypothesis is that a combined optimization strategy of anesthesia concerning hemodynamic, ventilation, and depth of anesthesia may improve short- and long- term outcome in elderly undergoing high risk surgery.	NO

The goal of this prospective, multicentre study is to investigate short- and long-term cardiovascular effects in cancer patients treated with immune checkpoint inhibitors (ICIs). The main question\[s\] it aims to answer are: * To investigate troponin and NT-proBNP values in patients receiving ICIs and their association with ICI-induced CV abnormalities and MACEs. * Study the calcium score, systolic, and diastolic (dys)function. * Evaluate associations between patient/disease characteristics / transthoracic echocardiography parameters / electrocardiography parameters and troponin / NT-proBNP levels. Participants will be closely monitored by performing the following additional visits and testing: * Chest CT scan prior to treatment start, after 12 and 24 months. * Consultation with a cardiologist at baseline, 3, 6, 12 and 24 months, who will perform an electrocardiogram and echocardiogram. * One additional blood sample prior to treatment start, after 3, 6, 12 and 24 months. An extra blood sample could be taken in case of sudden heart problems. * Non-invasive endothelial function tests prior to treatment start, after 12 and 24 months.	NO
Subclinical atherosclerosis is the atherosclerotic process identified before clinical symptoms and thus it can be a useful marker of future cardiovascular events. It can be evaluated by many methods. This study included the d	NO
With this study the investigators will assess early cardiac damage by means of Global Longitudinal Strain (GLS) in newly diagnosed breast cancer (BC) patients treated with anthracycline-based chemotherapy, and to investig	NO
Vasoconstrictive signaling via endothelin receptors is not limited to primary pulmonary arterial hypertension, but has also been documented in secondary pulmonary hypertension due to congestive heart failure, including card	NO
Although great progress has been made in treating breast cancer, long-term health may be impaired by cancer therapy. For example, some chemotherapy drugs (e.g., anthracyclines) are known to cause declines in heart heal	NO
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program a	NO
Pericardial effusion is a common complication in patients with metastatic malignancy. While pericardiocentesis provide effective relieve from life-threatening situation such as cardiac tamponade, recurrence of pericardial effu	NO
NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested While it is well recognized that hereditary factors contribute to the development of a subset of human cancers, the cause for many cancers remains unknown. The application of next generation sequencing (NGS) technologie The purpose of this protocol is to identify novel cancer predisposing genes and/or genetic variants. For this study, the investigators will establish a Data Registry linked to a Repository of biological samples. Health informatio PRIMARY OBJECTIVE: * Establish a registry of families with clustering of cancer in which clinical data are linked to a repository of cryopreserved blood cells, germline DNA, and tumor tissues from the proband and other family members. SECONDARY OBJECTIVE: * Identify novel cancer predisposing genes and/or genetic variants in families with clustering of cancer for which the underlying genetic basis is unknown.	NO
The aim of this study is to compare CHOP versus CEOP-induced cardiotoxicity in patients with aggressive B-cell lymphoma. The hypothesis is epirubicin is associated with less cardiotoxicity without compromising the effica	NO
The purpose of this research is to develop patient-centered palliative care interventions to improve patient-provider communication and Quality of Life (QoL) of ethnic and racial minority patients living with life-limiting illnesse	YES
Acute myeloid leukemia (AML) is a clonal neoplastic disease of the hematopoietic tissue associated with a mutation in the precursor cell of hematopoiesis, which results in a differentiation block and uncontrolled proliferation Anthracycline antibiotics have been an integral part of the treatment of acute myeloid leukemia since the 1970s. However, the clinical usefulness of anthracyclines is limited primarily by the high incidence of cardiotoxicity. Acc Anthracycline-induced cardiotoxicity is the negative effect of anthracyclines on normal cardiac activity due to their toxic effects on the heart muscle and the cardiac conduction system. Anthracycline-induced cardiotoxicity m Purpose of the study To optimize the early detection of endothelial dysfunction and left ventricular myocardial contractility in patients with acute myeloid leukemia during chemotherapy treatment based on a comprehensive a Expected results Based on a comprehensive analysis using laser Doppler flowmetry, stress echocardiography with the determination of global longitudinal strain of the myocardium, biochemical markers of endothelial damag	NO
Cardiac surgery using heart and lung machine produces an inflammatory reaction in the body. This leads in few percent of cases to heart, lung, and kidney disturbances that potentially causes death. White blood cells in cont	NO
Understudied drugs will be administered to children per standard of care as prescribed by their treating caregiver and only biological sample collection during the time of drug administration will be involved. A total of approxi	NO
The purpose of this study is to evaluate the cardiac safety of TAS-102 in patients with advanced solid tumors.	NO
G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of collecting clinical, laboratory, imaging, demographic, and socioecon	NO
The incidence of acute kidney injury after cardiopulmonary bypass cardiac surgery is high, which increases postoperative mortality and is not conducive to the prognosis of patients. Stellate ganglion blocks increase renal blo	NO
The purpose of this study is to evaluate the effects of low-dose aspirin and vitamin E in primary prevention of cardiovascular disease and cancer in apparently healthy women.	YES
Due to remarkable advances in childhood cancer therapy the 10-year survival rate increased to over 80% and late sequelae come to the fore. Childhood cancer survivors (CCS) suffer from significant excess in mortality risk a	NO
Rural patients with life-limiting illness are at very high risk of not receiving appropriate care due to a lack of health professionals, long distances to treatment centers, and limited palliative care (PC) clinical expertise. Secondly,	NO
This study is being done to see if losartan affects the chances of developing radiation-induced heart failure in patients who are receiving radiation therapy as part of standard of care treatment for breast cancer. The interventions involved in this study are: * Losartan * Radiation Therapy (standard of care)	NO
The purpose of this study is to evaluate the efficacy of a polypill strategy containing aspirin (100 mg), ramipril (2.5, 5 or 10 mgs), and atorvastatin (40 mgs) compared with the standard of care (usual care according to the loca	NO
The Primary objective of this study is: 1. To determine the cardiac safety of TH-302 in patients with advanced solid tumors The Secondary objectives are: 1. To assess the pharmacokinetics (PK) of TH-302 2. To evaluate whether there is an association between plasma exposure to TH-302 and its active metabolite, Br-IPM, and effects on cardiac repolarization 3. To assess the safety and antitumor activity of TH-302 in patients with advanced solid tumors	NO
The Wellness Incentives and Navigation (WIN) project is designed to help improve health self-management and reduce the incidence and consequences of chronic disease among non-elderly adult Medicaid Supplemental Se WIN uses person-centered wellness planning and navigation facilitated by trained, professional health Navigators, dedicated specifically to the WIN project, who use Motivational Interviewing (MI) techniques, and a personal v	NO
In response to Program Announcement (PA)-09-164, "NIH Exploratory/Developmental Research Grant Program (R21) a randomized pilot study testing the efficacy of SWIFT: Social Work Intervention Focused on Transitions ar	YES
Malignant anterior mediastinal tumors essentially include lymphomas and thymomas. The location of mediastinum is anatomically close to several critical organs such as heart, lung, and breasts, which might be affected mea The participants potentially included in the current study are mainly lymphoma patients with mediastinal malignant lymphoma or patients whose radiation therapy field essentially encompasses anterior mediastinum. Patients It is anticipated that long-term mediastinal RT-related late effects are prospectively and longitudinally surveyed through consistent heart examinations and lung function tests. Long-term effects are expected to be lower with This study aims to standardize the application of clinical examinations including cardiac echocardiography, lung function tests, and relevant laboratory tests as part of objective tools for monitoring patients' cardiac and pulm	NO
Suppression of effects of androgens with male sex hormones, androgen suppression treatment (AST), has been known to reduce deaths and prolong life in advanced prostate cancer. There have, however, been concerns rais	NO
Randomised trial to assess progression of carcinoid heart disease in patients treated with Lutathera therapy compared to best supportive care.	NO
The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary ever	NO
Other than optimizing medical management of cardiac risk factors, and reducing radiotherapy (RT) dose to the heart, there currently exist no interventions to mitigate or reverse the adverse cardiac effects of RT. Aerobic exerc	NO
In a proportion of patients with AL amyloidosis there is no improvement of cardiac function despite hematologic response to treatment. The aim of the study is to assess whether treatment with EGCG increases the rate of ca	NO
CT scans of the chest / thorax are of great importance both in the initial diagnosis and in the follow-up of pulmonary or thoracic diseases. As an example, CT angiography of the pulmonary arteries (CTPA) is worldwide consid The aim of this study is to measure and compare dose efficiency of modern CT scanners for unenhanced and contrast-enhanced scan protocols of the chest/thorax. Patients who are referred for a CT of the contrast/thorax will	NO
The serum albumin ascites gradient (SAAG) is a recommended tool for ascites diagnosis since values ≥1.1 g/dl are found in nearly 97% of patients with portal hypertension. However, it mislabels chronic liver disease and hea SAAG, ascitic fluid protein concentration, serum and ascites type-B Natriuretic Peptide and echocardiography will be performed in all patients. The final diagnosis of the cause of ascites will be adjudicated by independent ph	NO
HER2 positive breast cancer cells have more HER2 receptor (a protein on the surface of cells) than normal breast cells. Approximately 30% of patients with breast cancer have HER2 positive breast cancer. Before HER2 targe Unfortunately the use of HER2 targeted therapies can increase the risk of heart problems and for this reason these treatments were only studied and approved for patients with normal heart function. In this study we plan to give HER2 targeted therapies to patients with HER2 positive breast cancer and mildly decreased heart function along with concomitant evaluation by a heart doctor (called cardiologist) and appropriate We hypothesize that it is safe to administer HER2 targeted therapies to patients with breast cancer and mildly decreased heart function, i.e. LVEF between 40 and 50%, while on appropriate heart medications.	YES
The "Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AnglOgraphy IN Daily Practice in 2017" (PROTECTION-VI) study is a prospective registry and investigator-initiated initiative without third-pa A decade ago, the multicentre observational PROTECTION-I study has revealed that the dose-length-product of CCTA ranges between 568 - 1259 mGy x cm with a median of 885 mGy x cm. This corresponds to an estimate	NO
Breast cancer (BC) radiotherapy leads to incidental cardiac irradiation, resulting in an increased risk of various major cardiac events (MCEs). In addition, recent studies indicate that for the treatment of BC, the addition of cher	NO
Primary Objective: To determine the risk of bleeding from ASA therapy in thrombocytopenic patients who develop Acute Coronary Syndrome (ACS), and assess its effect on the overall morbidity and mortality in these patients as well as platelet	YES
The present study will investigative the physiological effects of the cytokines interleukin-6 (IL-6) and tumor necrosis factor (TNF) on the adaptive changes to exercise in patients with rheumatoid arthritis. The investigators hypo	NO
The purpose of this study is to determine if the measurement (with a standard nuclear camera) of radioactivity normally present in the nervous system of your heart at four hours after the injection of radioactive drug for your c One hour before being injected with the drug (I-123 MIBG) for your MIBG scan, you will be given a standard dose of non-radioactive iodine (Lugol's solution) to block your thyroid from receiving the small amount of radiation t	NO
Atrial fibrillation (AF) is a common complication associated with cancer but the risk of AF according to the cancer localization and status as well as the risk of thromboembolisms, bleedings and mortality are poorly known. The objective of this study is to use a very large French nationwide cohort to adress thèses questions.	NO
By dynamically observing the changes of echocardiogram and biomarkers in breast cancer patients using trastuzumab, evaluate the effect of trastuzumab on cardiac function; determine the sensitivity of echocardiography ar	NO
Early identification of patients at risk for cardiotoxicity represent a primary goal for cardiologist and oncologist From all adjuvant trials echocardiography is ideal for evaluating Left Ventricular function though its operator dependent. The use of other technique such as endomyocardial biopsy, is troublesome in clinical practice Cardiac magnetic resonance imaging (MRI) have greater reproducibility in evaluating left ventricular ejection fraction (LVEF). This technique provides morphological, functional, perfusion, and viability information in one assess	NO
The main goal of the current research program is to examine the use of nutraceuticals, in particular flaxseed (FLX), in the prevention of Doxorubicin and Trastuzumab (DOX+TRZ) mediated cardiotoxicity in the clinical setting. A	NO
Late subclinical cardiovascular disease in testicular cancer survivors exposed to cisplatin-based chemotherapy and bone marrow transplant	NO
ASPREE-XT is a post-treatment, longitudinal observational follow-up study of ASPREE participants \(ASPREE Investigator Group, 2013; www.aspree.org; McNeil et al 2017\). Although the ASPREE trial medication was cease	NO
This phase II trial compares two drug therapy plans for the correction of heart function changes (reduced ejection function) in patients who have undergone anthracycline-based treatment for lymphoma, sarcoma, or breast ca	NO

Health inequality and genetic disparity are a significant issue in the United Kingdom (UK). This study focuses on diseases that are associated with significant morbidity and mortality in the UK, and specifically examines the extent and basis of treatment failure in different patient populations. The vast majority of drug registration clinical trials have under-representation of ethnic minority populations. In addition, the wider Caucasian populations have reasonably different clinical characteristics to the population that This large real-world research study aims to identify whether commonly prescribed drugs are effective in treating illnesses that cause significant poor health and death in the different patient populations that represent the UK. The goal of this study is to generate large quantitative data-sets that may inform clinical practice to reduce the existing health inequality and genetic disparity in the UK.	NO
A Relational Agent (RA) "virtual counselor" (VICKY: VIrtual Counselor for Knowing Your Family History) has been developed to collect family health history information for common health conditions including heart disease, str	NO
Objectives: Evaluation of the cardiovascular (CV) risk in a sample of CV asymptomatic infertile women with polycystic ovary syndrome (PCOS). Patients \& Methods: 100 infertile PCOS women older than 30 years (PCOS group) and 50 fertile non-PCOS women (Non-PCOS group) underwent gynecological and laboratory diagnosis and then underwent a diagnostic pro	NO
The aim of this study is to assess whether prophylactic treatment with metoprolol or losartan is able to reduce the incidence of atrial fibrillation (AF) in patients undergoing thoracic surgery for lung cancer, showing elevated pl	NO
While trastuzumab has been shown to prevent recurrences of breast cancer, some women may also experience damage to their heart muscle (including heart failure) as a result of their treatment. The investigators hope to lea	NO
This is a global, multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered intravenously in adults with AL amyloidosis	YES
The purpose of the HOPE-2 study is to determine whether long term supplementation with folic acid, vitamins B6 and B12 aimed at homocyst(e)ine reduction reduces the rates of major fatal and nonfatal cardiovascular event	NO
Herceptin has shown significant improvement in breast cancer therapy and improved survival of patients over-expressing the HER-2 protein by 50%. However, Herceptin has shown to negatively affect the heart, and frequent	NO
Sufficient muscle strength helps to get out of a chair and can prevent falls. Up to 30% of older adults experience age-related loss of muscle strength, which can lead to frailty and health instability. Exercise helps to build mus	NO
Default options represent the events or conditions that are set into place if no alternatives are actively chosen. The setting of default options has well-established effects on a broad range of human decisions, but its influence This is a 3-armed randomized clinical trial in Veterans at high risk for critical illness, assessing the impact of Advance Directive (AD) forms framed with different default options. The central goals are to assess how default opti The investigators hypothesize that setting defaults in real ADs will increase the proportion of Veterans selecting comfort-oriented plans of care, decrease selections of life-extending therapies such as mechanical ventilation ar	NO
The investigators evaluated the cardiac effects of Thyroid-stimulating hormone (TSH) over-suppression in women with differentiated thyroid cancer (DTC) frequently encountered during suppression therapy.	NO
AF and cancer frequently coexist. Since these patients are usually excluded from randomized trials, information on their management and outcome is scarce. Occurrence of relevant clinical events, such as ischemic and hem A prospective observational registry collecting information, in a real world setting, on the clinical profile of patients with these clinical conditions and on the use of antithrombotic drugs in patients with AF and cancer could im	NO
From December 6, 2019 to March 23, 2020, the research group of Qingkun Fan found a novel protein(temporarily named protein F) in heparin anticoagulant plasma of three patients with heart disease. One patient was diagnc	NO
Cardiovascular disease (CVD) is a major contributor to morbidity and mortality in pediatric, adolescent and young adult (AYA) cancer survivors (hereafter referred to as AYA-CS). Exercise is a cornerstone of CVD prevention an	NO
Treatments-related cardiotoxicity is a critical issue in long term lymphoma survivors, particularly at young age, and its early identification is important to prevent clinically relevant cardiac events. Complete echocardiographic a	NO
Based upon Northern New England Cardiovascular Study Group data, the rate of post operative atrial fibrillation (POAF) requiring treatment following coronary artery bypass grafting (CABG) at Maine Medical Center (MMC) is Atrial fibrillation requires both an initiation trigger and favorable environment for maintenance and the sympathetic and parasympathetic nervous systems play important roles in this regard. Unfortunately, the precise mechani The stellate ganglion is formed by the fusion of the inferior cervical sympathetic ganglion and first thoracic sympathetic ganglion. By modulating the sympathetic component of the autonomic nervous system, stellate ganglior Preliminary studies of perioperative stellate ganglion block (SGB) in cardiac surgery suggest that this technique may reduce or prevent episodes of POAF requiring treatment. The investigator's ultimate goal is to determine wh	YES
To determine the feasibility of using myocardial PET imaging as a means to assess cardiovascular risk in men with prostate cancer planned for androgen- deprivation therapy with external beam radiation therapy.	NO
Major hepatectomies are high-risk surgeries offered more and more frequently for the curative treatment of primary or secondary liver cancer, and for complex cases, representing a real challenge for medical teams. The 1st p The major challenge is thus to restore cardiac output by refilling without excess, by correcting the hypovolemia that arose during the "post resection of the hepatic parenchyma" phase. Our hypothesis is that an individualized protocol for optimizing intraoperative cardiac flow by guided vascular filling during the "post hepatic resection" phase is accompanied by a reduction in postoperative complications in p	NO
Post-operative new-onset atrial fibrillation (POAF) is one of the most common arrhythmias in adults after direct intracardiac surgery with extracorporeal circulation. The incidence of POAF in coronary artery bypass grafting (C	NO
Rationale: Palliative care integration in treatment pathways, palliative care networks and institutional collaborations in health services delivery seems a promising approach reducing fragmentation and discontinuity. Integrated Objectives: To investigate how patients with advanced cancer, COPD and CHF, their family and professional caregivers within a selection of IPC initiatives in Belgium, Germany, Hungary, The Netherlands and United Kingdom * To investigate what opinions patients and family caregivers have on the (continuity and) quality of care delivered * To investigate how patients rate their symptoms and quality of life * To investigate how family caregivers rate their burden / rewards of care giving * To investigate how the care network of the patient is organised with respect to the type, properties and quality of relationships between patients and family / professional caregivers Study design: Longitudinal multiple embedded case study. Study population: Adult patients with advanced cancer, COPD, and CHF under the care of IPC initiatives in five participating countries, their family and professional caregivers. The investigators aim to enroll up to 288 patient Study parameters: Experiences with IPC initiatives, quality of care, quality of life, perceived symptoms, perceived collaboration between professional caregivers, burden and rewards of care giving. Methods: Semi-structured interviews, patient diary, Social Network Analysis and the following questionnaires: Palliative care Outcome Scale; Canhelp Lite, Caregiver Reaction Assessment. Patients and family caregivers will b Analysis: The overall analysis will involve a synthesis of the qualitative and quantitative data. For more information see Detailed Description.	NO
Head and neck cancer survivors and their primary caregivers (N=25 dyads) will be enrolled to pilot test a nutrition support system with a care planning clinic visit and a caregiver mobile App. Participants will be asked to comp	YES
The purpose of this study is to review cause of death in patients undergoing prostate brachytherapy at a single institution. Furthermore, we are analyzing patients undergoing androgen deprivation therapy and whether or not	NO
Severe radiation-induced lung injury (RILI) occurs in approximately 20% of the lung cancer patients, who are treated with curative chemoradiation. In this study the investigators want to evaluate the prognostic value of baseli	NO
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Dexrazoxane may lessen the side effects PURPOSE: Randomized phase III trial to compare combination chemotherapy with or without dexrazoxane and with or without high-dose methotrexate in patients with acute lymphoblastic leukemia or advanced lymphoblast	NO
Study to assess the potential effects of lurbinectedin (PM01183) at a therapeutic dose on the duration of the QTc interval, measured by electrocardiograms (ECGs), to characterize the PM01183 plasma concentration/QTc rela	YES
This phase IIb trial studies how well low-dose carvedilol works in preventing heart failure in cancer survivors exposed to high dose anthracyclines for management of childhood cancer. Patients who received high-dose anthra	NO
The purpose of this study is to determine whether discussions of life story, forgiveness, and future goals improve quality of life for patients with serious illness.	YES
Due to a risk of heart failure during HER2 directed therapy in breast cancer, treatment is monitored with imaging of myocardial function, which is resource demanding for both patients and the health care system. The purpose	NO
Virtual reality has been shown to be an effective way to treat pain and anxiety in various different settings. Palliative care is an area of medicine that often deals with patients suffering from pain and anxiety. The medication us	NO
The goal of this research agenda is to improve the quality of end-of-life care by explicitly identifying values that will guide the decision-making process, with a particular emphasis on the role of ethnic, racial and cultural factor	YES
This research study is being performed to begin to determine the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss in patients and promote improvemer T2DM is currently the 6th leading cause of mortality in the United States and is a major cause of kidney failure, blindness, amputations, heart attack, and other vascular and gastro-intestinal dysfunctions. Traditionally, treatme	NO
Atrial fibrillation is a very common complication of pulmonary resection. Patients who develop atrial fibrillation require additional treatment and are more likely to stay in the hospital for longer period of time increasing the cost	YES
Learning about the impact of anti-androgen treatment has on cardiac function in patients with prostate cancer may help plan treatment and help patients live more comfortably. This pilot clinical trial will utilize cardiac magnet	NO
Intraperitoneal insufflation of carbon dioxide may affect the sympathetic activity that leads to changes in ventricular re-polarization. This in turn can result in changes of heart rate-corrected QT (QTc) interval. Ramosetron is a s	NO
Preventing pre-surgical stress can help patients achieve positive outcomes on health and well-being. However, very few patients receive adequate stress relief support prior to a surgical procedure. Provision of education and According to this, the Software as a Medical Device (SaMD) CARINAE, aims to support patients and caregivers during the whole perioperative process. SaMD CARINAE consists of an mHealth mobile application for patients	NO
Hypothesis The overall hypothesis is that non-obese (BMI \<30) women with PCOS have high luteinising hormone (LH) and cortisol pulse frequency and amplitude and that repeated low-frequency EA restore these alterations	NO
This study regarding oncological patients for rehabilitation after specific cancer therapy involves three aims: (1) to evaluate the predictive value of myocardial work parameters on the improvement of exercise performance afte	NO
After lung resection, troponin elevation may be regulated by mechanisms other than myocardial ischemia. Perioperative natriuretic peptides measurement may help identify changes in ventricular function during thoracic surg	NO
The investigators have identified underuse of secondary prevention medications at discharge of patients underwent coronary artery bypass grafting (CABG) in China. The aim of this study is to develop series of quality improv	NO
This pilot trial studies how well education and mobile health applications work in reducing the effects of cancer treatment on the heart in participants with blood cancers that are in remission. Education and mobile health app	NO
The objective of this pilot study is to evaluate the efficacy and safety of preoperative administration of levosimendan in patients with chronic heart failure scheduled for major abdominal cancer surgery assuming the reduction	NO
Cardiac perfusion changes have been seen after whole breast / chest wall irradiation for breast cancer. The Active Breathing Coordinator (ABC) device theoretically decreases radiation exposure to the heart during radiation fo	YES
An interdisciplinary team with extensive garden study experience conducted a pilot randomized controlled clinical trial to see whether gardening reduced risk factors for diseases like cancer and heart disease. The pilot trial w	NO
Breast cancer is the most common form of cancer in women. Modern breast cancer treatments have led to increased survival, but at the same time, increased risk for cardiotoxicity and development of heart failure. In this st	NO
HER-2/neu (+) breast cancer is a more aggressive form of breast cancer. HER-2/neu is a protein that is overproduced by your tumor. It makes your cancer more aggressive. Standard treatments for this type of cancer will help The purpose of this study is to see if a new regimen will be effective in preventing cancer from coming back. This is a phase II trial. In this trial, patient get a drug regimen that has been tested in small groups of people to see	YES
The core hypothesis to be tested is that the radiosurgery of stellate ganglion (left one or both if left-sided without full relief of symptoms) is an effective therapy of refractory angina pectoris in patients with no other therapeutic	NO
Myocardial injury after noncardiac surgery is significantly related to postoperative 30-day mortality. Trigeminal cardiac reflex is one of the main causes of perioperative cardiac emergency. Therefore, the investigators' aim is to	NO
This is a Phase I, multicenter, 2-part study with Part 1 designed as a safety lead-in and Part 2 designed to evaluate the effect of GSK2118436 on cardiac repolarization (corrected QT interval \[QTc\] duration) as compared with Each part of the study will consist of screening (14 days prior to the start of the study treatment), treatment and follow-up period (14 days). In Part 1 in Cohort 1 six subjects will receive GSK2118436 225 mg twice a day (BID) on study days 1 to 7 and a single 225 milligram (mg) dose on morning of Day 8. Based on the safety data of subjects in Cohort 1 subjects v In Part 1 of the study the decision to proceed to the next cohort or Part 2 of the study will be based on the safety data of at least 6 evaluable subjects (\<=1 DLTs during the 14 days following the first dose of GSK2118436). In Part 2 of the study eligible subjects will receive a single dose of GSK2118436/placebo (4 capsules of 75 mg/highest tolerated dose) orally on the first 2 days of the study followed by 2 doses daily for 6 days and a single do In both the parts of the study serial blood samples for pharmacokinetic (PK) analysis for GSK2118436 and its metabolites (GSK2285403, GSK2298683 and GSK2167542) will be obtained at the same time points on the first a	NO
10-year CHD risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors.	NO
The study aims to investigate if physical capacity obtained in the cardiopulmonary exercise test can predict cardiovascular alterations in Hodgkin Lymphoma (HL) Survivors. In addition, to study the effects of exercise training	NO
The NOR-COR study is a cross-sectional, observational study designed to explore a large number of cardiovascular, inflammatory, genetic, behavioral, and psychosocial factors (including anxiety, depression, quality of life) in The main overall aim of the NOR-COR study is to develop new strategies to improve secondary prevention for underserved high risk patient-groups with CHD. The first study phase aims to collect information necessary to de The study will evaluate current secondary preventive programs and explore the mechanisms that link behavioral, psychosocial, inflammatory, and genetic factors to poor prognosis. The study will in short term provide new kn	NO
The purpose of this study is to find a way of detecting infection earlier in patients receiving bone marrow transplant. This is accomplished by continuous individualized monitoring of heart rate, respiratory rate and temperature	NO
Subtle myocardial deformation abnormalities in asymptomatic nf-1 patients: is cardiac screening needed?	NO
The primary objective is to assess the safety and efficacy of switching from direct oral anticoagulants to low molecular weight heparin in cancer patients during antineoplastic therapy	NO
Breast radiotherapy RT used until the 1990s was clearly responsible for increased mortality due to long term cardiac complications. Since the 2000s, improvements have appeared in dose distributions to organ at risks such a	NO
The purpose of this study is to assess the protective effect of Valsartan on chronic cardiotoxicity induced by CHOP.	NO
The purpose of this research study is to understand what effect near complete estrogen deprivation (NCED) therapy has on the heart in breast cancer patients. Investigators want to understand if NCED changes how the hear	NO
Breathlessness is a common and distressing symptom in patients with advanced diseases like cancer, chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF) or lung fibrosis, which broadly impacts on pat This single-blinded randomized controlled fast track trial evaluates the effectiveness of a multi-professional breathlessness service in patients with advanced and chronic diseases. The intervention group will get immediate ac	NO
observational prospective study, designed for patients with colorectal cancer receiving for the first time 5-FU or capecitabine, with or without other chemotherapy combinations.	NO
This is an observational study of the occurrence of cardiac toxicity in patients with breast cancer,lymphoma or leukemia receiving chemotherapy including an anthracycline. Patients will be identified at the oncology clinic and Safety will be assessed through reporting of serious adverse events (SAEs) related to study procedures.	NO
The potential cardiovascular toxicity of tumor treatment and its resulting cardiovascular events have gradually become an important health risk for tumor survivors. Prevention and early identification of cardiovascular toxicity One hundred and twenty breast cancer patients planning to undergo radiotherapy or chemotherapy will be included and randomly divided into a crocin group and a placebo group to observe the effect of total saffron tablets Primary study endpoints include the differences between groups in the difference in LVEF and GLS measured by echocardiography at the end of the experiment compared to baseline. Secondary study endpoint include the d	NO
The goal of this clinical research study is to learn if the radiation that you are receiving will result in an increase in certain proteins produced by the heart called cardiac biomarkers.	NO
Patients with loco-regional NSCLC planned for curative treatment with chemoradiotherapy will be invited to participate in a prospective study; besides routine treatment, the patients will be followed with an ECG and cardiac	NO
This study aims to discover more about radiation techniques for people treated for left-sided breast cancer that minimizes exposure to the heart, as noted by mean heart dose.	NO
This two-year pilot study will test whether a one-page "Jumpstart Form" will affect goals-of-care discussions in the hospital. This form will be provided to clinicians and will include patient-specific information about preferenc	NO

The current study is aimed to evaluate various imaging methods, including multidetector computed tomography (MDCT) as potential surrogates to assess the degree of damage caused to the heart by radiation therapy to the	NO
Surgery of large cerebellopontine angle (CPA) tumors (\>2 x 2 cm diameter), with compression of the pons exposes the patient to inadvertent parasympathetic nerve stimulation (IPNS) leading to bradycardia and asystole. The analgesia nociception index (ANI) monitor assesses the balance between analgesia and nociception through the detection of parasympathetic tone. ANI \>80 generally denotes excessive analgesia (EA). The main objectiv	NO
Background: - Research has shown that certain proteins in cells may be linked to higher risks of developing inflammations, tumors, and other medical problems. By examining how the blood cells of healthy volunteers respond to environm Objectives: - To examine how specific genes and proteins in blood cells respond to environmental exposures. Eligibility: - Healthy volunteers between 18 and 45 years of age. Design: * The study will involve one visit of 45 to 60 minutes. * Participants will be screened with a brief physical examination and finger stick to determine if they are eligible to donate blood for the study, and will complete a questionnaire about any medications or other drugs (e.g., ciga * Participants will provide a blood sample for research purposes.	NO
Subjects will include patients diagnosed with breast cancer or hematological cancer who are planned for chemotherapy treatment with anthracycline or trastuzumab; and who have one or more risk factors for cardiovascular	NO
The purpose of this study is to define the natural history of untreated cardiac tumors, study the pathology of primary cardiac tumors, review the surgical treatment and results of primary cardiac tumors and to determine the p	NO
Cancer survival has improved steadily due to earlier detection and treatment. Despite the established efficacy of anthracycline chemotherapy, its damaging effects on the heart (cardiotoxicity) limits treatment and confers acu Furthermore, these conventional therapies are constrained by important side effects that affect bone marrow, blood pressure, and the kidneys. Remote ischaemic conditioning (RIC) protects the heart by activating cell survival pathways through brief repeated inflations and deflations of a blood pressure cuff to limit blood flow temporarily (noninjurious ischaemia). Thes The investigators propose a pilot single centre randomised controlled trial to investigate the effect of RIC on reducing heart muscle damage (myocardial injury) in anthracycline-treated cancer patients. The investigators will as	NO
The purpose of this study is to determine whether concomitant radiotherapy and trastuzumab (patients treated for early breast cancer) is really safe for the heart even years after treatment and if the investigators should use t	NO
The purpose of this study is to see if MRI techniques can be used for early evaluation of cardiac amyloidosis which is sometimes seen in individuals with multiple myeloma. Cardiac amyloidosis is a medical disorder that decr	NO
Compelling epidemiological evidence indicates that alterations of relative telomere length (RTL) are associated with cardiac dysfunction caused by chemotherapy in children with acute leukemia (AL).The aim of this study was	NO
Cancer affects 1 in 2 people during their life. Major improvements in cancer treatment mean that many people are now living longer with cancer. But certain cancer drugs have the potential to damage the heart and blood ves Adverse cardiac events lead to disruption of chemotherapy and can lead to adverse cancer outcomes. Some patients will require alternative treatment. Most cardiac events occur during the early cycles of treatment with fluo Currently, we do not know how to predict which patients are most likely to be affected. Patients deemed to be at a high cardiovascular risk are often denied this treatment which is first line for all gastrointestinal cancers. Ther If we were able to confidently identify patients at the highest risk, then we could potentially reduce risk of toxicity by giving cardioprotective medications or we would be able to confidently identify those who should be given In this study, we will prospectively perform a cardiovascular risk assessment in patients prior to initiation of chemotherapy using QRisk3. We will also perform baseline and serial electrocardiography and cardiac biomarkers w	NO
The main objective of this study is to compare the proportions of late enhancement in patients with Left ventricular (LV) dysfunction as Herceptin ® and in a control group consisting of patients who did not have LV dysfunctio	NO
Survivors of Hodgkin Lymphoma (HL) are known to have an increased risk of developing late treatment sequelae such as cardiovascular events due to coronary artery disease. At present no active screening is performed in t	NO
Totally 60 subjects will be included in the study. The present study was aimed to observe and evaluate the effect of Xinmailong injection on reducing cardiovascular toxicity associated with adjuvant chemotherapy after breast	NO
Children with Cancer or congenital heart disease (CHD) experience complex, physical, psychosocial and behavioural symptoms and problems due to the illness, treatment, and medical procedures. To help children cope with This quasi-experimental study with 202 children age 7-12 with CHD or cancer will test the following hypotheses: When children use SiSom to report their symptoms and problems, and this information is provided to their clini * Children and parents will experience less anxiety. * Children and parents will be more satisfied with the outpatient visit. * There will be greater congruence between children's reported symptoms and problems and those addressed by their clinicians as evidenced in documented patient care. To better understand the mechanisms by which these effects may occur, the investigators will also explore: * Differences between control and experimental groups in patient-provider communication in terms of instrumental and affective behaviour, participation, initiative and person addressed; * The relationships among outcomes of patient-provider communication, congruence between patients' reported symptoms and those addressed by their clinicians and children's and parents' anxiety and satisfaction; and ho Finally, the investigators will investigate time requirements, ease of use and usefulness of SiSom by children and clinicians. For analyses the investigators will use inferential statistics and qualitative analyses of the video-taped consultation sessions. This study will contribute to improving patient-centred care for a particularly vulnerable population,	NO
This is a pilot study to determine if there are changes in heart function following completion of radiation therapy for breast cancer as measured by cardiac magnetic resonance imaging (cardiac MRI) scans. Additional purpose	NO
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoc PURPOSE: This randomized phase II trial is studying the side effects and how well giving doxorubicin together with cyclophosphamide followed by trastuzumab, paclitaxel, and lapatinib works in treating patients with early-s	YES
Helical tomotherapy nowadays provides the most precise data on radiotherapy (RT) dose delivered to each region of the heart in left-sided breast cancer therapy, which allows greater sparing of the heart from doses associat Objective: The pilot study aims to investigate the correlation of post-tomotherapy cardiovascular effects with myocardial perfusion and cardiac functional studies. Methods: The study plans to enroll female breast cancer patients who will undergo local RT after their surgery. Patients will receive global risk scoring assessment (Framingham Risk Score, FRS), blood sampling for basic bioc	NO
Patients with cancer have a higher incidence of AF but despite the higher incidence of AF in the cancer population, there are no randomized controlled trials (RCTs) for AF screening in this population. RCTs of AF screening in	NO
The primary objective of the study is to assess the relationship (both crude and adjusted) between voriconazole utilization and the development of non-melanoma skin cancer among adult patients who received a lung or hea	YES
This study evaluates the incidence of cardiac arrhythmias during the perioperative period in patients undergoing open kidney cancer surgery in the lateral position. All the participants will be randomly allocated to receive gen	YES
Several studies have been reported that heart rate is known to be associated with prognosis in chronic diseases and acute diseases. For example, a decrease in heart rate following myocardial infarction may lead to a higher The combined pituitary function test artificially induces hypoglycemia to observe the secretion of pituitary hormone. The degree of change in heart rate during hypoglycemia can predict the adequacy of the test, and heart rat In our study, we used a licensed device approved by KFDA (Korea Food and Drug Administration) to measure heart rate variability in patients with pituitary adenoma.	NO
A complete family history (FH) may identify persons at high risk for certain conditions. They can be offered genetic testing and life-saving screening and treatment. In practice, complete FH is rarely collected or entered into th	NO
This research study can help understand how cardiac changes may occur with radiation therapy to the heart based off measurements obtained through biomarkers and cardiac imaging. Researchers plan to perform cardiac imaging and biomarkers for any cardiac injury. Cardiac magnetic resonance imaging (CMR) provides the ability to quantitatively measure cardiac function and injury. The cardiac biomarke	NO
Liver stiffness measurement (LSM) by non invasive methods is increasingly used to estimate liver fibrosis in patients with chronic liver diseases. However, there is growing evidence that fibrosis is not the only determinant of li	NO
This proof-of-principle clinical trial at Mayo Clinic studies how patients and their physicians understand and utilize predictive genetic risk assessment. A critical goal of this clinical trial is to understand how individual patients	NO
The purpose of this study is to evaluate if carvedilol can prevent the cardiotoxicity after chemotherapy in breast cancer.	NO
The overall aim of this study is to improve our understanding of the effects of the build-up of amyloid deposits in the heart, in particular, our understanding of the risk of abnormal heart beats, or rhythms, associated with peop Some of these abnormal heart rhythms can be treated with medicine; others need electronic devices (e.g. pacemakers) implanted or inserted in the heart to prevent serious harm. The information on when is the best time to i This will help us answer some of the questions about what causes the abnormal heart rhythms, when they happen, and which patients are particularly likely to have them. Furthermore, it may help us to identify earlier, rather t	NO
There has been no study comparing the complication rates between internal jugular vein catheterization and subclavian vein catheterization when they are performed using sonographic view. This prospective study would rev	NO
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and pre	NO
Research shows that low-dose Aspirin prevents diseases of heart and blood vessels as well as cancer of the colon and rectum and it is also associated with risk of bleeding. In this study, they want to learn how patients rega	NO
The purpose of this research study is to demonstrate that Deep Inspiration Breath Hold (DIBH), the technique used at the University of North Carolina (UNC) for left-side breast cancer radiation therapy, can reduce side effects	NO
This study will explore whether ivabradine lowers heart rate, and thus improves exercise capacity, in survivors of lymphoma who have an elevated resting heart rate as a side effect of prior radiation treatment. The drugs involved in this study are: * Ivabradine * Placebo	YES
This is an observational, retrospective pharmacovigilance study based on reports registered and transmitted in VigiBase®, the WHO's international database. This study includes all reports identified as exposure to an ICI and suspect of inducing adverse drug reaction. The aim of the study is to characterize immune-related adverse reactions associated with immune-checkpoint inhibitors, particularly their time-to-onset, co-occurence, factors associate with their over-report and fatality.	NO
RASopathies are a group of syndromes, caused by variants of genes involved in the regulation of the Ras/MAP/ERK pathway. This intracellular transduction pathway profoundly affects embryogenic development, organogene RASopathies are characterized by multi-organ involvement, growth delay, premature aging and haemato-oncological manifestations. Based on evidences provided by literature, cancer screening protocols are applied in some individuals affected by RASopathies, even though detailed information about prevalence and molecular pathogenesis of such tumor	NO
Gastroesophageal reflux disease(GERD) mainly related to the reflux of stomach content induced by the dysfunction of lower esophageal sphincter. Proton pump inhibitors (PPI) can effectively block gastric acid secretion but t	NO
Neoplasia is the main cause of general death in the Brazilian population. In 2016, they were responsible for approximately 211,343 (16%) deaths, followed by cardiovascular diseases (12.6%). Despite the high mortality rate o	NO
An observational, prospective study to describe the rates and predictors of cardiovascular events in patients with acute leukemia.	NO
The purpose of this study is to compare the effects of the consumption of two different dietary patterns (low fat versus Mediterranean Diet) on the incidence of cardiovascular events of persons with coronary disease.	NO
The purpose of this study is to evaluate the cardiac safety of Caelyx in patients with metastatic breast cancer who have previously received chemotherapy with anthracyclines.	YES
At the time of hysterectomy for benign disease, the overall health benefits of preserving ovarian function in a large population of women have not been established.	NO
This randomized pilot clinical trial studies how well positron emission tomography (PET)-magnetic resonance imaging (MRI) works compared to standard-of-care PET-computed tomography (CT) in diagnosing patients with ca	YES
The purpose of this study is to describe the design, methodology and evaluation of the preclinical test of Carebot AI CXR software, and to provide evidence that the investigated medical device meets user requirements in ac	NO
This study will report the incidence of atrial fibrillation after elective colorectal cancer resection in the over 65 age group. This will be used to validate a risk model for the development of post-operative atrial fibrillation. Eligible patients will undergo electrocardiogram based screening for atrial fibrillation, as well as brain natriuretic peptide tests prior to surgery. They will undergo 24 hour holter monitor prior to surgery, and at 30 and 90 days fo The primary outcome will be occurrence of atrial fibrillation within 90 days of surgery. Secondary outcomes include quality of life change, use of hospital services for atrial fibrillation, and complications of atrial fibrillation. This	NO
The investigators aim to optimize the radiation treatment of early stage lung cancer patients. Therefore, detailed understanding is needed of the type of toxicity and the location of these toxicities for patients who receive high	NO
To assess the role of myocardial oedema on CMR (T2 mapping) after radiation therapy and cardiotoxic systemic therapy in predicting the incidence of cardiotoxicity, defined as by consensus guidelines* (decline of LVEF ≥10	NO
This phase IV clinical trial investigates the impact of prostate cancer treatment, specifically androgen deprivation therapy (ADT), on the heart and coronary vessels among men with localized, non-metastatic prostate cancer u	NO
The purpose of this study is to evaluate the feasibility and tolerability of delivering a full dose, on time schedule of dose-dense CDOP-R (cyclophosphamide, doxil, vincristine, prednisone, and rituximab) in NHL.	NO
This study will investigate the influence of systemic adjuvant/neoadjuvant therapy (SAT: chemotherapy +/- anti-HER2 antibodies (trastuzumab +/- pertuzumab) on heart function/rhythm and cardio-respiratory fitness in recentl	NO
This is a single cohort observational safety study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are plan	NO
The aim of the study is to analyze the protective impact on the cardiac damage of beta blockers and ACE inhibitors for breast cancer patients treated with anthracyclines-based chemotherapy with or without trastuzumab.	NO
This study aims to evaluate prevalence of sarcopenia and cachexia in patients with chronic cardiopulmonary disease. The investigators will also investigate metabolic disorders like glucose metabolism, presence of metabolic	NO
Real clinical practice register of Albuminuria detection in patients with previously undiagnosed chronic kidney disease	NO
Tyrosine kinase inhibitors such as sunitinib are used in the treatment of renal cell carcinoma and have significant off-target effects with cardiac toxicity and resultant ventricular cardiac dysfunction being a major concern. How	NO
This research is a multi-center prospective cohort interventional study aimed to determinate the capabilities of remote 1-minute single-lead electrocardiogram monitoring for cardiotoxicity detection, during two- three weeks (	NO
The purpose of the present study is to investigate the effect of ACE inhibitors and the sacubitril-valsartan complex in bone marrow transplant patients by assessing cardiovascular and endothelial parameters in order to searc	NO

Diffuse large B-cell lymphoma is the most prevalent subgroup within malignant lymphoma. Clinical benefit has been shown for the treatment with cyclophosphamide, doxorubicin, vincristin and prednisolone (CHOP regimen); Improved response and overall survival rates make it necessary to evaluate late toxicities of the therapy regimens. Cardiotoxicity is a known risk factor of specific chemotherapies, with 7% patients being affected if doxorubic The aim of this study is to evaluate alternative regimens for the treatment of diffuse large B-cell lymphoma, substituting liposomal doxorubicin (R-COMP) for conventional doxorubicin (R-CHOP).	NO
The purpose of this study is to determine whether providing individuals with personalized information on cellular aging, including telomere dynamics, will stimulate them to adhere to cardiac prevention strategies and improve	NO
This study will evaluate the change in cardiac iron load over a 53 week period measured by MRI in 2 cohorts of patients	NO
Aim of the work This study aims to evaluate the possible beneficial role of silymarin in attenuating both doxorubicin related cardiac and hepatic toxicities and paclitaxel associated peripheral neuropathy and improving cogniti This study will be a randomized placebo controlled parallel study. The study will be performed in accordance with the ethical standards of Helsinki declaration in 1964 and its later amendments. Group one: (Placebo group; n=28) which will receive four cycles of AC regimen (doxorubicin and cyclophosphamide; each cycle was given every 21 day) followed by 12 cycles of paclitaxel (each cycle was given in a weekly b Group two: (Silymarin group; n=28) which will receive the same regimen plus silymarin 140mg once daily	NO
Advances in medicine have led to an increased life expectancy even with complex disease courses of malignant diseases. This leads to frequent critical situations for patients and high risk surgical interventions. The majority of patients and their practitioners are not prepared for the consequences of a complex and possibly fatal course. Palliative medicine makes it possible to anticipate the further course of the disease. As a result, palliative medicine has become increasingly important. The beginning of palliative medical interventions has extended from acc An early integration of palliative medicine showed a positive effect on the quality of life, the degree of depression and survival in patients suffering from cancer, for example. Furthermore, patients were more able to accept a c What needs further investigating is how to adequately screen and identify the patient populations who could benefit from early palliative care, so that they are prepared for potentially critical and life-threatening situations. The investigator's objective is therefore whether the Anesthesiology Outpatient Clinic is a suitable screening location for initiating early integrated palliative care for patients with a serious, life-shortening illness and a high peri	NO
The study aims to identify specific or potential reasons that prolong the length of hospital stay after video-assisted thoracoscopic surgery lobectomy. The hypothesis is that patients who are still in hospital after video-assisted thoracoscopic surgery lobectomy are associated with prolonged air leak, infection, pneumonia, atrial fibrillation or other complications or social facto	NO
The purpose of this study is to discover genes that may cause Coronary Artery Disease (CAD) or Arteriovenous Malformation (AVM).	NO
This study examines TRPC6 in predicting and preventing chemotherapy related cardiac toxicity and heart failure in patients with breast cancer. Cardiac toxicity, changes in heart function is a well-recognized complication of c	NO
This phase III trial compares the effect of telotristat ethyl and the current standard of care somatostatin analog therapy or somatostatin analog therapy alone in treating patients with neuroendocrine tumor that has spread to o	NO
This is a protocol to facilitate on-site calibration of the technical aspects of the Siemens Biograph mMR (molecular MR) Positron Emission Tomography-Magnetic Resonance (PET-MR) scanner and the 3T Siemens Vida MR s	NO
Abiraterone associated with prednisone is used in prostate cancer. Abiraterone is a selective small-molecule inhibiting cytochrome P450 17A1 (CYP17A1), a key enzyme in androgen synthesis. CYP17A inhibition is also responsible for mineral corticosteroid related adverse events as hypokaliemia, fluid retention, and hypertension. Primary hyperaldosteronism is associated with cardiovascular toxicities such as atrial This study investigates reports of cardiovascular toxicities for treatment including L02 (sex hormones used in treatment of neoplastic diseases), and G03 (sex hormones) used in prostate cancer in the French pharmacovigilan	NO
To establish if the cardiac radiation dose assesment is well aproximated with routine 3D CT scan compared to 4D CT experimental scan with respiratory gating (breath motion monitoring). The study population relates to left s	NO
To determine associations between dietary factors and risk of major chronic diseases and their risk factors	NO
For patients with an advanced disease and their families an excellent and compassionate care is essential. However, in hospitals optimal end-of-life care is not yet fully realized and patient's needs are often not met. Palliative To improve the awareness of unmet needs patient-reported outcome measurement has been the pivot of latest palliative care research. Besides the improvement of care outcome measurement allows the evaluation of the qu The aim of the present study is to evaluate the quality of palliative care in different settings (palliative care unit, inpatient and outpatient consultation teams) using the Integrated Palliative Care Outcome Scale (IPOS). The IPOS The clinical study hypothesis bases on the assumption that palliative care can change the symptom burden, measured by a change in the IPOS overall profile score, and that there might be a difference in the size of the effec	NO
Until now, patients receiving doxorubicin chemotherapy should use only the cumulative dose related to known cardiotoxicity, or if cardiotoxicity occurs below the known cumulative dose, use of doxorubicin as chemotherapy	NO
Cardiomyopathy is a major complication of doxorubicin (DOX) chemotherapy, and 10-21% of breast cancer patients receiving DOX experience compromised cardiac function. Recent advancements have increased cancer su	NO
We hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whet	NO
This is a nationwide cohort study on real-world patients (n≈30,000) surviving a first myocardial infarction (MI) 2006-2013 and alive to attend a routine 1-year follow-up. Associations between Socioeconomic Status (SES) and s	NO
The overall aim is twofold: 1) to stretch the borderline regarding the present knowledge of clinical and economic cost-effectiveness of eHealth as an aid for facilitating and supporting self-management in families with long-ter A number of clinical studies are planned for, covering different parts of paediatric healthcare. The concept of child-centred care is essential. Experienced researchers from care science, medicine, economics, technology, and Child health is not only important in itself. Investments in child health may also generate significant future gains, such as improved educational and labour market performance. Six complex, long-term and costly challenges ir	NO
This study allows the evaluation of subjects in order to determine their ability to safely participate in other active research studies. After subjects complete the screening process, they will be offered the opportunity to participate in an active research study, or if no appropriate studies are available information and recommendations will be provided for oth	NO
The purpose of the study is to evaluate a new radiotracer called 64Cu-FBP8 for PET-MR imaging of thrombosis. The tracer has the potential of detecting thrombosis anywhere in the body, for instance in the left atrial appenda	NO
This study will describe the epidemiology including prognosis of heart failure related to treatment with anthracycline and trastuzumab for breast cancer. In a prospective study Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer patients scheduled for trastuzumab treatment at Odense University Hospital, will be offered advanced echocardiographic exa	NO
Semi-structured qualitative interviews will be conducted to understand key factors that would enable / facilitate patients with chronic breathlessness to potentially use an online breathlessness intervention (SELF-BREATHE).	NO
This is a single-center, double-arm, open-label, randomized feasibility study that will determine whether a novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and th	NO
RATIONALE: Tamoxifen may be able to increase bone density and decrease cholesterol in women who are undergoing chemotherapy for breast cancer. PURPOSE: Clinical trial to study the effectiveness of tamoxifen in preventing bone loss and heart disease caused by chemotherapy treatment in premenopausal women who have stage I or stage II breast cancer.	NO
The objective of this hybrid effectiveness-implementation study is to examine the effects of an EHR-based cardiovascular health assessment tool (AH-HA) among breast, prostate, colorectal, endometrial, and Hodgkin and nc	NO
The purpose of this prospective open-label phase II study, is to evaluate the efficacy of pasireotide twice daily subcutaneous injections for normalizing 24 hour urine free cortisol in patients with ectopic ACTH-producing tumo	NO
RATIONALE: Studying samples of blood in the laboratory from patients with cancer treated with trastuzumab may help doctors learn more about biomarkers related to heart dysfunction. It may also help doctors predict whic PURPOSE: This clinical trial is studying biomarkers to see how well they predict heart dysfunction in women with breast cancer treated with trastuzumab.	NO
The purpose of this study is to look at the rates of acute and long term adverse events of postoperative proton radiotherapy for complex loco-regional irradiation in women with loco-regionally advanced breast cancer. This st	NO
Dopamine agonists are first-line agents for the treatment of prolactinomas (1) and Parkinson's disease (2). There is evidence supporting a causal relationship between the occurrence of drug-induced "restrictive" valvular hear Two recent studies (7,8) have further demonstrated that both pergolide and cabergoline are associated with an increased risk of new cardiac valve regurgitation in patients treated for Parkinson's disease. The valvular abnormalities seen with ergot-derived dopamine agonists are similar to those observed in patients receiving ergot alkaloid agents (such as ergotamine and methysergide) in the treatment of migraine, or fenfluram Cardiac valve disease has never been reported in patients with prolactinomas who require treatment with dopamine-agonists even life-long (1). At variance with patients with Parkinson's disease, patients with prolactinomas a To assess the prevalence of cardiac valve disease in patients treated with cabergoline, we wish to perform an echocardiography screening in a large representative sample of patients with prolactinoma who were treated with	NO
Introduction Rare complex syndromes Patients with complex genetic syndromes, by definition, have combined medical problems affecting multiple organ systems, and intellectual disability is often part of the syndrome. Duri Increased life expectancy Although many genetic syndromes used to cause premature death, improvement of medical care has improved life expectancy. More and more patients are now reaching adult age, and the complex Medical guidelines for adults not exist and the literature on health problems in these adults is scarce. Although there is a clear explanation for the absence of adult guidelines (i.e. the fact that in the past patients with rare gen The aim of this study is to get an overview of medical needs of adults with rare genetic syndromes, including: 1. comorbidities 2. medical and their impact on quality of life 3. medication use 4. the need for adaption of medication dose according to each syndrome Methods and Results This is a retrospective file study. Analysis will be performed using SPSS version 23 and R version 3.6.0.	NO
This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.	YES
This is a no-profit, national, monocenter, retrospective, and prospective low-intervention study. It is a low-intervention study in terms of diagnostic additional procedure (CT scan). It is planned to recruit a maximum of 100 wo	NO
This is an observational study aiming to prospectively define the rate of occurrence, natural history and progression of cardiac dysfunction in adults, and to identify the patients at high risk of developing cardiovascular events	NO
A study to test the effectiveness of an investigational imaging technique for detecting cardiac injury after the administration of certain chemotherapies, such as doxorubicin. "Investigational" means that the imaging technique The chemotherapy drug that you have been scheduled to be treated with, doxorubicin, has been associated with the development of heart failure in some patients. Cardiac Magnetic Resonance (CMR) is a type of MRI scan t	NO
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemoprotective drugs such as dexrazox PURPOSE: Phase III trial to study the effectiveness of three combination chemotherapy regimens plus dexrazoxane in treating patients who have newly diagnosed nonmetastatic osteosarcoma.	NO
Recently, the medical management of cancer patients has considerably improved the prognosis of these patients and today some cancers are becoming "chronic diseases". As a result, new adverse effects (AEs) are observe These "new" cardiac AEs are the consequence of a significant increase in patients life expectancy (delayed AEs not previously seen) but also the use of new pharmacological classes of anticancer drugs such as kinase inhibit In this context, we started at the University Hospital of Caen Normandy in September 2017 a cardio-oncology program entitled "prevention and pharmacological management of cardiac adverse effects induced by drugs use The constitution of this cohort is only the first step towards the constitution in the near future (2 years) of an observatory and then a regional registry of cardiac AEs induced by anticancer drugs. The objectives associated with	NO
The purpose of this study is to determine if exercise preconditioning can mitigate the off target effects of chemotherapy treatment on measures of cardiovascular function, inflammatory responses, and quality of life.	NO
Primary Objective: -Evaluate incidence of cardiac complications in Phase I patients. Secondary Objective: -To identify variables (i.e. number of electrocardiograms (EKG) performed) that lead to the detection of cardiac events.	NO
Comparing preventive effect of myocardial global longitudinal strain-based cardioprotective stragety (angiotensin receptor blocker prophylaxis) with left ventricular ejection fraction-based strategy in breast cancer patients tre	NO
The goal of this behavioral research study is to learn if education and training about exercise can help to change the lifestyle of cancer survivors with symptoms of heart failure.	NO
The purpose of this study is to look at a new method for finding out if patients have a risk of heart complications from surgery. At the present, to find out if patients have a risk of heart complications from surgery, look at whet	NO
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This clinical trial is studying the effect of chemotherapy on heart function in treating women who have breast cancer with negative axillary lymph nodes and who are undergoing treatment on the SWOG-8897 clinic	NO
The aim of the BRAGATSTON study is to provide a low cost tool for measuring CAC in breast cancer patients, thereby identifying patients at increased risk of CVD. Breast cancer patients and doctors can act upon this, by ac	NO
The purpose of this study is to evaluate cardiac safety of brentuximab vedotin (SGN-35) in patients with CD30-positive cancers. The study will assess electrical activity of the heart before and after brentuximab vedotin admin	NO
This was a single center, proof-of-concept (PoC), Phase II study. Patients with histologically confirmed early stage (Stage I, II or III) HER-2 negative breast cancer and scheduled to receive doxorubicin-based (neo)adjuvant the 1. Screening/baseline, i.e. 2 weeks prior to initiating AC treatment (Visit 1) 2. After the 2nd and before the 3rd cycle of AC treatment (Visit 2) 3. After the 4th cycle of AC treatment and within 2 weeks (Visit 3) 4. At 12 weeks after the 4th cycle of AC treatment (Visit 4). The imaging procedures were conducted and analyzed. Bloodwork for cardiotoxicity biomarkers (troponin, N terminal pro B-type natriuretic peptide \(NT-proBNP\)) v	YES
Trastuzumab prolongs survival in patients with human epidermal growth factor receptor type 2-positive breast cancer. Sequential left ventricular (LV) ejection fraction (EF) assessment has been mandated to detect myocardial	NO
The purpose of this study is explore the impact of lung cancer surgery on the function of the right side of the heart.	NO
Anthracycline antibiotics are included in the chemotherapy regimens of approximately 82% of patients with bone cancer and 44% of those with soft tissue sarcoma diagnosed in childhood or adolescence. Impaired cardiac f This non-therapeutic study proposes a prospective, single arm study of serial changes in tissue Doppler imaging parameters, cTn-T and NT-BNP in children and adolescents with malignant bone and soft tissue tumors whose The proposed study will rigorously evaluate the usefulness of serial determinations of tissue Doppler imaging, cTn-T and NT-BNP for very early identification of anthracycline-related myocardial injury. Demonstration that one	NO
The purpose of this investigation is to see if the TRICENTO Valved Stent Graft implant reduces tricuspid regurgitation (TR) and improves the symptoms and quality of life in 15 participants with carcinoid heart disease, and wh	NO
The objective is to develop and test, through an iterative process, an intervention to address and support the development of infants with a confirmed diagnosis of neurogenetic disorders that leave individuals at risk for devel Participants will be infants with a confirmed diagnosis of a neurogenetic disorder (e.g., fragile X, Angelman, Prader-Willi, Dup15q, Phelan-McDermid, Rhett, Smith Magenis, Williams, Turner, Kleinfelter, Down syndromes, Duch The intervention, called Parent-infant Inter(X)action Intervention (PIXI) is a comprehensive program inclusive of parent education about early infant development and the neurogenetic disorder for which they were diagnosed, d	NO
Sympathetic activity could be increased during robot-assisted laparoscopic radical prostatectomy, which is performed in a steep trendelenburg position under CO2 pneumoperitoneum. Stimulation of the sympathetic nervous system prolongs the QT interval and can increases the susceptibility to life threatening cardiac arrhythmias. Dexmedetomidine has sympatholytic effects and potential antiarrhythmic properties. Perioperative administration of dexmedetomidine is a potential preventive and treatment strategy for tachyarrhythmia. Thus the investigato	NO
Advanced soft tissue sarcoma patients who have previously recieved anthracyclines might still benefit from doxorubicin, ifosfamide and dacarbazine. However doxorubicin might be stopped using because of chronic cumulat	NO
The aim of Patient-Centred Innovations for Persons With Multimorbidity (PACE in MM) study is to reorient the health care system from a single disease focus to a multimorbidity focus; centre on not only disease but also the p	NO
Anthracycline based anti-tumoral therapies are know to develop cardiac damage that could also lead to heart failure. Monocentric studies proved that a treatment with ACE inhibitors (ACEi) and betablockers (BB) during the f ICOS-ONE trial is a multicenter randomized trial comparing two therapeutic strategies. The main objective is to assess whether enalapril started concomitantly to AC-containing treatments, can prevent cardiac toxicity more e	NO

The purpose of this study is to improve the cardiovascular care of adult cancer survivors. The goal is to obtain the data necessary to plan and develop a nation-wide network of a screening program that can help provide cost	NO
1. PHACE syndrome(OMIM database number 606519) is the association of a vascular birthmark (hemangioma) on the face along with one or more of the following conditions: congenital heart defects, congenital anomalies of 2. A research study is currently being conducted at the Medical College of Wisconsin (MCW) to investigate if there is an inherited cause of PHACE syndrome. 3. We are hoping that this study will lead to a better understanding of how and why children develop PHACE syndrome.	NO
This study will develop a whole-of-body markerless tracking method for measuring the motion of the tumour and surrounding organs during radiation therapy to enable real-time image guidance. Routinely acquired patient data will be used to improve the training, testing and accuracy of a whole-of-body markerless tracking method. When the markerless tracking method is sufficiently advanced, according to the PI of	NO
A systematic literature search a goal-directed haemodynamic algorithm was created. The hypothesis of this study was that the goal-directed haemodynamic algorithm is feasible and can improve clinical outcome.	NO
The aim of Patient-Centred Innovations for Persons With Multimorbidity (PACE in MM) study is to reorient the health care system from a single disease focus to a multimorbidity focus; centre on not only disease but also the p	NO
Breast cancer is a chronic disease that has seen a boom in research into its treatments, improvements and effects in recent decades. These advances have also highlighted the need to use physical exercise as a countermea	NO
Management of patients with lymphoma is based on the administration of a chemotherapy containing anthracyclines (ATC), and allows cure rates of 65% to 80% at 5 years. The administration of ATCs can lead to an increase According to the recommendations of the European Society of Cardiology, this identification is based on the measurement of the left ventricular ejection fraction (LVEF) and the overall longitudinal strain (SLG) before and after	NO
The purpose of this study is to assess whether it is possible and acceptable to monitor patients at a distance who experience a condition called atrial fibrillation after their cancer surgery. Some patients have no other clinical	NO
Inadequate management of preoperative mental health disorders often contributes to poor postoperative outcomes, including increased rates of readmission, delirium, falls, and mortality. However, very little work has been de	NO
This pilot clinical trial studies the side effects of cytarabine and daunorubicin hydrochloride and to see how well they work in treating patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such	NO
Episodic breathlessness is a common and distressing symptom in patients with advanced disease such as cancer, chronic obstructive pulmonary disease (COPD) and chronic heart failure. Since the short duration of the majo The aim of the study is to test a brief cognitive and behavioural intervention for an improved management of episodic breathlessness. Initially, a Delphi procedure with international experts has been used to develop the brief i In the single-arm therapeutic exploratory trial (phase II), the feasibility and potential effects of the brief intervention, such as patient-reported breathlessness mastery, episodic breathlessness characteristics, quality of life, sym	NO
Currently patients with certain cancer usually have routine follow up (Computed Tomography of Thorax, Abdomen and Pelvis) CT TAP scans to see response to treatment or relapse. The study proposal allows the evaluation o	NO
Several large adjuvant trastuzumab trials have demonstrated improved overall survival, in participants with early stage breast cancer, with a 33% decrease in risk of death. However, retrospective analyses of participant outco At this time, investigators are unable to predict which participants are at increased risk of cardiac-related treatment complications. Currently all patients receive regular cardiac imaging throughout their one year of trastuzuma At this time, the optimal monitoring schedule for trastuzumab-related cardiotoxicity remains unknown, and several published consensus guidelines are currently in use as "standard of care.	NO
Lung cancer surgery causes significant changes in the small circulation as well as changes in the intrathoracic anatomy. The effects of lung cancer surgery on electrocardiography and the cardiac stress associated with the pr	NO
Late Cardiac Evaluation of the Three Arm Belgian Trial A phase III randomized trial involving node-positive early breast cancer patients with a long median follow-up (\~ 15 years) OBJECTIFS Primary: • To compare the incidence of late cardiac events between anthracycline and non-anthracycline chemotherapy given to node-positive breast cancer patients in the Belgian three arm randomized clinical trial Secondary: * To compare the late incidence of cardiac events between higher and lower dose anthracycline treated node-positive breast cancer patients; * To compare anthracyclines (higher and lower doses) and non-anthracycline chemotherapy for: * left ventricular diastolic function assessed by Echo * exercise capacity assessed by 6-minute walk test (6MWT) * cardiac morphology (myocardial inflammation or injury, fibrosis, LVEF) assessed by MRI * serum cardiac biomarkers (BNP and TNT) * patient-reported cardiac symptoms * patient-reported cardiac symptoms assessed by QOL questionnaires are associated with subclinical findings on LVEF assessment * cognitive function, functional autonomy, and psychological distress	NO
The purpose of this study is to determine whether discussions of life story, forgiveness, and future goals improve quality of life for patients with serious illness.	YES
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as dexrazoxane, may protect normal cells from the side effects of chemotherapy. M	NO
The purpose of this study is to investigate what effects, if any, picoplatin has on the heart rhythm.	NO
A patient undergoing ophthalmic arterial chemosurgery may experience a sudden, profound decrease in lung compliance when the microcatheter is in the ICA or ophthalmic artery. However, underlying pathophysiology of the	NO
This is an observational study for patients with breast cancer that will be treated with doxorubicin (Adriamycin) and/or trastuzumab (Herceptin). The study will help the investigators learn more about how these medications aff	NO
As for today, transcatheter aortic valve implantation (TAVI) is indicated only in symptomatic patients with severe aortic stenosis (AS) at high surgical risk. As cancer therapy improves, some AS patients suffering active maligna	NO

The essential arterial hypotension and allostasis registry is a prospective, observational research that has the purpose of demonstrating that essential blood pressure (BP) disorders and the associated comorbidities are a resu
 	
To do so, consecutive patients of any age and gender that visit a cardiologist's office in Medellin, Colombia, are recruited. Individuals are classified according to their arterial BP and allostasis and follow them in time to see wi
 	
HYPOTHESIS
 	
The causes of the diseases are multifactorial.
 	
Physical, biochemical, psychological, social, and cultural dimensions of development dynamically interact to shape the health development process.
 	
A person´s health depends on their:
 	
1. Biological and physiologic systems
2. External and internal environment (a) physical, b) internal behavioural and arousal state as registered by the brain.
3. Their interaction.
 	
The allostatic mechanisms to the internal and external stressors (allostatic load) involves a network composed by:
 	
1. Functional systems; mediated by:
 	
  1. The Autonomic Nervous System
  2. The endocrine system
  3. The immune system
2. Structural changes: whenever the internal and/or external stressors are long lasting and/or strength enough, they may induce changes in:
 	
  1. Epigenetic, endophenotypes, polyphenism.
  2. Plasticity
3. The interaction between a) and b).
 	
The network response do not affect exclusively the BP, propitiating the development of comorbidities, which may prompt strategies for prevention, recognition and ultimately, treatment.
 	
The allostatic model defines health as a state of responsiveness.
 	
The concept of psycho-biotype: The allostasis is the result of both: biological (allostasis) and psychological (psychostasis) abilities. It is proposed that both components behave in similar direction and magnitude.
 	
Immune disorders may be associated with the development of cancer. High BP population has a higher sympathetic and lower vagal tone, this has been associated with a decrease in the immune´s system function.
 	
Resources and energy depletion: Terms like weathering have been used to describe how exposures to different allostatic loads gradually scrape away at the protective coating that keeps people healthy. It is postulated that H
	NO

This research study will test whether atorvastatin, a drug commonly prescribed for reducing cholesterol levels, can protect the heart during chemotherapy with doxorubicin. Atorvastatin is from a family of medications that are	NO
To evaluate cardiac MRI and/or serum biomarkers for detecting cardiac cardiac toxicity in children who received anthracycline based chemotherapy (ABC).	NO
This is an observational study that will collect data from adult survivors of childhood cancer and compare it to data collected from age- and gender-matched controls for the purpose of assessing vascular risk among cancer s Advances in cancer therapies have led to increasing numbers of adults previously treated for a pediatric malignancy, many of whom experience late adverse health-related sequelae and are at risk for developing chronic conc	NO
The overall goal of the proposed research is to assess the feasibility of a randomized study evaluating the non-inferiority of an electronic Health (e-Health) delivery alternative (e.g. private web portal) as compared to return of a	NO
Radiotherapy is standard treatment for breast cancer after lumpectomy. Although this treatment showed substantial patient benefits and decrease of local recurrence and deaths from breast cancer, it also results in some sev	NO
The goal of this clinical research study is to learn whether different ways of viewing echocardiogram pictures along with blood tests can help to see heart-related side effects of chemotherapy and trastuzumab earlier than the	NO
This multicenter, prospective cohort study evaluates early cardiac dysfunction in adult survivors of childhood cancer. The hypothesis of this study is that cardiac dysfunction can be detected earlier when using speckle trackin	NO
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in patients with "relapsed or refractory multiple myeloma" (hereinafter referred to as "relapsed or refractory MM") who ha 1. Planned registration period This period started on the date of initial marketing of Revlimid and will end at the time when the planned number of patients to be enrolled, 300, is reached (estimated to be approximately 1 year 2. Planned surveillance period This period started on the date of initial marketing of Revlimid and will end 3 years after the last enrolled patient begins receiving Revlimid (estimated to be approximately 4 years and 3 months).	NO
The purpose of this study is to investigate whether cells from a biopsy taken from the patient skin can be transformed into cardiomyocytes the changes in cardiomyocyte (heart muscle cells) when grown in a special culture m	NO
This is a prospective, multicenter, cohort study aiming to explore the cardiotoxicity of targeted therapy for HER-2 positive breast cancer patients who lives in high altitude area. One hundred and thirty two HER-2 positive brea	NO
To develop a novel, proactive cardiac rehabilitation program for breast cancer survivors at enhanced risk of cardiovascular disease. Considering this program is secondary to the Michigan Medicine Cardiac Rehabilitation pro	NO
This study assesses cardiovascular injury and cardiac fitness in patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (locally advanced) receiving model based personalized chemoradiatior	NO
As part of National Institutes of Health Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) program, the goal of the RADxUP study is to develop, test, and evaluate a rapid, scalable capacity building proje	NO
The participant is being asked to take part in this trial, because the participant is a survivor of childhood cancer.	NO
Primary Objective To evaluate remote cardiomyopathy prediction via smartwatch and one clinical ECG and assess the concordance of the two ECGs in terms of predicted risk. Secondary Objective To build a novel predictive model solely on smartwatch ECG to predict risk for cardiomyopathy.	
The long term goal is to improve quality of care in Veterans with serious illnesses by aligning medical care with Veterans' goals and values. The objective of this study is to use a sequentially randomized trial to determine wha	NO
The BRAVADO Registry pretends to identify stratification, diagnosis, total atherosclerotic burden and treatment approaches in oncologic patients with Acute Coronary Syndrome (ACS) and identify strategies to improve health	NO
The purpose of this study is to evaluate and compare the changes by two modalities: Imaging by Strain by Speckle Tracking and Magnetic Resonance versus soluble markers of cardiac dysfunction as early predictors of card	NO
Calculating which cardiac substructure accepting with the highest radiation dose by conventional radiotherapy, then to investigate the relationship between the changes of global longitudinal strain or cardiac magnetic resona	NO
Immune checkpoint inhibitors (ICIs) might have high grade immune-related adverse events (irAEs) from rhumatologic, endocrinologic, cardiac or other system origin. This study investigates reports of drug induced irAEs with	NO
While sunitinib can be very helpful to treat kidney cancer, these medications can also cause side effects, including heart damage. Studies performed in the past did not look at heart function in detail, so the investigators do n	NO
The introduction of trastuzumab for the treatment of patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer has had a major impact upon cancer outcomes. However, cardiac toxicity remains a	NO
This is a randomized phase III clinical trial of Lanreotide combined with Telotristat ethyl or placebo for the first-line treatment in patients with advanced well differentiated small intestinal neuroendocrine tumours (siNET) with h In addition, the study allows evaluation of the biochemical response (5-HIAA and chromogranin-A), the reduction in the number of daily cutaneous flushing episodes, the improvement in abdominal pain/discomfort, health-rela Patients will enter into a screening/run-in period of 1 week to establish baseline characteristics and symptomatology. The baseline assessment of daily bowel movement, as assessed in an electronic diary, will be averaged ov Following the screening/run-in period, patients will be randomly assigned (1:1) to either the control arm or the experimental arm for 12 months. Randomization will be stratified according to the grade of tumour differentiation (Upon randomization, all patients will enter the 12-month treatment period with lanreotide + telotristat ethyl/placebo (blinded). In the experimental arm, patients will receive the deep subcutaneous injection of lanreotide (120 m After completion of a minimum of 6 months on randomized blinded-treatment, the protocol allows for patients on treatment with telotristat ethyl/placebo to be unblinded in the event of "lack of symptom control". Unblinding c All patients will be unblinded after a maximum of 12 months on randomized blinded-treatment. After a follow-up of 12 months, patients will go off study except patients with carcinoid heart disease. Patients off study will be further treated as per clinician discretion. Patients with carcinoid heart disease will continue open-label treatment on study (lanreotide + telotristat ethyl or lanreotide alone according to what they were receiving at unblinding at 12 months) for 4 additional years (open- All efficacy analyses will be conducted in the Intention-to-treat population as primary analyses i.e. all 94 randomized patients will be analyzed in the arm they were allocated by randomization. Safety analyses will be performe The translational research projects include blood metabolite discovery and targeted assays to find new biomarker candidates of response to Telotristat. Human biological material that will be collected for translational research purpose: * whole blood, plasma and serum at baseline, 4 hours after first dose, 4 weeks, 12 weeks and at end of treatment visit with telotristat/placebo (due to end of study, disease progression or lack of benefit) * archival tissue samples (formalin-fixed paraffin-embedded) will be retrieved for all patients at study entry. In addition, one EDTA blood tube of whole blood (10 ml) at baseline, 12 weeks and end of treatment (EOT visit) might Quality of life will be assessed with the EORTC Quality of Life Questionnaire (QLQ-C30) version 3, together with the QLQ-GI.NET21 specific module designed for Neuroendocrine Tumours. The computer-adaptive testing (CAT	NO
The aims of this study is to evaluate the role of 2D speckle-tracking echocardiography in diagnosis chemotherapy related left ventricular dysfunction in breast cancer patients with cardiovascular risks	NO
The purpose of this study is to better understand the following aims: 1. Aim 1: To evaluate the rate of recurrent Atrial Fibrillation (AF)/Atrial Flutter (AFL) in hematopoietic stem call transplant (HCST) patients with incident AF/AFL identified during the initial 30 days of the transplant 2. Aim 2: To evaluate incident episodes of 1) stroke/TIA; 2) other thromboembolic events (not stroke/TIA); 3) Heart failure events; 4) Ischemic heart events 3. Aim 3: To evaluate overall implantation safety in this population	NO
Video-assisted thoracoscopic extended thymectomy (VATET) is a minimally-invasive method for excision of mediastinal mass instead of open thymectomy. The iatrogenic capnothorax with one-lung ventilation during VATET r	NO
ICU care of patients considered "palliative" but without contraindications to admission to intensive care, for whom a do-not intubate order decision was made upon admission represents a particular target for non-invasive ox	NO
This clinical trial studies a novel single wave assessment in measuring cardiac dysfunction and metabolic syndrome in patients with cancer. The novel single wave assessment is a hand held device that can report left ventricu	NO

This study is intended to evaluate the ability of an intramyocardial strain analysis package with cardiac MRI to assist in the early detection and management of cardiotoxicity from therapeutics used to treat cancer.	NO
This project aims to determine whether a comprehensive cardiac rehabilitation program including supervised exercise training is able to prevent cardiotoxicity during treatment with anthracyclines and / or anti-HER-2 antibodi	NO
Psychological processes play a complex role in the pathophysiology of many diseases. However, the body and emotional perception of patients and the relationship between dreams and disease still need to be investigated. The investigators planned an observational and controlled research aimed at assessing some previously unaddressed baseline psychological characteristics and their changes at 1 and 5 years after a short-term psychotherap The patients that will be enrolled are: * 50 patients ≤ 75 year old with acute myocardial infarction; * 30 patients ≤ 75 year old with Tako-Tsubo syndrome; * 50 women ≤ 75 year old, recently operated on breast cancer: * 90 control subjects of the same age and gender of the enrolled patients, without relevant pathologies during the last 10 years. Relevant pathologies are defined as those that required a hospitalisation or a long-lasting medic At the enrolment all the subjects will undergo a complete medical evaluation, and the following psychometric tests: Self-evaluation test, Social Support Questionnaire, Beck Depression Inventory II (BDI II), MacNew Heart Dise In two distinct following meetings, an open questionnaire exploring the body and emotional perception, and another exploring past and recent dreams, will be administered. The same evaluation will be done for the healthy subjects. After the initial evaluation, all the patients will be given the choice to start a short-term psychotherapy lasting 6 months on top of medical therapy or to continue classic medical therapy only. Healthy subjects will be not offere At first year of follow-up, the battery of psychometric test, and the two questionnaires exploring the body and emotional perception, and changes and characteristics of dreams during the psychotherapy, will be re-administer The following data will be evaluated: Psychological characteristics at follow-up. Incidence of new relevant medical events Quality of life Relationship between psychological characteristics and health status, and quality of life At 5 year follow-up psychometric tests and the clinical data will be evaluated in all the groups.	NO
The purpose of this study is to identify patients at risk for future heart failure using novel markers of early cardiac damage and determine if exercise training can improve these emerging markers as well as overall fitness and c	NO
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in th	NO
RATIONALE: Antibodies, such as human immune globulin, can block the growth of abnormal cells in different ways. Some block the ability of abnormal cells to grow and spread. Others find abnormal cells and help kill them c PURPOSE: This phase I/II trial is studying the side effects and best dose of human immune globulin and to see how well it works in treating patients with primary amyloidosis that is causing heart dysfunction.	YES
Trastuzumab is an important treatment for HER 2 positive breast cancer. But trastuzumab can cause injury to the heart, and this is one of the main reasons it cannot be administered as planned. Heart injury can often be succ In SCHOLAR-2, we will compare two thresholds of withholding or discontinuing trastuzumab/pertuzumab/trastuzumab-emtansine: a threshold that is currently advocated for by existing treatment practice guidelines versus a	NO
Anthracyclines treat up to 60% of childhood malignancies with remarkable improvements survival rates. Unfortunately anthracyclines are associated with an increased cardiomyopathy risk. One study showed an almost six-fe Newer techniques such as tissue doppler and strain rate imaging have shown promise for early prediction of cardiomyopathy in adult studies. Biomarkers such as troponin and NT-proBNP have also shown a correlation with This study (n=208) aims to use echocardiography, strain imaging, holter monitoring and MRI for early detection of cardiomyopathy. Biomarkers, both currently used (for example, troponin and NTproBNP) and more novel (for This study will explore biomarker discovery by analysing an age/gender matched subgroup for the top differentially expressed microRNA and protein biomarkers. Selected biomarkers will then be validated in a larger cohort.	NO
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk o	NO
Radiation therapy (RT) of the breast is a critical component of modern breast cancer treatment. RT treatments have led to improved local control and overall survival of breast cancer patients. However, the incidence of radiati	NO
This is a non-randomized, non-interventional pilot observational study designed to follow high-risk patients through their surgical and hospital stay. The investigators will collect 2 4ml vial's of blood (total of 8ml) prior to surge	NO
Sub-optimal transfer of clinical information during inter-hospital transfer (IHT, the transfer of patients between acute care hospitals) is common and can lead to patient harm. To address this problem, the investigators will use	NO
Background: Bruton s tyrosine kinase inhibitors (BTKi) are used to treat a form of leukemia. But taking BTKi can also increase a person s risk of developing an abnormal heart rhythm. This can cause sudden death. In this natural history st Objective: To identify and monitor the effects of BTKi on the heart. Eligibility: People aged 18 and older currently receiving or planning to receive BTKi. Design: Participants who have not yet started BTKi will have 2 required clinic visits: 1 before they start taking BTKi, and 1 about 6 months later. Participants who are already taking BTKi will have 1 required visit. Participants will undergo multiple tests: A physical exam, including collection of blood and saliva. A test that measures heart activity via stickers placed on the chest. A test that uses sound waves to capture images of the heart. An exercise stress test that monitors heart activity and blood pressure while the participant works on a treadmill or stationary bike. Sound wave images of the heart may also be taken while the participant exercises. Stress magnetic resonance imaging (MRI) may be done in place of an exercise test. Participants will lie on a table that slides into a tube. They will be given drugs to stress the heart while images are taken. Participants may wear a device to monitor their heart at home. Participants may have repeat visits if they develop heart symptoms or if they need to stop taking BTKi. They will have follow-up phone calls each year for up to 3 years.	NO
The purpose of this study is to determine whether betadine (povidone-iodine) instillation during routine indwelling Tunneled Pleural Catheter (TPC) placement is efficacious in promoting pleurodesis and thus reducing the time	NO
This study assesses how blood cell growth patterns (clonal hematopoiesis), relates to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a y	NO
the investigator proposes to use the cardiac coherence technique coupled with a hypnosis session to improve post-operative recovery.	NO
The overall objective of this study is to use patient-centered in vitro and in vivo models to answer the fundamental question of whether or not pathogenic mutations in BRCA1/2 result in an increased risk of CV disease	NO
The purpose of this study is to identify the genetic variants that are associated with higher risk of doxorubicin-induced cardiotoxicity can contribute towards developing a predictive algorithm comprising both clinical and gen Hypothesis of this study is certain functional variants in genes that encode for metabolizing enzymes and/or targets in the doxorubicin pharmacology pathway may increase the risk of doxorubicin-induced cardiomyopathy	NO
The objective of this study is to investigative the influence of different levels of glycaemia or insulinemia in vascular endothelium in ischemia/reperfusion lesion after myocardial infarction	NO
NeoFit is a prospective, national, multicenter, single-arm open-label study. It will include a total of 300 participants under the age of 70 years treated with neoadjuvant chemotherapy for BC. Participants will receive a Withing	NO
Trastuzumab is an important treatment for HER 2 positive breast cancer. But trastuzumab can cause injury to the heart, and this is one of the main reasons it cannot be administered as planned. Heart injury can often be succ	NO
Every day many patients affected by chronic life-limiting illnesses are admitted into Internal Medicine wards, coming from the Emergency Department. Many studies suggest that providing palliative care to these patients may In a previous study the investigators screened for need of palliative care patients affected by progressive chronic diseases by means of a tool, based on the Italian Society of Anesthesia, Analgesia, Resuscitation, and Intensiv In the present study the investigators enroll chronically ill patients admitted to an Internal Medicine Unit from the Emergency Department, to be screened for palliative care need, using the previously cited SIAARTI/NCCN scre The aim of the study is to verify the accuracy of the SST in identifying chronically ill patients in need of a PC approach, in comparison to the SIAARTI/NCCN tool (EST). If the SST would show good accuracy, an easily manage	NO
This will be a cohort study of all patients receiving Cluster of Differentiation 19 (CD19)-specific CAR T cell therapy for relapsed/refractory B cell haematological malignancies. Patients will receive cardiac assessment and have	NO
Brief Summary: Persistent Physical Symptoms (PPS), also known as medically unexplained symptoms (MUS) is a term used to describe a range of persistent bodily symptoms for which the exact cause is unclear. Between 2	NO
Doxorubicin (Adriamycin), one of the drugs commonly used for the treatment of breast cancer, is in a class of medications called anthracyclines. Anthracyclines may cause heart damage that can lead to weakening of the hea Simvastatin is an oral medication approved by the FDA to lower cholesterol. Simvastatin is in a class of medications called statins. Some research has shown that statins may prevent heart damage that can be caused by ant The purpose of this study is to determine if taking simvastatin while receiving the chemotherapy Doxorubicin (Adriamycin) will minimize damage to the heart. This study is for women who will be receiving the anthracycline doxorubicin (Adriamycin) as part of their breast cancer treatment.	YES
The purpose of this study is to assess the prevalence of cardiac dysfunction and (undiagnosed) heart failure in women registered in general practice with a history of breast cancer who received chemotherapy and / or radioth	NO
Background: To effectively alleviate suffering and improve quality of life for patients with serious illness and their caregivers, palliative care (PC) services must be offered across multiple settings. Research is needed to determ Aim: The investigators will compare a standard HBPC model that includes routine home visits by a nurse and provider with a more efficient tech-supported HBPC model that promotes timely inter-professional team coordinat Design: Cluster randomized trial. Registered nurses (n\~130) will be randomly assigned to the tech-supported or standard HBPC model so that half of the patient-caregiver dyads will receive one of the two models. Setting/Participants: Kaiser Permanente (15 Southern California and Oregon sites). Patients (n=10,000) with any serious illness and a prognosis of 1-2 years and their caregivers (n=4,800) Methods: Patients and caregivers will receive standard PC services: comprehensive needs assessment and care planning, pain and symptom management, education/skills training, medication management, emotional/spirit Results: Primary patient outcomes: symptom improvement at 1 month and days spent at home in the last six months of life; caregiver outcome: perception of preparedness for caregiving. Conclusion: Should the more efficient tech-supported HBPC model achieves comparable improvements in outcomes that matter most to patients and caregivers, this would have a lasting impact on PC practice and policy.	NO
Upper limb complications and sleep disturbances are prevalent, persistent, and serious health problems in women with breast cancer. However, these problems are underrecognized in clinical practice and thus have substan	NO
The purpose of this study is to determine whether the early identification and more precise intervention of operating room (OR) patient fluid administration optimization using arterial pressure-based cardiac output (APCO) yiel	YES
This is a randomized Phase 1 study to evaluate the effects of Veliparib on cardiac repolarization in patients with solid tumors who's cancer has recurred or is no longer responding to current treatment.	NO
Breast cancer is the most commonly cancer in women in the overall global population. According to the World Cancer Research Fund International, there were more than 2.25 million new cases of breast cancer in women in	NO
To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing a	NO
This study measures circulating, misfolded ATTR oligomers in asymptomatic ATTRm amyloidosis genetic carriers longitudinally over five years.	NO
A Long-term Follow-up Study for Cardiac Safety in the Patients with HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC	NO
The SALTO-SNA study is an ancillary study of the SALTO study (Suivi À Long Terme en Oncologie des enfants guéris d'un cancer pédiatrique en régions Rhône-Alpes et Auvergne) coordinated by Dr. Claire Berger, pediatric o The rationale for this study is based on the observation that although the survival rate of childhood cancers has now reached 75%, complications of chemotherapy and radiotherapy are high and greatly increase the risk of m The morbidity risk of chemotherapy and radiotherapy can be quantified by assessing the activity of the intrinsic cardiac autonomic regulation, which represents a powerful predictor of cardiovascular morbidity to the individua	NO
The primary objective of this study is to evaluate the practice patterns of rivaroxaban usage invenous-thromboembolism (VTE) and non-valvular atrial fibrillation (NVAF) in cancer patients. The secondary objectives are to evaluate outcomes such as recurrent VTE, stroke and bleeding for cancer patients on rivaroxaban.	NO
In Europe, breast cancer is by far the most common form of cancer diagnosed in women today, accounting for 29% of all cases. The 5-year survival rate is approximately 90%. Surgery is usually combined with radiotherapy (Unfortunately, RT is associated with a broad spectrum of cardiovascular diseases, which includes coronary artery disease, valvular dysfunction, congestive heart failure and stroke, and is the most common non-malignancy c In this study the incidence and prevalence of cardiovascular diseases will be estimated 8 and 15 years after both conventional and laser assisted breath controlled RT, and compared with cardiovascular diseases in the gener	NO
As previously reported (IJC Heart \& Vasculature 2017; 17: 11.), our epidemiological analysis showing high incidence of cancers in patients with atherosclerotic cardiovascular diseases as compared with those with non-ather	NO
Radiotherapy associated Atrial Fibrillation (RADAF) is an observational study to evaluate onset time and frequency of atrial fibrillation in patients with thoracic malignancies and breast cancer. Each patient will have 12 lead ECG prior, and daily during radiotherapy.	NO
This study will demonstrate whether an end-of-life preparation and completion intervention reduces anxiety, depression, pain and other symptoms and improves functional status, spiritual well-being, and quality of life. If effec	NO
This parallel, randomized, non-inferiority trial will examine whether a ten week qigong intervention is not inferior to a ten week exercise-nutrition comparison group in reducing fatigue in cancer survivors. To build a more mech 1. data related to neural correlates of body awareness: cortical EEG data measuring each subject's ability to use attention to control neurons in primary somatosensory cortex (replication of Kerr et al 2011 study in mindfulnes 2. data related to inflammation measured via inflammatory cytokines (e.g., interleukin-6 and tnf-alpha) 3. data related to cardiorespiratory functioning including cardiac impedance (ICG) and mechanical lung function 4. data related to parasympathetic and sympathetic signaling between the nervous system and the rest of the periphery.	NO
This study is to prospectively investigate the cardiac dose-sparing effect and clinical benefit of deep inspiration breath-hold (DIBH) technique. Patients with left-sided breast cancer treated with breast conserving surgery follo	NO

Childhood cancer survivors are at an increased risk of cardiac toxicity due to prior anti-cancer therapy. However, adherence to cardiac screening in this population remains low. This study aims to assess the feasibility of an m	NO
This study will incorporate a prospective randomised open blinded end-point trial in participants with stage 2, 3 or 4 melanoma treated with ICI to evaluate the impact of statin therapy on changes in coronary plaque burden a	NO
The present study aims to investigate the chronic effect of treatment with doxorubicin and cyclophosphamide on neurovascular control and blood pressure in women undergoing adjuvant treatment for breast cancer.	NO
As the numbers of cancer survivors grow, the long-term adverse effects of cancer therapy are becoming increasingly apparent. Most prominent are the toxic effects on the heart (cardiotoxicity) which may lead to cardiac dysf Feasibility will be assessed by evaluating the recruitment, adherence and attrition rates, along with program safety. Efficacy will be assessed by evaluating changes in health-related outcomes.	NO
This is a multicenter, open-label, phase II study to evaluate the cardiac safety of Mitoxantrone Hydrochloride Liposome in patients with advanced malignant tumor who has received at least first-line treatment.	NO
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-bl	NO
This pilot trial studies how well a stress test works in detecting heart damage in premenopausal women with stage I-III breast cancer. Giving a stress test with adenosine or regadenoson and cardiovascular magnetic resonanc	NO
This is a randomized, multicenter, open, controlled Post-Marketing Study. 272 early stage female breast cancer patients who were histopathology confirmed with adjuvant chemotherapy indications were enrolled in this study	NO
Researchers are trying to determine if subjects with lack of access to healthy food and a long term health problem, are helped by a weekly box of healthy groceries and nutrition education.	NO
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune check	NO
This is a prospective, exploratory, randomised clinical trial. Patients with diagnosed cancer that are to be treated with 5-fluorouracil (5-FU) will be randomised into standard oncological treatment or a cardiological assessment	NO
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this laboratory research study is to collect and store blood and tissue from patients who have a diagnosis of heart disease and may be at a high risk for the development of heart failure. This blood may be used in This is an investigational study. All will be enrolled at MD Anderson.	NO
Background Thoracic or abdominal surgeries are followed by a shorter or longer period of immobilization and after major surgery there is a higher risk of developing cardiorespiratory complications. To prevent these complications, the pat Many patients also receive breathing training in connection with the surgery. There is currently no consensus on which method is preferable for which groups of patients. There are similarities and differences in practice in the The purpose of the study is to map when mobilization and breathing training starts after abdominal and thoracic surgery and what is then performed Method The study will be carried out as a quality follow-up with mapping of practice. Patients ≥ 18 years of age who are undergoing a planned or acute open, keyhole or robot-assisted surgery, who are extubated and who bu The material will be recruited from Swedish university hospitals and county hospitals for 20 days of surgery (Monday through Thursday) for five consecutive weeks. Clinical benefit The study will mean that clinical practice is presented which, with regard to mobilization, is the first study ever that will present when this takes place and what is done and, with regard to breathing training, the	NO
The purpose of this research is to investigate whether patients who previously had endoprosthesis surgery experience memory, thinking, or heart problems. It will also help determine how often these problems occur.	NO
The purpose of the study: to increase the efficiency of diagnosis, treatment and prediction of the course of coronary heart disease in patients with adenocarcinoma of the prostate gland, depending on the hormonal status by	NO
Randomized phase III trial to compare the effectiveness of combination chemotherapy, surgery, and radiation therapy with or without dexrazoxane and trastuzumab in treating women who have stage IIIA, stage IIIB or stage I	NO
RATIONALE: Drugs used in chemotherapy, such as docetaxel, fluorouracil, epirubicin hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping th PURPOSE: This randomized phase III trial is studying how well giving combination chemotherapy works compared with giving combination chemotherapy together with bevacizumab in treating patients with nonmetastatic br	NO
This study will enroll patients initiating Bruton Tyrosine Kinase (BTK) inhibitors without history of documented arrhythmia while on therapy using the Medtronic LINQ-2 insertable cardiac monitor (ILR). The incidence of new ons	NO
This observational study will assess the safety of Herceptin (trastuzumab) in patients with HER2-positive breast cancer in routine clinical practice. Eligible patients will be followed for up to 4 years.	NO
Carcinoid Heart Disease (CHD) is a rare form of heart disease, occurring in over 50% of the patients with carcinoid syndrome. Pathophysiology, prognostic factors of development of Carcinoid Heart Disease and progression This observational multicenter cohort study is designed to study the occurrence of Carcinoid Heart Disease in patients with differentiated carcinoid tumors, to describe numerous factors influencing the occurrence, severity, p	NO
The purpose of the study is to determine the Pharmacokinetics of Low Molecular Weight Heparin (LMWH) in Cancer patients, and compare it to the Pharmacokinetics of LMWH in Patients without cancer. We also intend to de	NO
This clinical trial studies a cardiac rehabilitation program in improving cardiorespiratory fitness in stage 0-III breast cancer survivors. Cardiovascular disease is the leading cause of death of women in both the general populati	NO
We will study the effects of ondansetron on measurements of electrical activity in the heart to make sure doses we are using to prevent nausea and vomiting in children receiving chemotherapy are safe.	NO
This is a randomized controlled trial. 80 patients with thoracic radiotherapy will be included. Participants will be randomly divided into experimental group or control group. Before radiotherapy, echocardiography, 2D STE, CK	NO
The standard treatment for breast cancer is surgery followed by adjuvant breast radiation therapy in most cases. For left sided breast cancers, the heart dose delivered by the radiation treatment is often of particular concern.	NO
The Hamburg City Health Study (HCHS) is a large, prospective, long-term, population-based cohort study and a unique research platform and network to obtain substantial knowledge about several risk and prognostic factor	NO
This study is designed to take a first step toward testing the efficacy and acceptability of heart rate variability biofeedback (HRVB) as a means of ameliorating psychological distress in survivors of Primary Brain Tumour (PBT). More specifically, this study has been designed to test several hypothesises. Each hypothesis is based on the prediction that, in a sample of psychologically distressed PBT survivors, a course of 8 HRVB sessions will demon * statistically significant reductions in levels of depression * statistically significant reductions in levels of anxiety * statistically significant increases in resting HRV * that reductions in anxiety and depression will be significantly, negatively correlated with increases in resting HRV * that the HRVB will be viewed as an acceptable intervention by the participants In addition to the hypothesises stated above, the study will also investigate in a discovery oriented manner if the HRVB intervention will have positive impacts on the participants: * levels of sleep impairment * levels of pain	NO
Many cancer survivors are at risk for cardiovascular disease (CVD); it is therefore important to identify patients at increased risk for cardiotoxicity, especially in the setting of CVRF or pre-existing CVD, and to design personaliz Thus, the aim of this study is to compare the impact of a Cardiac Rehabilitation Program (CRP) model versus a community-based exercise intervention plus usual care on cardiorespiratory fitness (CRF), physical function dom	NO
The purpose of this study is to examine adherence to cardio-oncology consultation.	NO
New therapies for cancer increased patient survival, but led to the recognition of adverse effects associated with cancer treatment, such as the use of chemotherapy. Cardiotoxicity is the most significant adverse effect, whic	NO
The purpose of this study is to compare plaque burden in the coronary and carotid arteries 5 years after adjuvant radiotherapy in women with right sided breast cancer vs left sided breast cancer.	NO
This multicenter RCT of 200 hospitalized patients and their family members evaluates an "informed assent" approach to discussing cardiopulmonary resuscitation, compared to usual care, in older seriously ill hospitalized pat	NO
Heart rate variability biofeedback (HRV-B) is a complementary, non-pharmacologic therapy that is being tested to see if it can help cancer survivors reduce their symptoms of pain, stress, insomnia, fatigue, or depression. HR	NO
The purpose of this study is to determine if medically tailored meals provided for either 2 weeks or 4 weeks (1 meal per day) to a Kaiser Permanente Colorado (KPCO) member after hospital discharge will improve their health.	NO
Primary Objective: To determine if there is a reduction in the mean symptom severity scores for the heart failure specific symptom items between baseline and at the end of three months between patients whose symptoms are managed using t Secondary Objectives: 1. Examine the correlation between mean symptom severity scores and the secondary endpoints of: a) exercise tolerance (6-minute walk), b) NYHA (New York Heart Association) functional classification, c) B-type natriuretic 2. Define symptom severity critical values in cancer patients with concurrent heart failure that trigger clinical intervention 3. Identify symptom clusters which may occur in cancer patients with concurrent heart failure.	NO
According to American Heart Association criteria, patients who have had Rheumatic Fever (RF) should be treated with antibiotic prophylaxis. Continuous prophylaxis is recommended in patients with well-documented historie There is a limited data regarding adherence of patients to treatment and efficacy of treatment. In this study, patients with RF who are older than 21 years will be collected from a computerized database of 'Maccabi Healthcare Services', one of the biggest Israeli Health Funds. Patients will be assigned to the study after Previous adherence to antibiotic prophylaxis will be examined according to computerized database of drugs which were issued to the patient since RF diagnosis. Past history of cardiac involvement, including past Echocardiograms, will be collected from computerized database. In addition, the current cardiac state will be assessed by an experienced cardiologist, including a full new E	NO
This randomized controlled trial will enrol patients with acute severe brain injury who pass a spontaneous breathing trial but have decreased level of consciousness. It will directly compare (1) prompt extubation vs. (2) usual c	NO
The aim of the present study is to examine whether the nature based 'Wild man Programme' can help to increase quality of life among men on sick leave compared to treatment as usual. Additionally, the study examines whic	NO
Public health policy is universal in recommending the adoption of low risk low-risk lifestyle behaviors for health promotion and prevention of chronic or non-communicable diseases (NCDs).These behaviors generally include a	NO
Cardio-oncology is an emerging field. Most of the data available have been issued from either retrospective analysis, industry data or pharmacovigilance data. These data sources include a number of bias. CONFUCIUS is a single tertiary centre prospective registry including all patients who have been referred for cardio-oncology assessemnt. The objectives are to provide a comprehensive vue of cardoi-oncology, enable to detect early signals of cardiotoxicity and enhance ancillary projetcts aiming at specific populations (e.g., type of cancer) and/or drugs.	NO
RATIONALE: Video-assisted surgery followed by radiation therapy may be an effective treatment in patients whose poor heart and lung function make them high risk for standard surgery. PURPOSE: Phase II trial to study the effectiveness of video-assisted surgery followed by radiation therapy in treating patients with stage I non-small cell lung cancer and poor heart and lung function.	NO
This study is a retrospective observational study that evaluates the rate of cardiovascular adverse events leading to hospitalization in metastatic colorectal cancer in the French county Calvados by drug exposure.	NO
Purpose: To evaluate reactions to and opinions of a messaging campaign. Participants: Participants will be recruited through Prime Panels and will be US-based adults (18 years old and older) who consumed red meat in the past 30 days. Procedures (methods): After completing a screening question about meat consumption, participants will review a consent form. If they select to participate in the study, participants will be randomly assigned to view control n Participants will also be asked about grocery shopping preferences and standard demographics questions.	NO
In this study, patients with endocardial myocardial biopsy were selected to observe the safety of the operation, and pathological examination was performed. If necessary, special tests such as viral examination, mass spectro	NO
The purpose of this study is to investigate the risk factors and mechanisms of cardiotoxicity following thoracic radiotherapy and to provide insights in preventing radiation-related cardiotoxicity. -Condition or disease : Thoracic irradiation -Intervention/treatment : Cardiac evaluation, Blood sampling	NO
Postoperative delirium（POD）is a common complication that can directly affect important clinical outcomes, and exert an enormous burden on patients, their families, hospitals, and public resources. In order to evaluate wh	NO
This observational study is conducted as part of a systematic pharmacovigilance activity, to provide a population-based context for Pazopanib use outside of the clinical trial setting. The aims of the study are to examine the i Two databases will be utilized for this study: a large healthcare claims database in the U.S. and the Dutch linked medical registries (PHARMO RLS). The databases will provide large, geographically varied, non-trial population	NO
In this clinical study, a single-center retrospective cohort study was used to explore the clinical characteristics and risk factors of patients with multiple myeloma myocardial amyloidosis. An exploratory study was conducted t	NO
The goal of this study is to see if a special type of heart scan called a diffusion weighted magnetic resonance imaging (DW-MRI) that uses extra measurements, can be used to find early signs of heart damage from chemothe	NO
This is a two-armed, parallel-design, pre-/post-intervention assessment study. The investigators will conduct a randomized controlled trial for ED GOAL on a cohort of 120 older adults with serious illness to collect patient-ce	NO
The study will begin in 2013 whereby patients having an early warning system (EWS) alert will be randomized to be seen by the rapid response team (RRT) for triage versus usual care. A RRT is usually made up of a nurse and	YES
Background: Stress is the critical method for survive of reacting to a condition including a threat, challenge or physical and psychological challenge. Stress either physiological or biological is an organism's response to a stre Purpose: The aims of this study are to evaluate the effects of aromatherapy on cancer patient receiving chemotherapy: 1) for physical effects by meridian electrical conductance, heart rate variability (HRV), vital sign, visual an Materials and methods: This is a prospective, pre post comparison study. A total of 40 cancer patients receiving chemotherapy will be recruited as participants in this study. The characteristics data will be collected in all part Expected outcomes: It is expected to understand more about the effects of aromatherapy on the meridian system, HRV and emotional status by undertaking 30 minutes session aromatherapy intervention for cancer patients	NO
The goal of this clinical research study is to learn if the radiation that you will receive for esophageal cancer may cause the heart to create more proteins called cardiac biomarkers. When cardiac biomarkers are above normal levels, there may be heart damage. The relationship between cardiac biomarkers and radiation therapy has not been well studied. Learning more about this relationship may lead to	NO

Radiotherapy (RT) has a major curative role in women with early breast cancer, and is recommended routinely after lumpectomy and selectively after mastectomy. It has contributed to a halving of breast cancer mortality in th Two potentially simple techniques reduce heart dose. In one, women are taught to breathe in deeply and to hold their breath for about 20 seconds while RT is given. The downward movement of the diaphragm pulls the heart	NO
The purpose of this study is to determine whether AZD1775 has any effect on the pharmacokinetics (PK) of three compounds (caffeine, omeprazole, and midazolam) that are probes for common drug-metabolizing enzymes (	NO
The investigators' objective is to assess the efficacy of the combined treatment with enalapril and carvedilol in the prevention of left ventricular systolic dysfunction in patients with hematological malignancies submitted to int The hypothesis is that these drugs administered during chemotherapy may prevent left ventricular systolic dysfunction.	NO
The purpose of this research study is to determine whether early administration of Dexrazoxane prevents Doxorubicin induced cardiotoxicity.	NO
The objective of this study is to use local topical anesthesia to numb the sensory input, captured by branches of the Trigeminal nerve found on the skin in and around the eye, to decrease a hemodynamic reflex seen during p Normally, one could block this sensorial input with ophthalmic peribulbar placement of local anesthetics, but these eyes have malignant growth and invasive procedures may cause more harm. The investigators are aiming to	NO
The purpose of this research study is to evaluate MR imaging in subjects receiving doxorubicin chemotherapy to see if MR can detect heart damage as well as or better than MUGA scans. This research study is expected to enroll approximately 10 subjects over 12 months at the University of Miami / Miller School of Medicine.	NO
Hematopoietic stem cell transplantation is an important method for the treatment of hematological diseases and cyclophosphamide is a commonly used chemotherapeutic agent for transplant pretreatment. The incidence of The purpose of our study is to find out non-invasive, reliable and sensitive echocardiographic parameters and plasma biomarkers for early detection and prediction cyclophosphamide -induced cardiac toxicity and to be help	NO
Prevention and early detection of chemotherapy-induced cardiotoxicity in children with bone tumors and Acute Myeloid Leukemia by giving capoten	NO
Women treated for breast cancer are at increased risk for cardiovascular disease, including heart failure. In this study, by using magnetic resonance imaging (MRI), the investigators want to assess if heart failure medications s	NO
Myeloproliferative neoplasms are heterogeneous group of clonal hematopoietic stem cell neoplasms with excessive proliferation of one or more of the erythroid, megakaryocytic, or myeloid lineages and relatively normal matu	NO
The use of epidural dexmedetomidine decreases the anaesthetic requirements and improved postoperative pain. Dexmedetomidine is a potent and highly selective a2-adrenoceptor agonist and has sympatholytic effect. Pow	NO
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration 2. Planned duration of the surveillance Anticipated to be 2 years and 6 months from the start date of release of Pomalyst	NO
Cancer therapy can place childhood cancer survivors at increased risk for heart disease which can lead to significant illness or early death. Interventions that occur late in the evolution of treatment-related heart disease are u	NO
Cardiac computed tomography (CT) is often performed in patients who are at high risk for lung cancer in whom screening is currently recommended. This pilot randomized study will test the feasibility, safety and diagnostic a	NO
The majority of early breast cancer patients are treated with adjuvant radiation therapy (RT) as part of their multimodal therapy. The aim of the RT is to lower the risk of local, regional and distant failure and improve survival. M	NO
using a contrast-enhanced (CE) cardiac magnetic resonance imaging(CMR) which included the measurement of T1 mapping, T2 mapping, T2* mapping and late gadolinium enhancement(LGE) sequences, as well as LVEF an	NO
The study will evaluate the effect of familial risk assessment and prevention prompts tailored to familial risk on health behaviors and use of preventive services among adults who are members of primary care practices in the	NO
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as dexrazoxane, may protect normal cells from the side effects of che PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without dexrazoxane in treating children who have Hodgkin's disease.	NO
This prospective cohort study is to investigate the incidence of atrial fibrillation after chemotherapy by aplying wearable ECG recoder and the risk factors on patients with newly diagonsed lymphoma	NO
This study uses a new breathing device called 'N-Tidal C' handset which measures breathing patterns. Investigators have found that people with cardiac and respiratory illnesses breathe out a gas, called carbon dioxide (CO2	NO
The purpose of this study is to assess the incidence of cardiovascular events in patients with esophageal/stomach or colorectal cancer treated by trifluridine/tipiracil +/- oxaliplatin after an episode of cardiac angina-related th	NO
This study aims to investigate the possible role of rosuvastatin in protection against cardiotoxicity in HER2 positive breast cancer patients receiving doxorubicin sequential with trastuzumab.	NO
Ultrasound guided percutaneous ethanol injection (PEI) is an established method in the treatment of hepatocellular carcinoma (HCC) and considered a safe procedure with severe complications occurring rarely. Previous stud	NO
This study will compare the effect of HFNC versus standard oxygen administration after elective esophagectomy for cancer.	NO
The association between radiation exposure and cardiac disease is well recognized, it is not fully understood if there exists an optimal or "safe" radiation dose-volume relationship.	YES
The objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over tim 1. To evaluate the effectiveness of a novel EHR-based (electronic health record) clinician Jumpstart guide, compared with usual care, for improving the quality of care; the primary outcome is documentation of a goals-of-care 2. To conduct a mixed-methods evaluation of the implementation of the intervention, guided by the RE-AIM framework for implementation science, incorporating quantitative evaluation of the intervention's reach and adoptio	YES
The hematopoietic stem cell transplant (HSCT) experience is emotionally and physically stressful for cancer patients who undergo this procedure. This study aims to evaluate the effects of Cognitively-Based Compassion Trai	NO
This randomized clinical trial studies how well genetic sequencing-informed targeted therapy works in treating patients with stage IIIB-IV non-small cell lung cancer. Targeted therapy is a type of treatment that uses drugs or c	YES
The goal of this clinical research study is to learn if Lipitor (atorvastatin) or fish oil supplements can help to control side effects of the heart that are commonly seen after lung surgery (such as irregular heartbeat). Researchers	YES
The main hypothesis being tested is that magnetic resonance imaging and serologic biomarkers of apoptosis and extracellular matrix remodeling will precede echocardiographic indices of systolic and diastolic function amor	NO
Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer d	NO
Biofeedback is an autonomic response observed during the exposure period to CEMBE. After prospectively evaluating 20 healthy individuals or 40 patients with advanced breast cancer or hepatocarcinoma, it was possible t Once CEMBE is administered through an intra-oral administration device, the human body absorbs the energy applied at the level of 0.2-1 mW / kg, with a peak absorption in 10 g of tissue between 55 and 132 mW / kg. Initia A specific pattern of response associated with exposure of a cancer-specific frequency group was also observed in patients diagnosed with neoplasia, since the control group of healthy individuals did not present these respo This specific signature of response to CEMBE-modulated exposure to cancer-specific frequencies was significantly altered only in patients with hepatocarcinoma after tumor withdrawal (Costa et al, 2015a).	NO
RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy. PURPOSE: This clinical trial is studying how well cardiac magnetic resonance imaging works in patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin lymphoma receiving doxorubicin.	NO
RATIONALE: Reducing the amount of drugs used to prevent transplant rejection may help a person's body kill tumor cells. Giving biological therapy, such as interferon alfa, which may interfere with the growth of cancer cells, PURPOSE: Phase II trial to study the effectiveness of reducing immunosuppression, and giving interferon alfa and combination chemotherapy, in treating patients who have malignant tumors that develop after organ transplar	NO
The primary objective is to evaluate the difference in cardiac strain rate evolution in elderly early BC patients treated with (neo) adjuvant anthracycline-based chemotherapy compared with a non-anthracycline regimen (Taxote This study also will compare the serum biomarkers profile during and after the (neo) adjuvant CT in both treatment arms, assess whether MRI allows detecting earlier than standard echocardiography the signs of cardiotoxicit	NO
This is an ancillary study to the "Pragmatic Randomized Trial of Proton vs Photon Therapy for Patients with non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectivenes	NO
The early detection of BVZ or Sunitinib mediated cardiotoxicity using cardiac biomarkers and novel Transthoracic Echocardiogram (TTE) techniques may allow one to adjust treatment and/or administer prophylactic cardiopro	NO
To estimate the impact of having a child with serious illness (SI) on the health and healthcare of other members of the child's family.	NO
In this population-based cohort study, data on patients diagnosed with nmGaC in 2004 through 2016, managed with resection and chemotherapy, followed up until the end of 2016, and surviving ≥1 month were retrieved fror	NO
To evaluate the efficacy and safety of R-CMOP regimen based on mitoxantrone hydrochloride liposome injection in the treatment of newly diagnosed diffuse large B-cell lymphoma (DLBCL) based on cardiac function screenir	NO
This trial in brain-injured patients will test which of the following will lead to better patient outcomes: (1) an airway management pathway consisting of daily assessments and removal of the breathing tube as soon as patients	NO
The purpose and the goal of this paper is to show whether the application of a combination of two local anesthetics, as opposed to the application of one local anesthetic at paravertebral block changes the hemodynamic va This research is to present the main results - the existence of the significant change in Stroke Volume Variation (SVV) between groups using invasive hemodynamic monitoring, the changes of Stroke Volume Variation(SVV) de	NO
The aim of the study is to study the risk of colorectal cancer and polyps in people older than 80 years compared to the younger age group. The researchers hypothesized that colonoscopy in older people is likely to have mor	NO
This is a non-randomized prospective pilot study in a single academic center with historic controls. This study will compare Cardiac Magnetic Resonance Images (MRI) of patients who have undergone childhood cancer treati	NO
The rationale of this study is to provide an overview on PCL (Primary Cardiac Lymphoma) in Italy, trying to shed light on unknown aspects of the disease and on unanswered questions about its management that could be hel	NO
International, multicenter, observational, longitudinal study to identify biomarker/s for Tuberous Sclerosis Complex and to explore the clinical robustness, specificity, and long¯-term variability of these biomarker/s	NO
The investigators will implement a patient-centered outcomes tool for participants in lung cancer screening programs that receive clinically important incidental findings relevant to heart, breast and lung health. The study obj	NO
This study aims to determine the relationship between heart rate variability and intraoperative brain relaxation conditions in patients with brain tumors.	NO
The RASopathies are a group of developmental disorders caused by genetic changes in the genes that compose the Ras/mitogen activated protein kinase (MAPK) pathway. New RASopathies are being diagnosed frequently.	NO
This trial will determine the clinical effectiveness of polygenic risk score testing among patients at high genetic risk for at least one of six diseases (coronary artery disease, atrial fibrillation, type 2 diabetes mellitus, colorectal	NO
The purpose of the present study is to evaluate cardiotoxicity during re-challenge of a different modality of fluoropyrimidine (primary end-point S-1 and secondary any other fluoropyrimidine) after having perceived cardiotoxic	NO
Atrial fibrillation (AF) is a common and serious complication after lung resection. The incidence is likely underestimated, and risk may persist after leaving hospital. Recent development of simple wearable patch ECG devices	NO
To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized	NO
Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic PreConditioning (RIPC) in Non-Hodgkin lymphon	NO
This trial studies how well cardiac biomarkers work in the early detection of cardiotoxicity in patients receiving sunitinib malate or sorafenib chemotherapy. Some chemotherapies are known to cause damage to heart muscle	NO
The activity of trastuzumab in early-stage, HER2-positive breast cancer, has been demonstrated in many studies, with meta-analyses showing that in combination with a variety of chemotherapy backbones, trastuzumab red	NO
Background: Fat and calcium can build up as plaque in artery walls. The Agatston score measures plaque using computed tomography (CT) that does not use an injected contrast agent. Plaque in the arteries of the pelvis and abdomen is Objective: To measure atherosclerotic plaques on CECT in a group of males. Eligibility: Men ages 30-90 with prostate cancer (proven with biopsies) who have abdomen CT studies in the PACS (picture archiving system) in the Clinical Center. Also, men or women of all ages who have multiphase abdomen and pe Design: This study will use data gathered since 1/1/2013. Data will also be taken from protocol 03-CC-0128 and clinical trials 15-C-0124, 16-C-0048, 14-C-0112, and 04-C-0274. Participants from these studies have allowed their sa Participants will be found via keyword searches on NIH databases. Their CT and MRI scans will be used. Data such as age, race, disease, and treatment will be used. Results of other tests may be used. The plaque in participants abdomen and iliac arteries will be measured. It will be compared with biomarkers related to CVD and prostate cancer, such as weight, age, and race. This study will take place at one site. Data will be stored on secure computers. Printouts will be kept in locked rooms.	NO

Cancer strikes about one in three women and one in two men in the U.S. and more than 600,000 die from it each year. The best chance to reduce these numbers and save lives is through early detection and intervention. The investigators are developing a blood test to detect cancer from a simple blood draw also referred to as a liquid biopsy. This test is based on orphan non-coding RNAs (oncRNAs) that are abundant in the blood of patients This is a prospective, observational study to collect blood samples and medical information from participants with and without cancer to represent the population in the USA. The investigators have designed the study to incl Each participant will be asked to donate a small blood sample and to share their medical information. The participant's medical information will be updated during the course of the study. The blood will be tested for oncRNA If this study is successful, the results will enable a world where cancer can be detected early with a simple blood test and diagnosed accurately, with better chances of cure. The investigators believe this study has the potent	NO
The purpose of this study is to investigate whether increases in the blood flow from the heart (the cardiac output), induced by the administration of intravenous fluids, lead to an increase in the blood flow to the vital organs, in This study will involve 2 phases. Firstly, potential volunteers will be invited to meet the research fellow (medical doctor) undertaking this study, who will check their suitability to participate in the study and who will obtain infor The second phase is the study itself which will take place whilst volunteers are having their bowel operation. They will attend theatre in the normal way, but once they have been anaesthetised (put to sleep), a special monitor After this, intravenous fluid will be administered in order to increase the amount of blood pumped out of the heart. Once the oesophageal doppler monitor suggests that an adequate amount of fluid has been given, a second At the completion of the operation, a third ultrasound scan will be performed and another sample of blood taken from the earlobe, to help assess blood flow to the organs.	NO
The goal of the HARMONIC-RT study is to evaluate late health and social outcomes of modern external beam radiotherapy techniques in paediatric patients, based on the setting-up of a European, long-term registry comple	NO
Chest pain is a common cause of visits in the Emergency Room and General Practice, and is most commonly connected as a symptom of coronary disease, as for instance angina pectoris and acute myocardial infarct. Appr This study is based on patients that are referred to a CT-examination of the coronary arteries on the background of chest pain, where the CT-examination shows normal coronary arteries. The study aims to evaluate whether providing an intervention to this group of patients has an effect on patient satisfaction, patient's worry of cardiac disease and incidence of chest pain. The intervention group will be compared with a similar group going through the same CT-examination, but is receiving the examination result from their regular general practitioner (RGP), which is considered standard care. The hypothesis is that patients with chest pain with no coronary findings receiving extended information before getting the normal examination results experience a better patient satisfaction than those receiving the examinat	NO
A multicenter, non-randomized, placebo-controlled, single dosing schedule, subject-blinded study to evaluate the effect of GSK1120212 on the electrical activity of the heart as compared to placebo in subjects with solid tur	NO
Study to evaluate the effect of rovalpituzumab tesirine on cardiac ventricular repolarization in subjects with small cell lung cancer (SCLC).	NO
The purpose of this study is to explain the provision of palliative care at the end of life by the implementation of the ELNEC course, as WBT Program using the Normalization Process Theory, that focus attention on how comp	NO
Despite the growing interest in investigating how the radiotherapy (RT) dose to anatomical substructures of the heart links to survival, the heart substructures at risk remain poorly defined. They are not delineated routinely as The study aims to evaluate subclinical cardiac dysfunction in consecutive NSCLC patients treated with definitive RT and to investigate the predictive value of the heart substructures dosimetric parameters for subclinical and	NO
Currently, surgical removal remains the main clinical treatment for cardiac tumor patients. However, part of tumors are hard to completely resect. Also, as thoracoscopic surgeries induce great operation trauma, some patients Our center have a 12-year experience of intervention treatment for solid tumors and has conducted several animal experiments to verify the effectiveness of transthoracic puncture ablation and radiofrequency ablation for ver The purpose of this study is to conduct new method of direct transthoracic cardiac tumor-targeted Radiofrequency Ablation (RFA) or Laser induced Interstitial Thermotherapy (LITT), make minimally invasive treatment plans fo	NO
This randomized pilot phase I trial studies the side effects of donor bone marrow derived mesenchymal stem cells in controlling heart failure in patients with cardiomyopathy caused by anthracyclines. Donor bone marrow der	NO
The goal of this study is to determine if co-administration of metformin and doxorubicin in breast cancer patients receiving neoadjuvant or adjuvant therapy will reduce the number of patients who develop a significant change	YES
Thoracic malignancy is the most commonly diagnosed cancer worldwide.1,2 The incidence of thoracic malignancy has decreased in North America, but not in Asia, where it continues to show an increasing trend. A notable r Cardiovascular morbidity is higher among women with thoracic malignancy involving the thorax who had received radiotherapy (RT) compared with those not involving the thorax but receiving the same treatment. Thus far, th Anthracyclines are important therapeutic agents for breast cancer. Anthracycline-based regimens have similar or improved outcomes relative to the standard treatment regimen of cyclophosphamide, methotrexate, and fluoro Therefore, cardiovascular disease is undoubtedly one of the most challenging health problems in the world. More efforts are needed to prevent and better control of this disease. Our proposed monitoring program is to use AI	NO
The purpose of this study is to find out if adding vericiguat to standard treatment for cancer therapy related cardiac dysfunction (CTRCD) is more effective than standard treatment alone. The addition of vericiguat to the usual	NO
This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq \[18F\]florbetaben and PET scanning of patients with suspected cardiac	NO
Heart transplant is a recognized therapeutic strategy in refractory heart failure. Its success is however hampered by severe cancer occurrence and recurrence. The new m-tor inhibiting drugs Sirolimus and Everolimus have sh	NO
Lung cancer (LC) is the leading cause of cancer-related death and is the most frequent cancer in both sexes.Respectable lung tumor with abnormal lung function, usually because of tobacco use, have chronic obstructive pul	NO
The purpose of this study is to determine whether a new technique of radiotherapy for breast cancer (helical tomotherapy) can induce cardiac toxicity that would be detected in the first two years after treatment. Screening of	NO
Patients enrolled in the study will receive standard of care adjuvant or definitive breast, chest wall or thoracic radiation therapy.Cardiac mitochondrial dysfunction is a hallmark of radiation-induced cardiac injury. Reactive oxy	NO
EMPACT (EMPAgliflozin in prevention of chemotherapy-related CardioToxicity) study is a randomized, multi-center, placebo-controlled, double-blind trial to evaluate efficacy of empagliflozin in prevention of left ventricular (LV	NO
Lung cancer rates are higher in Yorkshire than the rest of the UK, and this is due to higher rates of smoking. Deaths from lung cancer can be reduced using regular lung scans (screening) and by helping people stop smoking.	NO
In France, new cancer cases keep on increasing with around 150 000 deaths yearly. Cancer therapy research is constantly evolving. Indeed, several studies explore new treatments or their combination with conventional canc Several studies showed indirect interaction between vagus nerve and cancer. Firstly, vagus nerve regulates homeostasis and immunity by reducing systemic inflammation while maintaining local inflammation and antitumor ef This prospective, monocentric and randomized study is a collaboration between the Centre Hospitalier d'Avignon and the Institut de Formation en Ostéopathie du Grand Avignon. It focuses on using noninvasive osteopathic	NO
Non-invasive measurements of cardiac output (CO), systemic vascular resistance (SVR), corrected aortic flow time (FTc) and stroke volume (SV) are useful parameters during laparoscopic resection of pheochromocytoma (ad	NO
Recently chimeric antigen receptor (CAR) T-cell therapy, a new class of chemo therapy, has gained regulatory approval for the treatment of diseases such as B-cell lymphoma. Known side effects include cytokine release syn	NO
The CARTIER study is a randomized, multicenter, open-label clinical trial comparing, in elderly patients with cancer under anti-tumoral treatment, two different cardiotoxicity prevention strategies: primary (intensive cardiovasc The primary endpoint is to determine whether this primary prevention englobing cardiovascular monitoring plus intensive multidisciplinary management is superior to the current clinical practice in reducing all cause mortality. Other secondary objectives of the study are to analyze the impact of this intensive cardiovascular monitoring strategy on the incidence of cardiovascular mortality, oncological mortality, hospitalization and/or urgent care due A total of 514 patients ≥ 65 years old diagnosed with any of the following onco-hematological cancers, colon, breast, lymphoma, chronic lymphoma leukemia, chronic myeloid leukemia or myeloma, undergoing standardized The incidence of primary and secondary outcomes will be measured at 2 and 5 years	NO
The aim of this study is to investigate protective effects of ivabradine in adult cancer patients undergoing anthracycline-based chemotherapy.	NO
The purpose of this study is to determine if siltuximab has an effect on the heart function measured by ECG recordings and more specifically to determine if siltuximab has an effect on the QT interval in patients with Monoclo	NO
Ofatumumab is a fully-human monoclonal antibody that exhibits high binding affinity to an antigen on the surface of B lymphocytes. Antigen engagement by ofatumumab results in maximal B-cell killing through complement-	NO
Patients undergoing hematopoietic stem cell transplantation (HCT) often continue to experience anxiety, depression, isolation, and other psychosocial distress due to the severe nature of the transplant experience. Storytellin	NO
This project has focus on patients in palliation testing a digital platform TelePal.dk.	NO
This study is a prevelance trial looking at how sleep apnoea affects the heart especially heart rhythms. Previous research shows that patients suffering from sleep apnoea are much more likely to get heart disease and abnormal heart rhythms (arrhythmias). These defects are sometimes missed by the traditional methods of mor This study will recruit 200 participants over a period of 18 months. The research team will observe the heart rhythms of sleep apnoea patients by inserting an implantable loop recorder (ILR) in up to 100 participants. The othe Demonstrating the incidence of arrhythmia can lead onto a larger study which may change future sleep apnoea management improving their cardiovascular outcomes. Other markers of heart disease such as; blood tests, Ma	NO
The aim of the study is to assess survival of patients with advanced cardiac AL amyloidosis treated with high cut-off hemodialysis (HCO-HD) combined with chemotherapy.	NO
The purpose of this study is to collect DNA samples from patients undergoing routine care at the University of Chicago. These samples will be tested for differences in genes that may suggest greater risk of side effects or ch	NO
The outcome of this research will be a demonstration that family health history (FHH) risk data can be used efficiently to deliver more effective healthcare in geographically and ethnically diverse clinical care environments. Alth	YES
This study looks to find a causative or predictive aspect of the suPAR biomarker for heart failure in breast cancer patients receiving Doxorubicin drug chemo regimen. suPAR is a circulating protein which can be found in blood and/or urine and is associated with both kidney and heart disease. * Hypothesis 1: Higher suPAR at baseline will predispose to Doxorubicin-induced cardiomyopathy or heart failure, observed by histology (under the microscope and other lab techniques) in mouse models, and tested using h * Hypothesis 2: suPAR is a marker of Doxorubicin-induced cardiomyopathy or heart failure after exposure to Doxorubicin, observed by histology (under the microscope and other lab techniques) in mouse models, and tested The study will look at suPAR's association with three other biomarkers called troponin, B-Type Natriuretic Peptide (BNP) and C- Reactive Protein (CRP) that are also associated with heart disease. In this study, the patient will have blood drawn as a routine part of the cancer treatment. That is prior to starting the cancer therapy, then after the first 2 and last 2 doxorubicin cycles (4 cycles altogether); as well as at 3, 6, \&	NO
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy before surgery may shrink the tumor so that it can be removed during surgery. PURPOSE: This phase II trial is studying how well giving chemotherapy before and after surgery works in treating patients with osteosarcoma.	NO
Non-intubated thoracoscopic surgery has been proved as an adequate alternative for management of many lung conditions such as pneumothorax , lung volume reduction, pulmonary metastasectomy, removal of lung nodul	NO
This study is to evaluate the benefit/risk of hormone replacement treatment among early menopausal women in China. This is a multi-centre, random, prospective study.	NO
This study is being done to evaluate heart rate activity and sleep patterns, among participants in the Long-Term Follow-Up (LTFU) study. Primary Objective Using mobile health (mHealth) technologies in a large and well-characterized cohort of childhood cancer survivors, our primary objective is to understand the magnitude of increased risk of cardiac autonomic dysfunction by Secondary Objectives Among long-term (≥5 years) survivors of childhood cancer (a) identify demographic, disease, treatment and cognitive-behavioral factors associated with an increased risk of cardiac autonomic dysfunction, (b) develop and va	NO
This application proposes a prospective, single arm feasibility clinical trial of a 12-week period of combined endurance and resistance training in survivors of childhood cancer who were treated with doxorubicin and/or daunc Baseline and post intervention imaging, laboratory, and neuropsychological evaluations will be used to determine the effects of the intervention on body composition, serum lipid profile, exercise tolerance, and neurocognitive	NO
This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.	NO
To evaluate the application of fluid-infusion therapy with the combination of stroke volume variation (SVV) and cardiac index (CI) as the primary judgment in non-severe patients underwent resection of gastrointestinal tumor. F	YES
General anaesthesia often reduces blood pressure whereby blood flow to the brain and other vital organs may become insufficient. Thus, medicine is often administered during anaesthesia to maintain blood pressure. Howev Several factors may affect blood flow to the brain during anaesthesia. During surgery on the internal organs, a hormone may be released that dilates blood vessels and causes a so-called mesenteric traction syndrome chara This study will evaluate how blood flow to the brain is affected by anaesthesia and standard treatment of a possible reduction in blood pressure. Further, the study will assess whether blood flow to the brain is affected by dev Thirty patients planned for major abdominal surgery will be included in the project. The study will take place from the patient's arrival at the operation room and until two hours after the start of surgery. Placement of catheters	YES
We hypothesize that adding beneficial high fiber foods to the diet will result in better overall dietary quality (measured by the Alternate Healthy Eating Index), which has been shown to be associated with cancer, than either re	YES
This phase II trial studies how well dexrazoxane hydrochloride works in preventing heart-related side effects of chemotherapy in participants with blood cancers, such as acute myeloid leukemia, myelodysplastic syndrome, c	NO
This phase II trial studies how well linsitinib works in treating younger and adult patients with gastrointestinal stromal tumors. Linsitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell gro	YES
This is a Phase I, randomized, double-blind, placebo-controlled, study to estimate the effects of daily oral dosing of 800 mg pazopanib on electrocardiographic parameters (QTc interval duration) as compared with placebo in	NO
A randomized controlled trial with non-communicable disease patients from two medical hospitals in Norway will be recruited prior to hospital discharge. The intervention group will participate in a 42-day nurse-assisted eHe	NO
Does an educational intervention for untreated COPD and cardiovascular disease which is integrated in an existing lung cancer screening program improve guideline concordant medication adherence at 12 months	NO
The purpose of this study is to evaluate the safety and effectiveness of fish oil supplements in maintaining weight in people with disease-related weight loss and/or cachexia.	NO
This trial studies how well magnetic resonance imaging (MRI) works in detecting heart damage in patients with cancer receiving chemotherapy. Diagnostic procedures, such as MRI, may help doctors predict whether patients Exercise Capacity Addendum Brief Summary: This study is designed to demonstrate feasibility of performing the physical activity intervention and the primary outcome measures before, during and six months after initiating	YES
The investigators will identify 10 patients in the department of radiation oncology who will receive standard of-care radiation therapy, and the treating radiation oncologist anticipates a mean left ventricular dose of at least 5 G	NO
The goal of this clinical trial is to improve communication among clinicians, patients with memory problems, and their family members. We are testing a way to help clinicians have better conversations to address patients' go	NO
Radiotherapy plays an integral role in breast cancer therapy. Multiple randomized studies have demonstrated decreased local-regional recurrence rates and decreased breast-cancer mortality. However, balanced with this sur	NO
This study compares the effects of a standard smoking cessation treatment, including one-time brief counseling and provision of nicotine patch plus an 8-week moderate intensity exercise program versus the same standard	NO
This will be a systematic, combined, prospective assessment of the novel echographic, CMR, and PET imaging tools in newly-diagnosed patients with cardiac AL amyloidosis at baseline and after treatment.	NO
This is a 3-arm, parallel-group, active- and placebo-controlled, double-blind, randomized study, to compare treatment with intravenous custirsen at 640 mg (highest intended therapeutic dose) with placebo. The purpose of th	NO
Purpose: To determine unmet functional needs in patients referred to the Palliative Care Unit at Rigshospitalet, Copenhagen University Hospital will be asked to fill out self reported questionnaires regarding problem intensity,	NO
Smoking is the largest preventable health risk in the U.S. The Family Smoking Prevention and Tobacco Control Act of 2010 mandated the placement of larger pictorial warnings on cigarette packs as well as nine new stateme	NO
The purpose of this research is to test whether participating in either a physical activity intervention or a series of educational classes will help to preserve exercise capability, heart function, brain-based activities (like memory Participants will be randomized to 1 of 2 pathways: * First pathway consists of organized health workshops. These workshops are intended to provide information on topics such as proper nutrition, management of stress, sleep practices, and emphasis on a healthy lifestyle th * Second pathway participants will take part in some unsupervised and some potentially supervised moderate activity sessions each week throughout participants' cancer treatment to take place either remotely or in person,	NO
Retrospective multi-center cohort study. Consecutive patients hospitalized for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) up to October 2020 will be included. Patients are followed until discharge from h	NO
The objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over tim 1. To evaluate the efficacy of the Survey-based Patient/Clinician Jumpstart compared to the EHR based clinician Jumpstart and usual care for improving quality of care; the primary outcome is EHR documentation of a goals- 2. To conduct a mixed-methods evaluation of the implementation of the intervention, guided by the RE-AIM framework for implementation science, incorporating quantitative evaluation of the intervention's reach and adoptio	NO
The purpose of this study is to test if the use of Degarelix for 1 year associated with a lower rate of cardiovascular toxicity compared to Gonadotropin-releasing hormone (GnRH) agonists in patients with advanced prostate ca	NO
Breast cancer patients undergoing trastuzumab-based HER2-directed therapy are at risk of heart function decline or heart failure symptoms, but it is unknown if, when, and for how long cardiovascular protective strategies, e	NO

RATIONALE: Aerobic exercise may help prevent side effects caused by chemotherapy and help improve heart health. PURPOSE: This randomized clinical trial is studying the side effects of aerobic exercise and to see how well it works in patients receiving chemotherapy for cancer.	NO
This study will examine how to communicate with an underserved population about inherited disease risks. It will present information about inherited risk to a Latino population through either a lay health advisor (LHA) or thro Spanish-speaking Latino men and women over the age of 18 in the Oakland, CA, and Washington, DC, areas who have basic Spanish reading and writing skills may be eligible for this study. Participants are recruited to one of two groups. One group participates in group educational sessions with an LHA about inherited disease risks and family health history, and the other receives this information from a brochur Educational Sessions Groups of 5 to 8 individuals complete a questionnaire and then participate in a 45-minute educational session on concepts related to genetics, family health history, lifestyle and environment. Participants engage in role-playir Brochure-Only Participants complete a questionnaire and then read a Spanish-language brochure produced by the U.S. Surgeon General's Office about the importance of knowing one's family history. They then complete a second questio	NO
The purpose of this study is to determine the effects of a physiotherapy prehabilitation programme (walking and deep breathing exercises) in cardiac or thoracic patients by measuring changes in lung volumes, functional cap	NO
Informal caregivers provide a majority of care for patients during serious illness. Lack of preparation and completion may leave caregivers less capable of caring for a loved one or making crucial decisions influencing care. This study will examine whether a preparation and completion intervention reduces caregiver anxiety, depression, anticipatory grief, and burden and improves patient quality of life and health care use.	YES
Over 50% of the more than 270,000 childhood cancer survivors in the U.S. have been treated with anthracyclines and thus are at risk of developing cardiotoxicity. The impact of exercise training on LV structure has been exte	NO
Investigating the physiological effects of the interferons type 1 and 2 (IFNs), and the cytokines Interleukin 6 (IL-6) and tumor necrosis factor (TNF) on the adaptive changes to exercise in patients with systemic lupus erythemat The investigators hypothesize that the pathogenic blockage of IL-6 signalling that occurs in SLE, will decrease the cardiac and metabolic adaptations to aerobic exercise, and this decrease can be related to the IFN signature. 60 patients will be included in a 12-week investigator blinded 1:1 randomised high intensity aerobic exercise intervention study.	NO
Breast cancer is the leading cause of cancer among Canadian women with nearly 26,000 new cases diagnosed each year. Fortunately, advancements in diagnostic tools and curative treatments have significantly improved o	NO
This study compares the effectiveness of two different approaches to advance care planning among older African Americans and older Whites living in the community. The two approaches are a structured approach with an a	NO
The purpose of this study is to evaluate if radiation and chemotherapy treatment cause cardiac abnormalities among survivors of Hodgkin's lymphoma.	NO
The purpose of this study is to evaluate the feasibility of conducting a medical intervention trial in childhood cancer survivors with early echocardiographic evidence of cardiac remodeling.	NO
This trial studies cardiac changes after radiation or chemo-radiation for the treatment of lung or esophageal cancer that has not spread to other places in the body (non-metastatic) or has not come back (non-recurrent). Cont	NO
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in all patients who are treated with it under the actual condition of use pursuant to the conditions of approval. 1. Planned registration period This period started on the date of initial marketing of Revlimid and will end at the time when the planned number of patients to be enrolled is reached. 2. Planned surveillance period This period started on the date of initial marketing of Revlimid and will end on the day when the approval condition related to all-case surveillance is terminated.	NO
Breast cancer is the most common cancers among women worldwide.Although chemotherapy and surgery have greatly improved the survival rate, most types of chemotherapy have been reported to have varying degrees o	NO
A retrospective cohort study performed in the GPRD,UK. All patients with incident prostate cancer identified between 1 Jan 1999 and 31 Dec 2005 and a frequency-matched cohort of the general population will be followed-	NO
The overall purpose of this protocol is to identify subacute sepsis-associated cardiac disease in pediatric patients with cancer by CMR and evaluate the CMR findings during their follow-up. This will help inform heart failure n Primary Objectives: (Feasibility Phase) To determine the feasibility of cardiac MRI without anesthesia in the immediate post-sepsis period in children with cancer. CMR scanning will be completed within 10 days of presentation - this will allow us to ensure that possible hemodynamic or respiratory instability and renal dysfunction has resolved prior to transport to the MRI scanner during (Completion Phase) To estimate the frequency of subacute sepsis-associated cardiac disease, including myocardial inflammation and dysfunction, in the post-acute phase (within 10 days of presentation) of severe sepsis in c	NO
For many years, researchers and doctors have studied different kinds of treatments to improve the survival of men with testicular cancer. However, recent research has shown that many years later, men who had testicular ca	NO
Children having selective ophthalmic artery chemotherapy for retinoblastoma under general anaesthesia may experience troubles during the procedure. The troubles are transient, may be severe and include hypoxemia, hypo	NO
Primary: * To characterize the physiologic changes of the autonomic nervous system, demonstrated by heart rate variability (HRV) high frequency (HF) spectral analysis, before and after a 15 minute, one-time, guided relaxation progra Secondary: * To assess whether change of HRV correlates with subjective feeling for anxiety, based on visual analog scale scores.	YES
This is a Congressionally mandated study. In the original study, 16 demonstration programs provided care coordination services to beneficiaries with chronic illness in Medicare's fee-for-service program. A five-year CMS-fun In 2008 Congress extended the project for two of the original programs--Mercy Medical Center - North Iowa and Health Quality Partners in Pennsylvania--and they will enroll Medicare beneficiaries and provide care coordinat	NO
We hypothesise that fish oils will have a beneficial effect on cardiometabolic parameters in women with PCOS. The purpose of this study therefore is to examine the effects of fish oils on blood pressure, heart rate variability a	NO
This is a multicentre non-randomized phase II study of proton beam radiotherapy in patients with thymic epithelial tumours (i.e. thymoma and thymic carcinoma) in the post-operative setting or in inoperable patients with loca Patients not willing or for any reason unsuitable to undergo proton treatment will be asked to participate in a follow-up assessment after the regular photon treatment in the same manner as the included patients. Primary endpoints are:Toxicity (e.g. cardiac and pulmonary toxicity) and Local control at 5 year Secondary endpoints: PFS, Overall survival, Quality of life, measured by EORTC QLQ 30 + LC 13 and relapse pattern	NO
Medical progress and modification of lifestyles have prolonged life expectancy, despite the development of chronic diseases. The support and care are often provided by a network of informal caregivers composed of family, The aim of the Informal Carers of Elderly Cohort is to define, through a longitudinal study of their life course, the profiles of caregivers of patients with a diagnosis of one of the following diseases: cancer (breast, prostate, colo Thanks to an analytical and longitudinal definition of the profiles of informal caregivers, this study could gather precise information on their life courses and their health trajectory by identifying the consequences associated w	NO
Cardiovascular events are the leading non-cancer cause of mortality after childhood cancer, occurring at a significantly younger age than in the general population. The increased incidence of cardiovascular events adversely	NO
The purpose of the study is to look at the safety (what are the side effects) and efficacy (how well does it work) of gadobutrol when used for taking MR images of the body/extremities regions. The results of the MRI with gado	NO
This pilot clinical trial studies computed tomography (CT) scans and biomarker analysis in diagnosing coronary artery disease (CAD) in patients who have undergone a stem cell transplant but have no symptoms of CAD. CAD	NO
To provide a comprehensive analysis of risk factors for the development of clinical cardiotoxicities in over 6,000 children with cancer who had been treated on standardized protocols involving the use of anthracyclines alone	NO
The investigators will study the effects of an inhospital exercise intervention combined with lifestyle--including diet--counselling along the duration of treatment (neoadjuvant \[solid tumours\]/intense chemotherapy \[leukemia	NO
As the cancer-related prognosis improves thanks to recent advances in cancer-targeted therapies, the prognostic burden of chemotherapy-related complications - including cardiotoxicity - is increasingly recognised. So far, tl	NO
Investigators are conducting this study to find out more about what heart health means to participants and how healthcare providers can best help to manage heart health. Participants will be asked to view an electronic tool	NO
The purpose of this project is to quantify normal and abnormal skin blood flow regionally in different areas of the body(face, extremities, over burns and wounds) at baseline and over time in response to treatment or environm	YES
An adverse event (AE) is defined as unintended injury or complication, which results in disability, death or prolongation of hospital stay, and is caused by healthcare management (including omissions) rather than the patient's	NO
In this study, Valve replacement patients undergoing cardiopulmonary bypass were randomly divided into control group and experimental group (SGB Group) , main outcome measures: postoperative complications (pulmona	NO
Therapeutic massage is the most common non-traditional treatment option offered to improve quality of life, provide comfort and decrease pain in hospice and palliative care settings outside the hospital. Three systematic re Given the remarkable negative impact on QOL experienced by patients hospitalized with a serious progressive illness, a nationwide opioid crisis in the setting of public concern for untreated pain, and patient demand for inte We conducted a single center comparative effectiveness study to evaluate therapeutic massage "dosing" to improve self-reported quality-of-life in hospitalized patients receiving palliative care consultation.	NO
The purpose of this study is to evaluate the effect of entinostat on heart rate and other electrocardiogram (ECG) parameters. This study will also evaluate the safety and tolerability of entinostat, as well as pharmacokinetic an	NO
The aim of this study is to identify patients with problem list gaps and intervene to correct these gaps by creating clinical decision support interventions that alert providers to likely problem list gaps and offer clinicians the op	NO
In this study researchers want to learn more about the effect of low-dose Aspirin on cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine bef	NO
RATIONALE: Lisinopril or Coreg CR®, may help reduce side effects caused by trastuzumab. It is not yet known whether lisinopril or Coreg CR® are more effective than a placebo in reducing side effects caused by trastuzum PURPOSE: This phase II trial is studying lisinopril and Coreg CR® to see how well they work compared with a placebo in reducing side effects in patients with HER2-positive breast cancer receiving trastuzumab.	YES
The clinical use of genetic testing is expanding and, as a result, the number of variants identified in patients is growing. Knowledge of the clinical impact of these variants improves over time. However, the combination of mor	NO
The goal of this clinical research study is to compare the effects of sodium bicarbonate to normal saline when used for clearing mucus blockage in patients with airway stents.	NO
Postoperative breast radiotherapy (RT) has been associated with increased risk of heart toxicity. However, there is a lack of knowledge for radiation-induced early cardiovascular injury, especially for hypofractionated RT. This	NO
Systemic amyloidoses are rare diseases affecting approximately 1 in 100,000 persons each year. In systemic amyloidoses abnormal proteins deposit in bodily organs and severely impair their function, causing death if not treated effectively. Light chain (AL) amyloidosis is caused by a usually small population of plasma ce	NO
This is an open-label, single-arm, single-center, proof-of-concept study to assess the effects of melatonin on cardiac autonomic activity in melatonin non-proficient pinealectomized patients.	NO
The primary aim of the present study was to examine the haemodynamic changes in primary hypertension and secondary hypertension (renal diseases, endocrine diseases, obesity-associated hypertension) with a non-invasi	NO
The study hopes to determine whether patients with left-sided breast cancer are at an increased risk of cardiac changes due to radiation to the breast +/- Anthracycline-based chemotherapy +/- Herceptin and whether a deep	NO
A prospective randomized controlled trial studying the ordering of palliative care consultations in the emergency department (Ig) versus later palliative care consultations in the hospital--ICU or hospital ward(Cg). Patients will l	NO
The goal of this clinical research study is to learn if certain biomarker testing on blood samples can help to detect heart damage that may occur during chemotherapy. Biomarkers are chemical "markers" found in the blood th	NO
This phase II clinical trial aimed at influencing the improvement of major organ functions, especially the objective response rate, in Amyloid light-chain amyloidosis involving myocardium.	NO
This study aims to identify possible set of inflammatory biomarkers before, during and after anthracycline-based chemotherapy in breast cancer patients to identify (sub)clinical chemotherapy-related cardiac dysfunctionCRC	NO
Breast cancer is the most common cancer among women. The modern post-surgery treatment with chemotherapy, immunotherapy, radiation and hormone therapy has improved the overall 5-years survival drastically. Howev	NO
The investigators will prospectively evaluate for the presence of amyloid deposits in soft tissue samples obtained from patients undergoing trigger finger release surgery. Patients who have tissue that stains positive for amylo	NO
Anthracyclines (e.g. Doxorubicin) are an important and highly effective chemotherapeutic. They are used in various tumor entities and are established for breast cancer treatment. The most significant prognostic side effect is	NO
This research programme seeks to combine the resources of NHS primary care, with the leading spectroscopic work in low-magnetic fields of the Wilson Group (Nottingham Trent University) to demonstrate the potential for b	NO
According to the existing clinical data in our hospital, retrospective study was conducted to screen the risk factors with predictive value for TRC(trastuzumab-related cardiotoxicity) risk, and to construct the risk prediction mo	NO
The project is a passive follow-up of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study cohort. Originally, this was a large, randomized, double-blind, placebo-controlled, 2x2 factorial primary prevention t The primary purpose of the ATBC cohort follow-up is to use the existing risk factor data and biological specimens (i.e., serum, whole blood, DNA, red blood cells, and toenails) to test hypotheses relevant to cancer etiology, s	NO
Studies on radiation induced patients' skin lesions in interventional radiology highlighted the need for optimized and personalized patient dosimetry and adapted patient follow-up. Measurements using Gafchromic® films or t Radiation Dose Monitor (RDM from Medsquare) is a software program for archiving and monitoring of radiation dose (DACS, Dosimetry Archiving Communication System) used in routine in the investigator's hospitals. A new Main objective: to validate RDM software for calculating patient skin dose in interventional radiology.	NO
The main purpose of this study is to determine if it is possible to put into practice a cardiac screening program for survivors of Hodgkin's disease. In this study, we would also like to screen for cardiac risk factors that can be	NO
The purpose of the study is to inform decision-makers of the best strategies to implement advanced care planning (ACP). An advanced care plan (ACP) is a verbal or written instruction describing what kind of care an individual would want (or not want)if they are no longer able speak for themselves to make health care decisions.	NO
Investigators will evaluate the safety, tolerability, and feasibility of a risk-guided cardioprotective treatment strategy with carvedilol, as compared to usual care, in breast cancer patients undergoing treatment with doxorubicin,	NO
The goal of this observational study is to compare the image differences between conventional ultrasound and artificial intelligence-based ultrasound software in conscious adults. The main question it aims to answer is to evaluate the effectiveness by determining that the new image analysis method is considered valid if it helps to identify more than 30% of histological characteristics. Participants will undergo the examination using the two methods mentioned earlier after signing the consent form.	NO
This single arm therapeutic exploratory study of digoxin in patients with advanced or metastatic breast cancer investigates whether cardiac glycosides are able to disrupt CTC clusters in breast cancer patients.	NO
Two large homocysteine-lowering B-vitamin intervention trials have been performed in Norway during the period 1998 to 2005, NORVIT and WENBIT. The main objective in these trials was to study the clinical effects of homo There is so far no data on possible long-term effects following years of such B-vitamin treatment. Thus, the main objective of the combinded NORVIT-WENBIT study will will be to evaluate the long-term effect of the B-vitamin intervention on incident life-style diseases including cardiovascular disease, diabetes, osteoporo A secondary object will be the identification of risk phenotypes or genotypes, and if such risk associations are midified by the B-vitamin intervention	NO
This study is designed to evaluate the effects of talazoparib on cardiac repolarization in patients with advanced solid tumors with no available standard treatment options.	YES
Mediastinal irradiation for treatment of malignancy increases the risk for coronary artery disease (CAD), while diabetes mellitus or other known risk factors can be absent at the time of the first coronary event. Radiation-induc A novel hybrid imaging technique that combines SPECT and CTCA has been shown to overcome the individual pitfalls and the diagnostic challenges of stand-alone SPECT and CCTA, improve the lesion detectability and ser The aim of the study is to perform hybrid SPECT/CTCA in asymptomatic patients with HL who have received radiotherapy to the mediastinum in order to allow an early diagnosis of hemodynamically significant CAD that will	NO
The purpose of this study is to obtain QTc data, to assess the effects of tivozanib on ECG morphology, and to determine the pharmacokinetic pharmacodynamic (PK-PD) relationship between any observed changes in cardia	NO
The therapy of photofrin PDT was effective in improving life quality of patients with advanced esophageal and/or gastric cardiac cancer and the time optimizing for employing laser irradiation was of great importance.The purp	NO
Anti-cancer immunotherapy, one of the therapeutic revolutions of recent years. It is based on the use of antibodies that block immune system checkpoints that have been hijacked by cancer cells to benefit themselves. Block Cardiac autoimmune involvement in ICIs can involve the myocardium, pericardium, and/or vascular endothelium. These entities may be interrelated or, on the contrary, isolated. In the last 5 years, the number of described cases of myocarditis associated with ICIstreatment has increased. Their incidence remains low, estimated between 0.5 and 2%. This probably represents the most serious cardiova In recent years MRI has become very important in the noninvasive diagnosis of acute myocarditis. The latest update of the Lake Louise criteria in 2018 has thus confirmed cardiac MRI in its first place among noninvasive exa	NO
MEDIRAD-BRACE aims to determine the relationship between 3D dose distributions in cardiac structures and the risk of acute coronary events (ACE) and other cardiac complications in breast cancer (BC) patients to develop	NO

Investigators will evaluate the safety and feasibility of a biomarker-guided cardioprotection strategy using NTproBNP, as compared to usual care, in breast cancer and lymphoma patients treated with anthracyclines.	NO
A stroke is the second cause of deaths after heart attack, one of the most important causes of malfunction as far as adults are concerned and the second as for the frequency cause of dementia. In spite of a possibility of the There are many of potential causes of cardiac strokes, which are not entirely examined. More over many cryptogenic strokes are presumed to have an embolic etiology, and the frequent cause of these kind of strokes at young age is probably the mechanism of paradoxical embolism through patent foramen ovale As far as the investigators are concerned, at present there is lack of any recommendations for these scientific hypothesis.	NO
The goal of this observational study is to evaluate cardiac and vascular health status of pediatric cancer survivors.	NO
The purpose of this study is to improve care delivered to patients with serious illness by enhancing communication among patients, families, and clinicians in the outpatient setting. We are testing a new way to help patients s	YES
Adult patients undergoing elective non-cardiac surgery were enrolled. Anxiety before the operation was evaluated by The State Anxiety Inventory (S-AI). Logistics regression would be used for identifying the independent facto	NO
To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereina 1. Planned registration period 3 years 2. Planned surveillance period 4 years and 6 months after a month after the approval for partial changes in the approved items is granted for relapsed or refractory ATLL	NO
This is a pilot study to determine whether the addition of inspiratory hold (breath holding) can decrease the radiation dose that the heart and lung receive for patients being treated for left sided breast cancer.	YES
The Copenhagen City Heart Study is an ongoing cardiovascular population study initiated in 1976 which has examined approximately 25,000 individuals from the general population. The initial sample has been re-invited up t	NO
The investigator proposes to use the cardiac coherence technique (Cardiac Coherence) coupled with a hypnosis session to reduce pre-operative anxiety.	NO
Breast cancer represents the most frequent form of neoplasia in women worldwide, being responsible of 1.6% of annual deaths. Therefore, it is a major public health issue and research in this field should be a priority. Taxane	NO
The investigators use the cancer registration system of National Cheng Kung University Hospital to timely screen and evaluate those patients having breast cancer or lymphoma to enroll patients to participate in this clinical tr	NO
Longitudinal analysis of myocardial function using "Speckle Tracking Echocardiography" STE analysis and prediction of delayed toxic induced cardiomyopathy in young patients who received anthracycline therapy in childho	NO
Cardiovascular disease (CVD) is a major contributor to morbidity and mortality in pediatric, adolescent and young adult (AYA) cancer survivors (hereafter referred to as PAYA-CS). Exercise is a cornerstone of CVD prevention a	NO
Breast cancer (BC) radiotherapy leads to coincidental radiation of the heart, resulting in increased risk of a variety of heart diseases. Identifying BC patients with the highest risk of radiation-induced cardiac complications is ci In the framework of the European project MEDIRAD, the EARLY-HEART multicenter prospective cohort was launched in August 2017, involving 5 investigating centers from France, Netherlands, Germany, Spain and Portugal.	NO
RATIONALE: Studying samples of blood and tissue in the laboratory from women receiving doxorubicin and trastuzumab for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarke PURPOSE: This clinical trial is studying side effects involving the heart in women with breast cancer receiving doxorubicin and trastuzumab.	NO
Since September 1st, 2009, Taiwan has begun to pay attention to the care of patients with organ failure, dementia and the elderly, and brought eight of non-cancer terminal patients into health insurance subsidies to impleme In this study, a randomized experimental research design was applied by two-group pre-and post-test. The targets are the eight non-cancer terminal caregivers in a home care institution of a regional teaching hospital located	NO
Evaluation of the predictive value of serum levels of adipocytokines and primary phase reactant for recurrent atrial fibrillation (RAF) after catheter ablation in 26 patients had persistent and 91 patients had paroxysmal AF. Durir	NO
Lung cancer is the most common cause of cancer death in Canada. For approximately 30% of patients that present with locally-advanced non-small cell lung cancer (NSCLC), the standard treatment is curative-intent concur	NO
The treatments that aim to cure cancer in children can lead to "late effects" such as second cancers and heart disease. Screening tests can help find late effects, but most adult survivors of childhood cancer do not complete We have developed a program called ONLOOP to remind survivors in Ontario, Canada to get the screening tests they need. ONLOOP reminds survivors who are at higher risk for heart disease, breast cancer, and/or colorecta The goal of this clinical trial is to find out how well ONLOOP helps adult survivors of childhood cancer complete their screening tests. We also want to see if it could be turned into a long-term program in Ontario. Eligible surv The intervention includes usual care plus these ONLOOP materials: 1. Study invitation letter and invitation reminder 2. Those who sign up for ONLOOP will receive personalized health information and a screening reminder. Survivors will receive information about: 1. their cancer treatment 2. their risk(s) for late effects 3. the screening tests they should do 3. Survivors' primary care providers will be provided with the same health information provided to participants in (2)	NO
This registry is a observational, multi-center study designed to collect data and analyze it retrospectively on patients with cardiac amyloidosis who have been evaluated and treated at major amyloid centers across the US and	NO
This is an observational study for patients with prostate cancer that will be treated with Androgen Deprivation Therapy. The study will help the investigators learn more about how these medications affect the heart and how th	NO
A known risk of red blood cell transfusions is that it puts excess iron into the patient's body. Researchers are continually seeking the most effective method of measuring iron concentration. The purpose of this study is to det	NO
Breast cancer is the most common cancer amongst Canadian women. 15-20% of early breast cancers have high levels of a protein called HER2 which is associated with worse survival. Treatment of these patients with anthr The investigators will test the theory that, in women receiving treatment for breast cancer, heart edema detected by MRI at the end of anthracyclines will identify patients who will later develop heart dysfunction. MRI studies v The first 136 patients enrolled are included in the first part of the study, named EMBRACE-MRI 1. Enrollment for this part of the study is complete. The remaining 44 patients will be enrolled into EMBRACE-MRI 2, which includes slight differences in obtaining sequences in MRI imaging.	NO
Based on the follow-up data of elderly donation after cardiac death(DCD) donor liver transplant recipients from the CLTR, a database and official website for national data gathering. patients who met the enrollment criteria we	NO
Chemotherapy or radiation therapy-induced cardiotoxicity are well-recognized side effects in patients with cancer. The clinical significance of cardiotoxicity is growing with increasing cancer survivor-ship. Left ventricular (LV) functional assessment is the standard of reference to diagnose chemotherapy- or radiation therapy-induced cardiotoxicity. The investigators will investigate the usefulness of T1 mapping parameters for ea	NO
Rationale: In addition to surgery, effective breast cancer (BC) treatment typically requires chemotherapy, radiotherapy, or both. However, it is still unclear whether patients with BC are at increased risk of long-term cardiac dys Objective: The aim of the here proposed study is to clarify whether cardiac function in survivors of BC should be monitored by GPs, by assessing whether an unselected population of long-term BC survivors is at increased ris Study design: A new assessment of cardiac function among women included in the BLOC-I study. This produces a longitudinal matched cohort design consisting of two cohorts in primary care. Study population: Survivors of BC, diagnosed ≥11 years ago who received chemotherapy and/or radiotherapy, and a matched reference population with no history of cancer. All participants participated in the Breast cancer L Main study parameters/endpoints: Left ventricular systolic dysfunction. Systolic cardiac dysfunction is defined as a LVEF \<54/50/45%.	NO
The study is prepared to use CMR technology for early screening of myocardial lesions in 561 age-matched women with type 2 diabetes without PCOS, with PCOS without type 2 diabetes and with type 2 diabetes combined	NO
Patients with breast cancer receive low doses to smaller volumes of the heart, but they also have an excellent long-term survival, so it is crucial to study the effects of low dose radiotherapy. Indeed, a recent study suggests th	NO
Discover, optimize, standardize, and validate clinical-trial measures and biomarkers used to diagnose and differentiate cardiovascular, oncologic, neurologic, and other diseases and disorders. Specifically, our research study Additionally, the study aims to: * Evaluate data analysis techniques to improve diagnostic accuracy and reduce time to diagnosis. * Evaluate data analysis techniques to improve risk stratification for participants through machine learning algorithms. * Direct participants to relevant and applicable clinical trials.	NO
Breast irradiation is known to cause radiation-induced heart disease (RIHD) many years later after radiotherapy. Recent studies suggest that RIHD could be an earlier complication and that subclinical cardiac injury can be de The most used technique for breast cancer irradiation is tangential opposed field, but this technique exposes the left anterior descending coronary artery to high dose during left breast irradiation. There are different cardiac sparing techniques to reduce heart exposure such as: * Deep inspiration breath-hold (DIBH) which displaces the heart out of the radiation beam * Intensity-modulated radiation therapy (IMRT) which decreases heart exposure to high doses but changes the dose distribution in the heart and increases lower doses.	NO
It is well known that the Type 2 diabetes and vascular disease are preceded by over ten years by metabolic dysfunction and anatomic changes that can be quantified. In order to develop effective preventive strategies and re Prevalence of "prediabetes" among American adults is estimated to be \~84 million, or one out of three Americans. Over a 5-7 year period approximately one third of these prediabetic individuals will progress to type 2 diabet Insulin resistance is a common causal feature of many of the pathophysiologic mechanisms linking macrovascular disease and type 2 diabetes. Because hyperglycemia is the major factor responsible for the development of r By combining a standard medical evaluation with the evaluation of cardiovascular biomarkers, patients at intermediate risk of vascular disease can be identified. In these patients, carotid intima media thickness (IMT) and car The hypothesis of this observational study is that the characterization of the physiology and anatomy of patients at risk of developing type 2 diabetes and/or cardiovascular disease can stratify risk of developing disease and	NO
This study will test the effectiveness of integrating an evidence-based model of home-based palliative (HBPC) within primary care clinics on patient and caregiver outcomes. The investigators will conduct a randomized contr	NO
Perioperative hemodynamic optimization requires monitoring adapted to the risks of the surgery and the patient. The investigators currently use a local hemodynamic protocol based on the data of the literature. According to In our institute, most of the patients are fitted with a port for chemotherapy or parenteral nutrition. When PiCCO monitoring is necessary, a central venous catheter is inserted on the opposite side of the permanent implantabl The aim of this study was to assess whether measurement of the CI by TPTD was possible and reliable via the port. The investigators conducted a prospective study comparing the measurement of the CI by TPTD before an	NO
This is a multicenter study of a primary chemotherapy regimen in breast cancer patients at risk of developing cardiotoxicity. The aim of the study is to evaluate the response rate at surgery.	NO

Mental disorders have been shown to be associated with a number of general medical conditions (also referred to as somatic or physical conditions). The investigators aim to undertake a comprehensive study of comorbidity The investigators will examine the association between all 90 possible pairs of prior mental disorders and later GMC categories using the Danish national registers. Depending on whether individuals are diagnosed with a spe	NO
The main objective of this randomized controlled trial is to test the association between standard cardiac risk factors, biomarkers and parameters of echocardiography, electrocardiography, and cardiac magnetic resonance ir	NO
The goal of this clinical trial is to learn if heart function remains normal after stopping heart failure medication in patients who have received chemotherapy.	YES
ECMO(Extracorporeal membrane oxygenation) is being essential for cardiopulmonary failure patients. There are two types of ECMO, which is veno-veno (V-V) that can be used in respiratory failure patients and veno-arterial (\	NO
This project compares two models of the Serious Illness Care Program (SICP) in primary care: clinician-focused SICP and team-based SICP. Discussion and planning for serious illness care can help patients identify what is n	NO
This is a pilot prospective cohort study, in adult female subjects 18-85 years old with a diagnosis of invasive breast cancer who are planned for anthracycline-inclusive chemotherapy and followed up for a time period of 6 mo	NO
This is a multicenter, prospective, observational cohort study to comprehensively and longitudinally evaluate and characterizes the cardiovascular events with CLL patients who are initiating treatment with a Bruton's tyrosine	NO
This research study is evaluating the use of Cardiac Magnetic Resonance Imaging (CMR) as a method of detecting early signs of damage to the heart that can be associated with anthracycline-based chemotherapy for the tre	NO
To compare rates of coronary heart disease (CHD), cancer, total mortality and exercise injuries in 68,000 runners and 68,000 walkers during four years of surveillance	NO
This case control study aims to determine whether spontaneous coronary artery dissection (SCAD) is associated with autoimmune diseases and to update the incidence of SCAD in a population-based cohort.	NO
Back ground \& Aims Adult patients suffering from multimorbidity are at high risk of medication non-adherence. It has been well established that self-management support is an effective strategy to enhance medication adher Methods This study is a single centre, single-blind, two-arm randomised controlled trial. Adult patients with multi-morbidity will be recruited from NCCCR Qatar. A total of 100 participants will be randomly allocated to receive Outcome The primary outcome is medication adherence as measured by the 8-item Medication Adherence Report Scale. Secondary outcomes include medication self-management capacity (medication knowledge, medicat	NO
Since 2007, the cost of sequencing a diploid human genome has fallen dramatically, from approximately $70 million to $20,000. As affordable sequencing platforms become more widely available, the advancement of biomed An overall aim of this project is to obtain feedback on the informed consent process from some of the earliest particpants in studies using whole genome sequencing. A more specific goal is to characterize the salient persona Participants will be asked to complete a one-time, semi-structured telephone interview lasting approximately 45 minutes in the period 2-8 weeks following their initial informed consent session at the NIH. They will be recruite	NO
Breast cancer is the most common cancer in the United Kingdom (UK), but improvements in treatment mean 3 in 4 people survive for more than 10 years. Many people receive treatments called human epidermal growth fact	NO
REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy \>5 years ago.	NO
The objective of this study is to define the clinical significance of mechanistic biomarkers (including Neuregulin-1Beta) and novel echocardiographic measures of cardiac function in predicting the incident risk of cancer therap	NO
This is an open label Phase II study in elderly patients (65y or older) with early breast cancer who are candidate for adjuvant chemotherapy. A scheme with liposomal doxorubicin (Caelyx) and cyclophosphamide (endoxan) wil	NO
There is strong evidence that specific types of exercise can improve health and physical function in older adults. While community exercise classes exist, many older adults with chronic conditions may need guidance from cr	NO
Twenty-seven breast cancer women without heart failure, underwent CMR imaging (3T-Achieva, Philips) before and 3 times serially after 4-cycles of adjuvant DOX (60mg/m2). CMR assessed left ventricular (LV) ejection fractio	NO
Objectives: To evaluate the pressure pain threshold, shoulder biomechanics, cardiorespiratory function and the quality of life associated with the short and long-term physical therapy rehabilitation following breast cancer surg	NO
Communication about end-of-life issues is often suboptimal. A way to improve the quality of end-of-life care is Advance Care Planning (ACP). ACP is a discussion between an incurable ill patient and the health professionals a	NO
The human gut microbiome has been associated with many health factors but variability between studies limits the exploration of effects between them. This study aims to systematically characterize the gut microbiota of var	NO
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as enalapril, may protect normal cells from the toxic effects of chemot PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of enalapril with a placebo in treating heart damage in patients who received anthracycline chemotherapy for childhood cancer.	NO
This study aims to evaluate the effects of cardiotoxic cancer therapies on myocardial blood flow (MBF) and perfusion in a prospective sample of VA patients.	NO
This study explores how aromatase inhibitor therapy affects risk factors for heart disease in postmenopausal women with breast cancer.	NO
The overall objective of this proposal is to determine the utility of sensitive imaging and biomarker measures in detecting subclinical cardiotoxicity across a spectrum of radiation doses to the heart. We will focus specifically o	NO
To assess the need of respiratory gated radiotherapy in left sided breast cancer patients.	NO
Anthracyclines have been used commonly to treat children with solid tumours and haematological malignancies and have led to their increased survival. Nonetheless, anthracycline has the side effect of cardiotoxicity. The pu	NO
Sildenafil increases the therapeutic effect of doxorubicin used as treatment for cancers of solid tumors through both an increase in anti-tumor effects and protection from cardiac toxicity.	NO
This study aims to compare conventionally acquired Left Ventricle Ejection Fraction (LVEF) and Global Longitudinal Strain (GLS) data to Artificial Intelligence (AI) driven automated processing of 2 dimensional contrast and 2 d	NO
The purpose of this study is to treat participants with the combination of durvalumab (the study drug) and proton beam therapy. Proton beam therapy is a type of radiotherapy (RT) with a unique characteristic where the proto	NO
Atrial fibrillation is a common complication of both cancer and anticancer drugs but the consequences of such events remain poorly known and are not adressed in both phase III oncological trials and cardiological guideline	NO
This randomized phase II trial studies how well erlotinib hydrochloride with or without carboplatin and paclitaxel works in treating patients with stage III-IV non-small cell lung cancer. Erlotinib hydrochloride may stop the grow	YES
This pilot study wants to determine to which extent SPCCT allows obtaining images with improved quality and diagnostic confidence when compared to standard Dual Energy CT (DECT), both with and without contrast agen Depending on the anatomical structures/organs to be visualized during CT examinations, different scanning protocols are performed with quite variable ionizing radiation doses. Therefore, in order to obtain the most extensive	NO
Background: - Family-based approaches to reduce disease risk and promote healthy behaviors may be better than targeting individuals. Risk assessments based on family health history may help educate families on disease risks and enc Objectives: * To determine mothers influence on diet and health-related behaviors. * To study an intervention tool that connects family health history and disease risk. Eligibility: - 18 years of age who have at least one child living at home. Design: * Participants will complete a survey over the phone. The survey will take 30 to 40 minutes to complete. The survey will collect family health history on heart disease, diabetes, colorectal cancer, and breast cancer. * Researchers will give participants a Family Health Package (FHP). The FHP will provide information on family health history and disease risk. It will also recommend behaviors that can reduce health risks. * Two weeks after sending the FHP, participants will complete a phone survey about the FHP materials and their social networks. * Some participants will be invited to focus groups. The focus groups will explore diet and health behavior. They will look at food purchasing and preparation and meal sharing. The groups will also discuss attitudes toward he * Participants will be asked to complete an electronic survey regarding participants health status, causal health beliefs, risk perceptions, and intentions to communicate health information. * Then, participants will have the opportunity to use the electronic version of the FHP, which will assess family health history. * After using the FHeP, participants will complete a short electronic survey to identify knowledge and understanding gained from the use of the application, changes in communication intentions, and suggestions for improven * Upon completion of the electronic portion of the study, a study team member will conduct a semi-structured interview to allow the participants to qualitatively evaluate their user experience, including satisfaction and usefuln * This study process will take approximately 60-90 minutes.	NO
Microparticles are cellular fragments which are released actively or passively under conditions of inflammation and stress. The impact of surgical operations on quantity and quality of microparticles remains unknown. In this c	NO
CU-Med Biobank collaborates with different researchers for collecting and distributing human biospecimens and clinical data for assisting scientific research.	NO
A prospective study in paediatric, adolescent and young adult patients aged 7 to 18 years to evaluate the agreement between QTc measured using 12 lead electrocardiogram (ECG) and the wearable device ECG.	NO
Doxorubicin and other anthracyclines are commonly used to treat breast cancer and other types of cancer. Unfortunately, they can cause heart muscle damage, resulting in scarring, abnormal contraction and relaxation, and Few therapies have been shown to prevent heart damage in patients receiving anthracyclines. Small studies have suggested that other heart failure medications (ACE inhibitors, beta-blockers) may reduce the incidence of ca This study aims to investigate whether eplerenone protects the heart from the harmful effects of doxorubicin chemotherapy. Specifically, it will measure the effect that eplerenone has on heart muscle relaxation. It will random	NO
Lung cancer is the leading cause of death worldwide, with non-small-cell lung cancer (NSCLC) being the most common histotype according to the global cancer observatory 2022. A variety of therapeutic options for advance In the last two to three decades, hundreds of cancer biological prognostic markers for non-small cell lung cancer have been proposed. Although they have shown a potential in this field, validation studies are still required and	NO
The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. The present study aim to document the feasibility of detecting the potentia	NO
Phase I trial to study the effectiveness of oblimersen plus combination chemotherapy and dexrazoxane in treating children and adolescents who have relapsed or refractory solid tumors. Drugs used in chemotherapy use diffe	NO
The aim of our study is to compare plasma metanephrines in patients with cyanotic and acyanotic congenital heart disease and possible association with chronic hypoxic stress.	NO
The pathophysiological implications of various cancer diseases and anti-cancer therapies is the occurrence of a cardiac disease-like phenotype with cardiac dysfunction, cardiac wasting, and cardiac homeostasis changes (ir	NO
Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions. With a simple blood test, rare genetic conditions can be easily detected, and the Baby Detect Project is an innovative NBS program using a panel of target sequencing that aims to identify 126 treatable severe early onset genetic diseases at birth caused by 361 genes. The list of diseases has been establi	NO
This study aims to more accurately assess cardiac function, ventilation and exercise capacity in a non-invasive fashion, and to better characterize exercise intolerance in the setting of three populations of individuals with chr	NO
To identify patients that are at risk of heart damage after receiving chemotherapy (adriamycin).	NO
Prospective, monocentric clinical study. Patients selected for nivolumab therapy in AP-HM for melanoma and non-small cell lung cancer will be eligible. Do not include patients with conditions that do not allow MRI, prior carc Cardiovascular follow up will be identical to that recommended and realized in current care in the Cardio-Oncology unit of AP-HM. It will include clinical, biological (BNP and troponin) and trans-thoracic echocardiography (TT Primary endpoint will be left ventricular function evolution evaluated by global longitudinal strain (GLS, 2D speckles tracking) in TTE. Secondary endpoints will be left and right ventricular function parameters: LEVF by TTE and Number of required subjects: GLS is recommended for following up left ventricular function under anticancer treatments. Based on the hypothesis of a significant GLS decrease (15%) in 20% of cases with alpha risk of 0.05 a The inclusion period will be 18 months with a follow up if 6 months, ie a total duration of the study of 24 months.	NO
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them	NO

PROACT will establish the effectiveness of the angiotensin-converting enzyme inhibitor (ACEI) enalapril maleate (enalapril) in preventing cardiotoxicity in patients with breast cancer and non-Hodgkin lymphoma undergoing ac	NO
Consecutive patients with a first diagnosis of breast cancer will be identified at the Tom Baker Cancer Centre (TBCC) and included into the study, if they are going to receive chemotherapy with anthracyclines and / or Trastuz Time points for the CMR and clinic assessments will be co-coordinated with regularly scheduled test by the TBCC to avoid unnecessary burden for the patients. The oncologists at the TBCC will be blinded to the results of th Standardized CMR protocols will be employed and all interpretations will be blinded to the time course of the chemotherapy and cardiotoxic side effects. We will test the hypothesis, whether CMR can be useful in patients with potentially cardiotoxic chemotherapy to: * Identify patients at risk for the development of grade 2-4 cardiotoxic side effects as classified by the NCI guidelines (common toxicity criteria, 2001, 1-12) * Identify imaging parameters to predict early or late Cardiotoxicity * Provide additional clinical information to optimize medical treatment for heart failure	NO
Patients undergoing lung resection due to pulmonary cancer can be compromised in their postoperative period due to atrial fibrillation. A retrospective analysis performed at our institution indicates that 30 % of the population develope atrial fibrillation in the postoperative period. Amiodarone is known to diminish the occurence of postoperative atrial fibrillation after heart surgery, why this drug is chosen as a prophylactic agent for the mentioned population. Amiodarone is administrated twice a day for 5 days at a dose of 600 mg oral treatment after an initial loading bolus og 300 mg intravenously.	NO
Survival rates of children with cancers have improved significantly in the recent few decades. Nonetheless, the side effect of this class of drugs on heart function remains to be an issue of concern. Exploration of new strategi	NO
The purpose of this study is to evaluate the efficacy of pericardial instillation of bleomycin as a sclerosing agent after pericardial drainage for lung cancer-associated malignant pericardial effusion.	NO
Background: Chemoradiation is an important treatment strategy of locally advanced inoperable or unresectable disease. Radiation dose is an independent predictor of a pathological response. In addition, chemotherapy has further impac Since the impact of radiation-induced heart injury in patients with thoracic malignancies (including esophageal cancer, lung cancer, et al) is poorly documented, we try to delineate of RT-related cardiac effects and clinical imp Objective: This study aims to investigate the correlation of post-tomotherapy cardiovascular effects with myocardial perfusion and cardiac functional studies. Methods: The study plans to enroll thoracic cancer patients who will undergo local RT after complete staging. Patients will receive global risk scoring assessment (Framingham Risk Score, FRS), blood sampling for basic biochemistry, Expected results: We will obtain myocardial perfusion visual qualitative data in patients who received locoregional RT, respectively. These results will help in the understanding of pathophysiology, clinical management and follow-up of suspecte	NO
PULSE-ECCho will focus on trying to detect cardiotoxicity in cancer patients receiving chemotherapy early on in order to avoid irreversible damage. In addition to that, we will test if the PhysioFlow is non-inferior to the conve	NO
A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an adren	NO
PHEOCHROMOCYTOMA (PCC)/ PARAGANGLIOMA are catecholamine secreting tumors with varied manifestations. Besides hypertension, PCC patients may have subclinical to overt cardiac and vascular dysfunction, which The aim of this research is to study the cardiac and vascular changes in Pheochromocytoma/ Paraganglioma patients and their reversal following curative surgery	NO
Palliative care is believed to improve care of patients with life-limiting illnesses. This study evaluated the impact of a multi-center randomized trial of a palliative care team intervention on the quality and cost of care of hospita	NO
The goal-concordant care lab will develop and test strategies to optimize communication in advanced serious illness.	NO
Cardiomyopathy is a condition that affects the heart muscle, whereby it becomes enlarged, thick or rigid. When the heart muscle becomes involved, it affects the pumping action of the heart. This condition can affect as many	NO
In this randomized, controlled trial the investigators evaluate the effects of an exercise program lasting for 12 weeks on the physical performance, the cardiovascular function (24h blood pressure, rest blood pressure and hear	NO
The purpose of this study is explore the impact of lung cancer surgery on inflammation and function of the right side of the heart.	NO
This observational cohort will evaluate the cardiovascular effects of chemoradiation used to treat locally advanced, non-small cell lung cancer. Patients will be enrolled prior to the start of therapy and followed during and for a	NO
To determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.	NO
Background: RASopathies are a group of genetic diseases that affect a child s development. They cause physical, cognitive, and behavioral symptoms. Caring for a child with a RASopathy can be stressful. Acceptance and Commitment T Objective: To find out if Acceptance and Commitment Therapy (ACT) can help caregivers of children with a RASopathy better cope with parenting stress. Eligibility: People aged 18 years or older who care for a child (younger than 18 years) with a RASopathy. The child must live with the caregiver at least 50% of the time. Design: The study is fully remote. Participants need a mobile device that can play audio and video and connect to the internet. They can borrow an iPod if needed. Participants will download a free app called MetricWire. They will use this app to watch videos and answer questions. The first 8 participants will be in a pilot study. They will receive the ACT intervention starting the first week after they begin the study. After the pilot study, we will start a new phase called the randomized trial. In this phase, participants will have a 50-50 chance of being in the group that will start the intervention right away or the group that will start the interv Participants will fill out surveys on 5 random days each week. These surveys have 7 questions and take about 2 minutes. They will also fill out 3 longer questionnaires: once before ACT begins, once just after the 8-week stud Parenting stress Life satisfaction Self-compassion Uncomfortable feelings and thoughts Mindfulness Participants will take part in an 8-week ACT intervention. They will have one 75-minute session with an ACT coach in the first week. Participants will watch 9- to 17-minute videos each week. The videos talk about how to practice ACT techniques to cope with parenting stress. Participants will have 20- to 30-minute coaching sessions in weeks 3 and 6. The coach will help them practice exercises and work through any problems.	NO
Video-assisted thoracic surgery (VATS) is usually performed with general anesthesia and single lung ventilation. However, performing thoracic surgery under awake regional anesthesia has several potential advantages includi	NO
This is a randomized pilot study of Coronary CT Angiography (CCTA) for coronary atherosclerosis vs. Usual Care in patients with prostate cancer who are either planning to begin, or are currently taking androgen deprivation t	NO

Conditions
Multiple Myeloma|Heart Failure, Systolic|Cardiotoxins
Hodgkin Lymphoma in Remission|Leukemia in Remission|Lymphoblastic Lymphoma|Osteosarcoma|Recurrent Leukemia|Recurrent Lymphoma|Recurrent Malignant Neoplasm
Dyspnea
Chronic Disease|Neoplasm Metastasis|Lung Neoplasm|Pulmonary Disease, Chronic Obstructive|Heart Failure, Congestive|Liver Cirrhosis|Kidney Failure, Chronic|Multiple Organ Failure|Health Care Quality, Access, and Evalua
Cancer|Dyspnea, Paroxysmal
Neoplasms|Heart Failure|Cardiotoxicity|Chemotherapy Effect|Oncology
Multiple Myeloma|Shortness of Breath|Dyspnea|Cardiotoxicity
Advanced Cancer|Chronic Obstructive Pulmonary Disease (COPD)|Restrictive Lung Disease|Congestive Heart Failure|End Stage Liver Disease
Uterine Fibroids|Osteoporosis|Urinary Tract Infection|High Blood Pressure|Heart Disease|Arthritis|Depression|Headaches
Esophagus Cancer|Stomach Cancer|Small Bowel Cancer|Colon Cancer|Rectum Cancer
Pleural Effusion|Heart Failure|Malignant Neoplasm|Fluid Overload|Hypoalbuminemia|Renal Failure|Cirrhosis|Infections
Rheumatic Disease|Neoplasms|Parathyroid Diseases|Pulmonary Embolism|Heart Diseases|Thyroid Diseases|Kidney Diseases|Dementia|Parkinsonian Disorders
Pathogenesis|Cardiovascular Diseases|Cancer
Primary; Complex|Pigmented Nodular Adrenocortical Disease, Primary, 1|Periorificial Lentiginosis|Cardiac Myxoma
Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm
Circadian Rhythm Disorders|Anxiety|Breast Cancer
Polycystic Ovary Syndrome|Morbid Obesity
Breast Cancer|Heart Disease|Cardiotoxicity|Myocardial Dysfunction
Lung Cancer
Neuroendocrine Tumors|Heart Failure
Iron-Deficiency Anemia|Iron-Deficiency
Liver Transplant; Complications|Ischemia Reperfusion Injury|Cirrhosis|Liver Cancer|Liver Metastases|End Stage Liver Disease
Cushing's Syndrome|Pituitary Adenoma|Carney Complex|Primary Pigmented Nodular Adrenocortical Disease|Peutz-Jeghers Syndrome
Non-small Cell Lung Cancer|Malignant Pleural Effusion
Adult Rhabdomyosarcoma|Lung Metastases|Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Previously Treated Childhood Rhabdomyosarcoma|Recurrent Adult Soft Tissue Sarcoma|Recurrent Childh
Cancer|Heart Failure|Cardiotoxicity
Hodgkin Disease
Childhood Cancer
Breast Cancer|HER2-positive Breast Cancer|HER2-positive Metastatic Breast Cancer|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III|Breast Cancer Stage IV|Cardiotoxicity
Tako-Tsubo Cardiomyopathy|Stress-induced Cardiomyopathy|Acute Coronary Syndrome
Cerebrovascular Accident|Chronic Obstructive Pulmonary Disease|Chronic Renal Failure|Coronary Artery Disease|Diabetes Mellitus|Malignant Neoplasm|SARS Coronavirus 2 Infection
Cancer Treatment Induced Thrombocytopenia
Breast Carcinoma
Reactive Hyperemia|Micro RNA|Heart Rate Variability|DNA Strand Breaks|Oxidative Stress|Heat Stress
Adverse Reactions|Immune Checkpoint Inhibitor|Non-Small Cell Lung Cancer Patients|Cardiac Event
Neoplasms
Cardiomyopathy|Li-Fraumeni Syndrome|Parkinson's Disease|Atherosclerosis|Cardiovascular Capacity
Cancer
Breast Neoplasms|Lymphoma|Sarcoma
Cardiomyopathy Due to Anthracyclines
Cardiovascular Diseases|Pediatric Cancer
Cervical Intraepithelial Neoplasia
Trastuzumab Cardiotoxicity|HER2-Positive Breast Cancer Survivors
Doxorubicin Induced Cardiomyopathy|Chemotherapeutic Toxicity|B-cell Lymphoma|T-cell Lymphoma

Heart Failure
Breast Cancer
Atrial Fibrillation|Coronary Artery Disease|Aortic Valve Stenosis|Aortic Valve Disease|Mitral Valve Disease|Cardiac Arrythmias|Cardiac Tumor|Cardiac Surgery
Breast Neoplasms|Endothelial Dysfunction|Cardiovascular Disease|Metabolic Syndrome
Breast Neoplasms
Polycystic Ovary Syndrome
Colorectal Cancer|Breast Cancer|Coronary Heart Disease|Diabetes
Pancreatic Ductal Adenocarcinoma|Stage I Pancreatic Cancer AJCC v8|Stage IA Pancreatic Cancer AJCC v8|Stage IB Pancreatic Cancer AJCC v8
Her 2 Positive Breast Cancer
Breast Cancer
Hodgkin Disease|Lymphoma, Non-Hodgkin
Radiation Pneumonitis
Breast Cancer
Infarction|Stroke|Diabetes|Fracture|Aortic Stenosis|Cancer|Death
Amyloidosis, Primary|Cardiomyopathy
COVID-19|Chronic Heart Failure|Diabetes Mellitus|Chronic Kidney Diseases|Ischemic Heart Disease|Arrythmia|Hypertensive Heart Disease|Overweight and Obesity|Oncology|Ischemic Stroke|Myocardial Infarction|Atrial Fibrilla
Cancer|COPD|Asthma|Bronchiectasis Adult|Interstitial Lung Disease|Cystic Fibrosis|Chronic Heart Failure|Sickle Cell Disease|Renal Failure|Liver Failure|Post COVID-19|Dyspnea
Breast Neoplasms|Heart Failure
Breast Cancer
Cardiotoxicity.|Anti Her2 Therapy.|Metastatic Breast Cancer
Heart Failure|Multiple Myeloma
Breast Cancer
Prostate Cancer
Atrial Fibrillation|Diet Therapy|Prostate Cancer
Surgical Complication|Pulmonary Disease|Hematologic Diseases|Oncology|Cardiac Disease|Infections
Lung Carcinoma
Breast Cancer
Breast Cancer
Aortic Stenosis|Chemotherapy Induced Systolic Dysfunction|Carcinoid Syndrome
Neoplasms|Heart Failure|Kidney Diseases|Lung Diseases
Neoplasms|Heart Diseases|Adrenal Cortex Diseases
Stomach Cancer
Heart Cancer|Kidney Cancer|Lung Cancer|Pancreas Cancer|Liver Cancer
Peritoneal Carcinomatosis|Pseudomyxoma Peritonei|Mesothelioma Peritoneum
Physical Activity|Cancer|Hematologic Diseases
Breast Neoplasm Female|Lymphoma|Cardiotoxicity|Anthracyclines|Physical Activity
Heart Disease|Cancer
Cancer|Myocardial Infarction
Cardiac Toxicity|Lymphoma
Coronary Artery Disease|Cardiac Disease|Cardiac Toxicity|Radiation|Radiation Therapy|Atherosclerotic Heart Disease|Cardiotoxicity|Breast Cancer|Lung Cancer|Lymphoma|Cancer|Carcinoma, Intraductal, Noninfiltrating
Childhood Cancer|Cerebral Palsy|Chronic Lung Disease|Congenital Heart Disease|Congenital Metabolic Disorder|Gastrostomy
Breast Cancer
Breast Cancer|Cardiotoxicity|Cardiomyopathies|Chemotherapeutic Toxicity|Heart Failure|Oncology
Cardiotoxicity
Intrapericardial Teratoma Tumor|Tumors
Cardiovascular Diseases|Coronary Arteriosclerosis|Heart Diseases|Polycystic Ovary Syndrome
Leukemia, Chronic Lymphatic|Mantle Cell Lymphoma
Cardiac Disease|Cancer
Breast Neoplasms|Cardiotoxicity
Childhood Cancer
Solid Tumors
Cardiac Disease|Cancer|Hypercholesterolemia|Diabetes|Kidney Diseases|Neuromuscular Diseases
Squamous Cell Carcinoma of Head and Neck|Cancer|Carotid Stenosis|Atherosclerosis of Artery|Hodgkin Lymphoma, Adult|Non Hodgkin Lymphoma|HLH|Cardiac Sarcoidosis
Castration-resistant Prostate Cancer
Lung Cancer|Atrial Fibrillation|Stroke
Advanced Solid Tumor
Atherosclerosis|Cardiovascular Diseases|Heart Diseases|Carotid Artery Diseases|Coronary Disease|Polycystic Ovary Syndrome
Breast Cancer
Pulmonary Arteriovenous Malformations
Cardiac Complications
Breast Cancer Female
Primary Biliary Cholangitis|Heart Failure|Obesity|Digestive Diseases|Women Who Have Experienced a Cardiac Event|Cirrhosis, Liver|Post-Transplant|Cancer|Chronic Kidney Diseases|Other Chronic Physical Condition
Advanced Cancers
Breast Cancer
Non Small Cell Lung Cancer
Breast Cancer|Coronary Artery Disease|Stroke|Type2 Diabetes
Coronary; Ischemic|Arrhythmias, Cardiac|Heart Failure|Peripheral Vascular Diseases|Dementia|Stroke|Pulmonary Disease, Chronic Obstructive|Respiratory Insufficiency|Alcoholism|Cancer|Diabetes|Renal Insufficiency

Cancer|Immune-related Adverse Event|Cardiac Abnormalities, Variable|Immune Checkpoint Inhibitor-Related Myocarditis|Diastolic Dysfunction|Atherosclerosis|Cardiotoxicity
Primary Prevention
Cardiotoxicity|Breast Cancer|Chemotherapy Induced Systolic Dysfunction
SECONDARY PULMONARY HYPERTENSION|MITRAL STENOSIS|CHILDHOOD RHEUMATOID FEVER|CONGESTIVE HEART FAILURE
Cancer, Breast|Cardiotoxicity|Cardiovascular Diseases
Rare Disorders|Undiagnosed Disorders|Disorders of Unknown Prevalence|Cornelia De Lange Syndrome|Prenatal Benign Hypophosphatasia|Perinatal Lethal Hypophosphatasia|Odontohypophosphatasia|Adult Hypophosphata
Pericardial Effusion Malignant
Acute Leukemia|Adenomatous Polyposis|Adrenocortical Carcinoma|AML|BAP1 Tumor Predisposition Syndrome|Carney Complex|Choroid Plexus Carcinoma|Constitutional Mismatch Repair Deficiency Syndrome|Diamond-Bla
Lymphoma
COPD|Heart Failure|Cancer
Acute Myeloid Leukemia, Adult|Cardiotoxicity|Endothelial Dysfunction
Systemic Inflammatory Response Syndrome|Coronary Arteriosclerosis
Adenovirus|Anesthesia|Anxiety|Anxiolysis|Autism|Autistic Disorder|Bacterial Meningitis|Bacterial Septicemia|Benzodiazepine|Bipolar Disorder|Bone and Joint Infections|Central Nervous System Infections|Convulsions|Cytomeg
Advanced Solid Tumors (Excluding Breast Cancer)
Breast Cancer|Hematologic Malignancy|Immune Checkpoint Inhibitor-Related Myocarditis|Cardiotoxicity|Cardiovascular Diseases
Stellate Ganglion Block
Cardiovascular Diseases|Cerebrovascular Disorders|Coronary Disease|Heart Diseases|Myocardial Infarction|Myocardial Ischemia|Vascular Diseases
Childhood and Adolescence Cancer (Survivors and Deceased)
Cancer|Cardiac Disease|Pulmonary Disease|Neuro-Degenerative Disease|Renal Disease|Stroke|Sepsis|Hepatic Disease
Breast Cancer|Myocardial Fibrosis|Radiation-Induced Fibrosis
Myocardial Infarction|Cardiovascular Disease
Solid Tumors
Chronic Mental Illness|Chronic Physical Illness
Study Focus: 30-day Rehospitalizations Among At-risk Older Adults Randomized to a Social Work-driven Care Transitions Intervention|Heart Disease|Diabetes|Hypertension|Cancer|Depression|Asthma|Chronic Heart Failure|C
Mediastinal Lymphoma|Hodgkin Lymphoma|Non Hodgkin Lymphoma
Prostate Cancer
Carcinoid Heart Disease|Carcinoid Syndrome|Carcinoid Tumor
Cardiovascular Diseases|Breast Neoplasms
Lung Cancer|Esophageal Cancer|Thoracic Cancer|Hodgkin Lymphoma|Hodgkin Disease|Non-hodgkin Lymphoma|Sarcoma|Thymoma|Breast Cancer
Primary Amyloidosis of Light Chain Type
Pneumonia|Lung Cancer|Pulmonary Embolism|Pulmonary Disease|Aortic Stenosis
Heart Failure|Liver Cirrhosis|Ascites|Carcinomatosis
HER2 Positive Breast Cancer|Left Ventricular Function Systolic Dysfunction
Coronary Artery Disease|Cardiac Disease|Malignancy, Second
Cardiovascular Diseases
Thrombocytopenia|Myocardial Infarction
Rheumatoid Arthritis
Neuroendocrine Tumor
Atrial Fibrillation|Cancer|Thromboembolism|Bleeding
Cardiotoxicity|Antitumor Drugs|Breast Cancer|Trastuzumab
Breast Cancer
Cardiotoxicity
Testicular Cancer|Survivorship|ASCVD|Coronary Artery Disease|Lipid Disorder|Hypogonadism, Male|Cisplatin Adverse Reaction|Bone Marrow Transplant Complications
Functional Disability|Dementia|Heart Disease|Stroke|Cancer|Bleeding|Depression
Breast Carcinoma|Hematopoietic and Lymphoid Cell Neoplasm|Lymphoma|Sarcoma

Atrial Fibrillation|Coronary Heart Disease|Cardiovascular Diseases|Heart Failure|Hypertension|Peripheral Arterial Disease|Stroke, Ischemic|Asthma|Chronic Obstructive Pulmonary Disease|Obesity|Cancer|Chronic Kidney Disea
Heart Disease|Stroke|Diabetes|Cancer
Cardiac Disease
Lung Cancer|Atrial Fibrillation
Breast Cancer|Heart Failure
AL Amyloidosis
Cardiovascular Disease|Myocardial Infarction|Stroke|Cancer
Stage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic)
Arthritis|Cancer|Cardiovascular Diseases|Chronic Lung Disease|Congestive Heart Failure|Diabetes|Hypertension|Kidney Diseases|Obesity|Osteoporosis|Stroke|Frailty
COPD|Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy|Idiopathic Pulmonary Fibrosis|Other Interstitial Lung Disease Without Curative Therapy|Congestive Heart F
Malignant Neoplasm of Thyroid|Heart Diseases|Thyrotoxicosis on Thyroxine Therapy
Atrial Fibrillation|Cancer
Cardiac Disease|Multiple Myeloma
Heart Failure|Cardiotoxicity|Cancer
Lymphoma, Non-Hodgkin|Hodgkin Lymphoma|Toxicity, Cardiac
Atrial Fibrillation
Prostate Cancer
Primary or Metastatic Hepatic Adenocarcinoma
Stellate Ganglion Block
COPD|Cancer|Heart Failure
Head and Neck Cancer|Survivorship|Nutrition Aspect of Cancer
Prostate Cancer|Cardiovascular Death
NSCLC
Cardiac Toxicity|Leukemia|Lymphoma
Solid Tumors
Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm
Cancer|Congestive Heart Failure|Chronic Obstructive Pulmonary Disease
Cardiotoxicity|HER2-positive Breast Cancer
Cancer|Heart Failure|Copd|ALS
Congestive Heart Failure|Chronic Obstructive Pulmonary Disease|Cirrhosis|Colon Carcinoma|Lung Cancer|Chronic Kidney Disease
Type 2 Diabetes Mellitus|Obesity
Atrial Fibrillation|Lung Cancer
Cardiovascular Injury|Prostate Carcinoma
Prostate Cancer
Psychological Stress|Cardiopulmonary Bypass Surgery|Coronary Artery Bypass Surgery|Cardiac Valve Replacement|Hip Replacement|Orthognathic Surgery|Scoliosis|Knee Replacement|Prostate Cancer|Kidney Cancer|Bladd
Polycystic Ovary Syndrome
Oncology|Cardiac Toxicity
Cardiac Ischemia|Thoracic Cancer|Complication,Postoperative
Coronary Artery Bypass Grafting|Secondary Preventions
Acute Leukemia in Remission|Hematopoietic Cell Transplantation Recipient|Lymphoma
Heart Failure
Breast Neoplasms|Carcinoma, Ductal|Adenocarcinoma
Diet Modification|Physical Activity|Weight Gain|Chronic Disease|Lifestyle, Sedentary|Health Behavior
Breast Cancer|Metastatic Breast Cancer|Cancer Therapy-Related Cardiac Dysfunction|Cardiotoxicity|Heart Failure
Breast Cancer
Coronary Artery Disease|Angina Pectoris|Myocardial Ischemia
Myocardial Injury|Trigeminal Cardiac Reflex
Cancer
Breast Cancer
Hodgkin Lymphoma, Adult|Cardiovascular Diseases|Radiation Effect|Chemotherapy Effect
Secondary Coronary Prevention
Cancer
Neurofibromatosis Type 1
Cancer|Atrial Fibrillation
Breast Cancer|Cardiac Toxicity
Non-Hodgkin's Lymphoma
Breast Cancer|Triple Negative Breast Cancer|Cardiovascular Complications
Breathlessness|COPD|Cancer|Chronic Heart Failure|Interstitial Lung Disease
Colorectal Cancer
Breast Cancer|Lymphoma|Leukemia
Breast Cancer
Tumor
Cardiac Toxicity|Lung Cancer Stage III|Lung Cancer Stage II|Radiation Toxicity|Cardiac Disease
Breast Cancer|Ductal Carcinoma in Situ|Invasive Breast Cancer
Malignant Neoplasm|Leukemia, Lymphocytic, Chronic, B-Cell|Lung Disease Chronic|Congestive Heart Failure|Liver Failures, Chronic|Renal Insufficiency, Chronic|Dementia|Diabetes Complications|Peripheral Vascular Disease|

Breast Cancer
Bradycardia
HIV-1 Seropositive|Inflammation|Cancer|Cardiomyopathy
Heart Failure
Congenital Heart Disease
Cardiotoxicity
Breast Cancer
Multiple Myeloma
Cardiac Toxicity|Acute Leukemia|Childhood Cancer
Cardiotoxicity|Gastrointestinal Neoplasms
Cancer, Breast|LV Dysfunction
Radiation Therapy|Coronary Artery Disease|Hodgkin Lymphoma
Breast Neoplasms|Cardiac Event|Chemotherapeutic Toxicity
Cancer|Congenital Heart Disease
Breast Cancer
Breast Cancer|Cardiac Toxicity
Breast Cancer, Female
Cancer
Non-Melanoma Skin Carcinoma
Arrhythmia, Cardiac|Kidney Cancer|Surgery|Anesthesia, Local
Pituitary Adenoma
Cancer, Breast|Cancer, Ovarian|Cancer, Colorectal|Cancer, Prostate|Melanoma|Coronary Artery Disease|Diabetes Mellitus, Type 2
Breast Cancer|Lung Cancer (Non-Small Cell)|Thoracic Cancer|Thymic Cancer|Mesothelioma
Liver Fibrosis|Liver Cirrhosis|Viral Hepatitis|Liver Tumour|Cardiac Failure|Biliary Cholestasis.
Colon Cancer|Lung Cancer|Atrial Fibrillation|Diabetes Type 2|Obesity|Breast Cancer|Graves Disease|Osteoarthritis|Celiac Disease|Myocardial Infarction|Prostate Cancer
Breast Cancer|Heart Failure|Cardiotoxicity
Arrythmia|Cardiac Amyloidosis|Systemic AL Amyloidosis|Sudden Cardiac Death
Brain Tumor
Age-Related Macular Degeneration|Allergies|Alpha-Gal Syndrome|Alzheimer Disease|Amyloidosis|Ankylosing Spondylitis|Arthritis|Alopecia Areata|Asthma|Atopic Dermatitis|Autism|Autoimmune Hepatitis|Behcet's Disease|Beta
Cardiovascular Disease|Colorectal Cancer
Breast Cancer
Lymphoma|Autonomic Imbalance|Cancer Survivorship
Cancer|Immune-related Adverse Event|Immune Checkpoint Inhibitor-Related Myocarditis
RASopathy|Costello Syndrome|Cardio-Facio-Cutaneous Syndrome|Noonan Syndrome
Non-erosive Reflux Disease|Barrett's Esophagus
Cancer
Leukemia, Myeloid, Acute|Leukemia, Lymphoid, Acute|Cardiotoxicity
Myocardial Infarction|Unstable Angina|Malignancy|Cognitive Decline|Diabetes Mellitus|Metabolic Syndrome
Breast Neoplasm
Coronary Heart Disease|Stroke|Breast Cancer|Ovarian Cancer|Cancer|Hip Fracture|Death
Cardiac Disease|Dementia|Inflammatory Disease|Fever of Unknown Origin|Vasculitis|Osteomyelitis|FDG Avid Cancers
Artificial Intelligence|Lung Diseases|Pneumothorax|Pleural Effusion|Cardiomegaly|Lung Cancer|Pulmonary Edema|Consolidation|Pneumonia|Atelectasis|Hilar Calcification|Fracture Rib
Colorectal Cancer|Atrial Fibrillation New Onset
Lung Cancer Stage I|Lung Cancer Stage II|Lung Metastases
Cardiotoxicity
Biochemically Recurrent Prostate Carcinoma|Localized Prostate Carcinoma|Stage I Prostate Cancer AJCC v8|Stage II Prostate Cancer AJCC v8|Stage IIA Prostate Cancer AJCC v8|Stage IIB Prostate Cancer AJCC v8|Stage I
Diffuse Large B Cell Lymphoma|Lymphoma, Non-Hodgkin
Breast Cancer Female
Breast Cancer
Breast Cancer|Cardiotoxicity
Heart Failure|Chronic Obstructive Pulmonary Disease|Malignancy|Chronic Kidney Disease
Chronic Kidney Diseases|Hypertension|Chronic Heart Failure|Ischemic Heart Disease|Atrial Fibrillation|PreDiabetes|Chronic Obstructive Pulmonary Disease|Cancer|Urolithiasis|COVID-19
Renal Cell Carcinoma 4
Cardiotoxicity
Hematopoietic Stem Cell Transplantation|Cardiotoxicity

Diffuse Large B-Cell Lymphoma
Myocardial Infarction|Secondary Prevention
Hemoglobinopathies|Myelodysplastic Syndromes|Other Inherited or Acquired Anaemia|MPD Syndrome|Diamond-Blackfan Anemia|Other Rare Anaemias|Transfusional Iron Overload
Breast Cancer|Peripheral Neuropathy|Cardiac Toxicities|Hepatic Toxicity|Cognitive Impairment
Cancer|Heart Failure|Chronic Obstructive Pulmonary Disease|Postoperative Complications
Carcinoma, Non-Small-Cell Lung|Pain, Postoperative|Postoperative Nausea and Vomiting|Infection|Air Leakage|Atrial Fibrillation
Coronary Artery Disease|Arteriovenous Malformations|Myocardial Infarction
Breast Carcinoma|Cardiotoxicity
Locally Advanced Neuroendocrine Neoplasm|Metastatic Neuroendocrine Neoplasm
Cancer|Coronary Artery Disease
Arrhythmias, Cardiac|Atrial Fibrillation and Flutter|Tachycardia, Supraventricular|Cardiac Failure
Breast Cancer|Radiation-Induced Vascular Disease|Left Anterior Descending Coronary Artery Stenosis|Radiotherapy Side Effect|Cardiac Ischemia|Left Sided Breast Cancer|LAD (Left Anterior Descending) Coronary Artery Ste
Cardiovascular Diseases|Diabetes|Metabolic Syndrome|Cancer|Inflammatory Disease|Atherosclerosis|Cognitive Decline|Liver Diseases|Death|Pain, Chronic|Depression|Infection|Chronic Disease
Cancer|Chronic Heart Failure|COPD Exacerbation|Palliative Care
Breast Cancer
Anthracycline Related Cardiotoxicity in Breast Cancer
Carcinomas|Amyloidosis|Anal Cancer|Anemia|Cholangiocarcinoma of the Extrahepatic Bile Duct|Transitional Cell Carcinoma of Bladder|Bone Marrow Transplant Failure|Bone Cancer|Cancer of Brain and Nervous System|Brea
Socioeconomic Status|Secondary Prevention|Myocardial Infarction|Cardiovascular Disease|Stroke
Preterm Birth|Pediatric Cancer|Hirschsprung Disease|Congenital Malformation|Congenital Heart Disease|Nutrition Disorder, Child
Hematologic Disease and Disorders|Donors|Healthy Volunteer
Atrial Fibrillation|COVID-19|Cancer|Thrombosis
Heart Failure|Breast Cancer
COPD|Cancer|Heart Failure|Interstitial Disease|Dyspnea
Heart Failure|Coronary Artery Disease|Peripheral Artery Disease|Ischemia|Hypertension|Diabetes Mellitus|Cardiomyopathies|Cardiotoxicity
Breast Cancer|Osteoporosis
Breast Neoplasm|Prostatic Neoplasm|Colorectal Neoplasms|Endometrial Neoplasms|Hodgkin Disease|Non Hodgkin Lymphoma
Ectopic ACTH Syndrome
Breast Cancer|Cardiac Toxicity
Breast Cancer|Breast Neoplasm|Breast Tumor|Cancer of the Breast
Prolactinomas
Prader-Willi Syndrome|PWS-like Syndrome|Silver Russel Syndrome|Congenital Hypopituitarism|Klinefelter (XXY-)Syndrome|Congenital Adrenal Hyperplasia|XXXXY Syndrome|XXYY Syndrome|XXXX Syndrome (Tetra-X Syndro
Tuberous Sclerosis Complex (TSC)|Lymphangioleiomyomatosis (LAM)
Breast Cancer
Leukemia|Lymphoma|Cardiotoxicity|Risk Factor, Cardiovascular|Immunotherapy
Lymphoma
Cardiac Toxicity|Sarcoma
Cardio-oncology
Breast Cancer|Cardiotoxicity|Cardiovascular Diseases
Advanced Cancer
Cardiotoxicity|Breast Cancer|Prevention|Adjuvant|Trastuzumab
Heart Failure
High Risk for Postoperative Cardiovascular Events
Breast Cancer|Cardiac Toxicity
Breast Cancer|Cardiovascular Diseases
Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin
Breast Cancer|Doxorubicin Induced Cardiomyopathy
Left Ventricular Function Systolic Dysfunction|Cardiotoxicity
Lung Cancer|Ventricular Failure, Right
Osteosarcoma|Ewing's Sarcoma Family of Tumors|Rhabdomyosarcoma|Non-rhabdomyosarcoma Soft Tissue Sarcomas
Tricuspid Regurgitation|Tricuspid Valve Disease|Carcinoid Syndrome|Carcinoid Heart Disease
Fragile X Syndrome|Angelman Syndrome|Prader-Willi Syndrome|Dup15Q Syndrome|Duchenne Muscular Dystrophy|Phelan-McDermid Syndrome|Rett Syndrome|Smith Magenis Syndrome|Williams Syndrome|Turner Syndrome
Prostate Cancer|Robotic Surgery
Progression-free Survival|Overall Survival|Toxicity
Hypertension|Depression|Anxiety|Musculoskeletal Pain|Arthritis|Rheumatoid Arthritis|Osteoporosis|Chronic Obstructive Pulmonary Disease (COPD)|Asthma|Chronic Bronchitis|Cardiovascular Disease|Heart Failure|Stroke|Trans
Cancer

Cardiovascular Diseases|Cancer
PHACE Syndrome
Arrhythmias, Cardiac|Breast Cancer|Prostatic Cancer|Brain Cancer|Kidney Cancer|Head and Neck Cancer|Liver Cancer|Pancreatic Cancer|Spinal Neoplasm
Fracture of Surgical Neck of Humerus|Colonic Tumor|Stage IIIB Ovarian Carcinoma|Neoplasm of Head of Pancreas
Hypertension|Depression|Anxiety|Musculoskeletal Pain|Arthritis|Rheumatoid Arthritis|Osteoporosis|Chronic Obstructive Pulmonary Disease (COPD)|Asthma|Chronic Bronchitis|Cardiovascular Disease|Heart Failure|Stroke|Trans
Breast Cancer|Cardiotoxicity|Autonomic Imbalance
Lymphoma, Non-Hodgkin|Lymphoma, Hodgkin
Post-Operative Cancer Patients Experiencing Atrial|Fibrillation
Older Adults|Anxiety|Depression|Cardiac Surgery|Orthopedic Surgery|Major Surgical Resection of a Thoracic Malignancy|Major Surgical Resection of an Abdominal Malignancy
Acute Myeloid Leukemia
Dyspnea|Respiratory Insufficiency|Neoplasms|Pulmonary Disease, Chronic Obstructive|Lung Diseases|Heart Failure|Lung Diseases, Interstitial|Palliative Care|Palliative Medicine|Breathlessness
Coronary Stenosis
Breast Cancer
Lung Cancer|Surgery|Arrhythmia|Myocardial Ischemia
Breast Cancer
Cancer|Congestive Heart Failure (CHF)|Chronic Obstructive Pulmonary Disease (COPD)|End Stage Renal Disease (ESRD)
Breast Cancer
Solid Tumors
Parasympathetic Cardiovascular Function Disorder
Breast Cancer|Cardiotoxicity|Drug-Related Side Effects and Adverse Reactions|Cardiovascular Diseases
Aortic Valve Stenosis|Malignancy
Blood Pressure|Depression|Panic Attack|Fibromyalgia|POTS|Inappropriate Sinus Tachycardia|Coronary Heart Disease|Acute Coronary Syndrome (ACS)|Acute Myocardial Infarction (AMI)|Cerebrovascular Disease (CVD)|Transie
Heart Failure
Heart Failure|Cardiotoxicity
Cardiovascular Risk|Pediatric Cancer
Cancer|Cardiovascular Diseases|Hereditary Cancer|Hereditary Cardiac Amyloidosis
Genetic Markers|Cardiac Toxicity|Breast and Skin Motion
Breast Cancer
Cardiac Dysfunction|Cardiovascular Diseases|Childhood Cancer
Multiple Myeloma
Breast Cancer
HER2-positive Breast Cancer|Targeted Therapy|Cardiac Toxicity|High Altitude
Breast Cancer|Cardiovascular Diseases
Locally Advanced Lung Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8
Heart Failure|Coronary Artery Disease|Cancer|Chronic Kidney Diseases|COPD|Obesity|Sickle Cell Disease|Diabetes Mellitus, Type 2
Childhood Cancer|Cardiomyopathy, Primary
Seriously Ill Patients|Cancer|Heart Failure|Interstitial Lung Disease|Chronic Obstructive Pulmonary Disease|End-stage Renal Disease|End-stage Liver Disease|Dementia
ACS - Acute Coronary Syndrome|Oncology
Radiotherapy; Complications|Cardiotoxicity|Cancer|Lung Cancer|Breast Cancer|Esophageal Cancer
Non-small Cell Lung Cancer
Arthritis|Cancer|Cardiac Disease|Endocrine System Diseases|Autoimmune Diseases|Ophthalmopathy|Myositis|Neuropathy
Renal Cell Carcinoma|Cardiotoxicity|Heart Failure|Hypertension
Breast Cancer|HER2-positive Breast Cancer|Cardiotoxicity
Small Intestinal NET|Carcinoid Heart Disease
Cardiomyopathy Due to Drug|Breast Cancer|Cardiovascular Risk Factor
Hematopoietic Stem Cell Transplant|Atrial Fibrillation|Atrial Flutter
Mediastinal Tumors
Acute Respiratory Failure|Cancer|Hematologic Malignancy|Cardiac Insufficiency|Chronic Respiratory Insufficiency
Malignant Neoplasm

Cardiotoxicity|Breast Cancer|Lymphoma|Sarcoma|Leukemia|Myeloma|Lung Cancer
Cardiotoxicity|Cardiac Rehabilitation
Acute Myocardial Infarction|Tako Tsubo Cardiomyopathy|Breast Cancer
Doxorubicin Induced Cardiomyopathy|Breast Cancer|Gastric Cancer|Leukemia
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)|Solid Organ Transplant Complications|Lymphoproliferative Disorders|Allogeneic Hematopoietic Cell Transplant|Stem Cell Transplant C
Multiple Myeloma|Plasma Cell Neoplasm
Breast Cancer|Heart Failure
Anthracycline Induced Cardiotoxicity
Cardiotoxicity|Pediatric Cancer|Heart Failure
Left-Sided Breast Cancer|Radiation Toxicity
Coronary Artery Disease|Cerebral Vascular Disease|Peripheral Artery Disease|Renal Insufficiency|Diabetes|COPD|Hypertension|Active Smoker|Cancer|CHF|Prior DVT/PE
Infections|Heart Failure|COPD Exacerbation|Asthma|Gastrointestinal Diseases|Cardiac Event|Arrythmia|Renal Failure|Renal Disease|Rheumatic Diseases|Urologic Diseases|Neurologic Disorder|Hematologic Diseases|Oncology
Chronic Lymphocytic Leukemia (CLL)|Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia|Mantle Cell Lymphoma|Sudden Cardiac Death|Cardiac Arrhythmias|Hematologic Malignancies
Pleural Effusion|Pleurodesis|Malignant Pleural Effusion|Pleural Effusion Due to Congestive Heart Failure|Pleural Effusion in Conditions Classified Elsewhere|Pleural Effusions, Chronic
Cardiovascular Disorder|Clonal Hematopoiesis|Hodgkin Lymphoma
Breast Cancer|Gynecologic Cancer
Breast Cancer|Hereditary Breast/Ovarian Cancer (brca1, brca2)|Heart Diseases|Drug-Induced Cardiomyopathy
Breast Cancer
Myocardial Infarction
Breast Cancer
Heart Failure|Breast Cancer
Locally Advanced Cancer|Metastatic Cancer|Chronic Respiratory Failure|Chronic Heart Failure|Chronic Liver Failure|Chronic Renal Failure
Cardiovascular Diseases|B-cell Acute Lymphoblastic Leukemia|B-cell Lymphoma Refractory|B-cell Lymphoma Recurrent|Primary Mediastinal Large B-cell Lymphoma (PMBCL)|Diffuse Large B Cell Lymphoma|Cardiotoxicity|C
Persistent Physical Symptoms (PPS)
Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer
Breast Neoplasms
Cancer|Chronic Obstructive Pulmonary Disease|Heart Failure|Dementia|End Stage Liver Disease|End Stage Renal Disease|Neuromuscular Diseases
Upper Limb Functions|Sleep Quality|Upper Limb Muscle Strength|Shoulder Mobility|Heart Rate Variability|Mood|Health-related Quality of Life
Esophageal Diseases|Gastrointestinal Diseases|Disorder of the Genitourinary System|Gynecologic Diseases|Kidney Diseases|Liver Diseases|Pancreatic Diseases|Prostate Cancer|Spinal Disease
Breast Cancer|Ovarian Cancer|Colon Cancer|Lung Cancer|Gastric Cancer|Solid Tumors
Breast Cancer|Neoplasm, Breast|Breast Diseases|Antihypertensive Agents|Sacubitril/Valsartan|Angiotensin II Type 1 Receptor Blockers|Angiotensin Receptor Antagonists|Molecular Mechanisms of Pharmacological Action|He
Hematopoietic Stem Cell Transplant
Amyloidosis|Amyloid|Amyloid Neuropathies, Familial|Amyloid Cardiomyopathy|Amyloid - Primary|Transthyretin Amyloidosis|AL Amyloidosis
Breast Neoplasms
Cancer|Sequels|Complications|Autonomic Nervous System
Cancer|Deep-vein Thrombosis of the Lower and Upper Extremities|Pulmonary Embolism|Non-valvular Atrial Fibrillation
Breast Neoplasms|Cardiovascular Diseases
Cancers|Atherosclerоses, Coronary|Atherosclerosis of Artery
Atrial Fibrillation New Onset
Neoplasms|Pulmonary Disease, Chronic Obstructive|Heart Failure|Renal Disease
Fatigue|Cancer Survivorship
Breast Neoplasms|Heart Injuries|Radiation Toxicity

Childhood Cancer|Cardiac Toxicity|Pediatric Cancer
Melanoma|Atherosclerosis
Cardiotoxicity|Cardiovascular Disease|Neurovascular Disorder|Endothelial Disfunction|Breast Cancer
Neoplasms|Heart; Disease, Functional|Inflammation
Advanced Malignant Tumor
Cardiotoxicity|HER2/Neu Positive|Metastatic Malignant Neoplasm in the Brain|Recurrent Breast Carcinoma|Stage IV Breast Cancer AJCC v6 and v7
Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anaton
Early Breast Cancer
Diabetes|High Blood Pressure|Obesity|Hypertension|Heart Diseases|Stroke|TIA|Osteoarthritis|Cancer
Myocarditis Acute|Cancer
Solid Carcinoma|5-Fluorouracil Toxicity|Cardiotoxicity|Chemotherapeutic Toxicity|Acute Coronary Syndrome|Coronary Artery Calcification|Chest Pain
Heart Disease
Abdominal Cancer|Heart Diseases
Bone Tumor|Cancer of Bone|Heart Diseases|Cognitive Impairment|Cognitive Decline|Chemotherapy Effect|Memory Problem
Ischemic Heart Disease|Prostate Adenocarcinoma
Cardiac Toxicity|Inflammatory Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IV Breast Cancer
Breast Cancer|Cardiac Toxicity|Perioperative/Postoperative Complications
Atrial Fibrillation|Supraventricular Arrhythmia|Ventricular Arrhythmias and Cardiac Arrest|Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Breast Cancer
Carcinoid Heart Disease
Cancer|Thrombosis|Angina Pectoris
Cancer Survivor|Stage 0 Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
Malignant Childhood Neoplasm
Cardiotoxicity
Left-Sided Breast Cancer
Coronary Heart Disease|Stroke|Dementia|Cancer|Health Care|Vascular Diseases|Periodontal Diseases|Ocular Diseases|Respiratory Disease|Obesity
Depression|Anxiety|Sleep Impairment
Oncologic Disorders|Cardiovascular Diseases
Cancer
Insufficiency;Cardiac|Cancer|Cardiotoxicity|Heart Failure
Atherosclerosis
Severe Life-limiting COPD|Severe Life-limiting Heart Failure|Severe Life-limiting Cirrhosis|Severe Life-limiting Malignancy|Severe Functional Impairment|End Stage Renal Disease
Cancer
Heart Failure|Copd|Liver Failure|Diabetes Mellitus|Cancer|End Stage Renal Disease
Heart Failure|Cancer
Secondary Cardiac Damage in Rheumatic Fever
Acute Brain Injury
Stress|Anxiety|Depression|Cardiac Disease|Cancer|Diabetes|Copd
Cardiovascular Disease|Diabetes|Cancer|Mortality
Cancer|Cardiac Disease|Metabolic Syndrome|Arrhythmia|Heart Diseases
Lung Cancer
Colorectal Cancer Metastatic
Obesity|Heart Diseases|Cancer
Myocarditis|Cardiomyopathies|Heart Failure|Cardiac Tumor|Endocardiomyocardial Biopsy
Patients Who Receive Thoracic Irradiation
Stomach Neoplasms|Colonic Neoplasms|Rectal Neoplasms|Sigmoid Neoplasms|Liver Neoplasms|Kidney Neoplasms|Urinary Bladder Neoplasms|Prostatic Neoplasms|Osteoarthropathy|Fractures, Bone|Gynecologic Cancer
Carcinoma, Renal Cell
Multiple Myeloma|Amyloidosis Cardiac
Chemotherapy Induced Cardiotoxicity in Breast Cancer Patients
Congestive Heart Failure|Metastatic Cancer|Chronic Kidney Disease Requiring Chronic Dialysis|Chronic Obstructive Pulmonary Disease
Congestive Heart Failure|Chronic Obstructive Pulmonary Disease|Cancer|Diabetes Mellitus|Obstructive Sleep Apnea
Pain|Heart Rate Variability|Anxiety
Esophageal Cancer

Breast Cancer
Solid Tumours
Acute Myeloid Leukemia|Precursor-cell Lymphoblastic Leukemia-Lymphoma|Lymphoid Neoplasm|Multiple Myeloma|Lymphoma|Autologous Hematopoietic Stem Cell Transplantation
Healthy
Hemodynamic Instability
Breast Cancer
Cardio-oncology|Hematopoietic Stem Cell Transplantation|Cardiotoxicity|Cyclophosphamide|Echocardiography
Cardiotoxicity|Acute Myeloid Leukemia in Children|Bone Tumor
Breast Cancer|Heart Failure
Myeloproliferative Neoplasm
Gastric Cancer
Multiple Myeloma
Anthracycline-induced Cardiotoxicity
HEAVY SMOKING
Early Breast Cancer|Radiation Associated Cardiac Failure
Cardiotoxicity|Osteosarcoma|Myocardial Injury|Chemotherapy Induced Systolic Dysfunction|Doxorubicin Induced Cardiomyopathy
Coronary Heart Disease|Stroke|Diabetes|Breast Cancer|Ovarian Cancer|Colorectal Cancer
Cardiac Toxicity|Lymphoma
Atrial Fibrillation
COPD|Asthma|Lung Cancer|Anemia|Congestive Cardiac Failure|Bronchiectasis|Interstitial Lung Disease|Long COVID|Upper Respiratory Disease|Healthy
Colorectal Adenocarcinoma|Oesogastric
Chemotherapy-induced Cardiotoxicity|Breast Cancer
Arrhythmia|Respiratory Arrest
Esophageal Cancer|Postoperative Pulmonary Atelectasis|Postoperative Pneumonia|Postoperative Pneumothorax|Postoperative Infection of Incision|Postoperative Acute Myocardial Infarction
Node Positive Breast Cancer
Dementia|Chronic Disease|Neoplasm Metastasis|Lung Neoplasm|Pulmonary Disease, Chronic Obstructive|Heart Failure, Congestive|Liver Cirrhosis|Kidney Failure, Chronic|Lung Diseases, Interstitial|Peripheral Vascular Disea
Hematopoietic Stem Cell Transplant
Malignant Pericardial Effusion|Malignant Pleural Effusion|Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer
Advanced Cancers
Cardiovascular Disease
Cardiovascular Complication|Cardiovascular Insufficiency|Cardiac Complication|Oncologic Complications|Cardiac Insufficiency|Metabolic Disorder|Vascular Disorder|Cardiac Disorder
Hepatocellular Carcinoma
Cardiac Toxicity|Chemotherapeutic Agent Toxicity|Lymphoma
Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm
Breast Cancer
Breast Cancer|Cardiotoxicity
Cardiotoxicity
Family Members of: Newborns Extremely Premature|Family Members of: New Pediatric Oncology Patients|Family Members of: Critical Congenital Heart Defect Patients|Family Members of: Children Severe Neurological Impa
Long-term Heart-specific Mortality in the Presence of Competing Risks Among Patients With Gastric Adenocarcinoma Undergoing Resection and Chemotherapy
Diffuse Large B-cell Lymphoma
Acute Brain Injury
Breast Tumors|Hypotension|Bradycardia
Colorectal Neoplasms
Childhood Cancer
Primary Cardiac Lymphoma
Hypomelanotic Macules|Facial Angiofibroma|Shagreen Patches|Ungual Fibromas|Cortical Dysplasia|Cardiac Rhabdomyoma|Lymphangioleiomyomatosis|Renal Angiomyolipoma|Subependymal Giant Cell Astrocytoma
Coronary Disease|Emphysema or COPD|Breast Density
Supratentorial Brain Tumors
RAS Mutation|Neurofibromatosis 1|Noonan Syndrome|Noonan Syndrome With Multiple Lentigines|Noonan Neurofibromatosis Syndrome|Cardiofaciocutaneous Syndrome|Costello Syndrome|Legius Syndrome|Smith-Kingsmo
Coronary Artery Disease|Atrial Fibrillation|Type 2 Diabetes|Colorectal Cancer|Breast Cancer|Prostate Cancer
Solid Tumor
Lung Cancer|Atrial Fibrillation
Bone Diseases|Breast Neoplasms|Cardiovascular Diseases|Colonic Neoplasms|Coronary Disease|Heart Diseases|Myocardial Ischemia|Osteoporosis|Postmenopause
Anthracycline-induced Cardiac Toxicity|Non-Hodgkin Lymphoma
Malignant Neoplasm
Breast Cancer
Prostatic Neoplasms

Kidney Cancer|Liver Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Uterine Cancer|Bladder Cancer|Breast Cancer|Colorectal Cancer|Esophageal Cancer|Gastric Cancer|Arthritis|Benign Prostatic Hyp
Patients Undergoing Open Resection of Colorectal Tumours
Neoplasms
Chest Pain|Nonmalignant Condition
Cancer
Small Cell Lung Carcinoma
Cancer|Cardiac Anomaly|Cystic Fibrosis|Muscular Dystrophy|HIV/AIDS|Batten's Disease|Cerebral Palsy
Non-small Cell Lung Cancer|Radiation Toxicity|Cardiac Toxicity
Cardiac Tumors
Cardiomyopathy|Heart Failure|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm
Breast Cancer|Breast Tumors
Artificial Intelligent|Cardiotoxicity|Cardiac Monitor|Cancer Treatment|ECG
Breast Cancer|Cardiac Dysfunction
Cardiac Amyloidosis|AL Amyloidosis|ATTR Amyloidosis
Cardiac Transplantation|Skin Cancer
Lung Cancer Non Small Cell
Toxicity Due to Radiotherapy|Breast Cancer|Lesion; Cardiac
Thoracic Cancer|Left Sided Breast Cancer
Cardiotoxicity
Cancer, Lung|Respiratory Disease|Heart Diseases
Lung Cancer|Colorectal Cancer|Multiple Myeloma|Non Hodgkin Lymphoma
Pheochromocytoma
DLBCL|Multiple Myeloma|Cytokine Release Syndrome|Myocarditis|CAR T-cell Therapy|ALL|PCBCL|Follicular Lymphoma|MCL
Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)|Elderly|Antineoplastic Agents|Cardiotoxicity
Patients With Cancer
Monoclonal Gammopathy of Undetermined Significance|Multiple Myeloma|Plasma Cell Neoplasm
Leukaemia, Lymphocytic, Chronic
Hematopoietic Stem Cell Transplantation|Bone Marrow Transplant|Heart Rate Variability|Autonomic Nervous System|Stress|Mood|Psychological Distress|Emotion Regulation|Communication Research|Narrative
Cancer|Heart Failure|Chronic Obstructive Pulmonary Disease|Neurological Diseases
Obstructive Sleep Apnea|Cardiovascular Diseases|Arrhythmia|Atrial Fibrillation New Onset
Primary Amyloidosis of Light Chain Type
Patients Undergoing Routine Health Care|Heart Diseases|Inflammatory Bowel Diseases|Autoimmune Disease|Inflammatory Disease|Blood Coagulation Disorders|Hepatitis C|Non-Metastatic Neoplasm
Diabetes|Heart Disease|Cancer
Doxorubicin Adverse Reaction|Cardiomyopathies, Secondary|Breast Cancer
Cardiac Toxicity|Sarcoma
Lung Neoplasms
Menopausal Syndrome|Cardiovascular Disease|Osteoporosis|Breast Cancer
Autonomic Dysfunction|Childhood Cancer
Cardiomyopathy
Cardiac Toxicity|Early-stage Breast Cancer
Fluid Therapy
Gastrointestinal Neoplasms
Cancer|Heart Disease
Acute Myeloid Leukemia|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Blasts 10 Percent or More of Bone Marrow Nucleated Cells|High Risk Myelodysplastic Syndrome|Myeloid Sarcoma|Myeloproliferativ
Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma
Carcinoma, Renal Cell
Non Communicable Diseases|Heart Failure|Colon Rectal Cancer
COPD|Coronary Artery Calcification
Cancer|Cancer Cachexia|Chronic Obstructive Pulmonary Disease|Chronic Heart Failure|Rheumatoid Arthritis
Cardiac Toxicity|Malignant Neoplasm|Breast Cancer
Radiation Treatment|Cancer|Cardiotoxicity
Dementia|Chronic Disease|Neoplasm Metastasis|Lung Neoplasm|Pulmonary Disease, Chronic Obstructive|Heart Failure，Congestive|Liver Cirrhosis|Kidney Failure, Chronic|Lung Diseases, Interstitial|Peripheral Vascular Disea
Breast Cancer
Lung Cancer|Heart Disease|COPD
AL Amyloidosis
Cardiac Conduction and Repolarization
Cancer|Kidney Diseases|Heart Failure|Neurologic Disorder|Liver Diseases|Pulmonary Disease|Side Effect|Quality of Life|Physical Disorder
Lung Cancer|Heart Disease
Non Hodgkin Lymphoma|Heart; Functional Disturbance|Hodgkin Lymphoma|Quality of Life
Covid19
Dementia|Chronic Disease|Neoplasm Metastasis|Lung Neoplasms|Pulmonary Disease, Chronic Obstructive|Heart Failure，Congestive|Liver Cirrhosis|Kidney Failure, Chronic|Lung Diseases, Interstitial|Peripheral Vascular Dise
Hormone Sensitive Prostate Cancer|Prostate Cancer|Cardiac Event
Breast Cancer

Cardiac Toxicity|Chemotherapeutic Agent Toxicity|Unspecified Adult Solid Tumor, Protocol Specific
Healthy Volunteers
Coronary Artery Disease|Lung Cancer|Lung Tumor
Heart Failure|Pulmonary Disease|Cancer
Cancer|Cardiotoxicity
Systemic Lupus Erythematosus|Interferon Deficiency
Breast Cancer|Left Ventricular Dysfunction|Heart Failure, Systolic
Metastatic Cancer|Congestive Heart Failure|Chronic Obstructive Pulmonary Disease|Parkinson Disease|Interstitial Lung Disease|Amyotrophic Lateral Sclerosis|End Stage Liver Disease|End Stage Renal Disease|Diabetes Com
Hodgkin's Lymphoma
Childhood Cancer Survivors
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8|Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8|Clinical Stage I Esophageal Adenocarcinoma AJCC v8|Clinical Stage I Esophageal Squamous Cell Car
Multiple Myeloma|Myelodysplastic Syndromes
Breast Cancer|Chemotherapy Induced Systolic Dysfunction
Prostate Cancer
Acute Respiratory Distress Syndrome|Sepsis|Cardiovascular Shock
Testicular Cancer|Seminoma|Non-seminomatous
Retinoblastoma
Cancer
Congestive Heart Failure|Diabetes|Coronary Artery Disease|Chronic Obstructive Pulmonary Disease|Cancer|Cerebrovascular Disease|Alzheimer's Disease|Psychotic Disorder|Major Depression
Polycystic Ovary Syndrome
Cardiotoxicity|Pulmonary Toxicity|Thymus Neoplasms
Breast Cancer|Colorectal Cancer|Prostate Cancer|Alzheimer Disease|Age-related Macular Degeneration|Parkinson Disease|Cardiac Disease|Ischemic Stroke|Hemorrhagic Stroke
if Aortic Stiffness|Myocardial Wall Strain
Magnetic Resonance Imaging
Cancer Survivor|Diabetes Mellitus|Hypertension
Cardiovascular Diseases|Heart Diseases|Heart Failure, Congestive|Death, Sudden, Cardiac|Heart Failure
Adolescent Cancer
Breast Cancer|Lymphoma, Large B-Cell, Diffuse|Cardiotoxicity|Left Ventricular Dysfunction|Chemotherapy Effect
Endometrial Cancer|Survivorship
Hypertension|Heart Failure|Vascular Ischemia|Burns|Chemotherapy Effect|Radiation Injuries|Uveitis|Scleritis|Multiple Sclerosis|Autonomic Neuropathy|Stroke|Intracranial Hemorrhages|TIA|Migraine|Headache|Pain
Sepsis, Cancer, Heart Attack, Heart Failure, Abdominal Surgery, Trauma, Diabetes, Lung Disease, Gynaecology, Fertility, Cardiac Surgery,
Left Stellate Ganglion Block Can Quickly Restore the Left Stellate Ganglion|Possible Molecular Mechanism of Left Stellate Ganglion Block
Cancer|Heart Failure|COPD|Sepsis|HIV Infections|ESRD|Trauma|Stroke
Neoplasms|Neoplasms, Glandular and Epithelial|Neoplasms by Histologic Type|Bronchial Neoplasms|Lung Neoplasms|Respiratory Tract Neoplasms|Thoracic Neoplasms|Digestive System Neoplasms|Endocrine Gland Neopla
Attention Deficit Disorder With Hyperactivity|Asthma|COPD|Breast Cancer|Coronary Artery Disease|Congestive Heart Failure|Diabetes|Glaucoma|Hemophilia|Hypertension|Hyperthyroidism|Hypothyroidism|Myasthenia Gravis|C
Colorectal Cancer|Cardiovascular Disease|Bleeding
Breast Cancer|Cardiac Toxicity
Hypertrophic Cardiomyopathy|Hearing Loss|Cancer
Lung Neoplasms|Respiratory Failure|Pneumonia|Acute Coronary Syndromes|Unstable Angina|Myocardial Infarction|Cardiac Arrhythmia|Thromboembolic Disease
Breast Cancer|Cardiac Event
Cardiac AL Amyloidosis
Pineal Tumor
Primary Hypertension|Secondary Hypertension|Aortic Stenosis|Renal Insufficiency
Breast Cancer|Adverse Effect of Radiation Therapy
Multiple Organ Failure|End Stage Cardiac Failure|End Stage Chronic Obstructive Airways Disease|Chronic Kidney Disease Stage 5|Hepatic Encephalopathy|Sepsis|Dementia|Multiple Sclerosis|Parkinson's Disease|In-Hospital
Cardiac Toxicity|Unspecified Adult Solid Tumor, Protocol Specific
Amyloidosis Cardiac
Cardiotoxicity|Breast Cancer|Heart Failure
Breast Cancer Female|Heart Failure
Amyloidosis|Trigger Finger|Transthyretin Amyloidosis|Primary Amyloidosis of Light Chain Type
Breast Cancer|Myocardial Damage|Cardiotoxicity
Diabetes|Chronic Kidney Diseases|Cancer|Bowel Disease|Cardiovascular Diseases|Mononucleosis|Flu|Heart Diseases|HIV Infections|AIDS and Infections|Bulimia|Chest Infections|Arthritis|Leukaemia|Alcoholic Liver Disease|All
Cardiac Toxicity|Antitumor Drugs|Breast Cancer
Stroke|Diabetes Mellitus|Heart Disease|Cancer
Aneurysm|Arteriovenous Malformations|Coronary Occlusion|Lung Neoplasms|Liver Neoplasms
Hodgkin's Disease
Critical Illness|Chronic Obstructive Lung Disease|Congestive Heart Failure|Cirrhosis|Cancer
Cardiotoxicity|Risk Factor, Cardiovascular|Toxicity Due to Chemotherapy|Breast Cancer|Cardiomyopathies|Heart Failure
Chronic Liver Disease|Thyroid Disease|Benign Breast Disease|Malignant Breast Neoplasm|Acute Myocardial Infarction
Breast Cancer|Circulating Tumor Cells (CTCs)
Cancer|Myocardial Infarction|Cerebrovascular Stroke
Solid Tumor
Hodgkin Lymphoma Treated With Mediastinal Irradiation
Advanced Solid Tumors
Stage I Esophageal Adenocarcinoma|Stage II Esophageal Adenocarcinoma|Stage III Esophageal Adenocarcinoma|Stage I Esophageal Squamous Cell Carcinoma|Stage II Esophageal Squamous Cell Carcinoma|Stage III Esop
Myocarditis
Breast Cancer Female|Acute Coronary Events|Cardiac Complications

Cardiotoxicity|Toxicity Due to Chemotherapy|Breast Cancer|Lymphoma|Cardiomyopathies|Heart Failure
Embolic Stroke of Undetermined Source|Ischemic Stroke|Atrial Fibrillation and Flutter|Myocardial Infarction|Cardiac Tumor|Endocarditis|Patent Foramen Ovale
Left Ventricular Dysfunction|Heart Failure
Critical Illness|Chronic Disease|Terminal Care|Palliative Care|Communication|Advance Care Planning|Neoplasm Metastasis|Lung Neoplasms|Pulmonary Disease, Chronic Obstructive|Heart Failure|End Stage Liver Disease|Kidr
Myoma of Uterus|Colon Cancer|Gastric Carcinoma|Prostate Cancer|Femoral Head Necrosis
Lymphoma
Breast Cancer
Coronary Heart Disease|Stroke|Heart Failure|Cancer|Myocardial Infarction|Chronic Obstructive Pulmonary Disease
Surgery|Oncology
Breast Cancer
Chemotherapeutic Toxicity|Cardiotoxicity|Heart Failure|Breast Cancer|Lymphoma
Cardiotoxicity|Childhood Cancer
Heart Failure|Cardiotoxicity|Cancer
Breast Cancer Female
Breast Cancer|Cardiac Toxicity|Cardiovascular Complications
Alzheimer Disease, Late Onset|Stroke|Heart Failure|Pulmonary Disease, Chronic Obstructive|Cystic Fibrosis Pulmonary Exacerbation|Chronic Liver Disease and Cirrhosis|Kidney Failure, Acute|Kidney Failure, Chronic
Atrial Fibrillation
Non-small Cell Lung Cancer|Radiation Toxicity
Survivorship|Cancer|Heart Diseases|Secondary Cancer|Colorectal Cancer|Breast Cancer
Amyloidosis, Immunoglobulin Light-chain
Prostate Cancer|Cardiotoxicity|Drug-Related Side Effects and Adverse Reactions|Cardiovascular Diseases
Myelodysplastic Syndrome (MDS)
Breast Neoplasms
Liver Transplantation|Hepatocellular Carcinoma|Survival
Chemotherapy Induced Cardiotoxicity
Neoplasm, Breast|Heart Failure|Cardiotoxicity|Ventricular Dysfunction
Type2 Diabetes|Polycystic Ovary Syndrome
Breast Cancer
Cardiovascular Diseases|Cancer|Dementia|Traumatic Brain Injury
Breast Cancer
PreDiabetes|Insulin Resistance|Type2 Diabetes|NASH - Nonalcoholic Steatohepatitis|Diastolic Dysfunction|Dementia|Atrial Fibrillation|Cancer|Atherosclerosis|Carotid Plaque
Cancer|Congestive Heart Failure|Chronic Obstructive Pulmonary Disease
Medical Oncology
Breast Cancer

Organic, Including Symptomatic, Mental Disorders|Substance Use|Schizophrenia|Mood [Affective] Disorders|Neurotic, Stress-related and Somatoform Disorders|Eating Disorder|Disorders of Adult Personality and Behavior|Me
Cardiotoxicity|Cardiomyopathies|Breast Cancer
Heart Failure|Cancer Treatment Induced Left Ventricular Dysfunction
Interstitial Pulmonary Fibrosis ARDS|COPD (Chronic Obstructive Pulmonary Disease)|Bronchiectasis|Lymphangioleiomyomatosis|Primary Pulmonary Hypertension|ARDS (Acute Respiratory Distress Syndrome)
Congestive Heart Failure|Cancer|Chronic Obstructive Pulmonary Disease|Cerebrovascular Accident|Frail Elderly Syndrome|Cardiovascular Diseases
Cardiotoxicity|Heart Failure|Breast Cancer|Anthracycline Induced Cardiomyopathy|Biomarkers|Echocardiography
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
Breast Cancer
Coronary Disease|Cardiovascular Diseases|Heart Diseases|Coronary Heart Disease Risk Reduction|Breast Neoplasms|Neoplasms
SCAD|Addison Disease|Ankylosing Spondylitis|Antiphospholipid Antibody Syndrome|Celiac Disease|Crohn Disease|Dermatomyositis|Polymyositis|Guillain-Barre Syndrome|Hepatitis, Autoimmune|Graves Disease|Hashimoto T
Heart Diseases|CKD|Diabetes|Cancer|Asthma|Thyroid|Hypertension
Coronary Artery Disease|Proteus Syndrome|Coffin - Sins Syndrome|Familial Isolated Hyperparathyroidism|Dubouitz Syndrome
Cardiotoxicity|HER2-positive Breast Cancer|Heart Failure|Cancer, Therapy-Related
Coronary Artery Disease
Breast Cancer
Breast Cancer|Elderly
Chronic Disease|Frail|Diabetes Mellitus|Cancer|Chronic Lung Disease|Cardiovascular Diseases|Congestive Heart Failure|Hypertension|Osteoporosis, Osteopenia|Arthritis|Stroke|Kidney Diseases
Breast Cancer Female|Doxorubicin Induced Cardiomyopathy
Breast Cancer
Heart Failure|Pulmonary Disease|Neoplasms
Essential Hypertension|Liver Cancer|Nasopharyngeal Cancer|Pancreatic Cancer|Lung Cancer|Chronic Kidney Diseases|Acute Coronary Syndrome|Epilepsy|Gastric Cancer|Primary Aldosteronism|Subclinical hypothyroïdism
Cardiac Toxicity|Unspecified Childhood Solid Tumor, Protocol Specific
Cancer|Chemotherapeutic Toxicity|Coronary Artery Disease|Coronary Microvascular Disease
Breast Cancer
Breast Cancer|Lung Cancer|Mediastinal Lymphomas
Breast Neoplasm Female|Radiotherapy Side Effect|Heart Diseases
Childhood Cancers
Breast Cancer|Gastrointestinal Cancer|Genitourinary Cancer|Sarcoma|Gynecologic Cancer
Cardiotoxicity|Cancer
Non-Small Cell Lung Cancer
Cancer|Drug Toxicity|Atrial Fibrillation|Cardiovascular Complication
Lung Adenocarcinoma|Lung Adenosquamous Carcinoma|Malignant Pericardial Effusion|Malignant Pleural Effusion|Minimally Invasive Lung Adenocarcinoma|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Nor
Diabetic Foot Ulcer|Coronary Artery Disease|Parenchymatous; Pneumonia|Kidney Stone|Inner Ear Disease|Brain Stroke|Joint Diseases|Diabetes|Adrenal Incidentaloma|Hyperaldosteronism|Macroadenoma|Interstitial Lung Dise
Diabetes|Cancer|Heart Disease
Neoplasm, Hepatic|Pancreatic Neoplasms|Colorectal Neoplasms
Healthy|Cancer|Heart Diseases|Neurological Diseases or Conditions|Kidney Diseases|Diabetes|Other Disease
Neoplasms|Cardiac Arrhythmia
Breast Cancer
Non Small Cell Lung Cancer|Nephropathy|Cardiotoxicity
Arrhythmogenic Right Ventricular Dysplasia
Cardiac Toxicity|Unspecified Childhood Solid Tumor, Protocol Specific
Acyanotic Congenital Heart Disease|Cyanotic Congenital Heart Disease|Pheochromocytoma|Paraganglioma
Pre-terminal Cancer
Congenital Adrenal Hyperplasia|Familial Hyperinsulinemic Hypoglycemia 1|Phosphoglucomutase 1 Deficiency|Maturity Onset Diabetes of the Young|Cystic Fibrosis|Hypophosphatasia, Infantile|Congenital Hypothyroidism|DAV
Chronic Lung Disease|Chronic Obstructive Pulmonary Disease|Acute Lymphoblastic Leukemia|Heart Transplant
Cancer
Melanoma|Non-small Cell|Lung Cancer
Advanced Adult Primary Liver Cancer|Anaplastic Thyroid Cancer|Bone Metastases|Carcinoma of the Appendix|Distal Urethral Cancer|Fallopian Tube Cancer|Gastrinoma|Glucagonoma|Inflammatory Breast Cancer|Insulinoma|I

Breast Cancer|Non Hodgkin Lymphoma
Breast Cancer
Atrial Fibrillation
Cardiotoxicity
Malignant Pericardial Effusion
Thoracic Neoplasms|Late Effect of Radiation
Chemotherapy, Cancer, Cardiotoxicity, Physioflow
Cushing Syndrome|Cushing Disease|Ectopic ACTH Syndrome
Pheochromocytoma|Paraganglioma|Cardiovascular Morbidity
Cerebrovascular Accident|Cancer|Coronary Arteriosclerosis|Heart Failure, Congestive|Diabetes Mellitus|Acquired Immunodeficiency Syndrome|Failure to Thrive|Pulmonary Disease, Chronic Obstructive|Dementia|Kidney Failur
Cancer|Heart Failure|Copd|Dementia
Breast Cancer
Renal Cell Carcinoma
Lung Cancer|Ventricular Failure
Cardiotoxicity|Lung Cancer Stage III|Lung Cancer Stage II|Radiation Toxicity
Heart Failure|Heart Dysfunction
Neurofibromatosis 1|Noonan Syndrome|Legius Syndrome|Cardiofaciocutaneous Syndrome|Costello Syndrome
Pleural Effusion, Malignant|Pleural Mesothelioma|Pleural Empyema|Pulmonary Diseases or Conditions|Pleural Neoplasms|Pulmonary Atelectasis|Pleural Diseases|Pericardial Effusion|Mediastinal Lymphadenopathy|Pneumotho
Prostate Cancer

Interventions
DRUG: Bortezomib
OTHER: Assessment of Therapy Complications|OTHER: Laboratory Biomarker Analysis|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration
BEHAVIORAL: Breathlessness Intervention Service|BEHAVIORAL: Best supportive care (Standard Care)
BEHAVIORAL: Facilitator-Based Intervention
DRUG: Fentanyl|DRUG: Immediate release morphine
DRUG: Ivabradine|DRUG: Placebo
DEVICE: EndoPAT|DEVICE: Blood Pressure Cuff|DIAGNOSTIC_TEST: Echocardiogram|OTHER: Quality of Life Assessment|OTHER: Blood Tests
BEHAVIORAL: Training Program Intervention
DRUG: S-1|DRUG: Capecitabine|DRUG: Oxaliplatin
RADIATION: Scintigraphy
DIAGNOSTIC_TEST: micro RNA
PROCEDURE: Echocardiogram Recording|OTHER: Questionnaire Administration|PROCEDURE: Stress Cardiac Magnetic Resonance Imaging|DEVICE: Wireless Synchronized Cardiac Function Monitoring Device
DEVICE: Wrist-Actigraph - Octagonal Basic MotionIogger, Ambulatory monitoring Inc, New York, USA|DEVICE: Polysomnograph - Embla A10 (Medcare, Reykjavik, Iceland)|DEVICE: Holter monitor - Medilog AR12 (Oxford Inst
BEHAVIORAL: Crispbread
DRUG: Atorvastatin|DRUG: Placebo
DIAGNOSTIC_TEST: Blood tests & cardiac imaging
DRUG: no carrier added metaiodobenzylguanidine
DRUG: Iron isomaltoside 1000
DEVICE: Abdominal Regional Perfusion
DRUG: oCRH
DRUG: Bevacizumab
RADIATION: intensity-modulated radiation therapy
DRUG: Atorvastatin|DRUG: Placebo oral tablet
OTHER: Coronal calcium score measurement
DIAGNOSTIC_TEST: Cardiopulmonary Exercise Test|DIAGNOSTIC_TEST: Echocardiogram|DIAGNOSTIC_TEST: Echocardiography
OTHER: Registry of patients with Tako-Tsubo cardiomyopathy
OTHER: Best Practice|BIOLOGICAL: Tocilizumab
DRUG: rhTPO|DRUG: Control
OTHER: Laboratory Biomarker Analysis
OTHER: Firefighting training exercises with no fire|OTHER: Firefighting training exercises under wood fire|OTHER: Firefighting training exercises under gas fire
DRUG: renin-angiotensin system inhibitors or angiotensin-receptor-neprilysin inhibitor
DIAGNOSTIC_TEST: low dose CT
DRUG: 11C-Acetate|DRUG: 13N-Amonia
DRUG: lapatinib|DRUG: placebo matching lapatinib
PROCEDURE: Echocardiogram
BIOLOGICAL: Allo-MSCs|BIOLOGICAL: Placebo
DIAGNOSTIC_TEST: Exercise stress echocardiography
DRUG: Bupivacaine|DRUG: Adrenaline
DEVICE: 2D Echocardiogram|DEVICE: Cardiopulmonary exercise testing and post-CPET cardiac function
DIAGNOSTIC_TEST: 31-MRS at 7 Tesla (T)

DRUG: L-carnitine
DRUG: Carvedilol|OTHER: placebo
PROCEDURE: Cardiac surgery
PROCEDURE: Venous occlusion plethysmography|PROCEDURE: SphygmoCor|PROCEDURE: 24hour blood pressure|PROCEDURE: DEXA scan|BIOLOGICAL: Laboratory blood samples
DRUG: Formal study using hyperpolarized 13C-pyruvate injection|DRUG: Feasible study using hyperpolarized 13C-pyruvate injection
OTHER: Intervention
DEVICE: Activity Monitor|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration
PROCEDURE: Transthoracic echocardiogram (ultrasound)
DRUG: neratinib|OTHER: Placebo|DRUG: Moxifloxacin
OTHER: Survey
DRUG: Nicorandil
DEVICE: Breathe Well|DEVICE: RPM
RADIATION: F-18 florbetapir/C-11 acetate PET|DEVICE: MRI|RADIATION: N-13 ammonia PET
OTHER: SELF-BREATHE
DRUG: Pegylated liposomal doxorubicin|DRUG: Epirubicin|DRUG: Cyclophosphamid|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Docetaxel
DRUG: Liposomal Doxorubicin
BEHAVIORAL: Cognitive behavioral therapy (supportive counseling)|BEHAVIORAL: Virtual Cardiac Rehabilitation
PROCEDURE: ALA-rich diet
DEVICE: Vital signs measurements with new app
OTHER: Fludeoxyglucose F-18|PROCEDURE: Positron Emission Tomography|PROCEDURE: Computed Tomography|OTHER: Questionnaire Administration
OTHER: exercise
DIAGNOSTIC_TEST: 68Ga-FAPI and 18F-AlF-FAPI PET-MR
BEHAVIORAL: Making Your Wishes Known|BEHAVIORAL: Standard advance care planning
BEHAVIORAL: Case management
OTHER: Cardiac coherence|OTHER: Standard care
PROCEDURE: Cardiac Coherence|PROCEDURE: Adapted Physical Activity
OTHER: Exercise Training
BEHAVIORAL: Home environs-based lifestyle counseling|BEHAVIORAL: Cancer early detection
DEVICE: No nicotine electronic cigarette|OTHER: Standard counseling
BIOLOGICAL: bleomycin sulfate|BIOLOGICAL: filgrastim|DRUG: dexrazoxane hydrochloride|DRUG: doxorubicin hydrochloride|DRUG: etoposide|DRUG: vincristine sulfate|RADIATION: low-LET cobalt-60 gamma ray therapy|F
OTHER: GoalKeeper|OTHER: Standard Care
DRUG: AT1 blocker candesartan|DRUG: Placebo
DRUG: Antineoplastic and Immunomodulating Agents
OTHER: limit heart dose
OTHER: Cardiac MRI|OTHER: Echocardiogram|OTHER: Blood Draw
DRUG: AZD6094 200 mg|OTHER: Placebo|DRUG: Moxifloxacin
DRUG: 68GaNOTA-Anti-MMR-VHH2
OTHER: No Intervention on patients
DEVICE: iRhythm ZIO XT patch
DRUG: Tipifarnib
BEHAVIORAL: Online mind-body wellness program|BEHAVIORAL: Online mind-body wellness program + Weekly Check-ins
PROCEDURE: Nuclear Medicine Cardiac Scan|PROCEDURE: PET/CT Cardiac Scan
DIAGNOSTIC_TEST: Left Ventricular Ejection Fraction
BEHAVIORAL: Heart Rate Variability Biofeedback Training
BEHAVIORAL: Progressive combine training (PCT)|BEHAVIORAL: Attention Control (AC)
PROCEDURE: OPTI-AGED|PROCEDURE: Usual Care

PROCEDURE: Cardiology consultation|DIAGNOSTIC_TEST: Chest Computed Tomography (CT) without contrast|PROCEDURE: Non-invasive endothelial function tests|PROCEDURE: Electrocardiogram|DIAGNOSTIC_TEST: E
DIAGNOSTIC_TEST: CMR
DRUG: BOSENTAN
BEHAVIORAL: Aerobic exercise
DEVICE: Percutaneous Balloon Pericardiotomy
DRUG: CEOP regimen|DRUG: CHOP regimen
BEHAVIORAL: Storytelling Intervention for Patient Participants|BEHAVIORAL: Storytelling Intervention for Nurse Participants
DIAGNOSTIC_TEST: History taking|DIAGNOSTIC_TEST: Anthropometry|DIAGNOSTIC_TEST: Complete blood count|DIAGNOSTIC_TEST: Biochemical blood test|DIAGNOSTIC_TEST: Coagulogram|DIAGNOSTIC_TEST: Immur
PROCEDURE: Cell saver|PROCEDURE: No cell saver
DRUG: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
DRUG: TAS-102|DRUG: Placebo
OTHER: anonymized data collection during programmed surveillance clinical follow up
DRUG: Stellate ganglion block
DRUG: Aspirin|DRUG: Vitamin E|BEHAVIORAL: Placebo
OTHER: Active Intervention|OTHER: Usual Care
DRUG: Losartan|RADIATION: Radiation Therapy
DRUG: Cardiovascular Polypill|DRUG: Treatment Prevention for Secondary CV
DRUG: TH-302
BEHAVIORAL: Patient-Directed Wellness Account|BEHAVIORAL: Health Navigator
OTHER: SWIFT home intervention
RADIATION: Standard treatment protocol with combined chemoradiation
RADIATION: PET scan and ultrasound
DRUG: Lutathera
DRUG: raloxifene|DRUG: placebo
PROCEDURE: Home-based cardiac rehabilitation
DRUG: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias)|DRUG: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG
DIAGNOSTIC_TEST: Imaging on Scanner with Spectral Imaging Capabilities|DIAGNOSTIC_TEST: CT Scan using an Energy-Integrating Detector CT (128 slice MDCT)|DIAGNOSTIC_TEST: CT Scan using an Energy-Integrating
PROCEDURE: BNP, SAAG, ascites total protein, echocardiography
DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Ado Trastuzumab Emtansine
OTHER: Cardiac imaging modalities
DRUG: Aspirin
BEHAVIORAL: Exercise|BEHAVIORAL: No exercise
OTHER: Standard of care diagnostic MIBG scan for neuroendocrine tumor diagnosis.
OTHER: event occurence
DRUG: Trastuzumab
DRUG: Herceptin
DIETARY_SUPPLEMENT: Flax "milk"|DIETARY_SUPPLEMENT: Oat fibre "milk"
DIAGNOSTIC_TEST: Lipid profile|DIAGNOSTIC_TEST: Coronary artery assessment|DIAGNOSTIC_TEST: Hormone levels for hypogonadism
DRUG: 100 mg enteric-coated aspirin|DRUG: Placebo
DRUG: Carvedilol|DRUG: Lisinopril|DRUG: Pravastatin|DRUG: Spironolactone

BEHAVIORAL: VICKY|BEHAVIORAL: MFHP
DIAGNOSTIC_TEST: Cardiac risk ratio (CRR)
DRUG: Metoprolol|DRUG: Losartan
DRUG: perindopril OR bisoprolol OR placebo
DRUG: NEOD001|DRUG: Placebo
DRUG: Folic acid, vitamin B6 and B12 or placebo
PROCEDURE: Cardiac MRI|BIOLOGICAL: Biomarker Testing
OTHER: Exercise program|OTHER: Nutrition education
OTHER: Comfort Default AD forms|OTHER: Life Extension Default AD forms|OTHER: Standard Default AD forms
BEHAVIORAL: Cardio-oncology Rehabilitation (CORE)|BEHAVIORAL: PAI Group (PAI)|BEHAVIORAL: Exercise Guidelines for Cancer Survivors (ExGL)
PROCEDURE: Stellate Ganglion Block
DEVICE: myocardial PET imaging
BEHAVIORAL: Optimization of cardiac flow by base water-electrolyte supply|BEHAVIORAL: Control arm
PROCEDURE: Stellate nerve block
BEHAVIORAL: Heart APP
OTHER: No intervention was required
DRUG: asparaginase|DRUG: cytarabine|DRUG: dexrazoxane hydrochloride|DRUG: doxorubicin hydrochloride|DRUG: leucovorin calcium|DRUG: mercaptopurine|DRUG: methotrexate|DRUG: prednisone|DRUG: therapeutic hy
DRUG: lurbinectedin (PM01183)
DRUG: Carvedilol|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacogenomic Study|OTHER: Pharmacological Study|OTHER: Placebo Administration|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Admir
OTHER: Life completion and preparation|OTHER: Attention Control
DIAGNOSTIC_TEST: Biomarkers: Troponins and natriuretic peptides
DEVICE: Virtual Reality
OTHER: Values Inventory (VI)
PROCEDURE: Roux-en-Y Gastric Bypass Surgery|PROCEDURE: Laparoscopic Adjustable Gastric Banding|BEHAVIORAL: Lifestyle Weight Loss Intervention
DRUG: Amiodarone|OTHER: Control arm, standard care
PROCEDURE: Magnetic Resonance Imaging|BEHAVIORAL: Exercise Intervention|PROCEDURE: Perfusion Magnetic Resonance Imaging|BEHAVIORAL: Exercise Intervention|PROCEDURE: Spectroscopy|OTHER: Laboratory
DRUG: Ramosetron|DRUG: Normal saline
DEVICE: SaMD CARINAE
DEVICE: Low-frequency electro-acupuncture (EA)|OTHER: Meeting a therapist - attention control
DIAGNOSTIC_TEST: Cardiorespiratory exercise test
DIAGNOSTIC_TEST: serum high-sensitivity Troponin I (TnI) and NT-Pro-Brain Natriuretic Peptide (NT-proBNP)
BEHAVIORAL: Quality improvement strategies
DEVICE: Monitoring Device|OTHER: Informational Intervention|OTHER: Informational Intervention|OTHER: Questionnaire Administration
DRUG: Levosimendan|DRUG: Saline
DEVICE: Active Breathing Coordinator
BEHAVIORAL: Community Garden Intervention
DIETARY_SUPPLEMENT: Nicotinamide Riboside|DIETARY_SUPPLEMENT: Placebo
DRUG: AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)
PROCEDURE: Radiosurgery of ganglion stellatum
OTHER: Trigeminal cardiac reflex|OTHER: Non-trigeminal cardiac reflex
DRUG: GSK2118436 75 mg|DRUG: Placebo
PROCEDURE: Physical Characteristics|DIAGNOSTIC_TEST: Assessment of Heart rate variability|DIAGNOSTIC_TEST: Blood Pressure and Cardiac Autonomic Control|DIAGNOSTIC_TEST: Evaluation of Baroreflex Control|DIA
OTHER: no intervention
DEVICE: Zephyr Biopatch Device
DRUG: Low molecular weight heparin
OTHER: Subclinical cardiac lesions and biomarkers
DRUG: Valsartan
DRUG: Adenosine Stress Cardiac Magnetic Resonance Imaging|DIAGNOSTIC_TEST: Electrocardiogram|DIAGNOSTIC_TEST: Computed Tomography Angiogram|OTHER: Laboratory Testing|BEHAVIORAL: Quality of Life Surv
OTHER: Multi-professional breathlessness service (MBS)|OTHER: Delayed MBS Intervention
DIAGNOSTIC_TEST: Cardiac Imaging|OTHER: Data Collection
DRUG: crocin|DRUG: Placebo
OTHER: Chemoradiotherapy
OTHER: Deep Inspiration Breath Hold during Radiation|OTHER: Free breathing during radiation
BEHAVIORAL: Jumpstart Intervention

DEVICE: MDCT, ECG, Echocardiography
DEVICE: ANI
OTHER: Extra echocardiogram
PROCEDURE: Remote Ischaemic Conditioning|OTHER: Placebo
DEVICE: Administering three additional MRI images
DIAGNOSTIC_TEST: Relative telomere length
OTHER: Cardiac MRI
RADIATION: CT coronary angiography
DRUG: Xinmailong Injection
BEHAVIORAL: SiSom
PROCEDURE: Cardiac magnetic resonance (cardiac MRI)
BIOLOGICAL: trastuzumab|DRUG: cyclophosphamide|DRUG: doxorubicin hydrochloride|DRUG: lapatinib ditosylate|DRUG: paclitaxel|GENETIC: gene expression analysis|GENETIC: reverse transcriptase-polymerase chain re
RADIATION: Thallium-201 Myocardial Perfusion Study
DIAGNOSTIC_TEST: 30-second ECG using the Kardia Mobile|OTHER: routine care
DRUG: voriconazole (Vfend)|OTHER: no voriconazole (Vfend)
DRUG: Bupivacaine-fentanyl|DEVICE: Holter ECG monitor|PROCEDURE: Open kidney cancer surgery|PROCEDURE: General anesthesia|PROCEDURE: Epidural Anaesthesia
DEVICE: T-REX TRI00A
OTHER: FHAMe Intervention
OTHER: Complete Cardiac Magnetic Resonance Imaging (MRI)
DEVICE: ARFI measurement|DEVICE: ARFI measurement|DEVICE: ARFI measurement
GENETIC: SNP analysis
DRUG: Carvedilol|DRUG: Placebo
DEVICE: LINQ device - implantable cardiac monitor - referred to in the application as "implantable loop recorder" or "ILR")
PROCEDURE: Catheterization of subclavian vein|PROCEDURE: Catheterization of internal jugular vein
DIAGNOSTIC_TEST: Specimen sample
DRUG: Acetylsalicylic acid (Aspirin, BAYE4465)
OTHER: Cardiac SPECT perfusion scan
DRUG: Ivabradine|DRUG: Placebo Oral Tablet
DRUG: Immune checkpoint inhibitor
DIAGNOSTIC_TEST: Molecular characterization of solid tumor in RASopathies
DEVICE: Ryodoraku|DEVICE: ANSWatch|DEVICE: UGI endoscopy|OTHER: GerdQ|DRUG: PPI
DRUG: Carvedilol|DRUG: Placebo
OTHER: observation only
BEHAVIORAL: Mediterranean Diet|BEHAVIORAL: Low Fat Diet
DRUG: Pegylated Liposomal Doxorubicin
DEVICE: positron emission tomography|DEVICE: computed tomography|DEVICE: magnetic resonance imaging
DEVICE: Carebot AI CXR
DIAGNOSTIC_TEST: 24 Hour Holter Monitor
DIAGNOSTIC_TEST: Cardiac condition measurements
DIAGNOSTIC_TEST: Cardiac MRI
RADIATION: Radiation therapy|DRUG: Leuprolide|DRUG: Relugolix
DRUG: Doxil|DRUG: Cyclophosphamide|DRUG: Vincristine|DRUG: Prednisone|DRUG: Rituximab|DRUG: Pegfilgrastim
DRUG: trastuzumab [Herceptin]
DRUG: Bisoprolol|DRUG: Ramipril|DRUG: Placebo
DEVICE: Remote 1-minute single-lead electrocardiogram (ECG) monitoring in cancer patients after the first polychemotherapy cycle.
DRUG: ACE inhibitor, Sacubitril-Valsartan

DRUG: Rituximab|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: liposomal Doxorubicin|DRUG: Vincristin|DRUG: Prednisolone
BEHAVIORAL: Education regarding telomere length
DRUG: deferasirox
DRUG: Silymarin|DRUG: Placebo
OTHER: Prolong in-hospital stay
PROCEDURE: Biospecimen Collection|OTHER: Electronic Medical Record
DRUG: Placebo Administration|OTHER: Questionnaire Administration|DRUG: Telotristat Ethyl
OTHER: PET-MR imaging on Biograph mMR scanner|OTHER: MR-only imaging on Biograph mMR scanner|OTHER: MR imaging on the Siemens Vida 3T MR scanner
DRUG: L02 (sex hormones used in treatment of neoplastic diseases) and G03 (sex hormones)
OTHER: Respiratory gating
OTHER: specialized palliative care
DEVICE: Extracorporeal shock waves
DRUG: sulforaphane|DRUG: Placebo Oral Tablet
DEVICE: e-health device with application
DRUG: [64Cu]FBP8|DEVICE: PET/MR|PROCEDURE: Blood Collection|PROCEDURE: Electrocardiogram
OTHER: Qualitative research interviews to be conducted
OTHER: Clinical Decision Aid|OTHER: Standard Care
OTHER: AH-HA Tool in the EPIC EHR
DRUG: Pasireotide
BIOLOGICAL: trastuzumab|OTHER: laboratory biomarker analysis|PROCEDURE: assessment of therapy complications
RADIATION: Proton Radiotherapy
DRUG: Cabergoline
DIAGNOSTIC_TEST: Retrospective file studies
DRUG: Everolimus (RAD001)|DRUG: Everolimus Placebo
DIAGNOSTIC_TEST: CT scan and blood sample collection
DEVICE: Cardiac Magnetic Resonance Scan
DRUG: cisplatin|DRUG: dexrazoxane hydrochloride|DRUG: doxorubicin hydrochloride|DRUG: etoposide|DRUG: ifosfamide|DRUG: methotrexate|PROCEDURE: conventional surgery
OTHER: observational cohort with plasma samples
BEHAVIORAL: High Intensity Interval Exercise|BEHAVIORAL: Moderate Intensity Walking
DRUG: Candesartan
OTHER: Usual Care|BEHAVIORAL: Exercise Training|BEHAVIORAL: Dietary Counseling
OTHER: endothelial function testing
PROCEDURE: management of therapy complications
DRUG: brentuximab vedotin
RADIATION: 99mTc-rhAnnexin V-128
PROCEDURE: Lung resection
DEVICE: Transcatheter Tricuspid Valved Stent Graft
BEHAVIORAL: Parent-Infant Inter(X)action Intervention (PIXI)
DRUG: Dexmedetomidine|DRUG: Saline
DRUG: pegylated liposomal doxorubicin|DRUG: pirarubicin
BEHAVIORAL: DIMAC02
DRUG: Enalapril

DIAGNOSTIC_TEST: NT-pro-BNP|DIAGNOSTIC_TEST: Electrocardiogram|DIAGNOSTIC_TEST: Echocardiogram
BEHAVIORAL: TIP / IMPACT Plus Care Coordination
OTHER: Physical exercise program
OTHER: intervention
BEHAVIORAL: questionnaire about the use of ECG device
BEHAVIORAL: Behavioral Activation|OTHER: Medication Optimization
PROCEDURE: Bone Marrow Aspiration and Biopsy|DRUG: Cytarabine|DRUG: Daunorubicin Hydrochloride|OTHER: Laboratory Biomarker Analysis
BEHAVIORAL: Cognitive and Behavioral intervention for the Management of Episodic Breathlessness
RADIATION: CT TAP Scan
PROCEDURE: LVEF 3 month|PROCEDURE: LVEF 4 month
OTHER: cardiac MRI
OTHER: Life Completion|OTHER: Attention Control
DRUG: Dexrazoxane hydrochloride|DRUG: Dexrazoxane hydrochloride
DRUG: Picoplatin
OTHER: Social Determinants of Health
DEVICE: Native aortic valve|PROCEDURE: Transcatheter aortic valve implantation (TAVI)
DRUG: Placebo|DRUG: Atorvastatin
BEHAVIORAL: e-Health (web-based) disclosure portal|BEHAVIORAL: Provider mediated disclosure
PROCEDURE: Echocardiograms|PROCEDURE: Blood Test
DIAGNOSTIC_TEST: cardiac assessment
PROCEDURE: skin punch biopsy
OTHER: High altitude
OTHER: Cardiac Rehab
PROCEDURE: 6 Minute Walk Functional Test|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography|PROCEDURE: Exercise Cardiac Stress Test|OTHER: Questionnair
OTHER: Community outreach method
BEHAVIORAL: Clinician Implementation Strategy Stage 1|BEHAVIORAL: Clinician Implementation Strategy Stage 2|BEHAVIORAL: Low patient engagement|BEHAVIORAL: High patient engagement
OTHER: Cardiac biomarkers, Echocardiography,Cardiac magnetic resonance imaging
DRUG: Immune checkpoint inhibitor
DRUG: Telotristat Ethyl|DRUG: Lanreotide
DIAGNOSTIC_TEST: Echocardiography
OTHER: HSCT Patients
PROCEDURE: capnothorax
DEVICE: NIV|DEVICE: NFHC-O2
PROCEDURE: Diagnostic Imaging|OTHER: Laboratory Biomarker Analysis

DEVICE: MyoStrain®
OTHER: Cardiac rehabilitation
BEHAVIORAL: Short Term Psychotherapy
OTHER: Exercise
BIOLOGICAL: tabelecleucel
BIOLOGICAL: Human immune globulin intravenous (IGIV)
DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Trastuzumab emtansine
DIAGNOSTIC_TEST: Cardiac magnetic resonance imaging (MRI)|DIAGNOSTIC_TEST: Echocardiography|DIAGNOSTIC_TEST: Electrocardiogram
RADIATION: Confirmed Left-Sided Breast Cancer
OTHER: Health Information Exchange (HIE) platform
DRUG: Povidone-Iodine
PROCEDURE: Biospecimen Collection|OTHER: Electronic Health Record Review|PROCEDURE: Magnetic Resonance Imaging|OTHER: Survey Administration
OTHER: Cardiac coherence
DIAGNOSTIC_TEST: echocardiography|OTHER: Cardiopulmonary Exercise Testing|OTHER: Blood Collection
DRUG: Doxorubicin
DEVICE: Activity tracker
DRUG: standard-of-care treatments for LV impairment
OTHER: Screening for PC by means of two different screening tools
BEHAVIORAL: Cognitive behavioural therapy (CBT)
DRUG: Simvastatin|DRUG: Doxorubicin/cyclophosphamide
OTHER: Tech-supported HBPC|OTHER: Standard HBPC
OTHER: Yoga
DEVICE: Vigileo Monitor|DEVICE: FloTrac Sensor
DRUG: Veliparib (ABT-888)|DRUG: Placebo
DRUG: Sacubitril-valsartan
OTHER: Cardio-oncology program
DRUG: Herceptin (trastuzumab)|DRUG: SB3 (proposed trastuzumab biosimilar)
OTHER: Autonomic nervous system activity records
OTHER: Retrospective Chart Review
OTHER: incidece of cancers
DIAGNOSTIC_TEST: ECG
OTHER: Outlook Attention Control|OTHER: Outlook Intervention
BEHAVIORAL: Qigong|BEHAVIORAL: Healthy Living (CHIP + Pre-Train)
RADIATION: free-breathing|RADIATION: deep inspiratory breath-holding

BEHAVIORAL: Computerized Intervention Authoring Software (CIAS)
DRUG: Atorvastatin Calcium 40Mg Tab
PROCEDURE: Physical Characteristics|PROCEDURE: Muscular Sympathetic Nervous Activity|DIAGNOSTIC_TEST: Cardiac Function|DIAGNOSTIC_TEST: Heart rate|DIAGNOSTIC_TEST: Blood pressure|DIAGNOSTIC_TEST: E
OTHER: Moderate Intensity Exercise
DRUG: Mitoxantrone Hydrochloride Liposome
DRUG: Carvedilol|OTHER: Laboratory Biomarker Analysis|OTHER: Patient Observation
BIOLOGICAL: Adenosine|PROCEDURE: Magnetic Resonance Imaging|DRUG: Regadenoson|PROCEDURE: Stress Management Therapy
DRUG: PLD|DRUG: CTX|DRUG: Docetaxel|DRUG: Paclitaxel|DRUG: Doxorubicin
BEHAVIORAL: Nutrition Education
DRUG: Abatacept plus|DRUG: Placebo
PROCEDURE: Cardiologic assessment
PROCEDURE: Blood Sample
OTHER: Mobilization
BEHAVIORAL: Questionnaires|BEHAVIORAL: Interviews|DIAGNOSTIC_TEST: Blood Test|DIAGNOSTIC_TEST: Echocardiogram
DIAGNOSTIC_TEST: ISCHEMIC HEART DISEASE diagnostic
DRUG: dexrazoxane hydrochloride|DRUG: doxorubicin hydrochloride|DRUG: cyclophosphamide|DRUG: paclitaxel|BIOLOGICAL: trastuzumab|PROCEDURE: therapeutic conventional surgery|RADIATION: radiation therapy|DF
BIOLOGICAL: bevacizumab|DRUG: cyclophosphamide|DRUG: docetaxel|DRUG: epirubicin hydrochloride|DRUG: fluorouracil|PROCEDURE: assessment of therapy complications|PROCEDURE: neoadjuvant therapy|PROCED
DEVICE: Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)
OTHER: Study of the occurrence of Carcinoid Heart Disease
OTHER: Educational Intervention|BEHAVIORAL: Exercise Intervention|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration
DRUG: Ondansetron
DRUG: Trimetazidine
DEVICE: AlignRT system (VisionRT Ltd., London, UK)
BEHAVIORAL: heart rate variability biofeedback
OTHER: Cardiac Rehabilitation Program|OTHER: Community exercise intervention
OTHER: Cardiac Aggressive Risk MitigAtion Plan
OTHER: exercise training
BEHAVIORAL: Informed Assent Discussion|BEHAVIORAL: Usual Care with Attention Control
BEHAVIORAL: Biofeedback
OTHER: Medically Tailored Meals
BEHAVIORAL: MDASI-HF Questionnaire
DIAGNOSTIC_TEST: Echocardiogram
PROCEDURE: Extubation|PROCEDURE: Usual Care
OTHER: Nature-Body-Mind-Community|OTHER: Treatment as usual
BEHAVIORAL: Low-risk lifestyle behaviours
OTHER: No interventions are planned
PROCEDURE: adjuvant therapy|PROCEDURE: diagnostic thoracoscopy|PROCEDURE: therapeutic thoracoscopy|PROCEDURE: video-assisted surgery|RADIATION: radiation therapy
DRUG: Antineoplastic Agents
OTHER: Environmental message|OTHER: Health message|OTHER: Neutral Message
PROCEDURE: Endocardiomyocardial biopsy
PROCEDURE: Cardiac evaluation and blood sampling
DRUG: low-dose neuroleptanalgesia|DRUG: Placebo
DRUG: Pazopanib|DRUG: Other anti-VEGFs
DEVICE: NMR
DEVICE: cardiac MRI with DWI
BEHAVIORAL: ED GOAL
OTHER: Early warning system monitoring.|OTHER: routine care
OTHER: essential oils
OTHER: Cardiac Biomarker Blood Draws

PROCEDURE: Voluntary deep-inspiratory breath hold|PROCEDURE: Active-breathing-controlled deep-inspiratory breathhold|PROCEDURE: Prone treatment|DEVICE: Active-breathing-controlled deep-inspiratory breathhold
DRUG: CYP1A2 (caffeine)|DRUG: CYP2C19 (omeprazole)|DRUG: CYP3A (midazolam)|DRUG: Kytril (granisetron)|DRUG: Wee-1 kinase inhibitor AZD1775
DRUG: Enalapril and carvedilol
DRUG: Dexrazoxane
DRUG: Tetracaine 0.5%|DRUG: Lidocaine hydrochloride ophthalmic gel 3.5%
DRUG: Doxorubicin
DRUG: Capoten®
DRUG: Metoprolol|DRUG: Placebo|DRUG: Candesartan|DRUG: Placebo
DEVICE: Transthorathic echocardiogram
DRUG: preemptive dexmedetomidine epidural bolus injection(1.5 mcg/kg)|DRUG: normal saline
DIAGNOSTIC_TEST: Lung and coronary CT assessment|DIAGNOSTIC_TEST: Coronary CT assessment
RADIATION: Proton versus photon radiation therapy
DIAGNOSTIC_TEST: contrast-enhanced cardiac magnetic resonance imaging(MAGNETOM Aera 1.5T)
BEHAVIORAL: Familial risk assessment and personalized prevention messages
BIOLOGICAL: bleomycin sulfate|BIOLOGICAL: filgrastim|DRUG: cyclophosphamide|DRUG: dexrazoxane hydrochloride|DRUG: doxorubicin hydrochloride|DRUG: etoposide|DRUG: prednisone|DRUG: vincristine sulfate|RADIA
DEVICE: N-Tidal C handset
DRUG: Trifluridine/Tipiracil|DRUG: Oxaliplatin
DRUG: Rosuvastatin 20mg
DRUG: Atropine|DRUG: Placebo
DEVICE: AIRVO2|OTHER: STANDARD CARE
RADIATION: Radiation therapy groups
BEHAVIORAL: EHR-based Clinician Jumpstart
BEHAVIORAL: CBCT Intervention
OTHER: cytology specimen collection procedure|PROCEDURE: therapeutic procedure|DRUG: targeted therapy|OTHER: laboratory biomarker analysis
DRUG: Atorvastatin|DIETARY_SUPPLEMENT: Fish Oil Supplement|OTHER: Placebo
OTHER: Cardiac MRI
DRUG: Anti-Cancer Agents
OTHER: measuring hemodynamic parameters heart beat to heart beat during single-frequency exposure
DRUG: doxorubicin hydrochloride|PROCEDURE: contrast-enhanced magnetic resonance imaging
BIOLOGICAL: bleomycin sulfate|BIOLOGICAL: recombinant interferon alfa|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: doxorubicin hydrochloride|DRUG: etoposide|DRUG: methotrexate|DRUG: prednisone|DRUG: vi
DRUG: epirubicin, cyclophosphamide, docetaxel
RADIATION: Proton vs Photon Radiation
PROCEDURE: Resection and chemotherapy
DRUG: Rituximab|DRUG: Mitoxantrone hydrochloride liposome|DRUG: Cyclophosphamide|DRUG: Vincristine/Vindesine|DRUG: Prednisone
PROCEDURE: Airway Management Pathway|PROCEDURE: Usual Care
DRUG: levobupivacaine
PROCEDURE: Cardiac 3D MRI
OTHER: System implementation of patient-centered incidental findings report
DEVICE: ANSiscope
DIAGNOSTIC_TEST: Polygenic risk score (PRS)
DRUG: Fluoropyrimidine
DRUG: hormone replacement therapy|DRUG: estrogens|DRUG: progestins|DRUG: estrogen replacement therapy|BEHAVIORAL: diet, fat-restricted|DRUG: calcium|DRUG: vitamin D|BEHAVIORAL: dietary supplements
DEVICE: RIPC|DEVICE: Simulated RIPC (Sham)
PROCEDURE: Biospecimen Collection|OTHER: Questionnaire Administration
DRUG: Trastuzumab

DEVICE: Exai oncRNA blood test
DRUG: Hartmann's solution
OTHER: No intervention
OTHER: Extended information
DRUG: GSK1120212
DRUG: Rovalpituzumab Tesirine
GENETIC: end-of-life nursing education consortium-pediatric palliative care as web based-training plus usual care
DIAGNOSTIC_TEST: Echocardiography
PROCEDURE: Direct Transthoracic Cardiac Tumor Radio Frequency Ablation Therapy|PROCEDURE: Direct Transthoracic Cardiac Tumor Laser Ablation Therapy
OTHER: Best Practice|OTHER: Laboratory Biomarker Analysis|DRUG: Mesenchymal Stem Cell Transplantation|DRUG: Mesenchymal Stem Cell Transplantation
DRUG: Metformin|DRUG: Doxorubicin
DEVICE: Wisdom bracelet
DRUG: Vericiguat|OTHER: Optimal medical therapy
DRUG: [18F]florbetaben
DRUG: Everolimus
OTHER: usual care|BEHAVIORAL: Walk|BEHAVIORAL: Baduanjin|BEHAVIORAL: Baduanjin plus walk
OTHER: Helical tomotherapy for breast cancer
DIAGNOSTIC_TEST: [1-13C]pyruvate along with MRI imaging
DRUG: Empagliflozin 10 MG|OTHER: Placebo
OTHER: Intervention|OTHER: Usual Care
OTHER: Osteopathic intervention|BIOLOGICAL: CRP assessment|BEHAVIORAL: QLQ-C30 questionnaire
DIAGNOSTIC_TEST: Cardiac MRI
OTHER: Intensive cardiovascular monitoring|OTHER: No intervention
DRUG: Ivabradine
BIOLOGICAL: Siltuximab
BIOLOGICAL: Ofatumumab
BEHAVIORAL: Baseline Surveys|BEHAVIORAL: Heart rate variability biofeedback|BEHAVIORAL: Heart rate variability waitlist and Digital storytelling Control intervention
OTHER: Telepalliation
DEVICE: Reveal LINQ
DEVICE: High Cut-off Hemodialysis|DRUG: Chemotherapy
OTHER: MeTree
BIOLOGICAL: filgrastim|DRUG: cisplatin|DRUG: dexrazoxane hydrochloride|DRUG: doxorubicin hydrochloride|DRUG: leucovorin calcium|DRUG: methotrexate|PROCEDURE: adjuvant therapy|PROCEDURE: conventional surg
DRUG: estradiol plus MPA|DRUG: Ximingting Tablet|DRUG: estradiol plus progesterone
OTHER: 12 Week Exercise Intervention
DRUG: Lipitor 40mg Tablet
DEVICE: cardiac index|DEVICE: Stroke Volume Variation
OTHER: Study of cerebral blood flow
BEHAVIORAL: High Fiber Diet|BEHAVIORAL: low saturated fat diet|BEHAVIORAL: Combination diet
DRUG: Cladribine|DRUG: Cytarabine|DRUG: Dexrazoxane Hydrochloride|DRUG: Gemtuzumab Ozogamicin|DRUG: Idarubicin
OTHER: Laboratory Biomarker Analysis|DRUG: Linsitinib|OTHER: Pharmacological Study
DRUG: Pazopanib|OTHER: Placebo for pazopanib|DRUG: Moxifloxacin|OTHER: Placebo for moxifloxacin
BEHAVIORAL: eHealth@Hospital-2-Home
BEHAVIORAL: Educational material and treatment recommendations for patients, general practitioners and pharmacists
DRUG: Fish oil supplement
PROCEDURE: Magnetic resonance imaging|OTHER: Physical Activity|OTHER: Healthy Living|DEVICE: Cardiopulmonary Exercise Testing (CPET)|OTHER: Questionnaire Administration
DIAGNOSTIC_TEST: Cardiac Magnetic Resonance Imaging
BEHAVIORAL: Jumpstart Guide
PROCEDURE: Research Cardiac MRI|PROCEDURE: Biomarkers
BEHAVIORAL: Smoking cessation treatment plus moderate intensity exercise|BEHAVIORAL: Smoking cessation treatment plus health education
DRUG: [18F]Florbetaben
DRUG: Custirsen|DRUG: Placebo|DRUG: Moxifloxacin
BEHAVIORAL: Picture warning|BEHAVIORAL: Control
OTHER: Exercise with Trainerize application|DIAGNOSTIC_TEST: Cardiopulmonary exercise testing|DIAGNOSTIC_TEST: MRI scan|BEHAVIORAL: Quality of Life Questionnaires|BEHAVIORAL: Cognitive and Brain Function Qu
BEHAVIORAL: Survey-based Patient/Clinician Jumpstart|BEHAVIORAL: EHR-based Clinician Jumpstart
DRUG: Degarelix|DRUG: GnRH agonist
DRUG: Carvedilol

BEHAVIORAL: exercise intervention
BEHAVIORAL: Education
OTHER: Walking Programme|DEVICE: Incentive Spirometer|OTHER: Deep Breathing Exercises
OTHER: Preparation and life completion|OTHER: Attention Control
OTHER: Exercise program
BEHAVIORAL: High Intensity Interval Training
OTHER: Exercise Rehabilitation
BEHAVIORAL: Respecting Choices First Steps|BEHAVIORAL: Five Wishes Form
PROCEDURE: Cardiac Magnetic Resonance Imaging|PROCEDURE: Echocardiogram
DRUG: Perindopril
PROCEDURE: Biospecimen Collection|DEVICE: Cardiac Event Monitor|OTHER: Chemoradiotherapy|RADIATION: Radiation Therapy
DIAGNOSTIC_TEST: CMR examination
DIAGNOSTIC_TEST: Cardiac MRI
DIAGNOSTIC_TEST: Trans-thoracic echocardiography
OTHER: Guided Relaxation
BEHAVIORAL: Care Coordination
DIETARY_SUPPLEMENT: Ocean Nutrition 2050|DIETARY_SUPPLEMENT: Olive oil capsules
RADIATION: Proton radiation
BEHAVIORAL: Support provided by social worker|OTHER: Information booklet receipt
DRUG: Gadobutrol (Gadovist, BAY86-4875)|DRUG: Gadopentetate Dimeglumine (Magnevist, BAY86-4882)
PROCEDURE: computed tomography|OTHER: cytology specimen collection procedure|OTHER: laboratory biomarker analysis|OTHER: questionnaire administration
BEHAVIORAL: lifestyle and physical exercise
DRUG: Nebivolol|DRUG: Placebo
OTHER: PREVENT Cardiovascular Health Assessment Tool|OTHER: Survey|OTHER: Interview Regarding Heart Health
DEVICE: laser speckle flowgraphy
PROCEDURE: stellate ganglion block
OTHER: Therapeutic massage
DRUG: Entinostat|DRUG: Placebo
OTHER: MAPLE
DRUG: Acetylsalicylic Acid (Aspirin, BAYE4465)
DRUG: Coreg CR®|DRUG: lisinopril|OTHER: placebo
DEVICE: GeneInsight Clinic (GIC)
OTHER: Normal Saline|OTHER: Sodium Bicarbonate
DEVICE: Deep inspiration breath-hold technique
DRUG: Doxycycline|DRUG: Standard of care therapy
DRUG: Melatonin Replacement Therapy
DRUG: Nitroglycerin 0.25 mg (single dose, no longer given since January 2017)|DRUG: Salbutamol 400 µg (single dose, no longer given since January 2017)|DRUG: L-arginine (10 min infusion, no longer given since January 2
RADIATION: Radiation therapy
OTHER: Early order of palliative care consultation
OTHER: Laboratory Biomarker Analysis|BEHAVIORAL: Questionnaires
DRUG: Lenalidomide 25mg
DRUG: Sacubitril/valsartan
PROCEDURE: Biopsy
DIAGNOSTIC_TEST: Cardiac MRI and echocardiography, laboratory parameters
DRUG: Trastuzumab
PROCEDURE: Interventional radiology : skin dose measurements
PROCEDURE: Echo/Stress Echo
DRUG: Carvedilol
DRUG: Digoxin
DRUG: Talazoparib
OTHER: Not relevant (there is no intervention in the present study)
DRUG: tivozanib
DRUG: photosensitizer(photofrin)|DEVICE: 630 nm laser irradiation (DIOMED)
OTHER: additional time for the MRI
RADIATION: Radiotherapy

OTHER: Biomarker Guided Intervention
DIAGNOSTIC_TEST: ADMA (asymmetric dimethylarginine) , NTproBNP (N-terminal pro b-type natriuretic peptide), IL-6 (Interleukin 6), Adiponectina, Leptine, Syndecan, Resistin
DIAGNOSTIC_TEST: ECG, Echocardiography, cTnI, NT-ProBNP
BEHAVIORAL: Communication Feedback Form for Patients with Serious Illness
DRUG: Revlimid
RADIATION: Verify radiation dose to heart and lung
OTHER: cardiac coherence program coupled with hypnosis
DRUG: Prevention therapy|DRUG: Rescue therapy
DIAGNOSTIC_TEST: cardiac ultrasound with speckle tracking analysis
BEHAVIORAL: Cardio-oncology Rehabilitation (CORE)|BEHAVIORAL: Support|BEHAVIORAL: Passive Behavioural Support
OTHER: Cardiac imaging and circulating biomarkers
BIOLOGICAL: trastuzumab|DRUG: doxorubicin hydrochloride|GENETIC: polymorphism analysis|OTHER: laboratory biomarker analysis|OTHER: questionnaire administration|PROCEDURE: assessment of therapy complicatior
OTHER: Health Education Manual|OTHER: manual
DIAGNOSTIC_TEST: Measuring Serum bio-markers
RADIATION: Standard platinum-based chemoradiotherapy
BEHAVIORAL: ONLOOP program
OTHER: Registry
OTHER: Social Determinants of Health
OTHER: T2* Cardiac and Liver MRI
OTHER: Age
OTHER: Cardiac magnetic resonance imaging
DIAGNOSTIC_TEST: Echocardiography
PROCEDURE: Research Cardiac MRI|PROCEDURE: Biomarkers
OTHER: no interventions will be performed (observational)
OTHER: myocardial perfusion SPECT
OTHER: Lifestyle modification in routine care of patients
OTHER: Home-based palliative care|OTHER: Enhanced usual care
OTHER: Measurement of cardiac index
DRUG: Liposomal pegylated doxorubicine

OTHER: Organic Disorders|OTHER: Substance Use Disorders|OTHER: Schizophrenia Disorders|OTHER: Mood disorders|OTHER: Neurotic disorders|OTHER: Eating Disorders|OTHER: Personality Disorders|OTHER: Intellectua
OTHER: Subclinical cardiotoxicity surveillance and treatment
DEVICE: Echocardiograms|DEVICE: Electrocardiogram|BEHAVIORAL: Symptom Questionnaire|BEHAVIORAL: Telephone Follow-Up
PROCEDURE: Veno-veno-arterial ECMO
OTHER: Serious Illness Care Program (SICP)
DIAGNOSTIC_TEST: Electrocardiogram|DIAGNOSTIC_TEST: Echocardiogram|DIAGNOSTIC_TEST: Cardiac magnetic resonance imaging|DEVICE: Mobile cardiac telemetry|DIAGNOSTIC_TEST: Blood pressure monitoring|DIA
OTHER: Cardiac Magnetic Resonance Imaging (CMR)|OTHER: Echocardiogram (ECHO)
BEHAVIORAL: Motivational tteaching
OTHER: Phased withdrawal of heart failure medications
DIAGNOSTIC_TEST: Coronary CT
DIAGNOSTIC_TEST: Echocardiography|OTHER: Blood Collection|OTHER: Symptoms Questionnaire
DRUG: Caelyx|DRUG: endoxan
OTHER: Strength and Balance Training & Nutrition Education|OTHER: Usual Care
DRUG: Doxorubicin|DEVICE: Achieva, Philips Medical Systems (3T magnet)|DRUG: Gadoterate Meglumine
OTHER: Rehabilitation after breast cancer surgery
BEHAVIORAL: ACp conversation
OTHER: no intervention
DRUG: enalapril maleate|PROCEDURE: quality-of-life assessment
RADIATION: Radiation Therapy
DRUG: Doxorubicin|DRUG: Sildenafil
DEVICE: EchoGo
DRUG: Durvalumab|RADIATION: Proton beam therapy RT
OTHER: occurence of atrial fibrillation
DRUG: Carboplatin|DRUG: Erlotinib|DRUG: Erlotinib Hydrochloride|DRUG: Paclitaxel
DEVICE: Spectral Photon Counting Computed Tomography (SPCCT)|DEVICE: DECT (Dual Energy CT)
PROCEDURE: Specimen Collection
DEVICE: ECG application|DEVICE: 12 lead ECG
DRUG: Eplerenone|DRUG: Placebo
DRUG: Cisplatin injection
BIOLOGICAL: Peripheral immunological assessment on venous blood|BIOLOGICAL: Immunological assessment carried out on intracardiac material
BIOLOGICAL: oblimersen sodium|DRUG: dexrazoxane hydrochloride|DRUG: doxorubicin hydrochloride|DRUG: cyclophosphamide|BIOLOGICAL: filgrastim|OTHER: laboratory biomarker analysis|OTHER: pharmacological stu
DRUG: Heart failure medication|DRUG: Placebo
OTHER: Physical activity
DRUG: Nivolumab|DEVICE: MRI|BIOLOGICAL: BLOOD SAMPLES|DEVICE: trans-thoracic echocardiography
BIOLOGICAL: recombinant interleukin-12|BIOLOGICAL: ABI-007/carboplatin/trastuzumab

DRUG: Enalapril
OTHER: Cardio-vascular MRI
DRUG: Amiodarone
PROCEDURE: Remote Ischaemic Preconditioning|OTHER: Control
PROCEDURE: Observation alone after pericardial drainage|DRUG: Pericardial instillation of bleomycin after drainage
RADIATION: Thallium-201 Myocardial Perfusion Study
DRUG: CRN04894
OTHER: Observational study
BEHAVIORAL: Multidisciplinary palliative care team met with patient
BEHAVIORAL: Feedback
OTHER: Endurance exercise
PROCEDURE: Lung Resection
OTHER: Chemoradiation
DRUG: Sacubitril-valsartan|DRUG: Valsartan
BEHAVIORAL: Waitlist|BEHAVIORAL: ACT Intervention
PROCEDURE: Thoracic Epidural Anesthesia|PROCEDURE: General Anesthesia with One Lung Ventilation
DEVICE: Coronary CT Angiography (CCTA)

Primary Outcome Measures
Global longitudinal strain by echocardiography, 6 months
Left ventricular function and measures of pathologic remodeling (i.e., thickness-to-dimension ratio) assessed using standard 2-dimensional, M-mode, and Doppler echocardiogram, Univariate tests will be used as well as exa
Numerical rating Scale (NRS) for distress due to breathlessness, End of intervention (4 weeks after baseline for patients with a non-malignant diagnosis; 2 weeks after baseline for patients with malignant diagnoses)
Hospital Anxiety and Depression Scale (HADS) - family, Family member symptoms of depression and anxiety assessed with the Hospital Anxiety and Depression Scale (HADS), which has become standard for ICU and post-I
Time to onset of meaningful breathlessness relief, To determine the time to onset of meaningful breathlessness relief of fentanyl buccal tablet (FBT) in comparison to immediate-release morphine (IRM), minutes (by stop watch
Ventricular function, Reduction in global longitudinal strain of at least 10% (GLS), 365 days after randomization
Endothelial Function and Dyspnea Associations in Multiple Myeloma Patients, The association between baseline endothelial function and dyspnea in myeloma patients treated with carfilzomib. These associations will be asse
Patient and family ratings on the "End-of-Life domain" of the Quality of Communication Questionaire (QOC), 4/1/2007-3/31/2012
Frequency of coronary artery dysfunction, The frequency of subclinical coronary artery dysfunction is as assessed by comparing the coronary flow reserve during chemotherapy with the baseline coronary flow reserve, and th
Comparison of the diagnostic performance of PF NTproBNP level in the diagnosis of HF-associated pleural effusions with other conventional biochemical criteria, Pleural fluid NTproBNP will be measured in patients with pleu
Rate of images with a score greater than or equal to 4, Rate of images obtaining a score greater than or equal to 4 in visual image quality analysis on a 5-point LIKERT scale., Day 0
miRNA, Expression pattern of miRNA in blood, At enrollment|Cell free DNA from host, Quantity of cell free DNA derived from host in blood, At enrollment|Cell free DNA from microbiota, Expression pattern of cell free DNA dist
To assess the clinical manifestations of the CARNEY Complex (CNC) and/or the primary pigmented nodular adrenocortical disease (PPNAD), 6 months
Accuracy of ejection fraction (EF) in the clinic setting, and determine its reproducibility at home., Validate the accuracy of ejection fraction, as measured using a tonometry-based system (SphygmoCor® Xcel), in the clinic sett
Preoperative sleep architecture of breast cancer patients, Sleep architecture measured by Polysomnography (awake, stadium I-IV, REM sleep, sleep latency, awakenings)., 1 day preoperatively|Postoperative sleep architectur
Weight loss, One year
Change in Global Circumferential Strain (GCS) Measured by Cardiac MRI (CMRI), baseline to 12 months post initiation of statin intervention
The effect of radiation dose to the heart assessed using blood test (full blood count), The effect of radiation dose to the heart assessed using full blood count measurement at the following time points (before radiotherapy, wit
Radiation dosimetry, Radiation dosimetry was measured by imaging at several time points. Blood and urine samples were also collected to correlate with imaging parameters. Side effects were also assessed after drug admi
Attitude of patients towards IV iron treatment evaluated with questionnaire., Rate of patients with stability or positive change in attitude. Questionnaire comprises the following questions: 1. I am hesitant to be treated with IV iron. 2. I would consider IV iron treatment due to the physician´s choice. 3. I would consider IV iron treatment due to its safety compared to other iron treatment options. 4. I would consider IV iron treatment due to its efficacy compared to other iron treatment options., Change from baseline taking into account baseline (BL) and follow-up (FU) answers. Follow-up at the latest 12 weeks after ob
Primary non-function, Graft failure requiring re-transplantion, 1 week|Early allograft dysfunction, Transient non-functioning of the liver transplant but with usual recovery to full functioning liver, 1 week|Ischemic Cholangiopathy
Genotype and clinical phenotype correlation in patients with PPNAD, Carney Complex, Peutz-Jeghers Syndrome and related conditions., Genotype and clinical phenotype correlation in patients with PPNAD, Carney Comple
Lung cancer symptom, Evaluated by lung cancer symptom scale 21-30 days after the treatment
Feasibility of delivering cardiac-sparing IMRT with central quality control in 20 subjects, Feasibility of delivering whole lung IMRT will be demonstrated by obtaining QARC central quality control approval of institutional IMRT p
Cardiac MRI measured LVEF within 4 weeks of anthracycline completion, Cardiac MRI LVEF at the end of treatment will be measured before cancer treatment and within 4 weeks after completion of anthracycline-based treat
The number of patients who wear, return and have sufficient data for analysis of resting heart rate and HRV after removal of noise by WHOOP® HRV software data analysis algorithms., Feasibility will be considered adequate
Incidence of a calcium score, Incidence of a calcium score measured by the Agatston score\> 0 in the study population of adults treated during childhood or adolescence for cancer with irradiation of the heart area and / or tr
Baseline VO2peak in participants with HER2-positive breast cancer, The primary purpose is to evaluate baseline VO2peak in patients with HER2-positive solid tumors and left ventricular systolic dysfunction, At baseline
prevalence and incidence of cancer in patients with TTC, 5 years
7-day length of invasive mechanical ventilation (MV), The 7-day length of invasive MV for each arm will be estimated with 95% confidence intervals (CIs) using the exact binomial distribution. Their difference by the arms will b
Proportion of patients whose platelet count is ≥ 75×10^9/L after 2 cycles cancer treatment., Efficacy was defined as treatment without salvage therapy to increase platelet counts., After 2 cycles cancer treatment (month 1.5~
Identification of rare coding variants of large effect that predict the risk of CHF, Assessed by burden analysis., Baseline
Change in reactive hyperemia index - afternoon, Reactive hyperemia index (RHI) measured with the device EndoPAT 2000. A reactive hyperemia is induced by a blood cuff on the upper arm and the peripheral vasodilation res in levels of circulating micro RNA, Circulating micro RNA candidates will be measured by RNA extraction from serum samples, reverse transcribed into complementary DNA (cDNA) and analysed with quantitative polymerase
Major Adverse Cardiovascular Events, a) Primary Outcome is Major Adverse Cardiovascular Events（MACE）related to ICIs，includes: cardiovascular death, myocardial infarction(nonfatal), stroke(nonfatal), heart failure that
cardiomyopathy, Cardiomyopathy is defined as a decrease in the left ventricular ejection fraction by echocardiography of greater than 10 percentage points, to a value \< 53% (normal reference value for 2D echocardiography
Disease Diagnosis, This protocol will complement the aims of the Undiagnosed Diseases Program (UDP), which may admit some of its subjects through this protocol, to provide answers to subjects with conditions associate
Treatment Difference in Duration of Cardiac Ventricular Depolarization and Repolarization Interval (QT) in Fridericia-corrected QT Interval (QTcF) Values Between Placebo and Lapatinib 2000mg, A Holter monitor is an ambulat
Composite cardiotoxicity, Transthoracic echocardiograms with strain imaging, Up to 28 days prior to beginning chemotherapy, during chemotherapy (specifically, at the visit that will administer doxorubicin to a cumulative tot
Proportion of Major Adverse Cardiac Events (MACE), Proportion of adjudicated events including death, hospitalization for worsening heart failure, and/or other exacerbation of heart failure (non-hospitalization)., Baseline to 12
Feasibility Criteria 1 - Recruitment Rate, The number of children, adolescents and young adults with a history of pediatric cancer who agree to participate compared to the total number approached for this study., Throughout
Changes in Cardiac Output as measured by LiDCOplus monitor., After paracervical Block., 0-10 minutes
cardiac function, Exercise capacity will be assessed by CPET, and echocardiographic images will be obtained immediately after CPET to evaluate contractile reserve., 2 years
Changes in skeletal and cardiac muscle mitochondrial function, Assessed through 31P-MRS imaging. Parameters include: * PCr recovery rate (in seconds) * PCr/ATP ratio, Baseline, halfway (R-)CHOP treatment (+/- 9 weeks), after (R-)CHOP treatment (+/- 18 weeks)

To compare the effects of L-carnitine therapy versus placebo on left ventricular (LV) ejection fraction (EF) as a marker of anthracycline induced cardiotoxicity, 1 year
Maximum Change in LVEF at 3 Months, Value at 3 months minus value at baseline, 3 months|Maximum Change in LVEF at 6 Months, Value at 6 months minus value at baseline, 6 months|Maximum Change in LVEF at 9 Mont
Atrial fibrillation, Occurrence of atrial fibrillation, postoperatively until 5 years follow-up
Changes in endothelial dysfunction evaluated using plethysmography., Measured before start of chemotherapy (week 0), immediately after ended chemotherapy (week 18) and one year after ended chemotherapy (week 70).(
Detect subclinical anthracycline induced cardiotoxicity using hyperpolarized carbon-13 pyruvate, Detect the correlation between cardiac carbon-13 pyruvate metabolism and cardiac mechanical function at baseline and after
The correlation of PCOS betwwen metabolic and cardiovascular disease., Participant were followed for 1 month in study period.
Number of Subjects Who Discussed Disease Risk With Primary Care Provider, 3 months following primary care visit
Magnitude of heart rate variability (HRV) decline (Stage I), As measured by root mean square of the successive differences (RMSSD) in pancreatic ductal adenocarcinoma (PDAC) patients and in high-risk participants., Up to 1
Longitudinal Strain, Each transthoracic echocardiogram obtained during the patient's treatment will be assessed for longitudinal strain., Change in baseline longitudinal strain from beginning of study to end of study. Patients
QTc interval, 3 days
Measure changes in Cardiac ejection fraction score, Post Radiation Treatment|Measure changes in perfusion imaging score on the radionuclide cardiac profusion scan, Post Radiation
The rate of symptomatic radiation pneumonitis in patients with unresectable Stage II/III/ oligometastatic IV non-small cell lung carcinoma (NSCLC) who completed chemoradiation followed by nicorandil or not, Up to 2.5 years
Accuracy of Breathe Well, The accuracy will be measured by comparing 'Breathe Well' and RPM measurements with images acquired of the breast during the radiation treatment using an electronic portal imaging device (EPI
Change in F-18 florbetapir myocardial retention index from baseline to 6 months and 12 months, quantitative measure of F-18 florbetapir uptake by the heart muscle, Baseline, 6 and 12 months|Change in Serum oxidative str
death for any cause, rate of lethal outcomes, From date of hospitalization until the date of first documented date of death from any cause, assessed up to 12 months|hospitalization for any cause, rate of hospitalization for any
Feasibility: the number of patients recruited into this study over a 12-month period, The number of patients recruited into this study over a 12-month period, 12 months
Cardiotoxicity (Cardiac death; grade 3/4 arrhythmia or ischaemia; NYHA Class 3 or 4 heart failure decline in LVEF by >10% to a level <55%; decline in LVEF by >5% to a level <50%), Until 6 months after completing trastuzum
1-year incidence of cardiotoxicity, 1-year
To assesses blood levels of TNI and BNP during the first four cycles Trastuzumab&Pertuzumab and Taxanes treatment, Prior to every treatment cycle, blood samples will be taken for TNI \& BNP. Patients with elevated levels
Frequency of cardiac events of patients receiving PIs for MM., 18 months
Rate of symptomatic (type A) and asymptomatic (type B) cardiac events during the study treatment period, Following 12 months after first dose of the study treatment
Proportion of Completers, Proportion of screened eligible participants who complete the initial 2-hour psychosocial support session intake. The pilot study is considered feasible if the primary endpoint is met in at least 50% of patients. We will evaluate the 95% CI of the feasibility rate., 12 weeks
Data quality, The number (frequency) of patients having adequate data quality (defined as at least 60% of the monitoring time with simultaneous recording of SpO2, respiratory rate, heart rate), 30 days|user satisfaction, Numb
Change in mean standardized uptake value (SUV) changes in the heart, Measured by sarcoidosis fludeoxyglucose F-18 (FDG) positron emission tomography (PET)-computed tomography (CT) scans., Up to 30 months after ra
Global Longitudinal Strain, Assessed with 2D speckle tracking echocardiography, 24-48 hours after first doxorubicin and 7-14 days after completion of last doxorubicin cycle
Cardiotoxicity events according to CREC (Cardiac Review and evaluation Committee) criteria, either a cardiomyopathy with decreased left ventricular ejection fraction (LVEF), a reduction of LVEF ≥5% to \<55% with symptom
Fibrosis activity: Standardised uptake values (SUV, SUV, 1-2 years|Fibrosis activity:Tissue-to-Background Ratio, TBR, 1-2 years
Self-efficacy, Family caregiver self-efficacy is measured using a validated questionnaire to determine if they feel better prepared to serve as surrogates for their loved one., 6 weeks
The outcome measure for the number of emergency room visits will be calculated from the medical record counting the number of hospital emergency room visits; for access to primary physicians, the medical record will be r
Evaluate the heart-rate corrected QT (QTc) interval (msec) during robotic-assisted laparoscopic gastrectomy, (T0: Pre-induction T1: 10min after anesthetic induction T2: 1min after CO2 pneumoperitoneum T3: 5min after CO2
Number of solid cancers, Number of solid cancers, Ten Year followup
Cardiac Coherence Program Adherence Rate, Cardiac Coherence Program Adherence Rate. Patients are considered in "success" adhere to the program) if they will perform at least 20 of the 30 sessions scheduled until surg
Health-related quality of life, Health-related quality is assessed by the Quality of Life Questionnaire dedicated to cancer patients and including 30 items (QLQ-C30) developed by the European Organization for Research and T QLQ-C30 items are coded with the same response categories as items 6 to 28, namely "Not at all", "A little", "Quite a bit" and "Very much." Score ranges from 0 to 100, with higher score indicating higher levels of quality of li
Changes from baseline in left ventricular (LV) global longitudinal strain (GLS), GLS assessed by speckle tracking echocardiography is an established marker for LV systolic function with a good reproducibility, which has also b
Change in arterial stiffness as measured by pulse wave velocity, Pulse wave velocity is a measure of arterial stiffness that is sensitive to changes in health-related lifestyle changes., baseline, 6, 12, 24 months follow-up|Chang
Number of cigarettes smoked, two months after event (cancer or myocardial infarction)|psychological conditions, psychological conditions will be assessed by questionnaire, two months after event (cancer or myocardial infa
DLCO, The Wilcoxon test will be used to evaluate whether DLCO values differ between the two arms., 1 year post therapy
Multimodality Cardiology Assessment- EKG, Assess whether radiation to the heart is associated with increased pre-clinical and clinical cardiac disease (as determined by a composite of multimodality cardiology assessments Studies will be read using a standard, evidence based, set of criterion and documented using study templates) and compared to patients who did not receive radiation to the heart. All cardiac tests will be reviewed and reported as a composite with one the following; No evidence of disease/unrelated, preclinical disease, or clinical disease (non-numerically) based on the Cardiologists read of the study ba All cardiac tests will be reviewed and reported as a composite with one the following; No evidence of disease/unrelated, preclinical disease, or clinical disease (non-numerically) based on the Cardiologists read of the study ba All cardiac tests will be reviewed and reported as a composite with one the following; No evidence of disease/unrelated, preclinical disease, or clinical disease (non-numerically) based on the Cardiologists read of the study ba
Change in Parent Perception of Goal-Centered Care questionnaire from Baseline to 1-Month Follow-up, Parent perception of goal-centered care will be measured using a modified version of the "Patient Assessment of Chron
The occurrence of cardiotoxicity, defined as a decline in LVEF (MUGA) of more than 15% or a decrease of less than 15% to an absolute value below 45%., during 1 year trastuzumab therapy and during 26 weeks after discon
The number of participants with successful application of guideline-directed Cardio-Oncology assessments and surveillance., To calculate the percentage of patients who successfully completed all guideline required investig
Cardiotoxicity assessed clinically or by cardiac MRI, 24 months
Incidence of cardiovascular events on ibrutinib, Evaluate the incidence of cardiotoxicity (composite endpoint) in a cohort of patients referred to a cardio-oncology before initiation of ibrutinib., 6 months
Cardio-vascular toxicity of antineoplastic and immunomodulating agents, Identification and report of cardio-vascular toxicities of antineoplastic and immunomodulating agents. The research includes the report with MedDRA
cardiac toxicity event free survival, The time from the date of randomization to any recurrence of clinical or subclinical cardiac toxicity, 1 year
CMR, 1. Increased myocardial T2 relaxation time in the myocardium compared to baseline as measured by T2 mapping technique, From Baseline to one year after anthracycline therapy
Effect of AZD6094 at single therapeutic dose (600 mg) on ventricular repolarization by analysis of change from baseline-corrected QT, To assess the effect of AZD6094 at single therapeutic dose (600mg) on ventricular repolar
Impact of return of clinically actionable results on patient treatment, The network will abstract data from patient electronic health records (EHR) six months after clinically actionable results have been returned to the patients a
Correlation of uptake of 68GaNOTA-Anti-MMR-VHH2 before start of treatment in HNSCC lesions with time to treatment failure after radiotherapy or systemic treatment including immune checkpoint inhibition. (cohort 1), Upta
Evaluation of arterial hypertension, by creation of a weekly blood pressure diary, 24-hour blood pressure holter every six months, Evaluation of arterial hypertension, by creation of a weekly blood pressure diary, 24-hour blooc
Monthly rate of patient accrual, Proportion of patients who are determined to be eligible for study relative to the number of patients actually enrolled and consented for participation in the study. This will help to inform the will
The change from baseline in time-matched difference in QTc interval to post-baseline time points after a single 900 mg dose and multiple 600 mg BID doses of tipifarnib in subjects with Advanced Solid Malignancies, The ana
Cardiopulmonary Fitness, VO2peak assessed using cardiopulmonary exercise test, post-intervention (16 weeks)
Myocardial edema, Myocardial edema in the acute phase measured by a composite of multiple measures that include T1 and T2 mapping, signal enhancement in T2 weighted images., Time points will be measured over a 1 y
retrospective study of cardiac toxicity in left breast cancer received hypofractionated radiotherapy, detection of toxicity on cardiac ejection fraction in 45 patients received hypofractionated radiotherapy over left breast, baseli
Hospital Anxiety and Depression Scale (HADS), Depression and anxiety will be measured on the Hospital Anxiety and Depression Scale. The minimum value is 0, the maximum is 21, and higher scores mean a worse outcome
To compare the results, called an ejection fraction, of PET/CT and NM cardiac scans of heart., 5 Years
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, Participants have HER2-positive breast cancer treated with non-anthracycline trastuzumab-based therapy., 12 months from baselin
EORTC QLQ-C30 Questionnaire, Questionnaire developed to assess the quality of life of cancer patients. The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, t Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response
Change in Metabolic Dysregulation (MetD) After Completion of Phase 1 Progressive Combine Training (PCT) -Insulin Resistance, Changes from baseline in insulin resistance (IR) measured by Homeostasis Model Assessment
Incidence of a composite of mortality or major postoperative morbidity., One or more of major postoperative complications : acute kidney injury (defined by Kidney disease : improving Global Outcomes (KDIGO) stage 1 or hig

The incidence of an elevated hs-TnT above the ULN if the baseline value was normal; or 1.5 ≥ times baseline if the baseline value was above the ULN within the first three months of treatment. The maximum measured value
Carotid intima-media thickness (cIMT), Subclinical atherosclerosis evaluation by quantifying intima media thickness by Doppler, Four Weeks
Global Longitudinal Strain (GLS) change after chemotherapy compared to baseline, A relative reduction in Global Longitudinal Strain (GLS) assessed with CMR, Baseline and 2 weeks after the last chemotherapy cycle
SIX MINUTE WALKING DISTANCE, CHANGE IN SIX MINUTE WALKING DISTANCE AFTER 6 MONTHS OF THERAPY COMPARED TO PRE-TREATMENT VALUE., SIX MONTHS|MAXIMAL OXYGEN UPTAKE, CHANGE IN MA
Change in Left Ventricular (LV) Function, LV function will be assessed using serial transthoracic echocardiography (TTE) as well as tissue velocity imaging (TVI) and strain imaging (SI.) For 2-dimensional (2D) LV cavity dimensio
To accelerate research into rare disorders by connecting individuals who are interested in research and who have been diagnosed with a rare disorder (or a disorder of unknown prevalence, or who are undiagnosed) with rese
Pericardial effusion recurrence, Recurrence of pericardial effusion after index procedure, defined as development of moderate or more pericardial effusion (\>10mm) on follow-up imaging., 3 months|Procedural related compli
Identification of novel cancer predisposing genes, Probands and cancer affected and unaffected relatives from selected families will be sequenced using Whole Genome Sequencing (WGS) or possibly Whole Exome Sequenc
Cardiotoxicity (Class III or IV cardiotoxicity according to New York Heart Association (NYHA) Classification or LVEF abnormality [< 50% or a decrease in absolute LVEF ≥ 10%) by post-treatment RNA]), 18 weeks
Number of Completed Exit Interviews From Patients on Feasibility of Their Use of Their Narrative Integrated Into EHR, Using an observational design, this measure (exit interviews) were completed with 20 inpatient participant
Change of global longitudinal strain of 15% or more relative to the initial values, Change of global longitudinal strain of the myocardium according to stress echocardiography by 15% or more relative to the values obtained be
Concentrations of IL-1B, IL-6, IL-8, IL-10, IL-12p70, TNFa, TNF-R1, TNF-R2, PCT and LPS in patient blood., 6, 24 and 72 hours after termination of CPB.
Composite of pharmacokinetic outcomes for understudied drugs in children, As appropriate for each study drug, the following additional PK parameters will be estimated: * maximum concentration (Cmax) * time to achieve maximum concentration (Tmax) * absorption rate constant (ka) * elimination rate constant (kel) * half-life (t1/2) * area under the curve (AUC) Penetration into body fluids will be determined by comparing exposure (i.e. AUC, Cmax) ratios between the body fluid and plasma or comparison of concentrations in paired samples., Data will be collected throughout the ho
QTc interval, Predose (Day -2) to post-dose changes and absolute values in QTc interval after placebo (Day -1, Cycle 1), after a single dose of TAS-102 (Day 1, Cycle 1), and after multiple doses (Day 12, Cycle 1), Days -2, -1,
Cardiotoxicity, Any new cardiac event occurring during or after cancer treatment, 18 months of prospective follow up|New cardiovascular events, Heart failure, myocardial infarction, cardiac arrhythmias, syncope, coronary re
Changes in renal blood flow, Renal blood flow indicators, 30 minutes after the start of the operation , 30 minutes after the start of cardiopulmonary , 30 minutes after the end of cardiopulmonary bypassbypass|Indicators of ki
Number of Participants With Major Cardiovascular Events (a Combined Endpoint of Nonfatal Myocardial Infarction, Nonfatal Stroke, and Total Cardiovascular Death), Average follow-up 10.1 years|Number of Participants With
Heart failure, up to 35 years after exposure to childhood cancer therapy|Hypertension, up to 35 years after exposure to childhood cancer therapy
Patient symptom burden (Edmonton Symptom Assessment Scale [ESAS]), Change from baseline in patient-reported symptom burden measured using the Edmonton Symptom Assessment Scale (ESAS) at baseline; change t
Extracellular Volume (ECV) of Myocardial Fibrosis, The primary endpoint is detectable decrease in extracellular volume as measured by cardiac MRI, 6 months
Difference in the occurrence of Major Adverse Cardiovascular Events (MACE) between the Cardiovascular Combination Polypill AAR and the Standard of Care Treatment, Cardiovascular death, non-fatal myocardial infarction,
Evaluate the potential for QT/QTc interval prolongation of TH-302 in patients with solid tumors, 2 years
Self-reported physical health related quality of life (HRQOL) using the Short Form-12 (SF-12), The SF-12 has been validated across a number of chronic diseases and conditions. The survey consists of 12 questions measurin
30-day Hospital Readmission, The outcome measure is the number of readmissions experienced by participants in the Usual Care and Intervention groups within 30-days of their index discharge., 30-days post hospitalizatio
Change in heart function., The outcome assessed by cardiac echocardiography. Our study use the standard imaging modality -cardiac echocardiography, 12 month, and 24 month.
myocardial flow reserve, The change in global absolute MFR between baseline and follow up PET studies, at a patient level. MFR is defined as the ratio between regional blood flow with maximum vasodilation and baseline re
The rate of progression of moderate carcinoid heart disease (CHD), The rate of progression of carcinoid heart disease (CHD) in patients with moderate CHD will be compared across the Lutathera Therapy and Best Supportiv The rate of progression will be assessed at each study visit across both arms during the intervention and follow-up phase. If the study treatment is successful in delaying the rate of progression, then the rate of progression in
Time to first occurrence of coronary death, non-fatal myocardial infarction (MI), or hospitalized acute coronary syndrome other than MI combined after an expected 5 to 7.5 years of follow-up.|Time to first occurrence of invas
Feasibility of cardiac rehabilitation after definitive radiation therapy as measured by number of participants who complete at least 75% of prescribed cardiac rehabilitation sessions, -Cardiac rehabilitation will be considered as
Cardiac response, The primary objective is to assess whether treatment with EGCG increases the rate of cardiac response following chemotherapy in patients with AL amyloidosis. The primary endpoint is cardiac response a
Parameters of Objective Image Quality, Measured as signal, image noise and modulation transfer function equivalent parameters, 1 year|Parameters of Radiation Dose, measured as x-ray tube parameters such as dose lengt
diagnostic accuracy of BNP for the diagnosis of ascites due to heart failure, * ROC curves of different strategies with and without BNP levels for diagnosing heart failure as the cause of ascites. * Sensitivity, specificity, accuracy, predictive values, likelihood ratios., 6 months
Percentage of Patients Who Complete Planned Oncologic Therapy Without the Development of a Cardiac Event or Asymptomatic Worsening of Cardiac Function., Cardiac events are defined as any of the following: * Presence of symptoms attributable to heart failure as confirmed by a cardiologist * Cardiac arrhythmia requiring pharmacological or electrical treatment * Myocardial infarction * Sudden cardiac death or death due to myocardial infarct, arrhythmia or heart failure Asymptomatic worsening of cardiac function defined as: - Asymptomatic decline in LVEF \> 10% points from baseline and/or EF \< 35% corroborated by a confirmatory echocardiogram in 2-4 weeks Planned oncologic therapy is defined as: * In the adjuvant setting: completion of 1 year total of HER2 targeted therapy. If a patient already received part of the planned HER2 targeted therapy prior to enrollment in this trial, planned oncologic therapy will be achieved * In the metastatic setting: cessation of treating regimen due to progressive disease or non-cardiac toxicity or non-cardiac death., Up to 18 months.
Radiation dose estimates of cardiac CT angiographies in daily practice, Assessment after CT scan by radiologist or technical assistant, documented on questionnaire., Baseline
Left Ventricle Global Longitudinal Strain (LV-GLS) assessed by echocardiography, Increasement in left ventricle Global Longitudinal Strain (GLS) of at least 5%, 6 and 24 months after radiotherapy with reference to baseline
Participants With 7 Days Observation Without Severe Bleeding, Blood samples collected at baseline before or after aspirin is given and at 24 hours, 72 hours and 7 days after treatment has been initiated for those that remain
Change in left ventricular mass, measured by MRI scan, 12 weeks
The heart/mediastinal ratio (H/M) at one or two hours post injection of AdreView™ (I-123 MIBG) in neuroendocrine tumor patients is equivalent to the standard 4 hr calculation., Approximately 10 months
atrial fibrillation, occurrence of atrial fibrillation, from inclusion in the cohort up to 10 years|cancer, occurrence of cancer, ffrom inclusion in the cohort up to 10 years
Time ending, 180 days after chemotherapy, 6 months
Estimate the incidence /of Herceptin induced heart failure in our population, To evaluate the reversibility of damage in patients on long term follow- up for a period of up to three years. To identify the applicability of troponin / cardiac natriuretic peptides (CNPS) as bio marker that can predict the occurrence of clinically significant left ventricular dysfunction. To evaluate the role of MRI in identifying patient at risk to develop cardio toxicity. Determine the frequency of elevated Troponin and B-type natriuretic peptide (BNP) in patient receiving adjuvant herceptin., 3 years
Left ventricular ejection fraction (LVEF) change, Left ventricular ejection fraction (LVEF %) will be evaluated using transthoracic echocardiography at baseline and 12 month follow-up. A difference in LVEF\>10% from baseline
Lipid profile, HDL, LDL, Tg, Cholesterol, Novel Lipid biomarkers using blood draws, More than 10 years after testicular cancer diagnosis, At recruitment|Coronary plaque assessment, Coronary calcium score, coronary artery
The primary endpoint is death from any cause or incident, dementia or persistent physical disability., Dementia will be diagnosed based on DSM-IV criteria. Significant physical disability will be defined as a confirmed, and pe
Delta change in left ventricular ejection fraction [LVEF]), Will be a comparison of the average delta change in LVEF from start to six months of therapy between group 1 and 2 via an independent groups t-test or Wilcoxon as a

Ethnic disparities in treatment failure, Identify ethnic disparities in treatment failures for any of the 19 disease states under investigation. The primary outcome is treatment failure, as measured by the discontinuation of a treat
Accuracy of health conditions id'd (interview w/ genetic counselor gold standard. health conditions id'd by VICKY or MFHP id'd by genetic counselor (true +) divided by health conditions captured by genetic counselor (false -
Abnormal Cardiac Outcomes, incidence of abnormal cardiac risk parameters among PCOS women who were apparently cardiac free women, 1 to 3 months
Incidence of postoperative atrial fibrillation, up to 10 days
The primary objective is to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular (LV) remodeling among women with HER2+ early breast cancer., 3.5 years
Number of Participants With Cardiac Response and Non-Response, N-terminal pro-brain natriuretic peptide (NT-proBNP) best response (Response or Non-Response \[Stable, Progression\]) from baseline through 12 months
The composite of cardiovascular death, myocardial infarction (MI) and stroke
To compare CMR with MUGA scans for determining LVEF and LV volumes in breast cancer patients treated with trastuzumab., Five years
Recruitment, The number of participants recruited at the end of rollout and participant experience., Through study completion, an average of 12 weeks|Retention, The number of participants retained at post-rollout end, Throu
Evaluate how the setting of defaults influences the proportion of Veterans selecting comfort-oriented plans of care in real ADs, The primary outcome is the proportion of patients in each of the 3 groups who select a general p
comparison of cardiac fucntion and structure between groups, In DTC group, the investiagtors measured cardiac function and structure by echocardiography at 2009 (receiving TSH suppressive therapy for 5 to 9 years after t
Patients with AF and cancer treated with oral anticoagulant therapy and with other antithrombotic therapy, Number of patients with AF and cancer treated with oral anticoagulant therapy and with other antithrombotic therapy
Concentration of plasma protein F content, the protein F content was measured by turbidimetric assay in automatic biochemical analyzer, six month
Cardiorespiratory fitness, Assessed via cardiopulmonary exercise test and quantified as VO2peak, Baseline to 6-month follow-up (Primary RCT)
Left ventricular ejection fraction (LVEF), Left ventricular ejection fraction measured by echocardiography, Baseline, Change of LVEF from Baseline at 4/6 month (end of chemotherapy), Change of LVEF from Baseline at 6/8 mo
Success of Stellate Ganglion Block, Correct placement of stellate ganglion block as measured by a temperature rise of at least 1 degree Celsius in the ipsilateral hand, day of surgery
number of subjects who successfully complete Rb-82 myocardial PET Imaging assessments, 12-18 months
Evaluation of the cardiac output optimization strategy on the occurrence of postoperative complications, Assessment of the impact of an individualized protocol for optimizing perioperative cardiac flow guided by monitoring
The occurrence of new atrial fibrillation was detected by ECG monitoring, ECG monitor shows atrial fibrillation. To be specific: 1)Irregular R-R interval (when atrioventricular conduction is present), 2) P wave disappearance, 3)
Change from baseline Experiences with IPC initiatives at 3 months, The semi-structured interviews will be used to explore views of patients and family caregivers about their experiences with the integrated palliative care initia * An exploration of problems and needs of the patient * An exploration of the contacts and relationships of patients and family caregivers with professional caregivers * An exploration of satisfaction and perceived deficits in service provision from the perspective of patients and family caregivers * An exploration of the views of patients and family caregivers on collaboration between professional care providers in the care network of the patient., Baseline and Month 3|Change from baseline Quality of care at 1, 2 and 3 Outcomes will be explored in the interviews, see also "Experiences with IPC initiatives", Baseline, Month 1, Month 2, Month 3|Change from baseline Quality of life at 1, 2, and 3 months, Quality of Life will be measured using t Outcomes will be explored in the interviews, see also "Experiences with IPC initiatives", Baseline, Month 1, Month 2, Month 3|Change from baseline Perceived symptoms at 1, 2, and 3 months, Quality of Life will be measured Outcomes will be explored in the interviews, see also "Experiences with IPC initiatives"., Baseline, Month 1, Month 2, Month 3|Change from Perceived collaboration between professional caregivers at 3 months, Quality of Life
Number of Participants Meeting Patient-Caregiver Session and Care Plan Acceptability Criteria, Investigator developed questionnaire investigating acceptability of session intervention and care plan. Items were rated on a 6-p
Dyspnea score at three months after (chemo)radiotherapy, assessed by the patient version of the CTCv4.0, up to 3 months
Complete Continuous Remission, Since all patients receive the same induction, the endpoint will be CCR , i.e. complete continuous remission (the time to failure for any cause among patients achieving a complete response),
Change in QTcF (QT Corrected According to Fridericia's Formula), ΔQTCF (Change in QTcF); EOI (end of infusion); LSM (Least Square Means); PK (Pharmacokinetic(s)). On Day 1 (D1) of Cycle 1 (C1), LSM ΔQTcF should have low difference values, without any clear trend to change with time. Therefore, the upper bound (UB) of the (two-sided) 90%Confidence Interval (CI) at all time points had to be less than the protocol-specified cut-off of 20 ms at each time point. If so, non-inferiority of any ECG time point to ba
Left ventricular (LV) thickness-dimension ratio (LVT-D) derived from echocardiogram, reported in terms of LV posterior wall dimension in systole and LV dimension based on the internal diameter in diastole, Z-scores appropria
Quality of Life - Preparation, Quality Of Life At The End Of Life (the QUAL-E 2009) is a 31 item measure of quality of life at the end of life assessing five domains: life completion, relationship with health care providers, prepara
Left ventricular ejection fraction (LVEF), LVEF on cardiac MR., Three months after treatment has ended.
Opioid and Benzodiazepine use, Number of additional doses of opioids and benzodiazepines used on standard of care days will be compared to additional doses of opioids and benzodiazepines used on standard of care an
Presence of Discussions About End of Life Care Goals/Wishes, Qualitative content analysis of physician-patient encounters regarding presence of any type of discussion about end of life care goals/wishes, immediate
Feasibility of performing a randomized trial comparing two major types of bariatric surgery versus a lifestyle weight loss intervention (LWLI) induced by diet and increased physical activity in moderately obese patients with T2
Incidence of Post-operative Atrial Fibrillation, Number of patients with post-operative atrial fibrillation, 30 days
Heart rate (bpm), Up to 7 months post ADT initiation|Maximal rate of oxygen consumption, Up to 7 months post ADT initiation|Cardiac muscle mass, Up to 7 months post ADT initiation|Ventricular performance assessed by ca
Maximum change of QTc interval, Maximum change of QTc interval from continuous ECG monitoring in lead V5 were collected by using the LabChart software., Before induction of anesthesia in the supine position (Baseline)|
Visual Analog Scale for Stress, Patient and caregiver-reported visual analog scale question to assess subjective stress. Along a 100 mm horizontal line, patient and caregiver indicate their perceived stress intensity. Rating varies from 0 (minimum values) to 100 (maximum value). Ratings of 0 to 4 mm can be considered no stress; 5 to 44 mm, m Scores can range from 10 - 50, with higher scores representing higher levels of positive or negative affect., 45 days: From hospital admission to 14 days after the surgery|The Short Warwick-Edinburgh Mental Well-Being Scal
Frequent blood sampling every 10th minute during an overnight stay in order to measure changes in LH and cortisol pulsatility before and after treatment. A third assessment will be made in those participants who ovulate du
Change in peak volume oxygen - VO2 (L/min), represents the maximum oxygen consumption during incremental exercise that is measured during Cardiopulmonary Exercise test (CPET), being a measure of aerobic capacity o
NT-proBNP perioperative changes, Perioperative change in NT-Pro-Brain Natriuretic Peptide (NT-proBNP) levels in patients undergoing pulmonary resection. Cutt-of values will be NT-proBNP ≥ 300 pg/ml pg/ml, Change from
statins use at discharge, Proportion of statins prescription at discharge among eligible patients, 14 days on average (during hospitalization)
Enrollment rate among participants approached, Up to 1 year|Retention rate among participants enrolled, Retention is defined as completion of patient questionnaire and in-person assessment after 4-month intervention, Up
Changes in mechanical ventilation, The total duration of postoperative ventilation in days, Baseline and after two weeks
Efficacy of Active Breathing Coordinator (ABC) Device as Determined by the Mean Apical Perfusion Score, Efficacy of the ABC device in protecting the heart from radiation (XRT) damage in patients with L breast cancer is det
Change in fruit and vegetable intake from baseline at 20 weeks, 6 24-hour diet recalls will be collected at random, Measurements will occur during weeks 1-2 (3 random recalls) and weeks 18-20 (3 random recalls)|Change in
Whether the administration of nicotinamide riboside can prevent the reduction in left ventricular systolic function measured by cardiovascular magnetic resonance (CMR), compared to placebo., Change in left ventricular eject
Cardiac Saftey, LVEF by Muga scan, Baseline-18 months
Seattle Angina Questionnaire, The Seattle Angina Questionnaire is a cardiac disease-related quality-of-life measure with 19 items. A lower score corresponds to a lower level of functioning. The scores are classified as "minim
The incidence of postoperative myocardial injury, the elevation of plasma high sensitivity cardiac troponin I (hs-cTnI) caused by myocardial ischemia or injury (exclude other causes such as sepsis, pulmonary embolism, atrial
Part 1: Safety and tolerability of GSK2118436 as assessed by changes in physical examination findings, Safety and tolerability parameter will include a complete (head, eyes, ears, nose, throat, skin, thyroid, neurological, lung
The primary objective of this study is to define 10-year CHD risk according to Framingham risk score in postmenopausal early breast cancer patients who are taking aromatase inhibitors as an adjuvant treatment., 1 visit
Physical Capacity - Peak oxygen consumption (mL/kg/min), Oxygen consuption in crescent effort will be calculated by aggregation of volume (mL), body weight (Kg) and time (minutes)., 4 months
Cardiovascular risk factors, lifestyle, and drug adherence, Within 2 years after study inclusion
Initiation or broadening of antibiotic for the purpose of treatment of infection, Patients are monitored for a period of up to 10 days or until their white blood cell count goes up, which could take an expected average of 20 days
myocardial deformation indices as measured in percentage (change of original length), up to 2 years
Major bleeding, Death or a decrease in hemoglobin level of ≥ 2 g/dL over 24 hours or the need for transfusion of ≥ 2 units of packed red cells or clinically overt bleeding at critical site (eg, intracranial, retroperitoneal), 6 month
Number of patients with decreased myocardial function assessed by echocardiography, Number of patients with a decrease in the mean strain or strain rate measured from the echocardiography of the order of 5% between t
Cardiac Event after 3rd and 6th course of CHOP(-R), Basically 14-21 (at a maximum 28) days after the start of 3rd and 6th course of CHOP(-R).
Change in Myocardial Blood Flow - 24 months, Change in myocardial blood flow will be measured by adenosine CMR imaging. Comparisons will be made using longitudinal mixed models to examine within- and between- gr
Mastery of breathlessness (CRQ mastery subscale), Change from baseline in Mastery of breathlessness (at week 8) measured with the Chronic Respiratory Disease Questionnaire (CRQ) in a face-to-face interview. Mastery re
Assessment of the incidence of cardiovascular events during the first three cycles of therapy with capecitabine or 5-FU, 24 months
Myocardial extracellular volume (ECV), Cohort A, Change from baseline to 3, 6, 12,and 24 months|Myocardial extracellular volume (ECV), Cohort B, Change from baseline to prior study entry, 12 and 24 months post study ent
The change of LVEF measured by echocardiography, The differences between the two groups in the difference of LVEF measured by Echocardiography at the end of the experiment compared to that at the baseline., At the e
Elevation in cardiac biomarkers by measuring cardiac troponins (troponin T and troponin I), BNP, and CK-MB., 4 Time Points: within 1 week prior to radiation therapy (RT), within 1-3 days of RT completion, and at 1 and 3 mo
Overall survival, All cause mortality, 2 Years|Change in Left Ventricular Ejection Fraction, Change from baseline, evaluated by cardiac MR, Baseline, at 6, 12 and 24 months.|Number of participants with treatment related adver
Changes in EKG parameters prior to, during or after radiation therapy., Changes in QRS wave form will be categorized as 'present' or 'absent' based on the presentation (or lack) of a r' wave, or notched r or s wave on the EK
Documentation of goals of care, Presence or absence of documentation of goals of care discussions in the patient's electronic health record during the current hospitalization, At hospital discharge, an average of 2 weeks

Degree of damage to the coronary arteries as measured by MDCT, 5 to 15 years
Differences in instantaneous ANI (ANIi) values during bradycardia versus ANIi values when Remifentanil effect size concentration >6ng/mL, ANI, HR and Remifentanil effect site concentration were continuously recorded with
p53 target gene expression, The primary endpoint of this study is p53 target gene expression measured by RTPCR for the following five SNPs: p53 rs1042522, MDM2 rs2279744, FLT1 C-677T, TLR8 rs3761624 and RMM1 rs
Change in left ventricular ejection fraction (LVEF), a decrease in LVEF of ≥10 percentage points from baseline to a value of \< 50% OR a decrease of LVEF by ≥ 5 percentage points from baseline to LVEF \<50% for patients w
hs-Troponin T (hs-TnT) levels, Biomarker of myocardial injury using high-sensitivity Troponin-T for above time points as serial measurements., at baseline, at 3-24 hours after end of infusion of each chemotherapy cycle, then a
difference in LVEF (Left Ventricular Ejection Fraction), we will compare LVEF (LVEF 1) measured before treatment with adjuvant Trastuzumab and concomitant Radiotherapy of breast/thoracic wall with LVEF (LVEF 2) measured
This study is to see if MRI techniques can be used for early evaluation of cardiac amyloidosis which is sometimes seen in individuals with multiple myeloma., The time frame is five additional minutes & three additional images
Relative telomere length, The ratio of RTL to hemoglobin contents was calculated for each sample from standard curves. After that, the ratio for each sample was normalized to a calibrator DNA in order to standardize betwee
Adjudicated Cardiovascular events during fluoropyrimidine chemotherapy, Defined as: * Types 1-3 myocardial infarction with troponin \>99th percentile upper limit, * Incident myocardial ischaemia (chest pain with new inducible perfusion abnormality on perfusion cardiac MRI, --Myocarditis (diagnosed as per ESC Consensus statement * Incident heart failure diagnosis (symptoms with NTproBNP \>400pg/ml or HF hospitalization), * Incident arrhythmia (excluding isolated ectopy) or sudden cardiac death., 12 months
Proportions of late enhancement in patients with LV dysfunction as Herceptin ® and in a control group consisting of patients who did not have LV dysfunction after 6 months under the same treatment., A cardiac MRI is consi The primary endpoint is the proportion of delayed enhancement in the LV dysfunction group and the control group., 2 years
accurately identifying asymptomatic coronary artery disease, to determine whether Ct coronary angiography as a screening method acuurately identifies asymptomatic coronary artery disease in a high risk poulation (HL surv
The rate of no cardiac events during chemotherapy, Adverse events (AEs) and laboratory tests graded according to the NCI CTCAE (version 4.0) .No cardiac events were defined until all relevant indicators (Electrocardiograph
Patient-provider communication, Single measure, video recording of medical consultation lasting approximately one hour
Proportion of participants with changes in cardiac function., A change in cardiac function may include shifts from baseline measures of LV mass, strain, ejection fraction, and late gadolinium enhancement., 1 year after compl
Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment, 6 months
To investigate the correlation of post-RT cardiovascular effects with myocardial Tl-201 myocardial perfusion images, By literature reviewing, cardiovascular functional status in patients received helical tomography has not bee
The Investigators will compare the incidence of newly diagnosed AF identified by screening versus usual care, To compare the incidence of newly diagnosed AF with point-of-care screening using a mobile, single-lead ECG v
Number of Participants Who Developed Non-Melanoma Skin Cancer (NMSC), Baseline until non-melanoma skin cancer diagnosis, loss-to-follow-up due to death or termination of the health plan or end of the study, assessed
Incidence of Perioperative Cardiac Arrhythmias Evaluated by a Continuous ECG Holter Monitoring in the Perioperative Period, The investigator evaluates the incidence of cardiac arrhythmias, the type of arrhythmias and whe Arrhythmias observed: tachycardia \>100 bpm bradycardia \< 50 bpm pause (P-P interval \> 2 seconds) ventricular extrasystoles (VE) \> 1000/ 24 hours supraventricular extrasystoles (SVE) \>200/24 hours, 60 months
Changes in Heart rate variability according to the types of pituitary adenoma, 5 month of initial recruit
Proportion of patients with new documentation of family history in EMR, The proportion of patients with new documentation of family history in the EMR within 30 days after the visit, compared to patients in control group pra
Evaluate for evidence of changes in cardiac function measured by cardiac MRI prior to and following external beam radiotherapy who are receiving moderate doses of radiation to the heart., Baseline and 2 years|Evidence of
The elasticity parameter will be for each patient the median of ten ARFI values (m/s) in the right liver., One or two 30 min visit according to the patient group
Assess accessibility and feasibility, including positive and negative aspects of integrating predictive genomics at the clinic focusing on patients' and physicians' attitudes, March 2008-March 2009
Prevention of systolic dysfunction in patients undergoing chemotherapy with anthracycline. Systolic dysfunction is characterized by a 10% drop in ejection fraction of left ventricle., 96 weeks
Explore the characteristics (incidence and nature) of significant heart rhythm disturbances in subjects with cardiac amyloidosis by means of implantable cardiac monitor (ILR), Primary outcome measure is the presence of any
complication, any one of arterial puncture, hematoma, pneumothorax, hemothorax, during central vein catheterization and operation day
Biospecimen & Clinical Data Collection, To collect enough biospecimens and associated clinical data to allow researchers to come to statistically relevant scientific results, 10 years
Perceive of low dose aspirin, Using qualitative interviews to assess how patients and physicians perceive the benefits and risks of low-dose aspirin for the prevention of cardiovascular disease (CVD) and colorectal cancer (CR
Changes in cardiac perfusion, Cardiac perfusion will be assessed using SPECT cardiac perfusion scans pre- and 6 months post-radiation. Any post-radiation summed-rest score (SRS) \> 0 will be counted as a perfusion defe
To Investigate Whether Ivabradine Lowers Resting HR, Compared To Placebo, In Survivors Of Lymphoma, Calculate the change in resting HR (from Holter monitor data) from baseline to 6 weeks for each patient in the study. T
Factors associated with an increased rate of fatality among reports with an immune-related adverse event (irAE)., Reports with a fatal outcome will be compared to reports with no fatal outcome. Odds ratio will be calculated f
Prevalence of solid tumors in RASopathies, To detect prevalence of solid tumors in monocentric cohort of RASopathies, 5 years
gastroesophageal reflux disease questionnaire, To assess the severity of GERD, four weeks
Drop in ejection fraction within 12 months of starting treatment., Drop in ejection fraction\> 10% to values less than 50% of the left ventricle, 12 months|Cardiac events within 12 months of starting treatment., Cardiac events
Left Ventricular dysfunction, defined as a reduction in Left Ventricular Ejection Fraction of more than 10 percentage points from baseline and to less than 50%., 1 year
Combined apparition of hard cardiovascular events (myocardial infarction, revascularization, ischemic stroke, documented peripheral artery disease or cardiovascular death) after a median follow-up of 7 years., Combined ap
Cardiac Events, A cardiac event was defined as a decrease in left ventricular ejection fraction (LVEF) of \>=20 points from baseline if the resting LVEF remained in the normal range, or a decrease of \>=10 points if the LVEF be
mortality and morbidity due to the following conditions: coronary heart disease, stroke, breast cancer, ovarian cancer, other cancer, hip fracture and death from all causes., 28 years
Overall Image Quality Scores, Overall image quality scores obtained from the two imaging modalities will be compared with the hypothesis that hybrid PET-MRI images is as good as PET-CT images or superior (not inferior) to
Primary objective, Comparison of the accuracy of radiologist and Carebot AI CXR image assessment., 20-10-2022
Incidence of atrial fibrillation within 90 days of colorectal cancer surgery, defined as ≥30 seconds of atrial fibrillation identified on a 24-hour cardiac monitor OR absence of p waves and irregularly irregular rhythm on an electro
Percentage of patients with a change in cardiac condition, Percentage of patients with at least 5% change in cardiac arrhythmia (outcome 2) and/or at least 5% change in fibrosis (outcome 3) and/or at least 5% change in her
CMR T2 mapping, To assess the role of myocardial oedema on CMR (T2 mapping) after radiation therapy and cardiotoxic systemic therapy in predicting the incidence of cardiotoxicity, defined as by consensus guidelines* (d
Coronary plaque volume in major coronary arteries (i.e. left anterior descending, left circumflex, right major coronary arteries), Using cardiac computed tomography angiography (CCTA), coronary plaque volume will be determ
Safety assessment: National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTACAE) v3.0|Efficacy: tumor evaluations every three (q 3) cycles
Cardiac Function (stroke volume or ejection fraction), Cardiac function during/following treatment in breast cancer patients., At completion of treatment, an average of 13 months|Cardiac Rhythm (heart rate variability), Cardiac
Incidence of symptomatic congestive heart failure\n(CHF) using New York Heart Association class II, III and IV, and cardiac death, On treatment and up to 5 years follow-up
Left ventricular ejection fraction (LVEF), Change in LVEF (3-dimensional and 2-dimensional) at time-frame, at months 6,9,12,24|Global longitudinal strain (GLS), Change in GLS at time-frame, at months 6,9,12,24
Insulin resistance (HOMA-IR), HOMA-IR as calculated by formula using insulin and blood glucose, Baseline
Prevalence of AU and its severity., Day 1
Change from Baseline in Systolic Blood Pressure, 6 Months
Severe asymptomatic cancer-therapy related cardiac dysfunction, Left ventricular ejection fraction reduction (LVEF) to \< 40% ., Up to one month after the first cycle of chemotherapy treatment|Moderate asymptomatic cance * Second-degree atrioventricular block; not all P-waves are followed byQRS complexes. Second-degree atrioventricular blockMobitz type I- this manifest on the ECG as gradual increase of PR interval before a block of QRS complexes occurs. Second-degree atrioventricular blockMobitz type II-the block of QRS complexes occurs without gradual increase of PR interval. • Third degree atrioventricular block- on the ECG P-waves have no relation to the QRS complexes., Up to one month after the first cycle of chemotherapy treatment|Chemotherapy-induced QTc interval prolongation:, QTc\> 5
Effect of treatment in Left Ventricular Function, Left Ventricular Function is assessed by calculating Ejection fraction by 3D echocardiography., 2 years|Effect of treatment in left ventricular function, Left Ventricular function is a

Reduction of cardiotoxicity in the R-COMP arm versus R-CHOP, Study duration
Exercise capacity based on cardiopulmonary exercise testing, Online VO2 maximum, after 6-month cardiac rehabilitation program
Change in cardiac iron load and cardiac ejection fraction by MRI recorded at baseline and after 53 weeks., 12 months
change in ejection fraction, Doxorubicin related cardiotoxicity will be assessed through :Echocardiography at baseline, Before starting the first chemotherapy cycle (baseline), after the last AC cycle (for assessment of N-termi
Acceptance of the preoperative palliative counseling offer, Percentage of patients who accept the palliative counseling offer in relation to the total number of patients identified in the screening of the anesthesia outpatient clin
Length of postoperative hospital stay, Through study completion, an average of 2 days
Coronary Artery Disease, 2009|Arteriovenous Malformation, 2009
Significance ofTRPC6 coding sequencing, Will compare the prevalence of rare missense variants in our cases against the null hypothesis to assess the significance of TRPC6 coding sequencing data in patients with dox-indu
Percent change in N-terminal pro B-type natriuretic peptide (NT-proBNP), Baseline to 6 months
composite of measures of organ uptake, maximum target-to-background ratio and maximum standard uptake value as standard with FDG PET for maximum image quality for all standard protocols., The mMR is a FDA-appro
Analysis of disproportionality of reports for cardiotoxicity associated with abiraterone as compared to enzalutamide by performing a case- non-case study, Analysis of disproportionality of reports for cardiotoxicity associated
3D LAD mean dose vs 4D LAD mean dose, To determine if the mean LAD (left anterior descending artery) dose significantly changes statistically between an usual 3D CT scan versus a 4D CT with breathing motion monitorin
Based on stastical test with 95% confidence intervals, to evaluate if there is a significant difference between 4D CT LAD mean dose and 3D CT LAD mean dose., 1 week
Cardiovascular disease, Incidence of cardiovascular disease, Annually between March 1984 and December 2052|Carotid atherosclerosis, Progression of common carotid artery - intima-media thickness (CCA-IMT), From bas
symptom burden (IPOS), Change from baseline in palliative care needs and specific symptoms (at day 7) assessed with the Integrated Palliative Care Outcome Scale (IPOS). The IPOS includes 10 symptoms and 7 questions
Chemotherapy induced cardiomyopathy, Primary efficacy endpoint: Cardiomyopathy is defined as the LV longitudinal strain value, an echocardiographic index, and the incidence rate of cardiomyopathy between the experime
- When the strain value of the longitudinal axis of the left ventricle (LV global longitudinal strain) decreases to less than -17.5% or reduction of \>15% compared to the baseline value., 3months, 6months
Change in cardiac function after DOX therapy with or without sulforaphane through diagnostic studies, 2D Echo will be used to measure cardiac function amongst patients on DOX therapy who are exposed to sulforaphane o
Development of cardiomyopathy, Decrease in fractional shortening below normal (\<28%), Within 5 years after receiving anthracyclines.
first recurrent atherosclerotic cardiovascular disease event (rASCVD), composite outcome including non-fatal MI (I210-I214, I219, I220, I221, I228 or I229) or coronary heart disease death (CHD) (I210-I214, I219, I220, I221, I22
The PedsQL Healthcare Satisfaction Generic Module, The PedsQL Healthcare Satisfaction Generic Module is composed of 24 items comprising 6 dimensions. Item scaling: 5-point Likert scale: 0 (Never) to 4 (Always) and No
Primary endpoint is the results of clinical, imaging and laboratory assessments., Results of clinical, imaging and laboratory assessments, ongoing
Complete blood count, To model pharmacokinetics of \[64Cu\]FBP8 metabolism in healthy volunteers., 36 hours|Target to Background Ratio LAA, To determine the signal threshold of \[64Cu\]FBP8 that produces the highest a
Global longitudinal strain by two dimentional speckle tracking., Change in outcome from initiation of trastuzumab treatment and after 3,6, and 9 month.|Ratio between the mitral E velocity and early diastolic maximum global s
Descriptive qualitative analysis of patients' preferences, values and motivations that would influence the use of an online self - management intervention for chronic breathlessness (SELF-BREATHE)., Qualitative data, 12 mon
Medication use, The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject., Week 0|Medication use, The number of subjects in which m
Proportion of patients reporting at least one non-ideal or missing CVH topic, Discussion of non-ideal cardiovascular health (CVH) factors (yes or no). CVH discussions will be defined as patient-reported discussions with their
Evaluate the efficacy of pasireotide twice daily subcutaneous injections for normalizing 24 hour urine free cortisol in patients with ectopic ACTH-producing tumors, Effectiveness of pasireotide as measured by 24 hour urine fr
Cardiac biomarker levels in predicting cardiac dysfunction, End of trial|Development of a predictive model for use based on the most accurate and sensitive combination of biomarkers, End of trial
Determination of the rates of acute and late toxicities (acute and late adverse events) resulting from proton therapy radiation treatment., 5 years
Prevalence of regurgitation (graded as mild, moderate, severe) at any cardiac valve., 9 months
Presence of physical health problems, For example: presence of hypertension, diabetes mellitus, hypercholesterolemia, scoliosis, sleep apnea, hypothyroidism, obesity, psychosis etc., 1 year|Laboratory values, For example:
Angiomyolipoma Response Rate as Per Central Radiology Review, Angiomyolipoma response defined as the combination of the following criteria: reduction in angiomyolipoma volume of ≥ 50% relative to baseline, where an
For the everolimus (core/extension periods) treatment group, the baseline means the latest value on or before starting everolimus., From date of randomization until the earliest date of first documented AML progression, date
Primary Outcome Coronary calcium (CAC), Coronary calcium (CAC) assessment and its relationship with left-side or right-side breast radiation therapy and previously known cardiovascular risk factors. The quantification of C
Incidence of Left Ventricular (LV) Dysfunction, LV dysfunction, defined as a decrease in LV ejection fraction of at least 10% to less than or equal to 53%, 6 months
Myocardial ECV, - To determine if a novel cardiac magnetic resonance-based index, the extracellular volume fraction (ECV), of myocardial fibrosis is altered early after doxorubicin-based chemotherapy., 2 Years
Event Free Survival
Number of Participants With AntiCancer Drugs-Related Cardiac Adverse Events during the follow-up, 2 years
Subject Retention Percentage, This is a feasibility study designed to determine the extent to which eligible patients can be successfully recruited, randomized, and retained. Endpoint data will be used to justify and provide po
Incidence of Cardiac Complications in Participants on Phase I Protocols, Data review of studies, active between January 1, 2006 and December 31, 2009, who included ECGs in their safety evaluations. Use of identification a
Left ventricular ejection fraction (LVEF), Maximum change in LVEF, at months 3,6,9,12,18
Recruitment/Attendance/Drop-Out Rates, 1 Year
To determine whether endothelial dysfunction as measured by abnormal flow mediated dilation (FMD)., Identifies patients at high risk of cardiovascular complications after major thoracic or abdominal cancer surgery., 1 year
Incident (non-)fatal (cardiovascular) diseases, Up to 13 years of follow-up, in hazard ratios
QTc interval, 2-4 days postdose
Part I / Proof of Concept (PoC): Number of Participants Evaluated for Imaging Feasibility, The feasibility of imaging apoptotic activity using 99mTc-rhAnnexin V-128 was assessed in the first 10 patients who enrolled and comp
LV systolic dysfunction, LV systolic dysfunction was defined as following; 1. An EF unit drop of ≥10% from the baseline available echocardiogram or 2. Change in strain or strain rate : drop(decrement) corresponding to ≥1 SD of the relevant parameter assessed at the baseline available echocardiogram, 3-month F/U
Right ventricular ejection fraction, The primary objective of this study is determine whether RVEF falls post-operatively in patients undergoing lung resection. The primary outcome is RVEF at 3 days post-lung resection compa
Imaging measurement of potential cardiac muscle injury markers before and after cumulative anthracycline exposure., This study will serially evaluate imaging tests in previously untreated patients with osteosarcoma, Ewing's
The number of patients with successful implantation of the TRICENTO bioprosthesis, with a 35% change (reduction) in the V wave pressure in the Inferior Vena Cava (IVC), measured pre intervention and immediately after the
Social Validity and Acceptability, A social validity measure will be completed to better understand to inquire about family satisfaction with aspects of the intervention including curriculum, timing, goals targeted, and perceived
Enrollment target of 10-15 families 80% retention rate with at least 75% completing the 20 sessions across Phase 1 and Phase 2, Completion of Phase 1 (approximately six months of age)|Fidelity, Overall intervention fidelity
Enrollment target of 10-15 families 80% retention rate with at least 75% completing the 20 sessions across Phase 1 and Phase 2, Completion of Phase 2 (approximately twelve months of age)
Dexmedetomidine on heart-rate corrected QT(QTc) interval, QTc intervals (msec) are recorded from pre-induction until 60 min after the end of pneumoperitoneum, From pre-induciton until 60 min after the end of pneumoperit
progression-free survival, Progression-free survival is defined as time from randomisation to the first occurrence of progression of disease or death from any cause within 63 days of last response assessment or randomisatio
Evaluation of Intervention Effectiveness - Change in Self-Management outcomes, Health Education Impact Questionnaire (HeiQ). Score: Reliable improvement, T1: Initial evaluation; T2: after 4 months; T3: one year after T2; T
the occurrence of cTn elevation above the threshold in use at the local laboratory, at any time during the study, To assess whether enalapril administered concomitantly to anthracyclines (AC) containing treatments can prever
Cardiac toxicity is measured on the basis of cardiac troponin levels., up to 1 year after the completion of the anthracyclines containing chemotherapy.

Diagnostic performance of AI-ECG for left ventricular ejection fraction (LVEF) < 50%, Determination of the sensitivity, specificity, positive and negative prediction value as well as area under the curve for receiver operating cha
Establish a DNA and tissue bank., 5 years|Determine candidate genes for PHACE syndrome using a genome-wide approach., 10 years
Accuracy of markerless tracking, Proportion of markerless tracking within 5 mm of the ground truth for each of nine anatomical sites (cohorts), 3 years
hospital length of stay, The perioperative hospital length of stay is assessed., a period of 60 days
Evaluation of Intervention Effectiveness - Change in Self-Management outcomes, Health Education Impact Questionnaire (HeiQ). Score: Reliable improvement, T1: Initial evaluation; T2: after 4 months; T3: one year after T2;|E
Baseline Troponin, A haemogram will be carried out to analyse patients' Troponin I and T to detect their cardiotoxicity levels. Troponin results will be reported in ng/L., At baseline|After intervention Troponin, A haemogram will
Evaluation of the cardiac uptake of 18F-FDG, Evaluation of the cardiac uptake of 18F-FDG measured on Day 42 of the administration of ATCs to identify at 1 year the patients at risk of occurrence of a LVSD defined by a drop
Assess the feasibility and acceptance of continuous remote cardiac monitoring, In post-operative patients with respect to recurrence of post-operative atrial fibrillation upon discharge., 4 to 6 weeks
Reach of the study as measured by the number of participants who agree to participate in the study out of the total eligible participants, Completion of the study (estimated to be 27 months)|Reach of the intervention bundle a
Change in incidence of cardiac toxicity, defined as reduction in LVEF of >= 10% compared to baseline LVEF and EF =< 50% on the follow-up scan, assessed using MRI, In addition to point estimates of these rates, 95% conf
Enrollment rate (Feasibility), Ratio of patients screened and patients that signed informed consent, week 6|Study completion rate (Feasibility), Ratio of patients who signed the informed consent and filled out the final assessm
Objective Image quality analysis, Calculating image noise as measured by standard deviation (SD) in a region of interest., 20 minutes|Objective Image quality analysis, Calculating contrast-to-noise ratio (CNR), 20 minutes|Sut
LVEF results, Changes in LVEF results compared to baseline (by echocardiography or MUGA) throughout the course of trastuzumab based therapy, at year one
Postoperative electrocardiographic p-, R-, and T-wave amplitude changes, Amplitude changes in the 12-lead rest electrocardiography in millimeters, analyzed daily postoperatively., 2 weeks|Postoperative QRS-duration, The
Late cardiac toxicity, The primary objective of this study is to compare the incidence of cardiac events \[(defined as asymptomatic systolic dysfunction (LVEF \< 50%, asymptomatic NYHA I) or symptomatic heart failure NYHA
QUAL-E - Preparation Sub-scale, Quality Of Life At The End Of Life (the QUAL-E 2009) is a 31 item measure of quality of life at the end of life assessing five domains: life completion, relationship with health care providers, pr
Occurence of cardiac toxicity in patients with breast cancer receiving anthracycline chemotherapy, 1 year
ECG interval change, 24 hours
Heart rate variability, Heart rate variability, 5 min after microcatheter enters ophthalmic artery
Change in Left Ventricular Ejection Fraction (LVEF), Absolute change in LVEF by echocardiogram at follow-up, through study completion (expected to be 15 years)
Patients survival, Patients survival in days, 2 years
Relationship between Blood pressure group and comorbidities, Blood pressure group: 1) Essential arterial hypotension, 2) normotension and 3) Essential arterial hypertension.
Comorbidities: As describe in the protocol, as a summary: 1) cardiovascular, 2) metabolic, 3) Endocrine, 4) psychiatric disorders: depression and panic disorder, 5) orthostatic intolerance: neurally mediated syncope, vasovag
Cardiovascular mortality Total mortality, A 7-year prospective study|Relationship between adaptability group and comorbidities, Adaptability group: Hyper adaptable, normal adaptability, hypo adaptable. Comorbidities: As de
Cardiovascular mortality Total mortality, A 7-year prospective study|Relationship between blood pressure group, adaptability group and comorbidities, Blood pressure group: 1) Essential arterial hypotension, 2) normotension
Adaptability group: Hyper adaptable, normal adaptability, hypo adaptable. Comorbidities: As describe in the protocol, as a summary: 1) cardiovascular, 2) metabolic, 3) Endocrine, 4) psychiatric disorders: depression and pan
Cardiovascular mortality Total mortality, A 7-year prospective study
Left ventricular Ejection Fraction (LVEF), To determine if statins preserve the LVEF at 12 months, 12 months
Echocardiogram marker measurements pre ABC chemo and post ABC, •Measure echocardiogram markers on pre anthracycline based chemotherapy (ABC) and post ABC echocardiograms, using standard echocardiogram
Mean high sensitivity C-reactive protein (hsCRP), Once, at first clinic visit|Mean fibrinogen, Once, at first clinic visit|Mean CEC surface expression of vascular cell adhesion molecule-1 (VCAM-1), Once, at first clinic visit|Mean
Completion of surveys, Participant will self-complete surveys to collect psychological and knowledge outcomes, Baseline survey prior to disclosure of results, and then two post-disclosure surveys at 2-7 days and 6 months
skin and cardiac toxicity, 24 months post RT
Predictors of cardio-toxicity in female patients with breast cancer exposed to trastuzumab +/- previous anthracycline agents, Identification of heart-related side effects of chemotherapy and trastuzumab using echocardiogra
Prevalence of cardiac dysfunction, Conventional echocardiography: left ventricular ejection fraction (%), Baseline and longitudinal follow-up where clinically indicated|Prevalence of cardiac dysfunction, Speckle tracking echo
Adverse Events (AEs), Number of participants with adverse events, 3 years
derive iPSs from skin fibroblasts, described by Yamanaka et al with modification using the Millipore STEMCCA excisable polycystronic lentivirus reprogramming kit.2, 1 day
Incidence rate of cardiotoxicity, Cardiotoxicity includes death from cardiac cause, severe congestive heart failure (New York Heart Association Class III or IV), more than 10% decrease of left ventricular ejection fraction (LVEF)
Change in cardiovascular fitness (as assessed using VO2max) between baseline and after 12 weeks of participation in a tapered 12-week cardiac rehabilitation program., Change in cardiovascular fitness will be based on end
Increase in level of hs-TnT >= 5ng/L, Baseline up to end or chemoradiation (CRT), up to 24 months|Incidence of grade >= 2 cardiovascular events, Defined by Common Terminology Criteria for Adverse Events version 5.0., W
Proportion of tested patients, The proportion of patients who undergo testing within one month of initial contact (automated call vs text messaging) and by the end of the study period (to consider individuals who could not co
Standard 12-lead ECG, To be obtained during SLIFE Human Performance Lab appointment. Participant will receive a resting (supine) 12-lead ECG using a GE Mac 2000 Resting ECG System (General Electric Healthcare, Mil
Number of goals of care conversation notes completed among clinicians, Number of goals of care conversation notes completed among clinicians in both stages of the SMART., 6 months in Stage 1, 9 months in Stage 2
Major adverse cardiovascular events, Composite endpoint of All-cause Death, Myocardial Infarction, Stroke and Myocardial Revascularization, 30 days|Total Atherosclerotic burden and lesion complexity on angiography, The
Global Longitudinal Strain (Left Ventricle), \>5 Absolute drop or 12% Relative reduction from baseline, Baseline, 1 and 12 weeks after Treatment
Concentration of Troponin I, troponin T, hypersensitive troponin, brain natriuretic peptide and NT-proBNP, These levels are measured with the Siemens ADVIA Centaur XP Immunoassay System, normal ranges of Troponin I, tr
Adverse drug reactions induced by ICIs and reported in the World Health Organization (WHO) or the Base Nationale de Pharmacovigilance (BNPV), Identification and report of cases of adverse events associated with ICIs. Dr
Left Ventricular Systolic Dysfunction, To define the prevalence of left ventricular dysfunction in patients who received trastuzumab chemotherapy at least 5 years previously, Through study completion, on average <2years.|Re
Number of bowel movements (BMs), The change from baseline in the number of bowel movements (BMs) per day, 43 months after first patient in
The incidence of chemotherapy induced cardiomyopathy in breast cancer patients with cardiovascular risk, the incidence, two year follow-up|The kinetics of global longitudinal strain (GLS) in breast cancer patients treated by
Recurrent AF/AFL episodes, Any recurrent episodes of AF/AFL lasting ≥2 minutes identified in ICM monitoring, 1 year
The changes of the echocardiographic indices, pulmonary blood flow = PVA(cross sectional area of LUPV) x VTI(velocity time integral) x HR , Fractional area change = \[(LVAd-LVAs)/LVAd\] × 100 Ejection fraction = \[(LVEDV(L
Survival at day 14, Survival at day 14 in patients weaned from NIV and or HNFC-O2, day 14
Single wave measure of insulin resistance (delta omega) and markers of inflammation, The agreement of the single wave-based ejection fraction (EF) to EF measured by 2-dimensional (2D) echocardiography will be estimated

Sensitivity and accuracy of detection of patients with myocardial dysfunction who necessitate cardioprotection during cancer treatment using MyoStrain compared to standard of care (SOC) as measured by left ventricular ej
-. Considering many patients will have a complex management of cardioactive medications as well as cancer treatment regimen, the classification of cardiotoxicity status will be based on a clinical committee to designate wh
-. Considering many patients will have a complex management of cardioactive medications as well as cancer treatment regimen, the classification of cardiotoxicity status will be based on a clinical committee to designate wh
-. Considering many patients will have a complex management of cardioactive medications as well as cancer treatment regimen, the classification of cardiotoxicity status will be based on a clinical committee to designate wh
-. Considering many patients will have a complex management of cardioactive medications as well as cancer treatment regimen, the classification of cardiotoxicity status will be based on a clinical committee to designate wh
Change in left ventricular systolic function quantified by left ventricular ejection fraction and global longitudinal strain by transthoracic echocardiography, Fall of 10 absolute percentage points of left ventricular ejection fractio
Cumulative incidence of new relevant medical events, Relevant medical events are defined as any new medical condition significantly impairing normal daily activities or requiring hospitalization or needing specific and perma
Left ventricular strain, Spectral Doppler measure with General Electric software analysis of global longitudinal strain., 12 weeks
Objective response rate (ORR) in the SOT or HCT cohort, 2 years
Tolerance for Human Immune Globulin Intravenous (IGIV), as Reflected by the Number and Severity of Toxicity Incidents Occurring in Ten Patients Receiving at Least One Infusion of IGIV., Up to 1 year|Clinical Response of Pa
primary efficacy outcome, the proportion of participants completing trastuzumab, pertuzumab, or trastuzumab-emtansine (T-DM1) as planned at its initiation, one year|co-primary safety outcomes, 1. LVEF at the close-out vis 2. The composite of NYHA class III or IV heart failure or cardiovascular death., one year
Cardiotoxicity, Number of participants with anthracycline related cardiotoxicity as defined by the British Society of Echocardiography and British Cardio-Oncology Society guidelines, 2 years
Left ventricular ejection fraction (LVEF), LVEF is an assessment of left ventricular global systolic function., 5 years
Detection of Imaging Biomarkers of acute cardiac inflammation, 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG)-PET imaging to detect increase in cardiac inflammation compared to baseline with corresponding b
Cardiac ischemia/necrosis, 30 days|Venous thromboembolism, 30 days|Pulmonary embolism, 30 dyas|Myocardial infarction, 30 Days|Cerebral vascular event, 30 days|Death, 30 days|Transient ischemic attack, 30 days|Surgic
Total clinician-reported medical errors, Collected via a survey of admitting clinicians 48-72 hours after patient transfer., Up to 72 hours after transfer
arrhythmogenic cardiac effects of BTKi and sudden death within the first 12 months of BTKi therapy, 1. Clinically significant cardiac arrhythmias while on a BTKi (treatment emergent in those without a history of arrhythmias a
Time to Tunneled Pleural Catheter Removal, The time (in days) between Tunneled Pleural Catheter (TPC) placement to eventual removal within 6 months, 0-6 months
Proportion of therapy-related clonal hematopoiesis (t-CH) for patients with cardiovascular disease (CVD) after Hodgkin Lymphoma therapy, The proportions will be compared with one-sided Fisher's Exact Test with normal ap
Proportion of patients who have enrolled in the pre-habilitation program, A patient will be considered to have optimally adhered to the program if she performs at least 2/3 of the proposed cardiac coherence sessions (that rep
Left Ventricular Ejection Fraction, 6 years
Change the functional variants in genes involved in doxorubicin pharmacology with doxorubicin-induced cardiomyopathy in adult breast cancer survivors., Identification of genetic variants that are associated with higher risk
Change in endothelial function after ischemia/reperfusion injury, Compare the effects of euglycemic/hyperinsulinemic, hyperglycemic/hypoinsulinemic and hyperglycemic/hyperinsulinemic on endothelial reactivity, measured b
Describe physical activity profiles in breast cancer patients under 70 years of age treated by neoadjuvant chemotherapy, The activity tracker will register step counts for each day. the investigators will plot the average daily st
Safety outcomes, The primary safety outcome will be the development of cardiac dose-limiting toxicity (cDLT), defined as the occurrence of any of a)cardiovascular death, b)left ventricular ejection fraction (LVEF) \<40% toget
Accuracy of the Simplified Screening Tool (SST) with respect to the SIAARTI/NCCN screening tool (EST), BACKGROUND: The aims of this study were to evaluate the feasibility of an Emergency Department (ED)-initiated scre
METHODS: Eligible patients with a known diagnosis of chronic heart, lung, liver, and kidney failures, or advanced cancer, awaiting to be hospitalized after an ED visit, were assessed with both screening tools (ie, EST and SST
The outcome of this study is to evaluate the accuracy of the SST in identifying chronically ill patients in need of a palliative care assessment in the hospital setting., Through study completion, an average of 1 year
Detected abnormalities - Composite, The primary outcome is a composite of detected abnormalities on biomarkers, transthoracic echocardiogram (TTE), or Cardiac magnetic resonance (CMR) following CAR T cell infusion.,
Work and social adjustment scale, Measures impairment in functioning, 52 weeks post randomisation
Change in Echocardiographic Global Longitudinal Strain (GLS), To compare the absolute change in echocardiographic GLS (Global Longitudinal Strain) from baseline (T0) to 2-3 weeks after (T2) completion of 4 cycles of (neo
Cardiac dysfunction, systolic and diastolic parameters at time of inclusion, on average 11 years after treatment with breast cancer
Symptom severity (total score) using the Edmonton Symptom Assessment Scale (ESAS), The ESAS is a 10-item survey measuring symptom severity. Scores range from 0-100 with higher scores indicating worse symptoms.,
Upper limb functional status, score range 0-100%, higher score means more severe disability, Will be assessed using the short form of the Chinese (Hong Kong) version of the Disabilities of Arm-Shoulder-Hand Questionnaire
Length of Hospital Stay (LOS) by Participant, Length of hospital stay of arterial pressure-based cardiac output (APCO) monitor participants versus the participants using the global standard care guided by esophageal Dopple
To evaluate the effect of Veliparib on corrected QT interval calculated by Fridericia's formula (QTcF), Electrocardiograms (ECGs) will be done at Screening, 6 time points on Day 1 of Periods 1, 2 and 3 in triplicate, 1 time point
Decrease in left ventricular ejection fraction ≥ 5%, Reduction of LVEF assessed on magnetic resonance imaging (MRI), At 12 months from the randomization visit
Feasibility of a cardio-oncology prehabilitation program in high-risk HSCT candidates (Recruitment Rate)., Percent of eligible participants who are screened and give informed consent, 8 weeks post enrollment|Feasibility of a
Average % change in oligomers in patients with new onset TTR amyloid symptoms, Change (%) for oligomer level at the time of TTR amyloid symptoms compared to baseline, Annually over 5 years
The incidence of congestive heart failure and LVEF decrease, Incidence of symptomatic congestive heart failure (CHF) NYHA class II, III, and IV and asymptomatic significant LVEF decrease, 60 months
Autonomic nervous system activity, The autonomic status will be classified in sympatho-vagal equilibrium as "normal", "altered" or "severely abnormal" according to the values obtained for some temporal indices (SDNN, SD
Chart Review of Usage Pattern of Rivaroxaban in Participants with Cancer and Invenous-Thromboembolism (VTE) at MD Anderson Cancer Center, Proportion (95% confidence interval (CI)) of cancer patients who were on riva
Analyses made among patients with VTE summarizing practice patterns of rivaroxaban by means, SDs, and ranges for continuous variables (e.g. platelet counts before a procedure) and the counts and percentages for catego
Analyses made among patients with NVAF summarizing practice patterns of rivaroxaban by means, SDs, and ranges for continuous variables (e.g. platelet counts before a procedure) and the counts and percentages for cate
incidence of cardiovascular disease, compared with corresponding estimates from the female general population (HUNT-registry data, age-matched sample), 8 years|incidence of cardiovascular disease, compared with corre
inicidence of cancers, number of all types of cancers during follow-up periods, through study completion, an average of 3 years
Occurrence of atrial fibrillation, Occurrence of atrial fibrillation, 1 day During radiotherapy|Onset time of atrial fibrillation, Onset time of atrial fibrillation, 1 day During radiotherapy
QUAL-E subscale describing preparation for death (Quality of Life at End of Life, Steinhauser et al. 2004), Eight weeks
Reduction in Fatigue (via FACIT-Fatigue scale), Fatigue assessed via the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) questionnaire, Measured at baseline (time 1) and after 10-week intervention
Number of participants with treatment-related cardiac adverse events as assessed by CTCAE v4.0, The cardiac adverse events are regularly assessed with cardiac symptoms,cardiac enzymes(TnT, BNP),electrocardiogram(

Change in health belief model (HBM) construct scale of knowledge about echocardiograms and the effects of their treatment on health, Patients will be asked about their knowledge of echocardiograms and the effects of thei
Change in non-calcified plaque volume according to treatment with statins, Difference in non-calcified plaque volume as measured on serial CTCA between patients treated with and without statin therapy, 18 months
Muscle sympathetic nerve activity, Change in muscular sympathetic nerve activity measured by microneurography, 15-20 days after the end of AC regimen
Feasibility as measured by rate of recruitment, The rate of recruitment will be measured by comparing the number of patients screened to the number of patients enrolled (patients per month)., 12 Weeks|Number of adverse e
Cardiac adverse event, up to approximately 5 years.
Time to the first identification of cardiac dysfunction, Real-time, blinded, central echocardiography (ECHO) read as a decrease in the left ventricular ejection fraction (LVEF) of \>= 10 percentage points from baseline to a value
Myocardial perfusion reserve index (MPRI), Will first estimate 95% confidence intervals for each group at each time point as well as for the change from baseline to 3-6-months in each group., Baseline and 3-6 months
cardiotoxity, Congestive heart failure with clinical symptoms, or no symptoms but an abnormal LVEF, 2 years.
Change in the number of self-reported fruits per day, Number of self-reported fruits per day, Baseline, 3 months, 6 months|Change in the number of self-reported vegetables per day, Number of self-reported vegetables per d
Major adverse cardiac events, The rates of a composite of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrhythmias, significant bradyarrhythmias, or incident heart failure., 6
Acute coronary syndrome, Composite endpoint of the incidence of overall mortality, chest pain requiring hospital admittance, the incidence of coronary angiography intervention and acute coronary syndrome, 6 months
Baseline Patient Demographic Information (age, sex, race), One time visit.|Identification biological markers predisposing cancer patients to development of chemotherapy-induced congestive heart failure, One time visit for cc
When mobilization starts after surgery, Time from termination of anaesthesia to when mobilization starts, ie when the patients are sitting with the legs over the edge of the bed, Within 24 hours after surgery|Mobilization- Conte
Echo - Left Ventricular Ejection Fraction, The echocardiogram will measure changes in LV ejection fraction as a percent., Echo's will be taken at baseline, 1 year, and 2 years|Echo - Left Ventricular Mass, The echocardiogram
cardiovascular events, cardiovascular events development - myocardial infarction, stroke, 1 year
Median number of positive axillary lymph nodes, Compared in the Herceptin and no Herceptin groups and in the dexrazoxane versus no dexrazoxane groups using a chi-square test and a two-sample t test, respectively., At 2
Complete pathological response rates (tumor and lymph nodes)
Incidence of device detected atrial fibrillation (AF), Incidence of AF lasting 6 or more minutes at 18 months: each arrhythmic episode detected by the patient's device will be reviewed to determine if it is 1) an actual AF episod
Safety: Incidence of adverse events, up to approximately 4.5 years
Carcinoid Heart Disease, Percentage of patients with carcinoid heart disease at diagnosis and during follow-up (carcinoid heart disease diagnosis will be assessed by an annual echocardiography)., 10 years (at the end of stu
Pharmacokinetics of Low Molecular Weight Heparin (LMWH) in Cancer patients, Interim analysis and at the end of the trial
Feasibility of conducting a 14-week CR program, During the course of the 14-week intervention period, the CR medical director will monitor CR staff adherence to the study protocol. Every 2 weeks, they will review interventio
Change in QTc interval, QTc intervals will be estimated by performing ECGs on patients pre-investigational drug administration and post-investigational drug administration. The change in the QTc interval between the two EC
global longitudinal strain-A parameter of two dimensional speckle tracking echocardiography, The primary outcome of the trial was a decrease in global longitudinal strain ≥10%., pre-radiotherapy, 12 months after radiotherap
Reproducibility of ABC or vDIBH set-up as measured by Align RT., Reproducibility of set-up will be evaluated by determining discrepancies in patient's surface between treatment and CT simulation which will be acquired wit
i. Converting differences in heart position on 2D portal images acquired during treatment to 3D volumes on Pinnacle plans.
ii. Using the CBCT images (acquired weekly), to recalculate dose to heart based on the patient's position and anatomy that day., 2 years
self-reported Information on changes in health in the participants, coronary artery disease atrial fibrillation heart failure dementia stroke cancer such as prostate cancer and skin cancer chronic kidney diseases migraine muscu
Change from baseline in score on Beck Depression Inventory II at 8 weeks, Widely used self report measure to assess for symptoms of depression., comparison of scores immediately pre-intervention and then immediately p
Cardiorespiratory fitness, VO2peak measured by CPET, Change from baseline to 2 months
Number of participants who complete the cardio-oncology consultation visit, Adherence is defined as 70% of the participants completing the cardio-oncology consultation visit prior to or during radiotherapy., From baseline t
Measure muscular sympathetic nervous activity, The sympathetic nervous activity is assessed by the microneurography technique, 16 weeks
to compare plaque burden in the coronary and carotid arteries after radiotherapy for breast cancer, after 5 years of radiotherapy
Quality of Communication Questionnaire (QOCQ), slightly modified to focus on communication about cardiopulmonary resuscitation, Patient-Assessed Quality of Communication about CPR, Study day 5 +/- 1 or hospital disc
Reduced Pain, Participants will attend an HRV-B training session once a week for up to 6 weeks. They will complete a questionnaire which includes a symptom cluster assessment related to pain using the Brief Pain Inventor
Anxiety and Depression measured through the Hospital Anxiety and Depression Scale, Measured through the Hospital Anxiety and Depression Scale. 0 = Minimum. 21 = Maximum. Higher score is worse outcome., A change
Mean Symptom Severity Scores (MDASI-HF Symptom Assessment Scores), Baseline and at end of 3 Months
Cardiac function including vulvar involvement, Cardiac morphology and function measured by echocardiography, 60 days
ICU Free Days, The primary outcome is number of ICU free days to day 60, defined as the number of days spent alive and outside of an ICU until day 60.
The primary outcome will be measured to answer the following primary question: Among patients receiving minimal mechanical ventilatory support for severe and persistent brain injury, which of the following airway manager
Level of quality of life - total score, The primary outcome is self-experienced quality of life. The World Health Organization's brief quality of life questionnaire (WHOQOL-BREF) will be used. The questionnaire examines four do
Cardiovascular disease, Cardiovascular disease incidence and mortality, coronary heart disease incidence and mortality, stroke incidence and mortality, Up to 20 years|Diabetes, Diabetes incidence, Up to 20 years|Cancer, Ca
Incidence of cardio-toxicty, Number of patients with cardiotoxicity in a cohort of patients referred to a cardio-oncology clinic, 5 years
Determine the feasibility of video-assisted thoracoscopic wedge resection (VAR), Up to 10 years|Determine the incidence of locoregional recurrence in patients treated with this regimen, Up to 10 years|Determine the overall a
Difference in rates of cardiovascular adverse events leading to hospitalization between chemotherapy treated patients and chemotherapy-free patients., Any cardiovascular adverse event (e.g. the non limitative list: ischaemic
Any anticancer drug (chemotherapy) intake will be considered for the primary analysis.
We will use a competing risk statistical model., Between 2004 and 2017
Perceived Message Effectiveness (PME), Perceived effectiveness of the messages will be measured during the message using 4 items adapted from Baig et al. (2018): concern, unpleasantness, and discouragement. The ave
Questions: How much do these messages...
* make you concerned about the health effects of eating red meat? * make you concerned about the environmental effects of eating red meat? * discourage you from wanting to eat red meat? * make eating red meat seem unpleasant to you?
1. Not at all, 2=Very little, 3=Somewhat, 4=Quite a bit, 5=A great deal)., ~10 minute computer survey immediately after seeing messages
Incidence of MACE-4, incidences of MACE-4(cardiovascular death, myocardial infarction, stroke and hospitalized unstable angina), 10 year
Cardiotoxicity rate, 2 years
Incidences of POD after general anesthesia in elderly patients undergoing non-cardiac major surgery, Up to 7 days after surgery（or leaving hospital）
Cardiovascular ischemia, Cardiovascular ischemia including myocardial infarction, unstable angina, transient ischemic attack, and cerebrovascular accident, Over four years from approval of pazopanib
The long axial strain of echocardiography, The long axial strain of echocardiography was in the normal range（18%-22%）, From date of randomization until the date of first documented progression or date of death from an
presence of edema, associated with cardiotoxicity as visualized on DWI by the attending cardiac imagers we may explore the association of the presence of edema on DWI with a drop in LVEF \> 10% using exact logistic reg
Change in advance care planning (ACP) engagement with clinicians at one month, ACP engagement is a one-item question from the validated ACP engagement survey that measures participants' self-reported readiness to d
Sudore RL, Heyland DK, Barnes DE, Howard M, Fassbender K, Robinson CA, Boscardin J, You JJ. Measuring Advance Care Planning: Optimizing the Advance Care Planning Engagement Survey. J Pain Symptom Manage. 2
ICU Transfer, Patients transferred to the ICU from a general hospital ward will be assessed as having met the outcome., Patients will be assessed for the primary outcome measure during their hospital with an average of 14 d
pain score, Visual analogue scale for pain. Scores are recorded between 0 for "no pain" and 10 for "worst pain". A higher score indicates greater pain intensity., immediately after aromatherapy
Evaluation of Cardiac Biomarker Elevation with Radiation Therapy, Descriptive statistics used to summarize change from baseline in enzyme levels at each time point (beyond baseline). Each enzyme examined separately. Pe

Interfraction reproducibility of chest wall position (group A), The position of ipsilateral chest wall will be compared between the digitally reconstructed radiographs (derived from the planning CT) and the on-treatment electroni
Part A: Area under the plasma concentration-time curve from zero to infinity for cocktail parent compounds (midazolam, omeprazole and caffeine), To assess the effect of AZD1775 on the PK of probe substrates for CYP1A2 (
Change from baseline in left ventricular ejection fraction (LVEF) measured by echocardiography and by cardiac magnetic resonance imaging (CMR)., 6 months after randomization
Degradation of Topoisomerase 2 b, Topoisomerase 2 b degradation to less than 15 percent of baseline level in human blood of 5 volunteers., 48 hours after administration
Decrease in systolic Blood Pressure, Interventionalist will communicate to the investigator of the catheter placement and our outcome measure will be recorded soon after., 5 seconds|Drop in end-tidal C02, Interventionalist w
The purpose of this research study is to evaluate MR imaging in subjects receiving doxorubicin chemotherapy to see if MR can detect heart damage as well as or better than MUGA scans., Over a period of 12 months
changes of global longitudinal strain value between cardiotoxicity group and No cardiotoxicity, changes of global longitudinal strain value between cardiotoxicity group and No cardiotoxicity at the follow-up point, From the st
To determine the effect of ACE-I in preventing chemotherapy-related cardiotoxicity using both investigation techniques: Troponin I level and cardiac imaging (TTE, TDI, STE)., ALL patients will be subjected to the following ca
Plasma troponin I (TnI) concentration will be measured for all the patients at the each time intervals of the study., 3 years|To determine the role of Troponin I (TnI) as an early marker of cardiac toxicity, Troponin I (TnI) concentra
Plasma troponin I (TnI) concentration will be measured in both groupsas follows : * Early TnI: TnI concentration will be measured before and soon after each cycle of HDC. Determination of early TnI consists of a curve of assays (2ml blood sample): baseline initially, before \& after immediately, and 12 and 2 * Late TnI: TnI value also is to be determined at the end of treatment and 2, 3, 6, and 12 months after end of treatment in both groups., 3 years|To measure the accuracy of other radiological techniques for early detection of c
Change in left ventricular ejection fraction, as assessed by cardiac MRI, Baseline and end of study (up to 72 weeks)
number of patients with cardiac complications in myeloproliferative diseases., cardiac complications as valvular changes, ejection fraction changes, pulmonary hypertension, 30 minutes
Heart rate variability analysis, Heart rate variability analysis was performed according to the Task Force recommendations. Frequency domain analysis was based on fast Fourier transformation. Power spectrum densities were calculated for low frequencies (LF: 0.04-0.15 Hz) and high frequencies (HF: 0.15-0.4 Hz) informalized units, defined as the Baseline and 30min after the injection of the study drug., 5min perioids after fluid resuscitation.
Adverse event (AE), Number of participants with adverse events, 3 years
Cardiac Remodeling, The presence of one or more of the following: 1. Cardiac Remodeling defined as Left Ventricular Posterior Wall Thickness (LVPWT) or Thickness to Dimension Ratio (TDR) z-score \<-2.0 or a reduction in LVPWT or TDR z-score by at least 1 standard deviation compared to 2. Reduced left ventricular ejection fraction (LV EF) (\<55%); or 3. Symptomatic heart failure graded using New York Heart Association (NYHA) classification (or Ross heart failure class at least 2 in infants less than 2 years old), one year after last dose of anthracycline therapy in Acute Coh
Safety of computed tomography as measured by effective radiation dose (as measured in mSv), Measurement of the effective radiation dose (as measured in mSv) at time of computed tomography, Through study completion
Radiation associated ischaemic and valvular heart disease, The following incidences heart diseases according to ICD10: ischaemic heart disease codes I20-25 and valvular heart disease codes I00-09, I01.0, I09.2, I34-39, 10
Completion of chemotherapy with anthracycline drugs, Chemotherapy regimen completed., Through study completion, an average of 6 months.
Change in stage of adoption of health behaviors and referral for additional screening and follow up for high risk participants at 6 month post evaluation
Diffusing capacity of the lungs for carbon monoxide (DLCO), The Wilcoxon test will be used to evaluate whether DLCO values differ between the two arms., One year post therapy
Incidence, Incidence of atrial fibrillation after chemotherapy, 1 year after the first course of chemotherapy
Breath records from participants with Chronic Obstructive Pulmonary Disease (COPD), Tidal Breathing CO2 waveform data from 245 participants collected using the N-Tidal C Handset. Each participant delivering 2 x breath records per day for 14 days = 6860 records, 12 months from First Patient First Visit (FPFV)
Rate of cardiovascular events at 3 months., Assessment of the rate of cardiovascular events in patients treated by trifluridine/tipiracil +/- oxaliplatin over a 3-month period., At 3 months
change in left ventricular ejection fraction(LVEF) detected by electrocardiography transthoracic echocardiography, Patients will undergo transthoracic echocardiography 24 hours prior to the initiation of chemotherapy, after 3
Occurrence of dysrhythmias, during percutaneous ethanol instillation
POST-OPERATIVE PULMONARY COMPLICATIONS, Describe the frequency of PPC that include: pneumonia, pleural effusion, pneumothorax, atelectasis, ARDS, aspiration pneumonia, trachea-bronchial lesion, air leak, withir
Cardiac MRI Parameters, Cardiac MRI parameters include Left Ventricular (LV) ejection fraction, LV mass (indexed), LV dimensions, extracellular volume (ECV), and late gadolinium enhancement (LGE)., day of MRI scan
Proportion of Patients With EHR Documentation of Goals of Care Discussions, The primary outcome is the proportion of patients who have a goals-of-care (GOC) discussion that has been documented in the EHR in the perio
Change from Baseline Anxiety and Depression symptoms at 1 week after intervention, Hospital Anxiety and Depression Scale (HADS). The scale consists of 14 items, 7 for anxiety (HADS-A) and 7 items for depression (HADS
Progression Free Survival, A chi-square test (one-sided; alpha = .1) will be used to assess the efficacy of treating patients with targeted agents based in the Cancer-Code-50 in the second line setting. For each patient "succe
Incidences of Atrial Fibrillation During First 4 Days After Lung Resection, New onset of sustained (15 min or \>) or clinically significant (requiring intervention) atrial fibrillation (AF) during first 4 days post surgery as defined by c
To see if a CMRI is better at detecting occult asymptomatic cardiotoxicity, Changes in T1 mapping-derived relaxation time and left ventricular myocardial peak circumferential and longitudinal strain magnitude and segmental
Number of patients having a benefit after this specific cardio-oncology check up and follow up, 5 years
non-invasive hemodynamic parameter measurements during exposure AM RF EMF, Identification of hemodymanic alterations induced by the exposure to low levels of amplitude modulation radiofrequency electromagnetic fi
Change in myocardial function and structure, cMRI will be done prior to induction of doxorubicin based chemotherapy and at three months after completion of the doxorubicin based chemotherapy regimen.
Response, every 3 months while on protocol treatment
The difference between cardiac strain rates measured at baseline and after 4 cycles of chemotherapy., The primary null hypothesis is that the means are equal versus the alternative hypothesis that the means are different. We
One hundred twenty patients candidate to receive neoadjuvant or adjuvant CT for early BC will be randomized 1:1 to receive either epirubicin-cyclophosphamide (EC) or docetaxel (Taxotere) -cyclophosphamide (TC) for 4 cyc
Left ventricular ejection fraction (LVEF), Change in echocardiography derived LVEF from baseline, 14 months|Right Ventricular (RV) Fractional Area Change (FAC), Change in echocardiography derived RV FAC from baseline, 1
Number of participants with changes in Tissue velocity imaging (TVI), myocardial deformation indices (Strain, strain rate, twist and torsion), and diastolic function indices (Mitral Valve Pulsed Wave Doppler, Tissue Doppler Ima
New mental health diagnoses among parents, Outcome will be assessed based on diagnoses in de-identified claims data, 3 years|New mental health diagnoses among siblings, Outcome will be assessed based on diagnose
Cumulative mortality, Cumulative incidence functions (CIFs), which, unlike the standard Kaplan-Meier method, allow for estimation of the incidence of the occurrence of an event while taking competing risks from other cause
Objective Response Rate(ORR), Objective response rate (ORR) after 6 cycles of R-CMOP chemotherapy, up to 6 cycles of chemotherapy (each cycle is 21 days)
Total Duration of Mechanical Ventilation, Total duration of mechanical ventilation (to 60 days) accounting for the competing risk of death, Up to 60 Days
Stroke Volume Variation(SVV)within and between groups of patients, Determine which solution of local anesthetic with paravertebral block has a the most favorable effect with regard to the analgesic and hemodynamic effect Stroke Volume Variation(SVV)will be expressed in percentage change., 12 hours perioperative
Proportion of elderly patients (>80 yrs) with colorectal neoplasia, 2 years|proportion of patients with complications including perforation, bleeding, MI or CVA within 24 hours of colonoscopy in >80 vs. <80 agr group, 2 years
Ventricular Function Measurement, Quantify ventricular functional measurements including strain patterns and measurements using offline processing software that Dr. Fornwalt lab has., Up to 2 years
Overall survival (OS), Overall survival, the percentage of patients alive of the cohort (patients with cardiac lymphoma diagnosed from 01/01/2000 to 31/12/2020)., The endpoint will be evaluated within 2 months from the end c
Identification of TSC biomarker/s, All samples will be analyzed for the identification of biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged contro
Precaution Adoption Process Model (PAPM) health behavior stage, The PAPM is a theoretical, stages of change model that, in conjunction with the Health Belief model, has been used to guide the study of health behaviors, i
Brain relaxation, 1. Tight Brain-the brain surface is jutting out or expanding beyond the craniotomy margins, brain pulsations are not clearly defined. 2. Brain surface at level of craniotomy margins, Brain pulsations faintly observed 3. Brain surface just below the surface of craniotomy margin. Brain pulsations well seen. 4. Brain surface well below the surface of craniotomy margin, well retracted in to the cranial cavity with good brain pulsations.Brain relaxation score will me measured only once. There is no follow up, 2hours
Collection of biospecimen, Collect specimens derived from blood, buccal cells, sputum, urine, bone marrow, tumor tissue and residual specimens, including but not limited to pleural fluid, ascetic fluid, chyle, skin, lung, lymph
Time-to-new diagnosis of common complex disease, The primary outcome of the study is time-to-diagnosis both of undiagnosed prevalent cases of the 6 target conditions and incident cases during the study period. This co
Recurrence of fluoropyrimidine related cardiac toxicity after switch to S-1 based treatment, Cardiac tolerability according to NCI-CTCAE following cardiotoxicity initiated switch of fluoropyrimidine to S-1, After switch to and d
Absolute incidence of postoperative atrial fibrillation, Detected by device, 14 days postop
Primary efficacy endpoint: (RIC vs Sham) Absolute change in LVEF, change in LVEF between baseline and any follow-up CMRs, whichever shows worse LVEF UNITS: LVEF is expressed as % LVEF= (LV end-diastolic volume - LV end-systolic volume) / LV end-systolic volume), %, 9 weeks after the last chemotherapy cycle (anticipated to be between 150 and 200 days from enrollme
Sensitivity of each biomarker for detecting cardiotoxicity, Will estimate with exact 95% confidence intervals., Up to 6 months|Specificity of each biomarker for detecting cardiotoxicity, Will estimate with exact 95% confidence
Multiple site activation, Evaluating the feasibility of multiple Canadian site activation within the first year of study accrual. Achieved by the activation of at least 4 Canadian sites within 1 year of the first patient being accrued ir
1/Measure atherosclerotic plaques, Measure atherosclerotic plaques on contrast-enhanced computed tomography (CECT), End of study

Optimize non-invasive cancer biomarker tests based on its small noncoding (snc)RNA technology, Analyze small noncoding (snc)RNA profiles differentially expressed in specimens obtained from case and control subjects to
Changes in microvascular blood flow during colorectal surgery, Immediately following optimisation of cardiac output
Endocrinopathies, Late health outcomes, up to 20 years after RT|Cardiovascular diseases, Late health outcomes * Neurovascular diseases * Second and subsequent primary neaoplasms, up to 20 years after RT|Neurovascular diseases, Late health outcomes, up to 20 years after RT|Second and subsequent primary neaoplasms, Late health outcomes, up to 20 ye
Patient satisfaction: Seattle Angina Questionnaire, Our primary outcome is to examine whether patients with chest pain with normal coronary arteries experience greater satisfaction with their treatment if they receive extende This is measured with 2 single items in Seattle Angina Questionnaire regarding satisfaction with treatment. Values range from 1-5, 1 is the lowest level of satisfaction, and 5 is the highest level of satisfaction. Greater satisfacti In addition, there is a separate question of patients' trust in the CT examination measured with a VAS-scale , ranging from 1-10, 1 represents lowest possible degree of trust, and 10 represents highest possible degree of trust
Compare the effect of GSK1120212 on the baseline-adjusted, placebo-corrected, time-matched QTcF(QT interval corrected for heart rate by Fridericia's formula) interval duration in subjects with solid tumor cancers, from ba
Change in QTcF interval from baseline QTcF following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors., 12 weeks
The NoMAD Instrument, to describe respondents' experiences of using the intervention in the workplace., The data collection instrument is NoMAD \[1\]. The NoMAD translated into Arabic for the purpose of evaluating the nc
RT-induced systolic and diastolic function alterations, Systolic and diastolic function alterations assessed using traditional echocardiographic parameters as well as speckle tracking echocardiography analysis at 1, 6, and 12
Mortality, 24 months|Tumor size, If the maximum tumor size increases, the symptom gets deteriorated; If the maximum tumor size decreases, the symptom gets relieved., 24 months|Quantification of obstructive severity, Inve
Incidence of adverse events, Statistical analyses of safety will be descriptive., Up to 6 months|Change in left ventricular ejection fraction (LVEF), The comparison will be between the two groups of patients., Baseline to 6 mon
Number of Participants With Less Than or Equal to 5% Decrease in Left Ventricle Ejection Fraction (LVEF) on Echocardiogram, Determine whether the addition of metformin to standard doxorubicin therapy in breast cancer pa
death, death, divided into yes or no, Within a year|heart failure, Come back to the hospital for heart failure (Judged by the physician) after discharge, divided into yes or no, Within a year|Acute Coronary Syndrome, Coronary A
change in CRF (measured by VO2peak), For the primary analysis, intervention effect will be evaluated by comparing differences in mean VO2peak changes from baseline to month 6 between the investigational and control gr
Sensitivity and specificity of the visual assessment of [18F]florbetaben PET images for the diagnosis of cardiac AL amyloidosis., The results from the visual assessment of \[18F\]florbetaben PET images are compared to the c
Number of skin tumors per patients requiring surgery with histology control within 2 years, 2 years
The 24 points skin electric conductance over bilateral wrist and foot in patients undergoing lung operative, after admission baseline evaluation before lung operative as assessed using M.E.A.D (Meridian Energy Analysis Devi
Number of participants with subclinical cardiac lesions in myocardial levels and/or coronary levels, The primary outcome is defined as a decrease of at least 5% in strain or strain rate measures based on cardiac ultrasound e
To determine if radiation-induced cardiac injury causes myocardial mitochondrial dysfunction, To determine if radiation-induced cardiac injury causes myocardial mitochondrial dysfunction as measured by increase in \(1-13C
Number of participants with left ventricular systolic dysfunction, echocardiography, cardiovascular magnetic resonance, from date of randomization until the end of study, up to 24 months
7-day point prevalent CO validated smoking cessation., Exhaled Carbon Monoxide reading of 6ppm or less to validate smoking cessation, Three months after lung screening
Change of Heart Rate Variability measured by SDNN (Standard Deviation of all NN intervals) from baseline to the end of osteopathic treatment, To assess the effect of vagus nerve osteopathic stimulations on Heart Rate Varia
Cardiac output (CO), measured using esophageal doppler, parameter will be measured continously for the duration of adrenalectomy, an expected average of 3 hours|Systemic vascular resistance (SVR), measured using esop
Extent and pattern of acute cardiac effects of CAR T-cell therapy, To investigate to what extent and with which patterns CAR T cell therapy leads to acute cardiac effects in terms of inflammation, fibrosis, and myocardial dysf
All-cause mortality, Cumulative incidence of all-cause mortality, Two (mid-term analysis) and five years of follow-up
Change in left venticular dysfunction by global longitudinal strain (GLS)., Change in global longitudinal strain (GLS) at least by 3%., 1, 3 and 6 months
QTc interval, Screening through Week 10
Cardiac Repolarization (Fredericia's QTc), ECGs are collected in triplicate during the study to assess QTc effect., 25-week ofatumumab treatment period
Changes from Baseline Heart Rate Variability (HRV and coherence scores) at 2 weeks, The Emwave Pro Plus device from HeartMath will be used to collect HRV data and heart rate using a 3-minutes "neutral" protocol (we ca
Changes in Quality of life, Measured by the European Organization for Research and Treatment of Cancer, questionnaire regarding quality of life in palliative cancer care patients (EORTC QLQ-C15-PAL)., At baseline, week 1,
Incidence of arrhythmia, Incidence of arrhythmia in sleep apnoea patients as recorded by ILR vs a no ILR group, 3 years|Autonomic function before and after CPAP, Assess the changes to the heart in sleep apnoea patients b
Survival, The primary objective will be to assess survival of patients with advanced cardiac AL amyloidosis treated with HCO-HD combined with chemotherapy., 6 months
Feasibility of incorporating pharmacogenomic testing into routine medical care, 5 years
Number of Participants With Uptake of Genetic Counseling for Those at Risk of Hereditary Conditions at 1 Year, How many patients identified as meeting criteria for genetic counseling, how many providers ordered genetic co
Causality relationship between the suPAR blood level and doxorubicin-induced cardiomyopathy, A blood draw will be done at baseline for all participants. The blood samples will be processed by Centrifugation, to separate t Although there is no current consensus regarding normal suPAR blood level, a level of 3000 pg/mL is considered a high level. Higher baseline blood level of suPAR, will predispose patients with breast cancer undergoing chemo regimen containing doxorubicin, to develop heart toxicity (heart failure or cardiomyopathy). Heart failure or Cardiomyopathy will be diagnosed by the clinical evaluation with signs and symptoms, LVEF (Left Ventricular Ejection Fraction) with echocardiograms (heart ultrasound), and surrogate cardiovascular outcome Although there is no current consensus regarding normal suPAR blood level, a level less than 3000 pg/mL is considered a normal level. A normal baseline blood level of suPAR, with progressive elevation following doxorubicin exposure, along with other blood markers for heart failure, will be considered as a predictive marker for doxorubicin-induced cardiomy Heart failure or Cardiomyopathy will be diagnosed by the clinical evaluation with signs and symptoms, LVEF (Left Ventricular Ejection Fraction) with echocardiograms (heart ultrasound), and surrogate cardiovascular outcome
Rate of in vivo histologic response|Event-free survival|Overall survival
cardiac output after one lung ventilation, record the stroke volume and cardiac output during two lung ventilation till 15 minutes after one lung ventilation, 10-15 minutes
Change from Baseline in risk factors of cardiovascular disease at 12 months and 24 months, lipid profiles, high-sensitivity C-reactive protein, Hemoglobin A1C, fasting glucose, fasting insulin, blood pressure, waistline, hipline
Heart rate variability, Standard deviation of NN (normal to normal RR) intervals (SDNN), Measured over a 24 hour period
The primary aim of this proposal is to evaluate the feasibility of a 12-week exercise intervention among survivors of childhood cancer treated with anthracyclines and known to have cardiomyopathy., 12 Weeks
Number of Participants With at Least One Adverse Event will be measured using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 for five years, Adverse events (AEs) will be measured using Common Terminolo
Number of Days Needed for Anal Exsufflation After Surgery, record the number of days needed for anal exsufflation in non-severe patients after gastrointestinal tumor surgery, up to 8 weeks
Changes in Internal Carotid Artery Blood Flow by Treatment of Anaesthesia-induced Hypotension, Unilateral internal carotid artery blood flow \[ml/min\] assessed by duplex ultrasound., Two measurements; one measurement
Dietary Quality, Dietary quality was measured by the Alternative Healthy Eating Index (AHEI), a scale of healthy eating that goes from zero to 80 (best score)., 6 mos|Dietary Quality, Possible Score From Zero to 80 (Best Qualit
Percentage of patients experiencing a decrease in left ventricular ejection fraction (LVEF), Will assess a decrease in LVEF of 10 percent from baseline or decrease in LVEF below the normal limit of 50% during treatment with d
Number of Participants With Complete Response or Partial Response Using Response Evaluation Criteria in Solid Tumors Guideline Version 1.1, Determine the response rate, Complete Response (CR) or Partial Response (PR
Change from baseline in QTcF interval at each time point on Study Day 9 (average of at least 3 Holter ECG replicates per time point) as compared with time-matched placebo., 11 days
Change in patient confidence in self-management activities., Change in the patient's confidence in self-management of heart failure or colon-rectal cancer disease between baseline and post-1 and 2 will be measured by the
Guideline concordant statin therapy 1 year following the first low dose CT scan., Among patients with moderate to severe coronary artery calcifications (CAC) not on a statin at baseline, any statin prescribed for primary preve (aim 1), 1 year post CT|Guideline concordant inhaler therapy 1 year following the first low dose CT scan, Among patients who have untreated or inappropriately treated COPD at baseline, any long acting muscarinic antagonis
Body weight|lean body mass
Number of Participants Completing the Trial (Exercise Capacity Addendum), The number of participants who completed the intervention., 6 months after treatment initiation|Number of Participants Able to Complete Assessm
Change in myocardial strain, Assess for a change in myocardial strain, as measured by CMRI scans performed before and after RT, 2 years
EHR documentation of Goals of Care discussions, The primary outcome is the proportion of patients who have a goals-of-care discussion that has been documented in the EHR in the period by 90 days following randomizati
Number of patients in which cardiac MRI indicated subclinical cardiac abnormalities after radiotherapy that correlated with cardiac events, The study aims to characterize longitudinal changes in imaging characteristics of car
7-day point prevalence smoking abstinence verified by saliva cotinine taken, post-intervention (8 weeks after baseline)
Evaluation of the prognostic relevance of advanced imaging variables., - for CMR: T1, T2, ECV, indexed volumes, mass, ejection fraction (EF);, 12 months after diagnosis|Evaluation of the prognostic relevance of advanced im
Individually-corrected QT interval (QTcI), The primary ECG variable and endpoint for this study is the time-matched change from baseline in QTcI method on day 7 at each time point. Holter ECGs will be performed at baseline
Unmet physical functioning needs, The Three-Levels-of-Needs Questionnaire (3LNQ), At baseline
Intention to try to quit smoking in next 30 days, Assessed after 4 weeks of exposure to new labels
Change in Peak VO2, An analysis of covariance (ANCOVA) model will be used to assess post-intervention group differences in VO2, adjusted for baseline peak VO2., At baseline and 6 months after study intervention
In-hospital mortality, Description of the hospital mortality caused by the COVID19 disease, Until study completion, an average of 1 year|Mortality up to 3 months from admission, Description of the mortality patients up to 3 m
EHR documentation of Goals of Care discussions, The primary outcome is the proportion of patients who have a goals-of-care discussion that has been documented in the EHR in the period between randomization and 30 d
time to first cardiovascular event, To compare time to first cardiovascular event as estimated by the cumulated probability at the 1-year time-point of patients with advanced prostate cancer treated for one year with Degarelix
Rate of asymptomatic and symptomatic cardiac dysfunction, Incidence of heart failure or asymptomatic decline in left-ventricular ejection fraction (LVEF) by \>10% in patients whose LVEF is ≥50% or LVEF drop ≥5% in those

Percentage of patients enrolling in the study, day 1|Percentage of patients completing the study, 24 weeks|V02 peak before and after chemotherapy, 24 weeks
Intentions to seek information about family history.
Difference between groups functional activity from baseline to point of admission for surgery as measured by the 6MWT., The 6MWT is a validated test that requires no exercise equipment or "advanced" training for the asses
Caregiver Anxiety, Profile of Moods States (POMS) anxiety sub-scale The anxiety sub-scale from the modified Brief Profile of Mood States (POMS),7110 a six-item measure of psychological distress. Individual items used a 5
Small increase in the left and right ventricular volume, Small increase in the left and right ventricular volume, Baseline to Week 12|Small increase in left and right ventricular mass, Small increase in left and right ventricular mas
Changes in maximal aerobic capacity (VO2max), Measured by VO2max test, 12 weeks|Patient reported Fatigue, measured by Fatigue Severity Scale Questionnaire (FSS), 12 weeks
Cardiopulmonary Fitness, A cardiopulmonary exercise test will be completed following the Bruce or modified Bruce protocol. Breath-by-breath gas samples will be collected and averaged over a 20-second period using a cal
Proportion of African Americans who complete advance care planning, completion of an advance care planning document (living will, healthcare proxy, medical orders, Five Wishes, other); discussion with clinician documente
Cardiac Abnormalities As Measured By Cardiac MRI, Day 1|Cardiac Abnormalities As Measured By Echocardiogram, Day 1
Proportion of patients consenting to study, The number of eligible patients approached to join the study, the proportion consenting to the study, the proportion refusing the study (with reasons for refusal) and the proportion re
Cardiac event rate at 12 months, The proportion of failures (cardiac event) will be estimated by the number of cardiac events divided by the total number of evaluable patients. Confidence intervals for the true success propor
Adverse Events (AEs), Number of participants with adverse events for 6 month treatment, Up to 6 months
Composite endpoint of cardiac condition, Compose of ejection fraction (%), change between 1 and 6 months after treatment|Composite endpoint of quantitative fibrosis assessment, Compose of percentage of extracellular v
Coronary heart disease including acute myocardial infarction and death from CHD, From study start 1 Jan 1999 through 31December 2006|Heart Failure, From study start 1 Jan 1999 through 31December 2006
Feasibility of cardiac MRI in pediatric oncology patients with sepsis, The proportion of enrolled participants who have evaluable cMRI data within 10 days after onset of sepsis, within 10 days after onset of sepsis|Frequency c
Identification of pulmonary hypertension and/or right-sided heart failure (systolic arterial pulmonary pressure and visual function of the right ventricle is measured), Perioperative.
Differences Between Pre/Post ESAS Score, Total symptom burden as measured by Edmonton Symptom Assessment Scale (ESAS) in which there are eight visual analog scales (VAS) of 0 to 10, with 10 being most severe. The
Medicare program expenditures, Eight years
24 hour ambulatory systolic blood pressure, week 8 and week 24
Cardiotoxicity and pulmonary toxicity of therapy, Proportion of patients with cardiac and pulmonary toxicity measured by CTCAE 4.0 \> Grade 2, At 60 months from treatment|Local tumor control, Freedom from tumor progres
(Interventional Study) Comparison of caregivers' HRQoL according to the allocated intervention by randomization based on summaries score the MOS SF36, The main objective of the randomized study is to compare the Hea
To determine if aortic stiffness or myocardial wall strain is increased in childhood cancer survivors who received anthracycline chemotherapy, Day 1
The total score of the following 3 visualization parameters is used for primary variable: Degree of contrast enhancement; Border delineation; Internal morphology., At Day 0
Feasibility, defined by the percentage of patients that enroll onto the study, successful completion of all study measurements, ability of studies to be interpreted, and achievement of the recruitment goal, The current protocol
Change in left-ventricular (LV) function.(LV ejection fraction) from baseline to end of treatment, Echocardiography-determined LV ejection fraction (unit = %), Assessed at two time points: (1) at baseline (diagnosis); and (2) 14 t
Left Ventricular Ejection Fraction reduction assessed by Cardiac Magnetic Resonance, The primary endpoint is defined as Left Ventricular Ejection Fraction (LVEF) reduction (unit of measurement: %) assessed by Cardiac Mag
LVEF reduction is defined as the difference between LVEF at baseline and LVEF at 12 months follow-up (LVEF reduction = Baseline LVEF - 12 months LVEF)., from baseline to 12 months
Number of Participants to Complete Heart Health Assessment - Feasibility, Feasibility will be defined from the number of participants who complete the web-based assessment using exact 95% binomial confidence intervals
Imaging Blood Flow, Imaging blood flow in the tissue is of major importance in the clinical environment, One visit
Incidence of adverse events requiring a higher level of care, An adverse event is an unintended injury or complication, which results in disability at discharge, death or prolongation of hospital stay, and is caused by healthcare
Postoperative complications, Pulmonary infection, oxygenation injury, malignant arrhythmia, hemorrhage, enteroparalysis, incision infection, renal insufficiency, cognitive dysfunction and so on, within 1 week after operation
Change from baseline to post-intervention in McGill Quality of Life Questionnaire Single Item, The McGill QOL Questionnaire is a validated reliable tool to evaluate self-reported QOL. One item in the Questionnaire has been sl
Change from Baseline in Heart Rate (HR), Heart rate measured in beats per minute (bpm)., Baseline (pre-dose) through 24 hours post-dose|Change from Baseline in Electrocardiogram Procedures, Change from baseline in QT
Intervention acceptance, Of those providers who were shown (or who would have been shown, for the control group) the intervention, the number that added a problem across control and intervention groups., 6 months (May
Number of myocardial infarction and ischaemic stroke, Calculated results using a mimicked population, Up to 20 years|Number of death due to myocardial infarction or due to ischaemic stroke, Calculated results using a mim
Number of Participants With Trastuzumab-Induced Cardiotoxicity After 52 Weeks of Treatment, Reduction in incidence of trastuzumab-induced cardiotoxicity after 52 weeks of treatment as measured by preservation of Left V
Efficiency of Obtaining Updated Genetic Variant Information, Phone and email logging procedures will be implemented before study onset to establish a solid baseline. Laboratory staff will log each time they receive a phone
System auditing processes will capture data on when genetic variants are updated, when alerts are sent, and clinician accesses to online screens.
Centralized system data will be evaluated to track usage of the GIC patient search functions, using a flagging approach., Continuous across 21 months
Percentage of obstruction resolution as Good or Excellent, Response/efficacy of sodium bicarbonate versus normal saline in airway stents graded using scale. Percentage of obstruction resolution (relative to initial stent lume
Incidence of clinical or subclinical cardiac injury, predefined cardiac events, two years
proportion surviving, proportion surviving, 12 months
cardiac autonomic function - heart rate variability, The cardiac autonomic function was determined through heart rate variability (HRV) measures after polysomnography ECG recordings., 9 months
Change in haemodynamic variables during the follow-up, Haemodynamic measurements are performed at baseline, and after approximately 10 years of follow-up, baseline, ten years|Cardiovascular events, All cardiovascular
Radiation related acute and long term functional changes in patients treated with deep-inspiration breath hold compared to free-breathing technique, Using MRI-based cardiac functional imaging to measure radiation-related
The difference in the percentage of patients with a completed advance directive (AD) in Ig vs.Cg, 1 year
Use of Cardiac Biomarkers, B-type Natriuretic Peptide (BNP) and Troponin I (TnI), for Detecting Cardiotoxicity in Patients Undergoing Anthracycline-based Chemotherapy, Cardiotoxicity defined as presentation of one or more
Primary analysis performed using data from all subjects with at least one post baseline biomarker measure for BNP and/or troponin I., 12 months
Objective response rate (ORR), ORR is defined as the percentage of subjects with evidence of a confirmed CR(complete response), VGPR(very good partial response) or PR(partial response), After completion of 12 cycles of t
Cardiotoxicity during observational period, Defined according to IC-OS 2021 Consensus Criteria, continuous evaluation during observational period of 12 months
Change in left ventricular ejection fraction by cardiovascular magnetic resonance, From randomization to end of blinded therapy (18 months)
Incidence of amyloidosis in older patients undergoing trigger finger release, Incidence of amyloid deposits in soft tissue removed from trigger finger tenosynovium in older patients undergoing trigger finger release surgery, Ba
reduction of the left ventricular ejection fraction (LV-EF) by 10% to under 50%, volumetric determination of LV-EF, after 12 months
Signal to Noise, An \>0.97 (or 97%) area under the receiver operating characteristic (AUROC) of benchtop Nuclear Magnetic Resonance versus current Point of Care (POC) testing sensitivity/specificity in conditional classifica
Cardiac toxicity, The asymptomatic LVEF decreases ≥ 10% of the baseline value or to an absolute value \< 50%, 12 months|Cardiac toxicity, acute or chronic heart failure, 12 months|Cardiac toxicity, New or aggravated arrhy
Cancer, Annual linkage with Finnish Cancer Registry, Annually
Maximum absorbed skin dose and dose distribution, Measurement of the maximum absorbed dose value and dose mapping by the Gafchromic® film dosimeter (in-vivo measurements within interventional radiology procedu
To determine the feasibility of a cardiac screening program in patients who are 5 to 10 years our from initial mediastinal irradiation for Hodgkin's disease., Compliance of screening and follow up visits are tracked, 3 years
Extent of Implementation of ACP, a. Does the patient have an advance directive or living will or some other written document expressing their wishes? b.patient and/or family been informed of the patients' prognosis? c.Has t
Left Ventricular Ejection Fraction (LVEF), LVEF derived from quantitative analyses of echocardiography-derived measurements of left ventricular volumes in diastole and systole., up to 24 months|Treatment adherence as meas
Quantitative ultrasound information, Quantitative ultrasound images of heart, thyroid, and breast disease, 5 years
Change in mean CTC cluster size (in ng/ml), mean CTC cluster size (in patients with a digoxin serum level above 0.7 ng/ml) after treatment will be compared to mean CTC-cluster size before treatment, Blood samples drawn a
Possible effects of B-vitamin treatment on risk of developing cancer during the trial periods (completed by 2004 and 2005) and during post-trial follow-up., 1998-2014
Time-matched Mean Change From Baseline in Corrected QT Intervals Based on the Fridericia's Correction Fomulation (QTcF), QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to
Extent of coronary artery plaques and number of perfusion defects in patients enrolled., 12 months
Change from baseline in QTcF, 22 days
Partial remission rate, Photodynamic therapy for 3 months after the review of gastroscope for pathologic examination, to check the response rate, 3 months
cardiac MRI, ejection fraction, 1 day
Number of patients with an Acute Coronary Event after completion of RT treatment, First 10 years after RT treatment

Recruitment Rate, percent of eligible patients who are randomized, At baseline|Retention rate, percent of randomized patients who complete the study per protocol, Through study completion (expected to be 1 year)|Adheren
physiological parameter, CRP (C reactive protein), 24 months|physiological parameter, IL-6 (interleukin 6), 24 months|physiological parameter, ADMA (asymmetric dimethylarginine), 24 months|physiological parameter, NTproE
Rate of LV Dysfunction, Echocardiographic evaluation of left ventricular functions, From the first visit at cardio-oncology division through study completion, an average of 2 years
Occurrence of Discussion About Goals of Care at Target Visit, Patient's response to question, "Did you discuss with this doctor the kind of medical care you would want if you were too sick to speak for yourself?", 2 weeks af
Independent risk factors of preoperative anxiety and establishment of prediction model, To identify the independent factors related to preoperative anxiety, which would be analyzed by Logistic regression according to anxiety
Adverse Events (AEs), Number of participants with adverse events, Up to approximately 4 years
The Radiation Dose in Gy to the Heart and Lung Using Two Radiation Techniques., The primary endpoints of this study were to evaluate the feasibility of the combination of prone positioning and RPM pDIPH for breast cance
Registry based disease outcomes, mainly cardiovascular, pulmonary and cancer outcomes, Latest registry update december 31 2014
Visual Analogue Scale (VAS) of global anxiety, Visual Analogue Scale (VAS) of global anxiety is a anxiety self-assessment scale that allows the patient to self-assess his or her anxiety using a cursor. The scale ranges from 0 (n
CARDIOTOXICITY PREDICTION SCORE, To determine the change in left ventricular ejection fraction (LVEF) after 6 months, 1 or 2 years after treatment with taxanes for defining cardiotoxicity (LVEF less than 55% or reduction
Change in absolute global longitudinal strain value measured by left ventricular global peak systolic longitudinal strain, Left ventricular global peak systolic longitudinal strain by cardiac echo, 1 year
Left Ventricle Global Longitudinal 2D strain (LVGLS) expressed in percentage and obtained from cardiac ultrasound cineloop of 2D 4,3 and 2 apical views analyzed by the Tomtec STE Software., To compare the evolution at 5
Patient Access and Recruitment (feasibility target: >50% of eligible participants), Defined as the percent of consenting patients based on the total number of otherwise eligible participants (OEP; patients meeting all eligibility
Number of patients with decreased myocardial function assessed by echocardiography, Number of patients with an increased of at least 2.5% in the Global Longitudinal Strain (GLS) between baseline and 2 years after radiot
Change in cardiac function by echocardiogram, change in cardiac function as measured by serial echocardiograms, 5 years
the knowledge, attitudes, service intentions and service start-up effects of the eight major non-cancer disease end-stage caregivers on well-being and palliative care, The content of the outcome measurement questionnaire i
Recurrent Atrial Fibrillation, Recurrent Atrial Fibrillation after Catheter ablation, 12 months
Detection of Imaging Biomarkers of acute cardiac inflammation, FDG-PET imaging to detect increase in cardiac inflammation compared to baseline with corresponding blood markers (Erythrocyte Sedimentation Rate (ESR), H
Completion of guideline-recommended surveillance tests, Proportion of survivors who complete one or more of the guideline-recommended cardiac, breast or colon surveillance tests (echocardiography, mammogram and br
Quantify disease severity at diagnosis, progression and survival in patients with cardiac amyloidosis, Clinical Outcomes: Disease severity at presentation, progression, and survival \[time frame 3 years\]. Severity and progress
Change in Left Ventricular Ejection Fraction (LVEF), Absolute change in LVEF by echocardiogram at follow-up, through study completion (expected to be 15 years)
To evaluate the incidence of clinically significant cardiac iron overload in heavily transfused MDS patients using T2* MRI., A single T2* MRI will be performed on eligible patients.
The presence of myocardial edema stratified by the presence or absence of conventionally defined cardiotoxicity (this is a binary outcome)., Myocardial edema is defined as an 8% increase in segmental T2 values measured i
Post-operative survival time, Postoperative survival time for patients receiving liver transplantation, Time from the end of liver transplantation to the patient's death, or the end of follow-up by December 31, 2020. whichever ca
Decrease in LVEF (left ventricular ejection fraction), Decrease in LVEF : more than 10% compared to the baseline LVEF) or LVEF \< 50%, 1 year after CMR scanning|Decrease in LVEF (left ventricular ejection fraction), Decreas
Left ventricular systolic dysfunction, Prevalance of systolic cardiac dysfunction defined as a LVEF \<54%, through study completion (from Ocotober 2022 - December 2024)
the change level of cardiac extracellular volume (ECV), Compared with baseline, the change level of cardiac extracellular volume (ECV) in patients with type 2 diabetes without PCOS, PCOS without type 2 diabetes, and type
Number of patients in which cardiac MRI indicated subclinical cardiac abnormalities after radiotherapy that correlated with cardiac events, The study aims to characterize longitudinal changes in imaging characteristics of car
Prostate cancer Gleason score, Measure a patient's prostate cancer Gleason score for patients with a prostate cancer diagnosis and record the measurement again at 3, 6, 9 months and annually for 5 years after treatment. V
Evaluation of DIBH and IMRT efficacy in preventing perfusion defect for left-sided breast cancer after radiotherapy, Incidence of perfusion defects on follow-up myocardial perfusion SPECT scans, at 3 months from the end o
Number of participants who develop type 2 diabetes based on response to oral glucose tolerance test, Patients will be monitored for up to 20 years (10 year retrospective plus 10 year prospective). The outcome measure will
Change in Score on the Edmonton Symptom Assessment for patients, This is a brief and reliable (Cronbach alpha: 0.85) self-report assessment that measures the frequency and intensity of a variety of physical and psycholo
Assessment of the measurement of cardiac index with the transpulmonary thermodilution technique, During surgery, At inclusion
Pathological complete response (pCR). pCR is defined as the absence of invasive cancer in the surgical breast specimen. This definition includes evidence of carcinoma in situ only., At surgery.

Risk of circulatory system general medical conditions, These will be ascertained using the following criteria:
Diagnosis in the Danish National Patient Register or death in the Cause of Death register, for at least one of the following diseases: hypertension, dyslipidemia, ischemic heart disease, atrial fibrillation, heart failure, peripheral
Records in the Danish National Prescription Register for at least one of the following types of medications: antihypertensives, lipid-lowering drugs, antianginal drugs (at least two prescriptions for a type of medication in one y
Hazard ratios (HRs), with 95% confidence intervals, will be obtained to compare risk of diagnosis with a general medical condition in those with previous mental disorders, compared to those without. All persons, sex-specific
Diagnosis in the Danish National Patient Register or death in the Cause of Death register, for at least one of the following diseases: diabetes mellitus, thyroid disorders, gout.
Records in the Danish National Prescription Register for at least one of the following types of medications: antidiabetic, thyroid therapy drugs (at least two prescriptions for a type of medication in one year).
Hazard ratios (HRs), with 95% confidence intervals, will be obtained to compare risk of diagnosis with a general medical condition in those with previous mental disorders, compared to those without. All persons, sex-specific
Diagnosis in the Danish National Patient Register or death in the Cause of Death register, for at least one of the following diseases: chronic pulmonary disease, allergy.
Records in the Danish National Prescription Register for at least one of the following types of medications: obstructive airway disease drugs, non-sedative antihistamines and/or nasal antiallergics (at least two prescriptions fo
Hazard ratios (HRs), with 95% confidence intervals, will be obtained to compare risk of diagnosis with a general medical condition in those with previous mental disorders, compared to those without. All persons, sex-specific
Diagnosis in the Danish National Patient Register or death in the Cause of Death register, for at least one of the following diseases: ulcer/chronic gastritis, chronic liver disease, inflammatory bowel disease, diverticular disease
Hazard ratios (HRs), with 95% confidence intervals, will be obtained to compare risk of diagnosis with a general medical condition in those with previous mental disorders, compared to those without. All persons, sex-specific
Diagnosis in the Danish National Patient Register or death in the Cause of Death register, for at least one of the following diseases: chronic kidney disease, prostate disorders.
Records in the Danish National Prescription Register for at least one of the following types of medications: prostate hyperplasia therapy drugs (at least two prescriptions for a type of medication in one year).
Hazard ratios (HRs), with 95% confidence intervals, will be obtained to compare risk of diagnosis with a general medical condition in those with previous mental disorders, compared to those without. All persons, sex-specific
Diagnosis in the Danish National Patient Register or death in the Cause of Death register, for at least one of the following diseases: connective tissue disorders, osteoporosis.
Records in the Danish National Prescription Register for at least one of the following types of medications: osteoporosis drugs (at least two prescriptions for a type of medication in one year) or repeated prescriptions for anal
Hazard ratios (HRs), with 95% confidence intervals, will be obtained to compare risk of diagnosis with a general medical condition in those with previous mental disorders, compared to those without. All persons, sex-specific
Diagnosis in the Danish National Patient Register or death in the Cause of Death register, for at least one of the following diseases: vision problems, hearing problems, migraine, epilepsy*, Parkinson's Disease, multiple sclero
Records in the Danish National Prescription Register for at least one of the following types of medications: specific anti-migraine drugs, antiepileptic drugs* (at least two prescriptions for a type of medication in one year)
*Both a diagnosis of epilepsy AND two prescriptions of an antiepileptic drug in one year are required.
Hazard ratios (HRs), with 95% confidence intervals, will be obtained to compare risk of diagnosis with a general medical condition in those with previous mental disorders, compared to those without. All persons, sex-specific
Diagnosis in the Danish National Patient Register or death in the Cause of Death register, for at least one of the following diseases: HIV/AIDS, anemias.
Hazard ratios (HRs), with 95% confidence intervals, will be obtained to compare risk of diagnosis with a general medical condition in those with previous mental disorders, compared to those without. All persons, sex-specific
Cancer diagnosis in the Danish National Patient Register or death in the Cause of Death register.
Hazard ratios (HRs), with 95% confidence intervals, will be obtained to compare risk of diagnosis with a general medical condition in those with previous mental disorders, compared to those without. All persons, sex-specific
Event free survival, The cumulative incidence of clinical or subclinical cardiotoxicity, per randomized arm, in women with breast cancer at 1 year after treatment with neo- or adjuvant chemotherapy., 1 year after the completio
Determine the Percentage of Cancer Survivors That Maintain Left Ventricular Ejection Fraction (LVEF) ≥50% After Discontinuing Cardiac Medications: Beta Blockers, Angiotensin Converting Enzyme Inhibitors (ACE-I), or Angio
arterial blood oxygen partial pressure (PaO2), 5 min after jugular catheter flow 0ml/min|arterial blood oxygen partial pressure (PaO2), 5 min after jugular catheter flow 500 ml/min|arterial blood oxygen partial pressure (PaO2), 5
Global rating of goal-concordant care, patient-reported, Comparison between arms of whether care received corresponds to patient goals. This will be assessed at 12 months., 12 months after enrollment
Association of Heart Failure Biomarkers with Global Longitudinal strain rate, N Terminal-proBNP, hs troponin, ST2, galectin-3 with global longitudinal strain rate, up to 35 weeks
Incidence of atrial arrhythmias, Any documented evidence of atrial arrhythmia including symptomatic and asymptomatic events captured by EKG, 28-day mini cardiac telemetry, or monitoring of cardiac rhythm during echoca
Cardiotoxicity, Cardiotoxicity as measured by changes in left ventricular ejection fraction within one-year of completion of treatment, 1 year after completion of treatment
Odds of autoimmune disease in SCAD cases compared to controls, Through study completion, or approximately 50 years (average age of study participants)|Incidence Rate of SCAD, Through study completion, or approxima
Medication Adherence, The Morisky-8 is a self-reporting measure of unintentional and intentional medication non-adherent behaviors with a yes and no response. The total score of the moresky-8 ranges from 0 to 8, with a hi
Qualitative Description
Relapse in Cardiotoxicity, Number of participants with relapse in cardiotoxicity, defined based on International Cardio-Oncology Society 2021 Guidelines as (at least one of): 1. Asymptomatic left ventricular ejection fraction (LVEF) reduction by ≥10 percentage points to a LVEF of \<50% 2. Asymptomatic LVEF reduction by ≥5 percentage points to an LVEF of \<50% plus new relative decline in global longitudinal strain (GLS) by \>15% from baseline AND/OR new rise in cardiac biomarkers (\>2 fold increase in 3. Clinical heart failure (based on symptoms and clinical examination) with at least one of the following: fall in LVEF ≥5%, increase in cardiac biomarkers (as above), relative fall in GLS \> 15%, new arrhythmia (excluding ectop
Proportion of evaluated patients who should undergo CAD prevention, High clinical risk, or intermediate risk with CAC score \>0, 3 years
Cardiac dysfunction or signs or symptoms of heart failure, Cardiac dysfunction. as defined according to the Cardiac Review and Evaluation Committee (CREC) criteria as a decline in LVEF of 10% to less than 55% without sig
Investigate the effect on cardiac strain rate imaging (SRI) of Caelyx|The relation between cardiac SRI and classical ejection fraction measurement.|The relation between strain rate and blood markers such as troponin-I and BN
Feasibility - Recruitment, Definition: Number recruited at end of rollout. The criterion for success is to recruit 10 participants at each of 4 sites., 1 month (August 1 to 31st, 2019)|Feasibility - Retention, Definition: Number retra
The criterion for success is 70% or higher., 18 weeks after the start of the program
Quantification of fibrosis index by Cardiac Magnetic Resonance, Estimate the extracellular volume fraction derived from gadolinium-DTPA partition Coefficient of the myocardium, two years|Intracellular lifetime of water (τic) b
Pressure pain threshold over the shoulder of breast cancer patients after a physical therapy rehabilitation program following the surgery., This outcome will involve data regarding to pressure pain threshold assessment over th
The proportion of patients who had their preferences regarding place of care and place of death met, 1.7.2015
microbiome, The microbial composition of the stool and saliva samples was determined by 16S rRNA (ribosomal ribonucleic acid) gene sequencing analysis and metagenomics. Comparison of microbial abundance and diver
Cardiac functional status and quality of life, Cardiac functional status (depressed fractional shortening) and quality-of-life, will be assessed at baseline, two and five years into the study., baseline, two and five years
PET myocardial perfusion imaging (MPI)., Change from baseline in number of patients with perfusion defects measured as % total perfusion deficit (TPD) of the left ventricular myocardium by PET, Baseline (within 1 month pri
Body Composition, 12 months
Number of CV injury, 8 months
Measurement of distance from chestwall to the heart, Rigid and non-rigid measurement of distance from chestwall to the heart., 3 years|Measurement of distance from the heart to the mammary gland, Rigid and non-rigid me
Safety of concurrent sildenafil with doxorubicin-based chemotherapy, Sildenafil will be administered at least 7 days prior to scheduled first dose of doxorubicin and continue daily dosing through 2 weeks after last doxorubici
Compare the performance of automated EF and GLS measurements in resting transthoracic echocardiograms against conventional measurement acquisition., Measurements shall be compared using bias and 95% confidenc
Safety of intervention as defined by number of participants with Dose Limiting Toxicities (DLT) between first dose of Durvalumab and 30 days following completion of radiotherapy., Safety of intervention as defined by number
DLT for RT defined as: 1. Grade 4-5 non-hematologic serious adverse events (SAEs) considered by the Investigators to be probably or definitely related to protocol treatment. 2. Grade 3 or higher cardiac adverse events (e.g. severely symptomatic congestive heart failure (CHF), myocarditis, pericardial effusion, myocardial infarction, symptomatic arrhythmia) considered by the Investigators to be pr 3. Grade 3 or higher pulmonary adverse events (e.g. dyspnea/pneumonitis) considered by the Investigators to be probably or definitely related to protocol treatment and not responsive to steroids. 4. Failure to receive at least 54, Up to 30 days following end of treatment
Occurrence of major cardiovascular events and death of any cause at 1 year, Occurrence of death of any cause, cardiovascular death, heart failure, stroke, myocardial infarction in active cancer patients with atrial fibrillation.,
18 Weeks Progression Free Survival (PFS) Rate, The product limit estimator developed by Kaplan Meier will be used to graphically describe progression free survival for patients randomized to each study arm.
The 18 week progression-free survival rate was defined as the proportion of patients that were alive progression-free 18 weeks after registration into the study. Disease progression was assessed per modified RECIST criteria
quality of the images, A single four-point scale will be used (1: unacceptable, 2: usable under limited conditions, 3: probably acceptable, 4: fully acceptable) based on the European guidelines on quality criteria for computed t
Participants' comprehension of an intervention tool, Participants' comprehension of intervention tool outlining family health history and risk assessment of etiologically complex health conditions (heart disease, diabetes, brea
Postoperative morbidity, 30 days
To distribute human biospecimens for clinical research, By using the biological samples from CU-Med Biobank, translational studies can be done., 99 years|To discover the pathological mechanism of different acute and chro
Recording of a 12 lead ECG and wearable device ECG, 12 lead ECG and wearable device ECG recordings will be taken at the time point of care. The wearable device ECG will be placed on the left wrist to record a V1 (lead I)
Change in average E' (averaged septal E' and lateral E'), The average early diastolic tissue velocity of the mitral valve annulus measured by tissue Doppler echocardiography (averaged velocities of the mitral annulus measure
Nephrotoxicity, Change in Creatinine Clearance, 6 months
Identify the inflammatory components by C-reactive protein, Rate of C-reactive protein in the blood, 24 months|Identify the inflammatory components by interleukine1, Rate of interleukin 1 beta in the blood, 24 months|Identif
Dose-limiting toxic effects and recommended phase II dose, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0, Up to day 21|Change in pharmacokinetic behavior of this regimen, Da
Plasma metanephrine level, Level of plasma metanephrine, baseline, one point of time in a cross-sectional study|Plasma normetanephrine level, Level of plasma normetanephrine, baseline, one point of time in a cross-sectior
Days alive and able to wash themselves, patient performed act of washing by him/her-selves without interference of staff (regardless of whether as shower or bath, on a sink, or using a "sponge bath" in the bed), since baseli
Acceptability, The percentage of parents accepting the proposed screening in comparison with the number of mothers approached for consent, through study completion, an average of 1 year|Feasability - timing, The Turn-a
Measure of Peak O2 intake during test exercise, Maximal cardiopulmonary exercise testing (CPX) will be completed on cycle ergometer to determine peak oxygen uptake, a measure of cardiorespiratory fitness, 3-4 hours dur
The genetic profile of patients with anthracycline-induced elevation of troponin-I, one year
systolic pulmonary arterial pressure, trans-thoracic echocardiography, 6 months
Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 2.0 (CTCAE v2.0), Up to 52 weeks

Cardiac troponin T release, Cardiac troponin T release during anthracycline treatment, One month after last dose of anthracycline
Drop in ejection fraction of 10% as compared to baseline, 12 months
Free of atrial fibrillation, 31082009
High sensitivity cardiac troponin T (hs-cTnT), Biomarker of myocardial injury, hs-cTnT will be measured at baseline, and at 3 months after completion of all anthracycline. The change from baseline hs-cTnT to at 3 months afte
Survival without pericardial effusion at 2 months
To investigate the correlation of post-RT cardiovascular effects with myocardial Tl-201 myocardial perfusion images, By literature reviewing, cardiovascular functional status in patients received helical tomography has not bee
comparing the change in ejection fraction measured by physioflow and MUGA scan, at initial diagnosis and after 3 month
Proportion of participants with treatment emergent adverse events (TEAEs), Up to Day 15|Proportion of participants with adrenal insufficiency, Up to Day 15|Proportion of participants with safety findings determined by labora
Change of Systolic function indices measurement by 2D-Echocardiography from Baseline versus after alpha blockade and after surgery, Left ventricle end systolic and end diastolic diameter in millimeter, at baseline (Day 1), a
Quality and cost of care
Frequency of goals of care communication, Frequency of goals of care conversations in the last 6 months of life, 2 years|Timing of goals of care communication, Proximity of goals of care communication to death, 6 months
Cardiac Energetics, Cardiac MRI and MRS, At baseline|Cardiac Energetics, Cardiac MRI and MRS, Through study completion, up to sixteen weeks
Fatigue, 12 weeks
Can RV inflammation be assessed by T1 mapping CMR following lung resection by assessing the number of CMR studies which have an IQS>1?, The investigators will test and report inter- and intra-observer reproducibility
High Sensitivity C-Reactive Protein, Change in hsCRP from baseline, up to 12 months|Growth Differentiation Factor 15, Change in GDF-15 from baseline, up to 12 months|Placental Growth Factor, Change in PlGF from baseli
Determine feasibility of recruitment to this pilot trial by evaluating the eligibility requirements among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure., Number of participants screene
Feasibility & Acceptability, Feasibility defined by compliance with viewing \>50% of the weekly videos (proposed target rate of 5 out of 8 videos watched; must watch at least 80% of each video), and 70% of participants
Perioperative changes in blood gases, Ratio of arterial oxygen tension to fraction of inspired oxygen (PaO2/FiO2), arterial carbon dioxide tension (PaCO2). Hypoxemia is defined as peripheral oxygen saturation (SpO2) \< 92
Proportion of Atherosclerosis in CCTA Arm, Proportion of prostate cancer patients without cardiac symptoms in the CCTA arm who are reclassified into a higher risk group using automated plaque assessment from CCTA tha

Secondary Outcome Measures
Amount of late gadolinium enhancement by cardiac MRI, 6 months|High-sensitivity troponin T, 6 months|C-reactive protein, 6 months|Serum NT-proBNP, 6 months|Carboxyl-terminal telopeptide of collagen type I, 6 months|A
Quality of life based on self-report instruments, An analytic Markov model will be created and used. Estimates and their 95% confidence will be included to explore the sensitivity of any quality-adjusted life years estimates., E
Modified BORG, As for primary outcome measure|NRS Breathlessness at best/worst, as for primary outcome measure|Dyspnoea descriptors, as for primary outcome measure|CRQ, as for primary outcome measure|EQ-5D, a
Hospital Anxiety and Depression Scale (HADS) - patient, Patient symptoms of depression and anxiety assessed with the Hospital Anxiety and Depression Scale (HADS), which has become standard for ICU and post-ICU stud
Breathlessness intensity, Breathlessness intensity measured by NRS (range 0-10), at 0, 3, 5, 10, 15, 20, 30, 45 and 60 minutes after application of FBT/IRM|Numbers of rescue medication doses, If adequate breathlessness re
Composite endpoint of mortality or major cardiovascular outcomes, Composite endpoint of mortality or major cardiovascular outcomes (defined as acute myocardial infarction, heart failure, inappropriate sinus tachycardia an
Cardiovascular Toxicities Associated with Changes in Carfilzomib-Induced Endothelial Function, The association between changes in carfilzomib-induced endothelial function and frequency of cardiovascular toxicities stratifie
Patient symptoms of depression as assessed by the PHQ-8 (Memorial Symptom Assessment scale), 4/01/2007-3/31/2012|Patient-, family-, and nurse-assessed ratings of the quality of end-of-life care provided by study clini
Coronary artery blood flow rate, The coronary artery blood flow rate is measured with ultrasound. The rates are compared with the baseline and between the groups., 3 months|Cardiac arrythmias during 24-hour electrocardio
To measure the PF NTproBNP level in patients with pleural effusion of various aetiologies, 24 months|Correlation of clinical factors that may affect the levels of pleural fluid NTproBNP such as echocardiographic features, pres
collimator performance, Physical measurements of collimator performance on test object., Day 0
Genotype/phenotype correlation. To determine the frequency of PRKAR1A germline mutation in patients with isolated cardiac myxoma or isolated lentiginosis., 6 months
Cost-effectiveness of tonometry-based screening in the clinic setting and at home., Will apply the sensitivity and specificity of echo, CMR, and the Oscar 2™ ABPM system (clinic, home-based) to compare the number of asy
Preoperative heart-rate variability of breast cancer patients, Heart-rate variability measured by Holter monitor and a following analysis of frequency domain parameters., 1 day preoperatively|Postoperative heart-rate variability
Improvement of PCOS, diabetes type 2- and coronary heart disease-risk factors, one year
Change in Global Longitudinal Strain as Measured by CMRI, Baseline to 12 months of follow-up|Change in Peak Left Ventricular Twist as Measured by CMRI, Baseline to 12 months of follow-up|Change in Peak Left Ventricula
Effectiveness of treatment with IIM., Iron deficiency anemia (IDA): Hb (Hemoglobin) increase ≥ 1 g/dL., Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).|Effectiv
Questionnaire comprises the following questions: 1. I am hesitant to be treated with IIM. 2. I would consider IIM treatment due to the physician´s choice. 3. I would consider IIM treatment due to its safety compared to other iron treatment options. 4. I would consider IIM treatment due to its efficacy compared to other iron treatment options. 5. I would consider IIM treatment due to its specific dosing and administration schedule., Complete observation time-frame (the total observation period of this study will amount to 90 months).|Attitude of physicians towards 1. I am hesitant to treat with IV iron. 2. I would consider IV iron treatment due to the patient´s desire. 3. I would consider IV iron treatment due to its safety compared to other iron treatment options. 4. I would consider IV iron treatment due to its efficacy compared to other iron treatment options. And: 1. I am hesitant to treat with IIM. 2. I would consider IIM treatment due to the patient´s desire. 3. I would consider IIM treatment due to its safety compared to other iron treatment options. 4. I would consider IIM treatment due to its efficacy compared to other iron treatment options. 5. I would consider IIM treatment due to its specific dosing and administration schedule., Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).|Patient and disease p * Treatment-emergent adverse events (maximum grade per patient), * Grade 3/4 treatment-emergent adverse drug reactions, * Grade 3/4 treatment-emergent serious adverse events, * Treatment-emergent serious adverse drug reactions, * Pre-treatment adverse events, * Pre-treatment serious adverse events, * Follow-up adverse events, * Follow-up serious adverse events., Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
Overall patient survival, Patient Mortality at any time post transplant, 1 and 5 years|Graft survival, Need for retransplant secondary to graft failure of any cause, or death, 5 years
response rate, Evaluate response rate 21-30 days after the treatment|Time to progression, 1 year after the treatment of MPE.|Overall survival, 1 year after the treatment of MPE|Number of Participants with Adverse Events, on
causes of death during hospital stay and during follow-up, 5 years
Rate of intensive care (ICU) transfer, The rate of ICU transfer for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group a
Proportion of patients receiving salvage treatment to increase platelet counts., Salvage treatment including platelet infusion, rhIL-11, etc., during 3 cycles cancer treatment period(each cycle is 14, 21 or 28 days)|Changes in c
Changes in levels of follicle-stimulating hormone in serum, Follicle-stimulating hormone (FSH) will be measured in serum samples, Baseline, before firefighting without fire, day after firefighting without fire, before firefighting u
Common Terminology Criteria for Adverse Events (CTCAE), Common Terminology Criteria for Adverse Events (CTCAE) related to ICIs, includes: arrhythmia, cardiogenic chest pain, valvular heart disease, cardiomyopathy, myo
Change in CT-based left ventricular strain parameters, Change in CT-based left ventricular strain parameters before and after the chemotherapy, 12 months after completion of chemotherapy|Change in left ventricular global l
Understanding disease pathophysiolgy, to assist in the understanding of disease pathophysiology and in the generation of diagnoses in subjects with uncommon presentations of diseases with cardiovascular consequences.
Change From Baseline in the Holter ECG Parameters of QT Interval, Corrected QT Interval (QTc), Bazett Corrected QTc Interval (QTcB), Individual-corrected QT Interval (QTcI), RR Interval, PR Interval, and QRS Duration at Indi
Serum cardiac biomarkers as predictors of composite cardiotoxicity, Blood draw to measure Troponin and BNP levels, Up to 28 days prior to beginning chemotherapy, during chemotherapy (specifically, at the visit that will ac
Change From Baseline in Left Ventricular Ejection Fraction (LVEF), Change in left ventricular ejection fraction as assessed via cardiac MRI., Baseline to 12 months|Change From Baseline in Left Ventricular Ejection Fraction (LV
Sphericity index is the ratio of the long and short axis measurements of the left ventricle., Assessed as a trajectory (baseline, 6 months, and 12 months)|Change From Baseline in Area of Injury, Change in the scar percent (sca
Minimum and maximum scores for scale are 0 and 105 respectively. Lower scores indicative of better outcome., Assessed as a trajectory (baseline, 6 months, and 12 months)|Change From Baseline in N-Terminal Pro-Brain N
Reference Values of Healthy Peers, Assessment of reference values from age- and gender-matched healthy peers (matched pairs)., Throughout study completion, an average of 2 years|Analysis of Echocardiography Marker 1
Changes in Stroke Volume as measured by LiDCOplus monitor., After paracervical block., 0-10 minutes|Changes in Heart Rate as measured by LiDCOplus monitor., After paracervical block., 0-10 minutes|Changes in Total Pe
Adherence rates to the study protocol, Measured as: * recruitment/retention rates * completion of study measurements within timeframes, Baseline to 18 weeks.|Changes in physical fitness (Maximum short exercise capacity (Watt)), Assessed through Steep Ramp test, Baseline, halfway (R-)CHOP treatmen * Global health status * Summary score Functional scales: * Physical functioning * Role functioning * Emotional functioning * Cognitive functioning * Social functioning Symptom scales: * Fatigue * Nausea and vomiting * Pain * Dyspnoea * Insomnia * Appetite loss * Constipation * Diarrhoea * Financial difficulties, Baseline, halfway (R-)CHOP treatment (+/- 9 weeks), after (R-)CHOP treatment (+/- 18 weeks)|Changes in lymphoma specific symptoms, Measured using the add-on of the abovementioned EORTC QLQ Fatigue dimensions: * Physical fatigue * Emotional fatigue * Cognitive fatigue, Baseline, halfway (R-)CHOP treatment (+/- 9 weeks), after (R-)CHOP treatment (+/- 18 weeks)|Changes in skeletal muscle end-exercise pH, Assessed through 31P-MRS imaging., Baseline, halfway (R-)CH

To compare the effects of L-carnitine therapy versus placebo on: other potential markers of anthracycline induced cardiotoxicity such as LV volume, LV systolic and diastolic function, troponin T (TnT) and NT-pro-brain natriur
Incidence of Abnormal LVEF at 12 Months, The study is designed to detect an intergroup difference of absolute difference of 10 percentage points (simple difference) in the change in LVEF between the experimental and cont
Stroke, Occurrence of stroke, postoperatively until 5 years follow-up|Transient ischemic attack, Occurrence of Transient ischemic attack, postoperatively until 5 years follow-up|Myocardial infarction, Occurrence of Myocardial
Compliance statistics for wristband use for all participants (Stage I, II), Defined as the percentage of days during which data were collected for at least 70% of the hours., Up to 6 weeks and 6 months after enrollment and dev
Clinically evident congestive heart failure, Clinically evident congestive heart failure(symptoms of fluid overload such as shortness of breath, dyspnea on exertion, orthopnea or paroxysmal nocturnal dyspnea or physical findir
The quality of life (QOL) questionnaire, Baseline up to 2.5 years post-treatment|Biomarker analysis such as TGF-β, Serum surfactant proteins-A & -D, MMP1 and MMP7, Up to 97 days post-treatment|The overall survival in pa
Difference in set up times for Breathe Well vs RPM, The setup times for both systems, the 'Breathe Well' and the modified RPM system; will be measured for all fractions., 2 years|Patient comfort, To investigate patient comfo
Change in Myocardial energy efficiency from baseline to 6 months, Myocardial energy efficiency, Kmono reserve, will be determined by C-11 acetate PET, Baseline and 6 months|Light Chain Toxicity, Study subject urine light
onset of any disease diagnosed 1 year after discharge, rate of patients with onset of any disease diagnosed 1 year after discharge, 1 year after discharge|rate of demand for medical care, number of patients seeking for health
pCR in breast (pCRB), At the time of definitive surgery, an expected average of 23 weeks|pCR in breast and axilla (pCRBA), At the time of definitive surgery, an expected average of 23 weeks|Clinical objective response rate (c
Difference in Patient Health Questionnaire-9 (PHQ-9), 12 weeks|Difference of General Anxiety Disorder-7 (GAD-7) score, 12 weeks|Difference of Functional Assessment of Cancer Therapy-Prostate (FACT-P) score, 12 weeks
Ability of pre- to post-radiotherapy SUV changes in the heart, Measured by sarcoidosis FDG PET-CT scans., Up to 30 months after radiotherapy|Overall survival, Survival, Up to 30 months after radiotherapy|Cardiac toxicity, A
NT-proBNP, biomarker of cardiac injury, 24-48 hours after first doxorubicin and 7-14 days after completion of last doxorubicin cycle|Cardiac Troponin T, biomarker of cardiac injury, 24-48 hours after first doxorubicin and 7-14
Accuracy of medical decisions, Family caregiver responses to treatment decisions hypothetical clinical vignettes will be compared to the decisions for the same vignettes made by their loved one. Each vignette has 6-8 assoc
Twelve 5-point Likert-style questions on how the program presented various kinds of information; helped the user clarify values, choose a spokesperson, etc.; and helped the user document or be prepared communicate thei
Three 10-point Likert-style questions on user overall satisfaction, with the advance directive created by the intervention, and the amount of information provided.
One open-ended item asking how the intervention was helpful., 1st study visit
The outcomes for quality of life will be evaluated from the McGill Quality of Life Questionnaire.
Anxiety by using the visual analogue scale (VAS), This scale measures the anxiety of patient. It's a visual analogue scale which is also known as linear analogue scale. These scales require respondents to place a mark on a lir
The EORTC QLQ-C30 uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 ("very poor") to 7 ("excellent"). Half points are not allowed. The range is 6. First of all, raw score has to be calculated w
Fatigue improvement, Fatigue improvement is assessed by multidimensional fatigue inventory (MFI-20 survey).
MFI-20 consists of five subscales used to express: general fatigue, physical, reduced activities, reduced motivation, mental fatigue.
Each scale contains four items for which the person had to indicate the extent the items describe their situations in the recent few days on a 5-point Likert scale, ranging from "yes, that is true" to "no, that is not true" Scores
Higher scores indicate higher levels of depression or anxiety, through study completion: initially (T1), at 6 weeks (T2), 12 weeks (T3) and after at 24 weeks (T4) follow-up|Cardiac coherence improvement, Increased percentage
Change in Blood biomarkers, Blood samples will be collected to determine concentration of Brain Natriuretic Peptide (NT- proBNP) and high- sensitive cardiac Troponin (hsTnT). Cardiac troponin release after high-dose chem
Change in fasting glucose, Fasting blood glucose, baseline, 6, 12, 24 months|Changes in glycosylated hemoglobin A1c (HbA1c), Glycosylated hemoglobin A1c. Measure of glucose control over several months., baseline, 6, 1
* sex-specific excess waist circumference (men \> 102 cm, women \>88 cm), * fasting plasma triglycerides \>= 120 mg/dl, * fasting plasma HDL(men)\<40 or (women)\<50 mg/dl, * blood pressure \>=135/85, * fasting glucose \>=110 mg/dl). Each subject's metabolic syndrome marker level can range between zero and five, with zero representing no metabolic syndrome risk and five representing maximum risk. The a priori expecta
Agatston Score, Individual cardiac structures will be accessed using Agatston score. Agatston score is calculated using a CAC CT scan to measure for the presence of coronary artery disease based on the extent of coronary
Grading of coronary artery disease (based on total calcium score) measure is without units. Score categories are as follows: No evidence of disease/unrelated, preclinical disease, or clinical disease (non-numerically). Higher A
The assessment of calcium (Agatston score) on CAC CT will be compared to the dose received by the specified vessel as determined using deformable registration with prior radiation imaging (simulation CT scan)., 1 Year
Count of parent participants with change in perception of goal-centered care from baseline to 3-Month Follow-up based on Investigator assessment., Change in perception in quality of goal-centered care will be assessed by
The number of participants with cardiovascular disease (CVD) among patients with breast cancer prior to commencement of systemic chemotherapy., To assess the incidence of CVD at baseline, Baseline|The number of part
Incidence of supra-ventricular arrythmias, Number of patients with supra-ventricular arrythmias, 6 months|Incidence of systemic hypertension, Number of patients with systemic hypertension, 6 months|Incidence of arterial er
Causality assessment of reported cardiovascular events according to the WHO system, Case reported in the World Health Organization (WHO) of individual safety case reports to September 2018|Description of the type of ca
cardiac toxicity event free survival, The time from the date of randomization to any recurrence of clinical or subclinical cardiac toxicity, 5 years|cardiac toxicity event free survival, The time from the date of randomization to any
Effect of AZD6094 at therapeutic dose (600 mg) on additional time-matched ECG variables, To assess the effect of AZD6094 at therapeutic dose (600 mg) on additional time matched ECG variables using the dECG and pECG
Assessment of biochemical response, such as 50% change in total PSA from baseline in patients receiving apalutamide, Assessment of biochemical response, such as 50% change in total PSA from baseline in patients rece
Baseline incidence of asymptomatic atrial fibrillation before lung resection, Number of unknown/asymptomatic/occult atrial fibrillation in the high-risk malignant lung resection population before surgery so that we know wheth
Investigate safety and tolerability of tipifarnib according to NCI CTCAE v5.0, Incidence of adverse events, incidence of abnormal laboratory test results, abnormal vital signs, and abnormal ECG results, 30 days after treatmen
Visceral adipose tissue, Measured only in a subset (n=30) of participants via 1.5T MRI., post-intervention (16 weeks)|Left ventricular ejection fraction, Measured only in a subset (n=30) of participants via 1.5T MRI., post-interv
Modified Fatigue Impact Scale (MFIS), The Modified Fatigue Impact Scale (MFIS) assesses the effect of fatigue on cognitive functioning, physical functioning, and psychosocial functioning. The minimum value is 0, the maxim
Pittsburgh Sleep Quality Index (PSQI), Measure the quality and patterns of sleep in adults. It differentiates from "poor" and "good" sleep quality by measuring seven areas. The order of the PSQI items has been modified from
Compare Metabolic Dysregulation (MetD) in Progressive Combine Training (PCT) and Attention (AC) groups -Insulin Resistance, Compare changes from baseline in insulin resistance (IR) measured by Homeostasis Model Ass

The incidence of hs-TnT/NT-proBNP elevations at 6, 12, and 24 months., Cumulative incidences and 95% confidence intervals, considering death as a competing event., Through study completion, an average of 1 year|The i mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interac Peripheral arterial tonometry ratio: based on the response to reactive hyperemia using post and pre-occlusion values, Through study completion, an average of 1 year|Association between the evolution of troponin and calciu Peripheral arterial tonometry ratio: based on the response to reactive hyperemia using post and pre-occlusion values, Through study completion, an average of 1 year
Coronary artery calcium score, Subclinical atherosclerosis evaluation by Coronary Artery Calcium by CT, Four weeks|Brachial Ankle Index, Subclinical atherosclerosis evaluation by brachial ankle index (BAI) by blood pressure
ECHOCARDIOGRAPHIC PULMONARY PRESSURE, ECHOCARDIOGRAPHIC ASSESSMENT OF PEAK AND MEAN PULMONARY PRESSURE AT 6 MONTHS AFTER TREATMENT COMPARED WITH PRE-TREATMENT VALU
Change in Cardiac Electrical Activity, Cardiac electrocardiogram at rest will be assessed using a 12 lead ECG (General Electric Case System). Specifically, the duration (ms) of the PR interval, RR interval, QRS interval and QT
Survival, overall survival, 3 months|Pericardial effusion free survival, survival without recurrence of pericardial effusion, 3 months|cardiac tamponade, Occurrence of cardiac tamponade as defined by echocardiographic finding
Objective response rate, Six weeks
Change of the index of microcirculation according to laser Doppler flowmetry, Change of the microcirculation index according to the results of laser Doppler flowmetry in relation to the values obtained before the start of chem
Bleeding, Intra- and postoperatively|Need for allogenic blood transfusions and blood products, Within submission|Clinical effect focusing on known complications to cardiac surgery and CPB, Within submission
Composite pharmacodynamic outcomes of understudied drugs in children, When applicable, Monte Carlo simulations will be performed to evaluate therapeutic target attainment rates (pharmacodynamics) in the population c
Quantitative and Qualitative ECG parameters, Predose (Day -2) to postdose changes and absolute values in quantitative Holter ECG parameters (heart rate, RR, PR and QRS intervals) after placebo (Day -1, Cycle 1), after a si
Changes in the level of Cardiac output, The above results should be measured immediately after induction, at the beginning, into ICU 30 minutes|Changes in the level of SVR, The above results should be measured immediat
Myocardial infarction, up to 35 years after exposure to childhood cancer therapy|Late-occurring stroke, "late" is defined as 5 years or more after diagnosis of cancer, up to 35 years after exposure to childhood cancer therapy
Family satisfaction with care (FAMCARE-2), Change from baseline in family-reported satisfaction with care measured using the FAMCARE-2 scale at baseline; change from baseline measured using FAMCARE-2 at 7 days pos
Serum cardiac biomarker, The secondary objective of this study is to compare pre- and post-Radiation Therapy changes in serum TGF-β levels, 6 months
Incidence of the first occurrence of any component of the following composite endpoint: CV death, MI, stroke., Cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, and urgent revascularization, Ba * Nonfatal type 1 myocardial infarction. * Nonfatal ischemic stroke. * Urgent coronary revascularization., 18 months after treatment initiation|Evaluate the first occurrence of the individual components of the primary endpoint, * CV death. * Nonfatal type 1 myocardial infarction. * Nonfatal ischemic stroke. * Urgent coronary revascularization., 24 months after treatment initiation|Evaluate the first occurrence of the individual components of the primary endpoint, * CV death. * Nonfatal type 1 myocardial infarction. * Nonfatal ischemic stroke. * Urgent coronary revascularization., 36 months after treatment initiation|Evaluate the first occurrence of the individual components of the primary endpoint, * CV death. * Nonfatal type 1 myocardial infarction. * Nonfatal ischemic stroke. * Urgent coronary revascularization., 48 months after treatment initiation|Change in Treatment Adherence, The Morisky-Medication Adherence Scale (8 item) Questionnaire will be administered, 6 months after patient treatmen
Evaluate association between plasma exposure to TH-302 and its active metabolite, Br-IPM, and effects on cardiac repolarization, 2 years|Safety and antitumor activity of TH-302 in patients with advanced solid tumors, 2 yea
Change in Total Healthcare expenditures as measured through Medicaid claims data, We will use Medicaid claims and enrollment expenditure data to examine changes in total medical expenditures between the three groups
30-day Readmission Among Intervention Participants, The outcome measure is the rate of 30-day readmissions among Intervention group participants that declined to receive the in-home social work intervention versus thos
Change in cardiac biomarkers., The outcome assessed by plasma concentrations of BNP and NT-proBNP, 1 year, 2 years, 3 years|Change in lung function., The outcome assessed by lung function test. The lung function test
Regional myocardial perfusion, The change in absolute MFR between baseline and follow up tests for the 3 major coronary territories. Territories with severe reduction in flow or no flow on baseline images will be censored fro
Two-dimensional scans and pulse measures will be taken of the brachial artery with flow-mediated vasodilatation expressed as a percent change in arterial diameter from resting diameter., 6 - 9 months
Change in NYHA heart failure score, The association between Lutathera Therapy against Best Supportive Care will be assessed by comparing the change in NYHA heart failure score in patients enrolled in both study arms.
The NYHA Heart Failure Score is grade I to IV, with Grade I being No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath) and Grade IV being Unable
The change in grade will be assessed with an anticipated reduction in grade if the study treatment is successful in reducing symptoms., 5 years|Progressive disease, Progressive disease will be determined according to RECI
Tumour size according to RECIST 2.0 criteria will be examined with an anticipated decrease in tumour size should the study intervention be successful., 5 years|Reduction in urinary 5-HIAA levels, Reduction in urinary 5-HIAA
Elevated 5-HIAA levels are an indicator of Carcinoid Syndrome, which is the condition under study in this clinical trial. A reduction in urinary 5-HIAA levels is expected should the study intervention prove successful., 5 years|C
- European Organization for Research and Treatment of Cancer questionnaires, QLQ-C30 and QLQ-GI.NET2
The change in quality of life scores will be compared across the Lutathera Therapy arm and Best Supportive Care arm. If the study intervention is successful in moderating disease, a positive increase in the quality of life scor
After an expected 5 to 7.5 years of follow-up:|Cardiovascular death, non-fatal MI, hospitalized acute coronary syndrome other than MI, myocardial revascularization, and stroke (individually and combined)|All-cause hospitaliz
Rate of adverse events, The secondary objectives are to assess the safety of EGCG in cardiac AL amyloidosis, to determine whether EGCG can prevent or delay cardiac progression and to compare survival of patients receiv
Subjective Image Quality Evaluation (entire cohort and for individual disease groups), measured by blinded evaluation by radiologists, 1 year
Median Time to Development of an Event Defined as Cardiac Event or Asymptomatic Worsening of Left Ventricular Dysfunction, Among Patients Who Developed One Event., Up to 18 months.|Absolute Changes in LVEF Duri
Hold is defined as any delay or discontinuation of HER2 targeted therapy due to cardiac toxicity. One cycle of HER2 targeted therapy will be considered 3 weeks. One therapy hold will be defined as any 3-week HER2 targete
Use of dose-saving strategies, Use of Low tube potential imaging, Low tube current imaging, Automated Exposure Control, ECG-controlled tube current modulation (dose pulsing), Iterative image reconstruction techniques a
Quantitative Assessment includes Signal intensity, Image noise, Contrast-to-noise ratio, Signal-to-noise ratio. Qualitative assessment of each coronary artery is performed using a 3-point grading scale including excellent, inte
Changes in myocardial function assessed by echocardiography, Increasement of segmental strain measurements (unit of measures:%), 6 and 24 after completion of radiotherapy with reference to baseline|Anatomical change
Visceral adipose tissue mass, measured by MRI scan, 12 weeks|Stroke volume, Structural cardiac parameter: measured by MRI scan and echocardiography, 12 weeks|Left ventricular and atrial end-diastolic volume, Structura
The Visual Analogue Scale (VAS) is a self-report measure consisting simply of a 100 mm horixontal line with a statement at each end representing one extreme (0mm = nothing, 100mm = extreme), 12 weeks|RA disease speci
Total score is between 0-3.0. Increasing scores indicate worse functioning with 0 indicating no functional impairment and 3 indicating complete impairment., 12 weeks|RA disease specific outcomes 4, Change in Short Form 3
A 8-scale score within 8 domains.All items are scored so that a high score defines a more favorable health state., 12 weeks|RA disease specific outcomes 5, Change in the composite Disease Activity Score-28 ESR for Rheur
A DAS28 of greater than 5.1 implies active disease, less than 3.2 low disease activity, and less than 2.6 remission, 12 weeks|RA disease specific outcomes 6, Change in response criteria will be assessed according the clinica
The CDAI composite index quantifies disease activity in RA, by utilising four clinical parameters including tender and swollen joints and global assessment from both patient and assessor on a vasual analogue scale.
CDAI interpretation score CDAI ≥ 22,1: High Activity CDAI \< 22,1 og ≥10,1: Moderate Activity CDAI \<10,0 og ≥ 2,9: Low Activity CDAI \<2,9: Remission, 12 weeks|RA disease specific outcomes 7, Change in response criteri
thromboembolism, occurrence of thromboembolism, from inclusion in the cohort up to 10 years|bleeding, occurrence of bleeding, from inclusion in the cohort up to 10 years|mortality, occurrence of mortality, from inclusion in
Determine the incremental diagnostic value of Trop and BNP in predicting incidence of Hem CMP., Determine the incremental diagnostic value of Trop and BNP in predicting incidence of Hem cardiac marker (CMP).
Determine the relation between prior myocardial scaling and incidence of herceptin induced cardiac marker (CMP).
Determine the correlation between myocardial edema, BNP and heart failure incidence of CMP, 3 years
Hormone levels, Measurement of testosterone, More than 10 years after testicular cancer diagnosis, At recruitment|Serum platinum, Measurement of residual serum platinum levels, More than 10 years after testicular cancer
All-cause mortality, every 6 months|Fatal and non fatal cardiovascular events including a) coronary heart disease death, b) non-fatal MI, c) fatal and non-fatal stroke and d) any hospitalization for heart failure, every 6 months|F
Cardiac function recovery rates between group 1 and group 2, Incidence rates will be compared using a simple test for equality of binomial proportions (χ \^ 2 -test or Fisher Exact)., Baseline up to 6 months|Time to recovery

Ethnic disparities in disease incidence, Identifying ethnic disparities in disease incidence. The corresponding secondary outcome measure for this is, for each of the 19 diseases under consideration, the diagnosis of the disea
Family and provider communication (Communication of family health history with family members and health care providers), Communication of family health history with family members and health care providers., Baseline a
Evaluation of NT-proBNP in the days following the start of treatment and post surgery duration of hospital stay, up to 10 days
SF-36v2 PCS Score, Change in Short Form-36 (SF-36 version 2) questionnaire Physical Component Summary \[PCS\] Score. PCS scores are calculated based on responses to specific Short Form-36 (version 2) questions us
Non-response is defined as either stable or progression., Baseline through 12 months of treatment|NIS-LL Total Score, Change in Neuropathy Impairment Score-Lower Limb (NIS-LL) Total Score in subjects with peripheral ne
Total major ischemic events (includes CV [cardiovascular] death, MI, stroke, hospitalizations for UA [unstable angina] and revascularizations)|Hospitalization for unstable angina|Hospitalization for congestive heart failure (CHF)
To examine the association between changes in biomarker levels and changes in cardiac structure and function as measured by CMR in breast cancer patients receiving trastuzumab., Five years
Physical activity, A Physical Activity Screen (PAS) will be used to capture average minutes of moderate-to-vigorous physical activity each week(Clark et al., 2020). This tool was created based on questions used by Exercise is
Assess the influence of default options in ADs on Veterans' selections of specific life-extending therapies, The proportions of patients electing to receive each of the 5 specific life-extending interventions, 18 months|Determin
comparison of heart rate between groups, In DTC group, the investiagtors measured heart rate at 2009 (receiving TSH suppressive therapy for 5 to 9 years after thyroidectomy). As each DTC patient was enrolled, control subj
Patients treated with oral anticoagulant therapy, other antithrombotic therapy or not treated experiencing all cause stroke, Number of patients treated with oral anticoagulant therapy, other antithrombotic therapy or not treate
Number of Participants with Multiple myeloma, Develop or be diagnosed with multiple myeloma, 3 years
Cardiorespiratory fitness, Assessed via cardiopulmonary exercise test and quantified as VO2peak, Baseline to 24-month follow-up (Primary and Secondary RCTs)|Ventilatory threshold, Estimated using the V-slope method an
Anthracycline cumulative dose, Anthracycline cumulative dose, 4/6 month after baseline (end of chemotherapy)|T troponin, T troponin rate, Baseline, Before each chemotherapy administration, 4/6 month after baseline (end o
Rate of Atrial Fibrillation, The current rate of atrial fibrillation is measured by the Northern New England Cardiac Database, this existing database will track a-fib rates until the patients are discharged from the hospital after sur
Evaluation of grade III-IV postoperative complication in the Dindo-Clavien classification, To determine whether the strategy for optimizing cardiac output guided by dynamic dependence preload indices is associated with a di
Changes in the inflammatory factor interleukin-6, Detection of inflammatory factors by serum， It reflects the degree of inflammation in the body at different time points, Preoperatively, End of operation ， The first day after su
Ease of Use/System Usability, System Usability Scale (SUS) - The SUS consists of a 10 item questionnaire with five response options for respondents; from Strongly agree to Strongly disagree. Scores range from 0-100, with
Dyadic Efficacy is an investigator developed 1-item question "How confident are you that you and your loved one can work together as a team to manage the cancer-related problems that come up?" Item was answered on a
1 item to assess patient and caregiver perceptions concerning patient ability to manage symptoms. 0= can manage extremely well, 10= cannot manage at all, Baseline and 6 week follow up visit|Change From Baseline in Eme
Dyspnea score at six months after (chemo)radiotherapy, assessed by the patient version of CTCv4.0, up to 6 months|Changes in dyspnea score after radiotherapy, compared to baseline, up to 12 months|Change in Left Ventr
Abnormalities in the 31 week and the year 3 echocardiograms, Endpoint will be abnormalities in the 31 week and the year 3 echocardiograms (i.e. year 1 off therapy). Secondarily, we shall compare the CCR rates for the two t
Relationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Plasma Concentration), ΔQTcF (Change from Baseline in QT Corrected According to Fridericia's Formula); CI (Confidence Interval); Cma
Table below details the results of the linear mixed effects model to quantify the relationship between the lurbinectedin plasma concentrations and ΔQTcF and Predicted ΔQTcF and 90% CI at mean lurbinectedin Cmax., Throu
Table below details the results of the linear mixed effects model to quantify the relationship between the lurbinectedin plasma concentrations and ΔQTcF and Predicted ΔQTcF and 90% CI at mean lurbinectedin Cmax., Throu
Table below details the results of the linear mixed effects model to quantify the relationship between the lurbinectedin plasma concentrations and ΔQTcF and Predicted ΔQTcF and 90% CI at mean lurbinectedin Cmax., Throu
Afterload measurements, Evaluated in the manner described for primary outcome based on testing the significance of the interaction of time by group variables. The distribution of continuous variables will be examined graph
Functional Status ADL, Rosow-Breslau Activities of Daily Living scale range 17-51 with higher scores indicating greater ability., Baseline, 6 and 8 week follow ups|Center for Epidemiology Studies - Depression Scale (CES-D),
The number of treatment interruptions due to suspected cardiotoxicity, Number of times treatment was paused due to suspected cardiotoxicity either based on imaging or biomarkes as defined in the protocol., Through study
Patient perception of benefit, Patient will be asked to complete a Visual Analogue Scale for pain (scale from 0 to 10, 0 being no pain and 10 being worse pain imaginable) and and/or Visual Analogue Scale for anxiety (scale fr
Preliminary information regarding the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss with diet and increased physical activity., 6 months, 1 year
Length of Post-operative Hospital Stay, Length of hospital stay after the operation, 1 week on average
System Usability Scale, Questionnaire on SaMD CARINAE usability by patients, caregivers and healthcare professionals, 30 days: from hospital admission to 14 days after surgery|Usability questionnaire, Ad-hoc questionnair
Ovulation, health related quality of life, 16 weeks
Change in myocardial work (MW), Myocardial work (MW) is a non-invasive, less load-dependent echocardiographic parameter obtained during standard transthoracic echography using the pressure-strain loop data.
This parameter consists of the following measurements: Global constructive work (GCW) Global wasted work (GWW), Global work index (GWI), and Global work efficiency (GWE), change from baseline (before rehabilitation) a
In the evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS) from 0 ('the worst health you can imagine') - 100 ('the best health you can imagine'), change from baseline (b
ACEI/ARBs use at discharge, Proportion of β-blockers prescription at discharge among eligible patients, 14 days on average (during hospitalization)|β-blockers use at discharge, Proportion of β-blockers prescription at discha
Changes in Ejection fraction, The improvement in the ejection fraction in percentage., Baseline and after one week postoperative|Changes in cardiac index, The improvement in Cardiac index (Liters/minute/square meter), Bas
Change in HbA1C from baseline at 20 weeks, 20 weeks|Change in blood pressure from baseline at 20 weeks, 20 weeks|Change in lipid profile from baseline at 20 weeks, Including LDL, HDL, total cholesterol, triglycerides, 20
Assess whether the administration of nicotinamide riboside is associated with less reduction in left ventricular systolic function measured by echocardiography, From randomization to the end of blinded therapy:
Change in LVEF, as determined by echocardiography, Baseline, 3 months, 6 months for patients receiving extended chemotherapy, and extended follow up 12 months after initiation of chemotherapy|Assess whether the adm
Change in left ventricular global longitudinal strain (GLS), as determined by echocardiography, Baseline, 3 months, 6 months for patients receiving extended chemotherapy, and extended follow up 12 months after initiation of
Change in left ventricular global circumferential strain (GCS) and GLS, as determined by CMR, Baseline, 3 months, 6 months for patients receiving extended chemotherapy, and extended follow up 12 months after initiation of
Change in left ventricular end-systolic volume measured by CMR, Baseline, 3 months, 6 months for patients receiving extended chemotherapy, and extended follow up 12 months after initiation of chemotherapy|To assess wh
Change in circulating hs-cTnT, Baseline, 3 months, 6 months for patients receiving extended chemotherapy, and extended follow up 12 months after initiation of chemotherapy|To assess whether the administration of nicotina
Change in circulating hs-cTnI, Baseline, 3 months, 6 months for patients receiving extended chemotherapy, and extended follow up 12 months after initiation of chemotherapy|To assess whether the administration of nicotina
Change in distance in meters during 6-minute walk test, Baseline, 3 months, 6 months for patients receiving extended chemotherapy, and extended follow up 12 months after initiation of chemotherapy|To assess whether the
Change in force generated by handgrip strength test, Baseline, 3 months, 6 months for patients receiving extended chemotherapy, and extended follow up 12 months after initiation of chemotherapy
Usage of angina pectoris relief drugs, The change of angina pectoris relief drugs will be evaluated, 24 months|Six-minute walk test improvement, Change in the six-minute walk test will be evaluated before and after the proce
The duration time of trigeminal cardiac reflex during cerebellopontine angle tumor surgery., The duration time of trigeminal cardiac reflex during cerebellopontine angle tumor surgery., The whole cerebellopontine angle tumor
Part 1: Plasma concentration of GSK2118436 and its metabolites, Plasma concentrations of GSK2118436 and its metabolites GSK2285403, GSK2298683 and GSK2167542 will be recorded., On Day 1 and Day 8 at pre-dose
To describe 10-year CHD risk comparing to the historical data of 10-year cancer-specific mortality in breast cancer, 1 Visit|To analyse CHD management patterns according to defined 10-year CHD risk categories, 1 Visit|To d
Heart Hate (beat/min), Post-exercise heart rate will be evaluated by the number of beats in time masurement (one minute)., 4 months|Cardiac Function - Ejection Fraction, Ejection Fraction (EF=ESV-EDV/EDV) combines end s
Readmission with a coronary event, acute myocardial infarctrion and cardiovascular mortality, Within 5 years after study inclusion
Admission to ICU with organ failure or hospital, Patients are monitored for a period of up to 10 days or until their white blood cell count goes up, which could take an expected average of 20 days
Deep vein thrombosis or pulmonary embolism, t The first episode of symptomatic, documented deep vein thrombosis or pulmonary embolism, 6 months|Thromboembolic stroke or systemic embolism, The first episode of sy
Decrease in the strain or strain rate, 6 months after 3DCRTand 2 years after 3DCRT (baseline measures performed before radiotherapy)|Modification in series of circulating biomarkers of cardiac lesions, Classical biomarkers
Changes of ECG, UCG and serum markers after 3 and 6 courses of CHOP (-R), 14-21 (at a maximum 28) days after the start of 3rd and 6th course of CHOP(-R).
Change in Myocardial Blood Flow - 12 months, Change in myocardial blood flow will be measured by adenosine CMR imaging. Comparisons will be made using longitudinal mixed models to examine within- and between- gr
Breathlessness severity (NRS), Change from baseline in breathlessness severity (at week 8) measured with numerical rating scales (NRS). The NRS will be used to assess breathlessness over the last 24 hours on average,at r
The EQ-5D-5L is a standardized instrument applicable to a wide range of health conditions for use as a measure of health and is especially suited to cost effectiveness analyses., From Baseline to Follow-Up (0, 8, 16, 28 wee
Left ventricular (LV) systolic function (global and regional), Cohort A, Change from baseline to 3, 6, 12,and 24 months.|Biomarker of myocardial injury (high-sensitivity troponin (hs-cTn)), Cohort A, Change from baseline to 3, 6,
The incidences of the increase of serum troponin and/or NT-proBNP, Differences in the incidence rates of serum troponin exceeding the upper limit of normal value and NT-proBNP higher than the normal age reference value
Late enhacment, Evaluated by cardiac MR., At Baseline, 6, 12 and 24 months.|LVEDV changes, Left ventricular enddiastolic change in cMR, 2 years|LVESV changes, Left ventricular endsystolic change in cMR, 2 years|LV mas
Change in mitochondrial energy production, as measured in leukocytes (peripheral blood mononuclear cells) from patients prior to and after undergoing radiation therapy., Mitochondrial energy production will be measured by

Percentages of IPNS and EA cases, The percentages of IPNS or EA cases on the overall study population were calculated., Cases observed at Day 1 only during surgery (duration: 4-6 hours)
p53 promoter occupancy, Measured by ChIP analysis for the following SNPs: FLT1 C-677T, TLR8 rs3761624 and RMM1 rs1465952., analysis on blood drawn at visit
Survival status, alive or deceased, through study completion, an average of 1 year|Change in symptoms that may be indicative of heart failure, Presence of absence of symptoms, through study completion, an average of 1 ye
Major Adverse Clinical Cardiovascular Event (MACCE), Major Adverse Cardiovascular Event (myocardial infarction, clinical heart failure requiring admission, life-threatening arrhythmia atrioventricular (AV) block requiring pace
occurrence of cardiovascular events over time in both groups (RT for left/right breast), occurrence of cardiovascular events over time in both groups (irradiated left / right breast) will be showed by the method of Kaplan-Meier
Proportion of patients recovering at 6 months in the absence of late enhancement signal in MRI heart after injection of gadolinium and compare the results of biological assays, 2 years
prevalnce of cornary artery disease and frequency/type of subsequent intervention, to establish the prevelence of coronary abnormalities in HL survivors treated with mediastinal irradiation, and to determine the frequency an
Disease-free survival (DFS), The time between the start of a randomized clinical trial and the onset of disease recurrence or death from any cause, 5 years
Patient-provider communication, Single measure, video recording of medical consultation lasting approximately one hour|Time requirements, ease of use, Single measure, after collection of all patient data|Congruence betwe
Proportion of patients with serious cardiac side effects., Includes myocardial infarction, valve disorder, congestive heart failure, and angina., 1 year after completion of radiation therapy|Mean quality of life score., Comparison
Adverse Event Profile as Measured by NCI CTCAE v 3.0, Measured by number of patients with at least one with grade 3+, Grade 4+, Hem, and Non-Hem AEs., 5 years|Cumulative Incidence (CI) of Cardiac Events, Evaluable p
Cardiac events: symptomatic congestive heart failure (CHF), cardiac death and other cardiac events (NCI Common Terminology Criteria for Adverse Events (CTCAE) Grade \>=3), 5 years|Number of Patients Who Experience >
To determine the effect of screening-detected AF on initiation of anticoagulation., To determine the effect of screening-detected AF on initiation of anticoagulation. Patients diagnosed with AF through screening will be referre
The Prevention of Cardiac Arrhythmias Occurence by Epidural Anesthesia Added to General Anesthesia Evaluated by a Number and Type of Arrhythmias Observed, The investigator evaluates the incidence of cardiac arrhythr
Recruitment rate, Rate of practice and participant recruitment during the intervention period, 6 months|Participation rate, Proportion of patients completing the questionnaire, and providers attending the webinar, reviewing fa
Correlate changes in cardiac function measured by cardiac MRI with radiotherapy dose volume histograms evaluating multiple components of the heart., Baseline and 2 years|Correlate changes in cardiac function measured
Inter and intra observer reproducibility, Three 30 min visits in healthy volunteer group.|Median (m/s) of ARFI values between before and after effective treatment for liver reversible disease, From patient admission until patient
Assess effects of predictive genomics on self-reported health behavior and on physician-patient interaction, March 2008-March 2009
Prevention of myocardial injury measured by the levels of biomarkers (ultrasensitive troponin, BNP and miRNA-208) Effect of carvedilol in the prevention of diastolic dysfunction., 96 weeks
Examine the correlation between the characteristics of cardiac arrhythmias, as revealed by implantable cardiac monitor (ILR) with findings from other structural and functional assessment performed as standard of care (SOC)
Access time, from penetration of skin to aspiration of venous blood into the syringe, during central venous catheterization|Number of attempts, once/twice/three times, during central venous catheterization|catheter tip placer
(1) Superior vena cava and Rirht Atrium junction (2)Right internal jugular vein (3)Left Internal jugular vein (4)Right Axillary vein (5)Lt. Axillary vein, postoperative 1 day
Change in likelihood of AEs, Quantify the change in likelihood of adverse events (AEs) that patients are willing to accept in order to experience the benefits of low-dose aspirin for CRC and CVD prevention compared to CVD p
Wall-motion abnormalities, The incidence of wall-motion abnormalities will be assessed using SPECT in the same 12 segment scoring system used to quantify perfusion. Wall-motion abnormalities will be recorded as present
To Evaluate Whether Ivabradine Improves Exercise Duration, Compared To Placebo, In Survivors Of Lymphoma, Calculate the change in exercise duration (from exercise treadmill stress tests) from baseline to 6 weeks for eac
Factors associated with an increased reporting of main irAE types, Main irAEs are identified through MedDRA terms declared. For each irAE and each risk factors, an odds ratio will be calculated to assess a potential over-rep
Molecular characterization of solid tumors in RASopathies, NGS analysis on tumor tissue samples, 5 years
Upper gastrointestinal endoscopy, To assess the grade of reflux esophagitis, four weeks
Drop in ejection fraction within 24 months., Drop in ejection fraction greater than 10% and values less than 55%, 24 months|Reduction in myocardial strain in 24 months from the start of treatment., Relative reduction of more
Incidence of Cardiovascular Events, 1 year|Incidence of Symptomatic Heart Failure, 1 year|Incidence of Cardiac Death and all mortality, 1 year
Evolution of arteriosclerosis: Evaluation of arteriosclerosis at different vascular beds. Silent arteriosclerosis., Data from clinical and/or diagnostic tests will be analyzed, Seven Years|Concentration of LDL cholesterol., Concent
* myocardial infarction * revascularization * ischemic stroke * documented peripheral artery disease
* cardiovascular death, Up to Seven Years|Global Metabolomics, Global metabolomics in plasma, as well as techniques targeting specific sets of metabolites such as lipid-based lipid species, protein by proteomics, etc., Up
The effect of postmenopausal hormone use on mortality and morbidity due to the following conditions: coronary heart disease, stroke, breast cancer, ovarian cancer, other cancer, hip fracture and death from all causes., 28 y
Secondary objective, Comparison of the accuracy of radiologis with different experience vs. Carebot AI CXR. Weakness assessment of Carebot AI CXR., 20-10-2022
Quality of life change (EQ-5D-5L (Euroqol-five dimension-five level), Quality of life change as measured using EQ-5D-5L from baseline to 90 days post-surgery calculated as population adjusted health index based on total sc
Local fibrosis, Is there a correlation between the presence of local fibrosis and dose to this region, 1 year|Morphology changes, Are changes in morphology visible on the MRI scans made during treatment, compared to the p
GLS, To detect GLS decrease \>15% from baseline, measured on Echo over the time window of 12 months, Time window of 12 months from the end of radiation therapy|Myocardial edema, To assess the incidence of myoca
To assess the incidence of myocardial oedema on ECHO after radiation therapy and cardiotoxic systemic therapy., Time window of 12 months from the end of radiation therapy|Biomarkers (Troponine, pro-BNP, hs-CRP) corre
To see if the changes in pro-BNP (ng/L) will correlate with LVEF measurements, assessed by ECHO.
To see if the changes in pro-BNP (ng/L) will correlate with LVEF measurements, assessed by CMR.
To see if the changes in hs-CRP (mg/L) will correlate with LVEF measurements, assessed by ECHO.
To see if the changes in hs-CRP (mg/L) will correlate with LVEF measurements, assessed by CMR., Time window of 12 months from the end of radiation therapy|Biomarkers (Troponine, pro-BNP, hs-CRP) correlated with GLS,
To see if the changes in pro-BNP (ng/L) will correlate with GLS measurements, assessed by ECHO.
To see if the changes in hs-CRP (mg/L) will correlate with GLS measurements, assessed by ECHO., Time window of 12 months from the end of radiation therapy|Time to biomarkers (Troponine, pro-BNP, hs-CRP) increase, To
To compare the time to the pro-BNP (ng/L) positivity to the time to the decrease in GLS \>15% and/or decline of LVEF ≥10% points with a final LVEF \<53% measured on Echo.
To compare the time to the hs-CRP (mg/L) positivity to the time to the decrease in GLS \>15% and/or decline of LVEF ≥10% points with a final LVEF \<53% measured on Echo., Time window of 12 months from the end of rad
To see if the changes in pro-BNP (ng/L) will correlate with developement of cardiotoxicity, defined as by decline of LVEF ≥10% points with a final LVEF \<53%.
To see if the changes in hs-CRP (mg/L) will correlate with developement of cardiotoxicity, defined as by decline of LVEF ≥10% points with a final LVEF \<53%., Time window of 12 months from the end of radiation therapy|Ma
Acute and late patient-reported morbidity, Adverse events will be assess using patient-reported outcomes (PRO) questionnaires including EPIC-26, IPSS, and SHIM scoring. Assessment will be collected before and at the en
Physical activity level (accelerometer-based activity level 'counts'), Physical activity level during/following treatment in breast cancer patients., At completion of treatment, an average of 13 months|Cardiorespiratory function (
Time to onset and the time to recovery of symptomatic congestive heart failure, On treatment and up to 5 years follow-up|Incidence of asymptomatic cardiac failure and other significant cardiac conditions, On treatment and
Indexed left ventricular end diastolic volume (EDVI), Change in EDVI at time-frame, at months 6,9,12,24|Indexed left ventricular end systolic volume (ESVI), Change in ESVI at time-frame, at months 6,9,12,24
Muscle strength (Handgrip test), Handgrip test, Baseline|Change in exercise capacity (6 minute walk test), Determined by incremental exercise test, 6 minute walk test, baseline and after 5 weeks|Neurohormonal activation (N
Number of comorbidities per patient with AU., Day 1|Frequency of prescribing renoprotective drugs., Day 1|Calculation of eGFR according to CKD-EPI formula 2021 in different phenotypes from the study population., Day 1|F
Number of Participants with adverse events, Number of subjects with adverse events specifically, incident of hypertension and Cardiac dysfunction, 2 years

Significance of serial NT-proBNP measurements for determination of anthracycline-dependent cardiotoxicity, Study Duration|Feasibility of evaluation with Haematopoietic Cell Transplantation Comorbidity Index (HCT-CI), Stud
Adherence to supervised exercise sessions, Proportion of prescribed supervised on-site exercise sessions attended, 6 months|Activity assessment, Garmin recording, 6 months
Change in ventricular ejection fraction values, ventricular volumes and masses from baseline values after 53 weeks., 12 months|Change in cardiac T2* from baseline to 53 weeks in the MDS and other anaemias subgroup, cor
changes in serum levels of the measured biological markers., N-terminal prohormone of brain naturetic peptide "NT-proBNP") liver panel myeloperoxidase (MPO) neurofilament light chain (NFL) nuclear factor- Kabba B p65 (N
Advance planning documents, Percentage of patients who, as a result of the palliative medical consultation offer, create or want to create a living will or power of attorney, through study completion, an average of 1 year|Post
Number and frequency of postoperative complications, Up to 30 days|Numeric rating scale for postoperative pain in hospitalization, Patients are scored using a numeric rating scale ranging from 0 (no pain) to 10 (excruciating
Myocardial Infarction, 2009
Change in 6-minute walk test (6MWT), Baseline to 3 and 6 months|Change in Carcinoid Valvular Heart Disease (CVHD) score, Baseline to 3 and 6 months|Change (significant change or non-significant change) in global longitu
Compare the reporting of suspected drug-induced supraventricular arrhythmias with abiraterone as compared to enzalutamide by performing a disproportionality analysis, Compare the reporting of suspected drug-induced s
Type 2 diabetes, Incidence of type 2 diabetes, Annually between March 1984 and December 2052|Dementia, Incidence of dementia, Annually between March 1984 and December 2052|Cancer, Incidence of cancer, Annually b
Generic health-related quality of life (EQ-5D-5L), Change from baseline in patients' generic health-related quality of life measured with the EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L). The EQ-5
Chemotherapy induced cardiomyopathy 2, Secondary efficacy endpoint: To compare the rate of cardiomyopathy between the experimental group and the control group in breast cancer patients receiving doxorubicin-contain * A decrease of more than 10% in absolute left ventricular ejection fraction (LVEF) or * A decrease of less than 50% from the normal range of left ventricular ejection fraction (\>55%), 3months, 6months
Elevation of troponin levels as a surrogate evidence of DOX related cardiotoxicity will be checked at baseline, prior to each DOX therapy and then at 1 year from baseline assessment (Each cycle is 14 days)., Troponin will be
The child's general and specific health status, This questionnaire contains information about the health of each child both at the time when the study begins and when the study ends. It asks for information on the weight of th
Number of referrals to primary care and cardiology to manage CV risk, Medical chart abstraction of referrals and communication with providers regarding CVH at each survivor visit., 1 year|Number of CVH-relevant labs and te
Number of participants with abnormal laboratory values for urine free cortisol, Number of participants with abnormal laboratory values for hormones and metabolism as assessed by urine free cortisol, 6 months|Number of pa
Compare dosimetrically the dose volume histogram (DVH) of the PT plans with conventional external beam plans (either photon/electron intensity modulated radiotherapy(IMRT)plans, 3D-photon plans, or Tomotherapy plans)
Time to Angiomyolipoma Progression as Per Central Radiology Review, Time to angiomyolipoma progression (TTAP) is defined as time from date of randomization to date of first documented angiomyolipoma progression. Ar
For the everolimus (core/extension periods) treatment group, the time to angiomyolipoma progression is defined starting from the start of everolimus. The baseline means the latest value on or before starting everolimus., Fro
For the everolimus (core/extension periods) treatment group, the time to angiomyolipoma response is from the start of everolimus. The baseline in the response definition means the latest value on or before starting everolimu
Outcome 2 circulating markers, Evaluate circulating markers, mostly related to radiation-induced oxidative stress and correlate them to previous CV events and CT data obtained. Patients will undergo a blood sample withdra
Albumin thiolation: Mercaptoalbumin (HSA-SH) and thiolated albumin (+120 ± 2 Da, Thio-HSA) will be detected and their intensities used to calculate the relative abundances. Targeted Proteomics will be performed and relati
Incidence of Cardiovascular Events, Cardiovascular events are defined as hospitalization for symptomatic congestive heart disease, nonfatal acute coronary syndrome, cardiovascular death, nonfatal stroke, and all-cause mo
Alteration of serum biomarkers after doxorubicin based chemotherapy, - To determine if serum biomarkers of cardiac stress, collagen turn-over, and myocardial injury are altered after doxorubicin-based chemotherapy, 2 year
Plasmatic tests to predict anticancer drugs-related cardiac adverse events from the constitution of the plasma biobank, 2 years
VO2peak, Change in VO2peak (L/min) measured at pre-chemotherapy and post chemotherapy, 22 Weeks|Global Longitudinal Strain, Global longitudinal strain (%) will be used to assess changes in cardiac contractile functio
Overt chemotherapy induced cardiotoxicity, LVEF \< 45%, decline in LVEF by \>10% to a value to 45-49%, symptomatic congestive heart failure, any time|Changes in cardiac biomarker, NT-pro BNP, cardiac troponin, at mont
To obtain preliminary information on whether abnormal FMD adds predictive information beyond risk algorithms, proposed by the American Heart Association/American College of Cardiology., 1 year|To determine whether ab
ECG parameters, 2-4 days postdose|Blood MMAE levels, Through 4 days postdose|Incidence of proarrhythmic adverse events, Through 1 month following last dose|Incidence of adverse events and laboratory abnormalities,
99mTc-rhAnnexin V-128 Myocardial Uptake, Single-Photon Emission Computed Tomography (SPECT)/Computed Tomography (CT) scans of the thorax were acquired with a dual head SPECT/CT gamma camera with low-ene
LV systolic dysfunction, LV systolic dysfunction was defined as following; 1. An EF unit drop of ≥10% from the baseline available echocardiogram or 2. Change in strain or strain rate : drop(decrement) corresponding to ≥1 SD of the relevant parameter assessed at the baseline available echocardiogram, 6,9, and 12-month F/U
Association between RVEF and contractility / loading indices, Changes in RVEF must be interpreted in the context of changes in RV contractility and loading parameters. Changes in pre-load, contractility, afterload, ventriculo Preload - Right ventricular end-diastolic volume (RVEDV) Contractility - Peak systolic strain and strain rate Afterload - Pulmonary artery (PA) distensibility, PA peak velocitly, PA antegrade flow, Estimated PA systolic pressure,F Myocardial dysfunction: Brain natriuretic peptide and high sensitivity Troponin-T. Systemic inflammation: C-reactive protein and Pentraxin 3. Oxidative / Nitrosative stress: Malondialdehyde, nitrate and nitrite (determined in pla Angiopoietin (Ang) 1 \& 2, Von Willebrand factor (VWf), E-selectin (ESEL) and soluble intracellular adhesion molecule (sICAM))., 3 days|Association between RVEF and functional status, Association between RVEFpreop, RVEF
To assess the safety of the Tricuspid Valved Stent Graft implantation procedure in patients with carcinoid heart disease with severe symptomatic TR and significant systolic backflow in the hepatic and caval veins, and who ar * Rate of death all causes, At baseline, 1 month and 6 months|•To evaluate the reduced symptom burden according to New York Heart Association (NYHA) score, •NYHA assessment, At baseline, and post intervention at 1 m 2. assessment of oedema scored as: none = 0, ankle = 1, shin = 2, thigh = 3, anasarca = 4, At baseline, 1 month and 6 months|To evaluate the change in of number of admissions to hospital for heart failure, Count of number
Parent Implementation and Engagement, Internal parent implementation and engagement forms will be used to measure parent participation across both intervention phases. These components include parent readiness for t
overall survival, overall survival is defined as the duration from date of randomisation to the date of death from any cause., 12 months|objective response rate, ORR, objective response rate includes complete and partial respo
Evaluation of Intervention Effectiveness - Change in Chronic Diseases, Multimorbidity/Chronic Disease (MM-21): Score: number of Chronic diseases, T1: Initial evaluation; T2: after 4 months; T3: one year after T2; T4: one yea
admissions to hospital for cardiovascular causes,, to assess whether enalapril administered concomitantly to AC-containing treatments can reduce admissions to hospital for cardiovascular causes, up to 3 years after the cor

Absolute change in LVEF from baseline to 1 year from anthracycline-based therapy, Calculation of the the change in LVEF from baseline to 1 year from anthracycline-based therapy, 1 year|Absolute change in AI-ECG probabil
Clinical acceptability of markerless tracking system, Proportion of radiation therapists considering the markerless tracking system acceptable using a survey, 3 years
need for ventilator therapy, The perioperative need for ventilator therapy is assessed., a period of 60 days|monetary reimbursement for prolonged hospital stay, The monetary reimbursement for prolonged hospital stay is asse
Evaluation of Intervention Effectiveness - Change in Chronic Diseases, Multimorbidity/Chronic Disease (MM-21): Score: Number of Chronic diseases, T1: Initial evaluation; T2: after 4 months; T3: one year after T2;|Evaluation
Baseline heart rhyme, A resting electrocardiogram will be used to obtain patients' normal values for heart rate measurements in bpm, I-axis and aVF, Q-T interval, QRS complex, S-T segment and T-wave, in ms. Moreove
Evaluate with the echocardiography performed at the end of chemotherapy the sensitivity, specificity, the negative predictive value and the positive predictive value of the SLG change (difference of, SLG change is defined as
Completeness of planned primary outcome data collection at specified timepoints, Completion of study (estimated to be 27 months)
Change in EF, assessed by MRI and ECHO, Will determine the correlation between ECHO and MRI assessments performed pre-chemotherapy. Will assess correlations between post-chemotherapy ECHO and MRI assessme
Occurence of side-effects due to the brief cognitive and behavioral Intervention (Safety), closed-ended question (yes/no), week 6|Occurence of adverse events due to the brief cognitive and behavioral Intervention (Safety), cl
Dose estimation, The total exam dose-length product (DLP) displayed by the CT scanner at the end of each CTPA is recorded. The effective dose in mSv is calculated by multiplying the total DLP for each exam by the conver
Postoperative air leak, The presence and duration of (in days) postoperative air leak, 1 week|Need for reoperation, Need for reoperation due to for example bleeding., 1 week
Late cardiac and cognitive toxicity, * To compare the late incidence of cardiac events between higher and lower dose anthracycline treated node-positive breast cancer patients; * To compare anthracyclines (higher and lower doses) and non-anthracycline chemotherapy for: LVEF assessed by Echo; exercise capacity assessed by 6-minute walk test; cardiac morphology assessed by MRI; serum cardi
POMS Anxiety Sub-scale, The anxiety sub-scale from the modified Brief Profile of Mood States (POMS) is a 5-item measure of psychological distress.Items are on a 5-point likert scale with scoring ranging from 0-20. Higher
Relationship between serum level of cTnT/cTnI/ANP/BNP and cardiac toxicity, 1 year
Safety/Efficacy, 24 hours
Heart rate variability, Heart rate variability, 5 min after anesthesia induction|Heart rate variability, Heart rate variability, 5 min before end of anesthesia
Cancer therapy-related cardiac dysfunction (CTRCD), Incidence of CTRCD defined as at least a 10% absolute change in LVEF by echocardiogram at follow-up relative to baseline to a value \< 50%, through study completion
New York Heart Association Functional Classification (NYHA FC), Provides information regarding patients functional status on scale of 1-4., 2 years|Cause of death, Whether the cause of death is cardiovascular or non-cardio
Relationship between blood pressure group, habits and anthropometric, metabolic, endocrine, Electrocardiogram, Holter, ambulatory blood pressure monitoring (ABPM), Blood pressure group: 1) Essential arterial hypotensio
Habits: smoke and drink
Anthropometric variables: Body mass index, waist, hip
Metabolic variables: Fasting glucose, 2 hs postprandial plasma glucose, insulin plasma levels, homoeostasis model assessment (HOMA), total cholesterol, LDL, HDL, triglycerides.
Endocrine variables: plasma cortisol, free cortisol in 24 hs. urine, epinephrine, norepinephrine, metanephrines, vanilmandelic acid, ACTH, aldosterone, renin, thyrotropine, free thyroxine, triiodothyronine, testosterone
Electrocardiogram: HR; PR interval, QRS complex, cQT interval
Holter variables: HR, standard deviation of NN intervals (SDNN) and sympathovagal balance, at day, night and 24 hs.
ABPM: Systolic, diastolic, and heart rate, at day, night and 24 hs., BP matinal surge., A 7-year prospective study|Relationship between blood pressure group, adaptability group, habits anthropometric, metabolic, endocrine, e
Adaptability group: Hyper adaptable, normal adaptability, hypo adaptable.
Habits: smoke and drink
Anthropometric variables: Body mass index, waist, hip
Metabolic variables: Fasting glucose, 2 hs postprandial plasma glucose, insulin plasma levels, HOMA, total cholesterol, LDL, HDL, triglycerides.
Endocrine variables: plasma cortisol, free cortisol in 24 hs. urine, epinephrine, norepinephrine, metanephrines, vanilmandelic acid, ACTH, aldosterone, renin, thyrotropine, free thyroxine, triiodothyronine, testosterone
Electrocardiogram: PR interval, QRS complex, Heart rate, cQT interval
Holter variables: HR, SDNN and sympathovagal balance, at day, night and 24 hs.
ABPM: Systolic, diastolic, and heart rate, at day, night and 24 hs., BP matinal surge., A 7-year prospective study|For metabolic disorders what it matters the most: the anthropometric variables vs blood pressure group vs ada
Adaptability group: 1) Hyper adaptable, 2) normal adaptability and 3) hypo adaptable.
Habits: smoke and drink, exercise
Anthropometric variables: Body mass index, waist, hip
Metabolic and other variables: Fasting glucose, 2 hs postprandial plasma glucose, insulin plasma levels, HOMA, total cholesterol, LDL, HDL, triglycerides; thyrotropine,
Holter variables: HR, standard deviation of NN intervals (SDNN) and sympathovagal balance, at day, night and 24 hs.
ABPM: Systolic, diastolic, and heart rate, at day, night and 24 hs., BP matinal surge., A 7-year prospective study|Relationship between adaptability group, habits and anthropometric, metabolic, endocrine, Electrocardiogram,
Habits: smoke and drink Anthropometric variables: Body mass index, waist, hip
Metabolic variables: Fasting glucose, 2 hs postprandial plasma glucose, insulin plasma levels, HOMA, total cholesterol, LDL, HDL, triglycerides.
Endocrine variables: plasma cortisol, free cortisol in 24 hs. urine, epinephrine, norepinephrine, metanephrines, vanilmandelic acid, ACTH, aldosterone, renin, thyrotropine, free thyroxine, triiodothyronine, testosterone
Electrocardiogram: PR interval, QRS complex, Heart rate, cQT interval
Holter variables: HR, SDNN and sympathovagal balance, at day, night and 24 hs.
ABPM: Systolic, diastolic, and heart rate, at day, night and 24 hs., BP matinal surge., A 7-year prospective study
Number of Cardiac Events, To determine whether statins reduce cardiac events (new onset heart failure), 2 years|Myocardial Fibrosis, To determine The Effect Of Statins On Myocardial Fibrosis, 6 months|Troponin T and Glob
Detection of cardiac toxicity on MRI and echocardiogram, •Measure sensitivity of detecting cardiac toxicity between standard echocardiogram, speckle tracking on echo, and MRI, At the end of each cardiac MRI exam throug
Mean number of circulating endothelial cells (CECs), Once, at first clinic visit|Mean CEC surface expression of P-selectin, Once, at first clinic visit|Mean soluble vascular cell adhesion molecule-1 (VCAM-1), Once, at first clinic
prediction, 24 months post RT
pCR rate, Pathologic complete response (pCR) rate in patients received neoadjuvant therapy, 4 years|ORR, Objective remission rate in patients received neoadjuvant and palliative therapy, 4 years|DCR, Disease control rate ir
changes in upper body strength between baseline and after a 12-week hybrid cardiac rehabilitation program., Change in muscular strength will be assessed using 5-RM tests. The tests will be performed for leg extension, leg
Overall cardiac fitness, Assessed using 6 minute walk test., Up to 24 months after CRT|EuroQol 5 Dimension 5 Level: Patient reported outcomes, Score Range 0-100 (0) Worst health and (100) best health Level 1- No compla
Number vaccinated with flu vaccine, Number of patients who receive flu vaccine, 1 year|Proportion of patients who refer for testing, The proportion of study participants with eligible household members who refer household
Percent of eligible patients sent a letter, Percent of eligible patients sent a letter about goals of care conversations in both stages of the SMART., 3 months|Percent of eligible patients that view the PREPARE website, Percent
Cardiac Magnetic Resonance Cinema Imaging, Cinema imaging: Long axis balance, Balance 4 cameras, Short shaft full balance, Right ventricular balance, Baseline, 1 and 12 weeks after treatment|Cardiac Magnetic Resona
T2 map short axis apical section T2 map short axis medial section T2 map short axis basal section, Baseline, 1 and 12 weeks after treatment
Causality assessment of reported adverse drug reaction according to the WHO system, Case reported in the World Health Organization (WHO) or BNPV database of individual safety case reports to May 2018|Description of t
Urine/serum/plasma 5-HIAA and chromogranin-A, Intrapatient change from baseline in urine/serum/plasma 5-HIAA and chromogranin-A, 43 months after first patient in|Number of daily cutaneous flushing episodes, Change f
Incident Episodes of Interest, Incident episodes of: stroke/TIA; other thromboembolic events (not stroke/TIA); Heart failure events; ischemic heart events. Overall device implantation safety., 1 year
The changes of the oxygenation and respiratory dynamic parameters, shunt fraction Qs/Qt = (CcO2- CaO2)/(CcO2- CvO2) CcO2 = Hgb x 1.34 x ScO2 + PcO2 x 0.003, lung compliance : Compliance= Vt / Pplat, physiologic d
Clinical respiratory parameters evolution, respiratory rate improvement will be assessed by a decrease of respiratory rate below 20/min, day 1, day 2, day 3|Oxygenation parameters evolution, sPO2 (oxygen saturation) expres

Change in health-related quality of life assessed by the Functional Assessment of Cancer Therapy - Breast plus Arm Morbidity (FACT-B+4) questionnaire, Score achieved in the Functional Assessment of Cancer Therapy - Bre
\"Due to COVID-19 pandemic, participants' assessment with CPET had to be stopped for safety concerns. In such cases, functional capacity was estimated from the maximum work rate in the 6-minute walking test (6MWT).
Cumulative incidence of new relevant medical events, Relevant medical events are defined as any new medical condition significantly impairing normal daily activities or requiring hospitalization or needing specific and perma
Peak VO2, During a graded treadmill test, breath-by-breath sampling of expired air will be measured using a MGC Diagnostics gas exchange analysis system., 12 weeks|Percent body fat, Body fat will be analyzed using air di
Duration of response (DOR) in SOT and HCT cohorts separately, 2 years|ORR and DOR in SOT and HCT cohorts combined, 2 years|Rates of complete response (CR) and partial response (PR), 2 years|Time to response, 2 yea
secondary outcome measures the composite of NYHA class III or IV heart failure, breast cancer relapse, or all-cause mortality., the composite of NYHA class III or IV heart failure, breast cancer relapse, or all-cause mortality.,
Incidence of myocardial injury, Levels of high sensitivity troponin T and NT-proBNP, 2 years
Clinician-reported medical errors attributable to poor information exchange, Collected via a survey of admitting clinicians 48-72 hours after patient transfer., Up to 72 hours after transfer|Total clinician-reported adverse events
tests for identifying and monitoring cardiac arrhythmias in patients receiving BTKi, -Detection of arrhythmias on devices (rest EKG, stress EKG, ambulatory EKG monitor, KardiaMobile) -Clinically significant and other arrhythm
Pleurodesis Rate, Rate of patients who achieved successful pleurodesis within 2 months as defined as successful TPC removal with no reaccumulation of pleural effusion on subsequent imaging (usually 2-3 weeks later). Typ
Expansion of CH, The outcome is the expansion of the CH, which will be expressed as the variant allele fraction (VAF) (CH verses the total normal DNA in the sample). Graphic analysis to reveal the time varying trend in the as
The preoperative anxiety score by using the Amsterdam Preoperative Anxiety and Information Scale (APAIS), The anxiety scale consists of six items, each of which could be scored from 1 to 5 with the end poles "not at all" (1
Change in plasma pool of nitric oxide after ischemia/reperfusion injury, Compare the effects of euglycemic/hyperinsulinemic, hyperglycemic/hypoinsulinemic and hyperglycemic/hyperinsulinemic on nitric oxide generation bef
Analyze the effects of digital profiles on treatment toxicity, Occurence of severe toxicity (grade \>2) according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) Tests will be per
Tests will be performed to compare means (Student's t test), or categorical variables (chi2test). The investigators will also perform multinomial logistic regression analyses with univariate and multivariate models, to determine
Accuracy of Surprise Question (SQ), BACKGROUND: The surprise question (SQ), "Would the investigator be surprised if this patient died within the next year?" is effective in identifying the end-stage disease patients and the
METHODS: Eligible patients with a known diagnosis of chronic heart, lung, liver, and kidney failures, or advanced cancer, awaiting to be hospitalized after an ED visit, underwent an evaluation of life expectancy using the Surp
The outcome of this study is to evaluate the accuracy of SQ in identifying palliative care patients in their last year of life., Through study completion, an average of 1 year|Symptom control in palliative care patients, BACKGRO
OUTCOME MEASURE: Measurements will be aggregated to arrive at a comparison between admission and discharge times of: * frequency (n,%) of following symptoms: pain, activity, nausea, depression, anxiety, drowsiness, appetite, sense of well-being and shortness of breath * frequency (n,%) of use of pain killer, interventional procedures, palliative sedation, Through study completion, an average of 1 year|Intensity of symptoms in patients admitted in an acute palliative care unit, BACKGROUND:
METHODS: Eligible patients with a known diagnosis of chronic heart, lung, liver, and kidney failures, or advanced cancer, hospitalized after an ED visit, fully according to the screening tool score in an APCU, due to uncontroll
OUTCOME MEASURE DESCRIPTION: The aim of this study is to evaluate the survival time (day, months, years) from APCU admission to death for any cause (overall survival)., Through study completion, an average of 1 yea
METHODS: Eligible patients with a known diagnosis of chronic heart, lung, liver, and kidney failures, or advanced cancer, hospitalized after an ED visit, fully according to the screening tool score, in an APCU. OUTCOME MEASURE DESCRIPTION: This study is to evaluate: * the frequency of discharge at home and to hospice care * the frequency of unplanned hospital readmissions of palliative care patients discharged from our APCU., Through study completion, an average of 1 year|Clinical characteristics and outcomes of palliative care patients refer
METHODS: Patients with a known diagnosis of chronic heart, lung, liver, and kidney failures, or advanced cancer, hospitalized after an ED visit, fully according to the screening tool score, in an APCU. OUTCOME MEASURE: multiple measurements will be aggregated to arrive at one detailed description of: * frequency (n,%) of following symptoms: pain, activity, nausea, depression, anxiety, drowsiness, appetite, sense of well-being and shortness of breath * frequency (n,%) of discharge at home and to hospice care, Through study completion, an average of 1 year
Detected abnormalities - Individual, The secondary outcome measures includes a composite of detected abnormalities of factors on cardiac biomarkers (troponin and N-terminal pro B-type natriuretic peptide) , electrocardiog
Persistent Physical Symptom Questionnaire, Measures severity, distress, interference and problematic nature of PPS, 52 weeks post randomisation|Patient Health Questionnaire-15 (PHQ-15), Measures physical symptoms se
Number of Participants With Adverse Events as a Measure of Safety and Tolerability, Number of participants with concurrent administration of simvastatin with (neo)adjuvant anthracycline-based chemotherapy in early stage
Biomarkers +DNA, Plasma EDTA, lithium-heparin plasma and serum are stored at -80 freezer at the the time of inclusion. Determination of biomarkers will take place at the end of the study period Whole blood is frozen for DN
Days at home between study enrollment and death or study completion (365 days), Variable, up to 12 months|Patient quality of life measured with the PROMIS-10 survey, The PROMIS-10 is a 10-item survey measuring gene
Upper limb muscle strength, Will be determined using a handheld dynamometer, measures muscle strength in kg, higher score means better muscle strength, T1: baseline (before the study begins)|Change from baseline Upp
Pharmacokinetic sampling maximum observed plasma concentration (Cmax), Pharmacokinetic samples will be drawn at Screening, 6 time points on Day 1 of Periods 1, 2 and 3 and 1 time point on Day 2 of Periods 1, 2, and
Death from any cause or hospitalization for heart failure, Composite clinical endpoint, From Randomization till the end of blinded therapy - at 24 months|Death from any cause, From Randomization till the end of blinded thera
Symptom assessment scores after an 8-week cardio-oncology prehabilitation program., Frequency and severity of cardiovascular symptoms (fatigue, shortness of breath, edema) will be assessed using the short Kansas City
% change of oligomer levels relative to baseline level in patients with ATTR specific medication changes, Change (%) for oligomer level at the time of ATTR specific medication changes compared to baseline, Annually over 5
Doses of radiotherapy, Regarding radiotherapy, the doses of different vital organs of the body (151 anatomic sites) will be estimated from the radiotherapy technical records with the help of the Dos-EG software proposed by t
Chart Review of Stroke Outcome Evaluation of Rivaroxaban in Cancer Participants with Invenous-Thromboembolism (VTE) at MD Anderson Cancer Center, Proportions of patients with recurrent stroke along with 95% CIs, es
all-cause mortality, number of all types of death during follow-up periods, through study completion, an average of 3 years
Remaining subscales of the QUAL-E instrument (Quality of Life at End of Life, Steinhauser et al. 2004), Eight weeks
Electrocardiogram (ECG), Will be measured to calculate heart rate variability (HRV), Measured at baseline (time 1) and after 10-week intervention (time 2)|Impedance Cardiography, Will be used to assess exercise related impro

Change in health belief model (HBM) construct scale of perceived risk of having heart problems, Patients will be asked about their perceived risk of having heart problems on a 5 point scale, with 1 indicating no likelihood of h
Change in total plaque volume in patients treated with ICI compared to historical cohorts, Difference in total plaque volume as measured on serial CTCA between patients treated with ICI therapy against historical cohorts, 18
The score ranges for each individual section are: physical well-being 0-28, social well-being 0-28, emotional well-being 0-24, functional well-being 0-28, additional well-being 0-64, and melanoma-specific questions 0-32.
Interpretation of scoring depends on the individual sections in the questionnaire, with higher scores in the physical, emotional, additional and melanoma-specific questions indicating poorer quality of life, whilst lower scores i
Muscle blood flow, Change in muscle blood flow measured by venous oclusion plethysmography, 15-20 days after the end of AC regimen|Blood Pressure, Change in blood pressure measured by finometer, 15-20 days after t
Feasibility as measured by program adherence, The program adherence will be calculated by dividing the total number of exercise sessions by the number of actual session attended., 12 Weeks|Feasibility as measured by att
Overall response rate (ORR), up to approximately 3 years|Progression-free survival (PFS), up to approximately 3 years.|Overall survival (OS), up to approximately 5 years|Incidence of treatment emergent adverse event (TEAE),
Incidence of adverse events associated with beta blocker treatment, Adverse events associated with beta blocker treatment will be assessed., Up to 108 weeks|Rate of first interruption of trastuzumab, The distributions of tim
Myocardial rest myocardial fibrosis burden (T1) and left ventricular ejection fraction (LVEF), Will be used to correlate myocardial perfusion with T1 and myocardial function (LVEF)., Baseline and 3-6 months|Change in MPRI me
5-year DFS, 5-year disease-free survival rate, 5 years|5-year OS, 5-year overall survival rate, 5 years|Adverse events (AE), Incidence and Severity of adverse events according to the CTC AE V4.03, 5 years
Change in A1c, Identified through chart review, 6 months and 12 months|Change in BMI kg/m2 (weight in kg, height in meters), Identified through chart review, 6 months and 12 months|Change in Systolic and/or Diastolic Hyp
The individual components of the primary endpoint., The rates of the following between groups: cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrhythmias, significant bradyar 1. - No component of the primary endpoint; 2. - Incident heart failure; 3. - Significant bradyarrhythmia; 4. - Significant ventricular tachyarrhythmias; 5. - Cardiogenic shock; 6. - Sudden cardiac arrest; 7. - Cardiovascular death;, 6 months|The increase in serum troponin levels, The proportion of participants in each group with a \>50% increase in serum troponin value at any time during the incident hospitalization and follow 1. - Alive and off corticosteroids for myocarditis; 2. - Alive and on corticosteroids (provide dose) for myocarditis; 3. - Alive and on cellcept (provide dose) for myocarditis; 4. - Alive and on both corticosteroids (provide dose) and cellcept (provide dose) for myocarditis 5. - Dead (cancer, cardiovascular or other)., 6 months|Clinical status at 6 months after first infusion of study drug, Clinical status at visit 7 (6 months) with the highest being the worst: 1. - Alive and off corticosteroids for myocarditis; 2. - Alive and on corticosteroids (provide dose) for myocarditis; 3. - Alive and on cellcept (provide dose) for myocarditis; 4. - Alive and on both corticosteroids (provide dose) and cellcept (provide dose) for myocarditis 5. - Dead (cancer, cardiovascular or other)., 6 months|Fatal and non-fatal DVT and PE, The proportion of patients in each group with a fatal and non-fatal DVT and PE will be compared., 6 months|Other immune-related advers
Chest pain, Incidence of chest pain, 6 months
Psychometrist Testing - Intelligence Score, The change in participants' intelligence will be measured using the Wechsler Adult Intelligence Scale. The scale is based of scores of 50 to 150. The higher the score the better the c
Occurrence of grade 3 or higher late cardiac or neurological toxicity, or secondary acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS), Up to 10 years|Clinical/radiographic response in the breast and axilla after c
Disease-free survival|Overall survival|Pathological complete response rate in breast alone|Radiological response after 3 and 6 courses of chemotherapy|Rate of breast conservation|Toxicities, including cardiac safety and surg
Incidence of device detected ventricular arrhythmia (VA), Incidence of VA is defined as follows: greater than or equal to 3 sequential wide complex beats arising from the ventricles, rate \> 100 beats per minute at 18 months a
Incidence of symptomatic congestive heart failure (NYHA class II, III and IV), up to approximately 4.5 years|Incidence of asymptomatic LVEF decline, up to approximately 4.5 years|Frequency of treatment discontinuations/inte
Cardiac surgery, Percentage of patients requiring cardiac surgery for the cardiac carcinoid heart disease, 10 years (at the end of study)|5HIAA levels, Correlation between urinary 5HIAA levels at diagnosis and occurrence of ca
The role of heparanase on the Pharmacokinetics of Low Molecular Weight Heparin (LMWH) in Cancer patients, End of the study
Efficacy of CR in improving cardiorespiratory fitness, Analysis of follow-up VO2 max, in units of mL/kg/min, will be done using an analysis of covariance (ANCOVA) approach. If VO2 max values are missing at 14 weeks, will us
Rate of major adverse cardiovascular events, Proportion of patients with major adverse cardiovascular events (MACE) in total participants. MACE was defined as unstable angina, new arrhythmia, acute myocardial infarction,
The impact of Align RT with vDIBH as compared to vDIBH without AlignRT on quality of life as assessed by the EORTC core QoL questionnaire., QoL will be assessed using the EORTC core QoL questionnaire (QLQ-C30) whi
Change from baseline score on the Short Form McGill Pain Questionnaire (SFMPQ)(Melzack, 1987), The SFMPQ is a widely used measure of pain related experience., comparison of scores immediately pre-intervention and t
Ventilatory efficiency, minute ventilation to carbon dioxide production slope (VE/VCO2 slope) assessed by CPET, Change from baseline to 2 months|Sit-to-stand test, Sit-to-stand test during 60 seconds, Change from baseline
Number of participants who wear the FitBit device at least 10 hours per day for 4 out of the 7 days prior to each study visit, Proportion of participants who wear the FitBit device at least 10 hours per day for 4 out of the 7 day
-The Omron blood pressure monitor will be used to obtain blood pressure readings., From baseline to 3 months|Number of participants who obtain electrocardiogram (EKG) readings for at least 4 timepoints, Proportion of pa
-The AliveCor KardiaMobile EKG monitor will be used to obtain EKG readings, From baseline to 3 months|Rate of cardiovascular therapeutic medication intervention recommendations by the cardio-oncologist, Number of pa * Each question is either answered on a scale of 1-4 or strongly agree-strongly disagree, where higher scores indicate the highest level of burden or disagreement, respectively., At 3 months
Evaluate baroreflex activity, Evaluation of muscular sympathetic nervous activity at rest by the technique of microneurography, evaluation of the muscular blood flow by venous occlusion plethysmography technique, 16 week
Quality of Communication Questionnaire (QOCQ), slightly modified to focus on communication about cardiopulmonary resuscitation, Family-Assessed Quality of Communication about CPR, Study day 5 +/- 1 or hospital disc
Functional Status measured through the Katz Activities of Daily Living Scale, Measured through the Katz Activities of Daily Living. Minimum = 0, Maximum = 6. Higher score is better outcome., A change in score from baseline
Mortality,, Mortality at ICU discharge, mortality at hospital discharge, mortality at 3 months, mortality at 6 months, up to 6 months|Ventilator-Free Days, Days free of mechanical ventilation, total duration (days) of ventilation ar
Level of quality of life - physical health, The WHOQOL-BREF will be used. The domain of physical health is measured on a five-point Likert scale with five questions., 9 weeks|Level of quality of life - mental health, The WHOQ
Analysis of cardiotoxicity, Correlation of cardio-toxicity overall, and in predefined subgroups; statistical associatoin with outcomes., 5 years|Analysis of cardioprotective strategies, Correlation between the use of cardiovascula
Risk of cardiovascular adverse events (any) for each individual anticancer drug., Drug exposure will be defined as a binary variable for each drug. (intakes/no intakes). A competing risk model will be used., Between 2004 and
Attention, How much the message grabs one's attention. Measured using a a 1 to 5 likert scale, with higher scores representing a higher amount of the construct., ~10 minute computer survey immediately after seeing messa
Overall survival, 2 years|Cancer-specific survival, 2 years|Progression-free survival, 2 years|Other toxicity rates, 2 years
Length of hospital stay, Participants will be followed for the duration of hospital stay, an expected average of 7 days|Incidence of postoperative nausea and vomiting, Up to 7 days after surgery（or leaving hospital）|Patients'
Torsades de Pointes, Torsades de Pointes, Over four years from approval of pazopanib
Feeling heard and understood survey, A validated instrument for seriously ill patients to report how well they feel heard and understood about their wishes for end-of-life care. This instrument is a 5-point Likert scale: "not at a
Gramling R, Stanek S, Ladwig S, Gajary-Coots E, Cimino J, Anderson W, Norton SA; AAHPM Research Committee Writing Group, Aslakson RA, Ast K, Elk R, Garner KK, Gramling R, Grudzen C, Kamal AH, Lamba S, LeBlanc
Engelberg RA, Downey L, Curtis JR. Psychometric characteristics of a quality of communication questionnaire assessing communication about end-of-life care. J Palliat Med. 2006 Oct;9(5):1086-98., Baseline & at 1, 3, and 6
Sudore RL, Heyland DK, Barnes DE, Howard M, Fassbender K, Robinson CA, Boscardin J, You JJ. Measuring Advance Care Planning: Optimizing the Advance Care Planning Engagement Survey. J Pain Symptom Manage. 2
Sudore RL, Heyland DK, Barnes DE, Howard M, Fassbender K, Robinson CA, Boscardin J, You JJ. Measuring Advance Care Planning: Optimizing the Advance Care Planning Engagement Survey. J Pain Symptom Manage. 2
Mortality, Death during hospitalization will be used to determine the presence of this outcome., Patients will be asessed for the secondary outcome measure during an average of 28 days..
Anxiety, State-Trait Anxiety Inventory (STAI), immediately after aromatherapy
Incidence of Adverse Cardiac Outcomes, Incidence of adverse cardiac outcomes tabulated including myocardial infarction, heart failure, arrhythmias, all-cause and cardiac-specific mortality at same time points used to analy

Difference in NTDmean for heart, LAD, ipsilateral and whole lungs (group A), End of radiotherapy (3-4 weeks)|Comparison of standard deviation in mean LAD NTDmean over a treatment course (group B), End of radiotherapy (
Time to reach maximum plasma concentration for cocktail parent compounds (midazolam, omeprazole and caffeine), To describe the PK of midazolam, omeprazole and caffeine and their metabolites (1'-hydroxy-midazolam,
Incidence of death, heart failure or LV systolic disfunction (LVEF<45%), 6 months after randomization|Assessment of genetic polymorphisms involved in chemotherapy-induced cardiotoxicity, Baseline|Prognostic value for car
Recovery from Trigeminal-cardiac event, Investigator will communicate when the event is over or rescue drugs given., 2 minutes
changes of miRNA between cardiotoxicity group and No cardiotoxicity, changes of miRNA between cardiotoxicity group and No cardiotoxicity, From the start of cyclophosphamide injection to1 month after the completion of
Change in contrast enhancement by MRI, Baseline and approximately 4 weeks|Change in left 2D global strain, as assessed by echocardiography, Baseline and end of study (up to 72 weeks)|Incidence of clinical of heart failur
Epidural injection, And secondary data collection was done at 30 min after the epidural injection of the study drug. All of the HRV analysis was done before anaesthesia induction., at 30 min after the epidural injection of the study drug
Radiation associated second cancer, Incidences of second cancer associated with the RT: lung, esophagus, thyroid, sarcoma, contralateral breast, 10 years after RT|Distant failure, Incidences of distant failures, i.e. cancer rec
Incidence of Cancer therapy-related cardiac dysfunction, Cancer therapy-related cardiac dysfunction was defined as an LVEF reduction \>10% from baseline, or LVEF \<53%, From start of anthracycline therapy up to 6 mont
Primary care physicians' provision of preventive services in response to family medical history.
Breath records from Healthy volunteers (no previous or current cardiorespiratory diagnoses), Tidal Breathing CO2 waveform data from 55 participants collected using the N-Tidal C Handset. Each participant delivering 2 x breath records per day for 14 days = 1540 records, 12 months from First Patient First Visit (FPFV)|Breath records from participants with Asthma, Tidal Breathing CO2 waveform data from 55 par
Each participant delivering 2 x breath records per day for 14 days = 1540 records, 12 months from First Patient First Visit (FPFV)|Breath records from participants with Congestive cardiac failure, Tidal Breathing CO2 waveform
Each participant delivering 2 x breath records per day for 14 days = 1540 records, 12 months from First Patient First Visit (FPFV)|Breath records from participants with Anaemia, Tidal Breathing CO2 waveform data from 55 pa
Each participant delivering 2 x breath records per day for 14 days = 1540 records, 12 months from First Patient First Visit (FPFV)|Breath records from participants with Bronchiectasis, Tidal Breathing CO2 waveform data from
Each participant delivering 2 x breath records per day for 14 days = 1540 records, 12 months from First Patient First Visit (FPFV)|Breath records from participants with Lung cancer, Tidal Breathing CO2 waveform data from 55
Each participant delivering 2 x breath records per day for 14 days = 1540 records, 12 months from First Patient First Visit (FPFV)|Breath records from participants with Interstitial Lung Disease, Tidal Breathing CO2 waveform d
Each participant delivering 2 x breath records per day for 14 days = 1540 records, 12 months from First Patient First Visit (FPFV)|Breath records from participants with Long COVID, Tidal Breathing CO2 waveform data from 55
Each participant delivering 2 x breath records per day for 14 days = 1540 records, 12 months from First Patient First Visit (FPFV)|Breath records from participants with Upper airway obstruction disorder, Tidal Breathing CO2 w
Each participant delivering 2 x breath records per day for 14 days = 1540 records, 12 months from First Patient First Visit (FPFV)
Number of patients with treatment-related adverse events by CTCAE 5.0, Safety profile of the trifluridine/tipiracil and oxaliplatin combination, Assessed up to 48 months|Number of patients with disease control rate (DCR), DC
change of serum level of High sensitivity troponin I (hs-TnI)., Blood samples will be collected at baseline, after 3 months and after 6 months to evaluate High sensitivity troponin I (hs-TnI)., 6 months|change of serum level of M
Clinical complications, during percutaneous ethanol instillation and consecutive 24 hours
CARDIO-VASCULAR COMPLICATIONS, Describe the frequency of myocardial infarction, pulmonary edema, cardiac arrest, pulmonary embolism, deep venous thrombosis, stroke, pericardtis, within 30 days after surgery
Correlate Cardiac MRI Parameters, Correlate cardiac MRI parameters with pre-treatment heart imaging and cardiac dose volume constraints as a measure of cardiac injury after partial heart irradiation in women with node po
Intensity of Care/ICU Use: ICU Admissions, Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU admissions during the patient's (index) hospital stay will be collected from t
Response Rate Defined by RECIST 1.1, The response rate (with 95% two-sided confidence intervals) will be computed separately by arm. One-sided chi-square or Fisher's exact tests (alpha = .1) will be used to evaluate diffe
To quantitate serological markers of diffuse myocardial fibrosis and apoptosis, Testing changes in extracellular matrix remodeling and increases in tissue apoptosis occur in asymptomatic post chemotherapy patients, 1 year
Evaluating the overall survival of patients suffering from cardiovascular or metabolic side effect of oncology treatments, 5 years|All relevants staisticals associations between adverse events and anticancer drugs, 5 years|All re
Hemodynamic alteration´s comparison among advanced cancer patients and healthy controls, Comparison of hemodynamic alteration during exposure to a group of hepatocellular-specific AM RF EMF recorded in healthy ind
overall survival, every 3 months while on treatment, then every 6 months thereafter
LV systolic strain, Change in 2D echocardiography derived LV global longitudinal strain and circumferential strain from baseline, 14 months|Echocardiography derived Ventricular Arterial Coupling Measurement, Change from
Number of participants with changes in quantitative myocardial perfusion parameters including myocardial blood flow velocity and myocardial blood flow derived from contrast perfusion echocardiography, Baseline to 2 years
Emergency department usage among parents, Outcome will be assessed based on encounter data in de-identified claims data, 3 years|Emergency department usage among siblings, Outcome will be assessed based on enc
Complete remission rate(CRR), Complete remission rate(CRR) after 6 cycles of R-CMOP chemotherapy, up to 6 cycles of chemotherapy (each cycle is 21 days)|Duration of remission(DOR), Time from reaching CR or PR for th
Mortality at ICU discharge and Hospital Discharge, Mortality at ICU Discharge, Hospital Discharge, 3 months, and 6 months, ICU Discharge, Hospital Discharge, 3 months, and 6 months|Ventilator-Free Days at Day 60, Days a
postoperative analgesic consumption, Achieve satisfactory postoperative analgesia and thereby faster patient mobilization, 12 hours
Five year disease free survival and five year mortality rates after the diagnosis of colon cancer in older (>80 yrs) vs. younger group (<80 yrs), 2 years
Complete remission (CR), The Complete Remission is defined as the lack of detectable evidence of tumor in the cohort of patients (patients with cardiac lymphoma diagnosed from 01/01/2000 to 31/12/2020)., The endpoint v
Exploring the clinical robustness, specificity, and longterm variability of TSC biomarker/s, Samples will be analyzed for the candidate biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry
Hemodynamic Measurement-Heartrate, The change in hemodynamic variable heart rate in beats per minute will be measured through the study period, 2hours|Hemodynamic Measurement-Bloodpressure, The change in hem
Release of Specimens and Clinical Data to Other Investigators for use in RASopathy Research, Release of fresh or frozen specimens and clinical data to both CCHMC and external investigators. Applications for use of bio-sp
Diagnostic testing, Any evidence that the patient-participant underwent additional diagnostic testing for the six target diseases since enrollment: coronary artery disease (stress testing, cardiac CT for coronary artery calcium
Recurrence of fluoropyrimidine related cardiac toxicity after switch to any fluoropyrimidine, Cardiac tolerability according to NCI-CTCAE following cardiotoxicity initiated switch of fluoropyrimidine to another fluoropyrimidine c
* ECG abnormalities * Ejection fraction in % * Coronary artery status on angiogram * Cardiac arrhythmias in ECG, Holter or cardiac monitor registration * Plasma troponin concentration and other cardiac enzymes and other laboratory tests as within reference range ro abnormal * Serum alpha-fluoro-beta-alanine (FBAL) concentration, During one cycle (average 3 weeks) of fluoropyrimidine-based chemotherapy causing cardiac toxicity
Rate of accrual relative to the number of eligible patients per month, Determined by proportion of patients enrolled, 6-month recruitment period|90-day mortality, Determined by telephone follow-up and check of medical reco
Rate of anthracycline-induced cardiotoxicity events, Cardiotoxicity event is defined as one of the following: * Drop in LVEF between study CMRs of ≥10 absolute points regardless the absolute value of follow- up ejection fraction (EF). * Drop in LVEF between study CMRs of ≥5 to \<10 absolute points with a follow-up EF value \<50% UNITS: absolute number of patients in each arm qualifying for cardiotoxicity event (i.e. each patient will be qualified at the end of the study as YES/NO)., 9 weeks after the last chemotherapy cycle (anticipated to be between UNITS: absolute number of patients in each arm qualifying as responder or no responder (i.e. each patient will be qualified at the end of the study as YES/NO)., 9 weeks after the last chemotherapy cycle (anticipated to be be UNITS: absolute points in the questionnaire. minimum value 0 maximum value 84 the higher the total score, the better (greater the effect on a patient's QoL), 9 weeks after the last chemotherapy cycle (anticipated to be between 150 and 200 days from enrollment)|Change in Quality of Life-Euro Quality of Li UNITS: absolute points in the questionnaire. minimum value 0 maximum value 100 the higher the total score, the better (greater the effect on a patient's QoL), 9 weeks after the last chemotherapy cycle (anticipated to be between 150 and 200 days from enrollment)|Change in Quality of Life-Kansas City Card UNITS: absolute points in the questionnaire. minimum value 0 maximum value 65 the higher the total score, the better (greater the effect on a patient's QoL), 9 weeks after the last chemotherapy cycle (anticipated to be between 150 and 200 days from enrollment)|Rate of Heart Failure Hospitalization, Rate UNITS: Absolute number of patients in each arm experiencing a heart failure hospitalization, 6-42 months
Incidence of cardiotoxicity, Will use the methods of Gooley, et al (1999) to estimate the cumulative incidence of cardiotoxicity while considering deaths from other causes as a competing risk. Will estimate the cumulative incid
Cardiac events, Cardiac events defined as death from a cardiac or heart failure of New York Heart Association (NYHA) class III or IV, or with a decrease in the left ventricular ejection fraction of at least 10 percentage points fro
2/Plaque measurement and clinical biomarkers correlation, Find correlation between plaque measurement and clinical biomarkers of prostate cancer patients., End of study

Dysfunctions in endocrine hormone levels, measured as: 1. insulin-like growth factor-1, 2. anterior pituitary hormones (GH, ACTH, TSH, LH, FSH), 3. thyroid hormones (fT3, fT4), 4. sexual hormones, up to 10 years after radiation therapy|Changes in blood markers of cardiovascular diseases, measured as blood markers (incl. troponin, BNP, CPK), up to 10 years after radiation therapy|Changes in imagi
Worry of having heart disease, To examine if patients report less worry of having a heart attack or sudden death after having a CT examination of the heart's arteries, when receiving extended information and the normal exam
This is measured with a single item in Seattle Angina Questionnaire regarding worry of having heart attack or die suddenly. Values range from 1-5, 1 represents "worry all the time" and 5 represents "never worry". Less worry c
This is measured with 2 single items in Seattle Angina Questionnaire. One item regards limitations in everyday activities because of chest pain. Values range from 1-5, 1 represents lowest level, and 5 represents highest level c
In addition, clinical data regarding participants use of primary and secondary health care the last 4 weeks is collected at all times of follow-up and is compared to baseline data., 1 month, 6 months, 12 months|Patient satisfac
This is measured with 2 single items in Seattle Angina Questionnaire regarding satisfaction with treatment. Values range from 1-5, 1 is the lowest level of satisfaction, and 5 is the highest level of satisfaction. Greater satisfacti
Evidence of the relationships between the change in QTc(Corrected QT interval) from baseline and the plasma concentrations of GSK1120212 and predicted change in QTc(Corrected QT interval), From baseline as compared
Change in RR interval from baseline RR following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors., 12 weeks|Change in PR interval from basel
The interview, using framework analysis, informed by normalization process theory toolkit, Semi-structured face-to-face interviews will be conducted by all nurses on how successful passing ELNEC-PPC WBT course from th
The predictive value of cardiac substructures dosimetric parameters for cardiac toxicity as evaluated using STE and traditional echocardiographic parameters, Apart from the whole heart, which is routinely contoured, the follo
Quantification of cardiac function, Investigators use ejection fraction(EF) to quantify the cardiac function. If EF is higher after the operation, the cardiac function gets recovered; if EF is lower after the operation,the cardiac func
Change in improvement of left ventricular (LV) systolic function as assessed by LVEF, As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences ir
Arrhythmia, Re-hospitalization for Arrhythmia (Judged by the physician) after discharge, divided into yes or no, Within a year|Valvular Heart Disease, Re-hospitalization for Valvular Heart Disease (Judged by the physician) afte
CRF response rate, assessed by the number of participants with a change in VO2peak ≥ 1.32 ml O2 • kg-1 • min-1 (technical error of CRF measurement) from baseline to month 6. A change in VO2peak ≥ 1.32 ml O2 • kg-1 •
Sensitivity and specificity of [18F]florbetaben PET for the diagnosis of cardiac AL amyloidosis using quantification., The sensitivity and specificity of \[18F\]florbetaben PET for the diagnosis of cardiac AL amyloidosis will be d
New skin cancer, 2 years|Number of patients with new skin cancers, 2 years|Time of recurrence, 2 years|Number and histology of other types of skin cancer, 2 years|Graft function (including acute rejection, graft loss, death), 2
Number of participants with decrease in myocardial contractility (strain or strain rate measured with cardiac ultrasound exam"2D strain"), within the first 6 months after tomotherapy|Number of participants with modified meas
Determination of the prognostic value decreased of myocardial mitochondrial pyruvate flux in predicting clinically significant radiation induced cardiotoxicity., As a secondary outcome, we will measure if decreased myocardia
Rate of episodes of all-cause death, cardiovascular death, myocardial infarction, and stroke, medical records, from date of randomization until the end of study, up to 24 months|Percentage decrease in left ventricular ejectior
Self-reported continuous smoking cessation at three months, Participant self-report being quit continuously for three months after Lung Screening. Binary question " Have you smoked in the 3 months since Lung Screening,
Serum concentration of C-Reactive Protein, To assess the effect of vagus nerve osteopathic stimulations on systemic inflammatory, up to 84 days|Time to definitive improvement in global health status / QoL, To assess the ef
Changes in serum Concentration: Epinephrine, 7 timepoints during anesthesia (Administration of rocuronium, intubation, cut, intraabdominal air insufflation, ligature of v. suprarenalis, tumor exstirpation, end of operation)|Cha
Oncological mortality, Cumulative incidence of oncological mortality, Two and five years of follow-up|Cardiovascular mortality, Cumulative incidence of cardiovascular mortality, Two and five years of follow-up|Hospitalization,
Incidence of myocardial injury according to levels of high-sensitivity cardiac troponin T and NT-proBNP, Incidence of myocardial injury according to levels of high-sensitivity cardiac troponin T and NT-proBNP., 1, 3 and 6 mont
Additional safety evaluations, 6 months and, if eligible, up to 2 years of extended treatment|Efficacy evaluations, 6 months and, if eligible, up to 2 years of extended treatment|Pharmacokinetic and Pharmacodynamic evaluatio
Plasma concentrations of ofatumumab and electrocardiogram (ECG) parameters, The pharmacokinetic results will be correlated to ECG findings to determine if drug concentrations relate to any ECG effects., 25-week ofatum
Changes from Baseline Profile of Mood States (POMS) short version (Psychological Distress) at 2 weeks, Psychological distress will be measured using the Profile of Mood States (POMS) short version (15 items, 5-point Liker
Changes in medicine, Information on medicine for both groups will be collected at enrolment and every week from the electronic patient record (EPR). Changes in medicine over time will be analyzed., At enrolment and week
Onset and frequency of atrial fibrillation, Explore the onset and frequency of atrial fibrillation in sleep apnoea patients in order to determine what method of detection is efficient and cost effective., 3 years|Rate of Cardiovascu
tolerability of the experimental device, Secondary objectives will be to assess the feasibility and tolerability of HCO-HD in patients with advanced cardiac AL amyloidosis, the efficiency of HCO-HD plus chemotherapy in reduc
Find out whether availability of pharmacogenomic information impacts drug decision making in the health care setting, 5 years
Number of Participants Reporting Satisfaction When Using the MeTree Tool, The study will assess satisfaction associated with using the MeTree tool via 3 months survey after completing the family health history collection. T
Change from Baseline in BMD at 12 months and 24 months, DEXA bone mineral density, before the treatment, time point of taking the medicine for 1 year, time point of taking the medicien for 2 years|Change from Baseline ir
Autonomic Symptoms, Self-reported autonomic symptoms via the COMPASS31, Assessed at baseline|Perceived health, Self-reported perceived health via Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36
Patient reported outcome (PRO) for pain measured by the quality of Life questionnaire using PROMIS to measure pain, Quality of Life questionnaire using PROMIS will be administered at baseline, six, twelve and fifteen mont
the Incidence of Adverse Cardiovascular Events, including hypertension,hypotension,tachycardia,bradycardia, during the surgery|Oxygen Delivery（DO2）, oxygen delivery（DO2) in ml•min-1•m-2.Record the data of DO2 at
Changes in Internal Carotid Artery Blood Flow by Induction of Anaesthesia., Unilateral internal carotid artery blood flow \[ml/min\] assessed by duplex ultrasound., Two measurements; one measurement 5-10 min before induc
Internal carotid artery blood flow \[ml/min\] was assessed by duplex ultrasound. Mean arterial pressure \[mmHg\] was recorded by a transducer connected to an arterial line. Cardiac output \[l/min\] was evaluated by pulse co
The CO2 reactivity to hypocapnia when awake and during anaesthesia is calculated as the percentage change in internal carotid artery blood flow per kPa change in PaCO2. The CO2 reactivity when awake and when anaestl
Change in Weight From Baseline to 3 Months, 3 months|Change in Weight From Baseline to 6 Months, 6 months|Change in Calories From Baseline to 3 Months, kilocalories, 3 months|Change in Calories From Baseline to 6 M
Incidence of cardiac symptoms, Cardiac symptoms to be evaluated include: clinical heart failure, exertional dyspnea, orthopnea, S3 gallop, acute coronary syndrome, acute pulmonary edema and life-threatening arrhythmias
Clinical Benefit Rate Defined as Stable Disease (SD) >= 9 Months, Partial Response (PR) or Complete Response (CR), Prolonged non-progression is of clinical benefit (CR + PR + SD at 9 months)., Up to 2 years|Overall Surviv
SUVmax determined by: SUVmax = \[VOI activity (mCi/ml) * body wt (g)\]/injected dose (mCi) SUVpeak determined by identifying the hottest cubic centimeter within a VOI centered on the lesion with the highest FDG., Baseli
ECG parameters: RR interval, QT, QTcB, heart rate, PR, QRS intervals and morphology., 11 days|Plasma pazopanib and metabolites (GSK1268992, GSK1268997 and GSK1071306) concentrations and PK parameters AUC(0-
Change in patient experience with treatment and self-management., Change in the patient's experience with treatment and self-management of heart failure and colon-rectal cancer between baseline and post-1 and 2 will be
Medication possession ratio (MPR) - Aim 1, Reflects patient adherence. Days of drug supply over 1 year with cholesterol lowering medication in the previous 1 year from pharmacy dispensation records., 1 year post CT|Medic
COMRADE questionnaire will be sent to patients after their first meeting with their general practitioner up to 3 months after intervention., 3 months post intervention|Health Care Utilisation, Number of unplanned clinic visits, h
Peak Exercise Cardiac Output (Exercise Capacity Addendum), Peak exercise cardiac output refers to the amount of blood that the heart pumps out per minute. It is an important measure of how effectively the heart is working
T1 pre- and post-contrast values, Measured by scans performed before and after RT, 2 years|Extracellular volume fraction, Measured by scans performed before and after RT, 2 years|T2 values, Measured by scans performec
Anxiety and depression (HADS), Symptoms of depression and anxiety assessed with the Hospital Anxiety and Depression Scale (HADS). The HADS is a reliable, valid 14-item, 2-domain (anxiety and depression) tool used to a
Number patients in which blood and serum biomarkers were identified that correlated with cardiac damage due to radiation, The study aims to characterize longitudinal changes in potential early biomarkers of cardiac damag
7-day point prevalence smoking abstinence verified by saliva cotinine, taken one month post-intervention (12 weeks after baseline)
Fridericia-corrected QT interval (QTcF), QTcF time-matched change from baseline on day 7 at the following time points: 1, 2 (end of infusion), 2.5, 3, 4, 5, 6, 8, 12, 16, 20, and 23.5 hours, Up to 23.5 hours after study drug infu
Lower body physical function, 30 seconds Sit-To-Stand test, At baseline|Hand grip strength, Maximum strength test by handgrip dynamometer, At baseline|Walking endurance, Six Minute Walking Test, At baseline|Health-rela
Affective reactions toward cigarettes and smoking cues, After 4 weeks of exposure to the new warning labels
Change in Peak Exercise Cardiac Output, Measured on a continuous scale and will be analyzed using a repeated measures ANCOVA (RMANCOVA) approach., At baseline and 6 months after study intervention|Change in Cal
Admission to Intensive care unit (ICU), Description of the admission to ICU, Until study completion, an average of 1 year|Complications occurred during the hospital course, Description of the complications occurred during th
Intensity of care/ICU use: ICU admissions, Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU admissions during the patient's (index) hospital stay will be collected from th
time to first MACCE event, To compare time to first MACCE event as estimated by the cumulated probability at the 1-year timepoint of patients with advanced prostate cancer treated with Degarelix vs. GnRH agonist and cor
MACCE will be defined as: 1. Death of any cause 2. MI 3. CVA 4. Percutaneous coronary intervention, (PCI) with stent insertion, 1 year|cardiac echocardiography, To compare change in ejection fraction (EF) as measured by cardiac echocardiography of patients with advanced prostate ca
Cardiac function changes after completion of HER2-directed therapy, Delta change in LVEF from completion to one year after completion of trastuzumab-based HER2-directed therapy, 1 year|Gene variants and risk of cardiot

Functional capacity as measured by 6MWT on day of discharge and at return clinic appointment (up to 8 weeks), Measure of level of physical activity measured in metres, Date of discharge from physiotherapy and at return c
Spirituality, Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being (FACIT-SP) subscale. The 12-item measure assess spiritual well-being: faith, meaning, and purpose. Individual items use a 5 point likert scal
Left ventricular mass, measured by echocardiography, 12 weeks|stroke volume, measured by echocardiography, 12 weeks|left ventricular and atrial end-diastolic volume, measured by echocardiography, 12 weeks|global long Bout - Analyzed for Na,K,Cl, Analyzed for electrolytes, 12 weeks|Change in peripheral blood Adaptation to Acute Exercise Bout - Analyzed for hct, Analyzed for hematocrit., 12 weeks|Change in peripheral blood Adaptation to
Cardiovascular Risk Profile, This will be assessed using a standard blood requisition blood form including measurement of lipids, cholesterol, and triglyceride levels. Anthropometrics including body mass index, waist circumfe
The FACT-B questionnaire will be used as a measurement of health related quality of life for individuals with breast cancer., Baseline and 12 weeks
Difference in Proportion of Whites versus African Americans who complete advance care planning, Difference of proportion in whites versus African Americans who complete formal or informal advance care planning, 12 mon
LV wall thinning, Rate of change of the end-diastolic left ventricular posterior wall z-score and of the thickness to dimension ratio z-score, 18 months
Incidence of acute adverse events (AE), Descriptive statistics of frequency (percentage) will be used to summarize AE incidence and severity as measured by the Common Terminology Criteria for Adverse Events (CTCAE) 5.0
Claims-based and patient-reported quality of care, Eight years
24 hour heart rate variability, week 8 and week 24|liver fat content (MRI), week 8 and week 24
Quality of life questionnaire EORTC QLQ 30 (European Organisation for Research and Treatment of Cancer), Scale from 1-100 for 30 items, higher score indicates a better situation., At 60 months from treatment|Quality of life
(Interventional Study) Comparison of caregivers' HRQoL according to the intervention allocated by randomization based on summaries score the MOS SF36, To compare the Health Related Quality of Life based on summarie
To determine if aortic stiffness changes during treatment with anthracycline chemotherapy in childhood cancer patients, n=25, approximately 6 months
Sensitivity and specificity for the detection of malignant lesions, At Day 0|Exact match of the MR diagnosis with the final clinical diagnosis based on medical records up until 3 months after the scan, At Day 0|Confidence in di
Change in resting 'clinic' arterial blood pressure from baseline to end of treatment, Arterial blood pressure (BP) (ausculatory method) (units = mmHg), Assessed at two time points: (1) at baseline (diagnosis); and (2) 14 to 28 w
3-day, 24 h-dietary recalls will be used to record the participants' energy intake by either themselves or parents/caregivers. The investigators will provide participants with instructions on how to obtain a correct food record. D
3-day, 24 h-dietary recalls will be used to record the participants' energy intake by either themselves or parents/caregivers. The investigators will provide participants with instructions on how to obtain a correct food record. D
3-day, 24 h-dietary recalls will be used to record the participants' energy intake by either themselves or parents/caregivers. The participants will provide participants with instructions on how to obtain a correct food record. Di
3-day, 24 h-dietary recalls will be used to record the participants' energy intake by either themselves or parents/caregivers. The participants will provide participants with instructions on how to obtain a correct food record. Di
Left ventricular ejection fraction assessed by Cardiac Magnetic Resonance, Left ventricular ejection fraction (unit of measurement: %) assessed by Cardiac Magnetic Resonance at 12-month follow-up., at 12-month follow-up
* Transient ischemic attack: rapidly developed clinical signs of global disturbance of cerebral function lasting fewer \<24 hours, regardless of the presence of an acute clinically relevant brain lesion in imaging. * Ischemic stroke: rapidly developed clinical signs of focal or global disturbance of cerebral function lasting \>24 hours with imaging of an acute clinically relevant brain lesion. * Intracerebral haemorrhage: diagnosis must be confirmed by cerebral imaging., at 12-month follow-up|Hospitalization for heart failure, Hospitalization for heart failure will be defined as any unplanned hospital readmission du
Number of Participants Stating Satisfaction with PREVENT Tool, Patient satisfaction will be identified through post-visit survey with a 5-point Likert scale (strongly agree to strongly disagree) regarding liking the tool, helpfulne
Type adverse events, Divide the adverse events into categories, like diagnosis, therapy, medication, surgery, non-surgery, etc., 6 months|Clinical impact of adverse events in terms of outcome, Assess the impact of the advers
Mortality, Mortality, Within 30 days after surgery
Change from baseline to post-intervention in Edmonton Symptom Assessment Scale, The Edmonton Symptom Assessment Scale is a validated, reliable instrument developed to measure 9 different common symptoms in ad
Number of Participants with Treatment-emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs), An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant admini
Problem list prevalence, Number of patients with selected problems on their problem list pre and post intervention across intervention and control groups., pre and post intervention|Problem list incidence, For the conditions
Number of Patients With Trastuzumab Course Interruption, Measure indicates the number of patients who had an interruption of trastuzumab for any reason, 2 years|Quality-of-life Changes Between Baseline and 52-weeks,
Perception of Impact of Variant Update Significance Level Alerting on Clinician Workload, Surveys will be constructed that ask treating clinicians about their experience with using the GIC and its perceived impact on workloa
Haemodynamic response to head-up tilt and research drugs, Rapid haemodynamic responses are assessed during the same measurement session (the response to head-up tilt and to research drugs salbutamol, nitroglyceri
Radiation dosimetric comparison, Radiation dosimetry is the accurate calculation and measurement of radiation doses received by tissue resulting from the exposure to radiation. A radiation dosimetric comparison will be pe
The proportion of billed CMS ACP-CPT codes in Ig vs. Cg, The proportion of patients who received an ACP CMS billing codes (which took effect in January 2016), in Ig vs. Cg will be evaluated using one or both of the new C
Sensitivity and specificity of serial LVEF measurements in detecting cardiotoxicity, 12 months|Clinical management and outcomes of patients with abnormal cardiac biomarkers or clinically defined cardiotoxicity during chemo
Change of the cardiac function, Change of the cardiac function will be observed with the NTproBNP levels., At Baseline and the end of each 1-12 cycles (baseline and 1-12 months)|Change of the renal function, Change of th
Change in left ventricular ejection fraction by echocardiography, From randomization to end of blinded therapy (18 months)|Change in left ventricular systolic global longitudinal strain by echocardiography, From randomizatio
reduction of the left ventricular global longitudinal strain (GLS) by over 15%, determination of GLS via strain analysis, after 12 months
Causes of mortality, Anually
To prospectively collect data on the prevalence of modifiable cardiac risk factors and the spectrum of cardiac structural abnormalities in this patient populations, Data on modifiable cardiac risk factors, and outcome of scree
Effect of an audit and feedback process plus tailored interventions ACP, Compared to baseline, what is the effect of an audit and feedback process coupled with tailored interventions on use of and satisfaction with ACP at th
Diastolic function (E/e') by echocardiogram, The mitral valve inflow velocity divided by the average early diastolic tissue velocities of the mitral valve annulus (septal, lateral) measured by tissue Doppler echocardiography., up
Change in mean CTC cluster number, number of CTC-clusters before and after treatment will be compared, Blood samples drawn at Screening, on day 0 (2 hours after first oral intake of digoxin), on day 3, on day 7, on day 1
The possible effects of B-vitamin treatment on major cardiovascular events, all cause mortality and cause specific death during the trial periods (completed by 2004 and 2005) and during post-trial follow-up., 1998-2014
Time-matched Mean Change From Baseline in Corrected QT Intervals Based on the Bazett's Correction Fomulation (QTcB), QT interval is the time from electrocardiogram Q wave to the end of the T wave corresponding to el
Change from baseline in QTc with Bazett correction method (QTcB), 22 days|Change from baseline in heart rate (HR), 22 days|Change from baseline in PR interval, 22 days|Change from baseline in QRS interval, 22 days|Chan
The recent incidence of adverse reactions, Observe 7-10 days postoperatively in patients with the ratio of pain and difficulty swallowing, 7-10 days
Number of patients with other cardiac complications after completion of RT treatment, First 10 years after RT treatment|Number of patients with radiotherapy-induced late non-cardiac toxicity (e.g. secondary tumors), First 10

Change in NTproBNP, Change in clinically measured NTproBNP following initiation of neurohormonal antagonists in patients with NTproBNP above upper limit of normal in the biomarker guided arm, Through study completio
Occurrence of Discussion About Goals of Care at Target Visit, Electronic Health Record (EHR) documentation of discussion about advance care planning, prognosis, treatment preference, hospice, palliative care, or Physician
Measured with QOC items 1, 2, 5, \& 6 (measurement invariance imposed between groups and over time). Outcome is a latent variable, which is not observable, nor is it a composite score that can be mathematically comput
Theoretical range: unknown; the latent variable is a hypothetical - not an actual - variable Actual range: inapplicable; cannot be determined; this is an indirectly-measured latent variable; Higher value indicates better outcome
Individual QOC Items.
Theoretical range: 0-11 Actual range: 0-11 Higher value indicates better outcome (i.e., higher quality communication) Unit of measurement: units on a scale, 2 weeks from target visit|Patient Health Questionnaire (PHQ-8): Two
Two-Indicator Latent Construct: Measured with PHQ items 1 \& 2 (measurement invariance imposed between groups and over time). Outcome is a latent variable, which is not observable, nor is it a composite score that can
Theoretical range: unknown; the latent variable is a hypothetical - not an actual - variable Actual range: inapplicable; cannot be determined; this is an indirectly-measured latent variable Higher value indicates worse outcome
Eight-Item Scale: Sum of responses for the eight symptoms (weighted by 8/7 if only 7 items answered).
Theoretical range: 0-24 Actual range: 0-24 Higher value indicates worse outcome (i.e., higher level of depressive symptoms) Unit of measurement: scores on a scale, 3 months after target visit|Patient Health Questionnaire (PH
Two-Indicator Latent Construct: Measured with PHQ items 1 \& 2 (measurement invariance imposed between groups and over time). Outcome is a latent variable, which is not observable, nor is it a composite score that can
Theoretical range: unknown; the latent variable is a hypothetical - not an actual - variable Actual range: inapplicable; cannot be determined; this is an indirectly-measured latent variable Higher value indicates worse outcome
Eight-Item Scale: Sum of responses for the eight symptoms (weighted by 8/7 if only 7 items answered).
Theoretical range: 0-24 Actual range: 0-24 Higher value indicates worse outcome (i.e., higher level of depressive symptoms) Unit of measurement: scores on a scale, 6 months after target visit|Generalized Anxiety Disorder (G
Two-Indicator Latent Construct: Measured with GAD items 1 \& 2 (measurement invariance imposed between groups and over time). Outcome is a latent variable, which is not observable, nor is it a composite score that can
Theoretical range: unknown; the latent variable is a hypothetical - not an actual - variable Actual range: inapplicable; cannot be determined; this is an indirectly-measured latent variable Higher value indicates worse outcome
Seven-Item Scale: Sum of responses for the seven symptoms (weighted by 7/6 if only 6 items answered). (Strong floor effect.)
Theoretical range: 0-21 Actual range: 0-21 Higher value indicates worse outcome (i.e., higher level of anxiety symptoms) Unit of measurement: scores on a scale, 3 months after target visit|Generalized Anxiety Disorder (GAD-
Two-Indicator Latent Construct: Measured with GAD items 1 \& 2 (measurement invariance imposed between groups and over time). Outcome is a latent variable, which is not observable, nor is it a composite score that can
Theoretical range: unknown; the latent variable is a hypothetical - not an actual - variable Actual range: inapplicable; cannot be determined; this is an indirectly-measured latent variable Higher value indicates worse outcome
Seven-Item Scale: Sum of responses for the seven symptoms (weighted by 7/6 if only 6 items answered). (Strong floor effect.)
Theoretical range: 0-21 Actual range: 0-21 Higher value indicates worse outcome (i.e., higher level of anxiety symptoms) Unit of measurement: scores on a scale, 6 months after target visit|Avoidance of Life-Sustaining Therap
Incidence of preoperative anxiety, The State anxiety inventory (20-80，lower is better) was used to investigate the incidence of Preoperative anxiety, The 1 day before surgery
Determination of Cardiac Dose and Lung Dose Reduction in Women Receiving Prone Breast Radiotherapy When Inspiratory Gating is Added., This outcome was measured by looking at the maximum dose to the heart and m
Program compliance, Program compliance rate of patients in the experimental group. A patient is considered compliant if he declares to have completed at least 2/3 of the proposed Cardiac Coherence sessions + listening to
The scale scores six items from 1 to 5 (1 = absence, 5 = extreme). The APAIS scale will be used to determine the psychological profile of patients between "blunting" and "monitoring" types, Between -15 to -7 days before su
GENETIC DISORDERS AND CARDIOTOXICITY, To test implication of some genetic disorders in predicting cardiotoxicity, mainly through decrease of antioxidant capacity;, BASELINE|DIAGNOSTIC ACCURACY FOR CARDIO
Change in left ventricular ejection fraction value measured by echocardiography, Left ventricular ejection fraction by cardiac echo, 1 year|Heart failure hospitalization, admission due to heart function deterioration, 1 year|All-ca
Left Ventricle Ejection fraction (LVEF) by Simpson method (%), Compare the standard ultrasound parameter LVEF and the LVGLS obtained in "Speckle Anthra 2" on patients treated with anthracyclines in childhood and in the
Patient identification rate (feasibility target: >=50% of OEP), Defined as the average number of OEP identified each month, Initiation through end of study recruitment 12 months|Baseline assessment rate (feasibility target >=9
Changes in myocardial function measurements assessed by echocardiography, Increase of the segmental strain measurements (unit of measures:%), 6 months and 2 years after radiotherapy (baseline measurements perform
classical biomarkers of cardiac injury (C-reactive protein, Troponin I, Troponin T, B-type natriuretic peptide (BNP), N-terminal pro-brain natriuretic peptide (NT-Pro BNP), beta2-Microglobulin, Galectin 3); Inflammatory cytokines
Overall feasibility, 3 years
Tumour Response (metabolism), FDG-PET imaging to detect tumour metabolism changes compared to baseline., 6 weeks|Tumour Response (perfusion), DCE-CT imaging to detect changes in tumour perfusion compared to
Completion of guideline-recommended surveillance tests, Proportion of survivors who complete one or more of the guideline-recommended cardiac, breast or colon surveillance tests (echocardiography, mammogram and br
Cancer therapy-related cardiac dysfunction (CTRCD), Incidence of CTRCD defined as at least a 10% absolute change in LVEF by echocardiogram at follow-up relative to baseline to a value \< 50%, through study completion
Evaluate left ventricular ejection fraction as assessed by T2* MRI., A single T2* MRI will be performed on eligible patients.|Evaluate liver iron concentration as assessed by R2* MRI, A single T2* MRI will be performed on eligib
The presence of edema stratified by the presence or absence of any drop in LVEF ≥5% by CMR by end of therapy (this is a binary outcome)., Please see definition for edema above, 2-15 months
Surgery details, Detailed information such as operation time, Intraoperative|Post-operative complications in patients who underwent liver transplantation, Specific details of all post-operative complications in patients who und
MACE (Major adverse cardiac events), 1 year after CMR scanning|MACE (Major adverse cardiac events), 2 years after CMR scanning
Clinically used LVEF cut-off points <45% and <50%, Prevalance of systolic cardiac dysfunction defined as a LVEF \<45% and \<50%, through study completion (from Ocotober 2022 - December 2024)|Course of cardiac func
change in the level of troponin I (TNI), Compared with the baseline in three groups and T2DM with different phenotype of PCOS, the serum index related to myocardial injury such as change of TNI in ng/ml., 3 years|change in
Number patients in which blood and serum biomarkers were identified that correlated with cardiac damage due to radiation, The study aims to characterize longitudinal changes in potential early biomarkers of cardiac damag
Lower urinary tract symptoms (LUTS), Measure patient's prostate symptom score for patients with a prostate cancer diagnosis and repeat the survey at 3, 6, 9 months and annually for 5 years after treatment. We will use the
Assession of wall-motion abnormalities and left ventricular ejection fraction (LVEF) decrease, Incidence of left ventricular wall motion disorder and LVEF quantification on follow-up myocardial perfusion SPECT scans., up to 1
Change in Score on the Patient Health Questionnaire-9 (PHQ-9) for patients, This is a 9-item assessment to diagnose depression. It is based on the nine DSM-IV criteria for depression, At baseline and 1- and 2- months follo
Clinical response rate (complete plus partial responses). Clinical response will be assessed by imaging using the WHO criteria., Before and after treatment with paclitaxel.|Breast-conserving surgery: tumorectomy or quadrant

Event free survival, 5 and 10 years after the completion of the chemotherapy.|Overall survival, 1, 5 and 10 years after the completion of the chemotherapy.|The levels of serum biomarkers (hs-Troponin T (hs-TnT), B-type natriu
Risk Factors to Predict Early Decline of Myocardial Function During the Weaning of HF (Heart Failure) Medications., To identify an increased troponin-I that can predict the possibility of HF medication withdrawal failure., A tot
venous blood oxygen partial pressure (PvO2), 5 min after jugular catheter flow 0ml/min|venous blood oxygen partial pressure (PvO2), 5 min after jugular catheter flow 500 ml/min|venous blood oxygen partial pressure (PvO2),
Cumulative time spent at home, patient-reported questionnaires, Days at home will be reported over a 6-month range and will be compared between arms. Patients will report number of days spent in a hospital, nursing hom
Prediction of initiation/change in cardiovascular medications based on serum biomarkers, NT-proBNP, up to 35 weeks|Prediction of initiation/change in cardiovascular medications based on serum biomarkers, ST2, up to 35 v
Incidence of ventricular arrhythmias, Assessed by 28-day mobile telemetry, During 6 months of BTK inhibitor therapy|Severity of ventricular arrythmia, NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.
SCAD recurrence, Through study completion, or approximately 50 years (average age of study participants)
Medication Knowledge, Change medication knowledge using The Patients' Perceived Knowledge in Medication Use Questionnaire (PKMUQ). The response scale ranges from 1 = strongly disagree to 5 = strongly agree, and t A 5-point Likert scale ranging from 1 = strongly disagree to 5 = strongly agree is used. A higher score indicates stronger beliefs about the corresponding concepts in each subscale. the score range would be 5 to 90., 3 month
Cardiac Biomarkers (N-terminal pro B-type natriuretic peptide [NT-proBNP]), Change from baseline at 6 and 12 months in the cardiac biomarker NT-proBNP (measured in pg/L), 12 months|Cardiac Biomarkers (Troponin T), Ch
Proportion with critical CAD, Coronary stenosis \>70% by CT coronary angiogram, 3 years|Proportion at intermediate clinical risk, Intermediate clinical risk (0.8-2.0% annualized risk by Pooled Cohort Equation), 3 years|Statin
Change in quantitated Left Ventricular Ejection Fraction (LVEF), Change in LVEF over the course of chemotherapy; incident diastolic dysfunction by echocardiography; the combined endpoint of any incident adverse cardiovas
To assess the tolerability of Caelyx containing regimens in elderly breast cancer patients.
Body weight, Fried Frailty Index Components: We will measure the change in body weight with a calibrated scale. A change of 5% (greater or lower) in 1 year is considered worse., Start of the program and 18 weeks after the The EuroQol 5 dimension version 5-level (EQ-5D-5L) also records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' (100) and 'the worst hea
Left ventricular mass by Cardiac Magnetic Resonance, Electrocardiographically gated cine imaging with steady state free-precession to assess left ventricular mass., two years|Left ventricular volumes by Cardiac Magnetic R
Upper limb functionality of breast cancer patients after a physical therapy rehabilitation program following the surgery., This outcome will involve data regarding to a questionnaire of upper limb function during activity daily ro
Number of re-admissions to hospital from time of inclusion until death, 1.7.2015
biochemistry, Comparison of serum markers of healthy volunteers and patients with various diseases., baseline|metabonomics, Comparison of metabolites of healthy volunteers and patients with various diseases., baseline|p
Transthoracic echocardiography (TTE) global left ventricular systolic function., Change from baseline in number of patients with global systolic dysfunction measured as % left ventricular ejection fraction by TTE., Baseline (wi * new T-wave inversions * new ST-segment deviations \>/= 1mm * new left bundle branch block, Baseline (within 1 month prior to the initiation of cancer treatment), during cancer treatment (estimated at 1-6 months), and within 1 month post-cancer treatment completion (approximately 2-9 * high sensitivity troponin (ng/L) * cardiac C-reactive protein (mg/L) * brain-type natriuretic peptide (pg/mL) * fasting lipid panel: total cholesterol (mg/dL), low-density lipoprotein cholesterol (mg/dL), high-density lipoprotein cholesterol (mg/dL), triglycerides (mg/dL) * complete metabolic panel: total protein (g/dL), albumin (g/dL), total bilirubin (mg/dL), direct bilirubin (mg/dL), aspartate aminotransferase (IU/L), alanine transaminase (IU/L), alkaline phosphatase (IU/L), sodium (mmol/L), pota * complete blood count: white blood cell count (k/uL), hemoglobin (g/dL), hematocrit (%), platelet (k/uL), Baseline (within 1 month prior to the initiation of cancer treatment), during cancer treatment (estimated at 1-6 months),
Lipids, 12 months
Comparison of candidate early markers of cardiac injury, The fluctuation in the levels of biomarkers including novel ultra sensitive troponins and BNP, as well as tissue doppler imaging studies with echocardiography will analy
Feasibility of intervention defined by number of participants receiving full course of RT treatment and minimum of two doses of Durvalumab, Feasibility of intervention is defined as a participant receiving the entire course of p
Occurrence of major cardiovascular events and death of any cause at 1 year in prevalent and incident AF patients, Occurrence of death of any cause, cardiovascular death, heart failure, stroke, myocardial infarction in active Overall Response Rate, The proportion of patients who respond (completely or partially) to each combination regimen will be estimated. An exact binomial confidence interval will be computed for these estimates. Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR): disappearance of all target lesions; Partial Response (PR) 30% decrease in sum of longest diameter of target lesions, Duration of Study (up to 3 years)|Number of Participants With Grade 3, 4 or 5 A Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life Threatening; Grade 5: Death., Duration of study (up to 3 years)
Diagnostic confidence graded, The diagnostic confidence grade will be calculated on a four-point scale (1: insufficient, 2: poor, 3: average, 4: good)., Day 8|Subjective image quality graded, It will be calculated on a five-point The CTDI is an estimation of the dose delivered to the organs for each acquired section that is based on acquisition parameters of a water phantom with a 32 cm diameter. The value is expressed in milligray (mGy)., Day 8|Do The DLP is obtained as follows: CTDI * length of body explored = value in mGy.cm., Day 8|Equivalent dose (mSv), To determine the radiation dose delivered to the patients during the DECT and SPCCT imaging procedures. The equivalent dose is obtained by multiplying the DLP to the specific organ conversion factor., Day 8|Quantitatively image quality : Noise, The noise by selecting regions of interest (ROI) will calculated., Day 8|Quantitatively i
Efficacy of utilizing mothers to educate family members of disease risk and motivate healthy behaviors., Efficacy of utilizing mothers to educate family members of disease risk and motivate healthy behaviors., interim and enc
Hospital stay, 30 days|Mortality, 30 days
Number of Participants with Abnormal QTc that is greater than 0.48mm on 12 lead ECG and wearable device ECG, From the analysis of QT measurements from Outcome 2, prolonged or abnormal QTc measurement will be n
Development of worsening diastolic function, Development of worsening diastolic function, defined as a decline by at least one American Society of Echocardiography gradation of diastolic dysfunction, 6 months|Developme
Blood urea nitrogen, Change in Blood urea nitrogen, 6 months|Serum creatinine, change in Serum creatinine, 6 month|Cardiotoxicity, Change in ejection fraction, 6 months
Hypoxemia, Length of hypoxemia presence in years, baseline, one point of time in a cross-sectional study
Consequence of NBS on early treatment access - timing, The time passed between the birth of diagnostic-positive newborns to the initiation of their treatment, through study completion, an average of 1 year|Consequence o
The proportion of expiratory flow limitation (EFL), The proportion of expiratory flow limitation (EFL) during exercise while tracking dyspnea and perceived exertion, 3-4 hours during the onetime study visit day|Association betw
Assess the genetic profile of patient with anthracycline-induced left ventricular systolic and diastolic dysfunction, one year|Assess the relationship of quantitative increases of pro-oxidant stress and a specific genetic profile,
ventricular function evaluation., MRI, 6 MONTHS|serum troponin I, BLOOD SAMPLES, 1,3, 6 months|Brain natriuretic peptide (BNP), BLOOD SAMPLES, 1,3, 6 months

Cardiac function, Cardiac function assessed by echocardiogram, One month after last dose of anthracycline|Adherence to enalapril, Ability of participant to adhere to enalapril, One month after last dose of anthracycline|Adve
Cost-benefit analysis of amiodarone prophylactic, 31082009
Occurrence of clinical cardiovascular events, Clinical cardiovascular events include development of clinical congestive heart failure, occurrence of cardiac arrhythmias, the need to institute cardiac medications, and cardiac de
Successful extubation of pericardial drainage tube|time to extubation|survival without pericardial effusion at 1, 2, 4, 6, 12 months|symptom palliation|complication|long-term (> 6 months) effect on cardiac function
acceptance score on the five-point Likert Scale to measure tolerability, At the end of physioflow and or MUGA scan, a questionnaire to assess acceptance was proposed to all patients. The following aspects were evaluated:
Change from baseline in early morning serum cortisol, Day 11
Greater patient satisfaction|Lower ICU admissions|Lower total costs 6 months past hospitalization
Cardiac Imaging, Echocardiography, At baseline|Cardiac Imaging, Echocardiography, Through study completion, up to sixteen weeks|Blood Biomarkers, BNP and Troponins, At baseline|Blood Biomarkers, BNP and Troponins
VO2max, 12 weeks|Systolic and diastolic blood pressure (24 h), 12 weeks|Depression score, 12 weeks
Are T1 values at the ventricular insertion points increased following lung resection?, In all patients, the investigators willl measure T1 values at the ventricular insertion points using ROI tool to determine if T1 is increased follov
High-Sensitivity Troponin T, Change in hsTnT from baseline, up to 12 months|N-type pro Brain Natriuretic Peptide, Change in NTproBNP from baseline, up to 12 months|Left Ventricular Ejection Fraction (2D), Change in echo-
Evaluate early efficacy of sacubitril-valsartan in the treatment of stage B heart failure among survivors of cancer diagnosed at or before age 39., Number of deaths while on study due to cardiac event, 27 Months|Evaluate earl
To examine the feasibility of ecological momentary assessment methods to assess patterns of parenting stress levels over time, Feasibility defined by compliance with daily surveys (target rate of 30 out of 40 surveys (75%) c
Postoperative pain, The Visual Analogue Scale (VAS) consists of a 10 cm straight line with the endpoints defining extreme limits of "no pain at all" (0 cm) and "pain as bad as it could be" (10 cm). The patient is asked to mark t
Reduction in atherosclerotic cardiovascular disease (ASCVD) risk score, Changes in risk over time with intensive medical treatment tailored to plaque burden to test results in a reduction in cardiovascular risk factors including

Other Outcome Measures	Sponsor
	Oregon Health and Science University
	Children's Oncology Group
	Cambridge University Hospitals NHS Foundation Trust
Key Implementation Factors, Qualitative interviews after individual participation. Interviews will be guided by the Consolidated Framework for Implementation Research (CFIR) to explore the factors associated with implement	University of Washington
Number of (serious) adverse events (AE/SAE; Safety of FBNT/IRM), Counts of adverse events, through study completion, day 10 (e.g. final visit)|Severity of AE/SAE (Safety of FBNT/IRM), CTCAE tool v4.03 (National Cancer In	University of Cologne
Composite endpoint of mortality or major cardiovascular outcomes, Composite endpoint of mortality or major cardiovascular outcomes (defined as acute myocardial infarction, heart failure, inappropriate sinus tachycardia an	University of Sao Paulo
	University of Chicago
	University of Washington
	National Center for Complementary and Integrative Health (NCCIH)
	Heikki Joensuu
	Chinese University of Hong Kong
	Centre Hospitalier Régional d'Orléans
	Sakakibara Heart Institute
	Assistance Publique - Hôpitaux de Paris
	City of Hope Medical Center
	Melissa Voigt Hansen
	The Hospital of Vestfold
	Cedars-Sinai Medical Center
	Prof Corinne Faivre-Finn
	Bennett Chin
	Pierre Fabre Pharma AG
Biliary anastomotic stricture, Imaging or biochemical evidence of anastomotic stricture requiring intervention, 1 year|Biliary Anastomotic leak, Imaging or endoscopic evidence of bile leak requiring antibiotics or percutaneous	London Health Sciences Centre
	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
	Haihong Yang, MD, Pricipal investigator
	Ann & Robert H Lurie Children's Hospital of Chicago
Cardiac MRI measured LV end diastolic volume (LVEDV) and end systolic volume (LVESV) at the end of treatment, these measures will be obtained at the same time as the LVEF measures with pre-treatment measurements fa	University Health Network, Toronto
	St. Jude Children's Research Hospital
	Gustave Roussy, Cancer Campus, Grand Paris
	Memorial Sloan Kettering Cancer Center
possible predictors of short and long-term mortality in patients with TTC, 5 years	Deutsches Herzzentrum Muenchen
	Emory University
	The First Affiliated Hospital of Dalian Medical University
	National Cancer Institute (NCI)
	National Research Centre for the Working Environment, Denmark
	Shanghai Chest Hospital
	University of California, San Diego
	National Heart, Lung, and Blood Institute (NHLBI)
	GlaxoSmithKline
Pharmacogenomic biomarkers as predictors of composite cardiotoxicity (exploratory), Blood draw for genotyping, During chemotherapy (up to 12 months)	Daniel Rushing
	The University of Texas Health Science Center, Houston
	Technical University of Munich
	Helse Fonna
	Memorial Sloan Kettering Cancer Center
Changes in weight (kg), As measured by investigator during study visit., Baseline, halfway (R-)CHOP treatment (+/- 9 weeks), after (R-)CHOP treatment (+/- 18 weeks)|Height (cm), As measured by investigator during study vis	UMC Utrecht

	Ottawa Heart Institute Research Corporation
	Memorial Sloan Kettering Cancer Center
	University of Turku
	University of Aarhus
	University of Texas Southwestern Medical Center
	Taipei Medical University WanFang Hospital
	Brigham and Women's Hospital
	OHSU Knight Cancer Institute
	University of Florida
	Puma Biotechnology, Inc.
	University of Rochester
	Taipei Medical University WanFang Hospital
	University of Sydney
	University of Tromso
	Brigham and Women's Hospital
	Eurasian Association of Therapists
	King's College Hospital NHS Trust
	Royal Prince Alfred Hospital, Sydney, Australia
	Shanghai Pudong Hospital
	Rambam Health Care Campus
	Vanderbilt University Medical Center
	SOLTI Breast Cancer Research Group
	Stanford University
	University of Toronto
	University Hospital Bispebjerg and Frederiksberg
	Thomas Jefferson University
Patient-reported Symptoms, As assessed by standardized scores of physical and psychological distress by the Rotterdam Symptom Checklist, <1 week before the first doxorubicin, <3 days before the 2nd, 3rd, and 4th doxo	University of British Columbia
	West Pomeranian Cancer Center
	University of Edinburgh
	Milton S. Hershey Medical Center
	Metropolitan Jewish Health System
	Yonsei University
	University of Zurich
	Institut du Cancer de Montpellier - Val d'Aurelle
	Centre Hospitalier Universitaire de la Réunion
	Insel Gruppe AG, University Hospital Bern
	University of California, Los Angeles
	European Institute of Oncology
	Children's Oncology Group
Composite Assessment of Cardiac Disease, Sub-analysis for association of specific oncologic treatment(s) with cardiac disease (as per previously described study templates) will also be performed on patients who received r	Northwell Health
Change in parent perception of quality of shared decision making from baseline to 1 month, Parent perception will be measured using the "National Survey of Children with Special Health Care Needs Shared Decision Making	Lee Sanders
	The Netherlands Cancer Institute
	National University of Ireland, Galway, Ireland
	University of Minnesota
	Children's Healthcare of Atlanta
	University of Washington
	European Georges Pompidou Hospital
	Groupe Hospitalier Pitie-Salpetriere
	Ruijin Hospital
	Connecticut Children's Medical Center
	AstraZeneca
	Vanderbilt University Medical Center
	Universitair Ziekenhuis Brussel
	Ospedale Andrea Tortora di Pagani
	McMaster University
	Kura Oncology, Inc.
	National Heart, Lung, and Blood Institute (NHLBI)
Smoking Status, Smoking assessment history questionnaire, post-intervention (16 weeks)|Moderate-Intensity Physical Activity Time, PiezoRx® will be worn by participants for 7 days with data used to assess moderate activi	University of Toronto
	Imperial College London
	Connecticut Children's Medical Center
	Assiut University
Demoralization (Exploratory), Demoralization will be captured through self report using the Demoralization Scale-II. The minimum score is 0, the maximum score is 32, and a higher score means a worse outcome., 12 weeks|E	University of Alberta
	M.D. Anderson Cancer Center
	Memorial Sloan Kettering Cancer Center
	Abramson Cancer Center at Penn Medicine
	Dana-Farber Cancer Institute
	Centre Hospitalier Universitaire de Saint Etienne

	Algemeen Ziekenhuis Maria Middelares
	Instituto Dante Pazzanese de Cardiologia
	Radboud University Medical Center
	General Hospital of Chalkida
	Nova Scotia Health Authority
	Sanford Health
	Chinese University of Hong Kong
	St. Jude Children's Research Hospital
	Fudan University
Usability Assessment Via the System Usability Scale(SUS), Range of 0 to 100, With Higher Number Representing a Better Outcome SUS Scores Have a Range of 0 to 100, the Higher the Number Represents a Better Outcom	University of Colorado, Denver
	Samara State Medical University
	Rigshospitalet, Denmark
	Daniel Benjamin
	Taiho Oncology, Inc.
	The Cleveland Clinic
	Yangzhou University
	Brigham and Women's Hospital
	CVSS study
Exploratory Aim 1a. Patient symptom burden (Edmonton Symptom Assessment Scale [ESAS]), Patient symptom burden measured by Edmonton Symptom Assessment Scale \[ESAS\] mediated and/or moderated by hospital	University of Alabama at Birmingham
	Massachusetts General Hospital
	Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
	Threshold Pharmaceuticals
	University of Florida
	University of Southern California
	Chang Gung Memorial Hospital
	Ottawa Heart Institute Research Corporation
	King's College Hospital NHS Trust
	Eli Lilly and Company
	Washington University School of Medicine
	IRCCS Policlinico S. Matteo
	University Hospital Augsburg
	University of Sao Paulo
	Medstar Health Research Institute
	LMU Klinikum
	University Medical Center Groningen
	M.D. Anderson Cancer Center
	Rigshospitalet, Denmark
	Nuclear Medicine Consultants, Inc.
	University Hospital, Caen
	Peking University Third Hospital
	National Guard Health Affairs
	St. Boniface Hospital
	Indiana University
	Hennepin Healthcare Research Institute
	Mayo Clinic

	Future Genetics Limited
	Boston University
	Tanta University
	European Institute of Oncology
	University of Alberta
	Prothena Biosciences Ltd.
	Hamilton Health Sciences Corporation
To determine the long-term prognostic significance of reduced LVEF and myocardial injury detected by CMR and biomarkers in breast cancer patients treated with trastuzumab., Five years	Unity Health Toronto
	University of Waterloo
To document feasibility of a study of Advance Directives in the Veteran population, To document our ability to recruit and retain patients with advanced diseases, we will measure the proportions of patients approached for co	Corporal Michael J. Crescenz VA Medical Center
	Chuncheon Sacred Heart Hospital
	Heart Care Foundation
	Wuhan Asia Heart Hospital
Therapeutic alliance, Measured using the Working Alliance Inventory Short-Revised (WAI-SR) form., Baseline to 6-month follow-up (Primary RCT)|Testing Performance, Defined as the percent of tests that achieve 'peak' termi	University Health Network, Toronto
	Azienda Ospedaliera Città della Salute e della Scienza di Torino
	Christopher Connors, MD
	Abramson Cancer Center at Penn Medicine
	Institut Paoli-Calmettes
	Yangzhou University
	Radboud University Medical Center
	Medical University of South Carolina
	Prostate Cancer Foundation of Chicago
Cardiac Comorbidity according to ICD v10, up to 12 months|Radiomics (the evolving field of texture analysis) of normal tissue(heart and lung), up to 3 months|Mitochondrial DNA (prognostic value of mtDNA for development	Maastricht Radiation Oncology
	Children's Oncology Group
	PharmaMar
	Children's Oncology Group
	VA Office of Research and Development
Safty outcome of left ventricular ejection fraction, Drop in LVEF below 45 %, End of treatment	Odense University Hospital
	Riverview Health Centre
	VA Office of Research and Development
	University of Pittsburgh
	Beth Israel Deaconess Medical Center
	Ohio State University Comprehensive Cancer Center
	Yonsei University
	Adhera Health, Inc.
	Göteborg University
	Universitair Ziekenhuis Brussel
	Hospital Universitari Vall d'Hebron Research Institute
education on smoking cessation at discharge, Proportion of education on smoking cessation at discharge among eligible patients, 14 days on average (during hospitalization)|education on glycemic control at discharge, Prop	China National Center for Cardiovascular Diseases
	Fred Hutchinson Cancer Center
	National Cancer Institute, Egypt
	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
	University of Colorado, Boulder
Pharmacological endpoint: Change in circulating Nicotinamide adenine dinucleotide (NAD+) concentration from baseline to end of blinded therapy., Changes in the amount of circulating NAD+ will be measured using comme Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / Quality of life (QoL) represents a high QoL, but a high score for a symptom scale / item represe	University Hospital, Akershus
	Memorial Sloan Kettering Cancer Center
	University Hospital Ostrava
	Beijing Tiantan Hospital
	GlaxoSmithKline
	AstraZeneca
	University of Sao Paulo General Hospital
The hospital anxiety and depression scale (HADS), Within 2 years after study inclusion	Vestre Viken Hospital Trust
	Ottawa Hospital Research Institute
	Tel-Aviv Sourasky Medical Center
	AHEPA University Hospital
	Sophie JACOB
	Osaka City University
	Wake Forest University Health Sciences
	Ludwig-Maximilians - University of Munich
	Fondazione del Piemonte per l'Oncologia
	Montreal Heart Institute
	Qilu Hospital of Shandong University
	M.D. Anderson Cancer Center
	Odense University Hospital
	Medical College of Wisconsin
	University of Washington

	Western Galilee Hospital-Nahariya
	Association de Developpement de la Neuroanesthesie Reanimation
	National Institute of Environmental Health Sciences (NIEHS)
	The Guthrie Clinic
	Children's Healthcare of Atlanta
	University College, London
	Institute of Oncology Ljubljana
	University of Arkansas
	Air Force Military Medical University, China
	University College, London
	Centre Francois Baclesse
	Leiden University Medical Center
	Peking Union Medical College
	Oslo University Hospital
	University of Florida
	Mayo Clinic
	Far Eastern Memorial Hospital
	University of Oklahoma
	Pfizer
	Medical University of Warsaw
	Seoul St. Mary's Hospital
	University of Toronto
	University of Maryland, Baltimore
	University Hospital, Bordeaux
	Mayo Clinic
	University of Sao Paulo
	Marianna Fontana
	Seoul National University Bundang Hospital
	Sanguine Biosciences
	Bayer
	UNC Lineberger Comprehensive Cancer Center
To Evaluate Whether Ivabradine Improves Additional Markers of Cardiac Sympatho-vagal Balance, Compared To Placebo, In Survivors Of Lymphoma, Calculate the change in cardiac autonomic function (from cardiac autono	Dana-Farber Cancer Institute
	Groupe Hospitalier Pitie-Salpetriere
	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
	Taichung Tzu Chi Hospital
Diagnosis of neoplasia within 24 months., Diagnosis of another neoplasia, 24 months|Progression of oncological disease within 24 months., Progression of oncological disease, 24 months|Tumor recurrence within 24 months.	Hospital Sirio-Libanes
	Abramson Cancer Center at Penn Medicine
Endothelial function (Flow mediated dilation), Endothelium response to ischemia in the brachial artery. Area under the curve, flow peak and time to maximum flow will be performed, Up to Seven Years|genetics, genomics and	Hospital Universitario Reina Sofia de Cordoba
	Merck Sharp & Dohme LLC
	Parker, William H., M.D.
	Case Comprehensive Cancer Center
	Carebot s.r.o.
	Sheffield Teaching Hospitals NHS Foundation Trust
	The Netherlands Cancer Institute
	Oncology Institute of Southern Switzerland
	Emory University
	The Alvin and Lois Lapidus Cancer Institute
	Swansea University
	Hoffmann-La Roche
	Azienda Ospedaliero-Universitaria Careggi
	General and Teaching Hospital Celje
	Eurasian Association of Therapists
	Abramson Cancer Center at Penn Medicine
	I.M. Sechenov First Moscow State Medical University
	University of Athens

	Arbeitsgemeinschaft medikamentoese Tumortherapie
	Western University, Canada
	Novartis
	Tanta University
	Charite University, Berlin, Germany
	Rigshospitalet, Denmark
	John Barnard
	Mayo Clinic
	M.D. Anderson Cancer Center
	Cedars-Sinai Medical Center
	Groupe Hospitalier Pitie-Salpetriere
	Central Hospital Saint Quentin
	University of Eastern Finland
	University Hospital Muenster
	Ewha Womans University Mokdong Hospital
	Texas Tech University Health Sciences Center
	Daniel Bernstein
Goal: physical training program, participated in organized physical training program after the initial care, at 1-year revisit|Goal: LDL-C goal, attained LDL-C level below treatment target, at 1-year revisit|Goal: Blood pressure g	Karolinska Institutet
	Lund University
	National Heart, Lung, and Blood Institute (NHLBI)
	Massachusetts General Hospital
	Odense University Hospital
	King's College Hospital NHS Trust
	Medical College of Wisconsin
	Northwestern University
	Wake Forest University Health Sciences
	Cedars-Sinai Medical Center
	Cancer Trials Ireland
	Proton Collaborative Group
	Federico II University
	dr. Laura C. G. de Graaff-Herder
	Novartis Pharmaceuticals
	Centro Cardiologico Monzino
	Abramson Cancer Center at Penn Medicine
	Massachusetts General Hospital
	Children's Oncology Group
	University Hospital, Caen
	University of Virginia
	M.D. Anderson Cancer Center
	Samsung Medical Center
	M.D. Anderson Cancer Center
	Memorial Sloan Kettering Cancer Center
	SWOG Cancer Research Network
	UMC Utrecht
	Seagen Inc.
	Advanced Accelerator Applications
	Seoul National University Hospital
	University of Glasgow
	St. Jude Children's Research Hospital
	Queen Mary University of London
	RTI International
	Yonsei University
	Peking University People's Hospital
	Université de Sherbrooke
	European Institute of Oncology

	Mayo Clinic
	Medical College of Wisconsin
	University of Sydney
	Charite University, Berlin, Germany
	Lawson Health Research Institute
	GO fit Lab- Ingesport
	Assistance Publique - Hôpitaux de Paris
	Memorial Sloan Kettering Cancer Center
	Washington University School of Medicine
	Wake Forest University Health Sciences
	University of Cologne
	University Hospital Plymouth NHS Trust
	Ottawa Hospital Research Institute
	Tampere University Hospital
	Jules Bordet Institute
	VA Office of Research and Development
	Fudan University
	Poniard Pharmaceuticals
	Seoul National University Hospital
	Abramson Cancer Center at Penn Medicine
	Rabin Medical Center
Syncope Registry, Clinical syncope characteristics (age of first syncope, number of syncope episodes, trauma, duration, clinical score, convulse, sphincter relaxation, etc.) Syncope cause Blood pressure group Adaptability g TTT outcome for syncope: positive or negative TTT other outcomes: 1) Chronotropic incompetence, 2) arterial orthostatic hypotension, 3) carotid hypersensitivity, 4) POTS, 5) IST The relationship between TTT results and Clin The relationship between neurally mediated syncope response at the TTT and comorbidities., Up to 100 weeks|Sinus node function at the electrophysiological study (EPS), EPS variables: AH, AV, CL, sino atrial conduction tin Adaptability group: Hyper adaptable, normal adaptability, hypo adaptable. Comorbidities: As describe in the protocol, as a summary: 1) cardiovascular, 2) metabolic, 3) Endocrine, 4) psychiatric disorders: depression and pan Mortality, A 7-year prospective study|Psychobiotype: relationship between biological and psychological variables, Blood pressure group: 1) Essential arterial hypotension, 2) normotension and 3) Essential arterial hypertensior Adaptability group: Hyper adaptable, normal adaptability, hypo adaptable. Psychiatric variables: 1. Big Five Questionary (BFQ) for personality. 2. Modify of the Coping Scale (Scale of modified coping strategies) 3. Zung questionary for depression and anxiety 4. MINI in those patients with moderate or severe depression and/or anxiety at the Zung questionary, Up to 100 weeks|The role of high sodium intake in the development of essential hypertension. Comparison between esser Essential hypotension population is advised to increase the sodium (at least 10 grams a day) and water intake (at least 2 liters a day), or as much as possible, several have taken Fludrocortisone (is not a exclusion criteria). No This registry is a good opportunity to test how important sodium diet is to induce hypertension, or if by the contrary adaptability could prevail over high sodium intake in this registry. Blood pressure groups: essential hypotension and normotension and those with new essential hypertension. Adaptability groups. The results will be adjusted for age, gender and BMI., 4 years|White coat effect in the heart rate or masked bradycardia., Consistent bradycardia in the ECG at the office and normal HR in the holter monitoring or the contrary. There are patients with complaints that may be attributed to bradycardia, low blood pressure, hypothyroidism, or other entities. Some patients very often have bradycardia in the ECG taken in the office and normal HR in the 24 Holter monitoring, the opposite is also possible. Patients with bradycardia (without medication or physiological condition as exersice affecting heart rate) in at least 2 ECG (less 60 bpm) and at least 2 Holter monitoring will be analyzed, Other variables to consider are: Age, gender, blood pressure group, adaptability group, maximum HR in the treadmill test, white coat or masked hypertension, Tilt-Table-test result or syncope cause, Electrophysiological study if available. The acknowledge of this phenomenon could have clinical implications in the diagnosis of sick sinus syndrome and physiopathological ones., 1 year|Reversible Bradycardia Mimicking Sinus Node Dysfunction as a Manifestati Variables 1. HR at the ECG, Holter monitoring, stress text, and at the physical examination previous to pacemaker implantation, 2. Electrophysiological study (EPS): Basic cycle length, Sino-atrial conduction time, Sinus node recovery time, Corrected sinus node recovery time, Intrinsic HR when available 3. Pacemaker variables: HR at day and night or This will allow to characterize whether SVR and/or CO maintain BP. Until now BP levels are related with prognosis. In the prognosis model SVR and CO will be add them to know what matter the most: BP levels, SVR and/or C	CES University
	Massachusetts General Hospital
	Niti Dham
	St. Jude Children's Research Hospital
	University of Pennsylvania
	AHS Cancer Control Alberta
	M.D. Anderson Cancer Center
	University of Bern
	Celgene
	Memorial Sloan Kettering Cancer Center
	Affiliated Hospital of Qinghai University
	University of Michigan Rogel Cancer Center
	M.D. Anderson Cancer Center
	Jesse Nodora
	St. Jude Children's Research Hospital
	VA Office of Research and Development
	University of Sao Paulo General Hospital
High-sensitivity Cardiac Troponin-T, Troponin rises \>99%th percentile of the upper reference limit, Baseline, 1 and 12 weeks after treatment|N-Terminal pro-Brain Natriuretic Peptide, N-Terminal pro-Brain Natriuretic Peptide,	Pontificia Universidad Catolica de Chile
	Guizhou Medical University
	Groupe Hospitalier Pitie-Salpetriere
	AHS Cancer Control Alberta
T1 relaxation times (global and segmental), Left ventricular (LV) Parametric maps (T1, T2, Extracellular volume) will be assessed using a 16 segment model with bespoke MRI analysis software., Through study completion, on a	University of Glasgow
	European Organisation for Research and Treatment of Cancer - EORTC
	Gia Dinh People Hospital
	Abramson Cancer Center at Penn Medicine
	Yonsei University
	Poitiers University Hospital
	City of Hope Medical Center

	Washington University School of Medicine
Adherence and compliance to cardiac rehabilitation program (intervention group) assessed by number of training sessions attended/ number of sessions planned, Number of training sessions attended / number of sessions p	Hospital Clinico Universitario de Santiago
\" Due to the introduction of telematic exercise training during COVID-19 pandemic, questions were slightly modified to include assessment of satisfaction with this training modality., At the end of the cardiac rehabilitation pro	
	San Filippo Neri General Hospital
	Henry Ford Health System
	Atara Biotherapeutics
	University of Tennessee
	Population Health Research Institute
	Queen's University, Belfast
	Hari Narayan
	Lawson Health Research Institute
	NYU Langone Health
	Brigham and Women's Hospital
	National Heart, Lung, and Blood Institute (NHLBI)
	Yale University
Prevalence and nature of CVD, CH and CH with mutations associated with cardiovascular disease, The outcome is the expansion of the CH, which will be expressed as the variant allele fraction (VAF) (CH verses the total nor	Children's Oncology Group
	Institut du Cancer de Montpellier - Val d'Aurelle
	Abramson Cancer Center at Penn Medicine
	National University Hospital, Singapore
	University of Campinas, Brazil
	Institut Curie
	Population Health Research Institute
	Azienda Ospedaliera Città della Salute e della Scienza di Torino
	University College London Hospitals
PSYCHLOPS, Measures improvement of patient-defined self-rated problems, 52 weeks post randomisation	King's College London
	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Clinical complaints and signs at inclusion, Questionnaires (CVRM, HADS and MFI-20), a short physical examination and a electrocardiography at time of inclusion, on average 11 years after treatment with breast cancer	University Medical Center Groningen
	Kaiser Permanente
	The Hong Kong Polytechnic University
	M.D. Anderson Cancer Center
	AbbVie
	Silesian Centre for Heart Diseases
	University of Michigan Rogel Cancer Center
	The Cleveland Clinic
	Samsung Bioepis Co., Ltd.
	Centre Hospitalier Universitaire de Saint Etienne
	M.D. Anderson Cancer Center
	St. Olavs Hospital
	Sakakibara Heart Institute
	Istanbul University
	Duke University
Apple watches Heart Rate and Physical Steps Tracking, Apple watches will be supplied to interested participants to monitor their heart rate and physical steps taken throughout the day to assess changes in movement patte	The Miriam Hospital
	Shu lian Wang

	Washington University School of Medicine
	Monash University
	University of Sao Paulo General Hospital
	Nova Scotia Health Authority
	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
	SWOG Cancer Research Network
	Wake Forest University Health Sciences
	Fudan University
	Mayo Clinic
	Massachusetts General Hospital
	Vejle Hospital
	M.D. Anderson Cancer Center
	Göteborg University
	Mayo Clinic
	Dnipropetrovsk State Medical Academy
	National Cancer Institute (NCI)
	Cambridge University Hospitals NHS Foundation Trust
	Northwell Health
	Hoffmann-La Roche
	Hospices Civils de Lyon
	Shaare Zedek Medical Center
	Ohio State University Comprehensive Cancer Center
	University of Oklahoma
	Peking University Third Hospital
	Sunnybrook Health Sciences Centre
	Universitätsklinikum Hamburg-Eppendorf
	British Columbia Cancer Agency
	Associacao de Investigacao de Cuidados de Suporte em Oncologia
	Cedars-Sinai Medical Center
	University of Sao Paulo General Hospital
	Alexander Hindenburg, MD
	University of Vermont
	Prisma Health-Upstate
	Kaiser Permanente
	M.D. Anderson Cancer Center
	Assuta Hospital Systems
	Sunnybrook Health Sciences Centre
	University of Southern Denmark
	University of Toronto
	European Georges Pompidou Hospital
	Alliance for Clinical Trials in Oncology
	University Hospital, Caen
	University of North Carolina, Chapel Hill
	Second Affiliated Hospital, School of Medicine, Zhejiang University
	Yonsei University
	RenJi Hospital
	GlaxoSmithKline
	First Affiliated Hospital Xi'an Jiaotong University
	Memorial Sloan Kettering Cancer Center
	Brigham and Women's Hospital
	Washington University School of Medicine
	Show Chwan Memorial Hospital
	M.D. Anderson Cancer Center

	Royal Marsden NHS Foundation Trust
	AstraZeneca
	Hospital Clinic of Barcelona
	University of Arkansas
	University of Miami
	University of Miami
	Kai Mu
	Children's Cancer Hospital Egypt 57357
	University Hospital, Akershus
	Assiut University
	Yonsei University
	Celgene
	The Hospital for Sick Children
	University of Roma La Sapienza
	Danish Breast Cancer Cooperative Group
Changes of T1 mapping values, Change in T1 mapping values before and after anthracyclin chemotherapy, At timepoints 0 months, 2 months and 6 months (corresponding to the chemotherapy regimen controls)|Changes of	Second Affiliated Hospital, School of Medicine, Zhejiang University
	Centers for Disease Control and Prevention
	Children's Oncology Group
	Chinese PLA General Hospital
	TidalSense
	GERCOR - Multidisciplinary Oncology Cooperative Group
	Tanta University
	Medical University of Vienna
	Cristian Deana
Dose-volume Constraints for the Heart During Radiation Therapy for Breast Cancer., Trial data will improve the understanding of cardiac function after radiotherapy and allow oncologists to start to define safe dose-volume co	Medical College of Wisconsin
	University of Washington
Cortical activity, Measured by Near-Infrared Spectroscopy (NIRS), in an experiment using a paradigm of autobiographical events, remembering stressful and positive memories., baseline, 1 week after intervention|Heart rate v	Hospital Israelita Albert Einstein
Concordance of Variants (Arm B), The concordance of variants identified when sequencing will be performed on samples from the same patient collected at baseline and follow-up time points will also be measured., Up to 2	Fox Chase Cancer Center
	M.D. Anderson Cancer Center
To conduct phenotype analysis of DNA/microRNA of patients exposed to anthracycline, Analyzing DNA/microRNA in patients who were treated with high and low dose anthracyclines that may cause cardiotoxicity, 1 year	Connecticut Children's Medical Center
	Groupe Hospitalier Pitie-Salpetriere
Searching for cancer-specific frequency modulation, Identification of specifc hemodynamic alteration recorded during the exposure to a series of specific frequency modulations AM RF EMF recorded in healthy individuals an	Hospital Sirio-Libanes
	University of Nebraska
	SWOG Cancer Research Network
	Jules Bordet Institute
3D LVEF, Change in 3d echocardiography derived LVEF from baseline, 14 months|3D LV systolic strain, Change in 3D echocardiography derived longitudinal and circumferential strain from baseline, 14 months|LV Twist and Tc	Abramson Cancer Center at Penn Medicine
	Mayo Clinic
	Children's Hospital of Philadelphia
	The First Affiliated Hospital of Anhui Medical University
	The First Affiliated Hospital with Nanjing Medical University
	Sunnybrook Health Sciences Centre
	University Hospital Dubrava
	Midwest Biomedical Research Foundation
	Majd Makhoul
	Fondazione Italiana Linfomi - ETS
	CENTOGENE GmbH Rostock
	University of Montana
	DyAnsys, Inc.
	Children's Hospital Medical Center, Cincinnati
Provider knowledge and beliefs about PRS, Semi-structured interviews will collect qualitative data on participating providers' understanding of and perceived utility of the PRS risk information., 24 months after enrollment|Blo	Boston VA Research Institute, Inc.
	Helsinki University Central Hospital
	University of Manitoba
	National Heart, Lung, and Blood Institute (NHLBI)
	Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
	M.D. Anderson Cancer Center
	Ottawa Hospital Research Institute
	National Institutes of Health Clinical Center (CC)

	Exai Bio Inc.
	University of Nottingham
	Institut National de la Santé Et de la Recherche Médicale, France
	Haukeland University Hospital
	GlaxoSmithKline
	Stemcentrx
	Altoosi University College
	Military Institute of Medicine, Poland
	Xijing Hospital
	M.D. Anderson Cancer Center
	Avera McKennan Hospital & University Health Center
	Ju-Chi Liu
	Memorial Sloan Kettering Cancer Center
Sensitivity and specificity of [18F]florbetaben PET images for a differential diagnosis between AL CA, ATTR CA and non CA will be assessed., In this exploratory endpoint the sensitivity and specificity of \[18F\]florbetaben PE	Life Molecular Imaging GmbH
	Hospices Civils de Lyon
	Tzu Chi University
	Sophie JACOB
	University of Texas Southwestern Medical Center
	Maria Sklodowska-Curie National Research Institute of Oncology
	University of Nottingham
	Centre Hospitalier Henri Duffaut - Avignon
	Medical University of Vienna
	University Hospital, Bonn
	Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Incidence of symptomatic heart failure., Incidence of symptomatic heart failure., 1, 3 and 6 months|Changes in left ventricular and right ventricular dimensions by 2D and 3D echocardiography., Changes in left ventricular and	Vilnius University
	Janssen Research & Development, LLC
	GlaxoSmithKline
Changes from Baseline Depression at 2 weeks, Depression will be measured using the Center for Epidemiological Studies Depression Scale Revised (CESD-R-10) scale (10 items, 4-point Likert scale (0 = rarely or none of the	Arizona State University
	Aalborg University
	University Hospitals Coventry and Warwickshire NHS Trust
	IRCCS Policlinico S. Matteo
To determine whether access to pharmacogenomic information improves satisfaction with care., 5 years	University of Chicago
	Duke University
	Rush University Medical Center
	National Cancer Institute (NCI)
	National Taiwan University Hospital
Change from Baseline in thickness of endometrium at 12 months and 24 months, ultrasonography, before the treatment, time point of taking the medicine for 1 year, time point of taking the medicien for 2 years|uterine bleedi	Peking Union Medical College Hospital
	St. Jude Children's Research Hospital
	St. Jude Children's Research Hospital
Patient reported outcome (PRO) for pain measured by the quality of Life questionnaire using PROMIS to measure fatigue, Quality of Life questionnaire using PROMIS will be administered at baseline six, twelve and fifteen mo	Rutgers, The State University of New Jersey
The Volume of Crystalloid Infusion, Volume of crystalloid infusion in milliliter., during the surgery|The Volume of Colloid Infusion, Volume of colloid infusion in milliliter., during the surgery|Complication After Surgery, From the er	First Affiliated Hospital, Sun Yat-Sen University
	Rigshospitalet, Denmark
	University of Massachusetts, Worcester
Assessment of metal chelation effects of dexrazoxane and chemotherapy, Metal chelation effects assessed by utilizing technologies commonly used in the geochemistry., Up to 1 year|Assessment of minimal residual disease	M.D. Anderson Cancer Center
Time to Progression, Time to progression will be evaluated using cumulative incidence., Up to 3 years|Determine the Number of Participants With Tumor Metabolic Response Correlating With Anatomic Response and Clinical	National Cancer Institute (NCI)
	GlaxoSmithKline
Change in medication adherence in heart failure patients, Change in medication adherence will be measures using the Medication Adherence Reasons Scale-5 (MARS -5) containing 5 items., Post-1 (42 days following baselir	University of Stavanger
	Nicole Ezer, MD, FRCPC, MPH
	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
	Wake Forest University Health Sciences
	University of Colorado, Denver
	University of Washington
	Henry Ford Health System
	The Miriam Hospital
	IRCCS Policlinico S. Matteo
	Achieve Life Sciences
	Rigshospitalet, Denmark
	University of Pennsylvania
	Wake Forest University Health Sciences
	University of Milano Bicocca
Key Implementation Factors, Qualitative interviews after individual participation has concluded. Interviews will be guided by the RE-AIM and Consolidated Framework for Implementation Research (CFIR) to explore the factors	University of Washington
	Rabin Medical Center
	Mayo Clinic

	Wake Forest University Health Sciences
	National Human Genome Research Institute (NHGRI)
	Golden Jubilee National Hospital
	VA Office of Research and Development
	Connecticut Children's Medical Center
Muscle Biopsy for epigenetic markers of physical activity, Optional for Participants: NF-κB p65 DNA binding activity (ELISA), phosphorylated and total JNK, phosphorylated AMPK (p-AMPK) total AMPK (Western blotting), , as	Rigshospitalet, Denmark
Exercise Adherence, Adherence will be assessed using an attendance sheet for each the supervised sessions. If participants do not complete their target exercise prescription, the reasons will be recorded. The participants w	University Health Network, Toronto
	Duke University
	University of Florida
	The Hospital for Sick Children
Imaging changes, Imaging changes in the heart substructures associated with occurrence of cardiac events will be an exploratory component of this trial. Changes will be described at each time point using frequency distribu	Mayo Clinic
	Celgene
	RenJi Hospital
	AstraZeneca
	St. Jude Children's Research Hospital
	AHS Cancer Control Alberta
	Christian Kern
	M.D. Anderson Cancer Center
	Mathematica Policy Research, Inc.
	Keogh Institute for Medical Research
	Ass. Prof. Jan Nyman
	Centre Hospitalier Universitaire de Besancon
	Wake Forest University Health Sciences
	Bayer
Prevalence of asymptomatic CAD, as measured by CT angiography, Asymptomatic CAD will be defined as having either an abnormal coronary artery calcium (CAC) (\>= 100 Au) or more than minimal coronary luminal stenosi	City of Hope Medical Center
	National Heart, Lung, and Blood Institute (NHLBI)
	Universidad Europea de Madrid
	Giulio Stefanini
	Wake Forest University Health Sciences
	Randy Kardon
	Hasselt University
The concentration of blood factors in plasma, Plasma levels of IL-6, IL-10 and TNF-α were measured by enzyme-linked immunosorbent assay (Elisa) at 1,3,6,24 and 72 h after operation., Within 3 days after surgery	Zhonghua Chen,MD
	Medstar Health Research Institute
Changes in Immune Regulatory Cells after a Single Dose of Entinostat, when given at a Supratherapeutic Dose, Relative to Placebo Control, Pre-dose through 14 days post-dose|Variability and Changes in Protein Lysine Ace	Syndax Pharmaceuticals
	Brigham and Women's Hospital
	Bayer
	University of South Florida
	Brigham and Women's Hospital
	M.D. Anderson Cancer Center
	Shu lian Wang
	IRCCS Policlinico S. Matteo
	University of Sao Paulo
	Tampere University
	AHS Cancer Control Alberta
	Wayne State University
	M.D. Anderson Cancer Center
	Seoul National University Hospital
	University Hospital, Essen
Incidence of adverse events and serious adverse events, From randomization to end of blinded therapy (18 months)	Torbjorn Omland
	The Cleveland Clinic
	Heinrich-Heine University, Duesseldorf
	Willows Health
	Peking University Third Hospital
	National Cancer Institute (NCI)
	Assistance Publique - Hôpitaux de Paris
	Dana-Farber Cancer Institute
	Daren K. Heyland
	Abramson Cancer Center at Penn Medicine
	Seoul National University Bundang Hospital
	University Hospital, Basel, Switzerland
	Haukeland University Hospital
	Pfizer
	Rambam Health Care Campus
	AVEO Pharmaceuticals, Inc.
	The First Affiliated Hospital of Henan University of Science and Technology
	Centre Chirurgical Marie Lannelongue
	University Medical Center Groningen

Change in diastolic function on echo, Change in E/e' by echo, 12 months|Change in longitudinal strain, Change in global longitudinal strain by echocardiogram, 12 months|Change in circumferential strain, Change in circumfe	Abramson Cancer Center at Penn Medicine
	Medical University of Lodz
	Istanbul University
Group Differences - Treatment Preference (Adjustment Variable for Outcome Measuring Goal-concordant Care), Binary variable indicating whether patient's current preference was for life-extension or comfort care, 3 months	University of Washington
	RenJi Hospital
	Celgene
	University of Arizona
	Bispebjerg Hospital
	Institut du Cancer de Montpellier - Val d'Aurelle
	Carol Davila University of Medicine and Pharmacy
	National Cheng-Kung University Hospital
Known risk factors for cardiotoxicity, To assess the effect of known risk factors for anthracycline cardiotoxicity, the anthracycline cumulative dose will be collected, the day of inclusion|Troponin T on the experimental group, Ti	University Hospital, Montpellier
VO2peak, VO2peak measured by CPET, baseline, 6-, 12- and 24-month follow ups|Cardiac function, 2D LVEF measured by echocardiogram, baseline, 6-, 12- and 24-month follow ups|Cardiac function, 3D LVEF measured by	University Health Network, Toronto
	Institut de Radioprotection et de Surete Nucleaire
	Vanderbilt University
	Wen-Shiou Pan
	Tanta University
	Lawson Health Research Institute
	The Hospital for Sick Children
	Cedars-Sinai Medical Center
	Abramson Cancer Center at Penn Medicine
	Weill Medical College of Cornell University
	University Health Network, Toronto
	First Affiliated Hospital Xi'an Jiaotong University
	Yonsei University
Patient characteristics, age, BMI, menopausal state, through study completion (from Ocotober 2022 - December 2024)|Physical activity, Changes in Physical Acticity measured with Short Questionnaire to Assess Health-enha	University Medical Center Groningen
	RenJi Hospital
	University of Michigan Rogel Cancer Center
	HALO Diagnostics
	Institut de cancérologie Strasbourg Europe
	Pacific Coast Family Medical Group
	University of Southern California
	Gustave Roussy, Cancer Campus, Grand Paris
	SOLTI Breast Cancer Research Group

	University of Aarhus
	Karolinska University Hospital
	M.D. Anderson Cancer Center
	Yonsei University
	Oregon Health and Science University
Association between modifications in chemotherapy with detection of subclinical cardiotoxicity, frequency of chemotherapy changes with subclinical cardiotoxicity, up to 10 weeks	Stony Brook University
	Dana-Farber Cancer Institute
	Beth Israel Deaconess Medical Center
	National Heart, Lung, and Blood Institute (NHLBI)
Odds of laboratory markers for autoimmune disease in SCAD cases compared to controls, Through study completion, or approximately 50 years (average age of study participants)|Odds of validated rheumatoid arthritis in SC	Mayo Clinic
	Hamad Medical Corporation
	National Human Genome Research Institute (NHGRI)
	University College, London
	Baker Heart and Diabetes Institute
	Abramson Cancer Center at Penn Medicine
	Universitaire Ziekenhuizen KU Leuven
	University of Waterloo
Ultra-sensitive troponin, Cardiac troponin (ng/mL), two years	University of Campinas, Brazil
	Universidade Federal de Sao Carlos
The proportion of bereaved relatives who experienced symptoms of stress, anxiety and depression after the death of the patient, measured three months after the death of the patient, 1.7.2015|The proportion of patients who	University of Aarhus
	Zhujiang Hospital
	Children's Oncology Group
	University of California, Los Angeles
	University of Pittsburgh
	Abramson Cancer Center at Penn Medicine
	Technical University of Munich
	The University of Hong Kong
	Virginia Commonwealth University
	Ultromics Ltd
	Case Comprehensive Cancer Center
	University Hospital, Caen
Overall Survival, Overall survival (OS) is defined as the time from patient randomization (arm assignment) to death from any cause. The median OS with 95% CI was estimated using the Kaplan-Meier method., Time from rand EGFR mutations were performed at the Dana-Farber Cancer Institute using a sensitive heteroduplex method coupled with enzymatic digestion as previously reported (Janne PA, et al: A rapid and sensitive enzymatic method	National Cancer Institute (NCI)
	Hospices Civils de Lyon
	National Human Genome Research Institute (NHGRI)
	University of Bern
	Chinese University of Hong Kong
	Murdoch Childrens Research Institute
Incidence of hyperkalemia, Incidence of hyperkalemia defined as serum potassium \>5.5 mmol/L, 6 months|Incidence of adverse events leading to discontinuation of study drug, Incidence of adverse events leading to discon	University of British Columbia
	Ain Shams University
	University Hospital, Toulouse
	National Cancer Institute (NCI)
	University Medical Centre Ljubljana
	University Hospital, Essen
	Laurent Servais
	Masonic Cancer Center, University of Minnesota
	George Washington University
	Assistance Publique Hopitaux De Marseille
	National Cancer Institute (NCI)

	South Tees Hospitals NHS Foundation Trust
	University of Calgary
	Aarhus University Hospital
	The University of Hong Kong
	Japan Clinical Oncology Group
	Far Eastern Memorial Hospital
	McGill University Health Centre/Research Institute of the McGill University Health Centre
	Crinetics Pharmaceuticals Inc.
	Sanjay Gandhi Postgraduate Institute of Medical Sciences
	Kaiser Permanente
	Duke University
	University of Aberdeen
	Charite University, Berlin, Germany
	University of Glasgow
Overall Survival (5 Year), All Cause Mortality assessed by National Death Index Search performed 5 years after the last patient is enrolled., 5-8 years|Cardiovascular Specific Mortality (5 Year), Cardiovascular Specific Mortality	Abramson Cancer Center at Penn Medicine
	Virginia Commonwealth University
	National Cancer Institute (NCI)
	Mohamed Reda Ashour
	Indiana University

Collaborators	Sex	Age	Phases	Enrollment	Funder Type	Study Type
Millennium: The Takeda Oncology Company	ALL	ADULT, OLDER_ADULT		11	OTHER	OBSERVATIONAL
National Cancer Institute (NCI)	ALL	CHILD, ADULT, OLDER_ADULT		420	NETWORK	OBSERVATIONAL
University of Cambridge|King's College London	ALL	ADULT, OLDER_ADULT	PHASE3	120	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	950	OTHER	INTERVENTIONAL
Teva Branded Pharmaceutical Products R&D, Inc.	ALL	ADULT, OLDER_ADULT	PHASE2	10	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	160	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		50	OTHER	OBSERVATIONAL
National Institute of Nursing Research (NINR)	ALL	ADULT, OLDER_ADULT	PHASE3	6086	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT		3200	NIH	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE2	20	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		300	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	68	OTHER	INTERVENTIONAL
Japanese Foundation for Cancer Research	ALL	ADULT, OLDER_ADULT		66	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		133	OTHER	OBSERVATIONAL
National Cancer Institute (NCI)	ALL	CHILD, ADULT, OLDER_ADULT	NA	200	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT		12	OTHER	OBSERVATIONAL
Oslo University Hospital	FEMALE	ADULT	NA	61	OTHER	INTERVENTIONAL
California Breast Cancer Research Program	FEMALE	ADULT, OLDER_ADULT	PHASE2	2	OTHER	INTERVENTIONAL
The Leeds Teaching Hospitals NHS Trust|University of Manchester|University of Leeds|Manchester University NHS Foundation Trust	ALL	ADULT, OLDER_ADULT	NA	200	OTHER	INTERVENTIONAL
National Cancer Institute (NCI)|Molecular Insights Pharmaceuticals	ALL	ADULT, OLDER_ADULT	PHASE1	12	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		324	INDUSTRY	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	20	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		1387	NIH	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE2	22	OTHER	INTERVENTIONAL
Northwestern University|National Cancer Institute (NCI)	ALL	CHILD, ADULT	NA	20	OTHER	INTERVENTIONAL
Mount Sinai Hospital, Canada|Unity Health Toronto|Sunnybrook Health Sciences Centre|Scarborough General Hospital	ALL	ADULT, OLDER_ADULT	PHASE2	112	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		34	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	300	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT		30	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		800	OTHER	OBSERVATIONAL
National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT	PHASE3	0	OTHER	INTERVENTIONAL
Shenyang Sunshine Pharmaceutical Co., LTD.	ALL	ADULT, OLDER_ADULT	PHASE4	165	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		162	NIH	OBSERVATIONAL
University of Copenhagen|University Hospital Bispebjerg and Frederiksberg|Rigshospitalet, Denmark	ALL	ADULT, OLDER_ADULT	NA	35	OTHER_GOV	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		300	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	19	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		5000	NIH	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE4	58	INDUSTRY	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		12	OTHER	OBSERVATIONAL
National Heart, Lung, and Blood Institute (NHLBI)	ALL	ADULT, OLDER_ADULT	PHASE1	46	OTHER	INTERVENTIONAL
Ludwig-Maximilians - University of Munich	ALL	CHILD, ADULT		80	OTHER	OBSERVATIONAL
	FEMALE	ADULT	PHASE4	34	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT		58	OTHER	OBSERVATIONAL
Julius Clinical	ALL	ADULT, OLDER_ADULT		12	OTHER	OBSERVATIONAL

Canadian Institutes of Health Research (CIHR)	FEMALE	ADULT, OLDER_ADULT	PHASE2|PHASE3	36	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT	PHASE2	82	OTHER	INTERVENTIONAL
Brigham and Women's Hospital	ALL	ADULT, OLDER_ADULT		1001	OTHER	OBSERVATIONAL
Danish Cancer Society	FEMALE	ADULT, OLDER_ADULT	NA	76	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	EARLY_PHASE1	110	OTHER	INTERVENTIONAL
	FEMALE	CHILD, ADULT		169	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	6075	OTHER	INTERVENTIONAL
Oregon Health and Science University|American Association for Cancer Research|National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT		110	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		25	OTHER	OBSERVATIONAL
	ALL	ADULT	PHASE1	60	INDUSTRY	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		32	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE2	50	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT	NA	45	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		9700	OTHER	OBSERVATIONAL
National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)|American Heart Association	ALL	ADULT, OLDER_ADULT	NA	171	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		3554	OTHER	OBSERVATIONAL
King's College London	ALL	ADULT, OLDER_ADULT	NA	40	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT		220	OTHER	OBSERVATIONAL
CSPC Ouyi Pharmaceutical Co., Ltd.	FEMALE	ADULT, OLDER_ADULT	NA	204	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT		20	OTHER	OBSERVATIONAL
Takeda	ALL	ADULT, OLDER_ADULT		95	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT	PHASE2	83	OTHER	INTERVENTIONAL
	MALE	ADULT, OLDER_ADULT	NA	30	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE2		OTHER	INTERVENTIONAL
Rigshospitalet, Denmark	ALL	ADULT, OLDER_ADULT		3095	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	20	OTHER	INTERVENTIONAL
British Columbia Cancer Agency	FEMALE	ADULT, OLDER_ADULT	PHASE1	27	OTHER	INTERVENTIONAL
Pomeranian Medical University Szczecin	FEMALE	ADULT, OLDER_ADULT		128	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		180	OTHER	OBSERVATIONAL
National Institute of Nursing Research (NINR)|Brigham and Women's Hospital	ALL	ADULT, OLDER_ADULT	NA	570	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	500	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		30	OTHER	OBSERVATIONAL
University Hospital, Basel, Switzerland|Insel Gruppe AG, University Hospital Bern|Cantonal Hospital of St. Gallen|University Hospital,	ALL	CHILD, ADULT, OLDER_ADULT		1800	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	60	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	70	OTHER	INTERVENTIONAL
Spital STS AG|Bürgerspital Solothurn|Lindenhofspital|University of Bern	ALL	ADULT, OLDER_ADULT	NA	57	OTHER	INTERVENTIONAL
University of Southern California|National Heart, Lung, and Blood Institute (NHLBI)	ALL	ADULT, OLDER_ADULT	PHASE2	240	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	75	OTHER	INTERVENTIONAL
National Cancer Institute (NCI)|Children's Cancer Group	ALL	CHILD, ADULT	PHASE3	294	NETWORK	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT		201	OTHER	OBSERVATIONAL
National Cancer Institute (NCI)|Harvard University	ALL	ADULT, OLDER_ADULT	NA	67	OTHER	INTERVENTIONAL
AstraZeneca|Roche Pharma AG	FEMALE	ADULT, OLDER_ADULT	PHASE3	210	OTHER	INTERVENTIONAL
Clinical Research Facility Galway|CORRIB Research Centre for Advanced Imaging and Core Lab, Galway, Ireland	FEMALE	ADULT, OLDER_ADULT		100	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		40	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT			OTHER	OBSERVATIONAL
National Heart, Lung, and Blood Institute (NHLBI)	FEMALE	CHILD, ADULT, OLDER_ADULT			OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		60	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		500000	OTHER	OBSERVATIONAL
RenJi Hospital|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai 6th People's Hospital|Shanghai 10th Pe	ALL	ADULT, OLDER_ADULT	NA	220	OTHER	INTERVENTIONAL
Nationwide Children's Hospital	ALL	CHILD, ADULT		110	OTHER	OBSERVATIONAL
Parexel	MALE	ADULT	PHASE1	45	INDUSTRY	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		25380	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE2	140	OTHER	INTERVENTIONAL
	MALE	CHILD, ADULT, OLDER_ADULT		54	NETWORK	OBSERVATIONAL
McMaster Surgical Associates	ALL	ADULT, OLDER_ADULT	NA	27	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1	20	INDUSTRY	INTERVENTIONAL
	MALE	CHILD, ADULT, OLDER_ADULT			NIH	OBSERVATIONAL
Toronto Rehabilitation Institute	FEMALE	ADULT, OLDER_ADULT		100	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		0	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT		13	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT		45	OTHER	OBSERVATIONAL
Canadian Institutes of Health Research (CIHR)	ALL	ADULT, OLDER_ADULT	NA	500	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		5	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT		194	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	0	OTHER	INTERVENTIONAL
American Cancer Society, Inc.	FEMALE	ADULT, OLDER_ADULT	NA	160	OTHER	INTERVENTIONAL
Ministry of Health, France	ALL	OLDER_ADULT	NA	2495	OTHER	INTERVENTIONAL

	ALL	ADULT, OLDER_ADULT	NA	276	OTHER	INTERVENTIONAL
University of Campinas, Brazil	ALL	ADULT, OLDER_ADULT		340	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT		55	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1|PHASE2	10	OTHER_GOV	INTERVENTIONAL
Canadian Cancer Society (CCS)|Canadian Institutes of Health Research (CIHR)	FEMALE	ADULT, OLDER_ADULT	NA	100	OTHER	INTERVENTIONAL
National Ataxia Foundation|International WAGR Syndrome Association|4p- Support Group|ML4 Foundation|Cornelia de Lange Syndr	ALL	CHILD, ADULT, OLDER_ADULT		20000	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	150	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		3000	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE3	398	OTHER	INTERVENTIONAL
National Institute of Nursing Research (NINR)	ALL	ADULT, OLDER_ADULT		38	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	100	OTHER	INTERVENTIONAL
Danish Heart Foundation|Copenhagen Hospital Corporation	ALL	ADULT, OLDER_ADULT	PHASE3	30	OTHER	INTERVENTIONAL
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The Emmes Company, LLC	ALL	CHILD, ADULT		3520	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1	44	INDUSTRY	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		5000	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	60	OTHER	INTERVENTIONAL
National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)	FEMALE	ADULT, OLDER_ADULT	PHASE3	39876	OTHER	INTERVENTIONAL
Univ. Prof. Dr. med. Joerg Faber, Center for Pediatrics, Hematology, Oncology and Hemostaseology|Univ. Prof. Dr. med. Philipp S. Wi	ALL	ADULT		1000	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	352	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT	EARLY_PHASE1	10	OTHER	INTERVENTIONAL
Charite University, Berlin, Germany|Centre Hospitalier Universitaire de Besancon|Wroclaw Medical University|Semmelweis University|	ALL	OLDER_ADULT	PHASE3	2499	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1	40	INDUSTRY	INTERVENTIONAL
Centers for Medicare and Medicaid Services|RTI International|Econometrica, Inc.	ALL	ADULT	NA	1663	OTHER	INTERVENTIONAL
Huntington Hospital|National Institute on Aging (NIA)	ALL	OLDER_ADULT	NA	181	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		50	OTHER	OBSERVATIONAL
	MALE	ADULT, OLDER_ADULT	PHASE4	181	OTHER	INTERVENTIONAL
Advanced Accelerator Applications	ALL	ADULT, OLDER_ADULT	PHASE2	20	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT	PHASE3	10000	INDUSTRY	INTERVENTIONAL
The Foundation for Barnes-Jewish Hospital	ALL	ADULT, OLDER_ADULT	NA	25	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE2	86	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	2400	OTHER	INTERVENTIONAL
University of Sao Paulo General Hospital	ALL	ADULT, OLDER_ADULT	NA	278	OTHER	INTERVENTIONAL
Genentech, Inc.	ALL	ADULT, OLDER_ADULT	PHASE2	31	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		4502	OTHER	OBSERVATIONAL
Utrecht University	FEMALE	ADULT, OLDER_ADULT		148	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT	PHASE3	5	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	80	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		40	OTHER	OBSERVATIONAL
University Hospital, Tours	ALL	ADULT, OLDER_ADULT		5000000	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT		30	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT		50	OTHER_GOV	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT	NA	60	OTHER	INTERVENTIONAL
	MALE	ADULT, OLDER_ADULT		150	OTHER	OBSERVATIONAL
National Health and Medical Research Council, Australia|Bayer|Monash University|Berman Center for Outcomes and Clinical Researc	ALL	OLDER_ADULT		19114	OTHER	OBSERVATIONAL
National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT	PHASE2	0	OTHER	INTERVENTIONAL

	ALL	CHILD, ADULT, OLDER_ADULT		200000	OTHER	OBSERVATIONAL
Northeastern University|National Human Genome Research Institute (NHGRI)	ALL	ADULT, OLDER_ADULT	NA	279	OTHER	INTERVENTIONAL
	FEMALE	ADULT		150	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE3	320	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT	PHASE1|PHASE2	99	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE2	129	INDUSTRY	INTERVENTIONAL
Canadian Institutes of Health Research (CIHR)|Population Health Research Institute	ALL	ADULT, OLDER_ADULT	PHASE4	5000	OTHER	INTERVENTIONAL
Hoffmann-La Roche	ALL	ADULT, OLDER_ADULT		50	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	30	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	62	FED	INTERVENTIONAL
	FEMALE	ADULT		31	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		1514	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		100	OTHER	OBSERVATIONAL
Centre hospitalier de l'Université de Montréal (CHUM)|Queen Elizabeth II Health Sciences Centre|Alberta Health services|Vancouver C	ALL	ADULT	NA	696	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		118	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	25	OTHER	INTERVENTIONAL
	MALE	ADULT, OLDER_ADULT		18	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	186	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	60	OTHER	INTERVENTIONAL
European Union|Medical University of Pecs|Lancaster General Hospital|University Hospital, Bonn|KU Leuven|World Health Organizati	ALL	ADULT, OLDER_ADULT		576	OTHER	OBSERVATIONAL
National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT	NA	51	OTHER	INTERVENTIONAL
	MALE	CHILD, ADULT, OLDER_ADULT			OTHER	OBSERVATIONAL
Academisch Ziekenhuis Maastricht	ALL	ADULT, OLDER_ADULT		15	OTHER	OBSERVATIONAL
National Cancer Institute (NCI)	ALL	CHILD, ADULT	PHASE3	573	NETWORK	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT	PHASE2	39	INDUSTRY	INTERVENTIONAL
National Cancer Institute (NCI)	ALL	CHILD, ADULT, OLDER_ADULT	PHASE2	182	NETWORK	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	36	FED	INTERVENTIONAL
Aarhus University Hospital|Aalborg University Hospital|University of Copenhagen	FEMALE	ADULT, OLDER_ADULT	NA	220	OTHER	INTERVENTIONAL
Centre for Aging and Brain Health Innovation|Riverview Health Centre Foundation	ALL	CHILD, ADULT, OLDER_ADULT	NA	8	OTHER	INTERVENTIONAL
Baylor College of Medicine	ALL	ADULT, OLDER_ADULT	NA	120	FED	INTERVENTIONAL
National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	ALL	ADULT	NA	69	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE3	19	OTHER	INTERVENTIONAL
Pelontonia	MALE	CHILD, ADULT, OLDER_ADULT	NA	23	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	54	OTHER	INTERVENTIONAL
Maastricht University Medical Center|Hospital Sant Joan de Deu|Hospital Parc Taulí, Sabadell|Hospital Universitario Reina Sofía de C	ALL	CHILD, ADULT, OLDER_ADULT	NA	50	INDUSTRY	INTERVENTIONAL
	FEMALE	ADULT	NA	28	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	191	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		345	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT	NA	10009	OTHER_GOV	INTERVENTIONAL
National Cancer Institute (NCI)	ALL	ADULT	NA	41	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE2	60	OTHER	INTERVENTIONAL
Breast Cancer Research Foundation	FEMALE	ADULT, OLDER_ADULT	NA	57	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	16	OTHER	INTERVENTIONAL
ChromaDex, Inc.|Norwegian Cancer Society|Norwegian Breast Cancer Association|Helse Sor-Ost	FEMALE	ADULT, OLDER_ADULT	PHASE2	60	OTHER	INTERVENTIONAL
Amgen|Genentech, Inc.	FEMALE	ADULT, OLDER_ADULT	PHASE2	70	OTHER	INTERVENTIONAL
Nemocnice AGEL Trinec-Podlesi a.s.	ALL	ADULT, OLDER_ADULT	NA	10	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		591	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1	50	INDUSTRY	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT		1114	INDUSTRY	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	40	OTHER	INTERVENTIONAL
The Hospital of Vestfold|Oslo University Hospital|Kalmar County Hospital	ALL	ADULT, OLDER_ADULT		975	OTHER	OBSERVATIONAL
The Ottawa Hospital Academic Medical Association	ALL	ADULT, OLDER_ADULT		86	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT		50	OTHER_GOV	OBSERVATIONAL
Theagenio Cancer Hospital	ALL	ADULT, OLDER_ADULT		240	OTHER	OBSERVATIONAL
Institut de Radioprotection et de Surete Nucleaire|Clinique Pasteur|Institut National de la Santé Et de la Recherche Médicale, France	FEMALE	ADULT, OLDER_ADULT	NA	120	OTHER_GOV	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT	PHASE4	150	OTHER	INTERVENTIONAL
National Cancer Institute (NCI)	FEMALE	ADULT	EARLY_PHASE1	90	OTHER	INTERVENTIONAL
University Hospital Munich|Helmholtz Zentrum München|University of Cambridge|King's College London	ALL	ADULT, OLDER_ADULT	NA	183	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		200	OTHER	OBSERVATIONAL
AstraZeneca	ALL	ADULT, OLDER_ADULT		300	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT	NA	120	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		30	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		100	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	11	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	150	OTHER	INTERVENTIONAL

Rambam Health Care Campus	FEMALE	ADULT		100	OTHER_GOV	OBSERVATIONAL
University of Bordeaux	ALL	ADULT, OLDER_ADULT		100	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		178	NIH	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		0	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		70	OTHER	OBSERVATIONAL
University College London Hospitals	ALL	CHILD, ADULT, OLDER_ADULT	NA	128	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT		175	OTHER	OBSERVATIONAL
Siemens Molecular Imaging	ALL	ADULT, OLDER_ADULT		44	OTHER	OBSERVATIONAL
	ALL	CHILD		300	OTHER	OBSERVATIONAL
British Heart Foundation	ALL	ADULT, OLDER_ADULT		600	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT	PHASE2	19	OTHER	INTERVENTIONAL
	ALL	ADULT	NA	50	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE2	60	OTHER	INTERVENTIONAL
The Research Council of Norway	ALL	CHILD	NA	144	OTHER	INTERVENTIONAL
Ocala Royal Dames	ALL	ADULT, OLDER_ADULT		24	OTHER	OBSERVATIONAL
National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT	PHASE2	122	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT		60	OTHER	OBSERVATIONAL
	ALL	OLDER_ADULT	NA	480	OTHER	INTERVENTIONAL
University of Southern California	ALL	ADULT, OLDER_ADULT		467	INDUSTRY	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE4	50	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	50	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	627	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		6	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	109	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		26	OTHER	OBSERVATIONAL
Hospital A.C. Camargo|Instituto do Cancer do Estado de São Paulo	FEMALE	ADULT, OLDER_ADULT	PHASE3	200	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		100	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT	NA	1484	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		20000	INDUSTRY	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		1028	INDUSTRY	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT		25	OTHER	OBSERVATIONAL
Amgen	ALL	ADULT, OLDER_ADULT	PHASE2	23	OTHER	INTERVENTIONAL
Institut Curie	ALL	CHILD, ADULT, OLDER_ADULT		141630	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT	NA	100	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	120	OTHER	INTERVENTIONAL
Ministry of Health, Brazil	ALL	ADULT, OLDER_ADULT	PHASE4	1018	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		130	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	1002	OTHER_GOV	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT	PHASE4	1	INDUSTRY	INTERVENTIONAL
Ethicon, Inc.	FEMALE	ADULT		32175	OTHER	OBSERVATIONAL
National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT	NA	72	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		127	INDUSTRY	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		720	OTHER	OBSERVATIONAL
Dutch Cancer Society	ALL	ADULT, OLDER_ADULT	NA	10	OTHER	INTERVENTIONAL
Cardiocentro Ticino|North Estonia Medical Centre|Fondazione IRCCS Policlinico San Matteo di Pavia	FEMALE	ADULT, OLDER_ADULT		150	OTHER	OBSERVATIONAL
National Cancer Institute (NCI)	MALE	ADULT, OLDER_ADULT	PHASE4	94	OTHER	INTERVENTIONAL
Ortho Biotech Products, L.P.	ALL	ADULT, OLDER_ADULT	PHASE2	27	OTHER	INTERVENTIONAL
Abertawe Bro Morgannwg University Health Board	FEMALE	ADULT, OLDER_ADULT		17	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		3942	INDUSTRY	OBSERVATIONAL
University of Florence	FEMALE	ADULT, OLDER_ADULT	PHASE3	262	OTHER	INTERVENTIONAL
University of Ljubljana|General Hospital Murska Sobota|Maastricht University	ALL	ADULT, OLDER_ADULT		400	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		12000	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		98	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	128	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	90	OTHER	INTERVENTIONAL

	ALL	ADULT, OLDER_ADULT	PHASE2	94	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	200	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE4	118	INDUSTRY	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE2|PHASE3	56	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		100	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		160	OTHER	OBSERVATIONAL
National Heart, Lung, and Blood Institute (NHLBI)	ALL	ADULT, OLDER_ADULT		1461	OTHER	OBSERVATIONAL
National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT		300	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE3	60	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	40	OTHER	INTERVENTIONAL
	MALE	ADULT, OLDER_ADULT		1717	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT	NA	15	OTHER_GOV	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		2682	OTHER	OBSERVATIONAL
St. Franziskus Hospital|Raphaelsklinik Münster|Josephs Hospital Warendorf|Palliativnetz Muenster gGmbH	ALL	ADULT, OLDER_ADULT		347	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT	NA	72	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1|PHASE2	70	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT		99	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		30191	OTHER	OBSERVATIONAL
Skane University Hospital|Rigshospitalet, Denmark|Arba Minch University|University of Iceland	ALL	CHILD	NA	420	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		10000	NIH	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1	240	OTHER	INTERVENTIONAL
University of Southern Denmark	ALL	ADULT, OLDER_ADULT		45	OTHER	OBSERVATIONAL
King's College London	ALL	ADULT, OLDER_ADULT		25	OTHER	OBSERVATIONAL
The Cleveland Clinic	ALL	ADULT, OLDER_ADULT		60	OTHER	OBSERVATIONAL
National Cancer Institute (NCI)	FEMALE	ADULT		79	OTHER	OBSERVATIONAL
National Cancer Institute (NCI)|Washington University School of Medicine|University of Texas Southwestern Medical Center	ALL	ADULT, OLDER_ADULT	NA	645	OTHER	INTERVENTIONAL
Novartis	ALL	ADULT, OLDER_ADULT	PHASE2	0	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT		480	NETWORK	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE2	220	NETWORK	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		50	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		600	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE3	118	INDUSTRY	INTERVENTIONAL
Istituto Europeo di Oncologia	FEMALE	ADULT	NA	100	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		44	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		0	OTHER	OBSERVATIONAL
National Cancer Institute (NCI)	ALL	CHILD, ADULT	PHASE3	253	NETWORK	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		200	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT	NA	25	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		525	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT	NA	136	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	85	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		67	OTHER	OBSERVATIONAL
National Cancer Institute (NCI)	FEMALE	ADULT, OLDER_ADULT		180	NETWORK	OBSERVATIONAL
Erasmus Medical Center|Radboud University Medical Center	ALL	ADULT, OLDER_ADULT		16000	OTHER	OBSERVATIONAL
Millennium Pharmaceuticals, Inc.	ALL	ADULT, OLDER_ADULT	PHASE1	52	INDUSTRY	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT	PHASE2	14	INDUSTRY	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT		120	OTHER	OBSERVATIONAL
Golden Jubilee National Hospital	ALL	CHILD, ADULT, OLDER_ADULT		25	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT		0	OTHER	OBSERVATIONAL
Royal Free Hospital NHS Foundation Trust	ALL	ADULT, OLDER_ADULT	NA	15	OTHER	INTERVENTIONAL
University of North Carolina, Chapel Hill	ALL	CHILD, ADULT, OLDER_ADULT	NA	120	OTHER	INTERVENTIONAL
	MALE	CHILD, ADULT, OLDER_ADULT	NA	50	OTHER	INTERVENTIONAL
Peking University Shougang Hospital|Chinese PLA General Hospital|Beijing Jishuitan Hospital|Xijing Hospital|Peking Union Medical C	ALL	CHILD, ADULT, OLDER_ADULT	PHASE2|PHASE3	0	OTHER	INTERVENTIONAL
Canadian Institutes of Health Research (CIHR)|Western University, Canada|Agence de la Sante et des Services Sociaux du Saguenay	ALL	ADULT, OLDER_ADULT	NA	284	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE3	268	OTHER	INTERVENTIONAL

Miami Heart Research Institute	ALL	ADULT, OLDER_ADULT		200	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		341	OTHER	OBSERVATIONAL
Princess Alexandra Hospital, Brisbane, Australia|Calvary Mater Newcastle, Australia|Western Sydney Local Health District|Austin Hea	ALL	ADULT, OLDER_ADULT		300	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		774	OTHER	OBSERVATIONAL
Western University, Canada|Université de Sherbrooke|Canadian Institutes of Health Research (CIHR)|Sunnybrook Health Sciences Ce	ALL	ADULT, OLDER_ADULT	NA	175	OTHER	INTERVENTIONAL
Marqués de Valdecilla University Hospital|Center for Sport Studies, Rey Juan Carlos University	FEMALE	ADULT, OLDER_ADULT	NA	90	NETWORK	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	484	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		5	OTHER	OBSERVATIONAL
National Institute of Mental Health (NIMH)	ALL	ADULT, OLDER_ADULT	NA	29	OTHER	INTERVENTIONAL
National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT	PHASE2	40	OTHER	INTERVENTIONAL
University Hospital of Cologne|Bethanien Krankenhaus gGmbH	ALL	ADULT, OLDER_ADULT	NA	49	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		80	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT	PHASE4	200	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		100	OTHER	OBSERVATIONAL
Centre Hospitalier Universitaire de Tivoli|Clinique Sainte Elisabeth|Centre Hospitalier Jolimont-Lobbes|Réseau Hospitalier Médecine S	FEMALE	ADULT, OLDER_ADULT	PHASE2	73	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	221	FED	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT	PHASE2	12	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1	40	INDUSTRY	INTERVENTIONAL
	ALL	CHILD, ADULT		38	OTHER	OBSERVATIONAL
American Heart Association	FEMALE	ADULT, OLDER_ADULT		200	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		168	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		5000	OTHER	OBSERVATIONAL
Dana-Farber Cancer Institute|Brigham and Women's Hospital	ALL	ADULT, OLDER_ADULT	PHASE2	300	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT		42	OTHER	OBSERVATIONAL
University of Minnesota	ALL	ADULT, OLDER_ADULT		394	OTHER	OBSERVATIONAL
Fox Chase Cancer Center	ALL	ADULT, OLDER_ADULT	NA	100	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT		16	OTHER	OBSERVATIONAL
Massachusetts General Hospital	ALL	ADULT, OLDER_ADULT		45	OTHER	OBSERVATIONAL
University Hospital, Basel, Switzerland|University Children's Hospital Basel|Insel Gruppe AG, University Hospital Bern|Cantonal Hosp	ALL	ADULT, OLDER_ADULT		500	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		361	INDUSTRY	OBSERVATIONAL
Icahn School of Medicine at Mount Sinai	FEMALE	ADULT, OLDER_ADULT		70	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT		132	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	30	OTHER	INTERVENTIONAL
National Heart, Lung, and Blood Institute (NHLBI)	ALL	ADULT, OLDER_ADULT	PHASE1	100	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	37	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		1300	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	72	FED	INTERVENTIONAL
Instituto do Cancer do Estado de São Paulo|Beneficência Portuguesa de São Paulo|Instituto de Cardiologia do Rio Grande do Sul|Ins	ALL	ADULT, OLDER_ADULT		600	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		60	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		40	OTHER	OBSERVATIONAL
Institut National de la Santé Et de la Recherche Médicale, France	ALL	ADULT, OLDER_ADULT		1000	OTHER	OBSERVATIONAL
Cross Cancer Institute	ALL	ADULT, OLDER_ADULT		42	OTHER	OBSERVATIONAL
NHS Greater Glasgow and Clyde|Tenovus Scotland	FEMALE	ADULT, OLDER_ADULT		60	OTHER	OBSERVATIONAL
Ipsen	ALL	ADULT, OLDER_ADULT	PHASE3	0	NETWORK	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		300	OTHER	OBSERVATIONAL
Medtronic	ALL	ADULT, OLDER_ADULT		70	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	25	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		330	OTHER	OBSERVATIONAL
National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT		160	OTHER	OBSERVATIONAL

Myocardial Solutions	ALL	ADULT, OLDER_ADULT	PHASE2	49	OTHER	INTERVENTIONAL
Instituto de Salud Carlos III	FEMALE	ADULT, OLDER_ADULT	NA	122	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		220	OTHER	OBSERVATIONAL
Helen L. Kay Charitable Trust	ALL	ADULT, OLDER_ADULT	NA	29	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT	PHASE3	66	INDUSTRY	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1|PHASE2	10	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT	PHASE2	130	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		208	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT		60	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT		15	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		0	OTHER	OBSERVATIONAL
Agency for Healthcare Research and Quality (AHRQ)	ALL	ADULT, OLDER_ADULT	NA	1000	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		110	NIH	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE4	0	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT		161	NETWORK	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT	NA	53	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		79	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT		500	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		75	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT	NA	300	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT	PHASE1	20	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	660	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		150	OTHER	OBSERVATIONAL
South London and Maudsley NHS Foundation Trust	ALL	ADULT, OLDER_ADULT	NA	324	OTHER	INTERVENTIONAL
Avon Foundation	FEMALE	ADULT, OLDER_ADULT	PHASE2	34	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT		700	OTHER	OBSERVATIONAL
Patient-Centered Outcomes Research Institute	ALL	ADULT, OLDER_ADULT	NA	3999	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT	NA	34	OTHER	INTERVENTIONAL
Edwards Lifesciences	ALL	ADULT, OLDER_ADULT	PHASE4	49	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1	45	INDUSTRY	INTERVENTIONAL
Medical Research Agency, Poland	FEMALE	ADULT, OLDER_ADULT	PHASE4	600	OTHER	INTERVENTIONAL
National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)	ALL	ADULT, OLDER_ADULT	NA	10	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		30	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT		549	INDUSTRY	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		83	OTHER	OBSERVATIONAL
Janssen Scientific Affairs, LLC	ALL	ADULT, OLDER_ADULT		265	OTHER	OBSERVATIONAL
Norwegian University of Science and Technology|Alesund Hospital	FEMALE	ADULT, OLDER_ADULT		1600	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		8856	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		400	OTHER	OBSERVATIONAL
National Institute of Nursing Research (NINR)	ALL	ADULT, OLDER_ADULT	NA	154	OTHER	INTERVENTIONAL
Brown University	FEMALE	ADULT, OLDER_ADULT	NA	75	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT	NA	140	OTHER	INTERVENTIONAL

St. Jude Children's Research Hospital	ALL	ADULT, OLDER_ADULT	NA	50	OTHER	INTERVENTIONAL
National Health and Medical Research Council, Australia	ALL	ADULT, OLDER_ADULT	PHASE2	180	OTHER	INTERVENTIONAL
Universidade Federal Fluminense|Hospital Israelita Albert Einstein	FEMALE	ADULT	NA	15	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	12	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE2	120	INDUSTRY	INTERVENTIONAL
National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT	PHASE3	817	NETWORK	INTERVENTIONAL
National Cancer Institute (NCI)	FEMALE	CHILD, ADULT		25	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT	PHASE3	272	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	24	OTHER	INTERVENTIONAL
Bristol-Myers Squibb	ALL	ADULT, OLDER_ADULT	PHASE3	390	OTHER	INTERVENTIONAL
Region of Southern Denmark	ALL	ADULT, OLDER_ADULT	NA	200	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		1000	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT	NA	1492	OTHER	INTERVENTIONAL
National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)|National Institute on Aging (NIA)	ALL	ADULT, OLDER_ADULT		150	OTHER	OBSERVATIONAL
		CHILD, ADULT, OLDER_ADULT	NA	100	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT	PHASE3	396	NIH	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE3	800	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	50	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		657	INDUSTRY	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		600	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		25	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT	NA	25	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT	PHASE4	0	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE2|PHASE3	80	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT	NA	40	OTHER	INTERVENTIONAL
Universitäres Herzzentrum Hamburg-Eppendorf|Martini-Klinik am UKE GmbH	ALL	ADULT, OLDER_ADULT		45000	OTHER	OBSERVATIONAL
University of British Columbia	ALL	ADULT, OLDER_ADULT	NA	15	OTHER	INTERVENTIONAL
Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.|University Institute of Maia	ALL	ADULT, OLDER_ADULT	NA	80	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	20	OTHER	INTERVENTIONAL
InCor Heart Institute|Cancer Institute of Sao Paulo|Hospital Sirio-Libanes	ALL	ADULT, OLDER_ADULT	NA	20	OTHER	INTERVENTIONAL
Winthrop University Hospital	FEMALE	ADULT		20	OTHER	OBSERVATIONAL
University of Washington|Medical University of South Carolina|University of North Carolina, Chapel Hill	ALL	OLDER_ADULT	PHASE2|PHASE3	182	OTHER	INTERVENTIONAL
University of South Carolina	ALL	ADULT, OLDER_ADULT	NA	34	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	650	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		26	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		100	OTHER	OBSERVATIONAL
Canadian Institutes of Health Research (CIHR)	ALL	CHILD, ADULT, OLDER_ADULT	NA	27	OTHER	INTERVENTIONAL
TrygFonden, Denmark	MALE	ADULT, OLDER_ADULT	NA	76	OTHER	INTERVENTIONAL
Canadian Institutes of Health Research (CIHR)|The Physicians' Services Incorporated Foundation|Canadian Diabetes Association|Car	ALL	CHILD, ADULT, OLDER_ADULT		1	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		5000	OTHER	OBSERVATIONAL
National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT	PHASE2	66	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		2000	OTHER	OBSERVATIONAL
Wellcome Trust	ALL	ADULT, OLDER_ADULT	NA	1244	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE4	100	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		200	OTHER	OBSERVATIONAL
Shanghai 8th People's Hospital	ALL	OLDER_ADULT	PHASE4	200	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		1	INDUSTRY	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		500	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		28	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	120	OTHER	INTERVENTIONAL
The Foundation for Barnes-Jewish Hospital|American College of Chest Physicians	ALL	ADULT, OLDER_ADULT	NA	571	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	40	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		0	OTHER	OBSERVATIONAL

	FEMALE	ADULT, OLDER_ADULT	PHASE2|PHASE3	57	OTHER	INTERVENTIONAL
Quintiles, Inc.	ALL	ADULT, OLDER_ADULT	PHASE1	33	INDUSTRY	INTERVENTIONAL
Instituto de Salud Carlos III|European Union	ALL	ADULT, OLDER_ADULT	PHASE3	90	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT	PHASE1	25	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT	EARLY_PHASE1	0	OTHER	INTERVENTIONAL
Mallinckrodt	FEMALE	ADULT, OLDER_ADULT	PHASE1	3	OTHER	INTERVENTIONAL
	ALL	CHILD		40	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT	PHASE3	245	OTHER	INTERVENTIONAL
University of Oslo|Norwegian Cancer Society|AstraZeneca	FEMALE	ADULT, OLDER_ADULT	PHASE2	130	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT	NA	40	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	38	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		1149	INDUSTRY	OBSERVATIONAL
Canadian Institutes of Health Research (CIHR)|Ontario Institute for Cancer Research|Pediatric Oncology Group of Ontario|C17 Counc	ALL	CHILD, ADULT		1128	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	100	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	1502	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT		55	OTHER	OBSERVATIONAL
Case Western Reserve University|American Academy of Family Physicians National Research Network|Evanston Northwestern Healt	ALL	ADULT, OLDER_ADULT	PHASE1	8400	FED	INTERVENTIONAL
National Cancer Institute (NCI)	ALL	CHILD, ADULT	PHASE3	219	NETWORK	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		100	OTHER	OBSERVATIONAL
Innovate UK|National Institute for Health Research, United Kingdom	ALL	ADULT, OLDER_ADULT		744	INDUSTRY	OBSERVATIONAL
Servier	ALL	ADULT, OLDER_ADULT	PHASE2	49	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT	PHASE3	50	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE4	31	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	320	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT		20	OTHER	OBSERVATIONAL
National Institute on Aging (NIA)	ALL	ADULT, OLDER_ADULT	NA	2512	OTHER	INTERVENTIONAL
	ALL	ADULT	NA	80	OTHER	INTERVENTIONAL
National Cancer Institute (NCI)	ALL	CHILD, ADULT, OLDER_ADULT	NA	1	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE2|PHASE3	2	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT		80	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		5000	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	60	OTHER	INTERVENTIONAL
National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT	NA	13	OTHER	INTERVENTIONAL
National Cancer Institute (NCI)|Eastern Cooperative Oncology Group	ALL	CHILD, ADULT, OLDER_ADULT	PHASE2	20	NETWORK	INTERVENTIONAL
Sanofi	FEMALE	OLDER_ADULT	PHASE2	2	OTHER	INTERVENTIONAL
National Heart, Lung, and Blood Institute (NHLBI)	ALL	ADULT, OLDER_ADULT		175	OTHER	OBSERVATIONAL
The Asper Foundation|St. Boniface Hospital|Lantheus Medical Imaging	ALL	ADULT, OLDER_ADULT		43	OTHER	OBSERVATIONAL
Cigna Foundation	ALL	CHILD, ADULT, OLDER_ADULT		161000	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		21257	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	30	OTHER	INTERVENTIONAL
Canadian Institutes of Health Research (CIHR)	ALL	CHILD, ADULT, OLDER_ADULT	NA	332	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT	PHASE4	80	OTHER	INTERVENTIONAL
US Department of Veterans Affairs	ALL	ADULT, OLDER_ADULT		169	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT		0	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		43	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT		20	INDUSTRY	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	300	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		58	INDUSTRY	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		1000	OTHER	OBSERVATIONAL
VA Boston Healthcare System	ALL	ADULT, OLDER_ADULT	NA	1076	OTHER	INTERVENTIONAL
Tampere University Hospital	ALL	ADULT, OLDER_ADULT		200	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		100	OTHER	OBSERVATIONAL
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Cancer Institute (NCI)|National Institute on Agi	FEMALE	ADULT, OLDER_ADULT	PHASE3		NIH	INTERVENTIONAL
European Commission	ALL	ADULT, OLDER_ADULT	NA	608	OTHER	INTERVENTIONAL
National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT		55	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE4	20	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		1000	NIH	OBSERVATIONAL

	ALL	ADULT, OLDER_ADULT		2400	INDUSTRY	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		32	OTHER	OBSERVATIONAL
Barcelona Institute for Global Health|The West German Proton Therapy Centre, Essen|Gustave Roussy, Cancer Campus, Grand Paris	ALL	CHILD, ADULT		2670	OTHER_GOV	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	92	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1	60	INDUSTRY	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1	46	INDUSTRY	INTERVENTIONAL
Babylon University	ALL	ADULT, OLDER_ADULT	NA	172	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		100	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT	NA	10	OTHER	INTERVENTIONAL
National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT	PHASE1	72	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE2	30	OTHER	INTERVENTIONAL
Taipei Medical University WanFang Hospital|Taipei Medical University Hospital|Lotung Poh-Ai Hospital	ALL	ADULT, OLDER_ADULT		400	OTHER	OBSERVATIONAL
Merck Sharp & Dohme LLC	FEMALE	ADULT, OLDER_ADULT	PHASE2	50	OTHER	INTERVENTIONAL
pharmtrace klinische Entwicklung GmbH	ALL	ADULT, OLDER_ADULT	PHASE3	200	INDUSTRY	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE3	175	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	120	OTHER	INTERVENTIONAL
Institut de Radioprotection et de Surete Nucleaire|Institut Claudius Regaud|University Hospital, Toulouse|Institut National de la Santé	FEMALE	ADULT, OLDER_ADULT	NA	0	OTHER_GOV	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	EARLY_PHASE1	10	OTHER	INTERVENTIONAL
Medical Research Agency, Poland	ALL	ADULT, OLDER_ADULT	PHASE3	220	OTHER	INTERVENTIONAL
The Leeds Teaching Hospitals NHS Trust|University of Leeds|Cardiff University|University of Manchester|University College, London|U	MALE	ADULT, OLDER_ADULT	NA	1001	OTHER	INTERVENTIONAL
Institut de Formation en Ostéopathie du Grand Avignon	ALL	ADULT, OLDER_ADULT	NA	120	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		15	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		60	OTHER	OBSERVATIONAL
Instituto de Investigación Biomédica de Salamanca|Instituto de Salud Carlos III	ALL	OLDER_ADULT	NA	514	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE3	128	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1	30	INDUSTRY	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1	12	INDUSTRY	INTERVENTIONAL
HonorHealth Research Institute	ALL	ADULT, OLDER_ADULT	NA	18	OTHER	INTERVENTIONAL
Palliative Team,Hospital of South West Jutland|Center for Innovative Medical Technologies (CIMT), Odense University Hospital|Danish	ALL	ADULT, OLDER_ADULT	NA	182	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	200	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT	PHASE2	0	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		1200	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	2620	OTHER	INTERVENTIONAL
	FEMALE	ADULT		42	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT	PHASE2	100	NIH	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		71	OTHER	OBSERVATIONAL
	FEMALE	ADULT	PHASE4	1200	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		6000	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	22	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT	PHASE2	60	OTHER	INTERVENTIONAL
	ALL	ADULT	NA	50	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		30	OTHER	OBSERVATIONAL
American Cancer Society, Inc.	ALL	ADULT, OLDER_ADULT	NA	36	OTHER	INTERVENTIONAL
National Cancer Institute (NCI)	ALL	CHILD, ADULT, OLDER_ADULT	PHASE2	100	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE2	20	NIH	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1	2	INDUSTRY	INTERVENTIONAL
Helse Stavanger HF|St. Olavs Hospital	ALL	ADULT, OLDER_ADULT	NA	240	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	390	OTHER	INTERVENTIONAL
National Center for Complementary and Integrative Health (NCCIH)	ALL	ADULT, OLDER_ADULT	PHASE2	25	OTHER	INTERVENTIONAL
National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT	NA	28	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	10	OTHER	INTERVENTIONAL
National Institute on Aging (NIA)	ALL	ADULT, OLDER_ADULT	NA	1200	OTHER	INTERVENTIONAL
University of Michigan Rogel Cancer Center	FEMALE	ADULT, OLDER_ADULT		25	OTHER	OBSERVATIONAL
National Cancer Institute (NCI)	FEMALE	ADULT, OLDER_ADULT	PHASE2|PHASE3	59	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	69	OTHER	INTERVENTIONAL
Teva Branded Pharmaceutical Products R&D, Inc.	MALE	ADULT	PHASE1	155	INDUSTRY	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		43	OTHER	OBSERVATIONAL
Ohio State University	ALL	ADULT, OLDER_ADULT	PHASE3	245	OTHER	INTERVENTIONAL
National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT	NA	66	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		4555	OTHER	OBSERVATIONAL
National Institute on Aging (NIA)	ALL	ADULT, OLDER_ADULT	NA	600	OTHER	INTERVENTIONAL
Ferring Pharmaceuticals	MALE	ADULT, OLDER_ADULT	PHASE2	80	OTHER	INTERVENTIONAL
National Cancer Institute (NCI)|Miami Heart Research Institute	ALL	ADULT, OLDER_ADULT	PHASE2	450	OTHER	INTERVENTIONAL

National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT	NA	1	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	550	NIH	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	40	OTHER_GOV	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	286	FED	INTERVENTIONAL
Nationwide Children's Hospital	ALL	CHILD, ADULT, OLDER_ADULT		65	OTHER	OBSERVATIONAL
Copenhagen Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, Rigshospitalet	ALL	ADULT, OLDER_ADULT	NA	60	OTHER	INTERVENTIONAL
MSH-UHN AMO Innovation Fund|Canadian Institutes of Health Research (CIHR)	FEMALE	ADULT, OLDER_ADULT	NA	2	OTHER	INTERVENTIONAL
	ALL	OLDER_ADULT	NA	800	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		5	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT	PHASE2	0	OTHER	INTERVENTIONAL
National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT		24	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		4626	INDUSTRY	OBSERVATIONAL
Ruijin Hospital|Shanghai Fifth People's Hospital	FEMALE	ADULT, OLDER_ADULT		300	OTHER	OBSERVATIONAL
	MALE	ADULT, OLDER_ADULT		5103	INDUSTRY	OBSERVATIONAL
	ALL	CHILD, ADULT	NA	20	OTHER	INTERVENTIONAL
	MALE	ADULT, OLDER_ADULT		30	OTHER	OBSERVATIONAL
	ALL	CHILD		50	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT	NA	20	OTHER	INTERVENTIONAL
Centers for Medicare and Medicaid Services	ALL	CHILD, ADULT, OLDER_ADULT	NA	18277	OTHER	INTERVENTIONAL
Royal Perth Hospital	FEMALE	ADULT	PHASE4	40	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	40	NETWORK	INTERVENTIONAL
Methodological and quality of life unit in oncology (CHRU de Besançon)|University of Franche-Comté|University of Burgundy|Pôle de	ALL	ADULT, OLDER_ADULT	NA	186	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT		101	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE3	370	INDUSTRY	INTERVENTIONAL
National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT	NA	20	OTHER	INTERVENTIONAL
	MALE	CHILD, ADULT, OLDER_ADULT			NIH	OBSERVATIONAL
	ALL	CHILD, ADULT	NA	136	OTHER	INTERVENTIONAL
Agenzia Italiana del Farmaco	ALL	ADULT, OLDER_ADULT	PHASE3	80	OTHER	INTERVENTIONAL
National Cancer Institute (NCI)	FEMALE	ADULT, OLDER_ADULT	NA	42	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	1	OTHER	INTERVENTIONAL
Jessa Hospital|Algemeen Ziekenhuis Vesalius|Sint-Franciscus Ziekenhuis|Regionaal Ziekenhuis Sint-Trudo|Ziekenhuis Maas en Kemp	ALL	CHILD, ADULT, OLDER_ADULT		878	OTHER	OBSERVATIONAL
Shaoxing Hospital of Zhejiang University	ALL	ADULT, OLDER_ADULT	NA	60	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	405	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1	30	INDUSTRY	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	140	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		2000000	INDUSTRY	OBSERVATIONAL
National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT	PHASE2	468	OTHER	INTERVENTIONAL
National Institutes of Health (NIH)|National Library of Medicine (NLM)	ALL	CHILD, ADULT, OLDER_ADULT		40	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	43	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT		166	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE2|PHASE3	19	OTHER	INTERVENTIONAL
		CHILD, ADULT, OLDER_ADULT	EARLY_PHASE1	5	OTHER	INTERVENTIONAL
Finnish Foundation for Cardiovascular Research|Paavo Nurmi Foundation|Sigrid Jusélius Foundation|Finnish Cultural Foundation|Tam	ALL	ADULT, OLDER_ADULT		2000	OTHER	OBSERVATIONAL
Cross Cancer Institute	FEMALE	ADULT, OLDER_ADULT	PHASE2	63	OTHER	INTERVENTIONAL
Blue Cross Blue Shield of Michigan Foundation	ALL	OLDER_ADULT	NA	120	OTHER	INTERVENTIONAL
Alere San Diego	ALL	ADULT, OLDER_ADULT	NA	597	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE3	30	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		180	OTHER	OBSERVATIONAL
University Hospital, Akershus|Oslo University Hospital|University Hospital of North Norway|St. Olavs Hospital|Helse Stavanger HF|Klir	FEMALE	ADULT, OLDER_ADULT	PHASE2	214	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		107	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT	NA	69	OTHER	INTERVENTIONAL
Nottingham Trent University	ALL	ADULT, OLDER_ADULT		2000	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT		240	OTHER	OBSERVATIONAL
Finnish Institute for Health and Welfare	MALE	ADULT, OLDER_ADULT		29133	NIH	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		87	OTHER	OBSERVATIONAL
Brigham and Women's Hospital	ALL	ADULT, OLDER_ADULT	NA	210	OTHER	INTERVENTIONAL
Canadian Institutes of Health Research (CIHR)	ALL	ADULT, OLDER_ADULT		503	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT	PHASE1	69	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		196	OTHER	OBSERVATIONAL
ETH Zurich - The Aceto Lab	ALL	ADULT, OLDER_ADULT	EARLY_PHASE1	9	OTHER	INTERVENTIONAL
University of Tromso|Norwegian Foundation for Health and Rehabilitation	ALL	ADULT, OLDER_ADULT		6839	OTHER	OBSERVATIONAL
Medivation, Inc.	ALL	ADULT, OLDER_ADULT	PHASE1	38	INDUSTRY	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	100	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1	50	INDUSTRY	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT	PHASE3	40	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	200	OTHER	INTERVENTIONAL
The Netherlands Cancer Institute|Technical University of Munich|Institut de Radioprotection et de Surete Nucleaire	FEMALE	ADULT, OLDER_ADULT		7000	OTHER	OBSERVATIONAL

National Heart, Lung, and Blood Institute (NHLBI)	ALL	ADULT, OLDER_ADULT	PHASE1|PHASE2	105	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	100	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		54	OTHER	OBSERVATIONAL
Patient-Centered Outcomes Research Institute	ALL	ADULT, OLDER_ADULT	NA	817	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		424	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		80	INDUSTRY	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT	NA	15	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		23891	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	296	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	60	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	100	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT	NA	160	OTHER	INTERVENTIONAL
	ALL	ADULT	NA	162	OTHER	INTERVENTIONAL
Academisch Ziekenhuis Groningen|Technical University of Munich|Institut Català d'Oncologia|Hospital de Santa Maria, Portugal|Univ	FEMALE	ADULT, OLDER_ADULT	NA	250	OTHER_GOV	INTERVENTIONAL
National Cancer Institute (NCI)	ALL	ADULT, OLDER_ADULT		133	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT	NA	60	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	117	OTHER	INTERVENTIONAL
Canadian Institutes of Health Research (CIHR)	ALL	CHILD, ADULT, OLDER_ADULT		20	OTHER	OBSERVATIONAL
Women's College Hospital|Ottawa Hospital Research Institute	ALL	ADULT, OLDER_ADULT	NA	900	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		2000	OTHER	OBSERVATIONAL
American Heart Association	MALE	ADULT, OLDER_ADULT		200	OTHER	OBSERVATIONAL
Novartis Pharmaceuticals	ALL	ADULT, OLDER_ADULT	NA	15	OTHER	INTERVENTIONAL
Canadian Institutes of Health Research (CIHR)|University of Toronto	FEMALE	ADULT, OLDER_ADULT		180	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		11569	OTHER	OBSERVATIONAL
	FEMALE	CHILD, ADULT, OLDER_ADULT		2000	OTHER	OBSERVATIONAL
ZonMw: The Netherlands Organisation for Health Research and Development	FEMALE	CHILD, ADULT, OLDER_ADULT		455	OTHER	OBSERVATIONAL
	FEMALE	ADULT		561	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		23	OTHER	OBSERVATIONAL
HALO Affiliate Sites	MALE	ADULT, OLDER_ADULT		2000	INDUSTRY	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT	NA	58	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		5000	OTHER	OBSERVATIONAL
Patient-Centered Outcomes Research Institute	ALL	ADULT, OLDER_ADULT	NA	28	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		20	OTHER	OBSERVATIONAL
Schering-Plough	ALL	ADULT, OLDER_ADULT	PHASE2	50	OTHER	INTERVENTIONAL

	ALL	CHILD, ADULT, OLDER_ADULT		5940299	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT	NA	320	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	20	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	10	OTHER	INTERVENTIONAL
University of Wisconsin, Madison|University of Colorado, Denver|University of Iowa|Duke University|Laval University|University of Toro	ALL	ADULT, OLDER_ADULT	NA	1120	OTHER	INTERVENTIONAL
Gilead Sciences	FEMALE	ADULT, OLDER_ADULT		35	OTHER	OBSERVATIONAL
AstraZeneca	ALL	ADULT, OLDER_ADULT		160	OTHER	OBSERVATIONAL
American Heart Association|Dana-Farber Cancer Institute	FEMALE	ADULT, OLDER_ADULT		190	OTHER	OBSERVATIONAL
	MALE	CHILD, ADULT, OLDER_ADULT			NIH	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		114	OTHER	OBSERVATIONAL
Medical Research Council	ALL	ADULT, OLDER_ADULT	NA	100	INDUSTRY	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		30	NIH	OBSERVATIONAL
British Heart Foundation|Barts & The London NHS Trust|University College London Hospitals	ALL	ADULT, OLDER_ADULT	NA	90	OTHER	INTERVENTIONAL
Western Health, Australia|Northern Hospital, Australia|Menzies Institute for Medical Research|Peter MacCallum Cancer Centre, Austra	ALL	ADULT, OLDER_ADULT		748	OTHER	OBSERVATIONAL
	FEMALE	ADULT, OLDER_ADULT		700	OTHER	OBSERVATIONAL
	FEMALE	OLDER_ADULT	PHASE2	16	OTHER	INTERVENTIONAL
Canadian Institutes of Health Research (CIHR)|City of Lakes family Health Team|Schlegel Villages and Research Institute for Aging|YM	ALL	ADULT, OLDER_ADULT	NA	44	OTHER	INTERVENTIONAL
Fundação de Amparo à Pesquisa do Estado de São Paulo	FEMALE	ADULT, OLDER_ADULT	NA	27	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT	NA	36	OTHER	INTERVENTIONAL
TrygFonden, Denmark|Danish Cancer Society	ALL	ADULT, OLDER_ADULT	NA	360	OTHER	INTERVENTIONAL
National Natural Science Foundation of China	ALL	ADULT, OLDER_ADULT		12000	OTHER	OBSERVATIONAL
National Cancer Institute (NCI)	ALL	CHILD, ADULT, OLDER_ADULT	PHASE3	13	NETWORK	INTERVENTIONAL
VA Greater Los Angeles Healthcare System	ALL	ADULT, OLDER_ADULT		60	OTHER	OBSERVATIONAL
National Center for Research Resources (NCRR)	FEMALE	ADULT, OLDER_ADULT		20	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		147	OTHER	OBSERVATIONAL
	FEMALE	ADULT		150	OTHER	OBSERVATIONAL
	ALL	ADULT		142	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1	26	OTHER	INTERVENTIONAL
Mazankowski Alberta Heart Institute	ALL	ADULT, OLDER_ADULT		250	INDUSTRY	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	EARLY_PHASE1	7	OTHER	INTERVENTIONAL
Groupe Hospitalier Pitie-Salpetriere|University Hospital, Marseille, France|Hospices Civils de Lyon, France|University of Pennsylvania,	ALL	ADULT, OLDER_ADULT		1000	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE2	188	NIH	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	316	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		310	NIH	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		108	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		10000	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT	NA	40	OTHER	INTERVENTIONAL
Canadian Cancer Society (CCS)|Pfizer	FEMALE	ADULT, OLDER_ADULT	PHASE2|PHASE3	44	OTHER	INTERVENTIONAL
Misr International University	ALL	ADULT, OLDER_ADULT		178	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	NA	80	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT	PHASE1	15	NIH	INTERVENTIONAL
University of Ljubljana, Faculty of Medicine|University Rehabilitation Institute, Republic of Slovenia	ALL	ADULT, OLDER_ADULT		50	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE4	72	OTHER	INTERVENTIONAL
Centre Hospitalier Universitaire de Liege|University of Liege	ALL	CHILD		40000	OTHER	OBSERVATIONAL
	ALL	CHILD, ADULT		90	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		36	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE4	50	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1	15	NIH	INTERVENTIONAL

Newcastle University|University of Durham|Newcastle-upon-Tyne Hospitals NHS Trust	ALL	ADULT, OLDER_ADULT	PHASE3	128	OTHER	INTERVENTIONAL
	FEMALE	CHILD, ADULT, OLDER_ADULT		66	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE4	275	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT	NA	68	OTHER	INTERVENTIONAL
Ministry of Health, Labour and Welfare, Japan	ALL	CHILD, ADULT, OLDER_ADULT	PHASE3	80	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT		100	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		100	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1|PHASE2	18	INDUSTRY	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		55	OTHER_GOV	OBSERVATIONAL
Garfield Memorial Fund	ALL	ADULT, OLDER_ADULT	NA	550	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	5000	OTHER	INTERVENTIONAL
	FEMALE	ADULT, OLDER_ADULT		12	OTHER	OBSERVATIONAL
Pfizer	ALL	ADULT, OLDER_ADULT	PHASE3	70	OTHER	INTERVENTIONAL
	ALL	CHILD, ADULT, OLDER_ADULT		15	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT		221	OTHER	OBSERVATIONAL
	ALL	ADULT, OLDER_ADULT	PHASE1|PHASE2	30	OTHER	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	NA	70	NIH	INTERVENTIONAL
	ALL	ADULT, OLDER_ADULT	PHASE4	40	OTHER	INTERVENTIONAL
National Comprehensive Cancer Network|Pfizer|Myovant Sciences GmbH	MALE	ADULT, OLDER_ADULT	NA	100	OTHER	INTERVENTIONAL

Study Design	Other IDs	Start Date	Primary Completion Date	Completion Date	First Posted	Results First Posted
Observational Model: |Time Perspective: p	IRB00010254	2014-03-01	2016-12-31	2019-03-01	2014-01-03	
Observational Model: |Time Perspective: p	ALTE11C2|S0004187|ALTE11C2|COG-ALTE11C2|ALTE11C2|R01CA211996|U10CA095861|UG1CA189955	2013-08-05	2022-12-31	2023-12-31	2013-02-13	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE	PB-PG-0107-11134|ISRCTN04119516	2008-08	2010-12	2010-12	2008-05-15	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE	STUDY00005369	2019-04-17	2022-10-31	2023-01-31	2018-10-26	
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT	Uni-Koeln-1412|2011-005797-32|DRKS00004353	2013-03	2014-11	2014-12	2020-11-19	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	42559415520020065	2019-01-22	2021-10-01	2021-12-01	2018-08-28	
Observational Model: |Time Perspective: p	IRB20-1768	2021-03-22	2023-08-01	2024-08-01	2021-04-01	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	31466-G|R01NR009987	2007-04	2013-02	2013-03	2008-05-30	
Observational Model: |Time Perspective: p	F31AT001401-01	2001-04		2001-09	2003-08-15	
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT	HUS-01/2013|2013-003976-11	2015-01	2018-08	2018-08	2014-08-13	
Observational Model: |Time Perspective: p	NTProBNPPleuralEffusion1	2023-12-01	2025-11-30	2025-11-30	2023-04-04	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER	CHRO-2019-12	2020-10-05	2021-01-27	2021-01-27	2021-01-11	
Observational Model: |Time Perspective: p	SHIP02	2017-01-01	2019-12-01	2019-12-01	2017-02-13	
Observational Model: |Time Perspective: p	P060251	2008-01	2015-05	2016-01	2008-04-29	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING	21466|NCI-2021-11335|21466|P30CA033572|R21CA261797	2022-06-22	2024-11-15	2024-11-15	2021-12-01	
Observational Model: |Time Perspective: p	MVH-02	2011-02	2011-11	2011-11	2010-07-28	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	86-814d 6.2008.453	2008-10	2011-09	2012-02	2008-10-24	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT	IIT2015-12-Goodman-STOP	2016-05-05	2018-05-25	2018-05-25	2016-02-04	2019-03-25
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE	M401	2019-06-12	2022-04-01	2022-07-01	2018-08-24	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	Pro00019124 (MIP-CA130394-01)|5R44CA130394-03	2009-11	2011-06	2011-07	2012-11-21	
Observational Model: |Time Perspective: p	NIS-PFM-2019-2654	2020-06-02	2023-05-01	2023-05-01	2020-03-24	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	113712	2019-06	2021-06	2026-06	2019-05-13	
Observational Model: |Time Perspective: p	950059|95-CH-0059	1995-12-14			1999-11-04	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	GZTO1401	2014-01	2019-03	2019-03	2014-02-04	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	Lung IMRT	2011-02	2013-09	2015-09	2012-04-26	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	SPARE HF Pilot	2018-05-10	2021-12-21	2023-12	2017-06-14	
Observational Model: |Time Perspective: p	WHOOPHPP|NCI-2021-05183	2019-02-05	2021-01-19	2023-06-30	2019-02-12	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION	2017-A02256-47|2017/2610	2018-06-14	2023-09	2025-06	2018-07-27	
Observational Model: |Time Perspective: p	21-271	2021-08-27	2023-08-27	2023-08-27	2021-09-05	
Observational Model: |Time Perspective: p	TTAC	2011-02	2016-02	2016-02	2013-09-18	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	STUDY00000419|NCI-2020-02314|WINSHIP4998-20|P30CA138292	2020-04-07	2020-06-02	2020-06-02	2020-04-24	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	FJ-KS-KY-2022-28(X)	2022-06-06	2023-11	2024-06	2022-06-09	
Observational Model: |Time Perspective: p	NCI-2013-02291|NCI-2013-02291|ECOG-E5103T3|E5103T3|E5103T3|U10CA180820	2014-03-25	2100-01-01	2100-01-01	2015-11-20	
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE	72403|FFIKA WP4.3|AMFF 16-2022-03|H-21068847	2023-03	2024-06	2024-06	2023-03-03	
Observational Model: |Time Perspective: p	SHXKYY202005	2020-08-01	2022-08-01	2023-08-01	2020-07-16	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	160252	2018-01-09	2021-12-12	2021-12-12	2018-06-12	
Observational Model: |Time Perspective: p	100126|10-H-0126	2010-07-21			2010-06-14	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT	114271	2011-12	2015-03	2015-03	2011-04-04	2016-01-28
Observational Model: |Time Perspective: p	IUCRO-0483	2015-04-23	2018-02-01	2018-02-01	2015-04-22	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	HSC-SPH-15-0443|5UM1HL087318	2016-08	2019-11	2020-04-20	2015-07-27	2020-09-15
Observational Model: |Time Perspective: p	German Heart Foundation	2022-02-01	2023-10-31	2023-12-31	2022-03-02	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	49024|2014-004504-29|2014/1909/REK-vest	2015-05	2016-02	2016-02	2015-02-20	
Observational Model: |Time Perspective: p	15-258	2015-11	2023-11	2023-11	2015-11-25	
Observational Model: |Time Perspective: p	NL83538.041	2024-04	2025-12	2025-12	2023-02-16	

Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	CIHR #: 126541	2006-03	2010-10	2011-10	2005-11-02	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION	14-099	2014-06-24	2021-06-24	2021-06-24	2014-06-27	2022-06-07
Observational Model: |Time Perspective: p	T273/2015	2016-02-01	2025-12-31	2025-12-31	2018-02-23	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	ABCDE_AUH	2015-09	2018-06	2018-06	2016-01-12	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC	STU 072016-058	2018-07-01	2023-08	2023-08	2018-09-26	
Observational Model: |Time Perspective: p	WFH-PCOS-98076	2009-11	2010-08	2010-10	2010-05-03	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	2009P002762	2013-02	2014-12	2014-12	2011-11-09	2016-12-21
Observational Model: |Time Perspective: p	STUDY00021185|NCI-2020-03178|STUDY00021185|R01CA264133	2020-09-21	2022-09-30	2022-09-30	2020-05-26	
Observational Model: |Time Perspective: p	IRB201300763	2014-09	2016-10-28	2019-02-14	2014-03-06	
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT	3144A1-105	2008-05	2008-07	2008-07	2008-07-02	
Observational Model: |Time Perspective: p	ULYM07056	2008-08	2018-11	2020-04-09	2009-05-19	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	N201508038	2016-07	2019-07	2019-12	2016-06-22	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	BRAVEHeartV1	2018-09-15	2021-09-30	2023-08	2016-08-26	
Observational Model: |Time Perspective: p	UIT-ENDO-2011-2	2011-04	2016-07	2016-08	2011-07-15	
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	2015P002477|1R01HL130563-01A1	2016-04-01	2023-01-08	2023-01-08	2015-12-29	
Observational Model: |Time Perspective: p	ACTIV4	2022-02-21	2022-03-31	2023-04-21	2022-02-07	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	IRAS 285303|20/LO/1108	2020-01-11	2022-04-04	2022-06-30	2020-10-05	
Observational Model: |Time Perspective: p	X08-0296	2009-02	2013-07	2014-06	2009-03-09	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	kazuma	2021-07-01	2024-09	2025-09	2022-12-19	
Observational Model: |Time Perspective: p	Cardiotoxicity	2014-05	2016-03	2016-08	2014-04-02	
Observational Model: |Time Perspective: p	140404	2014-11	2019-07-15	2019-07-15	2014-07-01	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	SOLTI-1002|2012-001201-24	2013-06	2016-01	2016-01	2012-08-20	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	IRB-60375|PROS0109|NCI-2022-02832	2021-11-18	2023-11	2023-11	2021-10-29	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose:	REB15636				2006-03-31	
Observational Model: |Time Perspective: p	2203648	2021-02-01	2023-06-27	2023-12-22	2022-05-18	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	22D.705	2023-01-20	2026-01	2029-02	2023-03-20	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	H13-03090	2016-01-15	2016-05-25	2016-05-25	2013-12-10	2017-11-08
Observational Model: |Time Perspective: p	ZCO-2014-BD	2014-01	2016-06	2016-12	2014-02-19	
Observational Model: |Time Perspective: p	300754	2022-11-10	2025-11-10	2025-11-10	2023-03-06	
Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE	37476|1R01NR012757-01A1	2013-06-01	2017-06-30	2021-06-30	2015-04-29	
Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	Health Plus at Home	2006-05		2008-01	2006-10-11	
Observational Model: |Time Perspective: p	4-2015-0607	2015-09-23	2016-02-06	2016-02-06	2015-11-16	
Observational Model: |Time Perspective: p	FUP062|snctp000000587	2008-05	2018-05	2019-07	2015-01-07	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	PROICM 2019-12 COC	2021-09-21	2024-06	2024-06	2019-07-18	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE	2017/CHU/06	2018-01	2019-03	2019-06	2017-11-29	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	CAPRICE	2019-05-01	2022-12-31	2023-01-31	2019-02-21	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	1P50HL105188-6094|1P50HL105188	2010-10	2014-10	2014-10	2012-10-25	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	IEO S617/211	2011-06	2015-12	2015-12	2012-11-27	
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT	9426|POG-9426|CCG-P9426|CDR0000065013|COG-9426	1996-10	2004-10	2008-06	2004-05-26	
Observational Model: |Time Perspective: p	IIS-0046	2017-06-27	2018-06-26	2018-06-26	2017-08-01	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	1R01CA204585-01|1R01CA204585-01	2019-04-19	2021-06-30	2021-12-31	2018-08-08	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	M06HER|2006-001707-11	2007-06	2013-12	2014-12	2007-04-12	
Observational Model: |Time Perspective: p	C.A. 2890	2023-01-14	2026-01	2026-07	2023-06-27	
Observational Model: |Time Perspective: p	CV-2016-24434	2016-08	2022-09-01	2022-09-01	2016-06-14	
Observational Model: |Time Perspective: p	04-119	2004-12		2006-09	2005-09-30	
Observational Model: |Time Perspective: p	1144|R01HL065622	2001-09		2005-07	2002-05-17	
Observational Model: |Time Perspective: p	00011928 FABRIC	2020-05-21	2022-05-21	2022-11-30	2020-05-29	
Observational Model: |Time Perspective: p	CIC1421-18-12	2018-05-02	2022-05-01	2023-04-08	2018-05-21	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING	Cardio-RT	2017-06-27	2020-10-08	2025-10	2016-10-24	
Observational Model: |Time Perspective: p	18-137	2024-01	2028-08	2030-08	2019-07-29	
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT	D5084C00001	2017-09-06	2018-03-24	2018-03-24	2017-08-23	
Observational Model: |Time Perspective: p	eMERGEIII	2015-09-01	2020-04-01	2020-04-01	2018-01-09	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	UZBRU_VHH2_2|2020-002483-31	2021-01-26	2025-01-26	2025-01-26	2021-02-17	
Observational Model: |Time Perspective: p	APA-CARDIO_PAG_01	2020-07-16	2022-03	2022-09	2020-09-29	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING	SJHH_Lung_AF	2017-06-02	2020-08-28	2020-08-28	2015-09-11	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE	KO-TIP-011	2021-05-06	2023-05-15	2023-05-15	2021-04-29	
Observational Model: |Time Perspective: p	4903|R01HL044664	2000-09	2006-08	2006-08	2000-05-26	
Observational Model: |Time Perspective: p	19-5080	2022-03-14	2023-12	2023-12	2022-08-31	
Observational Model: |Time Perspective: p	IC/CLS10	2004-02	2008-03	2008-03	2008-08-13	
Observational Model: |Time Perspective: p	10-066	2013-02	2016-06-24	2023-06-24	2017-07-07	
Observational Model: |Time Perspective: p	left breast cancer	2022-04-27	2023-10-30	2023-11-30	2022-05-03	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	Pro00122568	2023-02-12	2024-07-31	2024-12-31	2023-03-27	
Observational Model: |Time Perspective: p	2004-0578	2004-09	2009-03	2009-03	2007-07-11	
Observational Model: |Time Perspective: p	19-045	2019-03-22	2024-03	2024-03	2019-06-12	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	UPCC 05518	2019-01-02	2019-04-11	2019-04-11	2018-09-17	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	20-221	2021-08-12	2025-06-15	2026-06-15	2021-01-20	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	1508190|ANSM	2017-02-03	2020-02-05	2021-03-16	2016-01-29	

Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION	MMS.2021.058	2022-01-07	2024-11-30	2026-11-30	2023-01-26	
Observational Model: |Time Perspective: p	3852	2010-02	2013-03	2013-03	2015-07-01	
Observational Model: |Time Perspective: p	108818	2020-03-01	2021-03-31	2021-03-31	2019-08-06	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	GHC2/29/22-09-2008	2010-12	2011-06	2011-06	2011-01-05	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	1024489|1024489	2019-04-29	2023-06-30	2023-12-31	2018-11-21	
Observational Model: |Time Perspective: p	03-10-014|Hypersomnia Foundation|National Ataxia Foundation|4p- Support Group|CdLS Foundation|Hype	2010-07	2100-12	2100-12	2013-02-15	
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	C18-004	2020-03-01	2024-03-30	2024-06-30	2020-07-15	
Observational Model: |Time Perspective: p	SJFAMILY	2017-04-06	2037-03-31	2037-03-31	2017-02-10	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	LMTG 09-01	2009-03	2012-12	2013-02	2009-03-03	
Observational Model: |Time Perspective: p	17-1885.cc|1K99NR016686-01A1	2017-11-15	2018-11-30	2018-11-30	2018-01-05	2019-09-26
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC	77880421319552	2022-12-01	2025-01-01	2025-08-03	2023-01-27	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	959583153|961501172|DHF: 03-2-3-35-22109|CHC: 20/fo03	2003-01		2004-02	2005-09-12	
Observational Model: |Time Perspective: p	Pro00029638|IND 113645|IND 114369|IND 114531|IND 118358|HHSN20100006|HHSN27500020|HHSN275	2011-11	2019-11	2019-11	2011-09-09	
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT	TPU-TAS-102-103|2013-000650-21	2013-06	2014-08	2015-04	2013-06-04	
Observational Model: |Time Perspective: p	IRB 22-211	2022-07-01	2025-07-01	2027-07-01	2022-10-28	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	20221107	2022-08-01	2023-08-01	2024-07-01	2022-12-15	
Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	69|R01HL043851|HL043851|CA047988	1992-09	2004-03	2005-02	1999-10-28	2011-12-05
Observational Model: |Time Perspective: p	CVSS-study	2013-10	2018-10	2028-10	2014-07-03	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE	IRB300002420	2020-08-24	2024-01-20	2024-06-30	2018-12-06	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	22-457	2023-01	2023-06-01	2023-12-01	2022-11-07	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	633765|2015-002868-17	2016-07	2021-10-31	2022-03-31	2015-11-04	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	TH-CR-414	2013-11	2016-07	2016-12	2013-12-24	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	168-2012	2012-06	2015-12	2016-12	2015-05-12	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH	UP-10-00372|5R21AG034557-02	2011-02	2013-10	2013-10	2014-09-05	2014-12-04
Observational Model: |Time Perspective: p	1810020038	2023-05-01	2028-12-31	2028-12-31	2019-05-31	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING	2008341-01H	2008-07	2011-09	2011-09	2010-10-29	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	263064	2020-10	2024-11	2024-12	2019-07-31	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: PREVENTION	1865|H3S-MC-GGIO	1998-06		2005-11	2005-09-19	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	201909133	2021-01-15	2023-09-30	2023-09-30	2019-08-28	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	AC-006-IT	2012-01	2016-07	2016-07	2012-01-18	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC	21-0368	2021-10-07	2023-10-06	2024-10-06	2021-08-09	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: DIAGNOSTIC	CapPesq0074/10	2010-06	2011-11	2012-03	2010-06-28	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	ML 28685	2013-10	2019-06	2020-06	2013-07-22	2020-09-11
Observational Model: |Time Perspective: p	MUC I002-16	2017-03-01	2017-10-31	2017-12-31	2016-12-19	
Observational Model: |Time Perspective: p	2018-06	2019-01-24	2023-09-04	2024-09-02	2018-07-02	
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	ID01-674	2002-02	2008-02	2008-02	2007-07-16	2009-09-24
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH	H-21010559	2021-12-01	2023-12-31	2024-03-30	2022-01-31	
Observational Model: |Time Perspective: p	11-MIBG-005	2011-10			2011-10-07	
Observational Model: |Time Perspective: p	PMSI_092022	2022-09-22	2030-01	2030-01	2022-10-03	
Observational Model: |Time Perspective: p	Cardiac safety study	2019-07-05	2021-12-01	2021-12-30	2021-07-14	
Observational Model: |Time Perspective: p	Herceptin	2012-06	2016-08	2016-08	2014-02-14	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION	CT/2019/CANFLAX	2020-10-21	2022-12-31	2022-12-31	2020-11-17	
Observational Model: |Time Perspective: p	12751	2022-10-11	2025-12-31	2025-12-31	2022-11-10	
Observational Model: |Time Perspective: p	HSR#09-3029|3U01AG029824-07S2	2010-01	2017-12	2024-04	2009-12-24	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE	19-007547|NCI-2021-13928	2020-09-01	2023-04-18	2023-04-18	2019-12-09	

Observational Model: |Time Perspective: p	EMPOWER-1	2021-02-01	2026-02-01	2028-02-01	2019-06-17	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SCREENING	H-32767|1R01HG007746-01	2016-11	2019-10	2019-10	2015-01-26	
Observational Model: |Time Perspective: p	35179/1/22	2020-03-21	2021-08-15	2021-11-17	2022-04-25	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	IEO S365/407|2007-003856-12	2008-04	2013-06	2013-10	2011-01-24	
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: DIAGNOSTIC	00027 / Ethics 25253	2010-09	2015-09	2016-09	2009-11-20	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	NEOD001-201	2016-03	2018-03	2018-03	2015-12-17	2018-10-03
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE|Primary Purpose: PREVENTION	HOPE-2, CIHR FRN # MT-15428	1999-12		2005-10	2005-04-01	
Observational Model: |Time Perspective: p	Cardiac CMR	2009-11	2019-12	2019-12	2009-12-01	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH	42206	2020-10-05	2021-04-09	2021-10-12	2020-12-11	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: HEALTH_SERVICES_RESEARCH	1381	2013-03	2015-06	2015-06	2013-03-25	
Observational Model: |Time Perspective: p	2009-19	2009-09	2013-11	2014-04	2016-01-05	
Observational Model: |Time Perspective: p	K21	2019-06-26	2021-09-30	2022-09-30	2019-04-10	
Observational Model: |Time Perspective: p	YX-2020-B002	2020-04-15	2025-03-14	2028-03-14	2020-04-08	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT	21-5391	2021-09	2026-09	2027-03	2021-08-27	
Observational Model: |Time Perspective: p	Cardiocare	2015-01	2022-07	2022-07	2018-03-29	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION	#4624	2016-05-31	2016-12-06	2016-12-07	2016-05-27	2019-04-22
Observational Model: |Time Perspective: p	UPCC 18817	2018-03-15	2019-04-19	2019-10-19	2018-05-24	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	OPTILIVER TRIAL-IPC 2018-022	2022-02-03	2024-03-03	2024-05-03	2020-12-07	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	20230609	2023-06-01	2023-12-01	2024-06-01	2023-07-06	
Observational Model: |Time Perspective: p	305555	2014-06	2015-12	2015-12	2014-06-26	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	0006621|R21CA215557-02	2020-12-04	2021-10-10	2021-10-10	2020-09-17	2022-10-07
Observational Model: |Time Perspective: p	MI-PB				2008-04-02	
Observational Model: |Time Perspective: p	echocardiographyRILI	2017-04-25	2019-09-12	2019-09-12	2015-07-17	
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE	9404|U10CA030969|POG-9404|CDR0000064664	1996-06	2001-09	2004-10	2010-10-29	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER	PM1183-B-005-14-QT	2015-08-12	2016-08-19	2016-08-19	2015-05-21	2018-10-17
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION	ALTE1621|NCI-2016-00232|ALTE1621|COG-ALTE1621|ALTE1621|R01CA196854|UG1CA189955	2016-04-04	2022-06-30	2023-09-30	2016-03-23	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose:	IAD 07-162	2008-12	2009-05	2009-05	2008-11-02	2014-10-03
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT	OP_1413	2021-10-01	2024-09-01	2025-09-01	2022-06-06	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	RiverviewHC	2020-10-01	2020-12-31	2021-03-30	2019-10-24	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH	IIR 02-224	2004-12	2009-09	2009-09	2005-07-21	2015-07-10
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	RC1DK086037|RC1DK086037|R01DK095128-01	2009-09-01	2024-07-01	2024-07-01	2010-01-13	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	2005P000376	2006-02	2009-10-13	2009-10-13	2006-03-09	2017-03-20
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	OSU-14186|NCI-2015-00029	2014-12	2017-11-13	2022-12-31	2016-03-30	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION	4-2017-0487	2017-08-01	2020-06-09	2020-06-12	2017-07-27	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	CAR-0320	2022-01-10	2022-04-30	2022-05-31	2022-01-11	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	PCOSLFEA-17611|2008-72VP-15445-01A|ALFFGBG-10984	2009-02	2010-12	2010-12	2009-06-16	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	BC032020_1	2020-08	2021-07	2022-08	2020-07-08	
Observational Model: |Time Perspective: p	621/2020	2021-05-19	2022-12-31	2023-12-31	2021-02-11	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH	MOST-2013BAI09B01-2	2015-06	2016-09-18	2017-09	2015-04-29	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	10037|NCI-2018-01168|10037|P30CA015704|RG1001769	2018-08-31	2020-01-22	2020-06-16	2018-06-29	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	Ehab-Raafat.Levo	2017-08-01	2018-02-01	2018-04-23	2018-06-14	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	J0609|NA_00002394	2006-06	2010-01	2010-01	2006-05-03	2019-05-24
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	16-0138, 16-0424	2016-06-02	2017-12-15	2017-12-30	2017-03-24	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	2021/156064(REK)	2023-03-16	2025-08-01	2035-09-30	2023-02-16	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	04-126	2004-12	2008-06	2008-06	2008-01-11	2014-11-24
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	RELIEF-AP Trial	2022-01-01	2024-12	2024-12	2022-10-31	
Observational Model: |Time Perspective: p	2021-12-12	2022-07-01	2024-12-31	2024-12-31	2022-01-20	
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	113773	2013-01-22	2014-11-28	2014-11-28	2012-11-30	
Observational Model: |Time Perspective: p	NIS-OKR-DUM-2009/1	2009-05	2010-03	2010-03	2009-04-22	
Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: PREVENTION	432715154	2017-10-21	2022-10-21	2023-10-21	2020-11-19	
Observational Model: |Time Perspective: p	NOR-COR REK ID 2013/1885	2014-02	2015-04	2015-04	2014-12-05	
Observational Model: |Time Perspective: p	20120564-01H	2013-03	2022-05	2022-05	2013-05-08	
Observational Model: |Time Perspective: p	TLV-0212-15	2015-10	2017-12	2018-12	2015-07-22	
Observational Model: |Time Perspective: p	MAFIC_2020	2020-08-01	2023-08	2023-12	2020-08-11	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING	IRSN_2015-A00990-49	2015-10	2019-09	2020-09	2015-11-16	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	OLSG-0401	2004-05	2010-09	2010-09	2005-09-13	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	IRB00083573|WFBCCC 98122|P30CA012197	2022-09-02	2024-12	2027-12	2022-04-04	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	01GY1331	2015-03-02	2019-02-01	2019-04-30	2015-12-04	
Observational Model: |Time Perspective: p	CheckPoint	2016-01	2018-01	2019-01	2016-01-27	
Observational Model: |Time Perspective: p	MHICC-2018-003	2021-12-02	2026-01	2026-01	2020-09-09	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	6010121027	2021-03-29	2023-06-25	2023-09-25	2022-08-17	
Observational Model: |Time Perspective: p	2007-0489	2008-10-06	2016-11-21	2016-11-21	2008-10-22	
Observational Model: |Time Perspective: p	S-20160086	2015-08	2023-01	2024-06	2022-02-28	
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION	PRO00030436	2018-03-03	2021-03-21	2021-03-21	2017-12-18	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE	STUDY00004821	2018-07-01	2020-06-30	2020-06-30	2018-11-19	

Observational Model: |Time Perspective: p	cardiotoxicity66809	2010-01	2011-12		2009-11-25	
Observational Model: |Time Perspective: p	DC 2015/143	2015-11	2017-11	2017-11	2019-06-07	
Observational Model: |Time Perspective: p	100134|10-E-0134	2012-05-21			2010-06-14	
Observational Model: |Time Perspective: p	20	2020-03	2020-05-28	2020-05-28	2020-06-04	
Observational Model: |Time Perspective: p	05-091	2005-05		2006-11	2005-09-22	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	15/0276	2015-12-16	2020-12	2021-12	2015-06-15	
Observational Model: |Time Perspective: p	eHER2-TM	2011-12	2012-07	2012-07	2012-04-06	
Observational Model: |Time Perspective: p	110104	2009-06	2017-05-30	2017-05-30	2009-11-25	
Observational Model: |Time Perspective: p	YL2019100602	2019-01-01	2020-05-01	2020-05-01	2020-06-01	
Observational Model: |Time Perspective: p	140342	2021-10-13	2024-04-01	2024-07-01	2021-12-16	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC	MRTOX	2012-02	2015-08	2017-05	2011-09-19	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING	NL31278.058.10	2011-01	2013-06	2013-06	2011-01-06	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	NCC1786	2019-01-01	2020-03-01	2025-03-01	2018-12-24	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	S-05288|175389/V50	2005-01	2010-10	2016-07	2011-01-20	
Observational Model: |Time Perspective: p	UFPTI 1419-BR02|IRB201800163|UFJ 2014-116	2014-09	2021-07-07	2025-04-22	2014-07-24	
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: |Primary Purpose: TREATMENT	CDR0000533793|P30CA015083|RC0639|06-004049	2007-03-16	2009-04	2019-07-22	2007-02-19	2012-10-22
Observational Model: |Time Perspective: p	FEMH-IRB-101085-F	2012-12	2014-12	2015-11	2013-01-01	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC	15595	2023-07-01	2023-12-31	2024-07-30	2023-03-27	
Observational Model: |Time Perspective: p	A1501098	2011-08	2012-03	2012-03	2011-11-28	2013-02-04
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC	U/1/2010	2010-06	2014-12	2016-12	2016-12-09	2017-01-16
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER	KC17OESI0205	2017-05-17	2017-10-16	2018-05-16	2017-05-23	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING	20-0270-E	2021-09-20	2022-06-30	2023-12	2021-01-27	
Observational Model: |Time Perspective: p	HP-00068503	2018-02-01	2022-09-09	2022-09-09	2016-02-23	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC	CHUBX 2009/21	2010-04	2013-04	2013-04	2010-03-08	
Observational Model: |Time Perspective: p	07-007414	2008-03	2010-01	2010-01	2008-10-31	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	Ceccy Trial	2013-04	2017-06	2017-06	2012-11-09	
Observational Model: |Time Perspective: p	20/NS/0038	2021-05-27	2023-05	2023-05	2021-04-23	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	B1112_069_003	2012-01-30	2018-04	2018-04	2012-01-16	
Observational Model: |Time Perspective: p	SAN-BB-02	2021-10-26	2023-10	2023-10	2022-12-02	
Observational Model: |Time Perspective: p	20211	2019-08-14	2019-10-14	2019-10-14	2018-07-27	
Observational Model: |Time Perspective: p	LCCC1239	2013-03	2016-03	2016-03	2013-05-08	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT	17-022	2018-02-27	2020-11-18	2020-11-18	2017-05-02	2022-01-19
Observational Model: |Time Perspective: p	CIC1421-23-05	2023-01-01	2023-07-01	2023-07-01	2023-07-06	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	4218	2021-10-12	2023-10-30	2026-10-12	2023-03-09	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING	REC103-20	2014-05	2016-07	2016-07	2014-05-29	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION	AVAP-NG 989	2021-08-01	2023-12-30	2024-12-30	2021-06-25	
Observational Model: |Time Perspective: p	UPCC48418	2018-12-10	2023-12	2023-12	2018-11-30	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION	CORDIOPREV	2009-11	2018-07	2021-05	2009-06-19	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	P04057|EUDRACT NO. 2004-001177-25	2006-02	2006-08	2006-08	2008-10-24	2010-02-11
Observational Model: |Time Perspective: p	PARW-OVCONS-0307	1980-01	2004-06	2004-06	2008-04-09	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	CASE16Z12|NCI-2014-00376|CASE16Z12|P30CA043703	2013-03-07	2016-09-14	2018-10-02	2014-03-11	2019-10-11
Observational Model: |Time Perspective: p	1	2022-08-15	2022-08-17	2022-10-20	2022-10-26	
Observational Model: |Time Perspective: p	STH20223	2020-01-16	2023-12-31	2024-03-31	2019-07-30	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING	M19CCR	2021-01-13	2023-04-01	2023-04-01	2019-06-12	
Observational Model: |Time Perspective: p	2019-01395CE3508	2020-09-15	2024-12-31	2024-12-31	2021-03-10	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	STUDY00003654|NCI-2022-00117|STUDY00003654|RAD5484-21|P30CA138292	2022-06-06	2024-04-29	2025-04-29	2022-04-11	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	LY-012006	2006-05			2006-06-02	
Observational Model: |Time Perspective: p	188676	2017-08-01	2019-09-28	2020-04-01	2017-08-30	
Observational Model: |Time Perspective: p	BO20652	2007-08-30	2016-05-31	2016-05-31	2010-06-29	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: PREVENTION	SAFE2014	2015-07	2022-06	2022-06	2014-09-11	
Observational Model: |Time Perspective: p	ML-MTB-001	2012-03	2016-07	2017-12	2015-09-16	
Observational Model: |Time Perspective: p	AURA	2023-02-27	2023-12-31	2023-12-31	2023-01-19	
Observational Model: |Time Perspective: p	UPCC 34810	2011-04	2017-12-31	2017-12-31	2011-06-09	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	FZ 01	2020-12-10	2023-06-30	2023-06-30	2023-01-09	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	ACE_SAVA_3Decho_BMT	2019-09-20	2020-09-01	2021-09-01	2019-09-17	

Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	NHL-14|EudraCT 2007-004970-24	2007-12	2012-01	2012-01	2007-12-18	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	109209	2019-03	2020-09	2020-09	2017-09-01	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	CICL670AAU01	2007-11	2011-09	2011-09	2008-05-07	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	35945/10/22	2022-10-28	2023-04-28	2024-10-28	2022-10-26	
Observational Model: |Time Perspective: p	EA1/292/20	2022-12-01	2023-11-30	2023-11-30	2022-10-12	
Observational Model: |Time Perspective: p	H-20014489	2020-04-20	2020-12-18	2021-09-18	2020-03-03	
Observational Model: |Time Perspective: p	GeneQuest|IRB4333|1R01HL121358	1995-01	2021-04-01	2021-04-01	2008-01-10	
Observational Model: |Time Perspective: p	22-001501|NCI-2022-05690|P30CA015083	2022-08-18	2026-09-01	2027-09-01	2022-08-19	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT	2019-1205|NCI-2021-00852|2019-1205	2021-05-18	2023-08-31	2023-08-31	2021-03-22	
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	35521	2014-09	2040-12	2040-12	2014-09-25	
Observational Model: |Time Perspective: p	CIC1421-17-08	2017-05-16	2017-07-13	2017-07-13	2017-08-09	
Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: OTHER	2022-A02337-36	2023-03-02	2023-06-05	2023-06-15	2023-02-14	
Observational Model: |Time Perspective: p	KIHD Nutrition	1984-03-01	2052-12-31	2052-12-31	2017-07-18	
Observational Model: |Time Perspective: p	UKM_POEM I	2017-09-11	2019-10	2019-12	2017-09-18	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	2020-12-044-012	2020-10-01	2023-06	2023-06	2022-10-18	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION	L19-065	2022-06-01	2025-11-01	2026-06-01	2019-05-02	
Observational Model: |Time Perspective: p	PEDSVAR0038|SU-11172008-1345	2008-11	2010-10	2010-10	2010-06-03	
Observational Model: |Time Perspective: p	3	2006-01-01	2018-12-31		2019-12-16	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	2018-01399	2019-10-15	2024-10-15	2024-12-31	2019-11-04	
Observational Model: |Time Perspective: p	970041|97-H-0041	1996-12-31			1999-11-04	
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	2015P002385	2016-08-01	2025-10-31	2026-01-30	2019-02-05	
Observational Model: |Time Perspective: p	S-20140090	2014-10	2018-08	2018-08	2015-05-12	
Observational Model: |Time Perspective: p	KCH20-056|ICA-CL-2018-04-ST2-001	2020-06-03	2020-11-11	2020-11-11	2020-07-10	
Observational Model: |Time Perspective: p	PRO00039290	2024-06	2025-12	2026-12	2022-05-17	
Observational Model: |Time Perspective: p	NU 95B2|NU-95B2|NCI-G00-1737	2000-02	2005-10	2005-10	2003-01-27	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	IRB00056774|NCI-2019-01362|R01CA226078|NCI-2019-01362	2020-10-01	2024-03-07	2024-03-07	2019-05-02	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	Pro34493	2015-12	2018-12	2019-06	2016-05-24	
Observational Model: |Time Perspective: p	08-01 ICORG|ICORG-08-01|EU-20948	2008-04	2014-04		2009-08-31	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	BRE008-12	2013-02	2025-01	2030-01	2013-01-01	
Observational Model: |Time Perspective: p	NeuroendoUnit-2	2007-01		2007-09	2007-04-16	
Observational Model: |Time Perspective: p	MEC-2018-1389	2018-10-01	2030-01-01	2030-01-01	2020-07-09	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	CRAD001M2302|2008-002113-48	2009-04	2011-06	2015-11	2008-11-13	2012-05-23
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING	CCM 1505	2022-03-24	2023-12	2024-06	2023-03-20	
Observational Model: |Time Perspective: p	UPCC01419	2019-07-22	2022-11-16	2022-11-16	2019-07-19	
Observational Model: |Time Perspective: p	11-443	2013-03	2018-08-25	2018-08-25	2013-07-24	
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	P9754|COG-P9754|POG-P9754|CCG-P9754|CDR0000067129	1999-09	2004-03	2008-06	2004-02-09	
Observational Model: |Time Perspective: p	2018-A00429-46	2019-02-26	2020-09-10	2021-01	2018-09-19	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE	220287	2023-04-01	2025-01-15	2025-03-15	2023-03-27	
Observational Model: |Time Perspective: p	DR11-0061	2011-01	2011-11	2011-11	2011-10-31	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	2018-11-128	2019-07-19	2022-07-18	2023-07-18	2020-06-12	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	2007-0822|NCI-2011-02123	2008-02-11	2024-05-31	2024-05-31	2008-03-12	
Observational Model: |Time Perspective: p	10-206	2010-12	2018-07-11	2018-07-11	2010-12-17	
Observational Model: |Time Perspective: p	CDR0000065237|U10CA032102|SWOG-9342	1997-02	2008-03		2003-01-27	
Observational Model: |Time Perspective: p	16/721 (IRB UMC Utrecht)	2017-01-01	2020-03-01	2020-03-01	2017-07-02	
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	SGN35-007	2010-01	2010-08	2011-08	2009-12-04	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	AAA-Annexin-05|CAAA113A42202	2016-11-02	2018-10-12	2018-10-12	2016-02-09	2020-09-21
Observational Model: |Time Perspective: p	H1106-026-365	2011-07	2013-12	2014-04	2012-08-15	
Observational Model: |Time Perspective: p	1-shelly	2013-08	2014-09	2016-08	2013-07-04	
Observational Model: |Time Perspective: p	MARCI	2010-05	2013-01	2013-01	2010-04-28	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	262072	2022-04-06	2023-10	2026-03	2021-10-01	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	18-2079	2018-11-30	2024-12-31	2025-06-30	2019-02-11	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	4-2015-0337	2015-08	2016-01	2016-01	2015-08-31	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	CBTRA-03	2017-11-06	2020-11-15	2020-12-30	2017-11-14	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER	2013-010	2016-04-22	2022-11-01	2022-11-01	2016-06-03	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	IEO S701/412|2012-002248-26	2012-12	2019-12	2023-12	2013-10-23	

Observational Model: |Time Perspective: p	21-006790	2022-03-03	2024-01	2024-01	2022-01-21	
Observational Model: |Time Perspective: p	PHACE_GENETICS	2007-02	2022-08-15	2022-08-15	2009-11-19	
Observational Model: |Time Perspective: p	IX-2021-DS-LEARN	2023-01-31	2026-01-31	2026-01-31	2022-01-11	
Observational Model: |Time Perspective: p	ERAS_feasibility	2007-09	2011-02	2011-06	2011-06-28	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER	104191	2016-01-12	2019-04-07	2022-10-19	2016-04-19	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE	CARDIEJERCAN	2021-09-13	2022-07-30	2022-09-20	2021-09-10	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION	APHP191102|IDRCB 2020-A01971-38	2022-04-01	2023-12	2024-10	2021-05-19	
Observational Model: |Time Perspective: p	10-213	2010-12	2011-11	2011-11	2010-12-03	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	202101103|1P50MH122351	2021-11-17	2023-01-06	2023-01-06	2021-11-08	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	IRB00040792|NCI-2016-01464|CCCWFU 22616|P30CA012197	2016-11	2018-03	2020-03	2016-11-23	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER	Uni-Koeln-0917	2019-02-09	2020-03-01	2020-03-15	2020-11-16	
Observational Model: |Time Perspective: p	14/P/152	2015-10	2016-02	2016-02	2014-10-27	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH	20150777-01H	2016-06	2020-05	2020-07	2016-03-02	
Observational Model: |Time Perspective: p	R21087	2022-02-01	2028-12-31	2028-12-31	2021-10-26	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC	CE1740	2010-07	2013-08	2013-08	2012-03-15	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE	IIR 10-050	2011-01	2014-02	2014-04	2010-01-07	2015-02-23
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	MBC0901 FUCH	2009-06	2012-02	2012-02	2009-08-10	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	701	2008-06	2009-03	2009-07	2008-07-04	
Observational Model: |Time Perspective: p	IAchemo_HRV	2018-04-09	2019-09-09	2019-09-09	2018-03-01	
Observational Model: |Time Perspective: p	UPCC 11121	2021-10-21	2039-10	2039-10	2021-10-14	
Observational Model: |Time Perspective: p	0136-17-RMC	2017-01-01	2019-03-01	2019-03-01	2017-06-09	
Observational Model: |Time Perspective: p	LEMD001	1995-01	2022-12-30	2022-12-30	2013-12-23	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT	16-440	2017-01-13	2022-09-16	2023-10-11	2016-10-24	
Observational Model: |Time Perspective: p	5405	2014-11	2018-03-11	2018-03-11	2017-02-01	
Observational Model: |Time Perspective: p	VASCC	2013-12	2016-07	2016-07	2013-12-12	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH	833373	2020-03-01	2023-06	2023-08	2020-01-27	
Observational Model: |Time Perspective: p	BR-1-0090	2006-07	2011-03	2011-03	2007-11-26	
Observational Model: |Time Perspective: p	2007-0339	2008-11	2011-08	2011-08	2008-12-10	
Observational Model: |Time Perspective: p	SCCSS_cardiac_FU	2018-02-13	2023-12-31	2024-01-01	2019-01-02	
Observational Model: |Time Perspective: p	NIS-Celgene-JP-PMS-001b	2011-02-18	2014-10-11	2014-10-11	2016-10-04	
Observational Model: |Time Perspective: p	16-025	2016-05-11	2026-05	2026-05	2016-05-13	
Observational Model: |Time Perspective: p	SL-2020076	2021-10	2024-12	2024-12	2021-10-01	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	UMCC 2023.010|HUM00230386	2023-07	2025-01	2025-01	2023-05-22	
Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: DIAGNOSTIC	2021-0071|NCI-2021-02280|2021-0071|1R01HL157273-01	2021-07-05	2026-02-23	2026-02-23	2021-08-18	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER	201505	2020-11-01	2021-11-15	2021-11-15	2022-04-07	
Observational Model: |Time Perspective: p	WATCH4ECG	2022-12-13	2024-01	2025-06	2022-11-15	
Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH	IIR 19-018|HX002935	2022-09-13	2024-09-30	2025-09-30	2021-08-11	
Observational Model: |Time Perspective: p	BRAvAdO	2016-09-01	2021-09-01	2021-09-01	2020-01-10	
Observational Model: |Time Perspective: p	11190071	2020-01-09	2022-10-31	2023-10-31	2021-05-21	
Observational Model: |Time Perspective: p	GuizhouMuu	2022-02-28	2022-12-30	2022-12-30	2022-02-23	
Observational Model: |Time Perspective: p	CIC1421-18-06	2018-02-01	2018-09-30	2018-09-30	2018-04-10	
Observational Model: |Time Perspective: p	00028 / 24942	2011-07	2012-11	2013-01	2009-11-16	
Observational Model: |Time Perspective: p	GN19ON381	2021-03-15	2022-05-25	2022-11-25	2021-08-24	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	EORTC-1715-GITCG	2020-04	2023-07	2027-10	2019-08-22	
Observational Model: |Time Perspective: p	230/HĐĐĐ-ĐHYD	2020-09-15	2023-05-30	2023-06-30	2020-09-14	
Observational Model: |Time Perspective: p	UPCC35420	2021-04-21	2023-04	2023-04	2019-10-08	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose:	4-2014-0492	2014-08	2015-03	2015-03	2014-08-19	
Observational Model: |Time Perspective: p	OXY-PAL	2018-08-07	2020-01	2020-01	2018-09-17	
Observational Model: |Time Perspective: p	15317|NCI-2015-01612|15317	2017-07-21	2023-12-31	2023-12-31	2019-07-10	

Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: SUPPORTIVE_CARE	201809177	2019-03-13	2023-03-02	2023-03-02	2019-03-05	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	PI17/01687	2018-08-01	2022-03-30	2023-01-01	2019-05-28	
Observational Model: |Time Perspective: p	v24-9-2017	2018-03-27	2022-12	2022-12	2018-02-19	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	HFHS-HF_PROACTIVE	2016-06	2018-12	2018-12	2016-06-10	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	ATA129-EBV-302	2017-12-29	2022-06	2027-06	2018-01-09	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	CDR0000572104|BRCC-BHS-06127|UTCI-2645	2007-10	2011-07	2011-07	2007-10-22	2013-02-04
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	PHRI.SCHOLAR-2	2021-07-01	2024-01-01	2025-12-01	2020-12-23	
Observational Model: |Time Perspective: p	B21/01	2021-10-20	2023-07	2024-01	2021-04-21	
Observational Model: |Time Perspective: p	181758	2019-09-30	2022-09-30	2029-09-30	2020-02-10	
Observational Model: |Time Perspective: p	112991	2019-01-01	2020-12-31	2021-12-31	2018-11-20	
Observational Model: |Time Perspective: p	S12-02513	2012-05	2020-01	2020-01	2013-03-13	
Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH	2022P001284	2022-11-01	2025-03-01	2027-06-30	2022-07-05	
Observational Model: |Time Perspective: p	10000923|000923-H	2023-03-01	2027-04-08	2027-04-08	2023-02-13	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT	2000020017	2018-07	2020-09	2021-06	2016-11-29	
Observational Model: |Time Perspective: p	ALTE21C1|NCI-2022-09972|COG-ALTE21C1|COG-ALTE21C1|ALTE21C1|UG1CA189955	2023-05-20	2028-10-01	2028-10-01	2023-01-30	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	PROICM 2019-06 COH	2020-02-14	2022-01-14	2022-01-14	2019-06-11	
Observational Model: |Time Perspective: p	UPCC 13117	2017-12-05	2022-05-31	2022-05-31	2018-04-27	
Observational Model: |Time Perspective: p	2013/01090	2013-11	2015-10		2014-03-05	
Observational Model: |Time Perspective: p	Ateroloab-1	2014-07	2016-02	2016-02	2014-09-26	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	IC 2020-20	2021-09-20	2023-09	2024-09	2021-08-18	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	SCHOLAR-2016	2016-11-01	2018-04-12	2018-04-12	2016-09-20	
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: SUPPORTIVE_CARE	14892	2017-05-23	2019-05-22	2019-10-15	2019-10-29	
Observational Model: |Time Perspective: p	20/SC/0301	2021-01-18	2023-03-01	2023-05-01	2021-11-23	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	STR130202 (Secondary)	2015-07	2019-01	2019-01	2015-04-27	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	J13160|J13160|NA_00091900	2014-05-20	2017-04-25	2024-03-01	2014-03-26	2019-05-14
Observational Model: |Time Perspective: p	686317	2013-06	2016-02-06	2017-10-24	2013-07-22	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	PLC-1609-36108	2019-01-07	2020-01-24	2020-01-24	2018-10-03	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	2023_Yoga_Breastcancer	2023-05-04	2023-07-30	2023-07-30	2023-05-22	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT	2007-0231	2007-08	2008-09	2008-09	2007-09-10	2011-12-08
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER	M12-020|2013-002028-18	2013-11	2014-12	2014-12	2013-12-12	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION	LCZ696ABM001.001	2023-02	2027-12	2028-02	2022-07-19	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	UMCC 2023.004|HUM00223835|U24HL157560	2023-07	2027-07	2027-07	2023-07-14	
Observational Model: |Time Perspective: p	17-1301	2018-02-01	2024-02-15	2024-02-15	2018-02-13	
Observational Model: |Time Perspective: p	SB3-G31-BC-E	2016-04	2020-12	2020-12	2016-05-13	
Observational Model: |Time Perspective: p	1108162|2011-A01357-34	2012-09	2014-12	2014-12	2012-04-10	
Observational Model: |Time Perspective: p	PA14-1027	2015-09-28	2022-03-15	2022-03-15	2015-07-20	
Observational Model: |Time Perspective: p	2015/583	2016-11	2029-12	2036-12	2015-09-04	
Observational Model: |Time Perspective: p	SHIP03	2009-01	2019-10	2019-10	2019-12-13	
Observational Model: |Time Perspective: p	COEXIST-1	2023-01-01	2023-06-01	2023-06-01	2023-07-03	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose:	Pro00011193|1P01NR010948-01	2010-02	2013-09	2013-09	2009-07-14	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	MiriamH 1040485	2017-07-24	2017-12-20	2018-01-30	2017-08-23	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	LC2016A09	2017-01-01	2020-01-30	2020-01-30	2018-03-12	

Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	202305110	2023-07-05	2024-01-07	2024-01-07	2023-06-28	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	SOCRATES	2022-11-07	2025-06	2025-06	2022-01-06	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	Breast Cancer Chemotherapy	2020-08-03	2022-09-03	2023-11-03	2020-09-29	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	EXACT2015	2016-02	2017-09	2017-09	2015-06-12	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	HE071-CSP-020	2022-03-07	2022-06-20	2022-12-30	2021-10-22	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE	S1501|NCI-2016-01047|S1501|SWOG-S1501|UG1CA189974	2017-11-01	2029-01-01	2029-01-01	2018-02-01	
Observational Model: |Time Perspective: p	IRB00049171|NCI-2018-00588|CCCWFU 98118|P30CA012197	2018-06-21	2020-03-05	2020-03-05	2018-04-23	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	CSPC -DMS- BC-08	2017-09-01	2019-10-31	2020-10-31	2019-05-14	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH	18-006630	2019-05-20	2019-11-20	2020-05-20	2019-05-06	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	2021P003690	2022-06-22	2026-11	2027-04	2022-04-20	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	CATCH2018	2018-04-11	2023-06-30	2024-06-30	2018-04-03	
Observational Model: |Time Perspective: p	ID02-359	2002-12-10	2020-12	2020-12	2007-07-13	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER	FoU i VGR: 275327	2021-09-01	2022-02-28	2022-06-30	2021-01-28	
Observational Model: |Time Perspective: p	20-008408|R01AG060920|R01HL147155-02	2021-03-12	2023-06	2024-01	2021-02-15	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: DIAGNOSTIC	832/18	2018-01-15	2018-04-15	2019-01-15	2018-03-23	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	NCI-2012-02380|CLB-49808|U10CA031946|CDR0000068617	2001-05	2005-03		2003-09-04	
Allocation: RANDOMIZED|Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT	CDR0000668530|CRCA-CCTC-WCTU-ARTemis|ISRCTN68502941|EUDRACT-2008-002322-11|EU-21017|	2009-04	2012-04		2010-03-25	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER	IRB 22-0256|ERP-2021-12882	2022-11-01	2024-05-01	2027-11-01	2022-12-08	
Observational Model: |Time Perspective: p	ML21975	2008-11	2013-02	2013-02	2013-11-25	
Observational Model: |Time Perspective: p	69HCL17_0700	2018-04	2033-04	2033-04	2018-04-13	
Observational Model: |Time Perspective: p	Nasser-2008-1CTIL	2009-02	2011-06	2011-06	2008-07-16	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	OSU-14060|NCI-2015-00810	2015-05-14	2018-10-23	2021-12-31	2017-02-01	
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	Pediatric ondansetron QTc	2013-10	2013-10	2013-10	2013-07-11	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	PKU Third Hospital	2021-06-25	2022-07-30	2022-08-31	2021-06-25	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	268-2017	2018-05-19	2021-12-31	2022-01-30	2018-03-09	
Observational Model: |Time Perspective: p	PV5131	2016-02-08	2022-12-31	2028-12-31	2019-05-02	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	HRVB-123	2013-01	2015-08	2016-06	2013-01-21	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	CORE Trial	2021-09-30	2022-06-23	2022-07-05	2021-11-24	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	IIT2021-07-Atkins-CARMA	2022-10-07	2023-08-31	2024-08-31	2022-06-03	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	SDC COP 002/15/002	2016-11-07	2021-02	2021-02	2019-08-07	
Observational Model: |Time Perspective: p	5018	2005-08	2007-05	2012-12	2009-08-17	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER	CHRMS 16-227	2016-12	2023-02	2024-12	2016-12-06	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	Pro00042898	2015-05-10	2017-04-19	2020-02-07	2018-10-02	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: OTHER	IRB-1556587	2020-04-16	2021-09-08	2021-12-31	2020-04-17	
Observational Model: |Time Perspective: p	2007-0722	2009-01	2011-08	2011-08	2009-01-23	
Observational Model: |Time Perspective: p	0137-16-ASMC	2017-06	2017-12	2019-05	2017-06-09	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH	NEURO-ETT (Vanguard)	2017-02-01	2019-06-19	2022-01-31	2016-09-30	
Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT	USouthernDenmarkpsychology	2018-06-01	2021-06-01	2021-06-01	2019-08-29	
Observational Model: |Time Perspective: p	CCS-Low risk lifestyle-2017	2016-06	2017-12	2017-12	2017-07-31	
Observational Model: |Time Perspective: p	11928	2017-01-01	2022-06-01	2027-06-01	2020-05-29	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	CALGB-9335|U10CA031946|CDR0000063987	1994-12	2005-04	2005-08	2003-01-27	
Observational Model: |Time Perspective: p	TPS 68479	2019-04	2019-06	2019-06	2019-04-22	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	20-2552|14380	2020-09-29	2020-10-01	2020-10-01	2020-09-24	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	2021-0131	2021-06-01	2031-06-01	2031-06-01	2023-02-08	
Observational Model: |Time Perspective: p	4-2020-1093	2020-12-22	2022-12	2022-12	2020-12-19	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	KY2020-125	2021-10-05	2022-04-10	2022-04-10	2021-10-05	
Observational Model: |Time Perspective: p	114428|WEUKSTV4602	2010-12	2013-12	2013-12	2011-10-05	
Observational Model: |Time Perspective: p	XJTU1AF-CRF-2022-033	2022-11-01	2024-12-31	2024-12-31	2023-02-08	
Observational Model: |Time Perspective: p	14-191	2014-10-22	2020-09-02	2020-09-02	2014-10-24	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	2021P003093	2022-03-01	2023-12-31	2024-06-30	2022-01-27	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION	201210003	2013-02	2013-05	2013-05	2012-12-05	2015-01-26
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	-SRD 109037.00	2021-05-12	2021-12	2022-03	2021-04-01	
Observational Model: |Time Perspective: p	2012-0004	2014-04	2024-04		2012-06-25	

Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT	CCR3593	2012-02	2014-05	2014-05	2016-06-09	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	D6014C00006	2017-12-01	2019-01-22	2019-01-22	2017-11-07	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	OVERCOME|2007-006604-38|FIS EC07/90211	2008-04	2011-12	2012-03	2010-04-27	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	262180	2021-09-14	2024-06	2025-06	2019-04-29	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION	20161001	2018-03	2020-06	2020-12	2016-11-04	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	1177-04-806|20043031 and 20050866	2004-07	2008-03	2008-03	2007-09-17	
Observational Model: |Time Perspective: p	QianfoshanH-210118	2021-07-10	2022-04-01	2022-06-01	2021-12-08	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	CCHE -AML0001	2017-11-14	2021-11-01	2021-11-01	2018-01-04	
Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	2709001/90005	2011-09	2014-09	2014-09	2011-09-14	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER	CCMPNS	2017-09-01	2018-08-31	2019-02-28	2017-06-06	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE	4-2011-0904	2012-02	2013-06	2013-08	2013-05-20	
Observational Model: |Time Perspective: p	NIS-Celgene-JP-PMS-002	2015-04-30	2015-12-10	2015-12-10	2016-10-03	
Observational Model: |Time Perspective: p	1000032746	2012-12	2018-09	2018-09	2013-03-06	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC	2018/D/789	2018-11-01	2018-12-31	2018-12-31	2018-11-01	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	DBCG Proton trial	2020-06-01	2027-06-01	2037-06-01	2020-03-02	
Observational Model: |Time Perspective: p	2019-523	2019-12-01	2021-12-01	2021-12-01	2020-07-08	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: PREVENTION	CDC-OGDP-4444|U36/CCU319276-MM-0630|U50/CCU300860-TS-1216|U36/CCU319276-MM-0789	2005-09		2007-10	2005-09-14	
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE|Primary Purpose: TREATMENT	9425|COG-9425|CDR0000065359|P9425	1997-03	2004-10	2008-06	2004-05-26	
Observational Model: |Time Perspective: p	LAF-20220523	2022-07-15	2023-07-01	2023-12-01	2022-07-12	
Observational Model: |Time Perspective: p	G001-21	2021-06-02	2022-11-02	2022-11-30	2021-06-25	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	ACOTAS G-098	2022-01-27	2025-01	2025-01	2021-05-20	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	rosuva2020	2020-09-15	2023-09-15	2023-09-15	2022-04-21	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	atropinePEI	2003-10		2008-01	2007-12-18	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	OSSIGENA	2023-04-01	2024-10	2025-01	2023-02-08	
Observational Model: |Time Perspective: p	Cardiac MRI post RT Breast Ca	2012-03	2014-11	2014-12	2015-01-28	2018-08-23
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE	STUDY00007031-A|1R01AG006244	2020-04-23	2021-04-26	2022-09-26	2020-02-24	2022-04-26
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: SUPPORTIVE_CARE	CEP 2.373.269	2018-04-03	2020-04-03	2020-07-01	2018-11-09	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	CGI-068|NCI-2014-00717|CGI-068|P30CA006927	2015-03	2016-08	2016-08	2014-05-07	2017-12-13
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT	2009-0591	2011-01	2011-09	2011-09	2010-12-14	2012-04-24
Observational Model: |Time Perspective: p	10-096 CCMC	2011-11-15	2017-10-06	2023-05-31	2012-08-23	
Observational Model: |Time Perspective: p	CIC1421-19-05	2019-03-01	2025-03-01	2025-03-01	2019-03-20	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	HSL 2016-83	2018-02-15	2019-04-15	2020-02-16	2018-02-28	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: DIAGNOSTIC	409-07|P30CA036727|UNMC-40907	2007-11	2012-12	2013-02	2007-12-20	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	CDR0000064200|SWOG-9239|E-S9239|U10CA032102	1995-05	2003-11	2011-07	2004-06-22	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC	IJB 11-01|2011-000562-35	2011-03	2013-03	2016-03	2011-02-23	
Observational Model: |Time Perspective: p	UPCC 17119	2020-08-01	2025-04	2025-04	2020-04-24	
Observational Model: |Time Perspective: p	12-005362	2013-06	2015-09	2015-09	2014-03-13	
Observational Model: |Time Perspective: p	FP00024612	2020-01-30	2020-07-31	2020-07-31	2019-06-03	
Observational Model: |Time Perspective: p	GaCCoR-01	2004-01-01	2016-12-31	2016-12-31	2021-03-29	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	CSPC-DED-DLBCL-K08	2023-03	2023-08	2024-08	2023-03-21	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH	NEURO-ETT	2020-04-01	2023-01-01	2023-01-01	2020-03-02	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT	260320131980	2013-08	2023-07	2023-10	2013-12-09	
Observational Model: |Time Perspective: p	AB0002	2006-08	2009-12	2009-12	2008-01-10	
Observational Model: |Time Perspective: p	14-0315	2014-05	2016-03	2016-03	2014-05-06	
Observational Model: |Time Perspective: p	FIL_Lympho-Heart	2023-05-01	2023-12-31	2024-02-29	2023-04-19	
Observational Model: |Time Perspective: p	TSC 08-2018	2018-08-01	2022-12-30	2022-12-30	2016-01-13	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH	25-0592-P0001	2024-10	2027-10	2029-03	2023-06-12	
Observational Model: |Time Perspective: p	CS009	2019-10-12	2020-10-03	2020-10-03	2019-09-19	
Observational Model: |Time Perspective: p	2016-7017	2017-06-27	2065-12	2065-12	2020-05-20	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING	594	2020-07-17	2025-09-30	2025-09-30	2020-04-02	
Observational Model: |Time Perspective: p	R18045	2018-06-01	2020-12	2025-12	2020-02-07	
Observational Model: |Time Perspective: p	HS23428	2020-04-01	2021-02-01	2021-06-01	2020-03-27	
Allocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: PREVENTION	114		2005-03		1999-10-28	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	RESILIENCE-H2020	2022-01-18	2025-08	2026-05	2022-02-04	
Observational Model: |Time Perspective: p	2006-0921|NCI-2018-02471|2006-0921|P30CA016672	2007-09-12	2018-05-02	2018-05-02	2007-09-19	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	REaCT-HER TIME	2021-12-13	2023-09	2023-09	2021-06-16	
Observational Model: |Time Perspective: p	10000123|000123-CC	2020-11-19	2030-08-30	2030-08-30	2020-12-04	

Observational Model: |Time Perspective: p	CP-23001	2023-07-30	2030-07-30	2030-07-30	2023-04-27	
Observational Model: |Time Perspective: p	13115	2015-01	2016-01	2016-06	2014-05-12	
Observational Model: |Time Perspective: p	C20-01|2020-A01037-32/1	2022-03-01	2040-09-30	2040-09-30	2021-02-10	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	2016/1380	2018-06-11	2019-03-04	2020-03-04	2018-12-20	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE	114655	2012-09-19	2014-04-05	2014-04-05	2012-08-07	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	SCRX001-007	2016-09	2018-09-12	2018-09-12	2016-08-22	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: OTHER	AltoosiUC	2020-07-01	2020-12-30	2021-09-01	2020-07-08	
Observational Model: |Time Perspective: p	20/WIM/2021	2021-05-01	2024-05-01	2024-05-01	2021-04-30	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	KY20162034-1	2016-04	2022-08	2022-08	2016-06-28	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	2015-0835|NCI-2016-01921|2015-0835	2020-07-18	2023-07-30	2023-07-30	2016-11-11	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	AMEM-2014-MET001	2014-07	2018-05-23	2018-05-23	2015-06-15	2019-09-05
Observational Model: |Time Perspective: p	ShuangHoH	2021-07-01	2023-06-30	2023-06-30	2021-05-13	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	23-050	2023-06	2028-04	2028-04	2023-04-10	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	FBB-02-01-21	2023-01-13	2024-06	2024-09	2022-01-11	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	2007.489/32	2008-10	2014-09		2008-11-27	
Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION	TCU-CHHuang-BaduanjinLungCa	2020-11-26	2021-05-27	2022-11-27	2020-12-17	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	2013-A00929-36	2014-11	2018-11	2019-11	2014-03-05	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	STU 2019-1099	2019-12-17	2023-12	2023-12	2019-08-05	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	ABM/03/00012	2023-05	2028-01-01	2028-02-01	2022-03-08	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	18046	2017-07-01	2022-03-21	2022-03-21	2018-11-21	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	OSTEOCAN	2021-01-12	2023-01-12	2023-01-12	2021-01-22	
Observational Model: |Time Perspective: p	pheo	2011-08	2013-07	2013-07	2011-08-30	
Observational Model: |Time Perspective: p	81/22	2022-05-16	2024-05	2025-12	2022-06-10	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	CARTIER	2019-08-02	2024-08-02	2025-11-30	2018-10-18	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT	ICO	2019-06-01	2020-06-01	2020-12-31	2019-07-24	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	CR017452|CNTO328SMM1001	2010-10	2012-06	2014-03	2010-10-13	
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER	112855	2010-05-13	2012-04-12	2012-06-26	2010-04-23	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE	STUDY00010085|PG12840	2020-02-04	2021-12-31	2022-02-04	2020-02-19	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	N-20200094	2021-05-26	2024-01-01	2024-06-30	2021-08-09	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	FO409918	2019-10-03	2023-04-15	2025-04-15	2019-03-07	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	AC-005-IT	2015-02	2015-12	2015-12	2012-02-13	
Observational Model: |Time Perspective: p	10-487-A	2011-01-14	2023-11-14	2023-12-14	2011-01-21	
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH	Pro00043372|Pro00047666	2014-04-11	2017-10-31	2017-10-31	2013-10-08	2019-02-18
Observational Model: |Time Perspective: p	16022426	2017-01-17	2020-07-06	2020-07-06	2018-04-23	
Allocation: |Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT	CDR0000067263|NCI-99-C-0125I	2000-03	2006-12	2011-10	2003-01-27	
Observational Model: |Time Perspective: p	201401037RINB	2014-05	2014-11	2014-12	2014-04-25	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	2008BAI57B04	2008-12	2012-10		2012-10-02	
Observational Model: |Time Perspective: p	WEARIT|NCT05132673	2023-08	2025-07-01	2026-07-01	2021-11-24	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	CARHAB	2010-02	2012-10	2012-10	2010-02-19	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	042201|Pro2022000290	2022-09-19	2026-09-01	2027-03-01	2022-09-29	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	[2014]No.60	2016-07-27	2019-05-18	2019-06-25	2016-07-21	2020-02-18
Observational Model: |Time Perspective: p	H-16036250	2016-12-08	2017-07-06	2017-07-06	2016-11-01	2017-10-06
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	IRG 93-033	2007-05	2008-05	2009-02	2007-11-21	2010-01-18
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	2017-0937|NCI-2018-01108|2017-0937|P30CA016672	2018-09-19	2025-12-31	2025-12-31	2018-07-18	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	NCI-2012-00708|NCI-2012-00708|CDR0000728619|SARC-022|SARC 022|SARC022|8945	2012-03	2015-10	2015-10	2012-03-22	2016-11-18
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	111485	2009-03-19	2010-02-15	2010-02-15	2009-03-13	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH	301472	2023-04-01	2024-06-30	2024-12-31	2023-03-02	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER	MP-37-2023-8641	2023-04	2026-04	2027-04	2022-07-05	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT	J0275|03-02-10-12|P50AT000437	2004-06	2007-09	2007-09	2004-10-21	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC	IRB00020968|NCI-2012-01613|P30CA012197|CCCWFU 99112|R01CA167821|R21CA226960	2013-01-01	2022-03-08	2022-03-08	2012-11-01	2023-03-01
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	20-0537.cc|NCI-2020-06349	2020-07-15	2024-03-27	2025-03	2020-07-24	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE	STUDY00015800|R01AG078169	2023-07	2025-06	2027-03	2022-10-27	
Observational Model: |Time Perspective: p	9481	2015-07	2017-12	2018-12	2015-07-14	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	1R03CA119747	2007-02	2008-06	2008-12	2007-01-09	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	AC-015-IT	2020-07-22	2025-02-28	2025-02-28	2020-05-19	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	TV1011-TQT-108	2013-05	2013-12	2014-01	2013-06-11	
Observational Model: |Time Perspective: p	2018-418 6670	2019-08-20	2019-11-08	2019-11-08	2019-08-26	
Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: PREVENTION	1R01CA157824-01A1	2013-01	2014-04	2014-04	2013-02-01	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE	IRB00087763|4R33CA226960-03|WFBCCC 98622	2023-03-01	2023-07	2023-08	2022-10-27	
Observational Model: |Time Perspective: p	Comorbidities	2020-12-30	2021-05-29	2021-05-29	2020-12-17	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE	STUDY00007031-B|1R01AG006244	2021-07-26	2023-09-01	2025-08-01	2020-02-25	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	0670-19-RMC	2020-01-17	2023-01-17	2023-01-17	2019-12-02	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	MC1932|R01CA233610|NCI-2019-08427	2019-08-21	2024-12-31	2025-09-30	2019-03-19	

Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	CDR0000601334|CCCWFU-99108|CCCWFU-IRB-IRB00006209	2008-06	2009-05	2009-05	2008-08-05	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER	999907102|07-HG-N102	2007-02-19	2007-12-12	2007-12-12	2007-02-28	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE	16/CARD/18	2016-09	2019-08	2019-08	2016-10-20	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE	IIR 11-347	2013-06	2015-12	2016-04	2012-08-24	2017-01-06
Observational Model: |Time Perspective: p	14-110	2015-06-19	2023-09-27	2023-09-27	2019-07-29	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE	H-21039032	2022-04-01	2024-03-01	2024-09-01	2022-07-28	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	CORE	2018-04-01	2018-05-01	2018-05-01	2017-03-24	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER	Pro00091633|OLC-1609-36381	2018-08-01	2024-04-01	2024-05-01	2018-05-07	
Observational Model: |Time Perspective: p	UFPTI-1431-HL02|IRB201703302	2015-04	2021-04-14	2021-04-14	2015-04-01	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	1000035483	2013-09	2015-07	2015-07	2013-09-23	
Observational Model: |Time Perspective: p	MC1723|NCI-2019-07938|MC1723	2019-09-23	2023-09-23	2024-09-23	2019-12-03	
Observational Model: |Time Perspective: p	NIS-Celgene-JP-PMS-001a	2010-07-20	2013-03-29	2013-03-29	2016-10-03	
Observational Model: |Time Perspective: p	2020-08-06R	2020-10-30	2023-09	2023-09	2020-08-12	
Observational Model: |Time Perspective: p	D6874C00008	2007-12	2009-06	2009-06	2008-06-03	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	CRIMSON2	2023-04-14	2023-12-31	2024-06-30	2023-07-05	
Observational Model: |Time Perspective: p	GU-24167	2008-09	2011-05	2012-07	2008-06-25	
Observational Model: |Time Perspective: p	2017-01539	2018-01-01	2019-05-31	2019-05-31	2018-06-18	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	2008-0028	2008-06	2008-09	2008-09	2008-08-15	2009-03-03
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH	MPR 8756|CMS 500-95-0047(09	2000-09	2015-08	2016-12	2008-02-29	
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMEN	EC 2008/049	2008-02	2008-12	2009-02	2008-02-21	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	PROTHYM 2.2	2018-04-18	2026-04-01	2029-04-01	2021-03-30	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER	P/2014/231	2015-10	2019-05	2019-05	2015-12-10	
Observational Model: |Time Perspective: p	IRB00014375|CCCWFU 99312	2012-08	2015-02	2015-02	2012-11-01	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: DIAGNOSTIC	13297	2010-01	2011-04	2011-04	2010-01-15	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	13385|NCI-2014-00419|13385	2014-02	2015-04	2015-04	2014-03-04	
Observational Model: |Time Perspective: p	4336|R03HL048020	1992-04		1994-03	2000-05-26	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	Universidad Europea de Madrid	2022-09-15	2025-12-31	2026-03-31	2022-09-14	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	012018CONTROL	2019-01-01	2023-02-28	2023-02-28	2023-02-15	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	IRB00095005|WFBCCC 99123|P30CA012197	2023-08	2024-01	2024-02	2023-04-03	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	201702725	2017-05-23	2019-03-02	2019-03-02	2018-09-06	2019-05-07
Observational Model: |Time Perspective: p	11.50/intens11.01	2011-11	2013-06	2013-06	2014-01-24	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_	2021-K-Y-294-01	2021-01-01	2022-12-01	2023-12-01	2022-10-19	
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	2017-260	2017-11-01	2019-03-26	2019-03-26	2021-06-07	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	SNDX-275-0140	2016-08-24	2017-03-13	2017-03-13	2016-09-13	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC	2009P001846	2010-05	2010-11	2017-11	2010-04-19	
Observational Model: |Time Perspective: p	20751	2019-04-15	2020-01-31	2020-01-31	2019-04-05	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE	SCUSF 0806|SCUSF-0806|5U10CA081920-11	2010-03	2017-08	2018-11	2009-11-09	2021-01-12
Observational Model: |Time Perspective: p	2009P002147|1RC1LM010526	2009-09	2012-12	2014-12	2010-10-21	
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: DIAGNOSTIC	2010-0990|NCI-2011-01119	2011-06-16	2023-06-30	2023-06-30	2011-06-09	
Observational Model: |Time Perspective: p	2020-2-4023	2021-09-01	2022-06-30	2023-06-30	2022-01-20	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	AC-012-EU	2019-02-11	2022-05-30	2022-05-30	2018-03-22	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	30460114.5.0000.0068	2017-05-02	2018-11-30	2019-02-28	2019-03-21	
Observational Model: |Time Perspective: p	R06086M|2006-002065-39|2009-014542-29|R07110M|R07053M|R08012|R09103M|R10056|R06086M|R21(	2006-05-25	2025-12-31	2025-12-31	2012-12-05	
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	Breast-26159	2014-10	2017-02	2017-03	2014-01-31	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE	BCBSMF PSACO	2016-06	2017-01		2016-08-08	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	CDR0000660615|MDA-2007-0914A|CDR0000660615|NCI-2011-01466	2011-01-25	2020-01	2021-01	2009-12-15	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	1810-089-981	2019-02-20	2021-03-15	2021-12-31	2020-03-06	
Observational Model: |Time Perspective: p	22-10590-BO	2022-04	2023-04	2023-12	2022-03-28	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	2017-004909-41	2019-01-14	2024-09-14	2025-09-14	2018-11-30	
Observational Model: |Time Perspective: p	18-1511	2019-05-01	2020-07-02	2021-12-02	2019-03-22	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	15-002	2015-06-03	2022-04-30	2022-04-30	2019-05-07	
Observational Model: |Time Perspective: p	CRT00442|315046	2023-01-01	2024-01-01	2025-06-22	2022-07-25	
Observational Model: |Time Perspective: p	Cardiotoxicity study	2021-01-08	2021-06-01	2021-12-30	2021-07-15	
Observational Model: |Time Perspective: p	999995012|OH95-C-N012	1995-03-03	2020-09-04	2020-09-04	2006-06-21	
Observational Model: |Time Perspective: p	APHP191082|2019-A02411-56	2020-10-13	2022-06-07	2022-06-07	2020-01-29	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	03-295	2004-02	2007-10	2025-12	2005-09-14	
Observational Model: |Time Perspective: p	ACCEPT Study	2011-09	2015-03	2015-05	2011-05-30	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	UPCC12118	2019-08-09	2024-08-31	2024-12-31	2019-07-17	
Observational Model: |Time Perspective: p	B-1910-570-301	2020-09-01	2026-03-31	2026-03-31	2023-05-01	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	2019-00673; sp19Kurzeder	2020-07-08	2023-07	2023-09	2019-04-26	
Observational Model: |Time Perspective: p	NSD-17895|REK-267.07|DT-08/00230-2/RVB|Hdir-08/623-	1998-12	2020-12	2021-01	2008-05-05	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	MDV3800-14|C3441005	2016-10-13	2017-05-30	2017-06-22	2017-02-03	2018-05-24
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	0390-10-RMB_BRODOV	2011-01	2012-01		2010-11-11	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose:	AV-951-10-112	2010-10	2011-03	2011-07	2010-09-29	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	FirstHenanUST,cancer center	2015-10	2017-10	2019-12	2015-12-11	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	ID RCB : 2021-A01656-35	2021-11-15	2023-11-15	2024-11-15	2021-11-18	
Observational Model: |Time Perspective: p	RT2017-08	2017-08-01	2020-08-01	2022-11	2017-07-07	

Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	UPCC 25920|R21HL152148	2021-03-18	2025-06	2025-06	2021-02-03	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION	1122017	2016-11-15	2017-11-30	2017-12-05	2017-12-19	
Observational Model: |Time Perspective: p	COEXIST-2	2023-01-01	2023-06-15	2023-06-22	2023-07-11	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	44023	2013-09	2016-12	2016-12	2013-09-02	2017-11-28
Observational Model: |Time Perspective: p	SSY04070224	2022-11-10	2023-10-17	2024-03-31	2022-10-27	
Observational Model: |Time Perspective: p	NIS-Celgene-JP-PMS-004	2017-05-30	2023-09-27	2023-09-27	2017-04-04	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	1409500149	2014-11-06	2016-07-03	2016-07-03	2015-03-05	2023-01-31
Observational Model: |Time Perspective: p	CCHS	1976-01	2014-01		2016-12-15	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	PROICM 2021-09 COH|2021-A01524-37	2022-04-21	2023-06	2023-09	2022-01-20	
Observational Model: |Time Perspective: p	4192910|112/27.10.2011	2012-01-01	2016-10-30	2017-01-31	2012-07-17	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	A-BR-110-021	2021-05-05	2025-12-31	2025-12-31	2023-06-07	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	RECHMPL22_0513	2023-03-16	2025-03-16	2025-09-30	2023-03-23	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	20-5236.0	2021-01	2024-09	2024-12	2020-10-22	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION	MEDIRAD EARLY-HEART_1.2	2017-09-01	2020-10-01	2021-05-31	2017-09-29	
Observational Model: |Time Perspective: p	CDR0000613213|P30CA068485|VU-VICC-BRE-0767	2008-06	2015-03	2015-03	2009-04-03	
Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: HEALTH_SERVICES_RESEARCH	WSPan	2021-09-14	2022-02-14	2022-05-30	2022-06-07	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: DIAGNOSTIC	34816/7/19	2019-07-01	2021-07-01	2021-08-01	2021-11-10	
Observational Model: |Time Perspective: p	R-17-360	2018-01-11	2019-03-01	2020-03-01	2018-01-31	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SCREENING	4152	2023-06	2025-06	2026-06	2023-04-27	
Observational Model: |Time Perspective: p	STUDY00000442	2020-01-08	2025-12	2025-12	2021-12-30	
Observational Model: |Time Perspective: p	UPCC 12821	2021-10-27	2028-10	2028-10	2021-10-27	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING	0803009687|CICL670A US23T	2008-07-31	2013-03-29	2013-03-29	2008-09-09	
Observational Model: |Time Perspective: p	13-6543C	2013-10	2024-08	2027-01	2014-12-03	
Observational Model: |Time Perspective: p	No. XJTU1AF-CRF-2019-029	2015-01-01	2018-12-31	2018-12-31	2022-05-02	
Observational Model: |Time Perspective: p	4-2016-0730	2016-12-01	2025-01	2025-01	2017-10-04	
Observational Model: |Time Perspective: p	202100903	2022-09-01	2025-12-31	2026-12-31	2023-05-09	
Observational Model: |Time Perspective: p	KY2020-198	2020-02-20	2022-02	2022-02	2021-03-18	
Observational Model: |Time Perspective: p	UMCC 2014.151	2015-06	2017-07	2017-07	2015-07-10	
Observational Model: |Time Perspective: p	HALO Dx 001|WIRB Pr. No.: 20213955	2022-03-16	2027-03	2037-03	2022-06-21	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION	2021-012|ID-RCB	2022-10-27	2024-10-27	2024-10-27	2022-07-12	
Observational Model: |Time Perspective: p	2017000308	2009-01-05	2027-09	2027-09	2017-10-13	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE	PCORI-1234	2017-08-19	2019-03-01	2019-03-01	2017-04-25	
Observational Model: |Time Perspective: p	2012-A00003-40|2012/1386	2012-10	2013-01	2013-01	2015-02-06	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	SOLTI0702|2007-001428-11	2007-09	2011-02	2016-08	2007-11-27	

Observational Model: |Time Perspective: p	COMO-GMC	2000-01-01	2016-12-31	2020-01-31	2019-02-20	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION	COBC	2014-07	2020-02	2020-02	2015-10-08	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	2012-0379	2012-09-10	2017-09-10	2017-09-10	2015-09-07	2018-05-01
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	4-2016-0124	2016-05-31	2016-10-14	2016-10-14	2016-08-08	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER	PLC-1609-36277	2019-02-28	2022-04-01	2023-07-01	2018-07-05	
Observational Model: |Time Perspective: p	922042	2017-04-18	2020-12	2020-12	2017-05-16	
Observational Model: |Time Perspective: p	22-301	2024-01	2026-01-01	2028-01-01	2022-08-30	
Observational Model: |Time Perspective: p	15-017	2018-09-10	2024-07-10	2024-07-10	2016-01-28	
Observational Model: |Time Perspective: p	5011|R01HL058621	1998-06		2004-05	2000-05-26	
Observational Model: |Time Perspective: p	19-002489	1995-01-01	2020-11-10	2020-11-10	2019-05-07	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	296	2022-12-01	2023-12-31	2023-12-31	2022-12-09	
Observational Model: |Time Perspective: p	999911185|11-HG-N185	2011-05-29		2014-01-31	2011-06-09	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	147133|FS/CRTF/22/24395|312432	2023-06	2025-09	2025-09	2023-05-30	
Observational Model: |Time Perspective: p	134-22	2023-02-06	2026-05-30	2026-05-30	2022-05-09	
Observational Model: |Time Perspective: p	UPCC 09110	2010-07	2037-04	2037-04	2010-08-02	
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	2005-002995-13|S28720 UZ KUL	2006-01		2007-04	2006-01-31	
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER	20190401	2019-09-24	2020-03-14	2020-09-01	2019-07-30	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	DOX-0675014600011	2012-07	2015-01	2016-07	2016-12-21	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	154/2019	2019-12-02	2020-05-30	2024-02-25	2019-10-04	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	50880	2013-11	2015-07	2015-07	2013-09-18	
Observational Model: |Time Perspective: p	CALM2101	2022-03-01	2024-12	2025-12	2022-12-06	
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE|Primary Purpose: SUPPORTIVE_CARE	P9480|POG-9480|NCI-P97-0086|CDR0000065745	2000-09	2003-07	2007-03	2004-03-01	
Observational Model: |Time Perspective: p	IRBNet 1668650-1	2023-06-01	2025-05-31	2026-05-31	2023-06-22	
Observational Model: |Time Perspective: p	PRO09060055|KL2RR024154-04	2010-03	2013-06	2013-06	2010-03-03	
Observational Model: |Time Perspective: p	UPCC 04115	2015-06-02	2018-11-26	2018-11-26	2016-05-11	
Observational Model: |Time Perspective: p	GATTUM -1	2018-05	2019-12	2019-12	2018-05-23	
Observational Model: |Time Perspective: p	UW 11-289	2011-08	2012-07	2012-07	2011-08-12	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	MCC-13419|NCI-2011-0098	2011-08-11	2017-08-04	2018-01-19	2011-06-17	
Observational Model: |Time Perspective: p	COL-04	2020-10-08	2021-03-31	2021-11-30	2021-05-07	
Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT	CASE1518	2019-08-30	2022-01-27	2022-01-27	2019-01-28	
Observational Model: |Time Perspective: p	Pharmaco122020	2021-09-01	2023-09-01	2024-01-01	2021-01-06	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	NCI-2009-00464|NCI-2009-00464|CDR0000437097|CALGB-30406|CALGB-30406|U10CA180821|U10CA03	2005-08-15	2010-06-30	2017-11-28	2005-08-04	2013-10-07
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	69HCL19_0486|ID-RCB	2021-01-29	2024-01-29	2024-01-29	2020-03-31	
Observational Model: |Time Perspective: p	120023|12-HG-0023	2012-01-03			2011-12-23	
Observational Model: |Time Perspective: p	KEK251_07	2008-02	2008-12	2010-01	2008-05-15	
Observational Model: |Time Perspective: p	CREC 2019.152	2020-01-01	2050-12-01	2050-12-01	2021-01-12	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	88476	2023-02-07	2023-07-01	2024-02-01	2022-11-14	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	H12-00185	2014-05	2016-11	2016-11	2012-10-17	
Observational Model: |Time Perspective: p	NSCLC-Genetics	2020-07-01	2023-03-01	2023-04-01	2023-02-28	
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC	RC31/21/0026	2022-02-01	2024-02-01	2024-02-01	2022-01-27	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	NCI-2012-01872|ADVL0211|U01CA097452|CDR0000069387	2002-11	2005-10		2003-01-27	
Observational Model: |Time Perspective: p	0	2019-11-01	2021-05-31	2021-06-09	2021-05-18	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT	22-10545-AF	2022-11-28	2024-05-31	2024-10-31	2022-12-05	
Observational Model: |Time Perspective: p	2021-239	2022-09-01	2023-08-31	2025-08-31	2023-01-18	
Observational Model: |Time Perspective: p	PEDS-2021-29482	2023-10-01	2024-08-01	2024-08-01	2021-08-27	
Observational Model: |Time Perspective: p	JL-001	2008-01	2011-12	2012-06	2008-03-17	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC	2017-01|2017-001197-42	2018-04-09	2024-10	2025-03	2017-10-18	
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT	NCI-2012-01398|99H0185|U01CA076576|CDR0000067282	1999-08	2009-02		2003-10-29	

Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	2016152	2017-10-04	2022-12-31	2023-05-31	2017-08-29	
Observational Model: |Time Perspective: p	Cardiotox_001	2008-05	2011-09	2011-09	2008-05-19	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	2612-3681	2008-08	2009-08	2009-12	2008-07-29	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION	UW17-143	2017-07-01	2022-06-01	2022-06-01	2017-05-25	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT	JCOG9811|C000000030	1999-08	2006-11	2006-11	2005-08-22	
Observational Model: |Time Perspective: p	FEMH-IRB-102032-F	2013-07	2014-07	2016-07	2013-08-01	
Observational Model: |Time Perspective: p	4073	2014-10	2016-07	2016-07	2014-08-20	
Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT	CRN04894-04	2023-04	2026-04	2026-04	2023-04-07	
Observational Model: |Time Perspective: p	2018-185-Mch-EXP-4	2019-01-19	2021-11-30	2022-01-31	2021-10-18	
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION	CO-02GGade-01 - H|NW-02RRich-01	2002-04		2004-07	2006-05-15	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	Pro00106230	2023-06	2024-07	2025-07	2023-05-30	
Observational Model: |Time Perspective: p	2-049-18	2020-02-01	2030-08-30	2030-08-30	2020-07-13	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE	SUIR8687	2009-12	2011-06		2009-03-25	
Observational Model: |Time Perspective: p	17/ANAES/06	2018-04-30	2019-04-19	2019-08-01	2018-05-14	
Observational Model: |Time Perspective: p	UPCC 13519	2020-09-14	2025-09	2028-09	2020-03-12	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE	MCC-21-18830|HM20023601	2022-03-09	2024-06-30	2024-06-30	2022-01-18	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	10000657|000657-C	2022-09-21	2024-07-01	2024-10-01	2022-05-05	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE	FMASU M D 389/2019	2020-01-15	2021-09-15	2021-10-15	2021-10-14	
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC	CTO-IUSCCC-0807	2023-08-01	2025-12-31	2026-12-31	2023-05-30	

Last Update Posted	Locations	Study Documents
2019-03-13		
2023-05-15	Children's Hospital of Alabama, Birmingham, Alabama, 35233, United States|Phoenix Childrens Hospital, Phoenix, Arizona, 85016, United States|Banner University Medical Center - Tucson, Tucson, Arizona, 85719, United States|Arkansas Children's Hospital, Little Rock, Arkansas, 72202-3591,	
2010-06-25	Addenbrooke's Hospital, Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom	
2021-12-08	Valley Medical Center, Renton, Washington, 98055, United States|UW Medicine - Harborview Medical Center, Seattle, Washington, 98104, United States|University of Washington Medical Center - Northwest, Seattle, Washington, 98133, United States|University of Washington Medical Center -	
2020-11-19	University Hospital Göttingen Center of Palliative Medicine, Göttingen, Hessen, 37075, Germany|Study Center Palliative Medicine, Cologne, NRW, 50937, Germany|Hospital Essen- Mitte, Departement of Palliative Medicine, Essen, NRW, 45136, Germany	
2019-04-02	Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, SP, 01246000, Brazil	
2023-04-28	University of Chicago, Chicago, Illinois, 60637, United States	
2014-09-16	Medical University of South Carolina, Charleston, South Carolina, 29425, United States|University of Washington; Harborview Medical Center, Seattle, Washington, 98104, United States|Veteran's Affairs Puget Sound HCS, Seattle, Washington, 98108, United States|University of Washington; UW	
2007-02-27		
2018-08-28	Helsinki University Central Hospital, Helsinki, 00029, Finland	
2023-04-04		
2021-11-03	CHR d'Orleans, Orléans, 45067, France	
2020-10-22	Sakakibara Heart Institute, Fuchu, 183-0003, Japan|The Cancer Institute Hospital for Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan	
2016-07-06	Hôpital Cochin, Paris, 75679, France	
2022-07-28	City of Hope Medical Center, Duarte, California, 91010, United States	
2013-03-08	Herlev Hospital, Copenhagen, 2730, Denmark	
2014-10-10	Kvinneklinikken, Rikshospitalet-Radiumhospitalet HF, Oslo, Norway	
2019-05-15	Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States	Study Protocol and Statistical Analysis Plan|Informed Consent Form
2021-08-02	Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom	
2012-11-21	Duke University Medical Center, Durham, North Carolina, 27710, United States	
2023-03-31	21, Basel, Switzerland|9, Basel, Switzerland|1, Bern, Switzerland|15, Biel, Switzerland|19, Brugg, Switzerland|18, Gossau, Switzerland|11, Kreuzlingen, Switzerland|12, Kreuzlingen, Switzerland|8, Kreuzlingen, Switzerland|5, Liestal, Switzerland|20, Opfikon, Switzerland|16, Rheinfelden, Switzerlar	
2019-05-13		
2023-07-11	National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States	
2019-03-29	The First Affiliated Hospital of Guangzhou MC, Guangzhou, Guangdong, 510120, China	
2013-09-24	Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, 30322, United States|Ann & Rober H Lurie Children's Hospital of Chicago, Chicago, Illinois, 60611, United States|Riley Hospital for Children, Indianapolis, Indiana, 46202-5225, United States|Dana-Farber Cancer Institute, Boston, Ma	
2022-02-08	Toronto General Hospital, Toronto, Ontario, M5G 2N2, Canada	
2023-01-25	Kirsten Ness, Memphis, Tennessee, 38105, United States	Study Protocol and Informed Consent Form
2023-05-17	Gustave Roussy, Villejuif, Val De Marne, 94805, France|Hôpital Bichat, Paris, France|Hôpital Trousseau, Paris, France	
2022-09-16	Memorial Sloan - Kettering Cancer Center, New York, New York, 10021, United States	
2013-09-18	Deutsches Herzzentrum München, Munich, Bavaria, 80636, Germany	
2020-06-18	Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, 30322, United States	
2023-01-04	Anqing Municipal Hospital, Anqing, Anhui, 246003, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, 100021, China|Penking University Shougang Hospital, Beijing, Beijing, 100144, China|Chinese PLA General Hospital, Beijing, Beijing, 100853, China|The Fourth Hc	
2023-05-06	Eastern Cooperative Oncology Group, Boston, Massachusetts, 02215, United States	
2023-03-03	The National Research Centre for the Working Environment, Copenhagen, 2100, Denmark	
2020-07-16		
2022-11-03	University of California San Diego Medical Center, San Diego, California, 92037, United States	
2023-07-11	National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States	
2016-06-08	GSK Investigational Site, Detroit, Michigan, 48202, United States|GSK Investigational Site, Lebanon, New Hampshire, 03756, United States|GSK Investigational Site, Durham, North Carolina, 27710, United States|GSK Investigational Site, Salt Lake City, Utah, 84112, United States	
2018-08-21	Indiana University Health Hospital, Indianapolis, Indiana, 46202, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, 46202, United States	
2020-11-05	Stanford University School of Medicine, Stanford, California, 94305, United States|University of Florida-Department of Medicine, Gainesville, Florida, 32610, United States|University of Miami-Interdiciplinary Stem Cell Institute	Informed Consent Form|Study Protocol and Statistical Analysis Plan
2022-03-02	Institute of Preventive Pediatrics, Department of Sport and Health Sciences, Technical University of Munich, Germany, Munich, 80992, Germany	
2016-08-19	Kirurgisk Klinikk-Anestesi, Haugesund, Rogaland, 5504, Norway	
2022-12-02	Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States	
2023-02-16	Diakonessenhuis, Utrecht, 3582 KE, Netherlands|UMC Utrecht, Utrecht, 3584CX, Netherlands	

2022-08-16	University of Ottawa Heart Institute, Ottawa, Ontario, K1Y 4W7, Canada	
2022-07-12	Memorial Sloan Kettering West Harrison, Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States	Study Protocol and Statistical Analysis Plan
2022-11-02	Turku University Hospital, Turku, 20520, Finland	
2019-10-09	Aarhus University Hospital, Aarhus, Jutland, 8000, Denmark	
2023-05-09	UT Southwestern - Advanced Imaging Research Center, Dallas, Texas, 75390, United States	
2014-01-01	Taipei Medical University WanFang Hospital, Taipei, 116, Taiwan	
2017-04-28	Brigham and Women's Hospital, Boston, Massachusetts, 02120, United States	
2022-11-22	University of Nebraska Medical Center, Omaha, Nebraska, 68198-7680, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, 10016, United States|OHSU Knight Cancer Institute, Portland, Oregon, 97239, United States	
2019-03-01	Univerisity of Florida, Gainesville, Florida, 32610, United States	
2012-05-14	Tacoma, Washington, 98418, United States	
2021-03-05	University of Rochester Medical Center, Rochester, New York, 14642, United States	
2016-06-23		
2021-12-16	Gillian Lamoury, St Leonards, New South Wales, 2065, Australia	
2016-11-11	University of Tromsø, Tromsø, 9037, Norway	
2022-10-25	Brigham and Womens' Hospital, Boston, Massachusetts, 02421, United States	
2023-05-09	Eurasian Association of Therapists, Moscow, 101000, Russian Federation	
2021-09-09	King's College Hospital NHS Foundation TRUST, London, SE5 9RS, United Kingdom	
2014-11-05	Royal Prince Alfred Hospital, Sydney, New South Wales, 2050, Australia|Royal North Shore Private Hospital, Sydney, New South Wales, 2065, Australia|Sydney Haematology Oncology Clinic, Sydney, New South Wales, 2077, Australia|Concord Hospital, Sydney, New South Wales, 2137, Australi	
2022-12-19	Shanghai Pudong Hospital, Shanghai, China	
2014-05-02	Rambam MC, Haifa, Israel	
2020-09-14	University of Pennsylvania/Smilow Center for Translational Research, Philadelphia, Pennsylvania, 19104-5159, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States	
2017-11-06	Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Complejo Hospitalario San Pedro de Alcántara, Cáceres, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Centr	
2023-06-23	Stanford University, Palo Alto, California, 94305, United States	
2012-06-13		
2023-06-26	Rigshospitalet, Copenhagen, 2100, Denmark	
2023-03-20	Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, 19107, United States	
2019-10-25	University of British Columbia Breast Cancer Research Exercise Gym, Vancouver, British Columbia, V5Z 4C2, Canada	
2016-12-08	Clinical Oncology Department, West Pomeranian Cancer Center, Szczecin, West Pomeranian, 71-730, Poland|Collegium Medicum of Jagiellonian University, Cracow, 31-513, Poland|Pomeranian Medical University, Department of Cardiology, Szczecin, 70-111, Poland	
2023-03-06	University of Edinburgh, Edinburgh, Scotland, NE7 7EY, United Kingdom	
2021-08-16	Brigham & Women's Hospital, Boston, Massachusetts, 02120, United States|Penn State Milton S. Hershey Medical Center / Penn State College of Medicine, Hershey, Pennsylvania, 17033, United States	
2006-10-11	Metropolitan Jewish Health System, Brooklyn, New York, 11220, United States	
2017-01-25	Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, 03722, Korea, Republic of	
2019-07-29	University Hospital Zurich, Division of Dermatology, Zurich, 8091, Switzerland	
2023-01-18	ICM, Montpellier, Hérault, 34298, France	
2017-12-19		
2023-02-27	Lindenhofgruppe, Bern, 3001, Switzerland|University Clinic for Cardiology, Bern, 3010, Switzerland|Bürgerspital Solothurn, Solothurn, 4500, Switzerland|Spital STS AG, Thun, 3600, Switzerland	
2012-10-25	Roybal Comprehensive Health Center, Los Angeles, California, 90022, United States	
2017-02-09	European Institute of Oncology, Milan, Italy|Istituto Scientifico San Raffaele del Monte Tabor IRCCS, Milan, Italy	
2013-08-26	Long Beach Memorial Medical Center, Long Beach, California, 90806, United States|Children's Hospital Los Angeles, Los Angeles, California, 90027-0700, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, 90095-1781, United States|Children's Hospital of O	
2019-05-21	Northwell Health, Lake Success, New York, 11042, United States	
2021-06-07	Stanford Children's Health, Palo Alto, California, 94304, United States	
2014-12-02	Medisch Centrum Alkmaar, Alkmaar, Netherlands|Flevoziekenhuis, Almere, Netherlands|The Netherlands Cancer Institute, Amsterdam, 1066 CX, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Slotervaart Hospital, Amsterdam, Netherlands|Wilhelmina Ziekenhuis, Assen, Net	
2023-07-06	Galway University Hospital, Galway, H91 T861, Ireland|Galway Clinic, Galway, Ireland|Mayo University Hospital, Mayo, Ireland|Sligo General Hospital, Sligo, Ireland	
2022-10-18	University of Minnesota, Minneapolis, Minnesota, 55455, United States	
2012-03-16	Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, 30322, United States	
2016-02-10		
2020-06-09	Assistance Publique Hôpitaux de Paris - Centre Université de Paris, Paris, 75015, France	
2023-04-13	AP-HP, Pitié-Salpêtrière Hospital,Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM., Paris, 75013, France	
2022-12-29	Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, 200025, China	
2023-02-06	Olga Salazar, Hartford, Connecticut, 06106, United States	
2020-02-20	Research Site, Baltimore, Maryland, 21225, United States	
2020-05-28		
2022-09-08	Uz Brussel, Brussels, Brussel, 1090, Belgium	
2020-09-29	Oncology Unit, Hospital Andrea Tortora, Pagani, Salerno, 84016, Italy|Oncology Unit, Ospedale Andrea Tortora, Pagani, Salerno, 84016, Italy	
2021-02-25	St. Joseph's Healthcare Hamilton, Hamilton, Ontario, L8N 4A6, Canada	
2023-04-05	Gabrail Cancer Center Research, Canton, Ohio, 44718, United States|NEXT Oncology, Austin, Texas, 78758, United States|NEXT Oncology, San Antonio, Texas, 78229, United States	
2016-07-29		
2022-08-31	Toronto Rehabilitation Institute, Toronto, Ontario, Canada	
2019-10-09	Imperial College Hammersmith Campus, London, W12 0NN, United Kingdom	
2023-02-06	Olga H Toro-Salazar, Hartford, Connecticut, 06106, United States	
2022-05-03		
2023-06-01	University of Alberta, Edmonton, Alberta, T6G2X8, Canada	
2012-08-01	U.T.M.D. Anderson Cancer Center, Houston, Texas, 77030, United States	
2023-01-26	Hartford Healthcare Cancer Institute @ Hartford Hospital (Data collection only), Hartford, Connecticut, 06102, United States|Memorial Sloan Kettering Cancer Center @ BaskingRidge (Consent and follow-up only), Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monr	
2020-04-07	Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States	
2022-09-13	Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States	
2021-08-26	CHU Amiens - Picardie, Amiens, France|CHU CAEN, Caen, France|Chu Clermont-Ferrand, Clermont-Ferrand, 63003, France|Chu Dijon, Dijon, 21079, France|Médipôle Lyon - Villeurbanne, Décines-Charpieu, France|Chu Grenoble, Grenoble 9, 38043, France|CHRU Lille - Salengro, Lille, 59000, F	

2023-06-01	AZ Sint-Vincentius Deinze, Deinze, East-Flanders, 9800, Belgium|Algemeen Ziekenhuis Maria Middelares, Ghent, East-Flanders, 9000, Belgium|AZ Sint-Elisabeth Zottegem, Zottegem, East-Flanders, 9620, Belgium|Antwerp University Hospital, Antwerp, 2650, Belgium	
2015-07-07	State University Of Campinas, Campinas, Sao Paulo, 13083-887, Brazil|Dante Pazzanese Institute of Cardiology, São Paulo, 04012-909, Brazil	
2020-03-16	Radboud University Medical Center, Nijmegen, 6500 HB, Netherlands	
2011-01-28	General Hospital of Chalkida, Chalkida, Evoia, 34100, Greece	
2022-12-06	St. Boniface Hospital, Winnipeg, Manitoba, R2H 2A6, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, B3H 1V8, Canada	
2022-06-27	Sanford Health, Sioux Falls, South Dakota, 57104, United States|Online Patient Enrollment System, Sydney, Australia	
2022-03-21	Prince of Wales Hospital, Hong Kong, Shatin, 0000, Hong Kong	
2023-05-17	St. Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States	
2014-08-20	Fudan University Cancer Hospital, Shanghai, Shanghai, 200032, China	
2021-02-18	University of Colorado Hospital, Aurora, Colorado, 80045, United States	Study Protocol|Informed Consent Form
2023-01-27	Clinics of the Samara Medical University, Samara, Samara Region, 443079, Russian Federation	
2008-01-14	Department of Cardiothoracic Surgery, Rigshospitalet, Copenhagen, 2100, Denmark	
2019-12-20	Alaska Native Medical Center, Anchorage, Alaska, 99508, United States|Arkansas Children's Hospital, Little Rock, Arkansas, 72202, United States|University of California at San Diego Medical Center, La Jolla, California, 92093, United States|Axis Clinical Trials, Los Angeles, California, 90036, U	
2015-11-09	Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States	
2022-10-28	Cleveland Clinic Florida, Weston, Florida, 33331, United States	
2022-12-15	the Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China	
2012-06-15		
2020-09-17	University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Rhineland-Palatinate, 55131, Germany	
2023-06-15	Russell Medical Center, Alexander City, Alabama, 35010, United States|Anderson Regional Medical Center, Meridian, Mississippi, 39301, United States|Highland Community Hospital, Picayune, Mississippi, 39466, United States|Aiken Regional Medical Center, Aiken, South Carolina, 29801, Unit	
2022-11-07	Massachusetts General Hospital Cancer Center, Boston, Massachusetts, 02114, United States	
2022-10-07	Fakultní nemocnice Královské Vinohrady, Praha, Praha 10, 10034, Czechia|Nemocnice Na Homolce, Praha, Praha 5, 15030, Czechia|Všeobecná fakultní nemocnice v Praze, Praha 2, Praha, 12808, Czechia|Nemocnice Rudolfa a Stefanie Benešov, Benešov, 25601, Czechia|Nemocnice Jihlava, Ji Universitario Gregorio Marañón, Madrid, 28009, Spain|Hospital Universitario Clinico San Carlos, Madrid, 28040, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Virgen de la Victoria, Málaga, 29010,	
2016-06-02	The University of Arizona Cancer Center, Tucson, Arizona, 85719, United States|Yuma Regional Cancer Center, Yuma, Arizona, 85364, United States	
2017-10-03	University of Florida, Institute for Child Health Policy, Gainesville, Florida, 32608, United States	
2017-02-10	University of Southern California, Los Angeles, California, 90089, United States|Huntington Hospital, Pasadena, California, 91105, United States	
2023-04-18	Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan	
2017-04-24	University of Ottawa Heart Institute, Ottawa, Ontario, K1Y 4W7, Canada	
2020-08-04		
2007-01-26	For additonal information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Minneapolis, Minnesota, United States	
2023-04-07	Washington University School of Medicine, Saint Louis, Missouri, 63110, United States	
2018-03-21	Centro per lo Studio e la Cura delle Amiloidosi Sistemiche - Fondazione IRCCS Policlinico S.Matteo, Pavia, 27100, Italy	
2022-03-08	University Hospital Augsburg, Augsburg, Bavaria, 86156, Germany	
2012-12-20	Federal University of Espirito Santo, Vitoria, Espirito Santo, 29045-402, Brazil|Hospital das Clinicas. University of São Paulo, Sao Paulo, 05403-000, Brazil	
2022-05-10	Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, 20010, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, 20057, United States	Study Protocol and Statistical Analysis Plan
2018-05-15	National Heart, Lung, and Blood Institute, Bethesda, Maryland, 20892-1061, United States|University of British Columbia, Department of Medical Imaging, Vancouver, British Columbia, Canada|Ludwig-Maximilians-Universitaet Muenchen, Medizinische Klinik I, Munich, Bavaria, 808303, German	
2023-05-22	UMCG, Groningen, 9713GZ, Netherlands	
2012-08-01	U.T.M.D. Anderson Cancer Center, Houston, Texas, 77030, United States	
2023-04-05	Rigshospitalet, Copenhagen, 2100, Denmark	
2012-09-18	Ochsner Medical Center - Kenner, Kenner, Louisiana, 70065, United States	
2022-10-03	Service de Cardiologie, Centre Hospitalier Universitaire Trousseau, Tours, 37000, France	
2021-07-14	Peking University Third Hospital, Peking, Beijing, 100191, China	
2016-05-13	National Guard Health Affairs, Riyadh, 11426, Saudi Arabia	
2020-11-17	St. Boniface Albrechtsen Research Centre, Winnipeg, Manitoba, R2E1J7, Canada	
2022-11-10	Indiana University, Indianapolis, Indiana, 46202, United States	
2021-04-05	The University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|Palo Alto Medical Foundation Research Institute, Palo Alto, California, 94301, United States|Howard University, Washington, District of Columbia, 20060, United States|University of Florida Department of Ag	
2023-05-24		

2023-02-15	Future Genetics, The Science Centre, Wolverhampton Science Park, Wolverhampton, West Midlands, WV10 9RU, United Kingdom	
2019-10-24		
2022-04-25	Tanta university, Tanta, El-Gharbyia, 13511, Egypt	
2014-06-18	European Institute of Oncology, Milan, 20141, Italy	
2016-02-09	University of Alberta/ Cross Cancer Institute, Edmonton, Alberta, Canada	
2019-04-05	City of Hope, Duarte, California, 91010, United States|Stanford Cancer Institute (SCI), Stanford, California, 94305, United States|Colorado Blood Cancer Institute, Denver, Colorado, 80218, United States|Mayo Clinic, Jackson	Study Protocol|Statistical Analysis Plan
2005-09-20	McMaster University and Hamilton Health Sciences Corporation, Hamilton, Ontario, L8L 2X2, Canada	
2017-07-12	Odette Cancer Centre/Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|St. Michael's Hospital, Toronto, Ontario, M5B 1W8, Canada	
2021-07-13	University of Waterloo, Waterloo, Canada	
2015-06-30	Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, 19104, United States	
2016-01-05		
2023-01-12	OLV ZIEKENHUIS AALST - Cardiology, Aalst, Belgium|AZ IMELDA - Cardiology, Bonheiden, Belgium|AZ ST-JAN - Cardiology, Brugge, Belgium|Hôpital Erasme - Cardiology, Brussels, Belgium|UCL Cliniques universitaires Saint-Luc - Cardiolgy, Brussels, Belgium|UZ Brussel - Cardiology, Brussel Italy|Ospedale Giovanni Bosco - Sc Cardiologia, Torino, TO, 10155, Italy|Ospedale Ss. Vito E Spirito - U.O.S. Di Cardiologia, Alcamo, TP, 91011, Italy|Azienda Ospedaliera Santa Maria - S.C. Di Cardiologia, Terni, TR, 05100, Italy|Asui Trieste - S.C. Centro Cardiovascolare, Trieste, TS, 34125, Italy	
2020-04-10		
2021-08-27		
2022-07-19	SC Ematologia - AOU Città della salute e della Scienza di Torino, Torino, 10126, Italy	
2019-07-08		
2020-06-17	Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States	Informed Consent Form
2022-03-23	Institut Paoli Calmettes, Marseille, 13009, France	
2023-07-06	the Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China	
2014-06-26	Katholieke Universiteit Leuven, Leuven, Belgium|University Hospital Bonn, Bonn, Germany|Medical University of Pecs, Pecs, Hungary|Radboud University Medical Centre Palliative consultation team, Nijmegen, Gelderland, Netherlands|Lancaster General Hospital, Lancaster, United Kingdom	
2023-01-20	Medical University of South Carolina, Charleston, South Carolina, 29425, United States	Study Protocol and Statistical Analysis Plan|Informed Consent Form:
2008-04-02	Chicago Prostate Center, Westmont, Illinois, 60559, United States	
2019-12-04	MAASTRO clinic, Maastricht, Limburg, 6229 ET, Netherlands|Maastricht University Medical Center, Maastricht, Limburg, 6229 HX, Netherlands	
2013-06-06		
2019-11-19	Sarcoma Oncology Research Center, Santa Monica, California, 90403, United States|University of Colorado Cancer Center, Aurora, Colorado, 80045, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|The University of Texas MD Anderson Cancer Center,	
2022-10-03	Children's Hospital of Alabama, Birmingham, Alabama, 35233, United States|Phoenix Childrens Hospital, Phoenix, Arizona, 85016, United States|Arkansas Children's Hospital, Little Rock, Arkansas, 72202-3591, United States|Kaiser Permanente Downey Medical Center, Downey, California, 902	
2016-03-22	Durham VA Medical Center HSR&D COE, Durham, North Carolina, 27705, United States	
2022-06-06	Aarhus University Hospital, Aarhus, Denmark|Herlev University Hospital, Herlev, Denmark|Odense University Hospital, Odense, 5000, Denmark	
2021-03-10	Riverview Health Centre, Winnipeg, Manitoba, R3L2P4, Canada	
2015-12-14	Michael E DeBakey VA Medical Center, Houston, Texas, 77030, United States	
2023-07-11	William F Gourash, Pittsburgh, Pennsylvania, 15213, United States	
2017-04-28	Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States	
2022-05-20	Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, 43210, United States	
2020-08-25	Professor, Department of Anesthesiology and Pain Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, 03722, Korea, Republic of	
2022-08-01	Istituto di Ricovero e Cura per Anziani, Ancona, Italy|Maastricht University Medical Center, Maastricht, Netherlands|Hospital Reina Sofía, Córdoba, Andalucía, 14004, Spain|Hospital San Joan de Deu, Esplugues De Llobregat, Catalunya, 08950, Spain|Hospital Parc Taulí, Sabadell, Catalunya, 082	
2018-08-15	Institute of Neuroscience and Physiology, Sahlgrenska Academy, Göteborg University, Göteborg, 40530, Sweden	
2020-07-08	Universitair Ziekenhuis Brussel, Jette, 1090, Belgium	
2022-09-06	Hospital Universitari Vall d'Hebron, Barcelona, Spain	
2019-03-21	China National Center for Cardiovascular Diseases, Beijing, Beijing, 100037, China	
2020-09-10	Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, 98109, United States	
2018-06-14	Department of Anesthesia and Pain medicine.National Cancer Institute, Cairo, 11796, Egypt	
2019-06-19	The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, 21205, United States	
2021-05-07	University of Colorado Boulder, Boulder, Colorado, 80303, United States	
2023-03-17	Akershus University Hospital, Lørenskog, Akershus, 1478, Norway	
2014-12-01	Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States	
2022-11-03	University Hospital Ostrava, Ostrava, Moravian-Silesian Region, 70852, Czechia|AGEL Podlesí Hospital Třinec, Třinec, Moravian-Silesian Region, 73961, Czechia	
2022-10-05	Beijing Tian Tan Hospital, Capital Medical University, Beijing, Beijing, 100070, China	
2017-11-13	GSK Investigational Site, Scottsdale, Arizona, 85259, United States|GSK Investigational Site, Memphis, Tennessee, 38120, United States|GSK Investigational Site, Nashville, Tennessee, 37203, United States|GSK Investigational Site, San Antonio, Texas, 78229, United States|GSK Investigational	
2010-06-29	Research Site, Cheonan, Chungcheongnam-do, Korea, Republic of|Research Site, Chuncheon, Gangwon-do, Korea, Republic of|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Research Site, Pohang, Gyeongsangbuk	
2023-05-10	Luciana de Souza Santos, Sao Paulo, SP, 05403-900, Brazil	
2015-06-15	Vestre Viken HF, Drammen Hospital and The Hospital of Vestfold, Drammen and Tønsberg, Buskerud and Vestfold, N-3004, Norway	
2022-11-21	Bone Marrow Transplant Clinic,The Ottawa Hospital, General Campus, Ottawa, Ontario, Canada	
2015-07-22		
2022-02-15	AHEPA University Hospital, Thessaloniki, 54636, Greece|Theagenio Cancer Hospital, Thessaloniki, Greece	
2018-06-19	Clinique Pasteur, Toulouse, 31300, France	
2012-05-08	Graduate School of Medicine, Osaka City University, Osaka, 545-8585, Japan	
2023-04-06	Duke Cancer Center, Durham, North Carolina, 27710, United States|Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, 27157, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, 23298, United States	
2019-08-09	Hospital of the University of Munich, Department of Palliative Medicine, Munich, Bavaria, 81377, Germany	
2016-09-23	Ospedale San Lazzaro - ASL CN 2 Alba Bra, Alba, Cuneo, 12051, Italy|Fondazione del Piemonte per l' Oncologia - IRCCS Candiolo, Candiolo, Turin, 10060, Italy|AO Ordine Mauriziano di Torino, Turin, 101028, Italy|AOU Città della Salute e della Scienza di Torino - Presidio Molinette - Oncologia	
2023-02-22	CIUSSS Ouest de l'ile de Montreal - St-Mary's Hospital, Montréal, Quebec, H3T 1M5, Canada|CIUSSS de l'Est-de-l'Île-de-Montréal - Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Montreal Heart Institute, Montréal, Quebec, Canada	
2022-09-22	Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China	Study Protocol and Statistical Analysis Plan|Informed Consent Form
2018-01-10	University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States	
2022-02-28	Odense University Hospital, Odense C, 5000, Denmark	
2022-08-03	Froedtert Hospital and Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States	
2020-11-04	Harborview Medical Center, Seattle, Washington, 98104, United States|University of Washington Medical Center, Seattle, Washington, 98195, United States	

2009-11-25		
2019-06-07	CHU Bordeaux University Hospital, Bordeaux, 33076, France	Study Protocol and Statistical Analysis Plan
2023-07-17	NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina, United States	
2020-06-04		
2012-03-16	Children's Healthcare of Atlanta, Atlanta, Georgia, 30322, United States	
2020-04-15	University College London Hospitals, London, WC1E 6BT, United Kingdom	
2014-10-16	Institut of oncology Ljubljana, Ljubljana, 1000, Slovenia	
2017-05-31	University or Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, 72205, United States	
2020-06-01	Xiao-Fan Zhu, Tianjin, Tianjin, 300000, China	
2021-12-16	St Bartholomews Hospital, London, EC1A 7BE, United Kingdom	
2017-07-28	Centre François Baclesse, Caen, 14076, France|Centre Georges-François Leclerc, Dijon, France|Clinique du Bois, Lille, France|CHU de NANCY, Nancy, 54511, France	
2013-06-12	Leiden University Medical Center, Leiden, Zuid-Holland, 2300WB, Netherlands	
2020-01-22	National Cancer Center, Beijing, China	
2017-04-06	Rikshospitalet-Radiumhospitalet, Oslo, 0027, Norway	
2022-07-08	University of Florida Proton Therapy Institute, Jacksonville, Florida, 32206, United States	
2022-08-05	Mayo Clinic Cancer Research Consortium, Rochester, Minnesota, 55905, United States	
2014-05-08	Far Eastern Memorial Hospital, New Taipei City, 220, Taiwan	
2023-03-27		
2013-03-11		
2017-05-30	I Department of Anaesthesiology and Intensive Care, Medical University of Warsaw, Warsaw, 02-005, Poland	
2017-05-23	Seoul St. Mary's hospital, Seoul, 06591, Korea, Republic of	
2022-08-15	Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada	
2022-10-13	Ummc Msgccc, Baltimore, Maryland, 21201, United States	
2014-11-07	University Hospital Bordeaux, Bordeaux, 33075, France	
2011-04-27	Mayo Clinic, Rochester, Minnesota, 55905, United States	
2018-02-05	Heart Institute University of Sao Paulo, Sao Paulo, 05403-000, Brazil	
2021-09-30	Royal Free London NHS Foundation Trust, London, NW3 2QG, United Kingdom	
2018-08-27	Seoul National University Bundang Hospital, Seongnam, Gyounggi, 463-707, Korea, Republic of	
2022-12-02	Sanguine Biosciences, Waltham, Massachusetts, 02451, United States	
2020-10-05	Many locations, Multiple Locations, Italy	
2016-05-12	University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill, North Carolina, 27599, United States	
2022-02-10	Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Boston Children Hospital, Boston, Massachusetts, 02115, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02115, Unite	Study Protocol and Statistical Analysis Plan|Informed Consent Form
2023-07-06	AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM., Paris, 75013, France|CIC Paris-Est, Paris, 75013, France	
2023-03-09	Department of Woman and Child Health and Public Health, Fondazione Policlinico A. Gemelli, IRCCS, Roma, 00168, Italy	
2014-11-20	Taichung Tzu Chi Hospital, Taichung City, 427, Taiwan	
2022-09-21	Hospital Sirio Libanes, São Paulo, Sao Paulo, 01308-050, Brazil	
2022-06-02	Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States	
2021-06-03	Reina Sofia University Hospital, Cordoba, 14001, Spain	
2015-07-14		
2008-04-09	Parker, Rosenman, Rodi Gynecology Group, Santa Monica, California, 90401, United States	
2019-10-29	Case Comprehensive Cancer Center, Cleveland, Ohio, 44106-5065, United States	
2023-07-13	Nemocnice Havířov, p. o., Havířov, 73601, Czechia	
2021-10-08	Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, S5 7AU, United Kingdom	
2023-05-24	Netherlands Cancer Institute, Amsterdam, 1066CX, Netherlands|Amsterdam UMC, location AMC, Amsterdam, 1105AZ, Netherlands|Leids Universitair Medisch Centrum (LUMC), Leiden, 2333ZA, Netherlands	
2023-03-23	Oncology Institute of Italian Switzerland, Bellinzona, Ticino, 6500, Switzerland	Study Protocol and Statistical Analysis Plan
2023-06-13	Emory Proton Therapy Center, Atlanta, Georgia, 30308, United States|Emory University Hospital Midtown, Atlanta, Georgia, 30308, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, 30322, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, 30342, United S	
2006-09-26	Sinai Hospital of Baltimore, Baltimore, Maryland, 21215, United States|Northwest Hospital Center, Randallstown, Maryland, 21133, United States	
2022-12-01	Singleton Hospital, Swansea, Wales, SA2 8PP, United Kingdom	
2018-01-25	Lkh-Univ. Klinikum Graz; Klinik Für Gynäkologie, Graz, 8036, Austria|LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie, Graz, 8036, Austria|Lhk Klagenfurt; Abt. Für Gynäkologie, Klagenfurt, 9026, Austria|LKH Hochsteiermark; Abt. für Innere Medizin, Leoben, 8700, Austria|Ordenski	
2022-02-01	Azienda Ospedaliero-Universitaria Careggi, Florence University, Florence, 50141, Italy	
2015-09-16	General Hospital Celje, Celje, SI-3000, Slovenia	
2023-05-16	Eurasian Association of Therapists, Moscow, Russian Federation	
2018-10-02	Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States	
2023-01-10	I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, 119991, Russian Federation	
2020-04-03	"Attikon" University General Hospital, Athens, Attiki, 12462, Greece	

2013-08-30	Landeskrankenhaus Feldkirch, Feldkirch, A-6806, Austria|Universitaetsklinik Innsbruck/ Klinik für Innere Medizin, Innsbruck, A-6020, Austria|A.ö. Landeskrankenhaus Leoben, Leoben, A-8700, Austria|Krankenhaus d. Barmherzigen Schwestern Linz, Linz, A-4010, Austria|Krankenhaus der Elisabe	
2018-10-26	London Health Sciences Centre, Western University, London, Ontario, N6A 5A5, Canada	
2017-02-23	Novarts Investigative Site, Adelaide, Australia|Novarts Investigative Site, Brisbane, Australia|Novarts Investigative Site, Melbourne, Australia|Novarts Investigative Site, Sydney, Australia	
2022-10-26	Tanta university, Tanta, 35945/10/2022, Egypt	
2023-02-14	Department of Anesthesia and operative intensive Care, Campus Benjamin Franklin, Charité - University Hospital Berlin, Berlin-Steglitz, Berlin, 12203, Germany	
2021-11-03	Rigshospitalet, Copenhagen, 2100, Denmark	
2021-05-17	Cleveland Clinic, Cleveland, Ohio, 44195, United States	
2023-01-12	Mayo Clinic in Florida, Jacksonville, Florida, 32224-9980, United States	
2023-02-08	M D Anderson Cancer Center, Houston, Texas, 77030, United States	
2022-03-08	Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States	
2018-10-18	Centre Régional de Pharmaco-vigilance - Paris, Pitié-Salpétrière, Paris, Ile De France, 75013, France	
2023-06-09	Saint Quentin Hospital, Saint-Quentin, Hauts-de-france, 02100, France	
2019-04-18		
2018-10-09	Hospital St. Raphael Muenster, Muenster, North Rhine-Westphalia, 48143, Germany|Hospital St. Franziskus Muenster, Muenster, North Rhine-Westphalia, 48145, Germany|University Hospital Muenster, Muenster, North Rhine-Westphalia, 48149, Germany|Palliativnetz Muenster, Muenster, North	
2023-06-02	Kiwhan Kim, Seoul, Yangcheon Gu, 03168, Korea, Republic of	
2022-07-19	Texas Tech University Health Sciences Center, Lubbock, Texas, 79430, United States	Study Protocol and Statistical Analysis Plan|Informed Consent Form
2015-11-17	Stanford University School of Medicine, Stanford, California, 94305, United States	
2020-02-20		
2022-12-09	Rigshospitalet, Copenhagen, Denmark|Hillerød Hospital, Hillerød, Denmark|Neonatal Department, Skåne University Hospital, Lund, Skåne, Sweden|Paediatric Cardiology Department, Skåne University Hospital, Lund, Skåne, Sweden|Paediatric Oncology Department, Skåne University Hospital,	
2023-06-22	National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States	
2022-12-21	Massachusetts General Hospital, Boston, Massachusetts, 02114, United States	
2019-05-01	Odense University Hospital, Odense c, 5000, Denmark	
2021-09-02	King's College Hospital NHS Foundation Trust, London, SE5 9RS, United Kingdom	
2023-07-03	Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States	
2011-02-21	Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, 60611, United States	
2023-03-03	Mercy Hospital Fort Smith, Fort Smith, Arkansas, 72903, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, 52403, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, 63011, United States|Mercy Hospital Saint Louis, Saint Louis, Mis	
2018-01-26	Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States	
2014-12-31	Bons Secours Hospital, Cork, Ireland|Cork University Hospital, Cork, Ireland|Our Ladies of Lourdes Hospital, Drogheda, Ireland|Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital, Dublin, 24, Ireland|St. Vincent's University Hospital, Dublin, 4, Ireland|Mater Miseri	
2023-04-04	Northwestern Medicine Chicago Proton Center, Warrenville, Illinois, 60555, United States|Maryland Proton Treatment Center, Baltimore, Maryland, 21201, United States|Princeton ProCure Managment LLC, Somerset, New Jersey, 08873, United States|Oklahoma Proton Center, Oklahoma City, C	
2008-04-16	Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, via S. Pansini 5 Naples, 80131, Italy	
2020-07-09	Erasmus Medical Center, Rotterdam, Zuid-Holland, 3015 GD, Netherlands	
2017-02-17	University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|Barrow Tuberous Sclerosis Center, Phoenix, Arizona, 85013, United States|Massachusetts General Hospital Massachussetts General Hospita, Boston, Massachusetts, 02114, United States|Minnesota Epilepsy C	
2023-03-20	IRCCS Centro Cardiologico Monzino, Milan, 20138, Italy	
2023-01-20	Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States	
2018-09-14	Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02215, United States|Dana Farber Cancer Insitute, Boston, Massachusetts, 02215, United States	
2014-08-05	University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, 35294-3300, United States|MBCCOP - Gulf Coast, Mobile, Alabama, 36688, United States|Arizona Cancer Center, Tucson, Arizona, 85724, United States|University of Arkansas for Medical Sciences, L Center, UNC, Chapel Hill, North Carolina, 27599-7295, United States|Carolinas Medical Center, Charlotte, North Carolina, 28232-2861, United States|Presbyterian Healthcare, Charlotte, North Carolina, 28233-3549, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, 27	
2019-04-04	CHU Caen, Caen, Normandy, 14000, France	
2023-03-27	University of Virginia University Hospital, Charlottesville, Virginia, 22903, United States	
2011-12-12	UT MD Anderson Cancer Center, Houston, Texas, 77030, United States	
2020-06-12	Samsung Medical Center, Seoul, 06351, Korea, Republic of	
2023-06-02	University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|The University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78249, United States	
2018-07-13	Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States	
2015-10-19	MBCCOP - Gulf Coast, Mobile, Alabama, 36688, United States|CCOP - Western Regional, Arizona, Phoenix, Arizona, 85006-2726, United States|Veterans Affairs Medical Center - Phoenix (Carl T. Hayden), Phoenix, Arizona, 85012, United States|Veterans Affairs Medical Center - Tucson, Tucson CCOP - Greenville, Greenville, South Carolina, 29615, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, 29303, United States|University of Tennessee Cancer Institute, Memphis, Tennessee, 38103, United States|Danville Radiation Therapy Center, Memphis, Tennessee, 381	
2018-10-19	Radboudumc, Nijmegen, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands	
2014-12-12	University of Alabama at Birmingham, Birmingham, Alabama, 35294-3300, United States|City of Hope National Medical Center, Duarte, California, 91010, United States|Stanford Cancer Center, Stanford, California, 94305, United States|University of Miami Hospital and Clinics, Miller School of M	
2020-12-11	University of Ottawa Heart Institute, Ottawa, Ontario, K1Y 4W7, Canada	Study Protocol|Statistical Analysis Plan
2014-04-29	Seoul National University Hospital, Seoul, 110-744, Korea, Republic of	
2016-05-16	Golden Jubilee National Hospital, Clydebank, United Kingdom	
2013-06-19		
2023-01-13	Barts Health NHS Trust, London, England, E1 1BB, United Kingdom	
2023-04-28	RTI International, Research Triangle Park, North Carolina, 27709, United States	
2016-01-29	Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institue, Yonsei Universiy College of Medicine, Seoul, 03722, Korea, Republic of	
2020-05-19	Peking University People's Hospital, Beijing, 100044, China	
2022-11-03	Université de Sherbrooke, Chicoutimi, Quebec, G7H 5H6, Canada|CIUSSS du Sageunay-Lac-Saint-Jean, Chicoutimi, Quebec, G7H 7K9, Canada	
2023-06-28	European Institute of Oncology, Milan, Italy	

2023-05-03	Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States	
2023-03-28	Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States	
2022-11-09	Royal North Shore Hospital, Saint Leonards, New South Wales, 2065, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Alfred Health, Melbourne, Victoria, 3000, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia	
2011-09-08	Charité - University Medicine Berlin, Berlin, 13353, Germany	
2023-03-17	Western University, London, Ontario, N6A 3K7, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Providence Healthcare, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Toronto Central Community	
2021-09-10	GOfit, Santander, Cantabria, 39011, Spain	
2022-11-25	Cardiology department, Paris, 75012, France	
2015-03-06	Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States	
2023-01-10	Washington University School of Medicine, Saint Louis, Missouri, 63110, United States	
2018-11-02	Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, 27157, United States	
2020-11-16	University Hospital of Cologne, Cologne, NRW, 50937, Germany	
2016-05-24	Plymouth Hospitals NHS Trust (PHNT), Plymouth, Devon, PL6 8DH, United Kingdom	
2021-03-03	The Ottawa Hospital, Ottawa, Ontario, K1H 8L6, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, K2H 8L6, Canada	
2022-05-02	Heart Hospita, Tampere University Hospital, Tampere, Pirkanmaa, 33580, Finland	
2013-08-30	Jules Bordet Institute, Brussels, 1000, Belgium	
2015-11-20	Durham VA Medical Center HSR&D COE, Durham, North Carolina, 27705, United States	
2012-02-28	Fudan University Cancer Hospital, Shanghai, Shanghai, 200032, China	
2009-09-24	Premiere Oncology of Arizona, Scottsdale, Arizona, 85258, United States|Moores UCSD Cancer Center, La Jolla, California, 92093, United States|Premiere Oncology, Santa Monica, California, 90404, United States|Georgia Cancer Specialists, Atlanta, Georgia, 30341, United States|UNM Cancer	
2021-10-04	Seoul National University Hospital, Seoul, 03080, Korea, Republic of	
2023-01-20	University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States	
2019-03-28	Rabin Medical Center,, Petaḥ Tiqwa, Israel	
2022-03-10	CES University, Medellín, Antioquia, 00, Colombia	
2022-11-15	Massachusetts general Hospital, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|University of Pennsylvania Medical System, Philadelphia, Pennsylvania, 19104, United States|McGill University Health Center, Toronto, Ca	
2018-12-04	Children's National Health System, Washington, District of Columbia, 20010, United States	
2016-07-27	St. Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States	
2023-02-02	University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States	
2016-02-24	Alberta Cancer Board, Edmonton, Alberta, Canada	
2012-07-23	Partners Healthcare Systems, Boston, Massachusetts, 02199, United States|UT MD Anderson Cancer Center, Houston, Texas, 77030, United States	
2023-03-14	Department of Cardiology, University Hospital Basel, Basel, Basel-City, 4031, Switzerland|Institute of Social and Preventive Medicine, University of Bern, Bern, BE, 3012, Switzerland|Department of Cardiology, Inselspital Bern, Bern, 3010, Switzerland|Department of Cardiology, University Hospit	
2022-06-14	Shinko Hospital, Kobe, Hyogo, 651-0072, Japan	
2023-06-02	Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States	
2021-10-01	Affiliated Hospital of Qinghai University, Xining, Qinghai, 810000, China	
2023-05-22	University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, 48109, United States	
2023-02-13	M D Anderson Cancer Center, Houston, Texas, 77030, United States	
2022-04-07	University of California, San Diego, La Jolla, California, 92093, United States	
2023-01-10	St. Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States	
2022-10-10	VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, 94304-1290, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, 90073, United States|Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado,	
2020-01-10	Carlos M Campos, São Paulo, 05403-900, Brazil	
2023-03-30	Pontificia Universidad Catolica de Chile, Santiago, Metropolitana, Chile	
2022-02-23		
2019-09-26	AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM., Paris, 75013, France	
2016-02-25	University of Alberta/ Cross Cancer Institute, Edmonton, Alberta, Canada	
2021-08-24	Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom	
2020-02-05		
2022-08-10	Nguyen Hoang Hai, Ho Chi Minh, Vietnam	
2022-06-02	Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States	
2015-04-17		
2018-09-28	Chu de Poitiers, Poitiers, 86000, France	
2023-03-30	City of Hope Medical Center, Duarte, California, 91010, United States	

2023-03-06	Washington University School of Medicine, Saint Louis, Missouri, 63110, United States	
2023-05-12	Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña, 15706, Spain	
2019-09-18	San Filippo Neri General Hospital, Roma, 00135, Italy	
2018-12-13	William Clay Ford Center for Athletic Medicine, Detroit, Michigan, 48202, United States	
2022-06-24	City of Hope (Adults and Pediatrics), Duarte, California, 91010, United States|University of California San Diego Moores Cancer Center (Adults only), La Jolla, California, 92093, United States|Loma Linda University Cancer Center (Adults only), Loma Linda, California, 92354, United States|Childre	
2013-09-19	Baptist Regional Cancer Center at Baptist Riverside, Knoxville, Tennessee, 37901, United States|St. Mary's Medical Center, Powell, Tennessee, 37849, United States	
2023-03-27	Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, 90035903 / 90410000, Brazil|Irmandade Da Santa Casa De Misericórdia De Porto Alegre, Porto Alegre, Rio Grande Do Sul, 90050-170, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, 01327-903, Brazil|Clínica de Pesquis	
2022-09-13	Belfast Health and Social Care Trust, Belfast, BT9 7AB, United Kingdom	
2021-04-30	Rady Children's Hospital, San Diego, California, 92123, United States	
2018-11-27	Lawson Health Research Institute, London, Ontario, N6C 2R5, Canada	
2015-11-17	NYU Hospital for Joint Diseases, New York, New York, 10003, United States	
2023-05-19	Brigham & Women's Hospital, Boston, Massachusetts, 02115, United States	
2023-07-17	National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States	
2019-01-11		
2023-04-11		
2022-01-24	Institut régional du cancer de Montpellier, Montpellier, Hérault, 34298, France	
2022-06-02	Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States	
2014-03-05	National University Hospital, Singapore, 119074, Singapore	
2014-09-26	Clinics Hospital, Campinas, Sao Paulo, 13083-888, Brazil	
2022-12-14	Institut Curie, Paris, 75005, France|Institut Jean Godinot, Reims, 51100, France|Institut Curie, Saint-Cloud, 92, France	
2020-10-09	Juravinski Hospital, Hamilton, Ontario, L8V 1C3, Canada	
2019-10-29	Pain Management and Palliative Care, Department of Anesthesia, Intensive Care and Emergency, Molinette Hospital, University of Turin, Turin, 10126, Italy	
2023-05-12	University College London Hospitals, London, United Kingdom	
2019-05-09	Guy's Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom|Queen Elizabeth Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|St Thomas' Hospital, London, United Kingdom|University Hospital Lewisham, London, United Kingdom	
2023-07-11	Kimmel Cancer Center at Johns Hopkins at Sibley Memorial Hospital, Washington, District of Columbia, 20016, United States|Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland, 21287-0013, United States	Study Protocol and Statistical Analysis Plan
2018-06-15	University Medical Center Groningen (UMCG), Groningen, 9700RB, Netherlands	
2020-02-20	Kaiser Permanente Southern California, Pasadena, California, 91101, United States|Kaiser Permanente Northwest, Portland, Oregon, 97227, United States	
2023-05-22	A university-affiliated rehabilitation laboratory, Hung Hom, Kowloon, Hong Kong|The Hong Kong Polytechnic University, Hong Kong, Hong Kong	
2012-01-16	U.T.M.D. Anderson Cancer Center, Houston, Texas, 77030, United States	
2017-11-20	Site Reference ID/Investigator# 116015, Scottsdale, Arizona, 85258, United States|Site Reference ID/Investigator# 116016, San Antonio, Texas, 78229, United States|Site Reference ID/Investigator# 117320, Groningn, 9713 GZ, Netherlands|Site Reference ID/Investigator# 117336, Maastricht, 62	
2022-07-19	Regional Cancer Centre in Opole, Opole, Opolskie, 45-061, Poland|Maria Sklodowska-Curie Institute - Oncology Centre (MSCI), Gliwice Branch, Gliwice, Silesia, 44102, Poland|Silesian Center for Heart Diseases, Zabrze, Silesia, 41800, Poland|Holy Cross Cancer Centre, Cardio-Oncology Divisi	
2023-07-14	University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, 48109, United States	
2023-04-18	Cleveland Clinic, Cleveland, Ohio, 44195, United States	
2021-01-07	Complex Oncological Center - Vratsa, EOOD, Vratsa, 3000, Bulgaria|ONKOCENTRUM Medicon Services s.r.o., Praha, 14000, Czechia|CHU Besançon - Hôpital Jean Minjoz, Besançon, 25030, France|Centre Hospitalier de Belfort-Montbeliard, Montbéliard, 25209, France|Bialostockie Centrum C	
2015-03-31	CHU de Clermont-Ferrand, Clermont-ferrand, 63000, France|CHU de Grenoble, Grenoble, 38000, France|IHOP, Lyon, 69000, France|CHU de Saint-Etienne, Saint-etienne, 42000, France	
2022-03-24	University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States	
2022-12-06	St Olavs University Hospital, Trondheim, Norway|Ålesund Hospital, Ålesund, Norway	
2019-12-18		
2023-07-03	Istanbul Faculty of Medicine, Fatih, Istanbul, 34093, Turkey	
2014-02-07	Duke University Medical Center, Durham, North Carolina, 27705, United States	
2017-08-23	Miriam Hospital Outpatient 146 West River Street, Providence, Rhode Island, 02904, United States	
2020-03-25	Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, China|Cancer Hosptical, Chinese Academy of Medical Sciences, Beijing, 100021, China	

2023-07-10	Washington University School of Medicine, Saint Louis, Missouri, 63110, United States	
2023-06-08	Monash Health, Clayton, Victoria, 3168, Australia|Cabrini Health, Malvern, Victoria, 3144, Australia|Latrobe Regional Hospital, Traralgon, Victoria, 3844, Australia	
2023-06-13	Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, 05403-900, Brazil	
2022-12-06	QEII Health Science Center, Nova Scotia Health Authority, Halifax, Nova Scotia, B3H 3A7, Canada	
2022-09-10	the first affiliated hospital of Dalian medical university, Dalian, Liaoning, 116011, China	
2023-06-09	Anchorage Associates in Radiation Medicine, Anchorage, Alaska, 98508, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, 99508, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, 99508, United States|Alaska Women's Cancer Care, Anchorage, A
2020-03-26	Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27157, United States	
2019-05-14	Fudan University affiliated cancer hospital, Shanghai, China	
2020-06-09	Mayo Clinic Health System, Mankato, Minnesota, 56001, United States	
2023-03-17	Cedars-Sinai Medical Center, Los Angeles, California, 02127, United States|University of California Los Angeles, Los Angeles, California, 90095, United States|University of Chicago, Chicago, Illinois, 60637, United States|Franciscan Health, Indianapolis, Indiana, 46237, United States|University
2022-08-09	Departments of Oncology and Medicine, Vejle Hospital, Vejle, Denmark	
2020-01-27	University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States	
2022-08-16	Sahlgrenska University Hospital, Göteborg, Västra Götaland, 41345, Sweden	
2023-02-22	Mayo Clinic, Rochester, Minnesota, 55905, United States	
2018-03-23	SE Dnipropetrovsk medical academy, Dnipro, Ukraine	
2013-01-16	Cancer and Leukemia Group B, Chicago, Illinois, 60606, United States	
2010-03-25	Addenbrooke's Hospital, Cambridge, England, CB2 2QQ, United Kingdom	
2022-12-08	Northwell (Northshore University/Long Island Jewish Hospitals), New Hyde Park, New York, 11040, United States	
2013-11-25	Algiers, 16000, Algeria|Annaba, 23000, Algeria|Blida, 9000, Algeria|Mascara, 29000, Algeria|Oran, 31000, Algeria|Sidi Belabes, 22000, Algeria|Tizi Ouzou, 15000, Algeria|Agadir, 80000, Morocco|Casablanca, 20000, Morocco|Casablanca, 20052, Morocco|Casablanca, 20100, Morocco|Casablanc
2018-04-13	Hôpital Edouard HERRIOT, Institut du Cancer - Hospices Civils de Lyon, Lyon, 69437, France	
2016-04-15	Shaare Zedek Medicla Center, Jerusalm, 91031, Israel	
2022-03-10	Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States	
2013-10-08	University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73104, United States	
2021-06-25		
2022-05-05	Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada	
2019-05-02	Universitätsklinikum Hamburg-Eppendorf, Hamburg, 20246, Germany	
2015-05-06	BC Cancer Agency, Vancouver, British Columbia, V2L-5L6, Canada	
2022-10-04	Centro Hospitalar Vila Nova de Gaia Espinho, E.P.E., Vila Nova De Gaia, Porto, 4434-502, Portugal	
2023-04-06	Cancer Clinical Trials Office, Los Angeles, California, 90048, United States	
2019-08-07	Heart Institute of University of São Paulo, São Paulo, Sao Paulo, 05403-900, Brazil	
2012-08-15	Winthrop University Hospital, Mineola, New York, 11501, United States	
2023-05-15	University of North Carolina, Chapel Hill, North Carolina, 27599, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|University of Vermont, Burlington, Vermont, 05405, United States|University of Washington, Seattle, Washington, 98104, United
2020-03-06	Greenville Health System Cancer Institute, Greenville, South Carolina, 29605, United States	
2022-02-17	St Joseph's Hospital, Denver, Colorado, 80218, United States|Good Samaritan Medical Center, Lafayette, Colorado, 80026, United States	
2012-07-23	UT MD Anderson Cancer Center, Houston, Texas, 77030, United States	
2017-06-09		
2020-02-05	University of Alberta Hospital, Edmonton, Alberta, T6G 2B7, Canada|Royal Columbian Hospital, New Westminster, British Columbia, V3L 3W7, Canada|Vancouver General Hospital, Vancouver, British Columbia, V5Z 1M9, Canada|Hamilton General Hospital, Hamilton, Ontario, L8N 3Z5, Canada|H
2020-11-04	Southern Danish University, Odense, Fyn, 5230, Denmark	
2017-08-03	The Toronto 3D (Diet, Digestive tract and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, Toronto, Ontario, M5C 2T2, Canada	
2020-05-29	Assistance Publique Hôpitaux de Paris - Centre Université de Paris, Paris, 75015, France	
2016-07-14	CCOP - Colorado Cancer Research Program, Incorporated, Denver, Colorado, 80224, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, 50309, United States|Mercy Cancer Center at Mercy Medical Center-Des Moines, Des Moines, Iowa, 50314,	
2019-04-22	CHU Caen, Caen, Normandy, 14000, France	
2020-10-05	Carolina Population Center, Chapel Hill, North Carolina, 27599, United States	Statistical Analysis Plan
2023-03-28	2nd Affiliated Hospital, School of Medicine, Zhejiang University, China, Hangzhou, Zhejiang, China	
2020-12-24	Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Korea, Republic of	
2021-10-06	Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, 200127, China|Shanghai Eighth People's Hospital, Shanghai, Shanghai, China	
2015-03-27		
2023-02-08	First Affiliated Hospital of Xian Jiaotong University, Xi'an, Shanxi, 710061, China	
2020-09-04	Memorial Sloan Kettering Westchester, Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States	
2023-06-22	Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States	Study Protocol and Statistical Analysis Plan
2022-05-11	Barnes-Jewish Hospital, Saint Louis, Missouri, 63110, United States	
2021-07-01	Show Chwan Memorial Hospital, Changhua, 500, Taiwan	
2014-07-28		

2016-06-09	The Royal Marsden NHS Foundation Trust, Sutton, SM2 5PT, United Kingdom	
2019-03-25	Research Site, Bingham Farms, Michigan, 48025, United States|Research Site, Detroit, Michigan, 48202, United States|Research Site, Lebanon, New Hampshire, 03756, United States|Research Site, Cincinnati, Ohio, 45229, United States|Research Site, Providence, Rhode Island, 02903, United	
2013-11-15	Hospital Clinic, Barcelona, Catalunya, 08035, Spain|Hospital Clinic, Barcelona, Catalunya, 08036, Spain	
2023-04-03	University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States	
2018-04-20		
2008-06-04	University of Miami Dept of Hematology/Oncology, Miami, Florida, 33136, United States|University of Miami Dept of Radiology, Miami, Florida, 33136, United States	
2021-12-08	Qianfoshan Hospital (The First Affiliated Hospital of Shandong First Medical University), Jinan, Shandong, 251400, China	
2022-11-08	Children's Cancer Hospital Egypt 57357 Cairo, Egypt, Cairo, Egypt	
2014-10-22	Akershus University Hospital, Lørenskog, 1478, Norway	
2017-06-06		
2014-02-05	Department of Anesthesiology and Pain Medicine, and Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea, Seoul, 120-752, Korea, Republic of	
2022-07-05	Local Institution - Japan, No City Provided, New Jersey, 00000, United States|Shinko Hospital, Kobe, Hyogo, 651-0072, Japan	
2019-07-08	Children's Hospital of Orange County, Orange, California, 92868, United States|McMaster Children's Hospital, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|SickKids, Toronto, Ontario, M5G	
2018-11-01		
2020-10-08	Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|The Danish Breast Cancer Cooperative Group, Copenhagen, DK-2100 Ø, Denmark|Rigshospitalet, Copenhagen, Denmark|Herlev Hospital, Herlev, Denmark|Naestved Hospital, Naestved, Denmark|Oder	
2020-07-08	2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310000, China	
2010-01-07	Evanston Northwestern Healthcare (ENH) internal medicine, family practice, and OB/GYN practices, Evanston, Illinois, 60201, United States|American Academy of Family Physicians National Research Network (AAFP-NRN)., Leawood, Kansas, 66211, United States|Great Lakes Research into Pr	
2014-07-24	University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, 35294, United States|MBCCOP - University of South Alabama, Mobile, Alabama, 36688, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States|University of California	
2022-07-12	General hospital of PLA, Beijing, Beijing, 100853, China	
2023-06-02	Modality Partnership, Birmingham, West Midlands, B19 1BP, United Kingdom	
2022-02-11	CHU Jean Minjoz, Besançon, France|Centre Hospitalier Boulogne/ Mer, Boulogne-sur-Mer, France|Hôptial Henri Mondor, Créteil, France|Chu Dijon, Dijon, France|Hôpital Privé Jean Mermoz, Lyon, France|GH Pitié Salpêtrière, Paris, France|Hôpital Saint Antoine, Paris, France|CHU Poitiers, Poitie	
2023-06-15	The Department of Clinical Oncology, Tanta University Hospital, Tanta, Egypt	
2008-01-25	Div. of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, 1090, Austria	
2023-04-25	Azienda Sanitaria Universitaria Friuli Centrale, Udine, 33100, Italy	
2021-03-03	Froedtert Hospital, Milwaukee, Wisconsin, 53226, United States	
2022-11-29	Harborview Medical Center, Seattle, Washington, 98104, United States|UW Medical Center - Northwest, Seattle, Washington, 98133, United States|UW Medical Center - Montlake (UWMC), Seattle, Washington, 98195, Unite	Study Protocol|Statistical Analysis Plan
2020-09-25	Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, SP, 05652901, Brazil|Hospital Israelita Albert Einstein, Sao Paulo, 05652901, Brazil	
2019-09-04	Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States	
2012-08-07	UT MD Anderson Cancer Center, Houston, Texas, 77030, United States	
2023-02-06	Connecticut Children's Medical Center, Hartford, Connecticut, 06106, United States	
2023-04-24	AP-HP, Saint-Antoine Hospital, Department of cardiology, Paris, 75012, France|AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, Paris, 75013, France|AP-HP, Tenon Hospital, Department of Cardiology, Paris, 75020, France	
2018-08-06	Hospital Sírio-Libanês, São Paulo, Brazil	
2018-12-10	UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, 68198-6805, United States	
2013-01-24	MBCCOP - University of South Alabama, Mobile, Alabama, 36688, United States|CCOP - Greater Phoenix, Phoenix, Arizona, 85006-2726, United States|Veterans Affairs Medical Center - Phoenix (Hayden), Phoenix, Arizona, 85012, United States|Veterans Affairs Medical Center - Tucson, Tucso 98109, United States|CCOP - Northwest, Tacoma, Washington, 98405-0986, United States	
2013-08-30	Institut Jules Bordet, Brussels, 1000, Belgium	
2023-06-12	University of Alabama, Birmingham, Alabama, 35233, United States|Northwestern Medicine, Warrenville, Illinois, 60555, United States|Johns Hopkins, Baltimore, Maryland, 21287, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Abramson Can	
2016-01-29	Mayo Clinic, Rochester, Minnesota, 55905, United States|St. Boniface General Hospital, Winnipeg, Manitoba, R2H 2A6, Canada	
2020-08-31	Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States	
2021-03-29		
2023-03-21		
2020-03-02	University of Alberta Hospital, Edmonton, Alberta, T6G 2B7, Canada|Royal Columbian Hospital, New Westminster, British Columbia, V3L 3W7, Canada|Vancouver General Hospital, Vancouver, British Columbia, V5Z 1M9, Canada|Nova Scotia Health Authority, Halifax, Nova Scotia, B3H 3A7, Can	
2022-05-18	University Hospital Dubrava, Zagreb, 10000, Croatia	
2012-10-26	Kansascity VA Medical center, Kansas city, Missouri, 64128, United States	
2016-11-15	UK Medical Center, Lexington, Kentucky, 40536, United States|University of Kentucky Medical Center, Lexington, Kentucky, 40536, United States	
2023-04-21	Presidio ospedaliero "A. TORTORA" - U.O. Onco-ematologia, Pagani, Salerno, 84016, Italy|AOU di Sassari - Ematologia, Sassari, SS, 07100, Italy|Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) - SC Ematologia, Trieste, TS, 34121, Italy|Ospedale Dell'angelo - U.O. Ematologia, Mestre,	
2023-02-10	University Hospital Center Mother Teresa, Tirana, 10001, Albania|Department of Pediatrics, Alexandria University Children's Hospital, Alexandria, 21131, Egypt|Departmnet of Molecular and Medical Genetics, Tbilisi State Medical University, Tbilisi, 0177, Georgia|Department of Pediatric Genetics	
2023-06-12		
2021-01-25	National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, 560029, India	
2023-07-12	Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States	Study Protocol|Informed Consent Form
2022-10-03	VA Boston Healthcare System, Boston, Massachusetts, 02130-4817, United States	Informed Consent Form
2020-02-07	Odense University Hospital, Odense, Denmark|Department of Oncology, Tampere, Pirkanmaa, 33520, Finland|Helsinki University Central Hospital, Helsinki, Uusimaa, 00290, Finland|Oulu university hospital, Oulu, Finland|Turku university hospital, Turku, Finland|Landspitali, Reykjavik, Iceland|St.	
2020-04-03	Health Sciences Centre, Winnipeg, Manitoba, R3A1R9, Canada	
2016-04-15		
2022-10-06	Aarhus University, Aarhus, Denmark|Henri Becquerel, Rouen, France|University Hospital Duesseldorf UDUS, Duesseldorf, Germany|Amsterdam UMC, Amsterdam, Netherlands|Hospital da Luz Learning Health (GLSMED), Lisboa, Portugal|IPO Lisboa, Lisboa, Portugal|Instituto Catalán de Oncolo	
2020-01-22	M D Anderson Cancer Center, Houston, Texas, 77030, United States	
2023-03-02	The Ottawa Hospital Cancer Centre, Ottawa, Ontario, K1H8M2, Canada	
2023-01-27	National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States	

2023-06-18		
2015-01-27	Royal Derby Hospital, Derby, Derbyshire, DE22 3NE, United Kingdom	
2021-03-16	KU Leuven, Leuven, Belgium|Aarhus University hospital, Aarhus, Denmark|Centre Régional François Baclesse, Caen, France|Gustave Roussy, Villejuif, France|University Hospital Essen, The West German Proton Therapy Centre Essen, Essen, Germany	
2020-10-14	Haukeland University Hospital, Bergen, 5021, Norway	
2017-11-13	GSK Investigational Site, San Antonio, Texas, 78229, United States|GSK Investigational Site, Salt Lake City, Utah, 84112, United States	
2018-09-24	University of California Los Angeles, Los Angeles, California, 90404, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, 30322, United States|University of Chicago Medical Center, Chicago, Illinois, 60637, United States|Parkview Research Center, Fort Wayne, Indiana, 46	
2020-07-27	1) Imam Sadiq (peace be upon him) Teaching Hospital; 2) Babylon Maternity and Children Teaching Hospital; 3) Al-Noor Hospital for Children; 4) Morgan Teaching Hospital; and 5) Babylon Oncology Center, Hilla, Babylon Province, Iraq	
2021-07-23	Department of Radiotherapy, Military Institute of Medicine, Warsaw, Mazowieckie, 04-141, Poland	
2022-08-31	Ultrasonic Diagnosis Department of Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China	
2023-06-15	M D Anderson Cancer Center, Houston, Texas, 77030, United States	
2019-10-16	Avera Cancer Institute, Sioux Falls, South Dakota, 57105, United States	Study Protocol and Statistical Analysis Plan
2021-05-13		
2023-05-03	Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, 10065, United States	
2023-02-16	Clínica Universidad de Navarra, Pamplona, 31008, Spain	
2013-12-12	HOSPICES CIVILS de LYON, Lyon, France	
2020-12-17	Tzu Chi University, Hualien City, 90093, Taiwan|Tzu Chi University, Hualien City, Taiwan	
2015-04-06	Institut Claudius Regaud, Toulouse, 31000, France	
2023-05-25	Department of Radiation Oncology; UT Southwestern Medical Center, Dallas, Texas, 75390, United States	
2023-03-14	Institute of Hematology and Transfusion Medicine, Warsaw, Poland|National Institute of Oncology, Warsaw, Poland	
2022-05-19	Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, LS9 7TF, United Kingdom	
2021-01-22	Centre Hospitalier Henri Duffaut, Avignon, 84000, France	
2014-02-13	Medical University of Vienna, Vienna, 1050, Austria	
2022-06-15	University Hospital Bonn, Bonn, NRW, 53127, Germany	
2022-05-31	Hospital Clínico Universitario de Santiago de Compostela, Santiago De Compostela, A Coruña, 15706, Spain|Hospital de Galdakao-Usansolo, Galdakao, Vizcaya, 48960, Spain|Hospital Universitario Vall d´Hebron, Barcelona, 08035, Spain|Hospital Universitario Reina Sofía, Córdoba, 14004, Spa	
2019-12-18	Vilnius University Hospital Santaros klinikos, Vilnius, 08661, Lithuania	
2015-01-19	Chicago, Illinois, United States|Dallas, Texas, United States|Houston, Texas, United States|Antwerpen, Belgium|Gent, Belgium|Izhevsk, Russian Federation|Moscow N/A, Russian Federation|Nizhni Novgorod, Russian Federation	
2017-11-13	GSK Investigational Site, La Jolla, California, 92093, United States|GSK Investigational Site, Randwick, New South Wales, 2031, Australia|GSK Investigational Site, Auckland, 1150, New Zealand|GSK Investigational Site, Christchurch, 8011, New Zealand	
2022-05-23	HonorHealth, Scottsdale, Arizona, 85258, United States	
2021-08-12	Palliative Team, South West Jutland Hospital, ESbjerg, Denmark	
2023-06-02	University Hospital Coventry & Warwickshire, Coventry, CV2 2DX, United Kingdom	
2018-03-21	Centro per lo Studio e la Cura delle Amiloidosi Sistemiche - Fondazione IRCCS Policlinico S.Matteo, Pavia, 27100, Italy	
2023-03-07	University of Chicago Medical Center, Chicago, Illinois, 60637, United States	
2019-11-25	David Grant Medical Center, Fairfield, California, 94535, United States|Essentia Institute of Rural Health, Duluth, Minnesota, 55805, United States|Duke University Medical Center, Durham, North Carolina, 27710, United State	Study Protocol and Statistical Analysis Plan
2021-04-27	Rush University Medical Center, Chicago, Illinois, 60612, United States|Rush Oak Park Hospital, Oak Park, Illinois, 60304, United States	
2015-06-08	Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, 20892-1182, United States|Oklahoma University Cancer Institute, Oklahoma City, Oklahoma, 73104, United States|Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, 76104, United St	
2014-12-04	National Taiwan University Hospital, Taipei, 100, Taiwan	
2012-10-02	PUMCH, Peking, Beijing, 100730, China	
2023-07-17	St. Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States	
2014-02-10	St. Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States	
2023-06-18	Trinitas Hospital and Comprehensive Cancer Center, Elizabeth, New Jersey, 07202, United States|RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton, Hamilton, New Jersey, 08690, United States|RWJBarnabas Health - - Jersey City Medical Medical, Jersey City, New Je	
2020-03-03		Study Protocol, Statistical Analysis Plan, and Informed Consent Form
2018-01-17	Department of Anaesthesia, Rigshospitalet 2043, Copenhagen, 2300, Denmark	Study Protocol|Statistical Analysis Plan
2011-09-02	UMass Medical School, Worcester, Massachusetts, 01655, United States	
2023-03-16	M D Anderson Cancer Center, Houston, Texas, 77030, United States	
2018-09-21	Stanford Cancer Institute, Palo Alto, California, 94304, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, 52242, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States|Dana-Farber/Harvard Cancer Center, Bos	
2017-11-14	GSK Investigational Site, Duarte, California, 91010, United States|GSK Investigational Site, Santa Monica, California, 90404, United States|GSK Investigational Site, Detroit, Michigan, 48201, United States|GSK Investigational Site, Lebanon, New Hampshire, 03756, United States|GSK Investigat	
2023-03-17		
2023-03-28		
2019-01-18	Johns Hopkins Hospital, Baltimore, Maryland, 21287, United States	
2023-05-19	Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, 27157, United States|Virginia Commonwealth University Health Sciences, Richmond, Virginia, 23284, United States	Study Protocol and Statistical Analysis Plan|Informed Consent Form
2023-04-25	University of Colorado Hospital, Aurora, Colorado, 80045, United States	
2023-05-11		
2022-03-03	Henry Ford Health System, Detroit, Michigan, 48202, United States	
2015-04-14	The Miriam Hospital, Providence, Rhode Island, 02903, United States	
2023-06-06	Fondazione IRCCS Policlinico San Matteo, Pavia, 27100, Italy	
2016-10-10	Teva Investigational Site 10565, Lenexa, Kansas, United States	
2020-04-01	Rigshospitalet, Copenhagen, Denmark	
2014-12-02	Lazenby Hall, Ohio State University, Columbus, Ohio, 43210, United States|Annenberg Public Policy Center, Philadelphia, Pennsylvania, 19104, United States	
2023-04-21	Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, 27157, United States|Virginia Commonwealth University, Richmond, Virginia, 23298, United States	
2022-11-09	ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy|ASST Spedali Civili, Montichiari, Italy|ASST Monza-Ospedale San Gerardo, Monza, Italy|Humanitas Clinical and Research Hospital, Rozzano, Italy|Centre for Tropical and Infectious Diseases and Microbiology, IRCCS Sacro Cuore, Ver	
2023-03-06	Harborview Medical Center, Seattle, Washington, 98104, United States|UW Medical Center - Northwest, Seattle, Washington, 98133, United States|UW Medical Center - Montlake (UWMC), Seattle, Washington, 98195, United States	
2019-12-02	Rabin Medical Center - Beilinson Hospital, Petah Tikva, 4941492, Israel	
2023-06-22	Mayo Clinic, Phoenix, Arizona, 85054, United States|Mayo Clinic in Florida, Jacksonville, Florida, 32224, United States|Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States|Washington University in St. Louis, Saint Louis, Missouri, 63110, United States|MD Anderson Cancer Ce	

2017-05-30	Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, 27157-1096, United States	
2017-07-02	La Raza, Oakland, California, United States|La Clinica del Pueblo, Washington, D.C., District of Columbia, 20009, United States	
2019-10-29	Golden Jubilee National Hospital, Glasgow, G81 4DY, United Kingdom	
2017-04-17	Durham VA Medical Center, Durham, NC, Durham, North Carolina, 27705, United States	
2023-02-06	CT Children's Medical Center, Hartford, Connecticut, 06106, United States|Nationwide Children's Hospital, Columbus, Ohio, 43205, United States	
2022-07-28	Center for Physical Activity Research, Copenhagen, 2200, Denmark	
2018-10-12	Toronto Rehabilitation Institute, Toronto, Ontario, Canada	
2023-01-06	University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|Emory University, Atlanta, Georgia, 30322, United States|University of South Carolina, Columbia, South Carolina, 29208, United States|University of Texas Southwestern, Dallas, Texas, 75235, United States	
2022-06-10	University of Florida Health Proton Therapy Institute, Jacksonville, Florida, 32206, United States	
2015-10-06	The Hospital for Sick Children, Toronto, Ontario, M5G1E2, Canada	
2023-05-17	Mayo Clinic in Arizona, Scottsdale, Arizona, 85259, United States	
2022-06-14	Shinko Hospital, Kobe, Hyogo, 651-0072, Japan	
2023-06-01	Renji Hospital, Shanghai, Shanghai, 200127, China	
2013-01-31		
2023-07-05	St. Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States	
2014-10-01	Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada	
2018-06-18	CHUV, Lausanne, Vaud, 1011, Switzerland	
2011-12-19	UT MD Anderson Cancer Center, Houston, Texas, 77030, United States	
2015-10-01	Hospice of the Valley MediCaring Project, Phoenix, Arizona, 85016, United States|Georgetown University Medical Center-Mind My Heart Program, Washington, District of Columbia, 20036, United States|Quality Oncology/Matria Healthcare, Sunrise, Florida, 33323, United States|CorSolutions/M	
2010-02-02	School of Medicine and Pharmacology, Royal Perth Hospital, Perth, Western Australia, 6000, Australia	
2021-03-30	Department of Oncology, Norrlands Universitetssjukhus, Umeå, Norrland, 901 85, Sweden|Department of Oncology, Karolinska University Hospital, Stockholm, Stockholm County, 171 76, Sweden|Department of Oncology, S	Study Protocol
2022-07-22	CHRU de Besançon, Besançon, 25030, France	
2018-07-05	Emory University School of Medicine, Atlanta, Georgia, 30322, United States|Wake Forset University Health Sciences, Winston-Salem, North Carolina, 27157, United States	
2014-12-30	Nanjing, Jiangsu, 210009, China|Suzhou, Jiangsu, 215006, China|Xi'an, Shanxi, 710032, China|Beijing, 100853, China|Shanghai, 200032, China|Shanghai, 200233, China|Kamogawa, Chiba, 296-0041, Japan|Matsuyama, Ehime, 791-0280, Japan|Chikushino, Fukuoka, 818-8516, Japan|Kobe, Hy	
2015-04-21	City of Hope Medical Center, Duarte, California, 91010, United States	
2016-03-16		
2022-11-03	UEM, Madrid, Spain|Universidad Europea de Madrid, Villaviciosa de Odón, 28670, Spain	
2023-02-23	IRCCS Humanitas Research Hospital, Rozzano, Milan, 20089, Italy	
2023-07-05	Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, 27157, United States	
2023-05-10	University of Iowa Department of Ophthalmology, Iowa City, Iowa, 52242, United States	Study Protocol
2014-01-24	Hasselt University, Hasselt, Limburg, 3500, Belgium	
2022-10-19	Zhonghua Chen,MD, Shaoxing, Zhejiang, China	
2022-12-13	MedStar Washington Hospital Center, Washington, District of Columbia, 20010, United States	
2022-04-28	The START Center for Cancer Care, San Antonio, Texas, 78229, United States	
2015-02-02	Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States	
2021-02-01	Mimicked Population, Mimicked Population, United Kingdom	
2021-03-30	Todd Cancer Institute at Long Beach Memorial Medical Center, Long Beach, California, 90806, United States|Olive View - UCLA Medical Center Foundation, Sylmar, California, 91342, United States|Aurora Presbyterian Hospi Center - St. Joseph, Saint Joseph, Michigan, 49085, United States|Lakeside Cancer Specialists, PLLC, Saint Joseph, Michigan, 49085, United States|Providence Cancer Institute at Providence Hospital - Southfield Campus, Bay Oncology, Limited at St. Mary's Hospital, Green Bay, Wisconsin, 54303, United States|Mercy Regional Cancer Center, Janesville, Wisconsin, 53547, United States|Gundersen Lutheran Center for Cancer and Blood, La Cr	Study Protocol and Statistical Analysis Plan
2014-01-24	Brigham and Women's Hospital Cardiovascular Genetics Center, Boston, Massachusetts, 02115, United States|Children's Hospital Boston's Cardiovascular Genetics Clinic, Boston, Massachusetts, 02115, United States|Children's Hospital Boston's Ear, Nose, and Throat Clinic, Boston, Massac	
2023-04-11	University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States	
2022-01-20	Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, China	
2022-05-05	Cross Cancer Insititue, University of Alberta, Edmonton, Canada|CHU Limoges, Limoges, France|University Hospital, Heidelberg, Germany|Alexandra Hospital, Athens, Greece|Fondazione IRCCS Policlinico San Matteo, Pavia, 27100, Italy|Hospital Clinic de Barcelona, Barcelona, Spain|Istanbul	
2019-03-21	University of São Paulo, São Paulo, Sao Paulo, 05508-000, Brazil	
2021-08-19	Tampere University, Tampere, Southern Finland, 33014, Finland|Tampere University Hospital, Tampere, Southern Finland, 33521, Finland	
2017-01-06	Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada	
2016-08-08	Detroit Medical Center Detroit Receiving Hospital, Detroit, Michigan, 48201, United States|Detroit Medical Center Sinai Grace Hospital, Detroit, Michigan, 48235, United States	
2019-05-21	Lyndon B. Johnson General Hospital (LBJ), Houston, Texas, 77026, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States	
2020-03-06	Seoul National University Hospital, Seoul, 03080, Korea, Republic of	
2022-03-28		
2023-03-17	Akershus University Hospital, Lørenskog, 1478, Norway|Stavanger University Hospital, Stavanger, Norway|University of North Norway, Tromsø, Norway|St Olavs Hospital, Trondheim, Norway	
2021-12-22	Cleveland Clinic, Cleveland, Ohio, 44195, United States	
2022-05-25	Division of Cardiology, Pulmonary Disease and Vascular Medicine, Dusseldorf, 40225, Germany	
2022-08-15	Willows Medical Centre, Leicester, Leicestershire, LE5 4LJ, United Kingdom	
2021-07-15	Peking University Third Hospital, Peking, Beijing, 100191, China	
2020-09-09	National Institute of Health and Welfare, Helsinki, Finland, Helsinki, Finland	
2023-02-16	AP-HP, Bicêtre Hospital, Nuclear medicine department, Le Kremlin-Bicêtre, 94275, France|AP-HP, Lariboisière Hospital, Cardiology department, Paris, 75010, France|AP-HP, Lariboisière Hospital, Neuroradiology department, Paris, 75010, France|AP-HP, Cochin Hospital, Radiology A departmen	
2023-06-23	Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States	
2020-12-16	Peter Lougheed Hospital, Calgary, Alberta, T1Y 6J4, Canada|Foothills Medical Centre, Calgary, Alberta, Canada|Royal Alexandra Hospital, Edmonton, Alberta, T5H 3V9, Canada|Royal Columbian Hospital, New Westminster, British Columbia, V3L 3W4, Canada|Vancouver Hospital, Vancouver, Br	
2022-10-17	Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States	
2023-05-01	Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, 13620, Korea, Republic of	
2023-07-13	Kantonspital Baselland (KSBL), Liestal, Baselland, 4410, Switzerland|Breast Cancer Center, University Hospital Basel, Basel, 4031, Switzerland|University Hospital Zurich (USZ), Zürich, 8091, Switzerland	
2015-11-05	Department of Heart Disease, Haukeland University Hospital, Bergen, 5021, Norway|University of Tromsø, Tromsø, 9037, Norway	
2019-12-17	CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, 93309, United States|UCLA Hematology/Oncology - Burbank, Burbank, California, 91505, United States|St. Jude Hospital Yor	Study Protocol|Statistical Analysis Plan
2010-11-11	Rambam Healthcare Campus, Haifa, Israel	
2011-09-26	TGEN Clinical Research Service at Scottsdale Healthcare, Scottsdale, Arizona, United States|Florida Cancer Specialists, Ft. Myers, Florida, United States|Horizon Oncology Research, Inc., Lafayette, Indiana, United States|Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD and Janet Burroff	
2015-12-11	The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, 471003, China	
2021-11-18	Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, 92350, France	
2020-11-13	University Medical Center Groningen, Groningen, 9700RB, Netherlands	

2023-04-13	City of Hope, Duarte, California, 91010, United States|Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|Chester County Hospital, West Chester, Pennsylvania, 19380, United States	
2017-12-19		
2023-07-11	Istanbul Faculty of Medicine, Fatih, Istanbul, 34093, Turkey	
2019-03-20	Valley Medical Center, Renton, Washington, 98058, United States|Harborview Medical Center, Seattle, Washington, 98104, United States|Swedish Medical Center, Seattle, Washington, 98122, United States|Northwest Hospital and Medical Center, Seattle, Washington, 98133, United States|Univ	
2023-05-31	Renji Hospital, Shanghai, 200127, China	
2022-06-21	ASO KK Iizuka Hospital, Iizuka, Fukuoka, 820-8505, Japan	
2023-05-17	Radiation Oncology Department at the University of Arizona Heath Network, Tucson, Arizona, 85724-5024, United States	Study Protocol and Statistical Analysis Plan
2016-12-15		
2022-05-09	Institut régional du cancer de Montpellier, Montpellier, Hérault, 34298, France|Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France|Institut Gustave Roussy, Villejuif, France	
2020-07-17	University and Emergency Hospital, Bucharest, 050098, Romania	
2023-06-07	National Cheng Kung University Hospital, Tainan, Taiwan	
2023-03-27	Pediatric and Congenital Cardiology and Pulmonology Department, Arnaud De Villeneuve University Hospital, Montpellier, 34295, France	
2020-10-22		
2018-06-19	IRSN - Clinique Pasteur, Toulouse, France|Klinikum rechts der Isar der Technischen Universität München, Munich, Germany|Academisch Ziekenhuis Groningen, Groningen, Netherlands|Associação para Investigação e Desen	Study Protocol, Statistical Analysis Plan, and Informed Consent Form
2018-02-19	University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, 40202, United States|Vanderbilt Heart One Hundred Oaks, Nashville, Tennessee, 37204, United States|MBCCOP - Meharry Medical College - Nashville, Nashville, Tennessee, 37208, United States|Vanderbilt-Ingra	
2022-06-08	Wen-Shiou Pan, Yilan, 260, Taiwan	
2021-11-10	Tanta university, Tanta, Egypt	
2018-01-31	Lawson Health Research Institute, London, Ontario, N6C 2R5, Canada	
2023-04-27		
2023-03-17	University of Arizona Sarver Heart Center, Tucson, Arizona, 85724, United States|UC San Diego Health, Sulpizio Cardiovascular Center, La Jolla, California, 92037, United States|Scripps Health, La Jolla, California, 92137, Uni	Study Protocol
2023-01-20	University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States	
2018-10-25	Weill Medical College of Cornell University, New York, New York, 10065, United States	
2023-02-14	Toronto General Hospital, Toronto, Ontario, M5G 2N2, Canada	
2022-05-02		
2019-01-11	Department of Radiology, Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, 03722, Korea, Republic of	
2023-05-09	University Medical Center Groningen, Groningen, 9700 AD, Netherlands	
2021-03-18	Renji Hospital Department of Endocrinology and Metabolism, Shanghai, Shanghai, 200127, China	
2019-07-30	University of Michigan, Ann Arbor, Michigan, 48109, United States	
2022-10-14	Desert Medical Imaging, Indian Wells, California, 92210, United States	
2022-11-29	Institut de cancérologie Strasbourg Europe, Strasbourg, France	
2022-04-22		
2019-10-01	USC Davis School of Gerontology, Los Angeles, California, 90089, United States	
2016-06-09	Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, 94805, France	
2017-10-12	Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, 08907, Spain|Hospital Son Llàtzer, Palma de Mallorca, Illes Balears, 07198, Spain|Hospital Universitario Sant Joan de Reus, Reus, Tarragona, 42301, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 08025, Spain|Hospital U	

2020-05-22		
2018-03-07	Karolinska University Hospital, Stockholm, 171 76, Sweden	
2020-02-05	University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States	Study Protocol and Statistical Analysis Plan
2018-07-18	Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institue, Yonsei Universiy College of Medicine, Seoul, 120-752, Korea, Republic of	
2021-05-06	State Networks of Colorado Ambulatory Practices and Partners, Aurora, Colorado, 80045, United States|Iowa Research Network, Iowa City, Iowa, 52242, United States|Duke Primary Care Research Consortium, Durham, North Carolina, 27705, United States|Oregon Rural Practice-based Resea	
2019-11-01	Stony Brook Medicine, Stony Brook, New York, 11738, United States	
2023-06-27	Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States	
2023-07-11	Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02115, United States	
2016-02-29		
2020-11-23	Mayo Clinic, Rochester, Minnesota, 55905, United States	
2022-12-09		Study Protocol and Statistical Analysis Plan|Informed Consent Form
2018-07-26	National Human Genome Research Institute (NHGRI), 9000 Rockville Pike, Bethesda, Maryland, 20892, United States	
2023-05-30	St Bartholemew's Hospital, London, EC1A 7BE, United Kingdom|University College London Hospital, London, NW1 2BU, United Kingdom	
2023-02-02		
2023-03-24	Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States	
2014-12-09	UZ gent, Gent, 9000, Belgium|UH gasthuisberg, Leuven, 3000, Belgium	
2020-11-03	Chaplin Family YMCA, Cambridge, Ontario, Canada|The Village of Arbour Trails, Guelph, Ontario, N1G 0C9, Canada|Village of Winston Park, Kitchener, Ontario, N2E 3K1, Canada|A.R. Kaufman Family YMCA, Kitchener, Onta	Study Protocol, Statistical Analysis Plan, and Informed Consent Form
2016-12-21	State University of Campinas, Campinas, São Paulo, 13083-887, Brazil	
2022-07-12	Catholic University of Maule, Talca, Maule, 3600000, Chile	
2014-12-23	Aarhus University, Aarhus, 8000, Denmark	
2022-12-21	Emergency General Hospital, Chaoyang, Beijing, 100028, China|The People's Hospital Of Nanchuan Chongqing, Nanchuan, Chongqing, 408400, China|YongChuan hospital of Chongqing Medical Univeristy, Yongchuan, Chongqing, 402177, China|Fujian Medical University Union Hospital, Fuzho	
2014-08-05	University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, 35294-3300, United States|MBCCOP - Gulf Coast, Mobile, Alabama, 36688, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States|University of Californ	
2023-06-22	West Los Angeles VA Medical Center, Los Angeles, California, 90073, United States	
2016-05-13	University of Pittsburgh, Department of Medicine., Pittsburgh, Pennsylvania, 15232, United States	
2019-01-09	Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States	
2018-05-23	Klinikum rechts der Isar; TUM, Munich, 81675, Germany	
2017-10-25	Queen Mary Hospital, Hong Kong, Hong Kong, China	
2019-08-26	Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, 23298-0037, United States	
2021-09-05	Mazankowski Alberta Heart Institute, Edmonton, Alberta, T6G 2J2, Canada	
2023-07-12	University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, 44106, United States	
2022-10-03	Alexandre, Caen, Normandy, 14000, France	
2019-08-07	East Bay Radiation Oncology Center, Castro Valley, California, 94546, United States|Eden Hospital Medical Center, Castro Valley, California, 94546, United States|Valley Medical Oncology Consultants-Castro Valley, Castro Valley, California, 94546, United States|Bay Area Breast Surgeons Inc, Er Roper Hospital, Charleston, South Carolina, 29401, United States|McLeod Regional Medical Center, Florence, South Carolina, 29506, United States|Saint Francis Hospital, Greenville, South Carolina, 29601, United States|Greenville Memorial Hospital, Greenville, South Carolina, 29605, United S	
2023-05-25	Hôpital Cardiologique Louis Pradel - Hospices Civils de Lyon, Bron, Avenue Doyen Lépine, 69500, France	
2023-06-26	National Institutes of Health Clinical Center, Bethesda, Maryland, 20892, United States	
2011-09-07	Department of visceral and transplant surgery, Bern University Hospital, Bern, 3010, Switzerland	
2022-03-09	CU-Med Biobank, Hong Kong, Hong Kong	
2023-02-23	The Royal Children's Hospital, Parkville, Victoria, 3052, Australia	
2017-01-05	British Columbia Cancer Agency, Vancouver Centre, Vancouver, British Columbia, V5Z 4E6, Canada	
2023-02-28	Ain Shams University, Cairo, 11315, Egypt	
2022-08-18	Toulouse University Hospital Center, Toulouse, France	
2013-01-17	Children's Oncology Group, Arcadia, California, 91006-3776, United States	
2021-05-18	Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia, Ljubljana, 1000, Slovenia	
2022-12-07		
2023-01-26	CRMN, Hôpital La Citadelle, Liege, Wallonia, 4000, Belgium	
2023-07-10		
2013-03-13	George Washington University, Washington, District of Columbia, 20037, United States	
2023-04-21	Assistance Publique Hopitaux de Marseille, Marseille, 13354, France	
2013-02-28	Ohio State University Medical Center, Columbus, Ohio, 43210, United States	

2022-10-24	South Tees Hospitals NHS FT, Middlesbrough, Teesside, TS4 3BW, United Kingdom	
2011-10-04	University of Calgary, Dept. of Cardiac Sciences and Tom Baker Cancer Centre, Calgary, Alberta, T2N 2T9, Canada	
2008-07-29	Aarhus University Hospital, Skejby, Aarhus, DK-8200, Denmark	
2022-06-08	Hong Kong Children's Hospital, Hong Kong, Hong Kong	
2016-09-22	Aichi Cancer Center Hospital, Nagoya,Chikusa-ku,Kanokoden,1-1, Aichi, 464-8681, Japan|Aichi Cancer Center,Aichi Hospital, Okazaki,Kake-machi,Kuriyado,18, Aichi, 444-0011, Japan|National Cancer Center Hospital East, Kashiwa,Kashiwanoha,6-5-1, Chiba, 277-8577, Japan|National Hospit	
2013-08-01	Far Eastern Memorial Hospital, New Taipei City, 220, Taiwan	
2015-09-23	McGill university health center, Royal Victoria hospital, Montreal, Quebec, h3a 1a1, Canada|Royal Victoria Hospital, Montreal, Quebec, h4a 1v3, Canada	
2023-04-07	National Institutes of Health (NIH) - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, 20892, United States	
2022-02-10	Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, 226014, India	
2006-05-15	Kaiser Permanente of Colorado, Aurora, Colorado, 80014, United States	
2023-05-30		
2022-09-02	Cardiovascular Research Facility, Aberdeen, Aberdeenshire, AB25 2ZD, United Kingdom	
2009-12-23	Section Sports Medicine, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, Berlin, 12200, Germany	
2018-05-29	Golden Jubilee National Hospital, Glasgow, Strathclyde, G814HX, United Kingdom	
2023-05-31	University of Alabama, Birmingham, Alabama, 35233, United States|The Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Rutger's University / Cancer Institute of New Jersey, N	
2023-05-10	Virginia Commonwealth University, Richmond, Virginia, 23298, United States	
2023-06-28	National Cancer Institute (NCI), Bethesda, Maryland, 20892, United States	
2021-10-14	Ain Shams University, Cairo, 1156, Egypt	Study Protocol and Statistical Analysis Plan|Informed Consent Form
2023-06-29	Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, 46202, United States	